"","Study_id_f","first author","study design","n_row","publication_date","clean_vaccine","vac_type","dose_number","dose","dose interval","timing_of_dose_days","population_detail","population_category","historyofCOVID","max duration follow-up","outcome_detail","outcome_category","outcome_final","variant_clean","VE","LCL","UCL","country_clean","Country.Code","continent","Region","GNI_per_c_WB","year_GNI","Economy","Income group","q_GNI_per_c_WB","min_period_days","max_period_days","include","justification","sensitivity"
"1",1,"Amit","Prospective cohort",1,2021-02-18,"BioNTech/Pfizer BNT162b2","mRNA","1+","1+",NA,"15-28 including some up to day 7 post dose 2","HCW","HCW","excluded",NA,"infection","infection","infection","other combinations",75,72,84,"Israel","ISR","Asia","Middle East & North Africa",43800,2019,"Israel","High income",4,NA,NA,NA,NA,NA
"2",1,"Amit","Prospective cohort",2,2021-02-18,"BioNTech/Pfizer BNT162b2","mRNA","1+","1+",NA,"15-28 including some up to day 7 post dose 2","HCW","HCW","excluded",NA,"symptomatic disease","symptomatic","symptomatic","other combinations",85,71,92,"Israel","ISR","Asia","Middle East & North Africa",43800,2019,"Israel","High income",4,NA,NA,NA,NA,NA
"3",2,"Immunisation and Countermeasures Division, National Infection Service, PHE","Screening method",3,2021-02-22,"BioNTech/Pfizer BNT162b2","mRNA","1","1",NA,">28","> 80 years","> 80 years","included",NA,"symptomatic disease","symptomatic","symptomatic","alpha",57,48,63,"UK","GBR","Europe","Europe & Central Asia",43240,2019,"United Kingdom","High income",4,NA,NA,NA,NA,NA
"4",2,"Immunisation and Countermeasures Division, National Infection Service, PHE","Screening method",4,2021-02-22,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"7","> 80 years","> 80 years","included",NA,"symptomatic disease","symptomatic","symptomatic","alpha",88,84,90,"UK","GBR","Europe","Europe & Central Asia",43240,2019,"United Kingdom","High income",4,NA,NA,NA,NA,NA
"5",3,"Dagan","Retrospective cohort",5,2021-02-24,"BioNTech/Pfizer BNT162b2","mRNA","1","1",NA,"14-21","general pop","general pop","excluded",NA,"infection","infection","infection","other combinations",46,40,51,"Israel","ISR","Asia","Middle East & North Africa",43800,2019,"Israel","High income",4,NA,NA,NA,NA,NA
"6",3,"Dagan","Retrospective cohort",6,2021-02-24,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,">7","general pop","general pop","excluded",NA,"infection","infection","infection","other combinations",92,88,95,"Israel","ISR","Asia","Middle East & North Africa",43800,2019,"Israel","High income",4,NA,NA,NA,NA,NA
"7",3,"Dagan","Retrospective cohort",7,2021-02-24,"BioNTech/Pfizer BNT162b2","mRNA","1","1",NA,"14-21","general pop","general pop","excluded",NA,"symptomatic disease","symptomatic","symptomatic","other combinations",57,50,63,"Israel","ISR","Asia","Middle East & North Africa",43800,2019,"Israel","High income",4,NA,NA,NA,NA,NA
"8",3,"Dagan","Retrospective cohort",8,2021-02-24,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,">7","general pop","general pop","excluded",NA,"symptomatic disease","symptomatic","symptomatic","other combinations",94,87,98,"Israel","ISR","Asia","Middle East & North Africa",43800,2019,"Israel","High income",4,NA,NA,NA,NA,NA
"9",3,"Dagan","Retrospective cohort",9,2021-02-24,"BioNTech/Pfizer BNT162b2","mRNA","1","1",NA,"14-21","general pop","general pop","excluded",NA,"hospitalization","severe","severe","other combinations",74,56,86,"Israel","ISR","Asia","Middle East & North Africa",43800,2019,"Israel","High income",4,NA,NA,NA,NA,NA
"10",3,"Dagan","Retrospective cohort",10,2021-02-24,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,">7","general pop","general pop","excluded",NA,"hospitalization","severe","severe","other combinations",87,55,100,"Israel","ISR","Asia","Middle East & North Africa",43800,2019,"Israel","High income",4,NA,NA,NA,NA,NA
"11",3,"Dagan","Retrospective cohort",11,2021-02-24,"BioNTech/Pfizer BNT162b2","mRNA","1","1",NA,"14-21","general pop","general pop","excluded",NA,"severe disease","severe","severe","other combinations",62,39,80,"Israel","ISR","Asia","Middle East & North Africa",43800,2019,"Israel","High income",4,NA,NA,NA,NA,NA
"12",3,"Dagan","Retrospective cohort",12,2021-02-24,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,">7","general pop","general pop","excluded",NA,"severe disease","severe","severe","other combinations",92,75,100,"Israel","ISR","Asia","Middle East & North Africa",43800,2019,"Israel","High income",4,NA,NA,NA,NA,NA
"13",4,"Hyams","Test-negative case-control",13,2021-11-01,"BioNTech/Pfizer BNT162b2","mRNA","1","1",NA,">14","> 80 years","> 80 years","included",NA,"hospitalization","severe","severe","alpha",79,47,93,"UK","GBR","Europe","Europe & Central Asia",43240,2019,"United Kingdom","High income",4,NA,NA,NA,NA,NA
"14",4,"Hyams","Test-negative case-control",14,2021-11-01,"Oxford/AstraZeneca ChAdOx1-S","Vectored","1","1",NA,">14","> 80 years","> 80 years","included",NA,"hospitalization","severe","severe","alpha",80,36,95,"UK","GBR","Europe","Europe & Central Asia",43240,2019,"United Kingdom","High income",4,NA,NA,NA,NA,NA
"15",5,"Mousten-Helms","Retrospective cohort",15,2021-03-09,"BioNTech/Pfizer BNT162b2","mRNA","1","1",NA,">14","LTCF residents","LTCF residents","excluded",NA,"infection","infection","infection","other combinations",21,-11,44,"Denmark","DNK","Europe","Europe & Central Asia",63020,2019,"Denmark","High income",4,NA,NA,NA,NA,NA
"16",5,"Mousten-Helms","Retrospective cohort",16,2021-03-09,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,">7","LTCF residents","LTCF residents","excluded",NA,"infection","infection","infection","other combinations",64,14,84,"Denmark","DNK","Europe","Europe & Central Asia",63020,2019,"Denmark","High income",4,NA,NA,NA,NA,NA
"17",5,"Mousten-Helms","Retrospective cohort",17,2021-03-09,"BioNTech/Pfizer BNT162b2","mRNA","1","1",NA,">14","LTCF staff","LTCF staff","excluded",NA,"infection","infection","infection","other combinations",17,4,28,"Denmark","DNK","Europe","Europe & Central Asia",63020,2019,"Denmark","High income",4,NA,NA,NA,NA,NA
"18",5,"Mousten-Helms","Retrospective cohort",18,2021-03-09,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,">7","LTCF staff","LTCF staff","excluded",NA,"infection","infection","infection","other combinations",90,82,95,"Denmark","DNK","Europe","Europe & Central Asia",63020,2019,"Denmark","High income",4,NA,NA,NA,NA,NA
"19",6,"Tande","Retrospective cohort",19,2021-03-11,"Multiple or heterologous RNA","mRNA","1+","1+",NA,">10 including some with dose 2","pre-surgical hospital patients","pre-surgical hospital patients","included",NA,"asymptomatic infection","asymptomatic","infection","original",79,63,88,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"20",6,"Tande","Retrospective cohort",20,2021-03-11,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,">0","pre-surgical hospital patients","pre-surgical hospital patients","included",NA,"asymptomatic infection","asymptomatic","infection","original",80,56,91,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"21",6,"Tande","Retrospective cohort",21,2021-03-11,"BioNTech/Pfizer BNT162b2","mRNA","1","1",NA,">10","pre-surgical hospital patients","pre-surgical hospital patients","included",NA,"asymptomatic infection","asymptomatic","infection","original",79,62,89,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"22",6,"Tande","Retrospective cohort",22,2021-03-11,"Multiple or heterologous RNA","mRNA","2","final",NA,">0","pre-surgical hospital patients","pre-surgical hospital patients","included",NA,"asymptomatic infection","asymptomatic","infection","original",80,56,91,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"23",7,"Britton","Retrospective cohort",23,2021-03-15,"BioNTech/Pfizer BNT162b2","mRNA","1+","1+",NA,">14 including some up to day 7 post dose 2","LTCF residents","LTCF residents","stratified",NA,"infection","infection","infection","original",63,33,79,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"24",7,"Britton","Retrospective cohort",24,2021-03-15,"BioNTech/Pfizer BNT162b2","mRNA","1+","1+",NA,">14 including some up to day 7 post dose 2","LTCF residents","LTCF residents","stratified",NA,"infection","infection","infection","original",60,30,77,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"25",8,"Yelin","Retrospective cohort",25,2021-03-17,"BioNTech/Pfizer BNT162b2","mRNA","1+","1+",NA,">35, most with dose 2","general pop","general pop","excluded",NA,"infection","infection","infection","alpha",91,89,93,"Israel","ISR","Asia","Middle East & North Africa",43800,2019,"Israel","High income",4,NA,NA,NA,NA,NA
"26",8,"Yelin","Retrospective cohort",26,2021-03-17,"BioNTech/Pfizer BNT162b2","mRNA","1+","1+",NA,">35, most with dose 2","general pop","general pop","excluded",NA,"symptomatic disease","symptomatic","symptomatic","alpha",99,95,99,"Israel","ISR","Asia","Middle East & North Africa",43800,2019,"Israel","High income",4,NA,NA,NA,NA,NA
"27",9,"Public Health England","Test-negative case-control",27,2021-03-17,"BioNTech/Pfizer BNT162b2","mRNA","1","1",NA,">28","> 70 years","> 70 years","unknown",NA,"symptomatic disease","symptomatic","symptomatic","alpha",58,49,65,"UK","GBR","Europe","Europe & Central Asia",43240,2019,"United Kingdom","High income",4,NA,NA,NA,NA,NA
"28",9,"Public Health England","Test-negative case-control",28,2021-03-17,"Oxford/AstraZeneca ChAdOx1-S","Vectored","1","1",NA,">35","> 70 years","> 70 years","unknown",NA,"symptomatic disease","symptomatic","symptomatic","alpha",58,38,72,"UK","GBR","Europe","Europe & Central Asia",43240,2019,"United Kingdom","High income",4,NA,NA,NA,NA,NA
"29",9,"Public Health England","Retrospective cohort",29,2021-03-17,"BioNTech/Pfizer BNT162b2","mRNA","1","1",NA,">14","> 70 years","> 70 years","included",NA,"hospitalization","severe","severe","alpha",42,32,51,"UK","GBR","Europe","Europe & Central Asia",43240,2019,"United Kingdom","High income",4,NA,NA,NA,NA,NA
"30",9,"Public Health England","Retrospective cohort",30,2021-03-17,"BioNTech/Pfizer BNT162b2","mRNA","1","1",NA,">14","> 70 years","> 70 years","included",NA,"death","death","death","alpha",54,41,64,"UK","GBR","Europe","Europe & Central Asia",43240,2019,"United Kingdom","High income",4,NA,NA,NA,NA,NA
"31",9,"Public Health England","Retrospective cohort",31,2021-03-17,"Oxford/AstraZeneca ChAdOx1-S","Vectored","1","1",NA,"14-21","> 70 years","> 70 years","included",NA,"hospitalization","severe","severe","alpha",35,4,56,"UK","GBR","Europe","Europe & Central Asia",43240,2019,"United Kingdom","High income",4,NA,NA,NA,NA,NA
"32",10,"Shrotri","Prospective cohort",32,2021-06-23,"BioNTech/Pfizer BNT162b2","mRNA","1","1",NA,"35-48","LTCF residents","LTCF residents","stratified",NA,"infection","infection","infection","other combinations",65,29,83,"UK","GBR","Europe","Europe & Central Asia",43240,2019,"United Kingdom","High income",4,NA,NA,NA,NA,NA
"33",10,"Shrotri","Prospective cohort",33,2021-06-23,"Oxford/AstraZeneca ChAdOx1-S","Vectored","1","1",NA,"35-48","LTCF residents","LTCF residents","stratified",NA,"infection","infection","infection","other combinations",68,34,85,"UK","GBR","Europe","Europe & Central Asia",43240,2019,"United Kingdom","High income",4,NA,NA,NA,NA,NA
"34",11,"Thompson","Prospective cohort",34,2021-03-29,"Multiple or heterologous RNA","mRNA","1","1",NA,">14","HCW","HCW","excluded",NA,"infection","infection","infection","original",80,59,90,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"35",11,"Thompson","Prospective cohort",35,2021-03-29,"Multiple or heterologous RNA","mRNA","2","final",NA,">14","HCW","HCW","excluded",NA,"infection","infection","infection","original",90,68,97,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"36",12,"Bouton","Prospective cohort",36,2021-03-30,"Multiple or heterologous RNA","mRNA","1+","1+",NA,">14 including some with dose 2","HCW","HCW","included",NA,"infection","infection","infection","original",82,68,90,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"37",13,"Regev-Yochay","Prospective cohort",37,2021-07-07,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,">11","HCW","HCW","included",NA,"asymptomatic infection","asymptomatic","infection","alpha",65,45,79,"Israel","ISR","Asia","Middle East & North Africa",43800,2019,"Israel","High income",4,NA,NA,NA,NA,NA
"38",13,"Regev-Yochay","Prospective cohort",38,2021-07-07,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,">11","HCW","HCW","included",NA,"asymptomatic infection (presumed infectious ct<30)","asymptomatic","infection","alpha",70,43,84,"Israel","ISR","Asia","Middle East & North Africa",43800,2019,"Israel","High income",4,NA,NA,NA,NA,NA
"39",13,"Regev-Yochay","Prospective cohort",39,2021-07-07,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,">11","HCW","HCW","included",NA,"symptomatic disease","symptomatic","symptomatic","alpha",90,84,94,"Israel","ISR","Asia","Middle East & North Africa",43800,2019,"Israel","High income",4,NA,NA,NA,NA,NA
"40",13,"Regev-Yochay","Prospective cohort",40,2021-07-07,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,">11","HCW","HCW","included",NA,"symptomatic disease  (presumed infectious ct<30)","symptomatic","symptomatic","alpha",88,80,94,"Israel","ISR","Asia","Middle East & North Africa",43800,2019,"Israel","High income",4,NA,NA,NA,NA,NA
"41",14,"Andrejko","Test-negative case-control",41,2021-07-20,"Multiple or heterologous RNA","mRNA","1","1",NA,">=15","general pop","general pop","excluded",NA,"infection","infection","infection","other combinations",66.9,28.7,84.6,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"42",14,"Andrejko","Test-negative case-control",42,2021-07-20,"Multiple or heterologous RNA","mRNA","2","final",NA,">=15","general pop","general pop","excluded",NA,"infection","infection","infection","other combinations",87.4,77.2,93.1,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"43",14,"Andrejko","Test-negative case-control",43,2021-07-20,"Multiple or heterologous RNA","mRNA","2","final",NA,">=15","general pop","general pop","excluded",NA,"asymptomatic infection","asymptomatic","infection","other combinations",68.3,27.9,85.7,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"44",14,"Andrejko","Test-negative case-control",44,2021-07-20,"Multiple or heterologous RNA","mRNA","2","final",NA,">=15","general pop","general pop","excluded",NA,"symptomatic disease","symptomatic","symptomatic","other combinations",91.3,79.3,96.3,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"45",14,"Andrejko","Test-negative case-control",45,2021-07-20,"Multiple or heterologous RNA","mRNA","2","final",NA,">=15","general pop","general pop","excluded",NA,"hospitalization","severe","severe","other combinations",100,NA,NA,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"46",14,"Andrejko","Test-negative case-control",46,2021-07-20,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,">=15","general pop","general pop","excluded",NA,"infection","infection","infection","other combinations",87,68.6,94.6,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"47",14,"Andrejko","Test-negative case-control",47,2021-07-20,"Moderna mRNA-1273","mRNA","2","final",NA,">=15","general pop","general pop","excluded",NA,"infection","infection","infection","other combinations",86.2,68.4,93.9,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"48",15,"Glampson","Retrospective cohort",48,2021-09-17,"BioNTech/Pfizer BNT162b2","mRNA","1","1",NA,"22-28",">= 16 years","general pop","unknown",NA,"infection","infection","infection","alpha",78,73,82,"UK","GBR","Europe","Europe & Central Asia",43240,2019,"United Kingdom","High income",4,NA,NA,NA,NA,NA
"49",15,"Glampson","Retrospective cohort",49,2021-09-17,"Oxford/AstraZeneca ChAdOx1-S","Vectored","1","1",NA,"22-28",">= 16 years","general pop","unknown",NA,"infection","infection","infection","alpha",74,65,81,"UK","GBR","Europe","Europe & Central Asia",43240,2019,"United Kingdom","High income",4,NA,NA,NA,NA,NA
"50",16,"Bjork","Retrospective cohort",50,2021-09-29,"BioNTech/Pfizer BNT162b2","mRNA","1","1",NA,">14","general pop","general pop","unknown",NA,"infection","infection","infection","other combinations",42,14,63,"Sweden","SWE","Europe","Europe & Central Asia",56230,2019,"Sweden","High income",4,NA,NA,NA,NA,NA
"51",16,"Bjork","Retrospective cohort",51,2021-09-29,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,">7","general pop","general pop","unknown",NA,"infection","infection","infection","other combinations",86,72,94,"Sweden","SWE","Europe","Europe & Central Asia",56230,2019,"Sweden","High income",4,NA,NA,NA,NA,NA
"52",17,"Mason","Case-control",52,2021-10-18,"BioNTech/Pfizer BNT162b2","mRNA","1","1",NA,"21-27","80-83 years","80-83 years","excluded",NA,"infection","infection","infection","alpha",55,40,66,"UK","GBR","Europe","Europe & Central Asia",43240,2019,"United Kingdom","High income",4,NA,NA,NA,NA,NA
"53",17,"Mason","Case-control",53,2021-10-18,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"35-41","80-83 years","80-83 years","excluded",NA,"infection","infection","infection","alpha",70,55,80,"UK","GBR","Europe","Europe & Central Asia",43240,2019,"United Kingdom","High income",4,NA,NA,NA,NA,NA
"54",17,"Mason","Case-control",54,2021-10-18,"BioNTech/Pfizer BNT162b2","mRNA","1","1",NA,"21-27","80-83 years","80-83 years","excluded",NA,"hospitalization","severe","severe","alpha",50,19,69,"UK","GBR","Europe","Europe & Central Asia",43240,2019,"United Kingdom","High income",4,NA,NA,NA,NA,NA
"55",17,"Mason","Case-control",55,2021-10-18,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"35-41","80-83 years","80-83 years","excluded",NA,"hospitalization","severe","severe","alpha",75,52,87,"UK","GBR","Europe","Europe & Central Asia",43240,2019,"United Kingdom","High income",4,NA,NA,NA,NA,NA
"56",17,"Mason","Case-control",56,2021-10-18,"BioNTech/Pfizer BNT162b2","mRNA","1","1",NA,"35-41","80-83 years","80-83 years","excluded",NA,"ED or UC visit","symptomatic","symptomatic","alpha",58,31,74,"UK","GBR","Europe","Europe & Central Asia",43240,2019,"United Kingdom","High income",4,NA,NA,NA,NA,NA
"57",17,"Mason","Case-control",57,2021-10-18,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"35-41","80-83 years","80-83 years","excluded",NA,"ED or UC visit","symptomatic","symptomatic","alpha",79,60,90,"UK","GBR","Europe","Europe & Central Asia",43240,2019,"United Kingdom","High income",4,NA,NA,NA,NA,NA
"58",18,"Hall","Prospective cohort",58,2021-04-23,"BioNTech/Pfizer BNT162b2","mRNA","1","1",NA,">21","HCW","HCW","excluded",NA,"infection","infection","infection","alpha",72,58,86,"UK","GBR","Europe","Europe & Central Asia",43240,2019,"United Kingdom","High income",4,NA,NA,NA,NA,NA
"59",18,"Hall","Prospective cohort",59,2021-04-23,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,">7","HCW","HCW","excluded",NA,"infection","infection","infection","alpha",86,76,97,"UK","GBR","Europe","Europe & Central Asia",43240,2019,"United Kingdom","High income",4,NA,NA,NA,NA,NA
"60",19,"Vasileiou","Prospective cohort",60,2021-04-23,"BioNTech/Pfizer BNT162b2","mRNA","1","1",NA,"28-34","general pop","general pop","excluded",NA,"hospitalization","severe","severe","other combinations",91,85,94,"UK","GBR","Europe","Europe & Central Asia",43240,2019,"United Kingdom","High income",4,NA,NA,NA,NA,NA
"61",19,"Vasileiou","Prospective cohort",61,2021-04-23,"Oxford/AstraZeneca ChAdOx1-S","Vectored","1","1",NA,"28-34","general pop","general pop","excluded",NA,"hospitalization","severe","severe","other combinations",88,75,94,"UK","GBR","Europe","Europe & Central Asia",43240,2019,"United Kingdom","High income",4,NA,NA,NA,NA,NA
"62",20,"Pritchard","Prospective cohort",62,2021-06-09,"BioNTech/Pfizer BNT162b2","mRNA","1","1",NA,">21",">= 16 years","general pop","excluded",NA,"infection","infection","infection","other combinations",66,60,71,"UK","GBR","Europe","Europe & Central Asia",43240,2019,"United Kingdom","High income",4,NA,NA,NA,NA,NA
"63",20,"Pritchard","Prospective cohort",63,2021-06-09,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,">0",">= 16 years","general pop","excluded",NA,"infection","infection","infection","other combinations",80,74,85,"UK","GBR","Europe","Europe & Central Asia",43240,2019,"United Kingdom","High income",4,NA,NA,NA,NA,NA
"64",20,"Pritchard","Prospective cohort",64,2021-06-09,"BioNTech/Pfizer BNT162b2","mRNA","1","1",NA,">21",">= 16 years","general pop","excluded",NA,"symptomatic disease","symptomatic","symptomatic","other combinations",78,72,83,"UK","GBR","Europe","Europe & Central Asia",43240,2019,"United Kingdom","High income",4,NA,NA,NA,NA,NA
"65",20,"Pritchard","Prospective cohort",65,2021-06-09,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,">0",">= 16 years","general pop","excluded",NA,"symptomatic disease","symptomatic","symptomatic","other combinations",95,91,98,"UK","GBR","Europe","Europe & Central Asia",43240,2019,"United Kingdom","High income",4,NA,NA,NA,NA,NA
"66",20,"Pritchard","Prospective cohort",66,2021-06-09,"Oxford/AstraZeneca ChAdOx1-S","Vectored","1","1",NA,">21",">= 16 years","general pop","excluded",NA,"infection","infection","infection","other combinations",61,54,68,"UK","GBR","Europe","Europe & Central Asia",43240,2019,"United Kingdom","High income",4,NA,NA,NA,NA,NA
"67",20,"Pritchard","Prospective cohort",67,2021-06-09,"Oxford/AstraZeneca ChAdOx1-S","Vectored","2","final",NA,">0",">= 16 years","general pop","excluded",NA,"infection","infection","infection","other combinations",79,65,88,"UK","GBR","Europe","Europe & Central Asia",43240,2019,"United Kingdom","High income",4,NA,NA,NA,NA,NA
"68",20,"Pritchard","Prospective cohort",68,2021-06-09,"Oxford/AstraZeneca ChAdOx1-S","Vectored","1","1",NA,">21",">= 16 years","general pop","excluded",NA,"symptomatic disease","symptomatic","symptomatic","other combinations",71,62,78,"UK","GBR","Europe","Europe & Central Asia",43240,2019,"United Kingdom","High income",4,NA,NA,NA,NA,NA
"69",20,"Pritchard","Prospective cohort",69,2021-06-09,"Oxford/AstraZeneca ChAdOx1-S","Vectored","2","final",NA,">0","general pop","general pop","excluded",NA,"symptomatic disease","symptomatic","symptomatic","other combinations",92,78,97,"UK","GBR","Europe","Europe & Central Asia",43240,2019,"United Kingdom","High income",4,NA,NA,NA,NA,NA
"70",21,"Goldberg","Prospective cohort",70,2022-03-30,"BioNTech/Pfizer BNT162b2","mRNA","1+","1+",NA,">14 days post dose 1 to <14 days post dose 2",">= 16 years","general pop","excluded",NA,"infection","infection","infection","alpha",65.9,65.4,66.4,"Israel","ISR","Asia","Middle East & North Africa",43800,2019,"Israel","High income",4,NA,NA,NA,NA,NA
"71",21,"Goldberg","Prospective cohort",71,2022-03-30,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"14+",">= 16 years","general pop","excluded","~8 weeks","infection","infection","infection","alpha",94.5,94.3,94.7,"Israel","ISR","Asia","Middle East & North Africa",43800,2019,"Israel","High income",4,NA,NA,NA,NA,NA
"72",21,"Goldberg","Prospective cohort",72,2022-03-30,"BioNTech/Pfizer BNT162b2","mRNA","1+","1+",NA,">14 days post dose 1 to <14 days post dose 2",">= 16 years","general pop","excluded",NA,"hospitalization","severe","severe","alpha",74.9,73.5,76.3,"Israel","ISR","Asia","Middle East & North Africa",43800,2019,"Israel","High income",4,NA,NA,NA,NA,NA
"73",21,"Goldberg","Prospective cohort",73,2022-03-30,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"14+",">= 16 years","general pop","excluded","~8 weeks","hospitalization","severe","severe","alpha",95.8,95.2,96.2,"Israel","ISR","Asia","Middle East & North Africa",43800,2019,"Israel","High income",4,NA,NA,NA,NA,NA
"74",21,"Goldberg","Prospective cohort",74,2022-03-30,"BioNTech/Pfizer BNT162b2","mRNA","1+","1+",NA,">14 days post dose 1 to <14 days post dose 2",">= 16 years","general pop","excluded",NA,"severe disease","severe","severe","alpha",72.1,69.9,74.1,"Israel","ISR","Asia","Middle East & North Africa",43800,2019,"Israel","High income",4,NA,NA,NA,NA,NA
"75",21,"Goldberg","Prospective cohort",75,2022-03-30,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"14+",">= 16 years","general pop","excluded","~8 weeks","severe disease","severe","severe","alpha",96.3,95.7,96.9,"Israel","ISR","Asia","Middle East & North Africa",43800,2019,"Israel","High income",4,NA,NA,NA,NA,NA
"76",21,"Goldberg","Prospective cohort",76,2022-03-30,"BioNTech/Pfizer BNT162b2","mRNA","1+","1+",NA,">14 days post dose 1 to <14 days post dose 2",">= 16 years","general pop","excluded",NA,"death","death","death","alpha",69.1,65.5,72.3,"Israel","ISR","Asia","Middle East & North Africa",43800,2019,"Israel","High income",4,NA,NA,NA,NA,NA
"77",21,"Goldberg","Prospective cohort",77,2022-03-30,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"14+",">= 16 years","general pop","excluded","~8 weeks","death","death","death","alpha",96,94.9,96.9,"Israel","ISR","Asia","Middle East & North Africa",43800,2019,"Israel","High income",4,NA,NA,NA,NA,NA
"78",22,"Tenforde","Test-negative case-control",78,2021-04-28,"Multiple or heterologous RNA","mRNA","1+","1+",NA,">14 days post dose 1 to 14 days post dose 2","hospital patients >= 65 years",">= 65 years","unknown",NA,"hospitalization","severe","severe","other combinations",64,28,82,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"79",22,"Tenforde","Test-negative case-control",79,2021-04-28,"Multiple or heterologous RNA","mRNA","2","final",NA,">14","hospital patients >= 65 years",">= 65 years","unknown",NA,"hospitalization","severe","severe","other combinations",94,49,99,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"80",23,"Gras-Valenti","Case-control",80,2021-04-29,"BioNTech/Pfizer BNT162b2","mRNA","1","1",NA,">12","HCW","HCW","included",NA,"infection","infection","infection","other combinations",53,1,77,"Spain","ESP","Europe","Europe & Central Asia",30370,2019,"Spain","High income",4,NA,NA,NA,NA,NA
"81",24,"Fabiani","Retrospective cohort",81,2021-04-29,"BioNTech/Pfizer BNT162b2","mRNA","1","1",NA,"14-21","HCW","HCW","excluded",NA,"infection","infection","infection","unknown",84,40,96,"Italy","ITA","Europe","Europe & Central Asia",34890,2019,"Italy","High income",4,NA,NA,NA,NA,NA
"82",24,"Fabiani","Retrospective cohort",82,2021-04-29,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,">7","HCW","HCW","excluded",NA,"infection","infection","infection","unknown",95,62,99,"Italy","ITA","Europe","Europe & Central Asia",34890,2019,"Italy","High income",4,NA,NA,NA,NA,NA
"83",24,"Fabiani","Retrospective cohort",83,2021-04-29,"BioNTech/Pfizer BNT162b2","mRNA","1","1",NA,"14-21","HCW","HCW","excluded",NA,"symptomatic disease","symptomatic","symptomatic","unknown",83,15,97,"Italy","ITA","Europe","Europe & Central Asia",34890,2019,"Italy","High income",4,NA,NA,NA,NA,NA
"84",24,"Fabiani","Retrospective cohort",84,2021-04-29,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,">7","HCW","HCW","excluded",NA,"symptomatic disease","symptomatic","symptomatic","unknown",94,51,99,"Italy","ITA","Europe","Europe & Central Asia",34890,2019,"Italy","High income",4,NA,NA,NA,NA,NA
"85",25,"Corchado-Garcia","Retrospective cohort",85,2021-11-02,"Janssen Ad26.COV2.S","Vectored","1","final",NA,">15","general pop","general pop","excluded",NA,"infection","infection","infection","other combinations",74.2,64.9,81.6,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"86",26,"Haas","Retrospective cohort",86,2021-05-05,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,">7","general pop","general pop","excluded",NA,"infection","infection","infection","alpha",95.3,94.9,95.7,"Israel","ISR","Asia","Middle East & North Africa",43800,2019,"Israel","High income",4,NA,NA,NA,NA,NA
"87",26,"Haas","Retrospective cohort",87,2021-05-05,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,">7","general pop","general pop","excluded",NA,"asymptomatic infection","asymptomatic","infection","alpha",91.5,90.7,92.2,"Israel","ISR","Asia","Middle East & North Africa",43800,2019,"Israel","High income",4,NA,NA,NA,NA,NA
"88",26,"Haas","Retrospective cohort",88,2021-05-05,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,">7","general pop","general pop","excluded",NA,"symptomatic disease","symptomatic","symptomatic","alpha",97,96.7,97.2,"Israel","ISR","Asia","Middle East & North Africa",43800,2019,"Israel","High income",4,NA,NA,NA,NA,NA
"89",26,"Haas","Retrospective cohort",89,2021-05-05,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,">7","general pop","general pop","excluded",NA,"hospitalization","severe","severe","alpha",97.2,96.8,97.5,"Israel","ISR","Asia","Middle East & North Africa",43800,2019,"Israel","High income",4,NA,NA,NA,NA,NA
"90",26,"Haas","Retrospective cohort",90,2021-05-05,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,">7","general pop","general pop","excluded",NA,"severe/critical hospitalization","severe","severe","alpha",97.5,97.1,97.8,"Israel","ISR","Asia","Middle East & North Africa",43800,2019,"Israel","High income",4,NA,NA,NA,NA,NA
"91",26,"Haas","Retrospective cohort",91,2021-05-05,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,">7","general pop","general pop","excluded",NA,"death","death","death","alpha",96.7,96,97.3,"Israel","ISR","Asia","Middle East & North Africa",43800,2019,"Israel","High income",4,NA,NA,NA,NA,NA
"92",27,"Abu-Raddad","Test-negative case-control",92,2021-07-08,"BioNTech/Pfizer BNT162b2","mRNA","1","1",NA,"15-21","general pop","general pop","unknown",NA,"infection","infection","infection","alpha",65.5,58.2,71.5,"Qatar","QAT","Asia","Middle East & North Africa",65700,2019,"Qatar","High income",4,NA,NA,NA,NA,NA
"93",27,"Abu-Raddad","Test-negative case-control",93,2021-07-08,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,">14","general pop","general pop","unknown",NA,"infection","infection","infection","alpha",90,86,92,"Qatar","QAT","Asia","Middle East & North Africa",65700,2019,"Qatar","High income",4,NA,NA,NA,NA,NA
"94",27,"Abu-Raddad","Test-negative case-control",94,2021-07-08,"BioNTech/Pfizer BNT162b2","mRNA","1","1",NA,"15-21","general pop","general pop","unknown",NA,"severe/fatal infection","severe","severe","alpha",72,32,90,"Qatar","QAT","Asia","Middle East & North Africa",65700,2019,"Qatar","High income",4,NA,NA,NA,NA,NA
"95",27,"Abu-Raddad","Test-negative case-control",95,2021-07-08,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,">14","general pop","general pop","unknown",NA,"severe/fatal infection","severe","severe","alpha",100,82,100,"Qatar","QAT","Asia","Middle East & North Africa",65700,2019,"Qatar","High income",4,NA,NA,NA,NA,NA
"96",27,"Abu-Raddad","Test-negative case-control",96,2021-07-08,"BioNTech/Pfizer BNT162b2","mRNA","1","1",NA,"15-21","general pop","general pop","unknown",NA,"infection","infection","infection","beta",46.5,38.7,53.3,"Qatar","QAT","Asia","Middle East & North Africa",65700,2019,"Qatar","High income",4,NA,NA,NA,NA,NA
"97",27,"Abu-Raddad","Test-negative case-control",97,2021-07-08,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,">14","general pop","general pop","unknown",NA,"infection","infection","infection","beta",75,71,79,"Qatar","QAT","Asia","Middle East & North Africa",65700,2019,"Qatar","High income",4,NA,NA,NA,NA,NA
"98",27,"Abu-Raddad","Test-negative case-control",98,2021-07-08,"BioNTech/Pfizer BNT162b2","mRNA","1","1",NA,"15-21","general pop","general pop","unknown",NA,"severe/fatal infection","severe","severe","beta",56.5,0,82.8,"Qatar","QAT","Asia","Middle East & North Africa",65700,2019,"Qatar","High income",4,NA,NA,NA,NA,NA
"99",27,"Abu-Raddad","Test-negative case-control",99,2021-07-08,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,">14","general pop","general pop","unknown",NA,"severe/fatal infection","severe","severe","beta",100,74,100,"Qatar","QAT","Asia","Middle East & North Africa",65700,2019,"Qatar","High income",4,NA,NA,NA,NA,NA
"100",27,"Abu-Raddad","Retrospective cohort",100,2021-07-08,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,">14","general pop","general pop","unknown",NA,"infection","infection","infection","alpha",87,82,91,"Qatar","QAT","Asia","Middle East & North Africa",65700,2019,"Qatar","High income",4,NA,NA,NA,NA,NA
"101",27,"Abu-Raddad","Retrospective cohort",101,2021-07-08,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,">14","general pop","general pop","unknown",NA,"infection","infection","infection","beta",72,66,77,"Qatar","QAT","Asia","Middle East & North Africa",65700,2019,"Qatar","High income",4,NA,NA,NA,NA,NA
"102",28,"Angel","Retrospective cohort",102,2021-05-06,"BioNTech/Pfizer BNT162b2","mRNA","1+","1+",NA,">7 days post dose 1 to 7 days post dose 2","HCW","HCW","excluded",NA,"symptomatic disease","symptomatic","symptomatic","alpha",89,83,94,"Israel","ISR","Asia","Middle East & North Africa",43800,2019,"Israel","High income",4,NA,NA,NA,NA,NA
"103",28,"Angel","Retrospective cohort",103,2021-05-06,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,">7","HCW","HCW","excluded",NA,"symptomatic disease","symptomatic","symptomatic","alpha",97,94,99,"Israel","ISR","Asia","Middle East & North Africa",43800,2019,"Israel","High income",4,NA,NA,NA,NA,NA
"104",28,"Angel","Retrospective cohort",104,2021-05-06,"BioNTech/Pfizer BNT162b2","mRNA","1+","1+",NA,">7 days post dose 1 to 7 days post dose 2","HCW","HCW","excluded",NA,"asymptomatic infection","asymptomatic","infection","alpha",36,-51,69,"Israel","ISR","Asia","Middle East & North Africa",43800,2019,"Israel","High income",4,NA,NA,NA,NA,NA
"105",28,"Angel","Retrospective cohort",105,2021-05-06,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,">7","HCW","HCW","excluded",NA,"asymptomatic infection","asymptomatic","infection","alpha",86,69,97,"Israel","ISR","Asia","Middle East & North Africa",43800,2019,"Israel","High income",4,NA,NA,NA,NA,NA
"106",29,"Lopez-Bernal","Test-negative case-control",106,2021-05-13,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,">=7","> 80 years","> 80 years","included",NA,"symptomatic disease","symptomatic","symptomatic","alpha",79,68,86,"UK","GBR","Europe","Europe & Central Asia",43240,2019,"United Kingdom","High income",4,NA,NA,NA,NA,NA
"107",29,"Lopez-Bernal","Test-negative case-control",107,2021-05-13,"BioNTech/Pfizer BNT162b2","mRNA","1+","1+",NA,"28-34 (includes some with dose 2)","> 70 years","> 70 years","included",NA,"symptomatic disease","symptomatic","symptomatic","alpha",61,51,69,"UK","GBR","Europe","Europe & Central Asia",43240,2019,"United Kingdom","High income",4,NA,NA,NA,NA,NA
"108",29,"Lopez-Bernal","Test-negative case-control",108,2021-05-13,"Oxford/AstraZeneca ChAdOx1-S","Vectored","1+","1+",NA,"28-34 (includes some with dose 2)","> 70 years","> 70 years","included",NA,"symptomatic disease","symptomatic","symptomatic","alpha",60,41,73,"UK","GBR","Europe","Europe & Central Asia",43240,2019,"United Kingdom","High income",4,NA,NA,NA,NA,NA
"109",30,"Pilishvili","Test-negative case-control",109,2021-05-14,"Multiple or heterologous RNA","mRNA","1+","1+",NA,">14 up to 6 days post dose 2","HCW","HCW","excluded",NA,"symptomatic disease","symptomatic","symptomatic","unknown",82,74,87,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"110",30,"Pilishvili","Test-negative case-control",110,2021-05-14,"Multiple or heterologous RNA","mRNA","2","final",NA,">7","HCW","HCW","excluded",NA,"symptomatic disease","symptomatic","symptomatic","unknown",94,87,97,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"111",31,"Ismail","Screening method",111,2021-05-12,"Oxford/AstraZeneca ChAdOx1-S","Vectored","1","1",NA,"28+","70-79 years","70-79 years","included",NA,"hospitalization","severe","severe","alpha",84,74,89,"UK","GBR","Europe","Europe & Central Asia",43240,2019,"United Kingdom","High income",4,NA,NA,NA,NA,NA
"112",31,"Ismail","Screening method",112,2021-05-12,"Oxford/AstraZeneca ChAdOx1-S","Vectored","1","1",NA,"28+",">= 80 years",">= 80 years","included",NA,"hospitalization","severe","severe","alpha",73,60,81,"UK","GBR","Europe","Europe & Central Asia",43240,2019,"United Kingdom","High income",4,NA,NA,NA,NA,NA
"113",31,"Ismail","Screening method",113,2021-05-12,"BioNTech/Pfizer BNT162b2","mRNA","1","1",NA,"28+","70-79 years","70-79 years","included",NA,"hospitalization","severe","severe","alpha",81,73,87,"UK","GBR","Europe","Europe & Central Asia",43240,2019,"United Kingdom","High income",4,NA,NA,NA,NA,NA
"114",31,"Ismail","Screening method",114,2021-05-12,"BioNTech/Pfizer BNT162b2","mRNA","1","1",NA,"28+",">= 80 years",">= 80 years","included",NA,"hospitalization","severe","severe","alpha",81,76,85,"UK","GBR","Europe","Europe & Central Asia",43240,2019,"United Kingdom","High income",4,NA,NA,NA,NA,NA
"115",31,"Ismail","Screening method",115,2021-05-12,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,">14",">= 80 years",">= 80 years","included",NA,"hospitalization","severe","severe","alpha",93,89,95,"UK","GBR","Europe","Europe & Central Asia",43240,2019,"United Kingdom","High income",4,NA,NA,NA,NA,NA
"116",32,"Ranzani","Test-negative case-control",116,2021-08-20,"Sinovac CoronaVac","Inactivated","1","1",NA,">14",">= 70 years",">= 70 years","included",NA,"symptomatic disease","symptomatic","symptomatic","gamma",12.5,3.7,20.6,"Brazil","BRA","South America","Latin America & Caribbean",9410,2019,"Brazil","Upper middle income",3,NA,NA,NA,NA,NA
"117",32,"Ranzani","Test-negative case-control",117,2021-08-20,"Sinovac CoronaVac","Inactivated","2","final",NA,">14",">= 70 years",">= 70 years","included",NA,"symptomatic disease","symptomatic","symptomatic","gamma",46.8,38.7,53.8,"Brazil","BRA","South America","Latin America & Caribbean",9410,2019,"Brazil","Upper middle income",3,NA,NA,NA,NA,NA
"118",32,"Ranzani","Test-negative case-control",118,2021-08-20,"Sinovac CoronaVac","Inactivated","1","1",NA,">14",">= 70 years",">= 70 years","included",NA,"hospitalization","severe","severe","gamma",16.9,5.7,26.8,"Brazil","BRA","South America","Latin America & Caribbean",9410,2019,"Brazil","Upper middle income",3,NA,NA,NA,NA,NA
"119",32,"Ranzani","Test-negative case-control",119,2021-08-20,"Sinovac CoronaVac","Inactivated","2","final",NA,">14",">= 70 years",">= 70 years","included",NA,"hospitalization","severe","severe","gamma",55.5,46.5,62.9,"Brazil","BRA","South America","Latin America & Caribbean",9410,2019,"Brazil","Upper middle income",3,NA,NA,NA,NA,NA
"120",32,"Ranzani","Test-negative case-control",120,2021-08-20,"Sinovac CoronaVac","Inactivated","1","1",NA,">14",">= 70 years",">= 70 years","included",NA,"death","death","death","gamma",31.2,17.6,42.5,"Brazil","BRA","South America","Latin America & Caribbean",9410,2019,"Brazil","Upper middle income",3,NA,NA,NA,NA,NA
"121",32,"Ranzani","Test-negative case-control",121,2021-08-20,"Sinovac CoronaVac","Inactivated","2","final",NA,">14",">= 70 years",">= 70 years","included",NA,"death","death","death","gamma",61.2,48.9,70.5,"Brazil","BRA","South America","Latin America & Caribbean",9410,2019,"Brazil","Upper middle income",3,NA,NA,NA,NA,NA
"122",33,"PHE","Test-negative case-control",122,2021-05-20,"BioNTech/Pfizer BNT162b2","mRNA","1","1",NA,"28+",">= 65 years",">= 65 years","excluded",NA,"symptomatic disease","symptomatic","symptomatic","alpha",54,50,58,"UK","GBR","Europe","Europe & Central Asia",43240,2019,"United Kingdom","High income",4,NA,NA,NA,NA,NA
"123",33,"PHE","Test-negative case-control",123,2021-05-20,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,">14",">= 65 years",">= 65 years","excluded",NA,"symptomatic disease","symptomatic","symptomatic","alpha",90,82,95,"UK","GBR","Europe","Europe & Central Asia",43240,2019,"United Kingdom","High income",4,NA,NA,NA,NA,NA
"124",33,"PHE","Test-negative case-control",124,2021-05-20,"Oxford/AstraZeneca ChAdOx1-S","Vectored","1","1",NA,"28+",">= 65 years",">= 65 years","excluded",NA,"symptomatic disease","symptomatic","symptomatic","alpha",53,49,57,"UK","GBR","Europe","Europe & Central Asia",43240,2019,"United Kingdom","High income",4,NA,NA,NA,NA,NA
"125",33,"PHE","Test-negative case-control",125,2021-05-20,"Oxford/AstraZeneca ChAdOx1-S","Vectored","2","final",NA,">14",">= 65 years",">= 65 years","excluded",NA,"symptomatic disease","symptomatic","symptomatic","alpha",89,78,94,"UK","GBR","Europe","Europe & Central Asia",43240,2019,"United Kingdom","High income",4,NA,NA,NA,NA,NA
"126",34,"Chung","Test-negative case-control",126,2021-08-20,"BioNTech/Pfizer BNT162b2","mRNA","1","1",NA,"14+","general pop","general pop","excluded",NA,"symptomatic disease","symptomatic","symptomatic","other combinations",59,55,62,"Canada","CAN","North America","North America",46580,2019,"Canada","High income",4,NA,NA,NA,NA,NA
"127",34,"Chung","Test-negative case-control",127,2021-08-20,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"7+","general pop","general pop","excluded","15 weeks","symptomatic disease","symptomatic","symptomatic","other combinations",91,88,93,"Canada","CAN","North America","North America",46580,2019,"Canada","High income",4,NA,NA,NA,NA,NA
"128",34,"Chung","Test-negative case-control",128,2021-08-20,"BioNTech/Pfizer BNT162b2","mRNA","1","1",NA,"14+","general pop","general pop","excluded",NA,"hospitalization or death","severe","severe","other combinations",69,59,77,"Canada","CAN","North America","North America",46580,2019,"Canada","High income",4,NA,NA,NA,NA,NA
"129",34,"Chung","Test-negative case-control",129,2021-08-20,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"0+","general pop","general pop","excluded","15 weeks","hospitalization or death","severe","severe","other combinations",96,82,99,"Canada","CAN","North America","North America",46580,2019,"Canada","High income",4,NA,NA,NA,NA,NA
"130",34,"Chung","Test-negative case-control",130,2021-08-20,"Moderna mRNA-1273","mRNA","1","1",NA,"14+","general pop","general pop","excluded",NA,"symptomatic disease","symptomatic","symptomatic","other combinations",72,63,80,"Canada","CAN","North America","North America",46580,2019,"Canada","High income",4,NA,NA,NA,NA,NA
"131",34,"Chung","Test-negative case-control",131,2021-08-20,"Moderna mRNA-1273","mRNA","2","final",NA,"7+","general pop","general pop","excluded","15 weeks","symptomatic disease","symptomatic","symptomatic","other combinations",94,86,97,"Canada","CAN","North America","North America",46580,2019,"Canada","High income",4,NA,NA,NA,NA,NA
"132",34,"Chung","Test-negative case-control",132,2021-08-20,"Moderna mRNA-1273","mRNA","1","1",NA,"14+","general pop","general pop","excluded",NA,"hospitalization or death","severe","severe","other combinations",73,42,87,"Canada","CAN","North America","North America",46580,2019,"Canada","High income",4,NA,NA,NA,NA,NA
"133",34,"Chung","Test-negative case-control",133,2021-08-20,"Moderna mRNA-1273","mRNA","2","final",NA,"0+","general pop","general pop","excluded","15 weeks","hospitalization or death","severe","severe","other combinations",96,74,100,"Canada","CAN","North America","North America",46580,2019,"Canada","High income",4,NA,NA,NA,NA,NA
"134",34,"Chung","Test-negative case-control",134,2021-08-20,"Multiple or heterologous RNA","mRNA","1","1",NA,"14+","general pop","general pop","excluded",NA,"symptomatic disease","symptomatic","symptomatic","alpha",61,56,66,"Canada","CAN","North America","North America",46580,2019,"Canada","High income",4,NA,NA,NA,NA,NA
"135",34,"Chung","Test-negative case-control",135,2021-08-20,"Multiple or heterologous RNA","mRNA","2","final",NA,"7+","general pop","general pop","excluded","15 weeks","symptomatic disease","symptomatic","symptomatic","alpha",90,85,94,"Canada","CAN","North America","North America",46580,2019,"Canada","High income",4,NA,NA,NA,NA,NA
"136",34,"Chung","Test-negative case-control",136,2021-08-20,"Multiple or heterologous RNA","mRNA","1","1",NA,"14+","general pop","general pop","excluded",NA,"hospitalization or death","severe","severe","alpha",59,39,73,"Canada","CAN","North America","North America",46580,2019,"Canada","High income",4,NA,NA,NA,NA,NA
"137",34,"Chung","Test-negative case-control",137,2021-08-20,"Multiple or heterologous RNA","mRNA","2","final",NA,"0+","general pop","general pop","excluded","15 weeks","hospitalization or death","severe","severe","alpha",94,59,99,"Canada","CAN","North America","North America",46580,2019,"Canada","High income",4,NA,NA,NA,NA,NA
"138",34,"Chung","Test-negative case-control",138,2021-08-20,"Multiple or heterologous RNA","mRNA","1","1",NA,"14+","general pop","general pop","excluded",NA,"symptomatic disease","symptomatic","symptomatic","other combinations",43,22,59,"Canada","CAN","North America","North America",46580,2019,"Canada","High income",4,NA,NA,NA,NA,NA
"139",34,"Chung","Test-negative case-control",139,2021-08-20,"Multiple or heterologous RNA","mRNA","2","final",NA,"7+","general pop","general pop","excluded","15 weeks","symptomatic disease","symptomatic","symptomatic","other combinations",88,61,96,"Canada","CAN","North America","North America",46580,2019,"Canada","High income",4,NA,NA,NA,NA,NA
"140",34,"Chung","Test-negative case-control",140,2021-08-20,"Multiple or heterologous RNA","mRNA","1","1","15 weeks","14+","general pop","general pop","excluded",NA,"hospitalization or death","severe","severe","other combinations",56,-9,82,"Canada","CAN","North America","North America",46580,2019,"Canada","High income",4,NA,NA,NA,NA,NA
"141",34,"Chung","Test-negative case-control",141,2021-08-20,"Multiple or heterologous RNA","mRNA","2","final","15 weeks","7+","general pop","general pop","excluded","beta & gamma","hospitalization or death","severe","severe","other combinations",100,NA,NA,"Canada","CAN","North America","North America",46580,2019,"Canada","High income",4,NA,NA,NA,NA,NA
"142",35,"Martinez-Bas","Prospective cohort",142,2021-05-27,"BioNTech/Pfizer BNT162b2","mRNA","1","1",NA,"14+","close contacts","close contacts","excluded",NA,"infection","infection","infection","alpha",21,3,36,"Spain","ESP","Europe","Europe & Central Asia",30370,2019,"Spain","High income",4,NA,NA,NA,NA,NA
"143",35,"Martinez-Bas","Prospective cohort",143,2021-05-27,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"14+","close contacts","close contacts","excluded","12 weeks","infection","infection","infection","alpha",65,56,73,"Spain","ESP","Europe","Europe & Central Asia",30370,2019,"Spain","High income",4,NA,NA,NA,NA,NA
"144",35,"Martinez-Bas","Prospective cohort",144,2021-05-27,"BioNTech/Pfizer BNT162b2","mRNA","1","1",NA,"14+","close contacts","close contacts","excluded",NA,"symptomatic disease","symptomatic","symptomatic","alpha",30,10,45,"Spain","ESP","Europe","Europe & Central Asia",30370,2019,"Spain","High income",4,NA,NA,NA,NA,NA
"145",35,"Martinez-Bas","Prospective cohort",145,2021-05-27,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"14+","close contacts","close contacts","excluded","12 weeks","symptomatic disease","symptomatic","symptomatic","alpha",82,73,88,"Spain","ESP","Europe","Europe & Central Asia",30370,2019,"Spain","High income",4,NA,NA,NA,NA,NA
"146",35,"Martinez-Bas","Prospective cohort",146,2021-05-27,"BioNTech/Pfizer BNT162b2","mRNA","1","1",NA,"14+","close contacts","close contacts","excluded",NA,"hospitalization","severe","severe","alpha",65,25,83,"Spain","ESP","Europe","Europe & Central Asia",30370,2019,"Spain","High income",4,NA,NA,NA,NA,NA
"147",35,"Martinez-Bas","Prospective cohort",147,2021-05-27,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"14+","close contacts","close contacts","excluded","12 weeks","hospitalization","severe","severe","alpha",94,60,99,"Spain","ESP","Europe","Europe & Central Asia",30370,2019,"Spain","High income",4,NA,NA,NA,NA,NA
"148",35,"Martinez-Bas","Prospective cohort",148,2021-05-27,"Oxford/AstraZeneca ChAdOx1-S","Vectored","1","1",NA,"14+","close contacts","close contacts","excluded",NA,"infection","infection","infection","alpha",44,31,54,"Spain","ESP","Europe","Europe & Central Asia",30370,2019,"Spain","High income",4,NA,NA,NA,NA,NA
"149",35,"Martinez-Bas","Prospective cohort",149,2021-05-27,"Oxford/AstraZeneca ChAdOx1-S","Vectored","1","1",NA,"14+","close contacts","close contacts","excluded",NA,"symptomatic disease","symptomatic","symptomatic","alpha",50,37,61,"Spain","ESP","Europe","Europe & Central Asia",30370,2019,"Spain","High income",4,NA,NA,NA,NA,NA
"150",35,"Martinez-Bas","Prospective cohort",150,2021-05-27,"Oxford/AstraZeneca ChAdOx1-S","Vectored","1","1",NA,"14+","close contacts","close contacts","excluded",NA,"hospitalization","severe","severe","alpha",92,46,99,"Spain","ESP","Europe","Europe & Central Asia",30370,2019,"Spain","High income",4,NA,NA,NA,NA,NA
"151",36,"Khan","Retrospective cohort",151,2021-05-31,"Multiple or heterologous RNA","mRNA","1+","1+",NA,"14+ up to 7 days post dose 2","hospital patients","general pop","included",NA,"infection","infection","infection","unknown",-1,-50,32,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"152",36,"Khan","Retrospective cohort",152,2021-05-31,"Multiple or heterologous RNA","mRNA","2","final",NA,"7+","hospital patients","general pop","included","14 weeks","infection","infection","infection","unknown",69,44,83,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"153",36,"Khan","Retrospective cohort",153,2021-05-31,"Multiple or heterologous RNA","mRNA","1+","1+",NA,"14+ up to 7 days post dose 2","hospital patients","general pop","included",NA,"hospitalization or death","severe","severe","unknown",9,-114,61,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"154",36,"Khan","Retrospective cohort",154,2021-05-31,"Multiple or heterologous RNA","mRNA","2","final",NA,"7+","hospital patients","general pop","included","14 weeks","hospitalization or death","severe","severe","unknown",49,-36,81,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"155",37,"Salo","Retrospective cohort",155,2022-03-04,"Multiple or heterologous RNA","mRNA","1","1",NA,"4 weeks","HCW","HCW","excluded",NA,"infection","infection","infection","alpha",44.4,30.4,55.6,"Finland","FIN","Europe","Europe & Central Asia",49950,2019,"Finland","High income",4,NA,NA,NA,NA,NA
"156",37,"Salo","Retrospective cohort",156,2022-03-04,"Multiple or heterologous RNA","mRNA","1+","1+",NA,"12 weeks (inlcudes 2 dose recipients)","HCW","HCW","excluded",NA,"infection","infection","infection","alpha",63,56.3,68.7,"Finland","FIN","Europe","Europe & Central Asia",49950,2019,"Finland","High income",4,NA,NA,NA,NA,NA
"157",38,"Thompson","Cohort",157,2021-06-30,"BioNTech/Pfizer BNT162b2","mRNA","1+","1+",NA,">14 up to 13 days post dose 2","HCW","HCW","excluded",NA,"infection","infection","infection","original",80,60,90,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"158",38,"Thompson","Cohort",158,2021-06-30,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,">14","HCW","HCW","excluded","13 weeks","infection","infection","infection","original",93,78,98,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"159",38,"Thompson","Cohort",159,2021-06-30,"Moderna mRNA-1273","mRNA","1+","1+",NA,">14 up to 13 days post dose 2","HCW","HCW","excluded",NA,"infection","infection","infection","original",83,40,95,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"160",38,"Thompson","Cohort",160,2021-06-30,"Moderna mRNA-1273","mRNA","2","final",NA,">14","HCW","HCW","excluded",NA,"infection","infection","infection","original",82,20,96,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"161",39,"Emborg","Cohort",161,2021-06-30,"BioNTech/Pfizer BNT162b2","mRNA","1","1",NA,">14","priority groups","priority groups","excluded",NA,"infection","infection","infection","other combinations",7,-1,15,"Denmark","DNK","Europe","Europe & Central Asia",63020,2019,"Denmark","High income",4,NA,NA,NA,NA,NA
"162",39,"Emborg","Cohort",162,2021-06-30,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,">7","priority groups","priority groups","excluded","10 weeks","infection","infection","infection","other combinations",82,79,84,"Denmark","DNK","Europe","Europe & Central Asia",63020,2019,"Denmark","High income",4,NA,NA,NA,NA,NA
"163",39,"Emborg","Cohort",163,2021-06-30,"BioNTech/Pfizer BNT162b2","mRNA","1","1",NA,">14","priority groups","priority groups","excluded",NA,"hospitalization","severe","severe","other combinations",35,18,49,"Denmark","DNK","Europe","Europe & Central Asia",63020,2019,"Denmark","High income",4,NA,NA,NA,NA,NA
"164",39,"Emborg","Cohort",164,2021-06-30,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,">7","priority groups","priority groups","excluded","10 weeks","hospitalization","severe","severe","other combinations",93,89,96,"Denmark","DNK","Europe","Europe & Central Asia",63020,2019,"Denmark","High income",4,NA,NA,NA,NA,NA
"165",39,"Emborg","Cohort",165,2021-06-30,"BioNTech/Pfizer BNT162b2","mRNA","1","1",NA,">14","priority groups","priority groups","excluded",NA,"death","death","death","other combinations",7,-15,25,"Denmark","DNK","Europe","Europe & Central Asia",63020,2019,"Denmark","High income",4,NA,NA,NA,NA,NA
"166",39,"Emborg","Cohort",166,2021-06-30,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,">7","priority groups","priority groups","excluded","10 weeks","death","death","death","other combinations",94,90,96,"Denmark","DNK","Europe","Europe & Central Asia",63020,2019,"Denmark","High income",4,NA,NA,NA,NA,NA
"167",40,"Skowornski","Test-negative case-control",167,2021-07-09,"Multiple or heterologous RNA","mRNA","1","1",NA,"21+","> 70 years","> 70 years","included",NA,"infection","infection","infection","alpha",67,57,75,"Canada","CAN","North America","North America",46580,2019,"Canada","High income",4,NA,NA,NA,NA,NA
"168",40,"Skowornski","Test-negative case-control",168,2021-07-09,"Multiple or heterologous RNA","mRNA","1","1",NA,"21+","> 70 years","> 70 years","included",NA,"infection","infection","infection","gamma",61,45,72,"Canada","CAN","North America","North America",46580,2019,"Canada","High income",4,NA,NA,NA,NA,NA
"169",40,"Skowornski","Test-negative case-control",169,2021-07-09,"Multiple or heterologous RNA","mRNA","1","1",NA,"21+","> 70 years","> 70 years","included",NA,"infection","infection","infection","original",72,58,81,"Canada","CAN","North America","North America",46580,2019,"Canada","High income",4,NA,NA,NA,NA,NA
"170",40,"Skowornski","Test-negative case-control",170,2021-07-09,"BioNTech/Pfizer BNT162b2","mRNA","1","1",NA,"21+","> 70 years","> 70 years","included",NA,"infection","infection","infection","other combinations",64,57,71,"Canada","CAN","North America","North America",46580,2019,"Canada","High income",4,NA,NA,NA,NA,NA
"171",40,"Skowornski","Test-negative case-control",171,2021-07-09,"Moderna mRNA-1273","mRNA","1","1",NA,"21+","> 70 years","> 70 years","included",NA,"infection","infection","infection","other combinations",71,56,81,"Canada","CAN","North America","North America",46580,2019,"Canada","High income",4,NA,NA,NA,NA,NA
"172",41,"Flacco","Retrospective cohort",172,2021-06-10,"BioNTech/Pfizer BNT162b2","mRNA","1","1",NA,"14+","general pop","general pop","unknown",NA,"infection","infection","infection","other combinations",55,40,66,"Italy","ITA","Europe","Europe & Central Asia",34890,2019,"Italy","High income",4,NA,NA,NA,NA,NA
"173",41,"Flacco","Retrospective cohort",173,2021-06-10,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"14+","general pop","general pop","unknown","~14 weeks","infection","infection","infection","other combinations",98,97,99,"Italy","ITA","Europe","Europe & Central Asia",34890,2019,"Italy","High income",4,NA,NA,NA,NA,NA
"174",41,"Flacco","Retrospective cohort",174,2021-06-10,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"14+","general pop","general pop","unknown","~14 weeks","hospitalization","severe","severe","other combinations",99,96,100,"Italy","ITA","Europe","Europe & Central Asia",34890,2019,"Italy","High income",4,NA,NA,NA,NA,NA
"175",41,"Flacco","Retrospective cohort",175,2021-06-10,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"14+","general pop","general pop","unknown","~14 weeks","death","death","death","other combinations",98,87,100,"Italy","ITA","Europe","Europe & Central Asia",34890,2019,"Italy","High income",4,NA,NA,NA,NA,NA
"176",41,"Flacco","Retrospective cohort",176,2021-06-10,"Moderna mRNA-1273","mRNA","1","1",NA,"14+","general pop","general pop","unknown",NA,"infection","infection","infection","other combinations",93,74,98,"Italy","ITA","Europe","Europe & Central Asia",34890,2019,"Italy","High income",4,NA,NA,NA,NA,NA
"177",41,"Flacco","Retrospective cohort",177,2021-06-10,"Oxford/AstraZeneca ChAdOx1-S","Vectored","1","1",NA,"21+","general pop","general pop","unknown",NA,"infection","infection","infection","other combinations",95,92,97,"Italy","ITA","Europe","Europe & Central Asia",34890,2019,"Italy","High income",4,NA,NA,NA,NA,NA
"178",42,"Sheikh","Test-negative case-control",178,2021-06-14,"BioNTech/Pfizer BNT162b2","mRNA","1","1",NA,"28+","general pop","general pop","unknown",NA,"infection","infection","infection","alpha",38,29,45,"UK","GBR","Europe","Europe & Central Asia",43240,2019,"United Kingdom","High income",4,NA,NA,NA,NA,NA
"179",42,"Sheikh","Test-negative case-control",179,2021-06-14,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"14+","general pop","general pop","unknown","~20 weeks","infection","infection","infection","alpha",92,90,93,"UK","GBR","Europe","Europe & Central Asia",43240,2019,"United Kingdom","High income",4,NA,NA,NA,NA,NA
"180",42,"Sheikh","Test-negative case-control",180,2021-06-14,"Oxford/AstraZeneca ChAdOx1-S","Vectored","1","1",NA,"28+","general pop","general pop","unknown",NA,"infection","infection","infection","alpha",37,32,42,"UK","GBR","Europe","Europe & Central Asia",43240,2019,"United Kingdom","High income",4,NA,NA,NA,NA,NA
"181",42,"Sheikh","Test-negative case-control",181,2021-06-14,"Oxford/AstraZeneca ChAdOx1-S","Vectored","2","final",NA,"14+","general pop","general pop","unknown","~20 weeks","infection","infection","infection","alpha",73,66,78,"UK","GBR","Europe","Europe & Central Asia",43240,2019,"United Kingdom","High income",4,NA,NA,NA,NA,NA
"182",42,"Sheikh","Test-negative case-control",182,2021-06-14,"BioNTech/Pfizer BNT162b2","mRNA","1","1",NA,"28+","general pop","general pop","unknown",NA,"infection","infection","infection","delta",30,17,41,"UK","GBR","Europe","Europe & Central Asia",43240,2019,"United Kingdom","High income",4,NA,NA,NA,NA,NA
"183",42,"Sheikh","Test-negative case-control",183,2021-06-14,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"14+","general pop","general pop","unknown","~20 weeks","infection","infection","infection","delta",79,75,82,"UK","GBR","Europe","Europe & Central Asia",43240,2019,"United Kingdom","High income",4,NA,NA,NA,NA,NA
"184",42,"Sheikh","Test-negative case-control",184,2021-06-14,"Oxford/AstraZeneca ChAdOx1-S","Vectored","1","1",NA,"28+","general pop","general pop","unknown",NA,"infection","infection","infection","delta",18,9,25,"UK","GBR","Europe","Europe & Central Asia",43240,2019,"United Kingdom","High income",4,NA,NA,NA,NA,NA
"185",42,"Sheikh","Test-negative case-control",185,2021-06-14,"Oxford/AstraZeneca ChAdOx1-S","Vectored","2","final",NA,"14+","general pop","general pop","unknown","~20 weeks","infection","infection","infection","delta",60,53,66,"UK","GBR","Europe","Europe & Central Asia",43240,2019,"United Kingdom","High income",4,NA,NA,NA,NA,NA
"186",43,"Stowe","Test-negative case-control",186,2021-06-14,"BioNTech/Pfizer BNT162b2","mRNA","1","1",NA,"21+","hospital patients","general pop","included",NA,"hospitalization","severe","severe","alpha",83,62,93,"UK","GBR","Europe","Europe & Central Asia",43240,2019,"United Kingdom","High income",4,NA,NA,NA,NA,NA
"187",43,"Stowe","Test-negative case-control",187,2021-06-14,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"14+","hospital patients","general pop","included","~20 weeks","hospitalization","severe","severe","alpha",95,78,99,"UK","GBR","Europe","Europe & Central Asia",43240,2019,"United Kingdom","High income",4,NA,NA,NA,NA,NA
"188",43,"Stowe","Test-negative case-control",188,2021-06-14,"Oxford/AstraZeneca ChAdOx1-S","Vectored","1","1",NA,"21+","hospital patients","general pop","included",NA,"hospitalization","severe","severe","alpha",76,61,85,"UK","GBR","Europe","Europe & Central Asia",43240,2019,"United Kingdom","High income",4,NA,NA,NA,NA,NA
"189",43,"Stowe","Test-negative case-control",189,2021-06-14,"Oxford/AstraZeneca ChAdOx1-S","Vectored","2","final",NA,"14+","hospital patients","general pop","included","~20 weeks","hospitalization","severe","severe","alpha",86,53,96,"UK","GBR","Europe","Europe & Central Asia",43240,2019,"United Kingdom","High income",4,NA,NA,NA,NA,NA
"190",43,"Stowe","Test-negative case-control",190,2021-06-14,"BioNTech/Pfizer BNT162b2","mRNA","1","1",NA,"21+","hospital patients","general pop","included",NA,"hospitalization","severe","severe","delta",94,46,99,"UK","GBR","Europe","Europe & Central Asia",43240,2019,"United Kingdom","High income",4,NA,NA,NA,NA,NA
"191",43,"Stowe","Test-negative case-control",191,2021-06-14,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"14+","hospital patients","general pop","included","~20 weeks","hospitalization","severe","severe","delta",96,86,99,"UK","GBR","Europe","Europe & Central Asia",43240,2019,"United Kingdom","High income",4,14,140,"yes",NA,0
"192",43,"Stowe","Test-negative case-control",192,2021-06-14,"Oxford/AstraZeneca ChAdOx1-S","Vectored","1","1",NA,"21+","hospital patients","general pop","included",NA,"hospitalization","severe","severe","delta",71,51,83,"UK","GBR","Europe","Europe & Central Asia",43240,2019,"United Kingdom","High income",4,NA,NA,NA,NA,NA
"193",43,"Stowe","Test-negative case-control",193,2021-06-14,"Oxford/AstraZeneca ChAdOx1-S","Vectored","2","final",NA,"14+","hospital patients","general pop","included","~20 weeks","hospitalization","severe","severe","delta",92,75,97,"UK","GBR","Europe","Europe & Central Asia",43240,2019,"United Kingdom","High income",4,14,140,"yes",NA,0
"194",44,"Azamgarhi","Retrospective cohort",194,2021-06-17,"BioNTech/Pfizer BNT162b2","mRNA","1","1",NA,">14","HCW","HCW","excluded",NA,"infection","infection","infection","other combinations",70,6,91,"UK","GBR","Europe","Europe & Central Asia",43240,2019,"United Kingdom","High income",4,NA,NA,NA,NA,NA
"195",45,"Young-Xu","Test-negative case-control",195,2021-10-06,"Multiple or heterologous RNA","mRNA","1","1",NA,"7+","general pop","general pop","excluded",NA,"infection","infection","infection","other combinations",58,54,62,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"196",45,"Young-Xu","Test-negative case-control",196,2021-10-06,"Multiple or heterologous RNA","mRNA","2","final",NA,"7+","general pop","general pop","excluded","~8 weeks","infection","infection","infection","other combinations",94,92,95,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"197",45,"Young-Xu","Test-negative case-control",197,2021-10-06,"Multiple or heterologous RNA","mRNA","1","1",NA,"7+","general pop","general pop","excluded",NA,"hospitalization","severe","severe","other combinations",40,27,50,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"198",45,"Young-Xu","Test-negative case-control",198,2021-10-06,"Multiple or heterologous RNA","mRNA","2","final",NA,"7+","general pop","general pop","excluded","~8 weeks","hospitalization","severe","severe","other combinations",89,81,93,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"199",45,"Young-Xu","Test-negative case-control",199,2021-10-06,"Multiple or heterologous RNA","mRNA","1","1",NA,"7+","general pop","general pop","excluded",NA,"death","death","death","other combinations",55,21,74,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"200",45,"Young-Xu","Test-negative case-control",200,2021-10-06,"Multiple or heterologous RNA","mRNA","2","final",NA,"7+","general pop","general pop","excluded","~8 weeks","death","death","death","other combinations",98.5,86.6,99.8,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"201",45,"Young-Xu","Test-negative case-control",201,2021-10-06,"Multiple or heterologous RNA","mRNA","1","1",NA,"7+","general pop","general pop","excluded",NA,"asymptomatic infection","asymptomatic","infection","other combinations",58,41.7,69.7,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"202",45,"Young-Xu","Test-negative case-control",202,2021-10-06,"Multiple or heterologous RNA","mRNA","2","final",NA,"7+","general pop","general pop","excluded","~8 weeks","asymptomatic infection","asymptomatic","infection","other combinations",69.7,47.7,82.5,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"203",45,"Young-Xu","Test-negative case-control",203,2021-10-06,"Multiple or heterologous RNA","mRNA","1","1",NA,"7+","general pop","general pop","excluded",NA,"hospitalization","severe","severe","other combinations",53,25.7,70.3,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"204",45,"Young-Xu","Test-negative case-control",204,2021-10-06,"Multiple or heterologous RNA","mRNA","2","final",NA,"7+","general pop","general pop","excluded","~8 weeks","hospitalization","severe","severe","other combinations",88.4,74.9,94.7,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"205",45,"Young-Xu","Test-negative case-control",205,2021-10-06,"Multiple or heterologous RNA","mRNA","1","1",NA,"7+","general pop","general pop","excluded",NA,"death","death","death","other combinations",55.6,26.6,73.2,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"206",45,"Young-Xu","Test-negative case-control",206,2021-10-06,"Multiple or heterologous RNA","mRNA","2","final",NA,"7+","general pop","general pop","excluded","~8 weeks","death","death","death","other combinations",97,91.7,98.9,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"207",46,"Pawlowski","Retrospective cohort",207,2021-06-17,"BioNTech/Pfizer BNT162b2","mRNA","1","1",NA,">14","general pop","general pop","excluded",NA,"infection","infection","infection","other combinations",61,50.8,69.2,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"208",46,"Pawlowski","Retrospective cohort",208,2021-06-17,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,">14","general pop","general pop","excluded","~17 weeks","infection","infection","infection","other combinations",88,84.2,91,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"209",46,"Pawlowski","Retrospective cohort",209,2021-06-17,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,">14","general pop","general pop","excluded","~17 weeks","hospitalization","severe","severe","other combinations",88.3,72.6,95.9,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"210",46,"Pawlowski","Retrospective cohort",210,2021-06-17,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,">14","general pop","general pop","excluded","~17 weeks","ICU admission","severe","severe","other combinations",100,18.7,100,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"211",46,"Pawlowski","Retrospective cohort",211,2021-06-17,"Moderna mRNA-1273","mRNA","1","1",NA,">14","general pop","general pop","excluded",NA,"infection","infection","infection","other combinations",66.6,51.9,77.3,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"212",46,"Pawlowski","Retrospective cohort",212,2021-06-17,"Moderna mRNA-1273","mRNA","2","final",NA,">14","general pop","general pop","excluded","~17 weeks","infection","infection","infection","other combinations",92.3,82.4,97.3,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"213",46,"Pawlowski","Retrospective cohort",213,2021-06-17,"Moderna mRNA-1273","mRNA","2","final",NA,">14","general pop","general pop","excluded","~17 weeks","hospitalization","severe","severe","other combinations",90.6,76.5,97.1,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"214",46,"Pawlowski","Retrospective cohort",214,2021-06-17,"Moderna mRNA-1273","mRNA","2","final",NA,">14","general pop","general pop","excluded","~17 weeks","ICU admission","severe","severe","other combinations",100,17.9,100,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"215",47,"Saciuk","Retrospective cohort",215,2021-12-30,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"7+","general pop","general pop","excluded","14 weeks","infection","infection","infection","other combinations",93,92.6,93.4,"Israel","ISR","Asia","Middle East & North Africa",43800,2019,"Israel","High income",4,NA,NA,NA,NA,NA
"216",47,"Saciuk","Retrospective cohort",216,2021-12-30,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"7+","general pop","general pop","excluded","14 weeks","hospitalization","severe","severe","other combinations",93.4,91.9,94.7,"Israel","ISR","Asia","Middle East & North Africa",43800,2019,"Israel","High income",4,NA,NA,NA,NA,NA
"217",47,"Saciuk","Retrospective cohort",217,2021-12-30,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"7+","general pop","general pop","excluded","14 weeks","death","death","death","other combinations",91.1,86.5,94.1,"Israel","ISR","Asia","Middle East & North Africa",43800,2019,"Israel","High income",4,NA,NA,NA,NA,NA
"218",48,"Baum","Prospective cohort",218,2021-11-18,"Multiple or heterologous RNA","mRNA","1","1",NA,"21+",">= 70 years",">= 70 years","excluded",NA,"infection","infection","infection","other combinations",45,36,53,"Finland","FIN","Europe","Europe & Central Asia",49950,2019,"Finland","High income",4,NA,NA,NA,NA,NA
"219",48,"Baum","Prospective cohort",219,2021-11-18,"Multiple or heterologous RNA","mRNA","2","final",NA,"7+",">= 70 years",">= 70 years","excluded","16 weeks","infection","infection","infection","other combinations",75,65,82,"Finland","FIN","Europe","Europe & Central Asia",49950,2019,"Finland","High income",4,NA,NA,NA,NA,NA
"220",48,"Baum","Prospective cohort",220,2021-11-18,"Multiple or heterologous RNA","mRNA","1","1",NA,"21+",">= 70 years",">= 70 years","excluded",NA,"hospitalization","severe","severe","other combinations",63,49,74,"Finland","FIN","Europe","Europe & Central Asia",49950,2019,"Finland","High income",4,NA,NA,NA,NA,NA
"221",48,"Baum","Prospective cohort",221,2021-11-18,"Multiple or heterologous RNA","mRNA","2","final",NA,"7+",">= 70 years",">= 70 years","excluded","16 weeks","hospitalization","severe","severe","other combinations",93,70,98,"Finland","FIN","Europe","Europe & Central Asia",49950,2019,"Finland","High income",4,NA,NA,NA,NA,NA
"222",48,"Baum","Prospective cohort",222,2021-11-18,"Multiple or heterologous RNA","mRNA","1","1",NA,"21+","chronically ill","chronically ill","excluded",NA,"infection","infection","infection","other combinations",40,26,51,"Finland","FIN","Europe","Europe & Central Asia",49950,2019,"Finland","High income",4,NA,NA,NA,NA,NA
"223",48,"Baum","Prospective cohort",223,2021-11-18,"Multiple or heterologous RNA","mRNA","2","final",NA,"7+","chronically ill","chronically ill","excluded","16 weeks","infection","infection","infection","other combinations",77,65,85,"Finland","FIN","Europe","Europe & Central Asia",49950,2019,"Finland","High income",4,NA,NA,NA,NA,NA
"224",48,"Baum","Prospective cohort",224,2021-11-18,"Multiple or heterologous RNA","mRNA","1","1",NA,"21+","chronically ill","chronically ill","excluded",NA,"hospitalization","severe","severe","other combinations",82,56,93,"Finland","FIN","Europe","Europe & Central Asia",49950,2019,"Finland","High income",4,NA,NA,NA,NA,NA
"225",48,"Baum","Prospective cohort",225,2021-11-18,"Multiple or heterologous RNA","mRNA","2","final",NA,"7+","chronically ill","chronically ill","excluded","16 weeks","hospitalization","severe","severe","other combinations",90,29,99,"Finland","FIN","Europe","Europe & Central Asia",49950,2019,"Finland","High income",4,NA,NA,NA,NA,NA
"226",48,"Baum","Prospective cohort",226,2021-11-18,"Oxford/AstraZeneca ChAdOx1-S","Vectored","1","1",NA,"21+","chronically ill","chronically ill","excluded",NA,"infection","infection","infection","other combinations",42,32,50,"Finland","FIN","Europe","Europe & Central Asia",49950,2019,"Finland","High income",4,NA,NA,NA,NA,NA
"227",48,"Baum","Prospective cohort",227,2021-11-18,"Oxford/AstraZeneca ChAdOx1-S","Vectored","1","1",NA,"21+","chronically ill","chronically ill","excluded",NA,"hospitalization","severe","severe","other combinations",62,42,75,"Finland","FIN","Europe","Europe & Central Asia",49950,2019,"Finland","High income",4,NA,NA,NA,NA,NA
"228",49,"Nasreen","Test-negative case-control",228,2022-02-07,"BioNTech/Pfizer BNT162b2","mRNA","1","1",NA,"14+","general pop","general pop","unknown",NA,"symptomatic disease","symptomatic","symptomatic","original",63,56,68,"Canada","CAN","North America","North America",46580,2019,"Canada","High income",4,NA,NA,NA,NA,NA
"229",49,"Nasreen","Test-negative case-control",229,2022-02-07,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"14+","general pop","general pop","unknown","18 weeks","symptomatic disease","symptomatic","symptomatic","original",92,87,95,"Canada","CAN","North America","North America",46580,2019,"Canada","High income",4,NA,NA,NA,NA,NA
"230",49,"Nasreen","Test-negative case-control",230,2022-02-07,"BioNTech/Pfizer BNT162b2","mRNA","1","1",NA,"14+","general pop","general pop","unknown",NA,"hospitalization or death","severe","severe","original",77,67,84,"Canada","CAN","North America","North America",46580,2019,"Canada","High income",4,NA,NA,NA,NA,NA
"231",49,"Nasreen","Test-negative case-control",231,2022-02-07,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"14+","general pop","general pop","unknown","18 weeks","hospitalization or death","severe","severe","original",97,88,99,"Canada","CAN","North America","North America",46580,2019,"Canada","High income",4,NA,NA,NA,NA,NA
"232",49,"Nasreen","Test-negative case-control",232,2022-02-07,"Moderna mRNA-1273","mRNA","1","1",NA,"14+","general pop","general pop","unknown",NA,"symptomatic disease","symptomatic","symptomatic","original",63,47,74,"Canada","CAN","North America","North America",46580,2019,"Canada","High income",4,NA,NA,NA,NA,NA
"233",49,"Nasreen","Test-negative case-control",233,2022-02-07,"Moderna mRNA-1273","mRNA","2","final",NA,"14+","general pop","general pop","unknown","18 weeks","symptomatic disease","symptomatic","symptomatic","original",98,83,100,"Canada","CAN","North America","North America",46580,2019,"Canada","High income",4,NA,NA,NA,NA,NA
"234",49,"Nasreen","Test-negative case-control",234,2022-02-07,"Moderna mRNA-1273","mRNA","1","1",NA,"14+","general pop","general pop","unknown",NA,"hospitalization or death","severe","severe","original",66,43,80,"Canada","CAN","North America","North America",46580,2019,"Canada","High income",4,NA,NA,NA,NA,NA
"235",49,"Nasreen","Test-negative case-control",235,2022-02-07,"Moderna mRNA-1273","mRNA","2","final",NA,"14+","general pop","general pop","unknown","18 weeks","hospitalization or death","severe","severe","original",100,NA,NA,"Canada","CAN","North America","North America",46580,2019,"Canada","High income",4,NA,NA,NA,NA,NA
"236",49,"Nasreen","Test-negative case-control",236,2022-02-07,"Oxford/AstraZeneca ChAdOx1-S","Vectored","1","1",NA,"14+","general pop","general pop","unknown",NA,"symptomatic disease","symptomatic","symptomatic","original",67,44,81,"Canada","CAN","North America","North America",46580,2019,"Canada","High income",4,NA,NA,NA,NA,NA
"237",49,"Nasreen","Test-negative case-control",237,2022-02-07,"Oxford/AstraZeneca ChAdOx1-S","Vectored","2","final",NA,"14+","general pop","general pop","unknown","~3 weeks","symptomatic disease","symptomatic","symptomatic","original",100,NA,NA,"Canada","CAN","North America","North America",46580,2019,"Canada","High income",4,NA,NA,NA,NA,NA
"238",49,"Nasreen","Test-negative case-control",238,2022-02-07,"Oxford/AstraZeneca ChAdOx1-S","Vectored","1","1",NA,"14+","general pop","general pop","unknown",NA,"hospitalization or death","severe","severe","original",92,45,99,"Canada","CAN","North America","North America",46580,2019,"Canada","High income",4,NA,NA,NA,NA,NA
"239",49,"Nasreen","Test-negative case-control",239,2022-02-07,"Oxford/AstraZeneca ChAdOx1-S","Vectored","2","final",NA,"14+","general pop","general pop","unknown","~3 weeks","hospitalization or death","severe","severe","original",100,NA,NA,"Canada","CAN","North America","North America",46580,2019,"Canada","High income",4,NA,NA,NA,NA,NA
"240",49,"Nasreen","Test-negative case-control",240,2022-02-07,"BioNTech/Pfizer BNT162b2","mRNA","1","1",NA,"14+","general pop","general pop","unknown",NA,"symptomatic disease","symptomatic","symptomatic","alpha",67,65,68,"Canada","CAN","North America","North America",46580,2019,"Canada","High income",4,NA,NA,NA,NA,NA
"241",49,"Nasreen","Test-negative case-control",241,2022-02-07,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"14+","general pop","general pop","unknown","~28 weeks","symptomatic disease","symptomatic","symptomatic","alpha",88,86,90,"Canada","CAN","North America","North America",46580,2019,"Canada","High income",4,NA,NA,NA,NA,NA
"242",49,"Nasreen","Test-negative case-control",242,2022-02-07,"BioNTech/Pfizer BNT162b2","mRNA","1","1",NA,"14+","general pop","general pop","unknown",NA,"hospitalization or death","severe","severe","alpha",82,81,84,"Canada","CAN","North America","North America",46580,2019,"Canada","High income",4,NA,NA,NA,NA,NA
"243",49,"Nasreen","Test-negative case-control",243,2022-02-07,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"14+","general pop","general pop","unknown","~28 weeks","hospitalization or death","severe","severe","alpha",96,94,97,"Canada","CAN","North America","North America",46580,2019,"Canada","High income",4,NA,NA,NA,NA,NA
"244",49,"Nasreen","Test-negative case-control",244,2022-02-07,"Moderna mRNA-1273","mRNA","1","1",NA,"14+","general pop","general pop","unknown",NA,"symptomatic disease","symptomatic","symptomatic","alpha",82,80,84,"Canada","CAN","North America","North America",46580,2019,"Canada","High income",4,NA,NA,NA,NA,NA
"245",49,"Nasreen","Test-negative case-control",245,2022-02-07,"Moderna mRNA-1273","mRNA","2","final",NA,"14+","general pop","general pop","unknown","~25 weeks","symptomatic disease","symptomatic","symptomatic","alpha",92,87,95,"Canada","CAN","North America","North America",46580,2019,"Canada","High income",4,NA,NA,NA,NA,NA
"246",49,"Nasreen","Test-negative case-control",246,2022-02-07,"Moderna mRNA-1273","mRNA","1","1",NA,"14+","general pop","general pop","unknown",NA,"hospitalization or death","severe","severe","alpha",80,76,84,"Canada","CAN","North America","North America",46580,2019,"Canada","High income",4,NA,NA,NA,NA,NA
"247",49,"Nasreen","Test-negative case-control",247,2022-02-07,"Moderna mRNA-1273","mRNA","2","final",NA,"14+","general pop","general pop","unknown","~25 weeks","hospitalization or death","severe","severe","alpha",95,92,97,"Canada","CAN","North America","North America",46580,2019,"Canada","High income",4,NA,NA,NA,NA,NA
"248",49,"Nasreen","Test-negative case-control",248,2022-02-07,"Oxford/AstraZeneca ChAdOx1-S","Vectored","1","1",NA,"14+","general pop","general pop","unknown",NA,"symptomatic disease","symptomatic","symptomatic","alpha",63,59,66,"Canada","CAN","North America","North America",46580,2019,"Canada","High income",4,NA,NA,NA,NA,NA
"249",49,"Nasreen","Test-negative case-control",249,2022-02-07,"Oxford/AstraZeneca ChAdOx1-S","Vectored","2","final",NA,"14+","general pop","general pop","unknown","~3 weeks","symptomatic disease","symptomatic","symptomatic","alpha",87,47,97,"Canada","CAN","North America","North America",46580,2019,"Canada","High income",4,NA,NA,NA,NA,NA
"250",49,"Nasreen","Test-negative case-control",250,2022-02-07,"Oxford/AstraZeneca ChAdOx1-S","Vectored","1","1",NA,"14+","general pop","general pop","unknown",NA,"hospitalization or death","severe","severe","alpha",87,83,90,"Canada","CAN","North America","North America",46580,2019,"Canada","High income",4,NA,NA,NA,NA,NA
"251",49,"Nasreen","Test-negative case-control",251,2022-02-07,"Oxford/AstraZeneca ChAdOx1-S","Vectored","2","final",NA,"14+","general pop","general pop","unknown","~3 weeks","hospitalization or death","severe","severe","alpha",92,41,99,"Canada","CAN","North America","North America",46580,2019,"Canada","High income",4,NA,NA,NA,NA,NA
"252",49,"Nasreen","Test-negative case-control",252,2022-02-07,"BioNTech/Pfizer BNT162b2","mRNA","1","1",NA,"14+","general pop","general pop","unknown",NA,"symptomatic disease","symptomatic","symptomatic","beta",50,15,70,"Canada","CAN","North America","North America",46580,2019,"Canada","High income",4,NA,NA,NA,NA,NA
"253",49,"Nasreen","Test-negative case-control",253,2022-02-07,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"14+","general pop","general pop","unknown","~28 weeks","symptomatic disease","symptomatic","symptomatic","beta",86,0,98,"Canada","CAN","North America","North America",46580,2019,"Canada","High income",4,NA,NA,NA,NA,NA
"254",49,"Nasreen","Test-negative case-control",254,2022-02-07,"BioNTech/Pfizer BNT162b2","mRNA","1","1",NA,"14+","general pop","general pop","unknown",NA,"hospitalization or death","severe","severe","beta",64,31,82,"Canada","CAN","North America","North America",46580,2019,"Canada","High income",4,NA,NA,NA,NA,NA
"255",49,"Nasreen","Test-negative case-control",255,2022-02-07,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"14+","general pop","general pop","unknown","~28 weeks","hospitalization or death","severe","severe","beta",92,39,99,"Canada","CAN","North America","North America",46580,2019,"Canada","High income",4,NA,NA,NA,NA,NA
"256",49,"Nasreen","Test-negative case-control",256,2022-02-07,"Moderna mRNA-1273","mRNA","2","final",NA,"14+","general pop","general pop","unknown","~25 weeks","symptomatic disease","symptomatic","symptomatic","beta",100,NA,NA,"Canada","CAN","North America","North America",46580,2019,"Canada","High income",4,NA,NA,NA,NA,NA
"257",49,"Nasreen","Test-negative case-control",257,2022-02-07,"Moderna mRNA-1273","mRNA","1","1",NA,"14+","general pop","general pop","unknown",NA,"hospitalization or death","severe","severe","beta",59,-77,90,"Canada","CAN","North America","North America",46580,2019,"Canada","High income",4,NA,NA,NA,NA,NA
"258",49,"Nasreen","Test-negative case-control",258,2022-02-07,"Moderna mRNA-1273","mRNA","2","final",NA,"14+","general pop","general pop","unknown","~25 weeks","hospitalization or death","severe","severe","beta",100,NA,NA,"Canada","CAN","North America","North America",46580,2019,"Canada","High income",4,NA,NA,NA,NA,NA
"259",49,"Nasreen","Test-negative case-control",259,2022-02-07,"Oxford/AstraZeneca ChAdOx1-S","Vectored","1","1",NA,"14+","general pop","general pop","unknown",NA,"symptomatic disease","symptomatic","symptomatic","beta",84,-13,98,"Canada","CAN","North America","North America",46580,2019,"Canada","High income",4,NA,NA,NA,NA,NA
"260",49,"Nasreen","Test-negative case-control",260,2022-02-07,"Oxford/AstraZeneca ChAdOx1-S","Vectored","2","final",NA,"14+","general pop","general pop","unknown","~3 weeks","symptomatic disease","symptomatic","symptomatic","beta",100,NA,NA,"Canada","CAN","North America","North America",46580,2019,"Canada","High income",4,NA,NA,NA,NA,NA
"261",49,"Nasreen","Test-negative case-control",261,2022-02-07,"Oxford/AstraZeneca ChAdOx1-S","Vectored","1","1",NA,"14+","general pop","general pop","unknown",NA,"hospitalization or death","severe","severe","beta",61,-64,91,"Canada","CAN","North America","North America",46580,2019,"Canada","High income",4,NA,NA,NA,NA,NA
"262",49,"Nasreen","Test-negative case-control",262,2022-02-07,"BioNTech/Pfizer BNT162b2","mRNA","1","1",NA,"14+","general pop","general pop","unknown",NA,"symptomatic disease","symptomatic","symptomatic","gamma",63,54,70,"Canada","CAN","North America","North America",46580,2019,"Canada","High income",4,NA,NA,NA,NA,NA
"263",49,"Nasreen","Test-negative case-control",263,2022-02-07,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"14+","general pop","general pop","unknown","~28 weeks","symptomatic disease","symptomatic","symptomatic","gamma",90,76,96,"Canada","CAN","North America","North America",46580,2019,"Canada","High income",4,NA,NA,NA,NA,NA
"264",49,"Nasreen","Test-negative case-control",264,2022-02-07,"BioNTech/Pfizer BNT162b2","mRNA","1","1",NA,"14+","general pop","general pop","unknown",NA,"hospitalization or death","severe","severe","gamma",80,70,87,"Canada","CAN","North America","North America",46580,2019,"Canada","High income",4,NA,NA,NA,NA,NA
"265",49,"Nasreen","Test-negative case-control",265,2022-02-07,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"14+","general pop","general pop","unknown","~28 weeks","hospitalization or death","severe","severe","gamma",94,59,99,"Canada","CAN","North America","North America",46580,2019,"Canada","High income",4,NA,NA,NA,NA,NA
"266",49,"Nasreen","Test-negative case-control",266,2022-02-07,"Moderna mRNA-1273","mRNA","1","1",NA,"14+","general pop","general pop","unknown",NA,"symptomatic disease","symptomatic","symptomatic","gamma",89,76,95,"Canada","CAN","North America","North America",46580,2019,"Canada","High income",4,NA,NA,NA,NA,NA
"267",49,"Nasreen","Test-negative case-control",267,2022-02-07,"Moderna mRNA-1273","mRNA","2","final",NA,"14+","general pop","general pop","unknown","~25 weeks","symptomatic disease","symptomatic","symptomatic","gamma",100,NA,NA,"Canada","CAN","North America","North America",46580,2019,"Canada","High income",4,NA,NA,NA,NA,NA
"268",49,"Nasreen","Test-negative case-control",268,2022-02-07,"Moderna mRNA-1273","mRNA","1","1",NA,"14+","general pop","general pop","unknown",NA,"hospitalization or death","severe","severe","gamma",88,63,96,"Canada","CAN","North America","North America",46580,2019,"Canada","High income",4,NA,NA,NA,NA,NA
"269",49,"Nasreen","Test-negative case-control",269,2022-02-07,"Moderna mRNA-1273","mRNA","2","final",NA,"14+","general pop","general pop","unknown","~25 weeks","hospitalization or death","severe","severe","gamma",100,NA,NA,"Canada","CAN","North America","North America",46580,2019,"Canada","High income",4,NA,NA,NA,NA,NA
"270",49,"Nasreen","Test-negative case-control",270,2022-02-07,"Oxford/AstraZeneca ChAdOx1-S","Vectored","1","1",NA,"14+","general pop","general pop","unknown",NA,"symptomatic disease","symptomatic","symptomatic","gamma",41,12,60,"Canada","CAN","North America","North America",46580,2019,"Canada","High income",4,NA,NA,NA,NA,NA
"271",49,"Nasreen","Test-negative case-control",271,2022-02-07,"Oxford/AstraZeneca ChAdOx1-S","Vectored","2","final",NA,"14+","general pop","general pop","unknown","~3 weeks","symptomatic disease","symptomatic","symptomatic","gamma",100,NA,NA,"Canada","CAN","North America","North America",46580,2019,"Canada","High income",4,NA,NA,NA,NA,NA
"272",49,"Nasreen","Test-negative case-control",272,2022-02-07,"Oxford/AstraZeneca ChAdOx1-S","Vectored","1","1",NA,"14+","general pop","general pop","unknown",NA,"hospitalization or death","severe","severe","gamma",76,40,90,"Canada","CAN","North America","North America",46580,2019,"Canada","High income",4,NA,NA,NA,NA,NA
"273",49,"Nasreen","Test-negative case-control",273,2022-02-07,"Oxford/AstraZeneca ChAdOx1-S","Vectored","2","final",NA,"14+","general pop","general pop","unknown","~3 weeks","hospitalization or death","severe","severe","gamma",100,NA,NA,"Canada","CAN","North America","North America",46580,2019,"Canada","High income",4,NA,NA,NA,NA,NA
"274",49,"Nasreen","Test-negative case-control",274,2022-02-07,"BioNTech/Pfizer BNT162b2","mRNA","1","1",NA,"14+","general pop","general pop","unknown",NA,"symptomatic disease","symptomatic","symptomatic","delta",57,53,61,"Canada","CAN","North America","North America",46580,2019,"Canada","High income",4,NA,NA,NA,NA,NA
"275",49,"Nasreen","Test-negative case-control",275,2022-02-07,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"14+","general pop","general pop","unknown","~28 weeks","symptomatic disease","symptomatic","symptomatic","delta",92,89,94,"Canada","CAN","North America","North America",46580,2019,"Canada","High income",4,NA,NA,NA,NA,NA
"276",49,"Nasreen","Test-negative case-control",276,2022-02-07,"BioNTech/Pfizer BNT162b2","mRNA","1","1",NA,"14+","general pop","general pop","unknown",NA,"hospitalization or death","severe","severe","delta",81,76,85,"Canada","CAN","North America","North America",46580,2019,"Canada","High income",4,NA,NA,NA,NA,NA
"277",49,"Nasreen","Test-negative case-control",277,2022-02-07,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"14+","general pop","general pop","unknown","~28 weeks","hospitalization or death","severe","severe","delta",98,96,99,"Canada","CAN","North America","North America",46580,2019,"Canada","High income",4,14,196,"yes",NA,0
"278",49,"Nasreen","Test-negative case-control",278,2022-02-07,"Moderna mRNA-1273","mRNA","1","1",NA,"14+","general pop","general pop","unknown",NA,"symptomatic disease","symptomatic","symptomatic","delta",70,64,76,"Canada","CAN","North America","North America",46580,2019,"Canada","High income",4,NA,NA,NA,NA,NA
"279",49,"Nasreen","Test-negative case-control",279,2022-02-07,"Moderna mRNA-1273","mRNA","2","final",NA,"14+","general pop","general pop","unknown","~25 weeks","symptomatic disease","symptomatic","symptomatic","delta",94,90,97,"Canada","CAN","North America","North America",46580,2019,"Canada","High income",4,NA,NA,NA,NA,NA
"280",49,"Nasreen","Test-negative case-control",280,2022-02-07,"Moderna mRNA-1273","mRNA","1","1",NA,"14+","general pop","general pop","unknown",NA,"hospitalization or death","severe","severe","delta",90,82,94,"Canada","CAN","North America","North America",46580,2019,"Canada","High income",4,NA,NA,NA,NA,NA
"281",49,"Nasreen","Test-negative case-control",281,2022-02-07,"Moderna mRNA-1273","mRNA","2","final",NA,"14+","general pop","general pop","unknown","~25 weeks","hospitalization or death","severe","severe","delta",98,93,100,"Canada","CAN","North America","North America",46580,2019,"Canada","High income",4,14,175,"yes",NA,0
"282",49,"Nasreen","Test-negative case-control",282,2022-02-07,"Oxford/AstraZeneca ChAdOx1-S","Vectored","1","1",NA,"14+","general pop","general pop","unknown",NA,"symptomatic disease","symptomatic","symptomatic","delta",68,57,76,"Canada","CAN","North America","North America",46580,2019,"Canada","High income",4,NA,NA,NA,NA,NA
"283",49,"Nasreen","Test-negative case-control",283,2022-02-07,"Oxford/AstraZeneca ChAdOx1-S","Vectored","2","final",NA,"14+","general pop","general pop","unknown","~ 3 weeks","symptomatic disease","symptomatic","symptomatic","delta",88,68,96,"Canada","CAN","North America","North America",46580,2019,"Canada","High income",4,NA,NA,NA,NA,NA
"284",49,"Nasreen","Test-negative case-control",284,2022-02-07,"Oxford/AstraZeneca ChAdOx1-S","Vectored","1","1",NA,"14+","general pop","general pop","unknown",NA,"hospitalization or death","severe","severe","delta",91,82,96,"Canada","CAN","North America","North America",46580,2019,"Canada","High income",4,NA,NA,NA,NA,NA
"285",49,"Nasreen","Test-negative case-control",285,2022-02-07,"Oxford/AstraZeneca ChAdOx1-S","Vectored","2","final",NA,"14+","general pop","general pop","unknown","~3 weeks","hospitalization or death","severe","severe","delta",90,67,97,"Canada","CAN","North America","North America",46580,2019,"Canada","High income",4,14,21,"yes",NA,0
"286",50,"Jara","Prospective cohort",286,2021-07-07,"Sinovac CoronaVac","Inactivated","1","1",NA,"14+","general pop","general pop","excluded",NA,"infection","infection","infection","other combinations",15.5,14.2,16.8,"Chile","CHL","South America","Latin America & Caribbean",14690,2019,"Chile","High income",3,NA,NA,NA,NA,NA
"287",50,"Jara","Prospective cohort",287,2021-07-07,"Sinovac CoronaVac","Inactivated","2","final",NA,"14+","general pop","general pop","excluded","8 weeks","infection","infection","infection","other combinations",65.9,65.2,66.6,"Chile","CHL","South America","Latin America & Caribbean",14690,2019,"Chile","High income",3,NA,NA,NA,NA,NA
"288",50,"Jara","Prospective cohort",288,2021-07-07,"Sinovac CoronaVac","Inactivated","1","1",NA,"14+","general pop","general pop","excluded",NA,"hospitalization","severe","severe","other combinations",37.4,34.9,39.9,"Chile","CHL","South America","Latin America & Caribbean",14690,2019,"Chile","High income",3,NA,NA,NA,NA,NA
"289",50,"Jara","Prospective cohort",289,2021-07-07,"Sinovac CoronaVac","Inactivated","2","final",NA,"14+","general pop","general pop","excluded","8 weeks","hospitalization","severe","severe","other combinations",87.5,86.7,88.2,"Chile","CHL","South America","Latin America & Caribbean",14690,2019,"Chile","High income",3,NA,NA,NA,NA,NA
"290",50,"Jara","Prospective cohort",290,2021-07-07,"Sinovac CoronaVac","Inactivated","1","1",NA,"14+","general pop","general pop","excluded",NA,"ICU admission","severe","severe","other combinations",44.7,40.8,48.3,"Chile","CHL","South America","Latin America & Caribbean",14690,2019,"Chile","High income",3,NA,NA,NA,NA,NA
"291",50,"Jara","Prospective cohort",291,2021-07-07,"Sinovac CoronaVac","Inactivated","2","final",NA,"14+","general pop","general pop","excluded","8 weeks","ICU admission","severe","severe","other combinations",90.3,89.1,91.4,"Chile","CHL","South America","Latin America & Caribbean",14690,2019,"Chile","High income",3,NA,NA,NA,NA,NA
"292",50,"Jara","Prospective cohort",292,2021-07-07,"Sinovac CoronaVac","Inactivated","1","1",NA,"14+","general pop","general pop","excluded",NA,"death","death","death","other combinations",45.7,40.9,50.2,"Chile","CHL","South America","Latin America & Caribbean",14690,2019,"Chile","High income",3,NA,NA,NA,NA,NA
"293",50,"Jara","Prospective cohort",293,2021-07-07,"Sinovac CoronaVac","Inactivated","2","final",NA,"14+","general pop","general pop","excluded","8 weeks","death","death","death","other combinations",86.3,84.5,87.9,"Chile","CHL","South America","Latin America & Caribbean",14690,2019,"Chile","High income",3,NA,NA,NA,NA,NA
"294",51,"Tenforde","Test-negative case-control",294,2021-08-06,"Multiple or heterologous RNA","mRNA","1+","1+",NA,"14+ up to 14 days post dose 2","hospital patients","general pop","included",NA,"hospitalization","severe","severe","other combinations",75.4,60.4,84.7,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"295",51,"Tenforde","Test-negative case-control",295,2021-08-06,"Multiple or heterologous RNA","mRNA","2","final",NA,"14+","hospital patients","general pop","included","~2 weeks","hospitalization","severe","severe","other combinations",86.6,79,91.4,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"296",51,"Tenforde","Test-negative case-control",296,2021-08-06,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"14+","hospital patients","general pop","included","~2 weeks","hospitalization","severe","severe","other combinations",84.7,74.1,91,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"297",51,"Tenforde","Test-negative case-control",297,2021-08-06,"Moderna mRNA-1273","mRNA","2","final",NA,"14+","hospital patients","general pop","included","~2 weeks","hospitalization","severe","severe","other combinations",88.9,78.7,94,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"298",51,"Tenforde","Test-negative case-control",298,2021-08-06,"Multiple or heterologous RNA","mRNA","2","final",NA,"14+","hospital patients","general pop","included","~2 weeks","hospitalization","severe","severe","alpha",92.1,82.3,96.5,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"299",52,"Chemaitelly","Test-negative case-control",299,2021-07-09,"Moderna mRNA-1273","mRNA","1","1",NA,"14+","general pop","general pop","unknown",NA,"infection","infection","infection","alpha",88.2,83.8,91.4,"Qatar","QAT","Asia","Middle East & North Africa",65700,2019,"Qatar","High income",4,NA,NA,NA,NA,NA
"300",52,"Chemaitelly","Test-negative case-control",300,2021-07-09,"Moderna mRNA-1273","mRNA","2","final",NA,"14+","general pop","general pop","unknown","13 weeks","infection","infection","infection","alpha",100,NA,NA,"Qatar","QAT","Asia","Middle East & North Africa",65700,2019,"Qatar","High income",4,NA,NA,NA,NA,NA
"301",52,"Chemaitelly","Test-negative case-control",301,2021-07-09,"Moderna mRNA-1273","mRNA","1","1",NA,"14+","general pop","general pop","unknown",NA,"infection","infection","infection","beta",68.2,64.3,71.7,"Qatar","QAT","Asia","Middle East & North Africa",65700,2019,"Qatar","High income",4,NA,NA,NA,NA,NA
"302",52,"Chemaitelly","Test-negative case-control",302,2021-07-09,"Moderna mRNA-1273","mRNA","2","final",NA,"14+","general pop","general pop","unknown","13 weeks","infection","infection","infection","beta",96,90.9,98.2,"Qatar","QAT","Asia","Middle East & North Africa",65700,2019,"Qatar","High income",4,NA,NA,NA,NA,NA
"303",52,"Chemaitelly","Test-negative case-control",303,2021-07-09,"Moderna mRNA-1273","mRNA","1","1",NA,"14+","general pop","general pop","unknown",NA,"severe/fatal infection","severe","severe","other combinations",83.7,74.1,89.7,"Qatar","QAT","Asia","Middle East & North Africa",65700,2019,"Qatar","High income",4,NA,NA,NA,NA,NA
"304",52,"Chemaitelly","Test-negative case-control",304,2021-07-09,"Moderna mRNA-1273","mRNA","2","final",NA,"14+","general pop","general pop","unknown","13 weeks","severe/fatal infection","severe","severe","other combinations",89.5,18.8,98.7,"Qatar","QAT","Asia","Middle East & North Africa",65700,2019,"Qatar","High income",4,NA,NA,NA,NA,NA
"305",52,"Chemaitelly","Test-negative case-control",305,2021-07-09,"Moderna mRNA-1273","mRNA","1","1",NA,"14+","general pop","general pop","unknown",NA,"symptomatic disease","symptomatic","symptomatic","other combinations",66,60.6,70.7,"Qatar","QAT","Asia","Middle East & North Africa",65700,2019,"Qatar","High income",4,NA,NA,NA,NA,NA
"306",52,"Chemaitelly","Test-negative case-control",306,2021-07-09,"Moderna mRNA-1273","mRNA","2","final",NA,"14+","general pop","general pop","unknown","13 weeks","symptomatic disease","symptomatic","symptomatic","other combinations",98.6,92,100,"Qatar","QAT","Asia","Middle East & North Africa",65700,2019,"Qatar","High income",4,NA,NA,NA,NA,NA
"307",52,"Chemaitelly","Test-negative case-control",307,2021-07-09,"Moderna mRNA-1273","mRNA","1","1",NA,"14+","general pop","general pop","unknown",NA,"asymptomatic infection","asymptomatic","infection","other combinations",47.3,37.6,55.5,"Qatar","QAT","Asia","Middle East & North Africa",65700,2019,"Qatar","High income",4,NA,NA,NA,NA,NA
"308",52,"Chemaitelly","Test-negative case-control",308,2021-07-09,"Moderna mRNA-1273","mRNA","2","final",NA,"14+","general pop","general pop","unknown","13 weeks","asymptomatic infection","asymptomatic","infection","other combinations",92.5,84.8,96.9,"Qatar","QAT","Asia","Middle East & North Africa",65700,2019,"Qatar","High income",4,NA,NA,NA,NA,NA
"309",52,"Chemaitelly","Retrospective cohort",309,2021-07-09,"Moderna mRNA-1273","mRNA","2","final",NA,"14+","general pop","general pop","excluded","13 weeks","infection","infection","infection","alpha",100,82.5,100,"Qatar","QAT","Asia","Middle East & North Africa",65700,2019,"Qatar","High income",4,NA,NA,NA,NA,NA
"310",52,"Chemaitelly","Retrospective cohort",310,2021-07-09,"Moderna mRNA-1273","mRNA","2","final",NA,"14+","general pop","general pop","excluded","13 weeks","infection","infection","infection","beta",87.8,73.4,95.5,"Qatar","QAT","Asia","Middle East & North Africa",65700,2019,"Qatar","High income",4,NA,NA,NA,NA,NA
"311",53,"Goldshtein","Retrospective cohort",311,2021-07-12,"BioNTech/Pfizer BNT162b2","mRNA","1+","1+",NA,"11-27 including some with dose 2","pregnant women","pregnant persons","excluded",NA,"infection","infection","infection","other combinations",54,33,69,"Israel","ISR","Asia","Middle East & North Africa",43800,2019,"Israel","High income",4,NA,NA,NA,NA,NA
"312",53,"Goldshtein","Retrospective cohort",312,2021-07-12,"BioNTech/Pfizer BNT162b2","mRNA","1+","1+",NA,"28+ including some with dose 2","pregnant women","pregnant persons","excluded",NA,"infection","infection","infection","other combinations",78,57,89,"Israel","ISR","Asia","Middle East & North Africa",43800,2019,"Israel","High income",4,NA,NA,NA,NA,NA
"313",54,"Bertollini","Prospective cohort",313,2021-07-13,"Multiple or heterologous RNA","mRNA","2","final",NA,"14+","general pop","general pop","included","~4 weeks","infection","infection","infection","other combinations",78,72,83,"Qatar","QAT","Asia","Middle East & North Africa",65700,2019,"Qatar","High income",4,NA,NA,NA,NA,NA
"314",55,"John","Retrospective cohort",314,2021-07-13,"Multiple or heterologous RNA","mRNA","1+","1+",NA,"28+ including some with dose 2","patients with cirrhosis","patients with cirrhosis","excluded",NA,"infection","infection","infection","other combinations",64.8,10.9,86.1,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"315",55,"John","Retrospective cohort",315,2021-07-13,"Multiple or heterologous RNA","mRNA","2","final",NA,"7+","patients with cirrhosis","patients with cirrhosis","excluded","~10 weeks","infection","infection","infection","other combinations",78.6,25.5,93.8,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"316",55,"John","Retrospective cohort",316,2021-07-13,"Multiple or heterologous RNA","mRNA","1+","1+",NA,"28+ including some with dose 2","patients with cirrhosis","patients with cirrhosis","excluded",NA,"hospitalization","severe","severe","other combinations",100,99.3,100,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"317",55,"John","Retrospective cohort",317,2021-07-13,"Multiple or heterologous RNA","mRNA","2","final",NA,"7+","patients with cirrhosis","patients with cirrhosis","excluded","~10 weeks","hospitalization","severe","severe","other combinations",100,99,100,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"318",55,"John","Retrospective cohort",318,2021-07-13,"Multiple or heterologous RNA","mRNA","1+","1+",NA,"28+ including some with dose 2","patients with cirrhosis","patients with cirrhosis","excluded",NA,"death","death","death","other combinations",100,99.3,100,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"319",55,"John","Retrospective cohort",319,2021-07-13,"Multiple or heterologous RNA","mRNA","2","final",NA,"7+","patients with cirrhosis","patients with cirrhosis","excluded","~10 weeks","death","death","death","other combinations",100,99,100,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"320",56,"Whitaker","Prospective cohort",320,2022-01-02,"BioNTech/Pfizer BNT162b2","mRNA","1","1",NA,"28-90","16-64 years","16-64 years","included",NA,"symptomatic disease","symptomatic","symptomatic","other combinations",64.1,50.1,74.1,"UK","GBR","Europe","Europe & Central Asia",43240,2019,"United Kingdom","High income",4,NA,NA,NA,NA,NA
"321",56,"Whitaker","Prospective cohort",321,2022-01-02,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"14+","16-64 years","16-64 years","included","~20 weeks","symptomatic disease","symptomatic","symptomatic","other combinations",48.6,-61.5,83.7,"UK","GBR","Europe","Europe & Central Asia",43240,2019,"United Kingdom","High income",4,NA,NA,NA,NA,NA
"322",56,"Whitaker","Prospective cohort",322,2022-01-02,"BioNTech/Pfizer BNT162b2","mRNA","1","1",NA,"28-90",">= 65 years",">= 65 years","included",NA,"symptomatic disease","symptomatic","symptomatic","other combinations",57.7,49.7,64.3,"UK","GBR","Europe","Europe & Central Asia",43240,2019,"United Kingdom","High income",4,NA,NA,NA,NA,NA
"323",56,"Whitaker","Prospective cohort",323,2022-01-02,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"14+",">= 65 years",">= 65 years","included","~20 weeks","symptomatic disease","symptomatic","symptomatic","other combinations",84.7,77.7,89.5,"UK","GBR","Europe","Europe & Central Asia",43240,2019,"United Kingdom","High income",4,NA,NA,NA,NA,NA
"324",56,"Whitaker","Prospective cohort",324,2022-01-02,"BioNTech/Pfizer BNT162b2","mRNA","1","1",NA,"28-90","immunosuprressed","immunocompromised, >= 16 years","included",NA,"symptomatic disease","symptomatic","symptomatic","alpha",24.3,-5.9,46,"UK","GBR","Europe","Europe & Central Asia",43240,2019,"United Kingdom","High income",4,NA,NA,NA,NA,NA
"325",56,"Whitaker","Prospective cohort",325,2022-01-02,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"14+","immunosuprressed","immunocompromised, >= 16 years","included","~8 weeks","symptomatic disease","symptomatic","symptomatic","alpha",59.6,-35.5,86.3,"UK","GBR","Europe","Europe & Central Asia",43240,2019,"United Kingdom","High income",4,NA,NA,NA,NA,NA
"326",56,"Whitaker","Prospective cohort",326,2022-01-02,"Oxford/AstraZeneca ChAdOx1-S","Vectored","1","1",NA,"28-90","16-64 years","16-64 years","included",NA,"symptomatic disease","symptomatic","symptomatic","alpha",65.3,56.2,72.5,"UK","GBR","Europe","Europe & Central Asia",43240,2019,"United Kingdom","High income",4,NA,NA,NA,NA,NA
"327",56,"Whitaker","Prospective cohort",327,2022-01-02,"Oxford/AstraZeneca ChAdOx1-S","Vectored","2","final",NA,"14+","16-64 years","16-64 years","included","~8 weeks","symptomatic disease","symptomatic","symptomatic","alpha",67.9,-1.1,89.8,"UK","GBR","Europe","Europe & Central Asia",43240,2019,"United Kingdom","High income",4,NA,NA,NA,NA,NA
"328",56,"Whitaker","Prospective cohort",328,2022-01-02,"Oxford/AstraZeneca ChAdOx1-S","Vectored","1","1",NA,"28-90",">= 65 years",">= 65 years","included",NA,"symptomatic disease","symptomatic","symptomatic","alpha",59.8,49.2,68.2,"UK","GBR","Europe","Europe & Central Asia",43240,2019,"United Kingdom","High income",4,NA,NA,NA,NA,NA
"329",56,"Whitaker","Prospective cohort",329,2022-01-02,"Oxford/AstraZeneca ChAdOx1-S","Vectored","2","final",NA,"14+",">= 65 years",">= 65 years","included","~8 weeks","symptomatic disease","symptomatic","symptomatic","alpha",81.7,59.6,91.7,"UK","GBR","Europe","Europe & Central Asia",43240,2019,"United Kingdom","High income",4,NA,NA,NA,NA,NA
"330",56,"Whitaker","Prospective cohort",330,2022-01-02,"Oxford/AstraZeneca ChAdOx1-S","Vectored","1","1",NA,"28-90","immunosuprressed","immunocompromised, >= 16 years","included",NA,"symptomatic disease","symptomatic","symptomatic","alpha",22.5,-15.2,47.9,"UK","GBR","Europe","Europe & Central Asia",43240,2019,"United Kingdom","High income",4,NA,NA,NA,NA,NA
"331",56,"Whitaker","Prospective cohort",331,2022-01-02,"Oxford/AstraZeneca ChAdOx1-S","Vectored","2","final",NA,"14+","immunosuprressed","immunocompromised, >= 16 years","included","~8 weeks","symptomatic disease","symptomatic","symptomatic","alpha",60,-63.6,90.2,"UK","GBR","Europe","Europe & Central Asia",43240,2019,"United Kingdom","High income",4,NA,NA,NA,NA,NA
"332",57,"Prunas","Retrospective cohort",332,2022-01-27,"BioNTech/Pfizer BNT162b2","mRNA","1+","1+",NA,"10+ including <10 days post dose 2","HHC of cases","HHC of cases","excluded",NA,"infection","infection","infection","other combinations",62.7,61.5,63.8,"Israel","ISR","Asia","Middle East & North Africa",43800,2019,"Israel","High income",4,NA,NA,NA,NA,NA
"333",57,"Prunas","Retrospective cohort",333,2022-01-27,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"10-90","HHC of cases","HHC of cases","excluded","~11 weeks","infection","infection","infection","other combinations",89.4,88.7,90,"Israel","ISR","Asia","Middle East & North Africa",43800,2019,"Israel","High income",4,NA,NA,NA,NA,NA
"334",57,"Prunas","Retrospective cohort",334,2022-01-27,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"90+","HHC of cases","HHC of cases","excluded","~26.5 weeks","infection","infection","infection","other combinations",58.3,45.8,67.9,"Israel","ISR","Asia","Middle East & North Africa",43800,2019,"Israel","High income",4,NA,NA,NA,NA,NA
"335",57,"Prunas","Retrospective cohort",335,2022-01-27,"BioNTech/Pfizer BNT162b2","mRNA","1+","1+",NA,"10+ including <10 days post dose 2","HHC of cases","HHC of cases","1+",NA,"infection","infection","infection","delta",72.1,66.7,75.6,"Israel","ISR","Asia","Middle East & North Africa",43800,2019,"Israel","High income",4,NA,NA,NA,NA,NA
"336",57,"Prunas","Retrospective cohort",336,2022-01-27,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"10-90","HHC of cases","HHC of cases","excluded","~11 weeks","infection","infection","infection","delta",72,65.9,77,"Israel","ISR","Asia","Middle East & North Africa",43800,2019,"Israel","High income",4,NA,NA,NA,NA,NA
"337",57,"Prunas","Retrospective cohort",337,2022-01-27,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"90+","HHC of cases","HHC of cases","excluded","~26.5 weeks","infection","infection","infection","delta",40.2,37.6,42.6,"Israel","ISR","Asia","Middle East & North Africa",43800,2019,"Israel","High income",4,NA,NA,NA,NA,NA
"338",58,"Butt","Retrospective cohort",338,2021-10-07,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"14+","pregnant women","pregnant persons","excluded","~17 weeks","infection","infection","infection","other combinations",87.7,43.5,97.3,"Qatar","QAT","Asia","Middle East & North Africa",65700,2019,"Qatar","High income",4,NA,NA,NA,NA,NA
"339",58,"Butt","Retrospective cohort",339,2021-10-07,"Moderna mRNA-1273","mRNA","2","final",NA,"14+","pregnant women","pregnant persons","excluded","~17 weeks","infection","infection","infection","other combinations",100,0,100,"Qatar","QAT","Asia","Middle East & North Africa",65700,2019,"Qatar","High income",4,NA,NA,NA,NA,NA
"340",59,"Balicer","Prospective cohort",340,2021-09-07,"BioNTech/Pfizer BNT162b2","mRNA","1","1",NA,"14-20","pregnant women","pregnant persons","excluded",NA,"infection","infection","infection","other combinations",67,40,84,"Israel","ISR","Asia","Middle East & North Africa",43800,2019,"Israel","High income",4,NA,NA,NA,NA,NA
"341",59,"Balicer","Prospective cohort",341,2021-09-07,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"7-56","pregnant women","pregnant persons","excluded","~18 weeks","infection","infection","infection","other combinations",96,89,100,"Israel","ISR","Asia","Middle East & North Africa",43800,2019,"Israel","High income",4,NA,NA,NA,NA,NA
"342",59,"Balicer","Prospective cohort",342,2021-09-07,"BioNTech/Pfizer BNT162b2","mRNA","1","1",NA,"21-27","pregnant women","pregnant persons","excluded",NA,"infection","infection","infection","other combinations",71,33,94,"Israel","ISR","Asia","Middle East & North Africa",43800,2019,"Israel","High income",4,NA,NA,NA,NA,NA
"343",59,"Balicer","Prospective cohort",343,2021-09-07,"BioNTech/Pfizer BNT162b2","mRNA","1","1",NA,"14-20","pregnant women","pregnant persons","excluded",NA,"symptomatic disease","symptomatic","symptomatic","other combinations",66,32,86,"Israel","ISR","Asia","Middle East & North Africa",43800,2019,"Israel","High income",4,NA,NA,NA,NA,NA
"344",59,"Balicer","Prospective cohort",344,2021-09-07,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"7-56","pregnant women","pregnant persons","excluded","~18 weeks","symptomatic disease","symptomatic","symptomatic","other combinations",97,91,100,"Israel","ISR","Asia","Middle East & North Africa",43800,2019,"Israel","High income",4,NA,NA,NA,NA,NA
"345",59,"Balicer","Prospective cohort",345,2021-09-07,"BioNTech/Pfizer BNT162b2","mRNA","1","1",NA,"21-27","pregnant women","pregnant persons","excluded",NA,"symptomatic disease","symptomatic","symptomatic","other combinations",76,30,100,"Israel","ISR","Asia","Middle East & North Africa",43800,2019,"Israel","High income",4,NA,NA,NA,NA,NA
"346",59,"Balicer","Prospective cohort",346,2021-09-07,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"7-56","pregnant women","pregnant persons","excluded","~18 weeks","hospitalization","severe","severe","other combinations",89,43,100,"Israel","ISR","Asia","Middle East & North Africa",43800,2019,"Israel","High income",4,NA,NA,NA,NA,NA
"347",60,"Layan","Prospective cohort",347,2022-03-03,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"7+","HHC of cases","HHC of cases","included","~12 weeks","infection","infection","infection","other combinations",79,56,92,"Israel","ISR","Asia","Middle East & North Africa",43800,2019,"Israel","High income",4,NA,NA,NA,NA,NA
"348",61,"Butt","Test-negative case-control",348,2021-07-20,"Multiple or heterologous RNA","mRNA","1","1",NA,"0+","general pop","general pop","excluded",NA,"infection","infection","infection","other combinations",85,84.2,85.8,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"349",61,"Butt","Test-negative case-control",349,2021-07-20,"Multiple or heterologous RNA","mRNA","2","final",NA,"7+","general pop","general pop","excluded","~6.5 weeks","infection","infection","infection","other combinations",97.1,96.6,97.5,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"350",61,"Butt","Test-negative case-control",350,2021-07-20,"BioNTech/Pfizer BNT162b2","mRNA","1","1",NA,"0+","general pop","general pop","excluded",NA,"infection","infection","infection","other combinations",84,82.7,85.1,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"351",61,"Butt","Test-negative case-control",351,2021-07-20,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"7+","general pop","general pop","excluded","~6.5 weeks","infection","infection","infection","other combinations",96.2,95.5,96.9,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"352",61,"Butt","Test-negative case-control",352,2021-07-20,"Moderna mRNA-1273","mRNA","1","1",NA,"0+","general pop","general pop","excluded",NA,"infection","infection","infection","other combinations",85.7,84.6,86.8,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"353",61,"Butt","Test-negative case-control",353,2021-07-20,"Moderna mRNA-1273","mRNA","2","final",NA,"7+","general pop","general pop","excluded","~6.5 weeks","infection","infection","infection","other combinations",98.2,97.5,98.6,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"354",62,"Lopez Bernal","Test-negative case-control",354,2021-07-21,"BioNTech/Pfizer BNT162b2","mRNA","1","1",NA,"21+","general pop","general pop","excluded",NA,"symptomatic disease","symptomatic","symptomatic","alpha",47.5,41.6,52.8,"UK","GBR","Europe","Europe & Central Asia",43240,2019,"United Kingdom","High income",4,NA,NA,NA,NA,NA
"355",62,"Lopez Bernal","Test-negative case-control",355,2021-07-21,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"14+","general pop","general pop","excluded","~17 weeks","symptomatic disease","symptomatic","symptomatic","alpha",93.7,91.6,95.3,"UK","GBR","Europe","Europe & Central Asia",43240,2019,"United Kingdom","High income",4,NA,NA,NA,NA,NA
"356",62,"Lopez Bernal","Test-negative case-control",356,2021-07-21,"Oxford/AstraZeneca ChAdOx1-S","Vectored","1","1",NA,"21+","general pop","general pop","excluded",NA,"symptomatic disease","symptomatic","symptomatic","alpha",48.7,45.2,51.9,"UK","GBR","Europe","Europe & Central Asia",43240,2019,"United Kingdom","High income",4,NA,NA,NA,NA,NA
"357",62,"Lopez Bernal","Test-negative case-control",357,2021-07-21,"Oxford/AstraZeneca ChAdOx1-S","Vectored","2","final",NA,"14+","general pop","general pop","excluded","~17 weeks","symptomatic disease","symptomatic","symptomatic","alpha",74.5,68.4,79.4,"UK","GBR","Europe","Europe & Central Asia",43240,2019,"United Kingdom","High income",4,NA,NA,NA,NA,NA
"358",62,"Lopez Bernal","Test-negative case-control",358,2021-07-21,"BioNTech/Pfizer BNT162b2","mRNA","1","1",NA,"21+","general pop","general pop","excluded",NA,"symptomatic disease","symptomatic","symptomatic","delta",35.6,22.7,46.4,"UK","GBR","Europe","Europe & Central Asia",43240,2019,"United Kingdom","High income",4,NA,NA,NA,NA,NA
"359",62,"Lopez Bernal","Test-negative case-control",359,2021-07-21,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"14+","general pop","general pop","excluded","~17 weeks","symptomatic disease","symptomatic","symptomatic","delta",88,85.3,90.1,"UK","GBR","Europe","Europe & Central Asia",43240,2019,"United Kingdom","High income",4,NA,NA,NA,NA,NA
"360",62,"Lopez Bernal","Test-negative case-control",360,2021-07-21,"Oxford/AstraZeneca ChAdOx1-S","Vectored","1","1",NA,"21+","general pop","general pop","excluded",NA,"symptomatic disease","symptomatic","symptomatic","delta",30,24.3,35.3,"UK","GBR","Europe","Europe & Central Asia",43240,2019,"United Kingdom","High income",4,NA,NA,NA,NA,NA
"361",62,"Lopez Bernal","Test-negative case-control",361,2021-07-21,"Oxford/AstraZeneca ChAdOx1-S","Vectored","2","final",NA,"14+","general pop","general pop","excluded","~17 weeks","symptomatic disease","symptomatic","symptomatic","delta",67,61.3,71.8,"UK","GBR","Europe","Europe & Central Asia",43240,2019,"United Kingdom","High income",4,NA,NA,NA,NA,NA
"362",63,"Kim","Test-negative case-control",362,2021-09-08,"Multiple or heterologous RNA","mRNA","1+","1+",NA,"14+ up to <14 days post dose 2","general pop","general pop","unknown",NA,"symptomatic disease","symptomatic","symptomatic","other combinations",75,55,87,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"363",63,"Kim","Test-negative case-control",363,2021-09-08,"Multiple or heterologous RNA","mRNA","2","final",NA,"14+","general pop","general pop","unknown","~18.5 weeks","symptomatic disease","symptomatic","symptomatic","other combinations",91,83,95,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"364",64,"Hitchings","Test-negative case-control",364,2021-10-28,"Oxford/AstraZeneca ChAdOx1-S","Vectored","1","1",NA,"28+","> 60 years","> 60 years","included",NA,"symptomatic disease","symptomatic","symptomatic","gamma",33.4,26.4,39.7,"Brazil","BRA","South America","Latin America & Caribbean",9410,2019,"Brazil","Upper middle income",3,NA,NA,NA,NA,NA
"365",64,"Hitchings","Test-negative case-control",365,2021-10-28,"Oxford/AstraZeneca ChAdOx1-S","Vectored","2","final",NA,"14+","> 60 years","> 60 years","included","~9.5 weeks","symptomatic disease","symptomatic","symptomatic","gamma",77.9,69.2,84.2,"Brazil","BRA","South America","Latin America & Caribbean",9410,2019,"Brazil","Upper middle income",3,NA,NA,NA,NA,NA
"366",64,"Hitchings","Test-negative case-control",366,2021-10-28,"Oxford/AstraZeneca ChAdOx1-S","Vectored","1","1",NA,"28+","> 60 years","> 60 years","included",NA,"hospitalization","severe","severe","gamma",55.1,46.6,62.2,"Brazil","BRA","South America","Latin America & Caribbean",9410,2019,"Brazil","Upper middle income",3,NA,NA,NA,NA,NA
"367",64,"Hitchings","Test-negative case-control",367,2021-10-28,"Oxford/AstraZeneca ChAdOx1-S","Vectored","2","final",NA,"14+","> 60 years","> 60 years","included","~9.5 weeks","hospitalization","severe","severe","gamma",87.6,78.2,92.9,"Brazil","BRA","South America","Latin America & Caribbean",9410,2019,"Brazil","Upper middle income",3,NA,NA,NA,NA,NA
"368",64,"Hitchings","Test-negative case-control",368,2021-10-28,"Oxford/AstraZeneca ChAdOx1-S","Vectored","1","1",NA,"28+","> 60 years","> 60 years","included",NA,"death","death","death","gamma",61.8,48.9,71.4,"Brazil","BRA","South America","Latin America & Caribbean",9410,2019,"Brazil","Upper middle income",3,NA,NA,NA,NA,NA
"369",64,"Hitchings","Test-negative case-control",369,2021-10-28,"Oxford/AstraZeneca ChAdOx1-S","Vectored","2","final",NA,"14+","> 60 years","> 60 years","included","~9.5 weeks","death","death","death","gamma",93.6,81.9,97.7,"Brazil","BRA","South America","Latin America & Caribbean",9410,2019,"Brazil","Upper middle income",3,NA,NA,NA,NA,NA
"370",65,"Carazo","Test-negative case-control",370,2021-08-30,"BioNTech/Pfizer BNT162b2","mRNA","1","1",NA,"14+","HCW","HCW","excluded",NA,"infection","infection","infection","other combinations",70.3,68.1,72.4,"Canada","CAN","North America","North America",46580,2019,"Canada","High income",4,NA,NA,NA,NA,NA
"371",65,"Carazo","Test-negative case-control",371,2021-08-30,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"7+","HCW","HCW","excluded","~20 weeks","infection","infection","infection","other combinations",85.5,80.4,89.3,"Canada","CAN","North America","North America",46580,2019,"Canada","High income",4,NA,NA,NA,NA,NA
"372",65,"Carazo","Test-negative case-control",372,2021-08-30,"BioNTech/Pfizer BNT162b2","mRNA","1","1",NA,"14+","HCW","HCW","excluded",NA,"symptomatic disease","symptomatic","symptomatic","other combinations",72.8,70.5,74.9,"Canada","CAN","North America","North America",46580,2019,"Canada","High income",4,NA,NA,NA,NA,NA
"373",65,"Carazo","Test-negative case-control",373,2021-08-30,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"7+","HCW","HCW","excluded","~20 weeks","symptomatic disease","symptomatic","symptomatic","other combinations",92.2,87.8,95.1,"Canada","CAN","North America","North America",46580,2019,"Canada","High income",4,NA,NA,NA,NA,NA
"374",65,"Carazo","Test-negative case-control",374,2021-08-30,"Moderna mRNA-1273","mRNA","1","1",NA,"14+","HCW","HCW","excluded",NA,"infection","infection","infection","other combinations",68.7,59.5,75.9,"Canada","CAN","North America","North America",46580,2019,"Canada","High income",4,NA,NA,NA,NA,NA
"375",65,"Carazo","Test-negative case-control",375,2021-08-30,"Moderna mRNA-1273","mRNA","2","final",NA,"7+","HCW","HCW","excluded","~20 weeks","infection","infection","infection","other combinations",84.1,34.9,96.1,"Canada","CAN","North America","North America",46580,2019,"Canada","High income",4,NA,NA,NA,NA,NA
"376",65,"Carazo","Test-negative case-control",376,2021-08-30,"Moderna mRNA-1273","mRNA","1","1",NA,"14+","HCW","HCW","excluded",NA,"symptomatic disease","symptomatic","symptomatic","other combinations",80.9,74.3,85.8,"Canada","CAN","North America","North America",46580,2019,"Canada","High income",4,NA,NA,NA,NA,NA
"377",65,"Carazo","Test-negative case-control",377,2021-08-30,"Multiple or heterologous RNA","mRNA","1","1",NA,"14+","HCW","HCW","excluded",NA,"hospitalization","severe","severe","other combinations",97.2,92.3,99,"Canada","CAN","North America","North America",46580,2019,"Canada","High income",4,NA,NA,NA,NA,NA
"378",65,"Carazo","Test-negative case-control",378,2021-08-30,"Multiple or heterologous RNA","mRNA","1","1",NA,"14+","HCW","HCW","excluded",NA,"infection","infection","infection","alpha",60,53.6,65.5,"Canada","CAN","North America","North America",46580,2019,"Canada","High income",4,NA,NA,NA,NA,NA
"379",65,"Carazo","Test-negative case-control",379,2021-08-30,"Multiple or heterologous RNA","mRNA","2","final",NA,"7+","HCW","HCW","excluded","~20 weeks","infection","infection","infection","alpha",92.6,87.1,95.8,"Canada","CAN","North America","North America",46580,2019,"Canada","High income",4,NA,NA,NA,NA,NA
"380",65,"Carazo","Test-negative case-control",380,2021-08-30,"Multiple or heterologous RNA","mRNA","1","1",NA,"14+","HCW","HCW","excluded",NA,"infection","infection","infection","original",77,72.6,80.7,"Canada","CAN","North America","North America",46580,2019,"Canada","High income",4,NA,NA,NA,NA,NA
"381",65,"Carazo","Test-negative case-control",381,2021-08-30,"Multiple or heterologous RNA","mRNA","2","final",NA,"7+","HCW","HCW","excluded","~20 weeks","infection","infection","infection","original",86.5,56.8,95.8,"Canada","CAN","North America","North America",46580,2019,"Canada","High income",4,NA,NA,NA,NA,NA
"382",67,"Amirthalingam","Test-negative case-control",385,2021-12-10,"BioNTech/Pfizer BNT162b2","mRNA","1","1",NA,"28+","> 80 years","> 80 years","excluded",NA,"infection","infection","infection","alpha",42,31,52,"UK","GBR","Europe","Europe & Central Asia",43240,2019,"United Kingdom","High income",4,NA,NA,NA,NA,NA
"383",67,"Amirthalingam","Test-negative case-control",386,2021-12-10,"BioNTech/Pfizer BNT162b2","mRNA","2","final","19-29 days","14+","> 80 years","> 80 years","excluded","~16 weeks","infection","infection","infection","alpha",77,56,88,"UK","GBR","Europe","Europe & Central Asia",43240,2019,"United Kingdom","High income",4,NA,NA,NA,NA,NA
"384",67,"Amirthalingam","Test-negative case-control",387,2021-12-10,"BioNTech/Pfizer BNT162b2","mRNA","2","1","65-84 days","14+","> 80 years","> 80 years","excluded",NA,"infection","infection","infection","alpha",90,83,94,"UK","GBR","Europe","Europe & Central Asia",43240,2019,"United Kingdom","High income",4,NA,NA,NA,NA,NA
"385",67,"Amirthalingam","Test-negative case-control",388,2021-12-10,"BioNTech/Pfizer BNT162b2","mRNA","1","final",NA,"28+","65-79 years","65-79 years","excluded","~16 weeks","infection","infection","infection","alpha",53,48,58,"UK","GBR","Europe","Europe & Central Asia",43240,2019,"United Kingdom","High income",4,NA,NA,NA,NA,NA
"386",67,"Amirthalingam","Test-negative case-control",389,2021-12-10,"BioNTech/Pfizer BNT162b2","mRNA","2","final","19-29 days","14+","65-79 years","65-79 years","excluded","~16 weeks","infection","infection","infection","alpha",77,66,85,"UK","GBR","Europe","Europe & Central Asia",43240,2019,"United Kingdom","High income",4,NA,NA,NA,NA,NA
"387",67,"Amirthalingam","Test-negative case-control",390,2021-12-10,"BioNTech/Pfizer BNT162b2","mRNA","2","final","65-84 days","14+","65-79 years","65-79 years","excluded","~16 weeks","infection","infection","infection","alpha",89,86,92,"UK","GBR","Europe","Europe & Central Asia",43240,2019,"United Kingdom","High income",4,NA,NA,NA,NA,NA
"388",67,"Amirthalingam","Test-negative case-control",391,2021-12-10,"BioNTech/Pfizer BNT162b2","mRNA","1","1",NA,"28+","50-64 years","50-64 years","excluded",NA,"infection","infection","infection","alpha",51,47,55,"UK","GBR","Europe","Europe & Central Asia",43240,2019,"United Kingdom","High income",4,NA,NA,NA,NA,NA
"389",67,"Amirthalingam","Test-negative case-control",392,2021-12-10,"BioNTech/Pfizer BNT162b2","mRNA","2","final","19-29 days","14+","50-64 years","50-64 years","excluded","~16 weeks","infection","infection","infection","alpha",88,67,96,"UK","GBR","Europe","Europe & Central Asia",43240,2019,"United Kingdom","High income",4,NA,NA,NA,NA,NA
"390",67,"Amirthalingam","Test-negative case-control",393,2021-12-10,"BioNTech/Pfizer BNT162b2","mRNA","2","final","65-84 days","14+","50-64 years","50-64 years","excluded","~16 weeks","infection","infection","infection","alpha",92,91,94,"UK","GBR","Europe","Europe & Central Asia",43240,2019,"United Kingdom","High income",4,NA,NA,NA,NA,NA
"391",67,"Amirthalingam","Test-negative case-control",394,2021-12-10,"Oxford/AstraZeneca ChAdOx1-S","Vectored","1","1",NA,"28+","> 80 years","> 80 years","excluded",NA,"infection","infection","infection","alpha",42,29,53,"UK","GBR","Europe","Europe & Central Asia",43240,2019,"United Kingdom","High income",4,NA,NA,NA,NA,NA
"392",67,"Amirthalingam","Test-negative case-control",395,2021-12-10,"Oxford/AstraZeneca ChAdOx1-S","Vectored","2","final","45-64 days","14+","> 80 years","> 80 years","excluded","~16 weeks","infection","infection","infection","alpha",96,68,99,"UK","GBR","Europe","Europe & Central Asia",43240,2019,"United Kingdom","High income",4,NA,NA,NA,NA,NA
"393",67,"Amirthalingam","Test-negative case-control",396,2021-12-10,"Oxford/AstraZeneca ChAdOx1-S","Vectored","2","final","65-84 days","14+","> 80 years","> 80 years","excluded","~16 weeks","infection","infection","infection","alpha",82,68,89,"UK","GBR","Europe","Europe & Central Asia",43240,2019,"United Kingdom","High income",4,NA,NA,NA,NA,NA
"394",67,"Amirthalingam","Test-negative case-control",397,2021-12-10,"Oxford/AstraZeneca ChAdOx1-S","Vectored","1","1",NA,"28+","65-79 years","65-79 years","excluded",NA,"infection","infection","infection","alpha",52,46,56,"UK","GBR","Europe","Europe & Central Asia",43240,2019,"United Kingdom","High income",4,NA,NA,NA,NA,NA
"395",67,"Amirthalingam","Test-negative case-control",398,2021-12-10,"Oxford/AstraZeneca ChAdOx1-S","Vectored","2","final","30-44 days","14+","65-79 years","65-79 years","excluded","~16 weeks","infection","infection","infection","alpha",73,25,90,"UK","GBR","Europe","Europe & Central Asia",43240,2019,"United Kingdom","High income",4,NA,NA,NA,NA,NA
"396",67,"Amirthalingam","Test-negative case-control",399,2021-12-10,"Oxford/AstraZeneca ChAdOx1-S","Vectored","2","final","65-84 days","14+","65-79 years","65-79 years","excluded","~16 weeks","infection","infection","infection","alpha",74,69,79,"UK","GBR","Europe","Europe & Central Asia",43240,2019,"United Kingdom","High income",4,NA,NA,NA,NA,NA
"397",67,"Amirthalingam","Test-negative case-control",400,2021-12-10,"Oxford/AstraZeneca ChAdOx1-S","Vectored","1","1",NA,"28+","50-64 years","50-64 years","excluded",NA,"infection","infection","infection","alpha",42,39,46,"UK","GBR","Europe","Europe & Central Asia",43240,2019,"United Kingdom","High income",4,NA,NA,NA,NA,NA
"398",67,"Amirthalingam","Test-negative case-control",401,2021-12-10,"Oxford/AstraZeneca ChAdOx1-S","Vectored","2","final","30-44 days","14+","50-64 years","50-64 years","excluded","~16 weeks","infection","infection","infection","alpha",55,34,69,"UK","GBR","Europe","Europe & Central Asia",43240,2019,"United Kingdom","High income",4,NA,NA,NA,NA,NA
"399",67,"Amirthalingam","Test-negative case-control",402,2021-12-10,"Oxford/AstraZeneca ChAdOx1-S","Vectored","2","final","65-84 days","14+","50-64 years","50-64 years","excluded","~16 weeks","infection","infection","infection","alpha",77,74,79,"UK","GBR","Europe","Europe & Central Asia",43240,2019,"United Kingdom","High income",4,NA,NA,NA,NA,NA
"400",68,"Gram","Retrospective cohort",403,2021-12-17,"Heterologous platforms","Multiple","1","1",NA,"14-20","general pop","general pop","excluded",NA,"infection","infection","infection","alpha",39,23,52,"Denmark","DNK","Europe","Europe & Central Asia",63020,2019,"Denmark","High income",4,NA,NA,NA,NA,NA
"401",68,"Gram","Retrospective cohort",404,2021-12-17,"Heterologous platforms","Multiple","2","final",NA,"14+","general pop","general pop","excluded","~20 weeks","infection","infection","infection","alpha",88,83,92,"Denmark","DNK","Europe","Europe & Central Asia",63020,2019,"Denmark","High income",4,NA,NA,NA,NA,NA
"402",68,"Gram","Retrospective cohort",405,2021-12-17,"Heterologous platforms","Multiple","1","1",NA,"105+","general pop","general pop","excluded",NA,"infection","infection","infection","alpha",-47,-208,30,"Denmark","DNK","Europe","Europe & Central Asia",63020,2019,"Denmark","High income",4,NA,NA,NA,NA,NA
"403",68,"Gram","Retrospective cohort",406,2021-12-17,"Heterologous platforms","Multiple","1","1",NA,"14+","general pop","general pop","excluded",NA,"hospitalization","severe","severe","alpha",93,80,98,"Denmark","DNK","Europe","Europe & Central Asia",63020,2019,"Denmark","High income",4,NA,NA,NA,NA,NA
"404",69,"Alali","Retrospective cohort",407,2021-07-29,"BioNTech/Pfizer BNT162b2","mRNA","1","1",NA,"14+","HCW","HCW","excluded",NA,"infection","infection","infection","alpha",91.4,65.1,97.9,"Kuwait","KWT","Asia","Middle East & North Africa",35680,2019,"Kuwait","High income",4,NA,NA,NA,NA,NA
"405",69,"Alali","Retrospective cohort",408,2021-07-29,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"7+","HCW","HCW","excluded","~18 weeks","infection","infection","infection","alpha",94.5,89.4,97.2,"Kuwait","KWT","Asia","Middle East & North Africa",35680,2019,"Kuwait","High income",4,NA,NA,NA,NA,NA
"406",69,"Alali","Retrospective cohort",409,2021-07-29,"Oxford/AstraZeneca ChAdOx1-S","Vectored","1","1",NA,"28+","HCW","HCW","excluded",NA,"infection","infection","infection","alpha",75.4,67.2,81.6,"Kuwait","KWT","Asia","Middle East & North Africa",35680,2019,"Kuwait","High income",4,NA,NA,NA,NA,NA
"407",70,"Lefvre","Retrospective cohort",410,2021-07-31,"BioNTech/Pfizer BNT162b2","mRNA","1+","1+",NA,"14+ up to t days after 2nd dose","LTCF residents","LTCF residents","included",NA,"infection","infection","infection","beta",55,13,76,"France","FRA","Europe","Europe & Central Asia",42470,2019,"France","High income",4,NA,NA,NA,NA,NA
"408",70,"Lefvre","Retrospective cohort",411,2021-07-31,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"7+","LTCF residents","LTCF residents","included","~16 weeks","infection","infection","infection","beta",49,14,69,"France","FRA","Europe","Europe & Central Asia",42470,2019,"France","High income",4,NA,NA,NA,NA,NA
"409",70,"Lefvre","Retrospective cohort",412,2021-07-31,"BioNTech/Pfizer BNT162b2","mRNA","1+","1+",NA,"14+ up to t days after 2nd dose","LTCF residents","LTCF residents","included",NA,"hospitalization or death","severe","severe","beta",86,32,97,"France","FRA","Europe","Europe & Central Asia",42470,2019,"France","High income",4,NA,NA,NA,NA,NA
"410",70,"Lefvre","Retrospective cohort",413,2021-07-31,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"7+","LTCF residents","LTCF residents","included","~16 weeks","hospitalization or death","severe","severe","beta",86,67,94,"France","FRA","Europe","Europe & Central Asia",42470,2019,"France","High income",4,NA,NA,NA,NA,NA
"411",71,"de Gier","Retrospective cohort",414,2021-08-05,"Oxford/AstraZeneca ChAdOx1-S","Vectored","1","1",NA,"14+","HHC of cases","HHC of cases","unknown",NA,"infection","infection","infection","alpha",2,-11,14,"Netherlands","NLD","Europe","Europe & Central Asia",51920,2019,"Netherlands","High income",4,NA,NA,NA,NA,NA
"412",71,"de Gier","Retrospective cohort",415,2021-08-05,"Oxford/AstraZeneca ChAdOx1-S","Vectored","2","final",NA,"7+","HHC of cases","HHC of cases","unknown","~15 weeks","infection","infection","infection","alpha",87,77,93,"Netherlands","NLD","Europe","Europe & Central Asia",51920,2019,"Netherlands","High income",4,NA,NA,NA,NA,NA
"413",71,"de Gier","Retrospective cohort",416,2021-08-05,"BioNTech/Pfizer BNT162b2","mRNA","1","1",NA,"14+","HHC of cases","HHC of cases","unknown",NA,"infection","infection","infection","alpha",-18,-43,2,"Netherlands","NLD","Europe","Europe & Central Asia",51920,2019,"Netherlands","High income",4,NA,NA,NA,NA,NA
"414",71,"de Gier","Retrospective cohort",417,2021-08-05,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"7+","HHC of cases","HHC of cases","unknown","~15 weeks","infection","infection","infection","alpha",65,60,70,"Netherlands","NLD","Europe","Europe & Central Asia",51920,2019,"Netherlands","High income",4,NA,NA,NA,NA,NA
"415",71,"de Gier","Retrospective cohort",418,2021-08-05,"Moderna mRNA-1273","mRNA","1","1",NA,"14+","HHC of cases","HHC of cases","unknown",NA,"infection","infection","infection","alpha",33,-27,64,"Netherlands","NLD","Europe","Europe & Central Asia",51920,2019,"Netherlands","High income",4,NA,NA,NA,NA,NA
"416",71,"de Gier","Retrospective cohort",419,2021-08-05,"Moderna mRNA-1273","mRNA","2","final",NA,"7+","HHC of cases","HHC of cases","unknown","~15 weeks","infection","infection","infection","alpha",91,79,97,"Netherlands","NLD","Europe","Europe & Central Asia",51920,2019,"Netherlands","High income",4,NA,NA,NA,NA,NA
"417",71,"de Gier","Retrospective cohort",420,2021-08-05,"Janssen Ad26.COV2.S","Vectored","1","final",NA,"14+","HHC of cases","HHC of cases","unknown","~15 weeks","infection","infection","infection","alpha",12,-71,54,"Netherlands","NLD","Europe","Europe & Central Asia",51920,2019,"Netherlands","High income",4,NA,NA,NA,NA,NA
"418",72,"Puranik","Retrospective cohort",421,2021-08-09,"BioNTech/Pfizer BNT162b2","mRNA","1","1",NA,"1-7","general pop","general pop","excluded",NA,"infection","infection","infection","other combinations",16,-20,42,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"419",72,"Puranik","Retrospective cohort",422,2021-08-09,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"14+","general pop","general pop","excluded","~26 weeks","infection","infection","infection","other combinations",76,69,81,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"420",72,"Puranik","Retrospective cohort",423,2021-08-09,"BioNTech/Pfizer BNT162b2","mRNA","1","1",NA,"1-7","general pop","general pop","excluded",NA,"hospitalization","severe","severe","other combinations",75,-30,97.4,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"421",72,"Puranik","Retrospective cohort",424,2021-08-09,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"14+","general pop","general pop","excluded","~26 weeks","hospitalization","severe","severe","other combinations",85,73,93,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"422",72,"Puranik","Retrospective cohort",425,2021-08-09,"BioNTech/Pfizer BNT162b2","mRNA","1","1",NA,"1-7","general pop","general pop","excluded",NA,"ICU admission","severe","severe","other combinations",100,-430,100,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"423",72,"Puranik","Retrospective cohort",426,2021-08-09,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"14+","general pop","general pop","excluded","~26 weeks","ICU admission","severe","severe","other combinations",87,46,98.6,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"424",72,"Puranik","Retrospective cohort",427,2021-08-09,"Moderna mRNA-1273","mRNA","1","1",NA,"1-7","general pop","general pop","excluded",NA,"infection","infection","infection","other combinations",-10,-50,24,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"425",72,"Puranik","Retrospective cohort",428,2021-08-09,"Moderna mRNA-1273","mRNA","2","final",NA,"14+","general pop","general pop","excluded","~26 weeks","infection","infection","infection","other combinations",86,81,90.6,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"426",72,"Puranik","Retrospective cohort",429,2021-08-09,"Moderna mRNA-1273","mRNA","1","1",NA,"1-7","general pop","general pop","excluded",NA,"hospitalization","severe","severe","other combinations",25,-150,79,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"427",72,"Puranik","Retrospective cohort",430,2021-08-09,"Moderna mRNA-1273","mRNA","2","final",NA,"14+","general pop","general pop","excluded","~26 weeks","hospitalization","severe","severe","other combinations",91.6,81,97,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"428",72,"Puranik","Retrospective cohort",431,2021-08-09,"Moderna mRNA-1273","mRNA","1","1",NA,"1-7","general pop","general pop","excluded",NA,"ICU admission","severe","severe","other combinations",100,-430,100,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"429",72,"Puranik","Retrospective cohort",432,2021-08-09,"Moderna mRNA-1273","mRNA","2","final",NA,"14+","general pop","general pop","excluded","~26 weeks","ICU admission","severe","severe","other combinations",93.3,57,99.8,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"430",73,"Chemaitelly","Retrospective cohort",433,2021-08-09,"Multiple or heterologous RNA","mRNA","2","final",NA,"14+","transplant patients","transplant patients","excluded","~17 weeks","infection","infection","infection","other combinations",46.6,0,73.7,"Qatar","QAT","Asia","Middle East & North Africa",65700,2019,"Qatar","High income",4,NA,NA,NA,NA,NA
"431",73,"Chemaitelly","Retrospective cohort",434,2021-08-09,"Multiple or heterologous RNA","mRNA","2","final",NA,"42+","transplant patients","transplant patients","excluded","~17 weeks","infection","infection","infection","other combinations",66,21.3,85.3,"Qatar","QAT","Asia","Middle East & North Africa",65700,2019,"Qatar","High income",4,NA,NA,NA,NA,NA
"432",73,"Chemaitelly","Retrospective cohort",435,2021-08-09,"Multiple or heterologous RNA","mRNA","2","final",NA,"56+","transplant patients","transplant patients","excluded","~17 weeks","infection","infection","infection","other combinations",73.9,33,89.9,"Qatar","QAT","Asia","Middle East & North Africa",65700,2019,"Qatar","High income",4,NA,NA,NA,NA,NA
"433",73,"Chemaitelly","Retrospective cohort",436,2021-08-09,"Multiple or heterologous RNA","mRNA","2","final",NA,"14+","transplant patients","transplant patients","excluded","~17 weeks","severe infection","severe","severe","other combinations",72.3,0,90.9,"Qatar","QAT","Asia","Middle East & North Africa",65700,2019,"Qatar","High income",4,NA,NA,NA,NA,NA
"434",73,"Chemaitelly","Retrospective cohort",437,2021-08-09,"Multiple or heterologous RNA","mRNA","2","final",NA,"42+","transplant patients","transplant patients","excluded","~17 weeks","severe infection","severe","severe","other combinations",85,35.7,96.5,"Qatar","QAT","Asia","Middle East & North Africa",65700,2019,"Qatar","High income",4,NA,NA,NA,NA,NA
"435",73,"Chemaitelly","Retrospective cohort",438,2021-08-09,"Multiple or heterologous RNA","mRNA","2","final",NA,"56+","transplant patients","transplant patients","excluded","~17 weeks","severe infection","severe","severe","other combinations",83.8,31.3,96.2,"Qatar","QAT","Asia","Middle East & North Africa",65700,2019,"Qatar","High income",4,NA,NA,NA,NA,NA
"436",74,"Tang","Test-negative case-control",439,2021-11-02,"BioNTech/Pfizer BNT162b2","mRNA","1","1",NA,"14+","general pop","general pop","included",NA,"infection","infection","infection","delta",42.8,18.2,60.1,"Qatar","QAT","Asia","Middle East & North Africa",65700,2019,"Qatar","High income",4,NA,NA,NA,NA,NA
"437",74,"Tang","Test-negative case-control",440,2021-11-02,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"14+","general pop","general pop","included","~25 weeks","infection","infection","infection","delta",50.6,45.4,55.3,"Qatar","QAT","Asia","Middle East & North Africa",65700,2019,"Qatar","High income",4,NA,NA,NA,NA,NA
"438",74,"Tang","Test-negative case-control",441,2021-11-02,"Moderna mRNA-1273","mRNA","1","1",NA,"14+","general pop","general pop","included",NA,"infection","infection","infection","delta",73.2,57.3,83.2,"Qatar","QAT","Asia","Middle East & North Africa",65700,2019,"Qatar","High income",4,NA,NA,NA,NA,NA
"439",74,"Tang","Test-negative case-control",442,2021-11-02,"Moderna mRNA-1273","mRNA","2","final",NA,"14+","general pop","general pop","included","~25 weeks","infection","infection","infection","delta",72,66.1,76.9,"Qatar","QAT","Asia","Middle East & North Africa",65700,2019,"Qatar","High income",4,NA,NA,NA,NA,NA
"440",74,"Tang","Test-negative case-control",443,2021-11-02,"BioNTech/Pfizer BNT162b2","mRNA","1","1",NA,"14+","general pop","general pop","included",NA,"severe, critical, fatal disease","severe","severe","delta",84.5,-25.2,98.1,"Qatar","QAT","Asia","Middle East & North Africa",65700,2019,"Qatar","High income",4,NA,NA,NA,NA,NA
"441",74,"Tang","Test-negative case-control",444,2021-11-02,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"14+","general pop","general pop","included","~25 weeks","severe, critical, fatal disease","severe","severe","delta",94.1,85.9,97.6,"Qatar","QAT","Asia","Middle East & North Africa",65700,2019,"Qatar","High income",4,14,175,"yes",NA,0
"442",74,"Tang","Test-negative case-control",445,2021-11-02,"Moderna mRNA-1273","mRNA","1","1",NA,"14+","general pop","general pop","included",NA,"severe, critical, fatal disease","severe","severe","delta",87.5,23.4,95.8,"Qatar","QAT","Asia","Middle East & North Africa",65700,2019,"Qatar","High income",4,NA,NA,NA,NA,NA
"443",74,"Tang","Test-negative case-control",446,2021-11-02,"Moderna mRNA-1273","mRNA","2","final",NA,"14+","general pop","general pop","included","~25 weeks","severe, critical, fatal disease","severe","severe","delta",96.1,71.4,99.5,"Qatar","QAT","Asia","Middle East & North Africa",65700,2019,"Qatar","High income",4,14,175,"yes",NA,0
"444",74,"Tang","Test-negative case-control",447,2021-11-02,"BioNTech/Pfizer BNT162b2","mRNA","1","1",NA,"14+","general pop","general pop","included",NA,"symptomatic disease","symptomatic","symptomatic","delta",56.2,30.6,72.4,"Qatar","QAT","Asia","Middle East & North Africa",65700,2019,"Qatar","High income",4,NA,NA,NA,NA,NA
"445",74,"Tang","Test-negative case-control",448,2021-11-02,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"14+","general pop","general pop","included","~25 weeks","symptomatic disease","symptomatic","symptomatic","delta",44.4,37,50.9,"Qatar","QAT","Asia","Middle East & North Africa",65700,2019,"Qatar","High income",4,NA,NA,NA,NA,NA
"446",74,"Tang","Test-negative case-control",449,2021-11-02,"Moderna mRNA-1273","mRNA","1","1",NA,"14+","general pop","general pop","included",NA,"symptomatic disease","symptomatic","symptomatic","delta",82.5,65.2,91.2,"Qatar","QAT","Asia","Middle East & North Africa",65700,2019,"Qatar","High income",4,NA,NA,NA,NA,NA
"447",74,"Tang","Test-negative case-control",450,2021-11-02,"Moderna mRNA-1273","mRNA","2","final",NA,"14+","general pop","general pop","included","~25 weeks","symptomatic disease","symptomatic","symptomatic","delta",73.9,65.9,79.9,"Qatar","QAT","Asia","Middle East & North Africa",65700,2019,"Qatar","High income",4,NA,NA,NA,NA,NA
"448",74,"Tang","Test-negative case-control",451,2021-11-02,"BioNTech/Pfizer BNT162b2","mRNA","1","1",NA,"14+","general pop","general pop","included",NA,"asymptomatic infection","asymptomatic","infection","delta",46.7,-56.2,81.8,"Qatar","QAT","Asia","Middle East & North Africa",65700,2019,"Qatar","High income",4,NA,NA,NA,NA,NA
"449",74,"Tang","Test-negative case-control",452,2021-11-02,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"14+","general pop","general pop","included","~25 weeks","asymptomatic infection","asymptomatic","infection","delta",46,32.3,56.9,"Qatar","QAT","Asia","Middle East & North Africa",65700,2019,"Qatar","High income",4,NA,NA,NA,NA,NA
"450",74,"Tang","Test-negative case-control",453,2021-11-02,"Moderna mRNA-1273","mRNA","1","1",NA,"14+","general pop","general pop","included",NA,"asymptomatic infection","asymptomatic","infection","delta",61.8,-9.6,86.7,"Qatar","QAT","Asia","Middle East & North Africa",65700,2019,"Qatar","High income",4,NA,NA,NA,NA,NA
"451",74,"Tang","Test-negative case-control",454,2021-11-02,"Moderna mRNA-1273","mRNA","2","final",NA,"14+","general pop","general pop","included","~25 weeks","asymptomatic infection","asymptomatic","infection","delta",53.6,33.4,67.6,"Qatar","QAT","Asia","Middle East & North Africa",65700,2019,"Qatar","High income",4,NA,NA,NA,NA,NA
"452",74,"Tang","Test-negative case-control",455,2021-11-02,"BioNTech/Pfizer BNT162b2","mRNA","1","1",NA,"14+","general pop","general pop","included",NA,"infection","infection","infection","beta",18.9,-1.8,35.4,"Qatar","QAT","Asia","Middle East & North Africa",65700,2019,"Qatar","High income",4,NA,NA,NA,NA,NA
"453",74,"Tang","Test-negative case-control",456,2021-11-02,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"14+","general pop","general pop","included","~25 weeks","infection","infection","infection","beta",74.3,70.3,77.7,"Qatar","QAT","Asia","Middle East & North Africa",65700,2019,"Qatar","High income",4,NA,NA,NA,NA,NA
"454",74,"Tang","Test-negative case-control",457,2021-11-02,"Moderna mRNA-1273","mRNA","1","1",NA,"14+","general pop","general pop","included",NA,"infection","infection","infection","beta",66.3,55.8,74.2,"Qatar","QAT","Asia","Middle East & North Africa",65700,2019,"Qatar","High income",4,NA,NA,NA,NA,NA
"455",74,"Tang","Test-negative case-control",458,2021-11-02,"Moderna mRNA-1273","mRNA","2","final",NA,"14+","general pop","general pop","included","~25 weeks","infection","infection","infection","beta",80.8,69,88.2,"Qatar","QAT","Asia","Middle East & North Africa",65700,2019,"Qatar","High income",4,NA,NA,NA,NA,NA
"456",74,"Tang","Test-negative case-control",459,2021-11-02,"BioNTech/Pfizer BNT162b2","mRNA","1","1",NA,"14+","general pop","general pop","included",NA,"severe, critical, fatal disease","severe","severe","beta",74.8,-7.6,94.1,"Qatar","QAT","Asia","Middle East & North Africa",65700,2019,"Qatar","High income",4,NA,NA,NA,NA,NA
"457",74,"Tang","Test-negative case-control",460,2021-11-02,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"14+","general pop","general pop","included","~25 weeks","severe, critical, fatal disease","severe","severe","beta",92.7,81.5,97.1,"Qatar","QAT","Asia","Middle East & North Africa",65700,2019,"Qatar","High income",4,NA,NA,NA,NA,NA
"458",74,"Tang","Test-negative case-control",461,2021-11-02,"Moderna mRNA-1273","mRNA","1","1",NA,"14+","general pop","general pop","included",NA,"severe, critical, fatal disease","severe","severe","beta",72.5,7.7,91.8,"Qatar","QAT","Asia","Middle East & North Africa",65700,2019,"Qatar","High income",4,NA,NA,NA,NA,NA
"459",74,"Tang","Test-negative case-control",462,2021-11-02,"Moderna mRNA-1273","mRNA","2","final",NA,"14+","general pop","general pop","included","~25 weeks","severe, critical, fatal disease","severe","severe","beta",100,NA,NA,"Qatar","QAT","Asia","Middle East & North Africa",65700,2019,"Qatar","High income",4,NA,NA,NA,NA,NA
"460",75,"Nanduri","Retrospective cohort",463,2021-08-18,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"14+","SNF residents","SNF residents","unknown","~16 weeks","infection","infection","infection","other combinations",74.2,69,78.7,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"461",75,"Nanduri","Retrospective cohort",464,2021-08-18,"Moderna mRNA-1273","mRNA","2","final",NA,"14+","SNF residents","SNF residents","unknown","~16 weeks","infection","infection","infection","other combinations",74.7,66.2,81.1,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"462",75,"Nanduri","Retrospective cohort",465,2021-08-18,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"14+","SNF residents","SNF residents","unknown","~22 weeks","infection","infection","infection","alpha",66.5,58.3,73.1,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"463",75,"Nanduri","Retrospective cohort",466,2021-08-18,"Moderna mRNA-1273","mRNA","2","final",NA,"14+","SNF residents","SNF residents","unknown","~22 weeks","infection","infection","infection","alpha",70.4,60.1,78,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"464",75,"Nanduri","Retrospective cohort",467,2021-08-18,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"14+","SNF residents","SNF residents","unknown","~25 weeks","infection","infection","infection","delta",52.4,48,56.4,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"465",75,"Nanduri","Retrospective cohort",468,2021-08-18,"Moderna mRNA-1273","mRNA","2","final",NA,"14+","SNF residents","SNF residents","unknown","~25 weeks","infection","infection","infection","delta",50.6,45,55.7,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"466",76,"Chin","Retrospective cohort",469,2022-01-27,"Multiple or heterologous RNA","mRNA","1","1",NA,"14+","incarcerated persons","incarcerated persons","excluded",NA,"infection","infection","infection","original",74,64,82,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"467",76,"Chin","Retrospective cohort",470,2022-01-27,"Multiple or heterologous RNA","mRNA","2","final",NA,"14+","incarcerated persons","incarcerated persons","excluded","~5 weeks","infection","infection","infection","original",97,88,99,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"468",76,"Chin","Retrospective cohort",471,2022-01-27,"Multiple or heterologous RNA","mRNA","1","1",NA,"14+","incarcerated persons, moderate/high risk for severe disease","incarcerated persons, moderate/high risk for severe disease","excluded",NA,"infection","infection","infection","original",74,62,82,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"469",76,"Chin","Retrospective cohort",472,2022-01-27,"Multiple or heterologous RNA","mRNA","2","final",NA,"14+","incarcerated persons, moderate/high risk for severe disease","incarcerated persons, moderate/high risk for severe disease","excluded","~5 weeks","infection","infection","infection","original",92,74,98,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"470",76,"Chin","Retrospective cohort",473,2022-01-27,"Moderna mRNA-1273","mRNA","1","1",NA,"14+","incarcerated persons","incarcerated persons","excluded",NA,"infection","infection","infection","original",71,58,80,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"471",76,"Chin","Retrospective cohort",474,2022-01-27,"Moderna mRNA-1273","mRNA","2","final",NA,"14+","incarcerated persons","incarcerated persons","excluded","~5 weeks","infection","infection","infection","original",96,67,99,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"472",77,"Tenforde","Case-control",475,2021-11-04,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"14+","general pop","general pop","included","~30 weeks","hospitalization","severe","severe","other combinations",81,77,84,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"473",77,"Tenforde","Case-control",476,2021-11-04,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"14-120","general pop","general pop","unknown",NA,"hospitalization","severe","severe","other combinations",85,82,88,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"474",77,"Tenforde","Case-control",477,2021-11-04,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"120+","general pop","general pop","unknown","~30 weeks","hospitalization","severe","severe","other combinations",64,51,73,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"475",77,"Tenforde","Case-control",478,2021-11-04,"Moderna mRNA-1273","mRNA","2","final",NA,"14+","general pop","general pop","unknown","~30 weeks","hospitalization","severe","severe","other combinations",89,86,92,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"476",77,"Tenforde","Case-control",479,2021-11-04,"Moderna mRNA-1273","mRNA","2","final",NA,"14-120","general pop","general pop","unknown",NA,"hospitalization","severe","severe","other combinations",91,87,93,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"477",77,"Tenforde","Case-control",480,2021-11-04,"Moderna mRNA-1273","mRNA","2","final",NA,"120+","general pop","general pop","unknown","~30 weeks","hospitalization","severe","severe","other combinations",85,77,91,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"478",77,"Tenforde","Case-control",481,2021-11-04,"Multiple or heterologous RNA","mRNA","2","final",NA,"14+","immunocompetent adults","immunocompetent adults","unknown","~30 weeks","hospitalization","severe","severe","other combinations",90,87,91,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"479",77,"Tenforde","Case-control",482,2021-11-04,"Multiple or heterologous RNA","mRNA","2","final",NA,"14+","immucompromised","immunocompromised, >= 16 years","unknown","~30 weeks","hospitalization","severe","severe","other combinations",51,31,65,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"480",77,"Tenforde","Case-control",483,2021-11-04,"Multiple or heterologous RNA","mRNA","2","final",NA,"14+","general pop","general pop","unknown","~30 weeks","hospitalization","severe","severe","alpha",90,84,94,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"481",77,"Tenforde","Case-control",484,2021-11-04,"Multiple or heterologous RNA","mRNA","2","final",NA,"14+","general pop","general pop","unknown","~30 weeks","hospitalization","severe","severe","delta",86,79,90,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"482",78,"Pouwels","Prospective cohort",485,2021-10-14,"BioNTech/Pfizer BNT162b2","mRNA","1","1",NA,"21+","general pop","general pop","included",NA,"infection","infection","infection","alpha",59,52,95,"UK","GBR","Europe","Europe & Central Asia",43240,2019,"United Kingdom","High income",4,NA,NA,NA,NA,NA
"483",78,"Pouwels","Prospective cohort",486,2021-10-14,"BioNTech/Pfizer BNT162b2","mRNA","1","1",NA,"21+","general pop","general pop","included",NA,"infection, ct<30","infection","infection","alpha",70,65,74,"UK","GBR","Europe","Europe & Central Asia",43240,2019,"United Kingdom","High income",4,NA,NA,NA,NA,NA
"484",78,"Pouwels","Prospective cohort",487,2021-10-14,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"14+","general pop","general pop","included","~28 weeks","infection","infection","infection","alpha",78,68,84,"UK","GBR","Europe","Europe & Central Asia",43240,2019,"United Kingdom","High income",4,NA,NA,NA,NA,NA
"485",78,"Pouwels","Prospective cohort",488,2021-10-14,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"14+","general pop","general pop","included","~28 weeks","infection, ct<30","infection","infection","alpha",94,94,96,"UK","GBR","Europe","Europe & Central Asia",43240,2019,"United Kingdom","High income",4,NA,NA,NA,NA,NA
"486",78,"Pouwels","Prospective cohort",489,2021-10-14,"Oxford/AstraZeneca ChAdOx1-S","Vectored","1","1",NA,"21+","general pop","general pop","included",NA,"infection","infection","infection","alpha",63,55,69,"UK","GBR","Europe","Europe & Central Asia",43240,2019,"United Kingdom","High income",4,NA,NA,NA,NA,NA
"487",78,"Pouwels","Prospective cohort",490,2021-10-14,"Oxford/AstraZeneca ChAdOx1-S","Vectored","1","1",NA,"21+","general pop","general pop","included",NA,"infection, ct<30","infection","infection","alpha",74,69,79,"UK","GBR","Europe","Europe & Central Asia",43240,2019,"United Kingdom","High income",4,NA,NA,NA,NA,NA
"488",78,"Pouwels","Prospective cohort",491,2021-10-14,"Oxford/AstraZeneca ChAdOx1-S","Vectored","2","final",NA,"14+","general pop","general pop","included","~28 weeks","infection","infection","infection","alpha",79,56,90,"UK","GBR","Europe","Europe & Central Asia",43240,2019,"United Kingdom","High income",4,NA,NA,NA,NA,NA
"489",78,"Pouwels","Prospective cohort",492,2021-10-14,"Oxford/AstraZeneca ChAdOx1-S","Vectored","2","final",NA,"14+","general pop","general pop","included","~28 weeks","infection, ct<30","infection","infection","alpha",86,71,93,"UK","GBR","Europe","Europe & Central Asia",43240,2019,"United Kingdom","High income",4,NA,NA,NA,NA,NA
"490",78,"Pouwels","Prospective cohort",493,2021-10-14,"BioNTech/Pfizer BNT162b2","mRNA","1","1",NA,"21+","general pop","general pop","included",NA,"infection","infection","infection","delta",57,50,63,"UK","GBR","Europe","Europe & Central Asia",43240,2019,"United Kingdom","High income",4,NA,NA,NA,NA,NA
"491",78,"Pouwels","Prospective cohort",494,2021-10-14,"BioNTech/Pfizer BNT162b2","mRNA","1","1",NA,"21+","general pop","general pop","included",NA,"infection, ct<30","infection","infection","delta",62,56,68,"UK","GBR","Europe","Europe & Central Asia",43240,2019,"United Kingdom","High income",4,NA,NA,NA,NA,NA
"492",78,"Pouwels","Prospective cohort",495,2021-10-14,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"14+","general pop","general pop","included","~28 weeks","infection","infection","infection","delta",80,77,83,"UK","GBR","Europe","Europe & Central Asia",43240,2019,"United Kingdom","High income",4,NA,NA,NA,NA,NA
"493",78,"Pouwels","Prospective cohort",496,2021-10-14,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"14+","general pop","general pop","included","~28 weeks","infection, ct<30","infection","infection","delta",84,82,86,"UK","GBR","Europe","Europe & Central Asia",43240,2019,"United Kingdom","High income",4,NA,NA,NA,NA,NA
"494",78,"Pouwels","Prospective cohort",497,2021-10-14,"Oxford/AstraZeneca ChAdOx1-S","Vectored","1","1",NA,"21+","general pop","general pop","included",NA,"infection","infection","infection","delta",46,35,55,"UK","GBR","Europe","Europe & Central Asia",43240,2019,"United Kingdom","High income",4,NA,NA,NA,NA,NA
"495",78,"Pouwels","Prospective cohort",498,2021-10-14,"Oxford/AstraZeneca ChAdOx1-S","Vectored","1","1",NA,"21+","general pop","general pop","included",NA,"infection, ct<30","infection","infection","delta",50,41,59,"UK","GBR","Europe","Europe & Central Asia",43240,2019,"United Kingdom","High income",4,NA,NA,NA,NA,NA
"496",78,"Pouwels","Prospective cohort",499,2021-10-14,"Oxford/AstraZeneca ChAdOx1-S","Vectored","2","final",NA,"14+","general pop","general pop","included","~28 weeks","infection","infection","infection","delta",67,62,71,"UK","GBR","Europe","Europe & Central Asia",43240,2019,"United Kingdom","High income",4,NA,NA,NA,NA,NA
"497",78,"Pouwels","Prospective cohort",500,2021-10-14,"Oxford/AstraZeneca ChAdOx1-S","Vectored","2","final",NA,"14+","general pop","general pop","included","~28 weeks","infection, ct<30","infection","infection","delta",70,65,73,"UK","GBR","Europe","Europe & Central Asia",43240,2019,"United Kingdom","High income",4,NA,NA,NA,NA,NA
"498",79,"Prasad","Retrospective cohort",501,2021-08-19,"Multiple or heterologous RNA","mRNA","2","final",NA,"14+","surgery patients","surgery patients","included","~8 weeks","post-operative infection","infection","infection","original",91,56,99,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"499",80,"Tartof","Retrospective cohort",502,2021-10-16,"BioNTech/Pfizer BNT162b2","mRNA","1","1",NA,"14+",">= 12 years","general pop","included",NA,"infection","infection","infection","other combinations",58,54,61,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"500",80,"Tartof","Retrospective cohort",503,2021-10-16,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"7+",">= 12 years","general pop","included","~29 weeks","infection","infection","infection","other combinations",73,72,74,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"501",80,"Tartof","Retrospective cohort",504,2021-10-16,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"7-36",">= 12 years","general pop","included","~3 weeks","infection","infection","infection","other combinations",88,86,89,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"502",80,"Tartof","Retrospective cohort",505,2021-10-16,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"157+",">= 12 years","general pop","included","~29 weeks","infection","infection","infection","other combinations",47,43,51,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"503",80,"Tartof","Retrospective cohort",506,2021-10-16,"BioNTech/Pfizer BNT162b2","mRNA","1","1",NA,"14+",">= 12 years","general pop","included",NA,"hospitalization","severe","severe","other combinations",54,43,63,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"504",80,"Tartof","Retrospective cohort",507,2021-10-16,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"7+",">= 12 years","general pop","included","~29 weeks","hospitalization","severe","severe","other combinations",90,89,92,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"505",80,"Tartof","Retrospective cohort",508,2021-10-16,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"7-36",">= 12 years","general pop","included","~3 weeks","hospitalization","severe","severe","other combinations",87,82,91,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"506",80,"Tartof","Retrospective cohort",509,2021-10-16,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"157+",">= 12 years","general pop","included","~29 weeks","hospitalization","severe","severe","other combinations",88,82,92,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"507",80,"Tartof","Retrospective cohort",510,2021-10-16,"BioNTech/Pfizer BNT162b2","mRNA","1","1",NA,"14+",">= 12 years","general pop","included",NA,"infection","infection","infection","delta",74,55,85,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"508",80,"Tartof","Retrospective cohort",511,2021-10-16,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"7+",">= 12 years","general pop","included","~29 weeks","infection","infection","infection","delta",75,71,78,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"509",80,"Tartof","Retrospective cohort",512,2021-10-16,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"7-36",">= 12 years","general pop","included","~3 weeks","infection","infection","infection","delta",93,85,97,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"510",80,"Tartof","Retrospective cohort",513,2021-10-16,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"127+",">= 12 years","general pop","included","~29 weeks","infection","infection","infection","delta",53,39,65,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"511",80,"Tartof","Retrospective cohort",514,2021-10-16,"BioNTech/Pfizer BNT162b2","mRNA","1","1",NA,"14+",">= 12 years","general pop","included",NA,"hospitalization","severe","severe","delta",79,-49,97,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"512",80,"Tartof","Retrospective cohort",515,2021-10-16,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"7+",">= 12 years","general pop","included","~29 weeks","hospitalization","severe","severe","delta",93,84,96,"USA","USA","North America","North America",66220,2019,"United States","High income",4,7,203,"yes",NA,0
"513",80,"Tartof","Retrospective cohort",516,2021-10-16,"BioNTech/Pfizer BNT162b2","mRNA","1","1",NA,"14+",">= 12 years","general pop","included",NA,"infection","infection","infection","other combinations",74,64,81,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"514",80,"Tartof","Retrospective cohort",517,2021-10-16,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"7+",">= 12 years","general pop","included","~29 weeks","infection","infection","infection","other combinations",91,88,92,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"515",80,"Tartof","Retrospective cohort",518,2021-10-16,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"7-36",">= 12 years","general pop","included","~3 weeks","infection","infection","infection","other combinations",97,95,99,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"516",80,"Tartof","Retrospective cohort",519,2021-10-16,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"127+",">= 12 years","general pop","included","~29 weeks","infection","infection","infection","other combinations",67,45,80,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"517",80,"Tartof","Retrospective cohort",520,2021-10-16,"BioNTech/Pfizer BNT162b2","mRNA","1","1",NA,"14+",">= 12 years","general pop","included",NA,"hospitalization","severe","severe","other combinations",75,21,92,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"518",80,"Tartof","Retrospective cohort",521,2021-10-16,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"7+",">= 12 years","general pop","included","~29 weeks","hospitalization","severe","severe","other combinations",95,90,98,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"519",81,"Golberg","Retrospective cohort",522,2021-10-27,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"168-203","16-39 years","16-39 years","excluded","28 weeks","infection","infection","infection","delta",55,50,60,"Israel","ISR","Asia","Middle East & North Africa",43800,2019,"Israel","High income",4,NA,NA,NA,NA,NA
"520",81,"Golberg","Retrospective cohort",523,2021-10-27,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"55-98","16-39 years","16-39 years","excluded","13 weeks","infection","infection","infection","delta",80,75,84,"Israel","ISR","Asia","Middle East & North Africa",43800,2019,"Israel","High income",4,NA,NA,NA,NA,NA
"521",81,"Golberg","Retrospective cohort",524,2021-10-27,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"168-203","40-59 years","40-59 years","excluded","28 weeks","infection","infection","infection","delta",57,53,61,"Israel","ISR","Asia","Middle East & North Africa",43800,2019,"Israel","High income",4,NA,NA,NA,NA,NA
"522",81,"Golberg","Retrospective cohort",525,2021-10-27,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"55-98","40-59 years","40-59 years","excluded","13 weeks","infection","infection","infection","delta",83,75,88,"Israel","ISR","Asia","Middle East & North Africa",43800,2019,"Israel","High income",4,NA,NA,NA,NA,NA
"523",81,"Golberg","Retrospective cohort",526,2021-10-27,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"168-203",">= 60 years",">= 60 years","excluded","28 weeks","infection","infection","infection","delta",57,52,62,"Israel","ISR","Asia","Middle East & North Africa",43800,2019,"Israel","High income",4,NA,NA,NA,NA,NA
"524",81,"Golberg","Retrospective cohort",527,2021-10-27,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"55-98",">= 60 years",">= 60 years","excluded","13 weeks","infection","infection","infection","delta",82,70,89,"Israel","ISR","Asia","Middle East & North Africa",43800,2019,"Israel","High income",4,NA,NA,NA,NA,NA
"525",81,"Golberg","Retrospective cohort",528,2021-10-27,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"168-203","40-59 years","40-59 years","excluded","28 weeks","severe disease","severe","severe","delta",98,94,99,"Israel","ISR","Asia","Middle East & North Africa",43800,2019,"Israel","High income",4,168,203,"no","sequential period",0
"526",81,"Golberg","Retrospective cohort",529,2021-10-27,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"168-203",">= 60 years",">= 60 years","excluded","13 weeks","severe disease","severe","severe","delta",93,86,97,"Israel","ISR","Asia","Middle East & North Africa",43800,2019,"Israel","High income",4,168,203,"no","sequential period",1
"527",81,"Golberg","Retrospective cohort",530,2021-10-27,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"109-159","40-59 years","40-59 years","excluded","22 weeks","severe disease","severe","severe","delta",92,87,95,"Israel","ISR","Asia","Middle East & North Africa",43800,2019,"Israel","High income",4,109,159,"yes",NA,0
"528",81,"Golberg","Retrospective cohort",531,2021-10-27,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"109-159",">= 60 years",">= 60 years","excluded","22 weeks","severe disease","severe","severe","delta",85,81,88,"Israel","ISR","Asia","Middle East & North Africa",43800,2019,"Israel","High income",4,109,159,"yes",NA,1
"529",82,"Chemaitelly","Test-negative case-control",532,2021-10-06,"BioNTech/Pfizer BNT162b2","mRNA","1","1",NA,"14+",">= 12 years","general pop","included",NA,"infection","infection","infection","other combinations",36.8,33.2,40.2,"Qatar","QAT","Asia","Middle East & North Africa",65700,2019,"Qatar","High income",4,NA,NA,NA,NA,NA
"530",82,"Chemaitelly","Test-negative case-control",533,2021-10-06,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"28-63",">= 12 years","general pop","included","7 weeks","infection","infection","infection","other combinations",73.2,71.3,75,"Qatar","QAT","Asia","Middle East & North Africa",65700,2019,"Qatar","High income",4,NA,NA,NA,NA,NA
"531",82,"Chemaitelly","Test-negative case-control",534,2021-10-06,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"175+",">= 12 years","general pop","included","~32 weeks","infection","infection","infection","other combinations",22.3,-1.7,40.7,"Qatar","QAT","Asia","Middle East & North Africa",65700,2019,"Qatar","High income",4,NA,NA,NA,NA,NA
"532",82,"Chemaitelly","Test-negative case-control",535,2021-10-06,"BioNTech/Pfizer BNT162b2","mRNA","1","1",NA,"14+",">= 12 years","general pop","included",NA,"symptomatic disease","symptomatic","symptomatic","other combinations",47.9,43.6,51.9,"Qatar","QAT","Asia","Middle East & North Africa",65700,2019,"Qatar","High income",4,NA,NA,NA,NA,NA
"533",82,"Chemaitelly","Test-negative case-control",536,2021-10-06,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"28-63",">= 12 years","general pop","included","7 weeks","symptomatic disease","symptomatic","symptomatic","other combinations",72.5,69.6,75.1,"Qatar","QAT","Asia","Middle East & North Africa",65700,2019,"Qatar","High income",4,NA,NA,NA,NA,NA
"534",82,"Chemaitelly","Test-negative case-control",537,2021-10-06,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"175+",">= 12 years","general pop","included","~32 weeks","symptomatic disease","symptomatic","symptomatic","other combinations",27.8,-1.4,48.7,"Qatar","QAT","Asia","Middle East & North Africa",65700,2019,"Qatar","High income",4,NA,NA,NA,NA,NA
"535",82,"Chemaitelly","Test-negative case-control",538,2021-10-06,"BioNTech/Pfizer BNT162b2","mRNA","1","1",NA,"14+",">= 12 years","general pop","included",NA,"asymptomatic infection","asymptomatic","infection","other combinations",22.2,12.1,31.2,"Qatar","QAT","Asia","Middle East & North Africa",65700,2019,"Qatar","High income",4,NA,NA,NA,NA,NA
"536",82,"Chemaitelly","Test-negative case-control",539,2021-10-06,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"28-63",">= 12 years","general pop","included","7 weeks","asymptomatic infection","asymptomatic","infection","other combinations",66.9,61.9,71.3,"Qatar","QAT","Asia","Middle East & North Africa",65700,2019,"Qatar","High income",4,NA,NA,NA,NA,NA
"537",82,"Chemaitelly","Test-negative case-control",540,2021-10-06,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"175+",">= 12 years","general pop","included","~29 weeks","asymptomatic infection","asymptomatic","infection","other combinations",-33.3,-181.8,36.9,"Qatar","QAT","Asia","Middle East & North Africa",65700,2019,"Qatar","High income",4,NA,NA,NA,NA,NA
"538",82,"Chemaitelly","Test-negative case-control",541,2021-10-06,"BioNTech/Pfizer BNT162b2","mRNA","1","1",NA,"14+",">= 12 years","general pop","included",NA,"severe, critical, fatal disease","severe","severe","other combinations",66.1,56.8,73.5,"Qatar","QAT","Asia","Middle East & North Africa",65700,2019,"Qatar","High income",4,NA,NA,NA,NA,NA
"539",82,"Chemaitelly","Test-negative case-control",542,2021-10-06,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"28-63",">= 12 years","general pop","included","7 weeks","severe, critical, fatal disease","severe","severe","other combinations",96.8,93.9,98.3,"Qatar","QAT","Asia","Middle East & North Africa",65700,2019,"Qatar","High income",4,NA,NA,NA,NA,NA
"540",82,"Chemaitelly","Test-negative case-control",543,2021-10-06,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"175+",">= 12 years","general pop","included","~32 weeks","severe, critical, fatal disease","severe","severe","other combinations",55.6,-44.3,86.3,"Qatar","QAT","Asia","Middle East & North Africa",65700,2019,"Qatar","High income",4,NA,NA,NA,NA,NA
"541",82,"Chemaitelly","Test-negative case-control",544,2021-10-06,"BioNTech/Pfizer BNT162b2","mRNA","1","1",NA,"14+",">= 12 years","general pop","included",NA,"infection","infection","infection","alpha",47.9,15.5,67.9,"Qatar","QAT","Asia","Middle East & North Africa",65700,2019,"Qatar","High income",4,NA,NA,NA,NA,NA
"542",82,"Chemaitelly","Test-negative case-control",545,2021-10-06,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"28-63",">= 12 years","general pop","included","7 weeks","infection","infection","infection","alpha",88.6,79.2,93.7,"Qatar","QAT","Asia","Middle East & North Africa",65700,2019,"Qatar","High income",4,NA,NA,NA,NA,NA
"543",82,"Chemaitelly","Test-negative case-control",546,2021-10-06,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"147+",">= 12 years","general pop","included","~29 weeks","infection","infection","infection","alpha",80,-71.2,97.7,"Qatar","QAT","Asia","Middle East & North Africa",65700,2019,"Qatar","High income",4,NA,NA,NA,NA,NA
"544",82,"Chemaitelly","Test-negative case-control",547,2021-10-06,"BioNTech/Pfizer BNT162b2","mRNA","1","1",NA,"14+",">= 12 years","general pop","included",NA,"infection","infection","infection","beta",25.8,-2,46.1,"Qatar","QAT","Asia","Middle East & North Africa",65700,2019,"Qatar","High income",4,NA,NA,NA,NA,NA
"545",82,"Chemaitelly","Test-negative case-control",548,2021-10-06,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"28-63",">= 12 years","general pop","included","7 weeks","infection","infection","infection","beta",63.9,52.6,72.5,"Qatar","QAT","Asia","Middle East & North Africa",65700,2019,"Qatar","High income",4,NA,NA,NA,NA,NA
"546",82,"Chemaitelly","Test-negative case-control",549,2021-10-06,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"147+",">= 12 years","general pop","included","~29 weeks","infection","infection","infection","beta",40,-151.1,85.7,"Qatar","QAT","Asia","Middle East & North Africa",65700,2019,"Qatar","High income",4,NA,NA,NA,NA,NA
"547",82,"Chemaitelly","Test-negative case-control",550,2021-10-06,"BioNTech/Pfizer BNT162b2","mRNA","1","1",NA,"14+",">= 12 years","general pop","included",NA,"infection","infection","infection","delta",63.4,42.6,76.6,"Qatar","QAT","Asia","Middle East & North Africa",65700,2019,"Qatar","High income",4,NA,NA,NA,NA,NA
"548",82,"Chemaitelly","Test-negative case-control",551,2021-10-06,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"28-63",">= 12 years","general pop","included","7 weeks","infection","infection","infection","delta",73.3,63.6,80.4,"Qatar","QAT","Asia","Middle East & North Africa",65700,2019,"Qatar","High income",4,NA,NA,NA,NA,NA
"549",82,"Chemaitelly","Test-negative case-control",552,2021-10-06,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"147+",">= 12 years","general pop","included","~29 weeks","infection","infection","infection","delta",17.9,-12.9,40.3,"Qatar","QAT","Asia","Middle East & North Africa",65700,2019,"Qatar","High income",4,NA,NA,NA,NA,NA
"550",83,"Nunes","Retrospective cohort",553,2021-09-23,"Multiple or heterologous RNA","mRNA","1","1",NA,"14+ up to <14 post 2nd dose","65-79 years","65-79 years","excluded",NA,"hospitalization","severe","severe","other combinations",78,61,87,"Portugal","PRT","Europe","Europe & Central Asia",23180,2019,"Portugal","High income",4,NA,NA,NA,NA,NA
"551",83,"Nunes","Retrospective cohort",554,2021-09-23,"Multiple or heterologous RNA","mRNA","2","final",NA,"14+","65-79 years","65-79 years","excluded","~14.5 weeks","hospitalization","severe","severe","other combinations",94,88,97,"Portugal","PRT","Europe","Europe & Central Asia",23180,2019,"Portugal","High income",4,NA,NA,NA,NA,NA
"552",83,"Nunes","Retrospective cohort",555,2021-09-23,"Multiple or heterologous RNA","mRNA","1","1",NA,"14+ up to <14 post 2nd dose","65-79 years","65-79 years","excluded",NA,"death","death","death","other combinations",77,56,88,"Portugal","PRT","Europe","Europe & Central Asia",23180,2019,"Portugal","High income",4,NA,NA,NA,NA,NA
"553",83,"Nunes","Retrospective cohort",556,2021-09-23,"Multiple or heterologous RNA","mRNA","2","final",NA,"14+","65-79 years","65-79 years","excluded","~14.5 weeks","death","death","death","other combinations",96,92,98,"Portugal","PRT","Europe","Europe & Central Asia",23180,2019,"Portugal","High income",4,NA,NA,NA,NA,NA
"554",83,"Nunes","Retrospective cohort",557,2021-09-23,"Multiple or heterologous RNA","mRNA","1","1",NA,"14+ up to <14 post 2nd dose",">= 80 years",">= 80 years","excluded",NA,"hospitalization","severe","severe","other combinations",55,36,69,"Portugal","PRT","Europe","Europe & Central Asia",23180,2019,"Portugal","High income",4,NA,NA,NA,NA,NA
"555",83,"Nunes","Retrospective cohort",558,2021-09-23,"Multiple or heterologous RNA","mRNA","2","final",NA,"14+",">= 80 years",">= 80 years","excluded","~22.5 weeks","hospitalization","severe","severe","other combinations",82,72,89,"Portugal","PRT","Europe","Europe & Central Asia",23180,2019,"Portugal","High income",4,NA,NA,NA,NA,NA
"556",83,"Nunes","Retrospective cohort",559,2021-09-23,"Multiple or heterologous RNA","mRNA","1","1",NA,"14+ up to <14 post 2nd dose",">= 80 years",">= 80 years","excluded",NA,"death","death","death","other combinations",56,35,70,"Portugal","PRT","Europe","Europe & Central Asia",23180,2019,"Portugal","High income",4,NA,NA,NA,NA,NA
"557",83,"Nunes","Retrospective cohort",560,2021-09-23,"Multiple or heterologous RNA","mRNA","2","final",NA,"14+",">= 80 years",">= 80 years","excluded","~22.5 weeks","death","death","death","other combinations",81,74,87,"Portugal","PRT","Europe","Europe & Central Asia",23180,2019,"Portugal","High income",4,NA,NA,NA,NA,NA
"558",84,"Katz","Prospective cohort",561,2021-12-10,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"14+","HCW","HCW","included","~18 weeks","infection","infection","infection","alpha",94.5,82.5,98.2,"Israel","ISR","Asia","Middle East & North Africa",43800,2019,"Israel","High income",4,NA,NA,NA,NA,NA
"559",84,"Katz","Prospective cohort",562,2021-12-10,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"7+","HCW","HCW","included","~18 weeks","symptomatic disease","symptomatic","symptomatic","alpha",97,72,99.7,"Israel","ISR","Asia","Middle East & North Africa",43800,2019,"Israel","High income",4,NA,NA,NA,NA,NA
"560",85,"Giansante","Retrospective cohort",563,2021-09-02,"Multiple or heterologous RNA","mRNA","1","1",NA,"14+","HCW and staff","HCW and staff","excluded",NA,"infection","infection","infection","other combinations",85.5,75.9,91.3,"Italy","ITA","Europe","Europe & Central Asia",34890,2019,"Italy","High income",4,NA,NA,NA,NA,NA
"561",85,"Giansante","Retrospective cohort",564,2021-09-02,"Multiple or heterologous RNA","mRNA","2","final",NA,"14+","HCW and staff","HCW and staff","excluded","~16 weeks","infection","infection","infection","other combinations",84.8,73.2,91.4,"Italy","ITA","Europe","Europe & Central Asia",34890,2019,"Italy","High income",4,NA,NA,NA,NA,NA
"562",85,"Giansante","Retrospective cohort",565,2021-09-02,"Multiple or heterologous RNA","mRNA","1","1",NA,"14+","HCW and staff","HCW and staff","excluded",NA,"symptomatic disease","symptomatic","symptomatic","other combinations",81.7,62.7,91,"Italy","ITA","Europe","Europe & Central Asia",34890,2019,"Italy","High income",4,NA,NA,NA,NA,NA
"563",85,"Giansante","Retrospective cohort",566,2021-09-02,"Multiple or heterologous RNA","mRNA","2","final",NA,"14+","HCW and staff","HCW and staff","excluded","~16 weeks","symptomatic disease","symptomatic","symptomatic","other combinations",87.1,69.3,94.6,"Italy","ITA","Europe","Europe & Central Asia",34890,2019,"Italy","High income",4,NA,NA,NA,NA,NA
"564",85,"Giansante","Retrospective cohort",567,2021-09-02,"Multiple or heterologous RNA","mRNA","1","1",NA,"14+","HCW","HCW","excluded",NA,"infection","infection","infection","other combinations",87.8,76.5,93.7,"Italy","ITA","Europe","Europe & Central Asia",34890,2019,"Italy","High income",4,NA,NA,NA,NA,NA
"565",85,"Giansante","Retrospective cohort",568,2021-09-02,"Multiple or heterologous RNA","mRNA","2","final",NA,"14+","HCW","HCW","excluded","~16 weeks","infection","infection","infection","other combinations",84.4,69.7,92,"Italy","ITA","Europe","Europe & Central Asia",34890,2019,"Italy","High income",4,NA,NA,NA,NA,NA
"566",85,"Giansante","Retrospective cohort",569,2021-09-02,"Multiple or heterologous RNA","mRNA","1","1",NA,"14+","HCW","HCW","excluded",NA,"symptomatic disease","symptomatic","symptomatic","other combinations",83.1,60,92.9,"Italy","ITA","Europe","Europe & Central Asia",34890,2019,"Italy","High income",4,NA,NA,NA,NA,NA
"567",85,"Giansante","Retrospective cohort",570,2021-09-02,"Multiple or heterologous RNA","mRNA","2","final",NA,"14+","HCW","HCW","excluded","~16 weeks","symptomatic disease","symptomatic","symptomatic","other combinations",86.5,62.9,95.1,"Italy","ITA","Europe","Europe & Central Asia",34890,2019,"Italy","High income",4,NA,NA,NA,NA,NA
"568",86,"Bruxvoort","Matched prospective cohort",571,2021-11-24,"Moderna mRNA-1273","mRNA","2","final",NA,"14+","adults","general pop","included","~20 weeks","infection","infection","infection","other combinations",87.4,85.6,89.1,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"569",86,"Bruxvoort","Matched prospective cohort",572,2021-11-24,"Moderna mRNA-1273","mRNA","2","final",NA,"14+","adults","general pop","included","~20 weeks","asymptomatic infection","asymptomatic","infection","other combinations",72.7,57.6,82.4,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"570",86,"Bruxvoort","Matched prospective cohort",573,2021-11-24,"Moderna mRNA-1273","mRNA","2","final",NA,"14+","adults","general pop","included","~20 weeks","symptomatic disease","symptomatic","symptomatic","other combinations",88.3,86.5,89.9,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"571",86,"Bruxvoort","Matched prospective cohort",574,2021-11-24,"Moderna mRNA-1273","mRNA","2","final",NA,"14+","adults","general pop","included","~20 weeks","hospitalization","severe","severe","other combinations",95.8,92.5,97.6,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"572",86,"Bruxvoort","Matched prospective cohort",575,2021-11-24,"Moderna mRNA-1273","mRNA","2","final",NA,"14+","adults","general pop","included","~20 weeks","death","death","death","other combinations",97.9,84.5,99.7,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"573",87,"Barlow","Test-negative case-control",576,2021-09-03,"Multiple or heterologous RNA","mRNA","2","final",NA,"14+",">= 15 years","general pop","excluded","~4 weeks","infection","infection","infection","delta",74,65,82,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"574",87,"Barlow","Test-negative case-control",577,2021-09-03,"Janssen Ad26.COV2.S","Vectored","1","final",NA,"14+",">= 15 years","general pop","excluded","~4 weeks","infection","infection","infection","delta",51,-2,76,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"575",88,"Tande","Retrospective cohort",578,2021-09-06,"Multiple or heterologous RNA","mRNA","1","1",NA,"20+","surgery patients","surgery patients","included",NA,"asymptomatic infection (January-March)","asymptomatic","infection","original",44,-6,71,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"576",88,"Tande","Retrospective cohort",579,2021-09-06,"Multiple or heterologous RNA","mRNA","2","final",NA,"14+","surgery patients","surgery patients","included","~10 weeks","asymptomatic infection (January-March)","asymptomatic","infection","original",91,72,98,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"577",88,"Tande","Retrospective cohort",580,2021-09-06,"Multiple or heterologous RNA","mRNA","1","1",NA,"20+","surgery patients","surgery patients","included",NA,"asymptomatic infection (April-May)","asymptomatic","infection","alpha",46,53,83,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"578",88,"Tande","Retrospective cohort",581,2021-09-06,"Multiple or heterologous RNA","mRNA","2","final",NA,"14+","surgery patients","surgery patients","included","~19 weeks","asymptomatic infection (April-May)","asymptomatic","infection","alpha",71,53,83,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"579",88,"Tande","Retrospective cohort",582,2021-09-06,"Multiple or heterologous RNA","mRNA","1","1",NA,"20+","surgery patients","surgery patients","included",NA,"asymptomatic infection (June-August)","asymptomatic","infection","delta",63,44,76,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"580",88,"Tande","Retrospective cohort",583,2021-09-06,"Multiple or heterologous RNA","mRNA","2","final",NA,"14+","surgery patients","surgery patients","included","~32 weeks","asymptomatic infection (June-August)","asymptomatic","infection","delta",63,44,76,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"581",89,"Iliaki","Retrospective cohort",584,2021-10-18,"Multiple or heterologous RNA","mRNA","1","1",NA,"14+","HCW","HCW","excluded",NA,"infection","infection","infection","alpha",80.2,57.5,90.8,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"582",89,"Iliaki","Retrospective cohort",585,2021-10-18,"Multiple or heterologous RNA","mRNA","2","final",NA,"14+","HCW","HCW","excluded","~10 weeks","infection","infection","infection","alpha",95.2,80,98.8,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"583",90,"Thompson","Test-negative case-control",586,2021-09-08,"BioNTech/Pfizer BNT162b2","mRNA","1","1",NA,"14+",">= 50 years",">= 50 years","excluded",NA,"hospitalization","severe","severe","other combinations",33,18,46,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"584",90,"Thompson","Test-negative case-control",587,2021-09-08,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"14+",">= 50 years",">= 50 years","excluded","~22 weeks","hospitalization","severe","severe","other combinations",87,85,90,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"585",90,"Thompson","Test-negative case-control",588,2021-09-08,"BioNTech/Pfizer BNT162b2","mRNA","1","1",NA,"14+",">= 50 years",">= 50 years","excluded",NA,"ED or UC visit","symptomatic","symptomatic","other combinations",58,46,68,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"586",90,"Thompson","Test-negative case-control",589,2021-09-08,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"14+",">= 50 years",">= 50 years","excluded","~22 weeks","ED or UC visit","symptomatic","symptomatic","other combinations",89,85,91,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"587",90,"Thompson","Test-negative case-control",590,2021-09-08,"Moderna mRNA-1273","mRNA","1","1",NA,"14+",">= 50 years",">= 50 years","excluded",NA,"hospitalization","severe","severe","other combinations",68,59,75,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"588",90,"Thompson","Test-negative case-control",591,2021-09-08,"Moderna mRNA-1273","mRNA","2","final",NA,"14+",">= 50 years",">= 50 years","excluded","20 weeks","hospitalization","severe","severe","other combinations",91,89,93,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"589",90,"Thompson","Test-negative case-control",592,2021-09-08,"Moderna mRNA-1273","mRNA","1","1",NA,"14+",">= 50 years",">= 50 years","excluded",NA,"ED or UC visit","symptomatic","symptomatic","other combinations",73,64,79,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"590",90,"Thompson","Test-negative case-control",593,2021-09-08,"Moderna mRNA-1273","mRNA","2","final",NA,"14+",">= 50 years",">= 50 years","excluded","20 weeks","ED or UC visit","symptomatic","symptomatic","other combinations",92,89,94,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"591",90,"Thompson","Test-negative case-control",594,2021-09-08,"Janssen Ad26.COV2.S","Vectored","1","final",NA,"14+",">= 50 years",">= 50 years","excluded","14 weeks","hospitalization","severe","severe","other combinations",68,50,79,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"592",90,"Thompson","Test-negative case-control",595,2021-09-08,"Janssen Ad26.COV2.S","Vectored","1","final",NA,"14+",">= 50 years",">= 50 years","excluded","14 weeks","ED or UC visit","symptomatic","symptomatic","other combinations",73,59,82,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"593",90,"Thompson","Test-negative case-control",596,2021-09-08,"Multiple or heterologous RNA","mRNA","1","1",NA,"14+",">= 50 years with >= 1 chronic respiratory condition",">= 50 years with >= 1 chronic respiratory condition","excluded",NA,"hospitalization","severe","severe","other combinations",56,47,64,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"594",90,"Thompson","Test-negative case-control",597,2021-09-08,"Multiple or heterologous RNA","mRNA","2","final",NA,"14+",">= 50 years with >= 1 chronic respiratory condition",">= 50 years with >= 1 chronic respiratory condition","excluded","~22 weeks","hospitalization","severe","severe","other combinations",90,88,92,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"595",90,"Thompson","Test-negative case-control",598,2021-09-08,"Multiple or heterologous RNA","mRNA","1","1",NA,"14+",">= 50 years with >= 1 chronic non-respiratory condition",">= 50 years with >= 1 chronic non-respiratory condition","excluded",NA,"hospitalization","severe","severe","other combinations",54,45,61,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"596",90,"Thompson","Test-negative case-control",599,2021-09-08,"Multiple or heterologous RNA","mRNA","2","final",NA,"14+",">= 50 years with >= 1 chronic non-respiratory condition",">= 50 years with >= 1 chronic non-respiratory condition","excluded","~22 weeks","hospitalization","severe","severe","other combinations",88,86,90,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"597",90,"Thompson","Test-negative case-control",600,2021-09-08,"Multiple or heterologous RNA","mRNA","2","final",NA,"14-27",">= 50 years",">= 50 years","excluded","~2 weeks","hospitalization","severe","severe","other combinations",88,84,92,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"598",90,"Thompson","Test-negative case-control",601,2021-09-08,"Multiple or heterologous RNA","mRNA","2","final",NA,"112+",">= 50 years",">= 50 years","excluded","~22 weeks","hospitalization","severe","severe","other combinations",86,74,93,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"599",90,"Thompson","Test-negative case-control",602,2021-09-08,"Multiple or heterologous RNA","mRNA","2","final",NA,"14-27",">= 50 years",">= 50 years","excluded","~2 weeks","ED or UC visit","symptomatic","symptomatic","other combinations",92,88,95,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"600",90,"Thompson","Test-negative case-control",603,2021-09-08,"Multiple or heterologous RNA","mRNA","2","final",NA,"112+",">= 50 years",">= 50 years","excluded","~22 weeks","ED or UC visit","symptomatic","symptomatic","other combinations",86,74,93,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"601",91,"Dagan","Prospective cohort",604,2021-09-07,"Multiple or heterologous RNA","mRNA","1","1",NA,"21-27","pregnant women","pregnant persons","excluded",NA,"infection","infection","infection","alpha",71,33,94,"Israel","ISR","Asia","Middle East & North Africa",43800,2019,"Israel","High income",4,NA,NA,NA,NA,NA
"602",91,"Dagan","Prospective cohort",605,2021-09-07,"Multiple or heterologous RNA","mRNA","2","final",NA,"7-56","pregnant women","pregnant persons","excluded","~11 weeks","infection","infection","infection","alpha",96,89,100,"Israel","ISR","Asia","Middle East & North Africa",43800,2019,"Israel","High income",4,NA,NA,NA,NA,NA
"603",91,"Dagan","Prospective cohort",606,2021-09-07,"Multiple or heterologous RNA","mRNA","1","1",NA,"21-27","pregnant women","pregnant persons","excluded",NA,"symptomatic disease","symptomatic","symptomatic","alpha",76,30,100,"Israel","ISR","Asia","Middle East & North Africa",43800,2019,"Israel","High income",4,NA,NA,NA,NA,NA
"604",91,"Dagan","Prospective cohort",607,2021-09-07,"Multiple or heterologous RNA","mRNA","2","final",NA,"7-56","pregnant women","pregnant persons","excluded","~11 weeks","symptomatic disease","symptomatic","symptomatic","alpha",97,91,100,"Israel","ISR","Asia","Middle East & North Africa",43800,2019,"Israel","High income",4,NA,NA,NA,NA,NA
"605",91,"Dagan","Prospective cohort",608,2021-09-07,"Multiple or heterologous RNA","mRNA","2","final",NA,"7-56","pregnant women","pregnant persons","excluded","~11 weeks","hospitalization","severe","severe","alpha",89,43,100,"Israel","ISR","Asia","Middle East & North Africa",43800,2019,"Israel","High income",4,NA,NA,NA,NA,NA
"606",92,"Grannis","Test-negative case-control",609,2021-09-10,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"14+",">= 18 years","general pop","included","4 weeks","hospitalization","severe","severe","delta",80,73,85,"USA","USA","North America","North America",66220,2019,"United States","High income",4,14,28,"yes",NA,0
"607",92,"Grannis","Test-negative case-control",610,2021-09-10,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"14+",">= 18 years","general pop","included","4 weeks","ED or UC visit","symptomatic","symptomatic","delta",77,74,80,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"608",92,"Grannis","Test-negative case-control",611,2021-09-10,"Moderna mRNA-1273","mRNA","2","final",NA,"14+",">= 18 years","general pop","included","4 weeks","hospitalization","severe","severe","delta",95,92,97,"USA","USA","North America","North America",66220,2019,"United States","High income",4,14,28,"yes",NA,0
"609",92,"Grannis","Test-negative case-control",612,2021-09-10,"Moderna mRNA-1273","mRNA","2","final",NA,"14+",">= 18 years","general pop","included","4 weeks","ED or UC visit","symptomatic","symptomatic","delta",92,89,93,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"610",92,"Grannis","Test-negative case-control",613,2021-09-10,"Janssen Ad26.COV2.S","Vectored","1","final",NA,"14+",">= 18 years","general pop","included","4 weeks","hospitalization","severe","severe","delta",60,31,77,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"611",92,"Grannis","Test-negative case-control",614,2021-09-10,"Janssen Ad26.COV2.S","Vectored","1","final",NA,"14+",">= 18 years","general pop","included","4 weeks","ED or UC visit","symptomatic","symptomatic","delta",65,56,72,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"612",93,"Polinski","Retrospective cohort",615,2022-03-17,"Janssen Ad26.COV2.S","Vectored","1","final",NA,"14+",">= 18 years","general pop","excluded","~14 weeks","infection","infection","infection","alpha",76,75,77,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"613",93,"Polinski","Retrospective cohort",616,2022-03-17,"Janssen Ad26.COV2.S","Vectored","1","final",NA,"14+",">= 18 years","general pop","excluded","~14 weeks","hospitalization","severe","severe","alpha",81,78,82,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"614",93,"Polinski","Retrospective cohort",617,2022-03-17,"Janssen Ad26.COV2.S","Vectored","1","final",NA,"14+","immunocompromised, >= 18 years","immunocompromised adults","excluded","~14 weeks","infection","infection","infection","alpha",64,59,68,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"615",93,"Polinski","Retrospective cohort",618,2022-03-17,"Janssen Ad26.COV2.S","Vectored","1","final",NA,"14+","immunocompromised, >= 18 years","immunocompromised adults","excluded","~14 weeks","hospitalization","severe","severe","alpha",67,57,74,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"616",93,"Polinski","Retrospective cohort",619,2022-03-17,"Janssen Ad26.COV2.S","Vectored","1","final",NA,"14+",">= 18 years","general pop","excluded","~14 weeks","infection (June-July)","infection","infection","delta",74,71,77,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"617",93,"Polinski","Retrospective cohort",620,2022-03-17,"Janssen Ad26.COV2.S","Vectored","1","final",NA,"14+",">= 18 years","general pop","excluded","~14 weeks","hospitalization (June-July)","severe","severe","delta",81,75,86,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"618",94,"Bajema","Test-negative case-control",621,2021-09-10,"Multiple or heterologous RNA","mRNA","2","final",NA,"<104 days","hospitalized veterans","hospitalized veterans","excluded","~13 weeks","hospitalization","severe","severe","other combinations",86.1,76.5,91.8,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"619",94,"Bajema","Test-negative case-control",622,2021-09-10,"Multiple or heterologous RNA","mRNA","2","final",NA,">104 days","hospitalized veterans","hospitalized veterans","excluded","~28.5 weeks","hospitalization","severe","severe","other combinations",87.2,78.2,92.5,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"620",94,"Bajema","Test-negative case-control",623,2021-09-10,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"14+","hospitalized veterans","hospitalized veterans","excluded","~28.5 weeks","hospitalization","severe","severe","other combinations",83.4,74,89.4,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"621",94,"Bajema","Test-negative case-control",624,2021-09-10,"Moderna mRNA-1273","mRNA","2","final",NA,"14+","hospitalized veterans","hospitalized veterans","excluded","~26.5 weeks","hospitalization","severe","severe","other combinations",91.6,83.5,95.7,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"622",94,"Bajema","Test-negative case-control",625,2021-09-10,"Multiple or heterologous RNA","mRNA","2","final",NA,"14+","hospitalized veterans","hospitalized veterans","excluded","~23 weeks","hospitalization (February-June)","severe","severe","alpha",84.1,74.1,90.2,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"623",94,"Bajema","Test-negative case-control",626,2021-09-10,"Multiple or heterologous RNA","mRNA","2","final",NA,"14+","hospitalized veterans","hospitalized veterans","excluded","~28.5 weeks","hospitalization (July-August)","severe","severe","delta",89.3,80.1,94.3,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"624",95,"Andrews","Test-negative case-control",627,2022-01-12,"BioNTech/Pfizer BNT162b2","mRNA","1","1",NA,"28+",">= 16 years","general pop","excluded",NA,"symptomatic disease","symptomatic","symptomatic","alpha",45.9,44.2,47.6,"UK","GBR","Europe","Europe & Central Asia",43240,2019,"United Kingdom","High income",4,NA,NA,NA,NA,NA
"625",95,"Andrews","Test-negative case-control",628,2022-01-12,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"14+",">= 16 years","general pop","excluded","~33.5 weeks","symptomatic disease","symptomatic","symptomatic","alpha",94.9,93.6,95.9,"UK","GBR","Europe","Europe & Central Asia",43240,2019,"United Kingdom","High income",4,NA,NA,NA,NA,NA
"626",95,"Andrews","Test-negative case-control",629,2022-01-12,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"70+",">= 16 years","general pop","excluded","~8 weeks","symptomatic disease","symptomatic","symptomatic","alpha",94.8,88.4,97.7,"UK","GBR","Europe","Europe & Central Asia",43240,2019,"United Kingdom","High income",4,NA,NA,NA,NA,NA
"627",95,"Andrews","Test-negative case-control",630,2022-01-12,"BioNTech/Pfizer BNT162b2","mRNA","1","1",NA,"28+",">= 16 years","general pop","excluded",NA,"hospitalization","severe","severe","alpha",85.2,81.6,88.1,"UK","GBR","Europe","Europe & Central Asia",43240,2019,"United Kingdom","High income",4,NA,NA,NA,NA,NA
"628",95,"Andrews","Test-negative case-control",631,2022-01-12,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"14-63",">= 16 years","general pop","excluded","~33.5 weeks","hospitalization","severe","severe","alpha",97.7,90.8,99.4,"UK","GBR","Europe","Europe & Central Asia",43240,2019,"United Kingdom","High income",4,NA,NA,NA,NA,NA
"629",95,"Andrews","Test-negative case-control",632,2022-01-12,"BioNTech/Pfizer BNT162b2","mRNA","1","1",NA,"28+",">= 16 years","general pop","excluded",NA,"death","death","death","alpha",73.1,65,79.3,"UK","GBR","Europe","Europe & Central Asia",43240,2019,"United Kingdom","High income",4,NA,NA,NA,NA,NA
"630",95,"Andrews","Test-negative case-control",633,2022-01-12,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"14+",">= 16 years","general pop","excluded","~33.5 weeks","death","death","death","alpha",96.6,94.4,96.5,"UK","GBR","Europe","Europe & Central Asia",43240,2019,"United Kingdom","High income",4,NA,NA,NA,NA,NA
"631",95,"Andrews","Test-negative case-control",634,2022-01-12,"Oxford/AstraZeneca ChAdOx1-S","Vectored","1","1",NA,"28+",">= 16 years","general pop","excluded",NA,"symptomatic disease","symptomatic","symptomatic","alpha",45.1,43.3,46.7,"UK","GBR","Europe","Europe & Central Asia",43240,2019,"United Kingdom","High income",4,NA,NA,NA,NA,NA
"632",95,"Andrews","Test-negative case-control",635,2022-01-12,"Oxford/AstraZeneca ChAdOx1-S","Vectored","2","final",NA,"14+",">= 16 years","general pop","excluded","~20.5 weeks","symptomatic disease","symptomatic","symptomatic","alpha",82.1,79.4,84.5,"UK","GBR","Europe","Europe & Central Asia",43240,2019,"United Kingdom","High income",4,NA,NA,NA,NA,NA
"633",95,"Andrews","Test-negative case-control",636,2022-01-12,"Oxford/AstraZeneca ChAdOx1-S","Vectored","2","final",NA,"14-63",">= 16 years","general pop","excluded","~8 weeks","symptomatic disease","symptomatic","symptomatic","alpha",82.4,79.6,84.7,"UK","GBR","Europe","Europe & Central Asia",43240,2019,"United Kingdom","High income",4,NA,NA,NA,NA,NA
"634",95,"Andrews","Test-negative case-control",637,2022-01-12,"Oxford/AstraZeneca ChAdOx1-S","Vectored","2","final",NA,"70+",">= 16 years","general pop","excluded","~20.5 weeks","symptomatic disease","symptomatic","symptomatic","alpha",76.2,49.8,88.7,"UK","GBR","Europe","Europe & Central Asia",43240,2019,"United Kingdom","High income",4,NA,NA,NA,NA,NA
"635",95,"Andrews","Test-negative case-control",638,2022-01-12,"Oxford/AstraZeneca ChAdOx1-S","Vectored","1","1",NA,"28+",">= 16 years","general pop","excluded",NA,"hospitalization","severe","severe","alpha",82.5,78.7,85.7,"UK","GBR","Europe","Europe & Central Asia",43240,2019,"United Kingdom","High income",4,NA,NA,NA,NA,NA
"636",95,"Andrews","Test-negative case-control",639,2022-01-12,"Oxford/AstraZeneca ChAdOx1-S","Vectored","2","final",NA,"14-63",">= 16 years","general pop","excluded","~20.5 weeks","hospitalization","severe","severe","alpha",95.1,86.7,98.2,"UK","GBR","Europe","Europe & Central Asia",43240,2019,"United Kingdom","High income",4,NA,NA,NA,NA,NA
"637",95,"Andrews","Test-negative case-control",640,2022-01-12,"Oxford/AstraZeneca ChAdOx1-S","Vectored","2","final",NA,"70+",">= 16 years","general pop","excluded","~20.5 weeks","hospitalization","severe","severe","alpha",100,NA,NA,"UK","GBR","Europe","Europe & Central Asia",43240,2019,"United Kingdom","High income",4,NA,NA,NA,NA,NA
"638",95,"Andrews","Test-negative case-control",641,2022-01-12,"Oxford/AstraZeneca ChAdOx1-S","Vectored","1","1",NA,"28+",">= 16 years","general pop","excluded",NA,"death","death","death","alpha",79.1,68.8,86,"UK","GBR","Europe","Europe & Central Asia",43240,2019,"United Kingdom","High income",4,NA,NA,NA,NA,NA
"639",95,"Andrews","Test-negative case-control",642,2022-01-12,"Oxford/AstraZeneca ChAdOx1-S","Vectored","2","final",NA,"14+",">= 16 years","general pop","excluded","~20.5 weeks","death","death","death","alpha",100,NA,NA,"UK","GBR","Europe","Europe & Central Asia",43240,2019,"United Kingdom","High income",4,NA,NA,NA,NA,NA
"640",95,"Andrews","Test-negative case-control",643,2022-01-12,"Moderna mRNA-1273","mRNA","1","1",NA,"28+",">= 16 years","general pop","excluded",NA,"symptomatic disease","symptomatic","symptomatic","alpha",58.1,11.7,80.1,"UK","GBR","Europe","Europe & Central Asia",43240,2019,"United Kingdom","High income",4,NA,NA,NA,NA,NA
"641",95,"Andrews","Test-negative case-control",644,2022-01-12,"BioNTech/Pfizer BNT162b2","mRNA","1","1",NA,"28+",">= 16 years","general pop","excluded",NA,"symptomatic disease","symptomatic","symptomatic","delta",51.2,50.7,51.7,"UK","GBR","Europe","Europe & Central Asia",43240,2019,"United Kingdom","High income",4,NA,NA,NA,NA,NA
"642",95,"Andrews","Test-negative case-control",645,2022-01-12,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"14+",">= 16 years","general pop","excluded","~33.5 weeks","symptomatic disease","symptomatic","symptomatic","delta",83.3,83.1,83.5,"UK","GBR","Europe","Europe & Central Asia",43240,2019,"United Kingdom","High income",4,NA,NA,NA,NA,NA
"643",95,"Andrews","Test-negative case-control",646,2022-01-12,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"14-69",">= 16 years","general pop","excluded","~8 weeks","symptomatic disease","symptomatic","symptomatic","delta",89.8,89.6,90,"UK","GBR","Europe","Europe & Central Asia",43240,2019,"United Kingdom","High income",4,NA,NA,NA,NA,NA
"644",95,"Andrews","Test-negative case-control",647,2022-01-12,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"140+",">= 16 years","general pop","excluded","~33.5 weeks","symptomatic disease","symptomatic","symptomatic","delta",69.7,68.7,70.5,"UK","GBR","Europe","Europe & Central Asia",43240,2019,"United Kingdom","High income",4,NA,NA,NA,NA,NA
"645",95,"Andrews","Test-negative case-control",648,2022-01-12,"BioNTech/Pfizer BNT162b2","mRNA","1","1",NA,"28+",">= 16 years","general pop","excluded",NA,"hospitalization","severe","severe","delta",91.1,89.7,92.3,"UK","GBR","Europe","Europe & Central Asia",43240,2019,"United Kingdom","High income",4,NA,NA,NA,NA,NA
"646",95,"Andrews","Test-negative case-control",649,2022-01-12,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"14+",">= 16 years","general pop","excluded","~33.5 weeks","hospitalization","severe","severe","delta",96.6,96.2,96.9,"UK","GBR","Europe","Europe & Central Asia",43240,2019,"United Kingdom","High income",4,14,234.5,"yes",NA,0
"647",95,"Andrews","Test-negative case-control",650,2022-01-12,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"14-69",">= 16 years","general pop","excluded","~8 weeks","hospitalization","severe","severe","delta",98.4,97.9,98.8,"UK","GBR","Europe","Europe & Central Asia",43240,2019,"United Kingdom","High income",4,14,69,"no","nested period",0
"648",95,"Andrews","Test-negative case-control",651,2022-01-12,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"140+",">= 16 years","general pop","excluded","~33.5 weeks","hospitalization","severe","severe","delta",92.7,90.3,94.6,"UK","GBR","Europe","Europe & Central Asia",43240,2019,"United Kingdom","High income",4,140,234.5,"no","nested period",0
"649",95,"Andrews","Test-negative case-control",652,2022-01-12,"BioNTech/Pfizer BNT162b2","mRNA","1","1",NA,"28+",">= 16 years","general pop","excluded",NA,"death","death","death","delta",88.6,78.8,93.9,"UK","GBR","Europe","Europe & Central Asia",43240,2019,"United Kingdom","High income",4,NA,NA,NA,NA,NA
"650",95,"Andrews","Test-negative case-control",653,2022-01-12,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"14+",">= 16 years","general pop","excluded","~33.5 weeks","death","death","death","delta",95.6,94.4,96.6,"UK","GBR","Europe","Europe & Central Asia",43240,2019,"United Kingdom","High income",4,NA,NA,NA,NA,NA
"651",95,"Andrews","Test-negative case-control",654,2022-01-12,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"14-69",">= 16 years","general pop","excluded","~8 weeks","death","death","death","delta",98.2,95.9,99.2,"UK","GBR","Europe","Europe & Central Asia",43240,2019,"United Kingdom","High income",4,NA,NA,NA,NA,NA
"652",95,"Andrews","Test-negative case-control",655,2022-01-12,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"140+",">= 16 years","general pop","excluded","~33.5 weeks","death","death","death","delta",90.4,85.1,93.8,"UK","GBR","Europe","Europe & Central Asia",43240,2019,"United Kingdom","High income",4,NA,NA,NA,NA,NA
"653",95,"Andrews","Test-negative case-control",656,2022-01-12,"Oxford/AstraZeneca ChAdOx1-S","Vectored","1","1",NA,"28+",">= 16 years","general pop","excluded",NA,"symptomatic disease","symptomatic","symptomatic","delta",45.1,43.4,46.7,"UK","GBR","Europe","Europe & Central Asia",43240,2019,"United Kingdom","High income",4,NA,NA,NA,NA,NA
"654",95,"Andrews","Test-negative case-control",657,2022-01-12,"Oxford/AstraZeneca ChAdOx1-S","Vectored","2","final",NA,"14+",">= 16 years","general pop","excluded","~20.5 weeks","symptomatic disease","symptomatic","symptomatic","delta",64.2,63.9,64.5,"UK","GBR","Europe","Europe & Central Asia",43240,2019,"United Kingdom","High income",4,NA,NA,NA,NA,NA
"655",95,"Andrews","Test-negative case-control",658,2022-01-12,"Oxford/AstraZeneca ChAdOx1-S","Vectored","2","final",NA,"14-69",">= 16 years","general pop","excluded","~8 weeks","symptomatic disease","symptomatic","symptomatic","delta",66.7,66.3,67,"UK","GBR","Europe","Europe & Central Asia",43240,2019,"United Kingdom","High income",4,NA,NA,NA,NA,NA
"656",95,"Andrews","Test-negative case-control",659,2022-01-12,"Oxford/AstraZeneca ChAdOx1-S","Vectored","2","final",NA,"140+",">= 16 years","general pop","excluded","~20.5 weeks","symptomatic disease","symptomatic","symptomatic","delta",47.3,45,49.6,"UK","GBR","Europe","Europe & Central Asia",43240,2019,"United Kingdom","High income",4,NA,NA,NA,NA,NA
"657",95,"Andrews","Test-negative case-control",660,2022-01-12,"Oxford/AstraZeneca ChAdOx1-S","Vectored","1","1",NA,"28+",">= 16 years","general pop","excluded",NA,"hospitalization","severe","severe","delta",80.7,78,83,"UK","GBR","Europe","Europe & Central Asia",43240,2019,"United Kingdom","High income",4,NA,NA,NA,NA,NA
"658",95,"Andrews","Test-negative case-control",661,2022-01-12,"Oxford/AstraZeneca ChAdOx1-S","Vectored","2","final",NA,"14+",">= 16 years","general pop","excluded","~20.5 weeks","hospitalization","severe","severe","delta",92.5,92,93,"UK","GBR","Europe","Europe & Central Asia",43240,2019,"United Kingdom","High income",4,14,143.5,"yes",NA,0
"659",95,"Andrews","Test-negative case-control",662,2022-01-12,"Oxford/AstraZeneca ChAdOx1-S","Vectored","2","final",NA,"14-69",">= 16 years","general pop","excluded","~8 weeks","hospitalization","severe","severe","delta",95.2,94.6,95.6,"UK","GBR","Europe","Europe & Central Asia",43240,2019,"United Kingdom","High income",4,14,69,"no","nested period",0
"660",95,"Andrews","Test-negative case-control",663,2022-01-12,"Oxford/AstraZeneca ChAdOx1-S","Vectored","2","final",NA,"140+",">= 16 years","general pop","excluded","~20.5 weeks","hospitalization","severe","severe","delta",77,70.3,82.3,"UK","GBR","Europe","Europe & Central Asia",43240,2019,"United Kingdom","High income",4,140,143.5,"no","nested period",0
"661",95,"Andrews","Test-negative case-control",664,2022-01-12,"Oxford/AstraZeneca ChAdOx1-S","Vectored","1","1",NA,"28+",">= 16 years","general pop","excluded",NA,"death","death","death","delta",86.9,77.5,92.4,"UK","GBR","Europe","Europe & Central Asia",43240,2019,"United Kingdom","High income",4,NA,NA,NA,NA,NA
"662",95,"Andrews","Test-negative case-control",665,2022-01-12,"Oxford/AstraZeneca ChAdOx1-S","Vectored","2","final",NA,"14+",">= 16 years","general pop","excluded","~20.5 weeks","death","death","death","delta",93.2,91.7,94.5,"UK","GBR","Europe","Europe & Central Asia",43240,2019,"United Kingdom","High income",4,NA,NA,NA,NA,NA
"663",95,"Andrews","Test-negative case-control",666,2022-01-12,"Oxford/AstraZeneca ChAdOx1-S","Vectored","2","final",NA,"14-69",">= 16 years","general pop","excluded","~8 weeks","death","death","death","delta",94.1,91.8,95.8,"UK","GBR","Europe","Europe & Central Asia",43240,2019,"United Kingdom","High income",4,NA,NA,NA,NA,NA
"664",95,"Andrews","Test-negative case-control",667,2022-01-12,"Oxford/AstraZeneca ChAdOx1-S","Vectored","2","final",NA,"140+",">= 16 years","general pop","excluded","~20.5 weeks","death","death","death","delta",78.7,52.7,90.4,"UK","GBR","Europe","Europe & Central Asia",43240,2019,"United Kingdom","High income",4,NA,NA,NA,NA,NA
"665",95,"Andrews","Test-negative case-control",668,2022-01-12,"Moderna mRNA-1273","mRNA","1","1",NA,"28+",">= 16 years","general pop","excluded",NA,"symptomatic disease","symptomatic","symptomatic","delta",64.9,64,65.7,"UK","GBR","Europe","Europe & Central Asia",43240,2019,"United Kingdom","High income",4,NA,NA,NA,NA,NA
"666",95,"Andrews","Test-negative case-control",669,2022-01-12,"Moderna mRNA-1273","mRNA","2","final",NA,"14+",">= 16 years","general pop","excluded","~7 weeks","symptomatic disease","symptomatic","symptomatic","delta",94.8,94.4,95.2,"UK","GBR","Europe","Europe & Central Asia",43240,2019,"United Kingdom","High income",4,NA,NA,NA,NA,NA
"667",95,"Andrews","Test-negative case-control",670,2022-01-12,"Moderna mRNA-1273","mRNA","2","final",NA,"14-63",">= 16 years","general pop","excluded","~7 weeks","symptomatic disease","symptomatic","symptomatic","delta",93.8,93.4,94.1,"UK","GBR","Europe","Europe & Central Asia",43240,2019,"United Kingdom","High income",4,NA,NA,NA,NA,NA
"668",95,"Andrews","Test-negative case-control",671,2022-01-12,"Moderna mRNA-1273","mRNA","2","final",NA,"70-104",">= 16 years","general pop","excluded","~7 weeks","symptomatic disease","symptomatic","symptomatic","delta",85.6,83.8,87.2,"UK","GBR","Europe","Europe & Central Asia",43240,2019,"United Kingdom","High income",4,NA,NA,NA,NA,NA
"669",95,"Andrews","Test-negative case-control",672,2022-01-12,"Moderna mRNA-1273","mRNA","1","1",NA,"28+",">= 16 years","general pop","excluded",NA,"hospitalization","severe","severe","delta",93.7,89.9,96,"UK","GBR","Europe","Europe & Central Asia",43240,2019,"United Kingdom","High income",4,NA,NA,NA,NA,NA
"670",95,"Andrews","Test-negative case-control",673,2022-01-12,"Moderna mRNA-1273","mRNA","2","final",NA,"14-69",">= 16 years","general pop","excluded","~7 weeks","hospitalization","severe","severe","delta",100,NA,NA,"UK","GBR","Europe","Europe & Central Asia",43240,2019,"United Kingdom","High income",4,14,69,"yes",NA,0
"671",96,"Glatman-Freedman","Retrospective cohort",674,2021-09-16,"BioNTech/Pfizer BNT162b2","mRNA","1","1",NA,"14-20",">= 16 years","general pop","excluded",NA,"infection","infection","infection","alpha",54.3,50.6,57.8,"Israel","ISR","Asia","Middle East & North Africa",43800,2019,"Israel","High income",4,NA,NA,NA,NA,NA
"672",96,"Glatman-Freedman","Retrospective cohort",675,2021-09-16,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"22-28",">= 16 years","general pop","excluded","2 weeks","infection","infection","infection","alpha",97.3,96.7,97.8,"Israel","ISR","Asia","Middle East & North Africa",43800,2019,"Israel","High income",4,NA,NA,NA,NA,NA
"673",96,"Glatman-Freedman","Retrospective cohort",676,2021-09-16,"BioNTech/Pfizer BNT162b2","mRNA","1","1",NA,"14-20",">= 16 years","general pop","excluded",NA,"symptomatic disease","symptomatic","symptomatic","alpha",58.3,54.7,61.6,"Israel","ISR","Asia","Middle East & North Africa",43800,2019,"Israel","High income",4,NA,NA,NA,NA,NA
"674",96,"Glatman-Freedman","Retrospective cohort",677,2021-09-16,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"22-28",">= 16 years","general pop","excluded","2 weeks","symptomatic disease","symptomatic","symptomatic","alpha",97.9,97.4,98.3,"Israel","ISR","Asia","Middle East & North Africa",43800,2019,"Israel","High income",4,NA,NA,NA,NA,NA
"675",96,"Glatman-Freedman","Retrospective cohort",678,2021-09-16,"BioNTech/Pfizer BNT162b2","mRNA","1","1",NA,"14-20",">= 16 years","general pop","excluded",NA,"hospitalization","severe","severe","alpha",74.5,69.1,79,"Israel","ISR","Asia","Middle East & North Africa",43800,2019,"Israel","High income",4,NA,NA,NA,NA,NA
"676",96,"Glatman-Freedman","Retrospective cohort",679,2021-09-16,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"22-28",">= 16 years","general pop","excluded","2 weeks","hospitalization","severe","severe","alpha",99,98.4,99.3,"Israel","ISR","Asia","Middle East & North Africa",43800,2019,"Israel","High income",4,NA,NA,NA,NA,NA
"677",96,"Glatman-Freedman","Retrospective cohort",680,2021-09-16,"BioNTech/Pfizer BNT162b2","mRNA","1","1",NA,"14-20",">= 16 years","general pop","excluded",NA,"severe/critical disease","severe","severe","alpha",77.3,71.2,82.1,"Israel","ISR","Asia","Middle East & North Africa",43800,2019,"Israel","High income",4,NA,NA,NA,NA,NA
"678",96,"Glatman-Freedman","Retrospective cohort",681,2021-09-16,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"22-28",">= 16 years","general pop","excluded","2 weeks","severe/critical disease","severe","severe","alpha",99.2,98.6,99.5,"Israel","ISR","Asia","Middle East & North Africa",43800,2019,"Israel","High income",4,NA,NA,NA,NA,NA
"679",96,"Glatman-Freedman","Retrospective cohort",682,2021-09-16,"BioNTech/Pfizer BNT162b2","mRNA","1","1",NA,"14-20",">= 16 years","general pop","excluded",NA,"death","death","death","alpha",71.7,64.1,77.7,"Israel","ISR","Asia","Middle East & North Africa",43800,2019,"Israel","High income",4,NA,NA,NA,NA,NA
"680",96,"Glatman-Freedman","Retrospective cohort",683,2021-09-16,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"22-28",">= 16 years","general pop","excluded","2 weeks","death","death","death","alpha",98.6,97,99.3,"Israel","ISR","Asia","Middle East & North Africa",43800,2019,"Israel","High income",4,NA,NA,NA,NA,NA
"681",97,"Self","Test-negative case-control",684,2021-09-17,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"14+",">= 18 years","general pop","excluded","~20 weeks","hospitalization","severe","severe","other combinations",88,85,91,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"682",97,"Self","Test-negative case-control",685,2021-09-17,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"14-120",">= 18 years","general pop","excluded","~20 weeks","hospitalization","severe","severe","other combinations",91,88,93,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"683",97,"Self","Test-negative case-control",686,2021-09-17,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,">120",">= 18 years","general pop","excluded","~20 weeks","hospitalization","severe","severe","other combinations",77,67,84,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"684",97,"Self","Test-negative case-control",687,2021-09-17,"Moderna mRNA-1273","mRNA","2","final",NA,"14+",">= 18 years","general pop","excluded","~20 weeks","hospitalization","severe","severe","other combinations",93,91,95,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"685",97,"Self","Test-negative case-control",688,2021-09-17,"Moderna mRNA-1273","mRNA","2","final",NA,"14-120",">= 18 years","general pop","excluded","~20 weeks","hospitalization","severe","severe","other combinations",93,90,95,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"686",97,"Self","Test-negative case-control",689,2021-09-17,"Moderna mRNA-1273","mRNA","2","final",NA,">120",">= 18 years","general pop","excluded","~20 weeks","hospitalization","severe","severe","other combinations",92,87,96,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"687",97,"Self","Test-negative case-control",690,2021-09-17,"Janssen Ad26.COV2.S","Vectored","1","final",NA,"14+",">= 18 years","general pop","excluded","~20 weeks","hospitalization","severe","severe","other combinations",71,56,81,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"688",97,"Self","Test-negative case-control",691,2021-09-17,"Janssen Ad26.COV2.S","Vectored","1","final",NA,">28",">= 18 years","general pop","excluded","~20 weeks","hospitalization","severe","severe","other combinations",68,49,80,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"689",98,"Skowronski","Test-negative case-control",692,2022-01-27,"BioNTech/Pfizer BNT162b2","mRNA","1","1",NA,"21+","50-69 years","50-69 years","excluded",NA,"infection","infection","infection","other combinations",70,68,72,"Canada","CAN","North America","North America",46580,2019,"Canada","High income",4,NA,NA,NA,NA,NA
"690",98,"Skowronski","Test-negative case-control",693,2022-01-27,"BioNTech/Pfizer BNT162b2","mRNA","1","1",NA,"14-20","50-69 years","50-69 years","excluded",NA,"infection","infection","infection","other combinations",55,48,61,"Canada","CAN","North America","North America",46580,2019,"Canada","High income",4,NA,NA,NA,NA,NA
"691",98,"Skowronski","Test-negative case-control",694,2022-01-27,"BioNTech/Pfizer BNT162b2","mRNA","1","1",NA,"98+","50-69 years","50-69 years","excluded",NA,"infection","infection","infection","other combinations",65,57,71,"Canada","CAN","North America","North America",46580,2019,"Canada","High income",4,NA,NA,NA,NA,NA
"692",98,"Skowronski","Test-negative case-control",695,2022-01-27,"BioNTech/Pfizer BNT162b2","mRNA","1","1",NA,"21+","50-69 years","50-69 years","excluded",NA,"hospitalization","severe","severe","other combinations",81,75,85,"Canada","CAN","North America","North America",46580,2019,"Canada","High income",4,NA,NA,NA,NA,NA
"693",98,"Skowronski","Test-negative case-control",696,2022-01-27,"Moderna mRNA-1273","mRNA","1","1",NA,"21+","50-69 years","50-69 years","excluded",NA,"infection","infection","infection","other combinations",75,71,78,"Canada","CAN","North America","North America",46580,2019,"Canada","High income",4,NA,NA,NA,NA,NA
"694",98,"Skowronski","Test-negative case-control",697,2022-01-27,"Moderna mRNA-1273","mRNA","1","1",NA,"14-20","50-69 years","50-69 years","excluded",NA,"infection","infection","infection","other combinations",67,57,75,"Canada","CAN","North America","North America",46580,2019,"Canada","High income",4,NA,NA,NA,NA,NA
"695",98,"Skowronski","Test-negative case-control",698,2022-01-27,"Moderna mRNA-1273","mRNA","1","1",NA,"98+","50-69 years","50-69 years","excluded",NA,"infection","infection","infection","other combinations",54,38,66,"Canada","CAN","North America","North America",46580,2019,"Canada","High income",4,NA,NA,NA,NA,NA
"696",98,"Skowronski","Test-negative case-control",699,2022-01-27,"Moderna mRNA-1273","mRNA","1","1",NA,"21+","50-69 years","50-69 years","excluded",NA,"hospitalization","severe","severe","other combinations",85,76,91,"Canada","CAN","North America","North America",46580,2019,"Canada","High income",4,NA,NA,NA,NA,NA
"697",98,"Skowronski","Test-negative case-control",700,2022-01-27,"Multiple or heterologous RNA","mRNA","1","1",NA,"14-20","50-69 years","50-69 years","excluded",NA,"hospitalization","severe","severe","other combinations",74,60,83,"Canada","CAN","North America","North America",46580,2019,"Canada","High income",4,NA,NA,NA,NA,NA
"698",98,"Skowronski","Test-negative case-control",701,2022-01-27,"Multiple or heterologous RNA","mRNA","1","1",NA,"98+","50-69 years","50-69 years","excluded",NA,"hospitalization","severe","severe","other combinations",65,47,77,"Canada","CAN","North America","North America",46580,2019,"Canada","High income",4,NA,NA,NA,NA,NA
"699",98,"Skowronski","Test-negative case-control",702,2022-01-27,"Oxford/AstraZeneca ChAdOx1-S","Vectored","1","1",NA,"21+","50-69 years","50-69 years","excluded",NA,"infection","infection","infection","other combinations",60,54,65,"Canada","CAN","North America","North America",46580,2019,"Canada","High income",4,NA,NA,NA,NA,NA
"700",98,"Skowronski","Test-negative case-control",703,2022-01-27,"Oxford/AstraZeneca ChAdOx1-S","Vectored","1","1",NA,"14-20","50-69 years","50-69 years","excluded",NA,"infection","infection","infection","other combinations",25,10,37,"Canada","CAN","North America","North America",46580,2019,"Canada","High income",4,NA,NA,NA,NA,NA
"701",98,"Skowronski","Test-negative case-control",704,2022-01-27,"Oxford/AstraZeneca ChAdOx1-S","Vectored","1","1",NA,"98+","50-69 years","50-69 years","excluded",NA,"infection","infection","infection","other combinations",62,36,77,"Canada","CAN","North America","North America",46580,2019,"Canada","High income",4,NA,NA,NA,NA,NA
"702",98,"Skowronski","Test-negative case-control",705,2022-01-27,"Oxford/AstraZeneca ChAdOx1-S","Vectored","1","1",NA,"21+","50-69 years","50-69 years","excluded",NA,"hospitalization","severe","severe","other combinations",93,85,97,"Canada","CAN","North America","North America",46580,2019,"Canada","High income",4,NA,NA,NA,NA,NA
"703",98,"Skowronski","Test-negative case-control",706,2022-01-27,"Oxford/AstraZeneca ChAdOx1-S","Vectored","1","1",NA,"14-20","50-69 years","50-69 years","excluded",NA,"hospitalization","severe","severe","other combinations",67,30,84,"Canada","CAN","North America","North America",46580,2019,"Canada","High income",4,NA,NA,NA,NA,NA
"704",98,"Skowronski","Test-negative case-control",707,2022-01-27,"Oxford/AstraZeneca ChAdOx1-S","Vectored","1","1",NA,"84+","50-69 years","50-69 years","excluded",NA,"hospitalization","severe","severe","other combinations",74,-4,94,"Canada","CAN","North America","North America",46580,2019,"Canada","High income",4,NA,NA,NA,NA,NA
"705",98,"Skowronski","Test-negative case-control",708,2022-01-27,"BioNTech/Pfizer BNT162b2","mRNA","1","1",NA,"21+","50-69 years","50-69 years","excluded",NA,"infection","infection","infection","alpha",77,73,80,"Canada","CAN","North America","North America",46580,2019,"Canada","High income",4,NA,NA,NA,NA,NA
"706",98,"Skowronski","Test-negative case-control",709,2022-01-27,"BioNTech/Pfizer BNT162b2","mRNA","1","1",NA,"21+","50-69 years","50-69 years","excluded",NA,"hospitalization","severe","severe","alpha",85,72,92,"Canada","CAN","North America","North America",46580,2019,"Canada","High income",4,NA,NA,NA,NA,NA
"707",98,"Skowronski","Test-negative case-control",710,2022-01-27,"Moderna mRNA-1273","mRNA","1","1",NA,"21+","50-69 years","50-69 years","excluded",NA,"infection","infection","infection","alpha",84,77,89,"Canada","CAN","North America","North America",46580,2019,"Canada","High income",4,NA,NA,NA,NA,NA
"708",98,"Skowronski","Test-negative case-control",711,2022-01-27,"Moderna mRNA-1273","mRNA","1","1",NA,"21+","50-69 years","50-69 years","excluded",NA,"hospitalization","severe","severe","alpha",78,44,91,"Canada","CAN","North America","North America",46580,2019,"Canada","High income",4,NA,NA,NA,NA,NA
"709",98,"Skowronski","Test-negative case-control",712,2022-01-27,"Oxford/AstraZeneca ChAdOx1-S","Vectored","1","1",NA,"21+","50-69 years","50-69 years","excluded",NA,"infection","infection","infection","alpha",69,61,75,"Canada","CAN","North America","North America",46580,2019,"Canada","High income",4,NA,NA,NA,NA,NA
"710",98,"Skowronski","Test-negative case-control",713,2022-01-27,"BioNTech/Pfizer BNT162b2","mRNA","1","1",NA,"21+","50-69 years","50-69 years","excluded",NA,"infection","infection","infection","gamma",77,72,81,"Canada","CAN","North America","North America",46580,2019,"Canada","High income",4,NA,NA,NA,NA,NA
"711",98,"Skowronski","Test-negative case-control",714,2022-01-27,"BioNTech/Pfizer BNT162b2","mRNA","1","1",NA,"21+","50-69 years","50-69 years","excluded",NA,"hospitalization","severe","severe","gamma",89,79,94,"Canada","CAN","North America","North America",46580,2019,"Canada","High income",4,NA,NA,NA,NA,NA
"712",98,"Skowronski","Test-negative case-control",715,2022-01-27,"Moderna mRNA-1273","mRNA","1","1",NA,"21+","50-69 years","50-69 years","excluded",NA,"infection","infection","infection","gamma",85,76,90,"Canada","CAN","North America","North America",46580,2019,"Canada","High income",4,NA,NA,NA,NA,NA
"713",98,"Skowronski","Test-negative case-control",716,2022-01-27,"Moderna mRNA-1273","mRNA","1","1",NA,"21+","50-69 years","50-69 years","excluded",NA,"hospitalization","severe","severe","gamma",96,71,99,"Canada","CAN","North America","North America",46580,2019,"Canada","High income",4,NA,NA,NA,NA,NA
"714",98,"Skowronski","Test-negative case-control",717,2022-01-27,"Oxford/AstraZeneca ChAdOx1-S","Vectored","1","1",NA,"21+","50-69 years","50-69 years","excluded",NA,"infection","infection","infection","gamma",67,58,74,"Canada","CAN","North America","North America",46580,2019,"Canada","High income",4,NA,NA,NA,NA,NA
"715",98,"Skowronski","Test-negative case-control",718,2022-01-27,"Oxford/AstraZeneca ChAdOx1-S","Vectored","1","1",NA,"21+","50-69 years","50-69 years","excluded",NA,"hospitalization","severe","severe","gamma",93,78,98,"Canada","CAN","North America","North America",46580,2019,"Canada","High income",4,NA,NA,NA,NA,NA
"716",98,"Skowronski","Test-negative case-control",719,2022-01-27,"BioNTech/Pfizer BNT162b2","mRNA","1","1",NA,"21+","50-69 years","50-69 years","excluded",NA,"infection","infection","infection","delta",58,52,63,"Canada","CAN","North America","North America",46580,2019,"Canada","High income",4,NA,NA,NA,NA,NA
"717",98,"Skowronski","Test-negative case-control",720,2022-01-27,"BioNTech/Pfizer BNT162b2","mRNA","1","1",NA,"21+","50-69 years","50-69 years","excluded",NA,"hospitalization","severe","severe","delta",73,60,82,"Canada","CAN","North America","North America",46580,2019,"Canada","High income",4,NA,NA,NA,NA,NA
"718",98,"Skowronski","Test-negative case-control",721,2022-01-27,"Moderna mRNA-1273","mRNA","1","1",NA,"21+","50-69 years","50-69 years","excluded",NA,"infection","infection","infection","delta",70,64,76,"Canada","CAN","North America","North America",46580,2019,"Canada","High income",4,NA,NA,NA,NA,NA
"719",98,"Skowronski","Test-negative case-control",722,2022-01-27,"Moderna mRNA-1273","mRNA","1","1",NA,"21+","50-69 years","50-69 years","excluded",NA,"hospitalization","severe","severe","delta",86,72,93,"Canada","CAN","North America","North America",46580,2019,"Canada","High income",4,NA,NA,NA,NA,NA
"720",98,"Skowronski","Test-negative case-control",723,2022-01-27,"Oxford/AstraZeneca ChAdOx1-S","Vectored","1","1",NA,"21+","50-69 years","50-69 years","excluded",NA,"infection","infection","infection","delta",41,15,59,"Canada","CAN","North America","North America",46580,2019,"Canada","High income",4,NA,NA,NA,NA,NA
"721",98,"Skowronski","Test-negative case-control",724,2022-01-27,"Oxford/AstraZeneca ChAdOx1-S","Vectored","1","1",NA,"21+","50-69 years","50-69 years","excluded",NA,"hospitalization","severe","severe","delta",61,-8,86,"Canada","CAN","North America","North America",46580,2019,"Canada","High income",4,NA,NA,NA,NA,NA
"722",98,"Skowronski","Test-negative case-control",725,2022-01-27,"BioNTech/Pfizer BNT162b2","mRNA","1","1",NA,"21+","50-69 years","50-69 years","excluded",NA,"infection","infection","infection","original",88,75,95,"Canada","CAN","North America","North America",46580,2019,"Canada","High income",4,NA,NA,NA,NA,NA
"723",98,"Skowronski","Test-negative case-control",726,2022-01-27,"Moderna mRNA-1273","mRNA","1","1",NA,"21+","50-69 years","50-69 years","excluded",NA,"infection","infection","infection","original",78,31,93,"Canada","CAN","North America","North America",46580,2019,"Canada","High income",4,NA,NA,NA,NA,NA
"724",98,"Skowronski","Test-negative case-control",727,2022-01-27,"Oxford/AstraZeneca ChAdOx1-S","Vectored","1","1",NA,"21+","50-69 years","50-69 years","excluded",NA,"infection","infection","infection","original",93,70,98,"Canada","CAN","North America","North America",46580,2019,"Canada","High income",4,NA,NA,NA,NA,NA
"725",99,"Pilishvili","Test-negative case-control",728,2021-09-22,"Multiple or heterologous RNA","mRNA","2","final",NA,"14+","HCW","HCW","excluded","~14 weeks","symptomatic disease","symptomatic","symptomatic","alpha",88.9,84.7,92,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"726",99,"Pilishvili","Test-negative case-control",729,2021-09-22,"Multiple or heterologous RNA","mRNA","2","final",NA,"15-28","HCW","HCW","excluded","~14 weeks","symptomatic disease","symptomatic","symptomatic","alpha",96.3,92.5,98.2,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"727",99,"Pilishvili","Test-negative case-control",730,2021-09-22,"Multiple or heterologous RNA","mRNA","2","final",NA,"85-98","HCW","HCW","excluded","~14 weeks","symptomatic disease","symptomatic","symptomatic","alpha",80.7,61,90.4,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"728",99,"Pilishvili","Test-negative case-control",731,2021-09-22,"Multiple or heterologous RNA","mRNA","1","1",NA,"14+ through dose 2 or later (at least one dose)","immunocompromised HCW","immunocompromised HCW","excluded",NA,"symptomatic disease","symptomatic","symptomatic","alpha",39.1,-45,74.4,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"729",99,"Pilishvili","Test-negative case-control",732,2021-09-22,"Multiple or heterologous RNA","mRNA","1","1",NA,"14+ through dose 2 or later (at least one dose)","pregnant HCW","pregnant HCW","excluded",NA,"symptomatic disease","symptomatic","symptomatic","alpha",77.1,32.2,92.2,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"730",99,"Pilishvili","Test-negative case-control",733,2021-09-22,"BioNTech/Pfizer BNT162b2","mRNA","1","1",NA,"14+ up to <7 days post 2nd dose","HCW","HCW","excluded",NA,"symptomatic disease","symptomatic","symptomatic","alpha",77.6,70.9,82.7,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"731",99,"Pilishvili","Test-negative case-control",734,2021-09-22,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"7+","HCW","HCW","excluded","~14 weeks","symptomatic disease","symptomatic","symptomatic","alpha",88.8,84.6,91.8,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"732",99,"Pilishvili","Test-negative case-control",735,2021-09-22,"Moderna mRNA-1273","mRNA","1","1",NA,"14+ up to <7 days post 2nd dose","HCW","HCW","excluded",NA,"symptomatic disease","symptomatic","symptomatic","alpha",88.9,78.7,94.2,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"733",99,"Pilishvili","Test-negative case-control",736,2021-09-22,"Moderna mRNA-1273","mRNA","2","final",NA,"7+","HCW","HCW","excluded","~14 weeks","symptomatic disease","symptomatic","symptomatic","alpha",96.3,91.3,98.4,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"734",100,"Meyer","Retrospective cohort",737,2021-09-09,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"7+","LTCF residents and staff","LTCF residents and staff","unknown","~11 weeks","infection","infection","infection","alpha",56,15,77,"Germany","DEU","Europe","Europe & Central Asia",49470,2019,"Germany","High income",4,NA,NA,NA,NA,NA
"735",101,"Glatman-Freedman","Retrospective cohort",738,2021-09-27,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"8-28","12-15 years","12-15 years","excluded","2 weeks","infection","infection","infection","delta",91.5,88.2,93.9,"Israel","ISR","Asia","Middle East & North Africa",43800,2019,"Israel","High income",4,NA,NA,NA,NA,NA
"736",102,"Eyre","Retrospective cohort",739,2022-01-05,"BioNTech/Pfizer BNT162b2","mRNA","1","1",NA,"0+ up to 13 days post dose 2","contacts of SARS-CoV-2 index cases of all ages","contacts of index cases","included",NA,"infection","infection","infection","alpha",15,12,18,"UK","GBR","Europe","Europe & Central Asia",43240,2019,"United Kingdom","High income",4,NA,NA,NA,NA,NA
"737",102,"Eyre","Retrospective cohort",740,2022-01-05,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"14+","contacts of SARS-CoV-2 index cases of all ages","contacts of index cases","included","~20.5 weeks","infection","infection","infection","alpha",85,79,89,"UK","GBR","Europe","Europe & Central Asia",43240,2019,"United Kingdom","High income",4,NA,NA,NA,NA,NA
"738",102,"Eyre","Retrospective cohort",741,2022-01-05,"Oxford/AstraZeneca ChAdOx1-S","Vectored","1","1",NA,"0+ up to 13 days post dose 2","contacts of SARS-CoV-2 index cases of all ages","contacts of index cases","included",NA,"infection","infection","infection","alpha",6,2,9,"UK","GBR","Europe","Europe & Central Asia",43240,2019,"United Kingdom","High income",4,NA,NA,NA,NA,NA
"739",102,"Eyre","Retrospective cohort",742,2022-01-05,"Oxford/AstraZeneca ChAdOx1-S","Vectored","2","final",NA,"14+","contacts of SARS-CoV-2 index cases of all ages","contacts of index cases","included","~8 weeks","infection","infection","infection","alpha",60,41,73,"UK","GBR","Europe","Europe & Central Asia",43240,2019,"United Kingdom","High income",4,NA,NA,NA,NA,NA
"740",102,"Eyre","Retrospective cohort",743,2022-01-05,"BioNTech/Pfizer BNT162b2","mRNA","1","1",NA,"0+ up to 13 days post dose 2","contacts of SARS-CoV-2 index cases of all ages","contacts of index cases","included",NA,"infection","infection","infection","delta",33,31,35,"UK","GBR","Europe","Europe & Central Asia",43240,2019,"United Kingdom","High income",4,NA,NA,NA,NA,NA
"741",102,"Eyre","Retrospective cohort",744,2022-01-05,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"14+","contacts of SARS-CoV-2 index cases of all ages","contacts of index cases","included","~29 weeks","infection","infection","infection","delta",81,77,84,"UK","GBR","Europe","Europe & Central Asia",43240,2019,"United Kingdom","High income",4,NA,NA,NA,NA,NA
"742",102,"Eyre","Retrospective cohort",745,2022-01-05,"Oxford/AstraZeneca ChAdOx1-S","Vectored","1","1",NA,"0+ up to 13 days post dose 2","contacts of SARS-CoV-2 index cases of all ages","contacts of index cases","included",NA,"infection","infection","infection","delta",31,28,34,"UK","GBR","Europe","Europe & Central Asia",43240,2019,"United Kingdom","High income",4,NA,NA,NA,NA,NA
"743",102,"Eyre","Retrospective cohort",746,2022-01-05,"Oxford/AstraZeneca ChAdOx1-S","Vectored","2","final",NA,"14+","contacts of SARS-CoV-2 index cases of all ages","contacts of index cases","included","~16 weeks","infection","infection","infection","delta",58,55,62,"UK","GBR","Europe","Europe & Central Asia",43240,2019,"United Kingdom","High income",4,NA,NA,NA,NA,NA
"744",103,"Martinez-Baz","Prospective cohort",747,2021-09-30,"BioNTech/Pfizer BNT162b2","mRNA","1","1",NA,"14+","contacts of SARS-CoV-2 index cases of all ages","contacts of index cases","excluded",NA,"infection","infection","infection","other combinations",57,52,61,"Spain","ESP","Europe","Europe & Central Asia",30370,2019,"Spain","High income",4,NA,NA,NA,NA,NA
"745",103,"Martinez-Baz","Prospective cohort",748,2021-09-30,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"14+","contacts of SARS-CoV-2 index cases of all ages","contacts of index cases","excluded","~31 weeks","infection","infection","infection","other combinations",69,66,72,"Spain","ESP","Europe","Europe & Central Asia",30370,2019,"Spain","High income",4,NA,NA,NA,NA,NA
"746",103,"Martinez-Baz","Prospective cohort",749,2021-09-30,"BioNTech/Pfizer BNT162b2","mRNA","1","1",NA,"<90","contacts of SARS-CoV-2 index cases of all ages","contacts of index cases","excluded",NA,"infection","infection","infection","other combinations",57,51,61,"Spain","ESP","Europe","Europe & Central Asia",30370,2019,"Spain","High income",4,NA,NA,NA,NA,NA
"747",103,"Martinez-Baz","Prospective cohort",750,2021-09-30,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"<90","contacts of SARS-CoV-2 index cases of all ages","contacts of index cases","excluded","~11 weeks","infection","infection","infection","other combinations",70,67,73,"Spain","ESP","Europe","Europe & Central Asia",30370,2019,"Spain","High income",4,NA,NA,NA,NA,NA
"748",103,"Martinez-Baz","Prospective cohort",751,2021-09-30,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"90+","contacts of SARS-CoV-2 index cases of all ages","contacts of index cases","excluded","~18 weeks","infection","infection","infection","other combinations",63,58,68,"Spain","ESP","Europe","Europe & Central Asia",30370,2019,"Spain","High income",4,NA,NA,NA,NA,NA
"749",103,"Martinez-Baz","Prospective cohort",752,2021-09-30,"BioNTech/Pfizer BNT162b2","mRNA","1","1",NA,"14+","contacts of SARS-CoV-2 index cases of all ages","contacts of index cases","excluded",NA,"symptomatic disease","symptomatic","symptomatic","other combinations",66,60,71,"Spain","ESP","Europe","Europe & Central Asia",30370,2019,"Spain","High income",4,NA,NA,NA,NA,NA
"750",103,"Martinez-Baz","Prospective cohort",753,2021-09-30,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"14+","contacts of SARS-CoV-2 index cases of all ages","contacts of index cases","excluded","~31 weeks","symptomatic disease","symptomatic","symptomatic","other combinations",72,69,75,"Spain","ESP","Europe","Europe & Central Asia",30370,2019,"Spain","High income",4,NA,NA,NA,NA,NA
"751",103,"Martinez-Baz","Prospective cohort",754,2021-09-30,"BioNTech/Pfizer BNT162b2","mRNA","1","1",NA,"14+","contacts of SARS-CoV-2 index cases of all ages","contacts of index cases","excluded",NA,"hospitalization","severe","severe","other combinations",86,69,94,"Spain","ESP","Europe","Europe & Central Asia",30370,2019,"Spain","High income",4,NA,NA,NA,NA,NA
"752",103,"Martinez-Baz","Prospective cohort",755,2021-09-30,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"14+","contacts of SARS-CoV-2 index cases of all ages","contacts of index cases","excluded","~31 weeks","hospitalization","severe","severe","other combinations",93,88,96,"Spain","ESP","Europe","Europe & Central Asia",30370,2019,"Spain","High income",4,NA,NA,NA,NA,NA
"753",103,"Martinez-Baz","Prospective cohort",756,2021-09-30,"Moderna mRNA-1273","mRNA","1","1",NA,"14+","contacts of SARS-CoV-2 index cases of all ages","contacts of index cases","excluded",NA,"infection","infection","infection","other combinations",66,56,73,"Spain","ESP","Europe","Europe & Central Asia",30370,2019,"Spain","High income",4,NA,NA,NA,NA,NA
"754",103,"Martinez-Baz","Prospective cohort",757,2021-09-30,"Moderna mRNA-1273","mRNA","2","final",NA,"14+","contacts of SARS-CoV-2 index cases of all ages","contacts of index cases","excluded","~28 weeks","infection","infection","infection","other combinations",82,78,86,"Spain","ESP","Europe","Europe & Central Asia",30370,2019,"Spain","High income",4,NA,NA,NA,NA,NA
"755",103,"Martinez-Baz","Prospective cohort",758,2021-09-30,"Moderna mRNA-1273","mRNA","1","1",NA,"<90","contacts of SARS-CoV-2 index cases of all ages","contacts of index cases","excluded",NA,"infection","infection","infection","other combinations",65,56,73,"Spain","ESP","Europe","Europe & Central Asia",30370,2019,"Spain","High income",4,NA,NA,NA,NA,NA
"756",103,"Martinez-Baz","Prospective cohort",759,2021-09-30,"Moderna mRNA-1273","mRNA","2","final",NA,"90+","contacts of SARS-CoV-2 index cases of all ages","contacts of index cases","excluded","~15 weeks","infection","infection","infection","other combinations",67,50,78,"Spain","ESP","Europe","Europe & Central Asia",30370,2019,"Spain","High income",4,NA,NA,NA,NA,NA
"757",103,"Martinez-Baz","Prospective cohort",760,2021-09-30,"Moderna mRNA-1273","mRNA","1","1",NA,"14+","contacts of SARS-CoV-2 index cases of all ages","contacts of index cases","excluded",NA,"symptomatic disease","symptomatic","symptomatic","other combinations",71,61,79,"Spain","ESP","Europe","Europe & Central Asia",30370,2019,"Spain","High income",4,NA,NA,NA,NA,NA
"758",103,"Martinez-Baz","Prospective cohort",761,2021-09-30,"Moderna mRNA-1273","mRNA","2","final",NA,"14+","contacts of SARS-CoV-2 index cases of all ages","contacts of index cases","excluded","~28 weeks","symptomatic disease","symptomatic","symptomatic","other combinations",85,80,89,"Spain","ESP","Europe","Europe & Central Asia",30370,2019,"Spain","High income",4,NA,NA,NA,NA,NA
"759",103,"Martinez-Baz","Prospective cohort",762,2021-09-30,"Moderna mRNA-1273","mRNA","1","1",NA,"14+","contacts of SARS-CoV-2 index cases of all ages","contacts of index cases","excluded",NA,"hospitalization","severe","severe","other combinations",73,-10,93,"Spain","ESP","Europe","Europe & Central Asia",30370,2019,"Spain","High income",4,NA,NA,NA,NA,NA
"760",103,"Martinez-Baz","Prospective cohort",763,2021-09-30,"Moderna mRNA-1273","mRNA","2","final",NA,"14+","contacts of SARS-CoV-2 index cases of all ages","contacts of index cases","excluded","~28 weeks","hospitalization","severe","severe","other combinations",98,82,100,"Spain","ESP","Europe","Europe & Central Asia",30370,2019,"Spain","High income",4,NA,NA,NA,NA,NA
"761",103,"Martinez-Baz","Prospective cohort",764,2021-09-30,"Oxford/AstraZeneca ChAdOx1-S","Vectored","1","1",NA,"14+","contacts of SARS-CoV-2 index cases of all ages","contacts of index cases","excluded",NA,"infection","infection","infection","other combinations",41,34,48,"Spain","ESP","Europe","Europe & Central Asia",30370,2019,"Spain","High income",4,NA,NA,NA,NA,NA
"762",103,"Martinez-Baz","Prospective cohort",765,2021-09-30,"Oxford/AstraZeneca ChAdOx1-S","Vectored","2","final",NA,"14+","contacts of SARS-CoV-2 index cases of all ages","contacts of index cases","excluded","~16 weeks","infection","infection","infection","other combinations",54,48,60,"Spain","ESP","Europe","Europe & Central Asia",30370,2019,"Spain","High income",4,NA,NA,NA,NA,NA
"763",103,"Martinez-Baz","Prospective cohort",766,2021-09-30,"Oxford/AstraZeneca ChAdOx1-S","Vectored","1","1",NA,"<90","contacts of SARS-CoV-2 index cases of all ages","contacts of index cases","excluded",NA,"infection","infection","infection","other combinations",40,31,47,"Spain","ESP","Europe","Europe & Central Asia",30370,2019,"Spain","High income",4,NA,NA,NA,NA,NA
"764",103,"Martinez-Baz","Prospective cohort",767,2021-09-30,"Oxford/AstraZeneca ChAdOx1-S","Vectored","2","final",NA,"<90","contacts of SARS-CoV-2 index cases of all ages","contacts of index cases","excluded","~11 weeks","infection","infection","infection","other combinations",54,47,60,"Spain","ESP","Europe","Europe & Central Asia",30370,2019,"Spain","High income",4,NA,NA,NA,NA,NA
"765",103,"Martinez-Baz","Prospective cohort",768,2021-09-30,"Oxford/AstraZeneca ChAdOx1-S","Vectored","1","1",NA,"90+","contacts of SARS-CoV-2 index cases of all ages","contacts of index cases","excluded",NA,"infection","infection","infection","other combinations",52,37,64,"Spain","ESP","Europe","Europe & Central Asia",30370,2019,"Spain","High income",4,NA,NA,NA,NA,NA
"766",103,"Martinez-Baz","Prospective cohort",769,2021-09-30,"Oxford/AstraZeneca ChAdOx1-S","Vectored","1","1",NA,"14+","contacts of SARS-CoV-2 index cases of all ages","contacts of index cases","excluded",NA,"symptomatic disease","symptomatic","symptomatic","other combinations",46,37,54,"Spain","ESP","Europe","Europe & Central Asia",30370,2019,"Spain","High income",4,NA,NA,NA,NA,NA
"767",103,"Martinez-Baz","Prospective cohort",770,2021-09-30,"Oxford/AstraZeneca ChAdOx1-S","Vectored","2","final",NA,"14+","contacts of SARS-CoV-2 index cases of all ages","contacts of index cases","excluded","~16 weeks","symptomatic disease","symptomatic","symptomatic","other combinations",56,48,63,"Spain","ESP","Europe","Europe & Central Asia",30370,2019,"Spain","High income",4,NA,NA,NA,NA,NA
"768",103,"Martinez-Baz","Prospective cohort",771,2021-09-30,"Oxford/AstraZeneca ChAdOx1-S","Vectored","1","1",NA,"14+","contacts of SARS-CoV-2 index cases of all ages","contacts of index cases","excluded",NA,"hospitalization","severe","severe","other combinations",78,54,89,"Spain","ESP","Europe","Europe & Central Asia",30370,2019,"Spain","High income",4,NA,NA,NA,NA,NA
"769",103,"Martinez-Baz","Prospective cohort",772,2021-09-30,"Oxford/AstraZeneca ChAdOx1-S","Vectored","2","final",NA,"14+","contacts of SARS-CoV-2 index cases of all ages","contacts of index cases","excluded","~16 weeks","hospitalization","severe","severe","other combinations",95,79,99,"Spain","ESP","Europe","Europe & Central Asia",30370,2019,"Spain","High income",4,NA,NA,NA,NA,NA
"770",103,"Martinez-Baz","Prospective cohort",773,2021-09-30,"Janssen Ad26.COV2.S","Vectored","1","final",NA,"14+","contacts of SARS-CoV-2 index cases of all ages","contacts of index cases","excluded","~23 weeks","infection","infection","infection","other combinations",50,42,57,"Spain","ESP","Europe","Europe & Central Asia",30370,2019,"Spain","High income",4,NA,NA,NA,NA,NA
"771",103,"Martinez-Baz","Prospective cohort",774,2021-09-30,"Janssen Ad26.COV2.S","Vectored","1","final",NA,"<90","contacts of SARS-CoV-2 index cases of all ages","contacts of index cases","excluded","~11 weeks","infection","infection","infection","other combinations",52,44,59,"Spain","ESP","Europe","Europe & Central Asia",30370,2019,"Spain","High income",4,NA,NA,NA,NA,NA
"772",103,"Martinez-Baz","Prospective cohort",775,2021-09-30,"Janssen Ad26.COV2.S","Vectored","1","final",NA,"90+","contacts of SARS-CoV-2 index cases of all ages","contacts of index cases","excluded","~10 weeks","infection","infection","infection","other combinations",28,-8,53,"Spain","ESP","Europe","Europe & Central Asia",30370,2019,"Spain","High income",4,NA,NA,NA,NA,NA
"773",103,"Martinez-Baz","Prospective cohort",776,2021-09-30,"Janssen Ad26.COV2.S","Vectored","1","final",NA,"14+","contacts of SARS-CoV-2 index cases of all ages","contacts of index cases","excluded","~23 weeks","symptomatic disease","symptomatic","symptomatic","other combinations",54,45,62,"Spain","ESP","Europe","Europe & Central Asia",30370,2019,"Spain","High income",4,NA,NA,NA,NA,NA
"774",103,"Martinez-Baz","Prospective cohort",777,2021-09-30,"Janssen Ad26.COV2.S","Vectored","1","final",NA,"14+","contacts of SARS-CoV-2 index cases of all ages","contacts of index cases","excluded","~23 weeks","hospitalization","severe","severe","other combinations",74,43,88,"Spain","ESP","Europe","Europe & Central Asia",30370,2019,"Spain","High income",4,NA,NA,NA,NA,NA
"775",103,"Martinez-Baz","Prospective cohort",778,2021-09-30,"Heterologous platforms","Multiple","2","final",NA,"14+","contacts of SARS-CoV-2 index cases of all ages","contacts of index cases","excluded","~21 weeks","infection","infection","infection","other combinations",86,70,93,"Spain","ESP","Europe","Europe & Central Asia",30370,2019,"Spain","High income",4,NA,NA,NA,NA,NA
"776",103,"Martinez-Baz","Prospective cohort",779,2021-09-30,"Heterologous platforms","Multiple","2","final",NA,"<90","contacts of SARS-CoV-2 index cases of all ages","contacts of index cases","excluded","~11 weeks","infection","infection","infection","other combinations",85,69,93,"Spain","ESP","Europe","Europe & Central Asia",30370,2019,"Spain","High income",4,NA,NA,NA,NA,NA
"777",103,"Martinez-Baz","Prospective cohort",780,2021-09-30,"Heterologous platforms","Multiple","2","final",NA,"14+","contacts of SARS-CoV-2 index cases of all ages","contacts of index cases","excluded","~21 weeks","symptomatic disease","symptomatic","symptomatic","other combinations",91,71,97,"Spain","ESP","Europe","Europe & Central Asia",30370,2019,"Spain","High income",4,NA,NA,NA,NA,NA
"778",103,"Martinez-Baz","Prospective cohort",781,2021-09-30,"Heterologous platforms","Multiple","2","final",NA,"14+","contacts of SARS-CoV-2 index cases of all ages","contacts of index cases","excluded","~21 weeks","hospitalization","severe","severe","other combinations",95,79,99,"Spain","ESP","Europe","Europe & Central Asia",30370,2019,"Spain","High income",4,NA,NA,NA,NA,NA
"779",103,"Martinez-Baz","Prospective cohort",782,2021-09-30,"BioNTech/Pfizer BNT162b2","mRNA","1","1",NA,"14+","contacts of SARS-CoV-2 index cases of all ages","contacts of index cases","excluded",NA,"infection","infection","infection","alpha",54,37,67,"Spain","ESP","Europe","Europe & Central Asia",30370,2019,"Spain","High income",4,NA,NA,NA,NA,NA
"780",103,"Martinez-Baz","Prospective cohort",783,2021-09-30,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"14+","contacts of SARS-CoV-2 index cases of all ages","contacts of index cases","excluded","~31 weeks","infection","infection","infection","alpha",71,61,78,"Spain","ESP","Europe","Europe & Central Asia",30370,2019,"Spain","High income",4,NA,NA,NA,NA,NA
"781",103,"Martinez-Baz","Prospective cohort",784,2021-09-30,"Moderna mRNA-1273","mRNA","1","1",NA,"14+","contacts of SARS-CoV-2 index cases of all ages","contacts of index cases","excluded",NA,"infection","infection","infection","alpha",60,14,81,"Spain","ESP","Europe","Europe & Central Asia",30370,2019,"Spain","High income",4,NA,NA,NA,NA,NA
"782",103,"Martinez-Baz","Prospective cohort",785,2021-09-30,"Moderna mRNA-1273","mRNA","2","final",NA,"14+","contacts of SARS-CoV-2 index cases of all ages","contacts of index cases","excluded","~28 weeks","infection","infection","infection","alpha",86,56,95,"Spain","ESP","Europe","Europe & Central Asia",30370,2019,"Spain","High income",4,NA,NA,NA,NA,NA
"783",103,"Martinez-Baz","Prospective cohort",786,2021-09-30,"Oxford/AstraZeneca ChAdOx1-S","Vectored","1","1",NA,"14+","contacts of SARS-CoV-2 index cases of all ages","contacts of index cases","excluded",NA,"infection","infection","infection","alpha",37,21,50,"Spain","ESP","Europe","Europe & Central Asia",30370,2019,"Spain","High income",4,NA,NA,NA,NA,NA
"784",103,"Martinez-Baz","Prospective cohort",787,2021-09-30,"Oxford/AstraZeneca ChAdOx1-S","Vectored","2","final",NA,"14+","contacts of SARS-CoV-2 index cases of all ages","contacts of index cases","excluded","~16 weeks","infection","infection","infection","alpha",38,-42,73,"Spain","ESP","Europe","Europe & Central Asia",30370,2019,"Spain","High income",4,NA,NA,NA,NA,NA
"785",103,"Martinez-Baz","Prospective cohort",788,2021-09-30,"Janssen Ad26.COV2.S","Vectored","1","final",NA,"14+","contacts of SARS-CoV-2 index cases of all ages","contacts of index cases","excluded",NA,"infection","infection","infection","alpha",77,27,92,"Spain","ESP","Europe","Europe & Central Asia",30370,2019,"Spain","High income",4,NA,NA,NA,NA,NA
"786",103,"Martinez-Baz","Prospective cohort",789,2021-09-30,"BioNTech/Pfizer BNT162b2","mRNA","1","1",NA,"14+","contacts of SARS-CoV-2 index cases of all ages","contacts of index cases","excluded",NA,"infection","infection","infection","delta",63,51,73,"Spain","ESP","Europe","Europe & Central Asia",30370,2019,"Spain","High income",4,NA,NA,NA,NA,NA
"787",103,"Martinez-Baz","Prospective cohort",790,2021-09-30,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"14+","contacts of SARS-CoV-2 index cases of all ages","contacts of index cases","excluded","~31 weeks","infection","infection","infection","delta",67,59,74,"Spain","ESP","Europe","Europe & Central Asia",30370,2019,"Spain","High income",4,NA,NA,NA,NA,NA
"788",103,"Martinez-Baz","Prospective cohort",791,2021-09-30,"Moderna mRNA-1273","mRNA","1","1",NA,"14+","contacts of SARS-CoV-2 index cases of all ages","contacts of index cases","excluded",NA,"infection","infection","infection","delta",72,51,84,"Spain","ESP","Europe","Europe & Central Asia",30370,2019,"Spain","High income",4,NA,NA,NA,NA,NA
"789",103,"Martinez-Baz","Prospective cohort",792,2021-09-30,"Moderna mRNA-1273","mRNA","2","final",NA,"14+","contacts of SARS-CoV-2 index cases of all ages","contacts of index cases","excluded","~28 weeks","infection","infection","infection","delta",77,64,85,"Spain","ESP","Europe","Europe & Central Asia",30370,2019,"Spain","High income",4,NA,NA,NA,NA,NA
"790",103,"Martinez-Baz","Prospective cohort",793,2021-09-30,"Oxford/AstraZeneca ChAdOx1-S","Vectored","1","1",NA,"14+","contacts of SARS-CoV-2 index cases of all ages","contacts of index cases","excluded",NA,"infection","infection","infection","delta",53,26,70,"Spain","ESP","Europe","Europe & Central Asia",30370,2019,"Spain","High income",4,NA,NA,NA,NA,NA
"791",103,"Martinez-Baz","Prospective cohort",794,2021-09-30,"Oxford/AstraZeneca ChAdOx1-S","Vectored","2","final",NA,"14+","contacts of SARS-CoV-2 index cases of all ages","contacts of index cases","excluded","~16 weeks","infection","infection","infection","delta",55,39,67,"Spain","ESP","Europe","Europe & Central Asia",30370,2019,"Spain","High income",4,NA,NA,NA,NA,NA
"792",103,"Martinez-Baz","Prospective cohort",795,2021-09-30,"Janssen Ad26.COV2.S","Vectored","1","final",NA,"14+","contacts of SARS-CoV-2 index cases of all ages","contacts of index cases","excluded",NA,"infection","infection","infection","delta",42,18,53,"Spain","ESP","Europe","Europe & Central Asia",30370,2019,"Spain","High income",4,NA,NA,NA,NA,NA
"793",103,"Martinez-Baz","Prospective cohort",796,2021-09-30,"Heterologous platforms","Multiple","2","final",NA,"14+","contacts of SARS-CoV-2 index cases of all ages","contacts of index cases","excluded","~21 weeks","infection","infection","infection","delta",86,45,97,"Spain","ESP","Europe","Europe & Central Asia",30370,2019,"Spain","High income",4,NA,NA,NA,NA,NA
"794",104,"Bruxvoort","Test-negative case-control",797,2021-12-15,"Moderna mRNA-1273","mRNA","1","1",NA,"14+",">= 18 years","general pop","excluded",NA,"infection","infection","infection","delta",77,60.7,86.5,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"795",104,"Bruxvoort","Test-negative case-control",798,2021-12-15,"Moderna mRNA-1273","mRNA","2","final",NA,"14+",">= 18 years","general pop","excluded","~25 weeks","infection","infection","infection","delta",86.7,84.3,88.7,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"796",104,"Bruxvoort","Test-negative case-control",799,2021-12-15,"Moderna mRNA-1273","mRNA","2","final",NA,"14-60",">= 18 years","general pop","excluded","~6.5 weeks","infection","infection","infection","delta",94.1,90.5,96.3,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"797",104,"Bruxvoort","Test-negative case-control",800,2021-12-15,"Moderna mRNA-1273","mRNA","2","final",NA,"151-180",">= 18 years","general pop","excluded","~23.5 weeks","infection","infection","infection","delta",80,70.2,86.6,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"798",104,"Bruxvoort","Test-negative case-control",801,2021-12-15,"Moderna mRNA-1273","mRNA","2","final",NA,"14+",">= 18 years","general pop","excluded","~25 weeks","hospitalization","severe","severe","delta",97.5,92.7,99.2,"USA","USA","North America","North America",66220,2019,"United States","High income",4,14,175,"yes",NA,0
"799",104,"Bruxvoort","Test-negative case-control",802,2021-12-15,"Moderna mRNA-1273","mRNA","2","final",NA,"14-60",">= 18 years","general pop","excluded","~6.5 weeks","infection","infection","infection","other combinations",98.6,97.3,99.3,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"800",104,"Bruxvoort","Test-negative case-control",803,2021-12-15,"Moderna mRNA-1273","mRNA","2","final",NA,"121-150",">= 18 years","general pop","excluded","~19.5 weeks","infection","infection","infection","other combinations",88.7,73.2,95.2,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"801",104,"Bruxvoort","Test-negative case-control",804,2021-12-15,"Moderna mRNA-1273","mRNA","1","1",NA,"14+",">= 18 years","general pop","excluded",NA,"infection","infection","infection","alpha",90.1,82.9,94.2,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"802",104,"Bruxvoort","Test-negative case-control",805,2021-12-15,"Moderna mRNA-1273","mRNA","2","final",NA,"14+",">= 18 years","general pop","excluded","~25 weeks","infection","infection","infection","alpha",98.4,96.9,99.1,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"803",104,"Bruxvoort","Test-negative case-control",806,2021-12-15,"Moderna mRNA-1273","mRNA","1","1",NA,"14+",">= 18 years","general pop","excluded",NA,"infection","infection","infection","gamma",74.2,43.8,88.1,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"804",104,"Bruxvoort","Test-negative case-control",807,2021-12-15,"Moderna mRNA-1273","mRNA","2","final",NA,"14+",">= 18 years","general pop","excluded","~25 weeks","infection","infection","infection","gamma",95.5,90.9,97.8,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"805",105,"Liu","Test-negative case-control",808,2022-05-24,"Multiple or heterologous RNA","mRNA","2","final",NA,"14+",">= 18 years","general pop","excluded","~35 weeks","infection","infection","infection","other combinations",59,52,65,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"806",105,"Liu","Test-negative case-control",809,2022-05-24,"Multiple or heterologous RNA","mRNA","2","final",NA,"14+","immunocompromised, >= 18 years","immunocompromised adults","excluded","~35 weeks","infection","infection","infection","other combinations",57,45,66,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"807",106,"Ranzani","Test-negative case-control",810,2021-10-18,"Janssen Ad26.COV2.S","Vectored","1","final",NA,"28+",">= 18 years","general pop","excluded","~10 weeks","symptomatic disease","symptomatic","symptomatic","gamma",50.9,35.5,63,"Brazil","BRA","South America","Latin America & Caribbean",9410,2019,"Brazil","Upper middle income",3,NA,NA,NA,NA,NA
"808",106,"Ranzani","Test-negative case-control",811,2021-10-18,"Janssen Ad26.COV2.S","Vectored","1","final",NA,"28+",">= 18 years","general pop","excluded","~10 weeks","hospitalization","severe","severe","gamma",72.9,35.1,91.1,"Brazil","BRA","South America","Latin America & Caribbean",9410,2019,"Brazil","Upper middle income",3,NA,NA,NA,NA,NA
"809",106,"Ranzani","Test-negative case-control",812,2021-10-18,"Janssen Ad26.COV2.S","Vectored","1","final",NA,"28+",">= 18 years","general pop","excluded","~10 weeks","ICU admission","severe","severe","gamma",92.5,54.9,99.6,"Brazil","BRA","South America","Latin America & Caribbean",9410,2019,"Brazil","Upper middle income",3,NA,NA,NA,NA,NA
"810",106,"Ranzani","Test-negative case-control",813,2021-10-18,"Janssen Ad26.COV2.S","Vectored","1","final",NA,"28+",">= 18 years","general pop","excluded","~10 weeks","death","death","death","gamma",90.5,31.5,99.6,"Brazil","BRA","South America","Latin America & Caribbean",9410,2019,"Brazil","Upper middle income",3,NA,NA,NA,NA,NA
"811",107,"Arregoces","Matched-pair cohort",814,2021-10-19,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"14+",">= 60 years",">= 60 years","excluded","~9 weeks","hospitalization","severe","severe","mu",90.3,87.1,92.7,"Colombia","COL","South America","Latin America & Caribbean",6630,2019,"Colombia","Upper middle income",3,NA,NA,NA,NA,NA
"812",107,"Arregoces","Matched-pair cohort",815,2021-10-19,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"14+",">= 60 years",">= 60 years","excluded","~9 weeks","post-hospitalization death","death","death","mu",98.5,97.8,98.9,"Colombia","COL","South America","Latin America & Caribbean",6630,2019,"Colombia","Upper middle income",3,NA,NA,NA,NA,NA
"813",107,"Arregoces","Matched-pair cohort",816,2021-10-19,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"14+",">= 60 years",">= 60 years","excluded","~9 weeks","death without prior hospitalization","death","death","mu",89.2,85.6,91.9,"Colombia","COL","South America","Latin America & Caribbean",6630,2019,"Colombia","Upper middle income",3,NA,NA,NA,NA,NA
"814",107,"Arregoces","Matched-pair cohort",817,2021-10-19,"Sinovac CoronaVac","Inactivated","2","final",NA,"14+",">= 60 years",">= 60 years","excluded","~11 weeks","hospitalization","severe","severe","mu",67.2,63.7,70.4,"Colombia","COL","South America","Latin America & Caribbean",6630,2019,"Colombia","Upper middle income",3,NA,NA,NA,NA,NA
"815",107,"Arregoces","Matched-pair cohort",818,2021-10-19,"Sinovac CoronaVac","Inactivated","2","final",NA,"14+",">= 60 years",">= 60 years","excluded","~11 weeks","post-hospitalization death","death","death","mu",77.1,75.5,78.6,"Colombia","COL","South America","Latin America & Caribbean",6630,2019,"Colombia","Upper middle income",3,NA,NA,NA,NA,NA
"816",107,"Arregoces","Matched-pair cohort",819,2021-10-19,"Sinovac CoronaVac","Inactivated","2","final",NA,"14+",">= 60 years",">= 60 years","excluded","~11 weeks","death without prior hospitalization","death","death","mu",69.8,66.7,72.6,"Colombia","COL","South America","Latin America & Caribbean",6630,2019,"Colombia","Upper middle income",3,NA,NA,NA,NA,NA
"817",107,"Arregoces","Matched-pair cohort",820,2021-10-19,"Oxford/AstraZeneca ChAdOx1-S","Vectored","2","final",NA,"14+",">= 60 years",">= 60 years","excluded","~7 weeks","hospitalization","severe","severe","mu",75.4,48.2,88.3,"Colombia","COL","South America","Latin America & Caribbean",6630,2019,"Colombia","Upper middle income",3,NA,NA,NA,NA,NA
"818",107,"Arregoces","Matched-pair cohort",821,2021-10-19,"Oxford/AstraZeneca ChAdOx1-S","Vectored","2","final",NA,"14+",">= 60 years",">= 60 years","excluded","~7 weeks","post-hospitalization death","death","death","mu",96.3,88.4,98.8,"Colombia","COL","South America","Latin America & Caribbean",6630,2019,"Colombia","Upper middle income",3,NA,NA,NA,NA,NA
"819",107,"Arregoces","Matched-pair cohort",822,2021-10-19,"Oxford/AstraZeneca ChAdOx1-S","Vectored","2","final",NA,"14+",">= 60 years",">= 60 years","excluded","~7 weeks","death without prior hospitalization","death","death","mu",88.7,64.8,96.4,"Colombia","COL","South America","Latin America & Caribbean",6630,2019,"Colombia","Upper middle income",3,NA,NA,NA,NA,NA
"820",107,"Arregoces","Matched-pair cohort",823,2021-10-19,"Janssen Ad26.COV2.S","Vectored","1","final",NA,"14+",">= 60 years",">= 60 years","excluded","~4 weeks","hospitalization","severe","severe","mu",80,19.9,95,"Colombia","COL","South America","Latin America & Caribbean",6630,2019,"Colombia","Upper middle income",3,NA,NA,NA,NA,NA
"821",107,"Arregoces","Matched-pair cohort",824,2021-10-19,"Janssen Ad26.COV2.S","Vectored","1","final",NA,"14+",">= 60 years",">= 60 years","excluded","~4 weeks","death without prior hospitalization","death","death","mu",75,0,93.8,"Colombia","COL","South America","Latin America & Caribbean",6630,2019,"Colombia","Upper middle income",3,NA,NA,NA,NA,NA
"822",108,"Olson","Test-negative case-control",825,2021-10-19,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"14+","12-15 years","12-15 years","unknown","~12 weeks","hospitalization","severe","severe","delta",91,74,97,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"823",108,"Olson","Test-negative case-control",826,2021-10-19,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"14+","16-18 years","16-18 years","unknown","~12 weeks","hospitalization","severe","severe","delta",94,78,99,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"824",110,"Chin","Retrospective cohort",866,2021-10-20,"Moderna mRNA-1273","mRNA","2","final",NA,"14+","incarcerated men","incarcerated men","included","~27 weeks","infection","infection","infection","delta",56.6,42,67.5,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"825",110,"Chin","Retrospective cohort",867,2021-10-20,"Moderna mRNA-1273","mRNA","2","final",NA,"14+","incarcerated men","incarcerated men","included","~27 weeks","symptomatic disease","symptomatic","symptomatic","delta",84.2,56.4,94.3,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"826",110,"Chin","Retrospective cohort",868,2021-10-20,"Moderna mRNA-1273","mRNA","2","final",NA,"14+","incarcerated men","incarcerated men","previously infected only","~27 weeks","infection","infection","infection","delta",80.5,52.8,92,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"827",110,"Chin","Retrospective cohort",869,2021-10-20,"Moderna mRNA-1273","mRNA","2","final",NA,"14+","incarcerated men","incarcerated men","excluded","~27 weeks","infection","infection","infection","delta",49.5,31.5,62.7,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"828",111,"Ranzani","Test-negative case-control",870,2022-02-09,"Oxford/AstraZeneca ChAdOx1-S","Vectored","1","1",NA,">21",">= 18 years","general pop","excluded",NA,"infection","infection","infection","other combinations",31,12.7,45.5,"Brazil","BRA","South America","Latin America & Caribbean",9410,2019,"Brazil","Upper middle income",3,NA,NA,NA,NA,NA
"829",111,"Ranzani","Test-negative case-control",871,2022-02-09,"Oxford/AstraZeneca ChAdOx1-S","Vectored","2","final",NA,"14+",">= 18 years","general pop","excluded","~31 weeks","infection","infection","infection","other combinations",59,33.1,74.8,"Brazil","BRA","South America","Latin America & Caribbean",9410,2019,"Brazil","Upper middle income",3,NA,NA,NA,NA,NA
"830",111,"Ranzani","Test-negative case-control",872,2022-02-09,"Oxford/AstraZeneca ChAdOx1-S","Vectored","1","1",NA,">21",">= 18 years","general pop","excluded",NA,"symptomatic disease","symptomatic","symptomatic","other combinations",31.6,12,46.8,"Brazil","BRA","South America","Latin America & Caribbean",9410,2019,"Brazil","Upper middle income",3,NA,NA,NA,NA,NA
"831",111,"Ranzani","Test-negative case-control",873,2022-02-09,"Oxford/AstraZeneca ChAdOx1-S","Vectored","2","final",NA,"14+",">= 18 years","general pop","excluded","~31 weeks","symptomatic disease","symptomatic","symptomatic","other combinations",65.1,40.9,79.4,"Brazil","BRA","South America","Latin America & Caribbean",9410,2019,"Brazil","Upper middle income",3,NA,NA,NA,NA,NA
"832",111,"Ranzani","Test-negative case-control",874,2022-02-09,"Oxford/AstraZeneca ChAdOx1-S","Vectored","1","1",NA,">21",">= 18 years","general pop","excluded",NA,"asymptomatic infection","asymptomatic","infection","other combinations",26.6,-53.8,65,"Brazil","BRA","South America","Latin America & Caribbean",9410,2019,"Brazil","Upper middle income",3,NA,NA,NA,NA,NA
"833",112,"Nordstrom","Retrospective cohort",875,2022-02-04,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"15-30",">= 18 years","general pop","excluded","~30 weeks","symptomatic disease","symptomatic","symptomatic","delta",92,92,93,"Sweden","SWE","Europe","Europe & Central Asia",56230,2019,"Sweden","High income",4,NA,NA,NA,NA,NA
"834",112,"Nordstrom","Retrospective cohort",876,2022-02-04,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"210+",">= 18 years","general pop","excluded","~30 weeks","symptomatic disease","symptomatic","symptomatic","delta",23,-2,41,"Sweden","SWE","Europe","Europe & Central Asia",56230,2019,"Sweden","High income",4,NA,NA,NA,NA,NA
"835",112,"Nordstrom","Retrospective cohort",877,2022-02-04,"Moderna mRNA-1273","mRNA","2","final",NA,"15-30",">= 18 years","general pop","excluded","~30 weeks","symptomatic disease","symptomatic","symptomatic","delta",96,94,97,"Sweden","SWE","Europe","Europe & Central Asia",56230,2019,"Sweden","High income",4,NA,NA,NA,NA,NA
"836",112,"Nordstrom","Retrospective cohort",878,2022-02-04,"Moderna mRNA-1273","mRNA","2","final",NA,"210+",">= 18 years","general pop","excluded","~30 weeks","symptomatic disease","symptomatic","symptomatic","delta",59,18,79,"Sweden","SWE","Europe","Europe & Central Asia",56230,2019,"Sweden","High income",4,NA,NA,NA,NA,NA
"837",112,"Nordstrom","Retrospective cohort",879,2022-02-04,"Oxford/AstraZeneca ChAdOx1-S","Vectored","2","final",NA,"15-30",">= 18 years","general pop","excluded","~30 weeks","symptomatic disease","symptomatic","symptomatic","delta",68,52,79,"Sweden","SWE","Europe","Europe & Central Asia",56230,2019,"Sweden","High income",4,NA,NA,NA,NA,NA
"838",112,"Nordstrom","Retrospective cohort",880,2022-02-04,"Oxford/AstraZeneca ChAdOx1-S","Vectored","2","final",NA,"210+",">= 18 years","general pop","excluded","~30 weeks","symptomatic disease","symptomatic","symptomatic","delta",-19,-97,28,"Sweden","SWE","Europe","Europe & Central Asia",56230,2019,"Sweden","High income",4,NA,NA,NA,NA,NA
"839",112,"Nordstrom","Retrospective cohort",881,2022-02-04,"Heterologous platforms","Multiple","2","final",NA,"15-30",">= 18 years","general pop","excluded","~30 weeks","symptomatic disease","symptomatic","symptomatic","delta",89,79,94,"Sweden","SWE","Europe","Europe & Central Asia",56230,2019,"Sweden","High income",4,NA,NA,NA,NA,NA
"840",112,"Nordstrom","Retrospective cohort",882,2022-02-04,"Heterologous platforms","Multiple","2","final",NA,"210+",">= 18 years","general pop","excluded","~30 weeks","symptomatic disease","symptomatic","symptomatic","delta",66,41,80,"Sweden","SWE","Europe","Europe & Central Asia",56230,2019,"Sweden","High income",4,NA,NA,NA,NA,NA
"841",113,"Lin","Retrospective cohort",883,2022-03-10,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"1.25 months",">= 18 years","general pop","unknown","~27 weeks","symptomatic disease","symptomatic","symptomatic","other combinations",94.5,94.1,94.9,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"842",113,"Lin","Retrospective cohort",884,2022-03-10,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"7.25 months",">= 18 years","general pop","unknown","~27 weeks","symptomatic disease","symptomatic","symptomatic","other combinations",67.8,65.9,69.7,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"843",113,"Lin","Retrospective cohort",885,2022-03-10,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"1.25 months",">= 18 years","general pop","unknown","~27 weeks","hospitalization","severe","severe","other combinations",96.4,95.1,97.4,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"844",113,"Lin","Retrospective cohort",886,2022-03-10,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"7.25 months",">= 18 years","general pop","unknown","~27 weeks","hospitalization","severe","severe","other combinations",92.4,89.7,94.4,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"845",113,"Lin","Retrospective cohort",887,2022-03-10,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"1.25 months",">= 18 years","general pop","unknown","~27 weeks","death","death","death","other combinations",98,95.5,99.1,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"846",113,"Lin","Retrospective cohort",888,2022-03-10,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"7.25 months",">= 18 years","general pop","unknown","~32 weeks","death","death","death","other combinations",95.5,92.2,97.4,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"847",113,"Lin","Retrospective cohort",889,2022-03-10,"Moderna mRNA-1273","mRNA","2","final",NA,"1 month",">= 18 years","general pop","unknown","~32 weeks","symptomatic disease","symptomatic","symptomatic","other combinations",95.9,95.5,96.2,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"848",113,"Lin","Retrospective cohort",890,2022-03-10,"Moderna mRNA-1273","mRNA","2","final",NA,"7 months",">= 18 years","general pop","unknown","~32 weeks","symptomatic disease","symptomatic","symptomatic","other combinations",77.8,75.9,79.6,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"849",113,"Lin","Retrospective cohort",891,2022-03-10,"Moderna mRNA-1273","mRNA","2","final",NA,"1 month",">= 18 years","general pop","unknown","~32 weeks","hospitalization","severe","severe","other combinations",97.2,96.1,98,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"850",113,"Lin","Retrospective cohort",892,2022-03-10,"Moderna mRNA-1273","mRNA","2","final",NA,"7 months",">= 18 years","general pop","unknown","~32 weeks","hospitalization","severe","severe","other combinations",94.9,92.4,96.6,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"851",113,"Lin","Retrospective cohort",893,2022-03-10,"Moderna mRNA-1273","mRNA","2","final",NA,"1 month",">= 18 years","general pop","unknown","~32 weeks","death","death","death","other combinations",98.6,97.3,99.3,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"852",113,"Lin","Retrospective cohort",894,2022-03-10,"Moderna mRNA-1273","mRNA","2","final",NA,"7 months",">= 18 years","general pop","unknown","~22 weeks","death","death","death","other combinations",96,92.8,97.8,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"853",113,"Lin","Retrospective cohort",895,2022-03-10,"Janssen Ad26.COV2.S","Vectored","1","final",NA,"2 months",">= 18 years","general pop","unknown","~22 weeks","symptomatic disease","symptomatic","symptomatic","other combinations",71.4,68.3,74.2,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"854",113,"Lin","Retrospective cohort",896,2022-03-10,"Janssen Ad26.COV2.S","Vectored","1","final",NA,"6 months",">= 18 years","general pop","unknown","~22 weeks","symptomatic disease","symptomatic","symptomatic","other combinations",64,60.3,67.4,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"855",113,"Lin","Retrospective cohort",897,2022-03-10,"Janssen Ad26.COV2.S","Vectored","1","final",NA,"2 months",">= 18 years","general pop","unknown","~22 weeks","hospitalization","severe","severe","other combinations",85.8,74.9,91.9,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"856",113,"Lin","Retrospective cohort",898,2022-03-10,"Janssen Ad26.COV2.S","Vectored","1","final",NA,"6 months",">= 18 years","general pop","unknown","~22 weeks","hospitalization","severe","severe","other combinations",81.7,68.6,89.3,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"857",113,"Lin","Retrospective cohort",899,2022-03-10,"Janssen Ad26.COV2.S","Vectored","1","final",NA,"2 months",">= 18 years","general pop","unknown","~22 weeks","death","death","death","other combinations",82.2,46.3,94.1,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"858",113,"Lin","Retrospective cohort",900,2022-03-10,"Janssen Ad26.COV2.S","Vectored","1","final",NA,"6 months",">= 18 years","general pop","unknown","~22 weeks","death","death","death","other combinations",71.2,40.8,86,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"859",114,"Skowronski","Test-negative case-control",901,2022-04-19,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"14+",">= 18 years","general pop","excluded","~38 weeks","Infection","infection","infection","other combinations",89,89,89,"Canada","CAN","North America","North America",46580,2019,"Canada","High income",4,NA,NA,NA,NA,NA
"860",114,"Skowronski","Test-negative case-control",902,2022-04-19,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"14-27",">= 18 years","general pop","excluded","~38 weeks","Infection","infection","infection","other combinations",93,92,94,"Canada","CAN","North America","North America",46580,2019,"Canada","High income",4,NA,NA,NA,NA,NA
"861",114,"Skowronski","Test-negative case-control",903,2022-04-19,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"252-279",">= 18 years","general pop","excluded","~38 weeks","Infection","infection","infection","other combinations",80,75,83,"Canada","CAN","North America","North America",46580,2019,"Canada","High income",4,NA,NA,NA,NA,NA
"862",114,"Skowronski","Test-negative case-control",904,2022-04-19,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"14+",">= 18 years","general pop","excluded","~38 weeks","Hospitalization","severe","severe","other combinations",97,97,98,"Canada","CAN","North America","North America",46580,2019,"Canada","High income",4,NA,NA,NA,NA,NA
"863",114,"Skowronski","Test-negative case-control",905,2022-04-19,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"14-27",">= 18 years","general pop","excluded","~38 weeks","Hospitalization","severe","severe","other combinations",98,96,99,"Canada","CAN","North America","North America",46580,2019,"Canada","High income",4,NA,NA,NA,NA,NA
"864",114,"Skowronski","Test-negative case-control",906,2022-04-19,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"252-279",">= 18 years","general pop","excluded","~38 weeks","Hospitalization","severe","severe","other combinations",96,86,99,"Canada","CAN","North America","North America",46580,2019,"Canada","High income",4,NA,NA,NA,NA,NA
"865",114,"Skowronski","Test-negative case-control",907,2022-04-19,"Moderna mRNA-1273","mRNA","2","final",NA,"14+",">= 18 years","general pop","excluded","~38 weeks","Infection","infection","infection","other combinations",90,89,90,"Canada","CAN","North America","North America",46580,2019,"Canada","High income",4,NA,NA,NA,NA,NA
"866",114,"Skowronski","Test-negative case-control",908,2022-04-19,"Moderna mRNA-1273","mRNA","2","final",NA,"14-27",">= 18 years","general pop","excluded","~38 weeks","Infection","infection","infection","other combinations",95,94,96,"Canada","CAN","North America","North America",46580,2019,"Canada","High income",4,NA,NA,NA,NA,NA
"867",114,"Skowronski","Test-negative case-control",909,2022-04-19,"Moderna mRNA-1273","mRNA","2","final",NA,"252-279",">= 18 years","general pop","excluded","~38 weeks","Infection","infection","infection","other combinations",55,40,66,"Canada","CAN","North America","North America",46580,2019,"Canada","High income",4,NA,NA,NA,NA,NA
"868",114,"Skowronski","Test-negative case-control",910,2022-04-19,"Moderna mRNA-1273","mRNA","2","final",NA,"14+",">= 18 years","general pop","excluded","~38 weeks","Hospitalization","severe","severe","other combinations",97,97,98,"Canada","CAN","North America","North America",46580,2019,"Canada","High income",4,NA,NA,NA,NA,NA
"869",114,"Skowronski","Test-negative case-control",911,2022-04-19,"Moderna mRNA-1273","mRNA","2","final",NA,"14-27",">= 18 years","general pop","excluded","~38 weeks","Hospitalization","severe","severe","other combinations",99,95,100,"Canada","CAN","North America","North America",46580,2019,"Canada","High income",4,NA,NA,NA,NA,NA
"870",114,"Skowronski","Test-negative case-control",912,2022-04-19,"Moderna mRNA-1273","mRNA","2","final",NA,"252-279",">= 18 years","general pop","excluded","~38 weeks","Hospitalization","severe","severe","other combinations",95,65,99,"Canada","CAN","North America","North America",46580,2019,"Canada","High income",4,NA,NA,NA,NA,NA
"871",114,"Skowronski","Test-negative case-control",913,2022-04-19,"Oxford/AstraZeneca ChAdOx1-S","Vectored","2","final",NA,"14+",">= 18 years","general pop","excluded","~38 weeks","Infection","infection","infection","other combinations",74,72,76,"Canada","CAN","North America","North America",46580,2019,"Canada","High income",4,NA,NA,NA,NA,NA
"872",114,"Skowronski","Test-negative case-control",914,2022-04-19,"Oxford/AstraZeneca ChAdOx1-S","Vectored","2","final",NA,"14-27",">= 18 years","general pop","excluded","~38 weeks","Infection","infection","infection","other combinations",77,57,87,"Canada","CAN","North America","North America",46580,2019,"Canada","High income",4,NA,NA,NA,NA,NA
"873",114,"Skowronski","Test-negative case-control",915,2022-04-19,"Oxford/AstraZeneca ChAdOx1-S","Vectored","2","final",NA,"168-195",">= 18 years","general pop","excluded","~38 weeks","Infection","infection","infection","other combinations",67,48,80,"Canada","CAN","North America","North America",46580,2019,"Canada","High income",4,NA,NA,NA,NA,NA
"874",114,"Skowronski","Test-negative case-control",916,2022-04-19,"Oxford/AstraZeneca ChAdOx1-S","Vectored","2","final",NA,"14+",">= 18 years","general pop","excluded","~38 weeks","Hospitalization","severe","severe","other combinations",95,94,97,"Canada","CAN","North America","North America",46580,2019,"Canada","High income",4,NA,NA,NA,NA,NA
"875",114,"Skowronski","Test-negative case-control",917,2022-04-19,"Oxford/AstraZeneca ChAdOx1-S","Vectored","2","final",NA,"28-55",">= 18 years","general pop","excluded","~38 weeks","Hospitalization","severe","severe","other combinations",97,71,97,"Canada","CAN","North America","North America",46580,2019,"Canada","High income",4,NA,NA,NA,NA,NA
"876",114,"Skowronski","Test-negative case-control",918,2022-04-19,"Oxford/AstraZeneca ChAdOx1-S","Vectored","2","final",NA,"168-195",">= 18 years","general pop","excluded","~38 weeks","Hospitalization","severe","severe","other combinations",91,35,99,"Canada","CAN","North America","North America",46580,2019,"Canada","High income",4,NA,NA,NA,NA,NA
"877",114,"Skowronski","Test-negative case-control",919,2022-04-19,"Multiple or heterologous RNA","mRNA","2","final",NA,"14+",">= 18 years","general pop","excluded","~38 weeks","Infection","infection","infection","other combinations",90,89,90,"Canada","CAN","North America","North America",46580,2019,"Canada","High income",4,NA,NA,NA,NA,NA
"878",114,"Skowronski","Test-negative case-control",920,2022-04-19,"Multiple or heterologous RNA","mRNA","2","final",NA,"14-27",">= 18 years","general pop","excluded","~38 weeks","Infection","infection","infection","other combinations",95,91,97,"Canada","CAN","North America","North America",46580,2019,"Canada","High income",4,NA,NA,NA,NA,NA
"879",114,"Skowronski","Test-negative case-control",921,2022-04-19,"Multiple or heterologous RNA","mRNA","2","final",NA,"168-195",">= 18 years","general pop","excluded","~38 weeks","Infection","infection","infection","other combinations",96,73,99,"Canada","CAN","North America","North America",46580,2019,"Canada","High income",4,NA,NA,NA,NA,NA
"880",114,"Skowronski","Test-negative case-control",922,2022-04-19,"Multiple or heterologous RNA","mRNA","2","final",NA,"14+",">= 18 years","general pop","excluded","~38 weeks","Hospitalization","severe","severe","other combinations",98,97,98,"Canada","CAN","North America","North America",46580,2019,"Canada","High income",4,NA,NA,NA,NA,NA
"881",114,"Skowronski","Test-negative case-control",923,2022-04-19,"Multiple or heterologous RNA","mRNA","2","final",NA,"14-27",">= 18 years","general pop","excluded","~38 weeks","Hospitalization","severe","severe","other combinations",96,75,100,"Canada","CAN","North America","North America",46580,2019,"Canada","High income",4,NA,NA,NA,NA,NA
"882",114,"Skowronski","Test-negative case-control",924,2022-04-19,"Multiple or heterologous RNA","mRNA","2","final",NA,"140-167",">= 18 years","general pop","excluded","~38 weeks","Hospitalization","severe","severe","other combinations",96,92,98,"Canada","CAN","North America","North America",46580,2019,"Canada","High income",4,NA,NA,NA,NA,NA
"883",114,"Skowronski","Test-negative case-control",925,2022-04-19,"Heterologous platforms","Multiple","2","final",NA,"14+",">= 18 years","general pop","excluded","~38 weeks","Infection","infection","infection","other combinations",89,88,89,"Canada","CAN","North America","North America",46580,2019,"Canada","High income",4,NA,NA,NA,NA,NA
"884",114,"Skowronski","Test-negative case-control",926,2022-04-19,"Heterologous platforms","Multiple","2","final",NA,"14-27",">= 18 years","general pop","excluded","~38 weeks","Infection","infection","infection","other combinations",94,89,97,"Canada","CAN","North America","North America",46580,2019,"Canada","High income",4,NA,NA,NA,NA,NA
"885",114,"Skowronski","Test-negative case-control",927,2022-04-19,"Heterologous platforms","Multiple","2","final",NA,"140-167",">= 18 years","general pop","excluded","~38 weeks","Infection","infection","infection","other combinations",82,78,85,"Canada","CAN","North America","North America",46580,2019,"Canada","High income",4,NA,NA,NA,NA,NA
"886",114,"Skowronski","Test-negative case-control",928,2022-04-19,"Heterologous platforms","Multiple","2","final",NA,"14+",">= 18 years","general pop","excluded","~38 weeks","Hospitalization","severe","severe","other combinations",99,99,100,"Canada","CAN","North America","North America",46580,2019,"Canada","High income",4,NA,NA,NA,NA,NA
"887",114,"Skowronski","Test-negative case-control",929,2022-04-19,"Heterologous platforms","Multiple","2","final",NA,"14-27",">= 18 years","general pop","excluded","~38 weeks","Hospitalization","severe","severe","other combinations",93,48,99,"Canada","CAN","North America","North America",46580,2019,"Canada","High income",4,NA,NA,NA,NA,NA
"888",114,"Skowronski","Test-negative case-control",930,2022-04-19,"Heterologous platforms","Multiple","2","final",NA,"140-167",">= 18 years","general pop","excluded","~38 weeks","hospitalization","severe","severe","other combinations",98,91,99,"Canada","CAN","North America","North America",46580,2019,"Canada","High income",4,NA,NA,NA,NA,NA
"889",114,"Skowronski","Test-negative case-control",931,2022-04-19,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"14+",">= 18 years","general pop","excluded","~38 weeks","Infection","infection","infection","delta",89,89,89,"Canada","CAN","North America","North America",46580,2019,"Canada","High income",4,NA,NA,NA,NA,NA
"890",114,"Skowronski","Test-negative case-control",932,2022-04-19,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"14-27",">= 18 years","general pop","excluded","~38 weeks","Infection","infection","infection","delta",93,93,94,"Canada","CAN","North America","North America",46580,2019,"Canada","High income",4,NA,NA,NA,NA,NA
"891",114,"Skowronski","Test-negative case-control",933,2022-04-19,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"252-279",">= 18 years","general pop","excluded","~38 weeks","Infection","infection","infection","delta",79,75,83,"Canada","CAN","North America","North America",46580,2019,"Canada","High income",4,NA,NA,NA,NA,NA
"892",114,"Skowronski","Test-negative case-control",934,2022-04-19,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"14+",">= 18 years","general pop","excluded","~38 weeks","hospitalization","severe","severe","delta",98,97,98,"Canada","CAN","North America","North America",46580,2019,"Canada","High income",4,14,266,"yes",NA,0
"893",114,"Skowronski","Test-negative case-control",935,2022-04-19,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"14-27",">= 18 years","general pop","excluded","~38 weeks","hospitalization","severe","severe","delta",98,95,99,"Canada","CAN","North America","North America",46580,2019,"Canada","High income",4,14,27,"no","nested period",0
"894",114,"Skowronski","Test-negative case-control",936,2022-04-19,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"196-223",">= 18 years","general pop","excluded","~38 weeks","hospitalization","severe","severe","delta",94,87,97,"Canada","CAN","North America","North America",46580,2019,"Canada","High income",4,196,223,"no","nested period",0
"895",114,"Skowronski","Test-negative case-control",937,2022-04-19,"Moderna mRNA-1273","mRNA","2","final",NA,"14+",">= 18 years","general pop","excluded","~38 weeks","Infection","infection","infection","delta",90,89,90,"Canada","CAN","North America","North America",46580,2019,"Canada","High income",4,NA,NA,NA,NA,NA
"896",114,"Skowronski","Test-negative case-control",938,2022-04-19,"Moderna mRNA-1273","mRNA","2","final",NA,"14-27",">= 18 years","general pop","excluded","~38 weeks","Infection","infection","infection","delta",95,94,96,"Canada","CAN","North America","North America",46580,2019,"Canada","High income",4,NA,NA,NA,NA,NA
"897",114,"Skowronski","Test-negative case-control",939,2022-04-19,"Moderna mRNA-1273","mRNA","2","final",NA,"196-223",">= 18 years","general pop","excluded","~38 weeks","Infection","infection","infection","delta",55,41,66,"Canada","CAN","North America","North America",46580,2019,"Canada","High income",4,NA,NA,NA,NA,NA
"898",114,"Skowronski","Test-negative case-control",940,2022-04-19,"Moderna mRNA-1273","mRNA","2","final",NA,"14+",">= 18 years","general pop","excluded","~38 weeks","hospitalization","severe","severe","delta",97,97,98,"Canada","CAN","North America","North America",46580,2019,"Canada","High income",4,14,266,"yes",NA,0
"899",114,"Skowronski","Test-negative case-control",941,2022-04-19,"Moderna mRNA-1273","mRNA","2","final",NA,"14-27",">= 18 years","general pop","excluded","~38 weeks","hospitalization","severe","severe","delta",98,94,100,"Canada","CAN","North America","North America",46580,2019,"Canada","High income",4,14,27,"no","nested period",0
"900",114,"Skowronski","Test-negative case-control",942,2022-04-19,"Moderna mRNA-1273","mRNA","2","final",NA,"196-223",">= 18 years","general pop","excluded","~38 weeks","hospitalization","severe","severe","delta",95,80,99,"Canada","CAN","North America","North America",46580,2019,"Canada","High income",4,196,223,"no","nested period",0
"901",114,"Skowronski","Test-negative case-control",943,2022-04-19,"Oxford/AstraZeneca ChAdOx1-S","Vectored","2","final",NA,"14+",">= 18 years","general pop","excluded","~38 weeks","Infection","infection","infection","delta",73,72,75,"Canada","CAN","North America","North America",46580,2019,"Canada","High income",4,NA,NA,NA,NA,NA
"902",114,"Skowronski","Test-negative case-control",944,2022-04-19,"Oxford/AstraZeneca ChAdOx1-S","Vectored","2","final",NA,"14-27",">= 18 years","general pop","excluded","~38 weeks","Infection","infection","infection","delta",70,39,86,"Canada","CAN","North America","North America",46580,2019,"Canada","High income",4,NA,NA,NA,NA,NA
"903",114,"Skowronski","Test-negative case-control",945,2022-04-19,"Oxford/AstraZeneca ChAdOx1-S","Vectored","2","final",NA,"168-195",">= 18 years","general pop","excluded","~38 weeks","Infection","infection","infection","delta",67,48,80,"Canada","CAN","North America","North America",46580,2019,"Canada","High income",4,NA,NA,NA,NA,NA
"904",114,"Skowronski","Test-negative case-control",946,2022-04-19,"Oxford/AstraZeneca ChAdOx1-S","Vectored","2","final",NA,"14+",">= 18 years","general pop","excluded","~38 weeks","Hospitalization","severe","severe","delta",95,93,97,"Canada","CAN","North America","North America",46580,2019,"Canada","High income",4,14,266,"yes",NA,0
"905",114,"Skowronski","Test-negative case-control",947,2022-04-19,"Oxford/AstraZeneca ChAdOx1-S","Vectored","2","final",NA,"28-55",">= 18 years","general pop","excluded","~38 weeks","Hospitalization","severe","severe","delta",89,67,97,"Canada","CAN","North America","North America",46580,2019,"Canada","High income",4,28,55,"no","nested period",0
"906",114,"Skowronski","Test-negative case-control",948,2022-04-19,"Oxford/AstraZeneca ChAdOx1-S","Vectored","2","final",NA,"168-195",">= 18 years","general pop","excluded","~38 weeks","Hospitalization","severe","severe","delta",91,34,99,"Canada","CAN","North America","North America",46580,2019,"Canada","High income",4,168,195,"no","nested period",0
"907",114,"Skowronski","Test-negative case-control",949,2022-04-19,"Multiple or heterologous RNA","mRNA","2","final",NA,"14+",">= 18 years","general pop","excluded","~38 weeks","Infection","infection","infection","delta",90,89,90,"Canada","CAN","North America","North America",46580,2019,"Canada","High income",4,NA,NA,NA,NA,NA
"908",114,"Skowronski","Test-negative case-control",950,2022-04-19,"Multiple or heterologous RNA","mRNA","2","final",NA,"14-27",">= 18 years","general pop","excluded","~38 weeks","Infection","infection","infection","delta",94,90,97,"Canada","CAN","North America","North America",46580,2019,"Canada","High income",4,NA,NA,NA,NA,NA
"909",114,"Skowronski","Test-negative case-control",951,2022-04-19,"Multiple or heterologous RNA","mRNA","2","final",NA,"168-195",">= 18 years","general pop","excluded","~38 weeks","Infection","infection","infection","delta",96,73,99,"Canada","CAN","North America","North America",46580,2019,"Canada","High income",4,NA,NA,NA,NA,NA
"910",114,"Skowronski","Test-negative case-control",952,2022-04-19,"Multiple or heterologous RNA","mRNA","2","final",NA,"14+",">= 18 years","general pop","excluded","~38 weeks","Hospitalization","severe","severe","delta",98,97,98,"Canada","CAN","North America","North America",46580,2019,"Canada","High income",4,NA,NA,NA,NA,NA
"911",114,"Skowronski","Test-negative case-control",953,2022-04-19,"Multiple or heterologous RNA","mRNA","2","final",NA,"28-55",">= 18 years","general pop","excluded","~38 weeks","Hospitalization","severe","severe","delta",97,93,99,"Canada","CAN","North America","North America",46580,2019,"Canada","High income",4,NA,NA,NA,NA,NA
"912",114,"Skowronski","Test-negative case-control",954,2022-04-19,"Multiple or heterologous RNA","mRNA","2","final",NA,"140-167",">= 18 years","general pop","excluded","~38 weeks","Hospitalization","severe","severe","delta",96,92,98,"Canada","CAN","North America","North America",46580,2019,"Canada","High income",4,NA,NA,NA,NA,NA
"913",114,"Skowronski","Test-negative case-control",955,2022-04-19,"Heterologous platforms","Multiple","2","final",NA,"14+",">= 18 years","general pop","excluded","~38 weeks","Infection","infection","infection","delta",88,88,89,"Canada","CAN","North America","North America",46580,2019,"Canada","High income",4,NA,NA,NA,NA,NA
"914",114,"Skowronski","Test-negative case-control",956,2022-04-19,"Heterologous platforms","Multiple","2","final",NA,"14-27",">= 18 years","general pop","excluded","~38 weeks","Infection","infection","infection","delta",94,88,97,"Canada","CAN","North America","North America",46580,2019,"Canada","High income",4,NA,NA,NA,NA,NA
"915",114,"Skowronski","Test-negative case-control",957,2022-04-19,"Heterologous platforms","Multiple","2","final",NA,"140-167",">= 18 years","general pop","excluded","~38 weeks","Infection","infection","infection","delta",82,77,85,"Canada","CAN","North America","North America",46580,2019,"Canada","High income",4,NA,NA,NA,NA,NA
"916",114,"Skowronski","Test-negative case-control",958,2022-04-19,"Heterologous platforms","Multiple","2","final",NA,"14+",">= 18 years","general pop","excluded","~38 weeks","Hospitalization","severe","severe","delta",99,99,100,"Canada","CAN","North America","North America",46580,2019,"Canada","High income",4,NA,NA,NA,NA,NA
"917",114,"Skowronski","Test-negative case-control",959,2022-04-19,"Heterologous platforms","Multiple","2","final",NA,"14-27",">= 18 years","general pop","excluded","~38 weeks","Hospitalization","severe","severe","delta",91,33,99,"Canada","CAN","North America","North America",46580,2019,"Canada","High income",4,NA,NA,NA,NA,NA
"918",114,"Skowronski","Test-negative case-control",960,2022-04-19,"Heterologous platforms","Multiple","2","final",NA,"140-167",">= 18 years","general pop","excluded","~38 weeks","Hospitalization","severe","severe","delta",98,91,99,"Canada","CAN","North America","North America",46580,2019,"Canada","High income",4,NA,NA,NA,NA,NA
"919",114,"Skowronski","Test-negative case-control",961,2022-04-19,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"14+",">= 18 years","general pop","excluded","~38 weeks","Infection","infection","infection","alpha",96,92,98,"Canada","CAN","North America","North America",46580,2019,"Canada","High income",4,NA,NA,NA,NA,NA
"920",114,"Skowronski","Test-negative case-control",962,2022-04-19,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"14+",">= 18 years","general pop","excluded","~38 weeks","Hospitalization","severe","severe","alpha",96,83,99,"Canada","CAN","North America","North America",46580,2019,"Canada","High income",4,NA,NA,NA,NA,NA
"921",114,"Skowronski","Test-negative case-control",963,2022-04-19,"Moderna mRNA-1273","mRNA","2","final",NA,"14+",">= 18 years","general pop","excluded","~38 weeks","Infection","infection","infection","alpha",95,84,98,"Canada","CAN","North America","North America",46580,2019,"Canada","High income",4,NA,NA,NA,NA,NA
"922",114,"Skowronski","Test-negative case-control",964,2022-04-19,"Oxford/AstraZeneca ChAdOx1-S","Vectored","2","final",NA,"14+",">= 18 years","general pop","excluded","~38 weeks","Infection","infection","infection","alpha",75,33,91,"Canada","CAN","North America","North America",46580,2019,"Canada","High income",4,NA,NA,NA,NA,NA
"923",114,"Skowronski","Test-negative case-control",965,2022-04-19,"Multiple or heterologous RNA","mRNA","2","final",NA,"14+",">= 18 years","general pop","excluded","~38 weeks","Infection","infection","infection","alpha",96,73,99,"Canada","CAN","North America","North America",46580,2019,"Canada","High income",4,NA,NA,NA,NA,NA
"924",114,"Skowronski","Test-negative case-control",966,2022-04-19,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"14+",">= 18 years","general pop","excluded","~38 weeks","Infection","infection","infection","gamma",92,88,95,"Canada","CAN","North America","North America",46580,2019,"Canada","High income",4,NA,NA,NA,NA,NA
"925",114,"Skowronski","Test-negative case-control",967,2022-04-19,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"14+",">= 18 years","general pop","excluded","~38 weeks","Hospitalization","severe","severe","gamma",95,82,98,"Canada","CAN","North America","North America",46580,2019,"Canada","High income",4,NA,NA,NA,NA,NA
"926",114,"Skowronski","Test-negative case-control",968,2022-04-19,"Moderna mRNA-1273","mRNA","2","final",NA,"14+",">= 18 years","general pop","excluded","~38 weeks","Infection","infection","infection","gamma",95,85,98,"Canada","CAN","North America","North America",46580,2019,"Canada","High income",4,NA,NA,NA,NA,NA
"927",114,"Skowronski","Test-negative case-control",969,2022-04-19,"Oxford/AstraZeneca ChAdOx1-S","Vectored","2","final",NA,"14+",">= 18 years","general pop","excluded","~38 weeks","Infection","infection","infection","gamma",91,63,98,"Canada","CAN","North America","North America",46580,2019,"Canada","High income",4,NA,NA,NA,NA,NA
"928",114,"Skowronski","Test-negative case-control",970,2022-04-19,"Multiple or heterologous RNA","mRNA","2","final",NA,"14+",">= 18 years","general pop","excluded","~38 weeks","Infection","infection","infection","gamma",94,76,99,"Canada","CAN","North America","North America",46580,2019,"Canada","High income",4,NA,NA,NA,NA,NA
"929",114,"Skowronski","Test-negative case-control",971,2022-04-19,"Heterologous platforms","Multiple","2","final",NA,"14+",">= 18 years","general pop","excluded","~38 weeks","Infection","infection","infection","gamma",96,69,99,"Canada","CAN","North America","North America",46580,2019,"Canada","High income",4,NA,NA,NA,NA,NA
"930",115,"Nordstrom","Retrospective cohort",972,2021-10-18,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"14+",">= 18 years","general pop","excluded","~11 weeks","symptomatic disease","symptomatic","symptomatic","delta",78,78,79,"Sweden","SWE","Europe","Europe & Central Asia",56230,2019,"Sweden","High income",4,NA,NA,NA,NA,NA
"931",115,"Nordstrom","Retrospective cohort",973,2021-10-18,"Moderna mRNA-1273","mRNA","2","final",NA,"14+",">= 18 years","general pop","excluded","~11 weeks","symptomatic disease","symptomatic","symptomatic","delta",87,84,88,"Sweden","SWE","Europe","Europe & Central Asia",56230,2019,"Sweden","High income",4,NA,NA,NA,NA,NA
"932",115,"Nordstrom","Retrospective cohort",974,2021-10-18,"Oxford/AstraZeneca ChAdOx1-S","Vectored","2","final",NA,"14+",">= 18 years","general pop","excluded","~11 weeks","symptomatic disease","symptomatic","symptomatic","delta",50,41,58,"Sweden","SWE","Europe","Europe & Central Asia",56230,2019,"Sweden","High income",4,NA,NA,NA,NA,NA
"933",115,"Nordstrom","Retrospective cohort",975,2021-10-18,"Heterologous platforms","Multiple","2","final",NA,"14+",">= 18 years","general pop","excluded","~11 weeks","symptomatic disease","symptomatic","symptomatic","delta",67,59,73,"Sweden","SWE","Europe","Europe & Central Asia",56230,2019,"Sweden","High income",4,NA,NA,NA,NA,NA
"934",115,"Nordstrom","Retrospective cohort",976,2021-10-18,"Heterologous platforms","Multiple","2","final",NA,"14+",">= 18 years","general pop","excluded","~11 weeks","symptomatic disease","symptomatic","symptomatic","delta",79,62,88,"Sweden","SWE","Europe","Europe & Central Asia",56230,2019,"Sweden","High income",4,NA,NA,NA,NA,NA
"935",116,"Reis","Retrospective cohort",977,2021-10-20,"BioNTech/Pfizer BNT162b2","mRNA","1","1",NA,"14-20","12-18 years","12-18 years","excluded",NA,"infection","infection","infection","delta",59,52,65,"Israel","ISR","Asia","Middle East & North Africa",43800,2019,"Israel","High income",4,NA,NA,NA,NA,NA
"936",116,"Reis","Retrospective cohort",978,2021-10-20,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"7-21","12-18 years","12-18 years","excluded","~12 weeks","infection","infection","infection","delta",90,88,92,"Israel","ISR","Asia","Middle East & North Africa",43800,2019,"Israel","High income",4,NA,NA,NA,NA,NA
"937",116,"Reis","Retrospective cohort",979,2021-10-20,"BioNTech/Pfizer BNT162b2","mRNA","1","1",NA,"21-27","12-18 years","12-18 years","excluded",NA,"infection","infection","infection","delta",66,59,72,"Israel","ISR","Asia","Middle East & North Africa",43800,2019,"Israel","High income",4,NA,NA,NA,NA,NA
"938",116,"Reis","Retrospective cohort",980,2021-10-20,"BioNTech/Pfizer BNT162b2","mRNA","1","1",NA,"14-20","12-18 years","12-18 years","excluded",NA,"symptomatic disease","symptomatic","symptomatic","delta",57,39,71,"Israel","ISR","Asia","Middle East & North Africa",43800,2019,"Israel","High income",4,NA,NA,NA,NA,NA
"939",116,"Reis","Retrospective cohort",981,2021-10-20,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"7-21","12-18 years","12-18 years","excluded","~12 weeks","symptomatic disease","symptomatic","symptomatic","delta",93,88,97,"Israel","ISR","Asia","Middle East & North Africa",43800,2019,"Israel","High income",4,NA,NA,NA,NA,NA
"940",116,"Reis","Retrospective cohort",982,2021-10-20,"BioNTech/Pfizer BNT162b2","mRNA","1","1",NA,"21-27","12-18 years","12-18 years","excluded",NA,"symptomatic disease","symptomatic","symptomatic","delta",82,73,91,"Israel","ISR","Asia","Middle East & North Africa",43800,2019,"Israel","High income",4,NA,NA,NA,NA,NA
"941",117,"Sheikh","Retrospective cohort",983,2021-10-20,"BioNTech/Pfizer BNT162b2","mRNA","1","1",NA,"14+","40-59 years","40-59 years","unknown",NA,"death","death","death","other combinations",100,NA,NA,"UK","GBR","Europe","Europe & Central Asia",43240,2019,"United Kingdom","High income",4,NA,NA,NA,NA,NA
"942",117,"Sheikh","Retrospective cohort",984,2021-10-20,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"14+","40-59 years","40-59 years","unknown","~25 weeks","death","death","death","other combinations",95,79,99,"UK","GBR","Europe","Europe & Central Asia",43240,2019,"United Kingdom","High income",4,NA,NA,NA,NA,NA
"943",117,"Sheikh","Retrospective cohort",985,2021-10-20,"BioNTech/Pfizer BNT162b2","mRNA","1","1",NA,"14+",">= 60 years","60+ years","unknown",NA,"death","death","death","other combinations",75,26,91,"UK","GBR","Europe","Europe & Central Asia",43240,2019,"United Kingdom","High income",4,NA,NA,NA,NA,NA
"944",117,"Sheikh","Retrospective cohort",986,2021-10-20,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"14+",">= 60 years","60+ years","unknown","~25 weeks","death","death","death","other combinations",87,77,93,"UK","GBR","Europe","Europe & Central Asia",43240,2019,"United Kingdom","High income",4,NA,NA,NA,NA,NA
"945",117,"Sheikh","Retrospective cohort",987,2021-10-20,"Oxford/AstraZeneca ChAdOx1-S","Vectored","1","1",NA,"14+","40-59 years","40-59 years","unknown",NA,"death","death","death","other combinations",96,85,99,"UK","GBR","Europe","Europe & Central Asia",43240,2019,"United Kingdom","High income",4,NA,NA,NA,NA,NA
"946",117,"Sheikh","Retrospective cohort",988,2021-10-20,"Oxford/AstraZeneca ChAdOx1-S","Vectored","2","final",NA,"14+","40-59 years","40-59 years","unknown","~25 weeks","death","death","death","other combinations",88,76,93,"UK","GBR","Europe","Europe & Central Asia",43240,2019,"United Kingdom","High income",4,NA,NA,NA,NA,NA
"947",117,"Sheikh","Retrospective cohort",989,2021-10-20,"Oxford/AstraZeneca ChAdOx1-S","Vectored","1","1",NA,"14+",">= 60 years","60+ years","unknown",NA,"death","death","death","other combinations",97,86,99,"UK","GBR","Europe","Europe & Central Asia",43240,2019,"United Kingdom","High income",4,NA,NA,NA,NA,NA
"948",117,"Sheikh","Retrospective cohort",990,2021-10-20,"Oxford/AstraZeneca ChAdOx1-S","Vectored","2","final",NA,"14+",">= 60 years","60+ years","unknown","~25 weeks","death","death","death","other combinations",90,84,94,"UK","GBR","Europe","Europe & Central Asia",43240,2019,"United Kingdom","High income",4,NA,NA,NA,NA,NA
"949",117,"Sheikh","Retrospective cohort",991,2021-10-20,"BioNTech/Pfizer BNT162b2","mRNA","1","1",NA,"14+",">= 18 years","general pop","unknown",NA,"death","death","death","delta",92,66,98,"UK","GBR","Europe","Europe & Central Asia",43240,2019,"United Kingdom","High income",4,NA,NA,NA,NA,NA
"950",117,"Sheikh","Retrospective cohort",992,2021-10-20,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"14+",">= 18 years","general pop","unknown","~25 weeks","death","death","death","delta",90,83,94,"UK","GBR","Europe","Europe & Central Asia",43240,2019,"United Kingdom","High income",4,NA,NA,NA,NA,NA
"951",117,"Sheikh","Retrospective cohort",993,2021-10-20,"Oxford/AstraZeneca ChAdOx1-S","Vectored","1","1",NA,"14+",">= 18 years","general pop","unknown",NA,"death","death","death","delta",96,89,99,"UK","GBR","Europe","Europe & Central Asia",43240,2019,"United Kingdom","High income",4,NA,NA,NA,NA,NA
"952",117,"Sheikh","Retrospective cohort",994,2021-10-20,"Oxford/AstraZeneca ChAdOx1-S","Vectored","2","final",NA,"14+",">= 18 years","general pop","unknown","~25 weeks","death","death","death","delta",91,86,94,"UK","GBR","Europe","Europe & Central Asia",43240,2019,"United Kingdom","High income",4,NA,NA,NA,NA,NA
"953",118,"Embi","Test-negative case-control",995,2021-12-30,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"14+","immunocompromised, >= 18 years","immunocompromised adults","included","~33 weeks","hospitalization","severe","severe","other combinations",71,65,76,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"954",118,"Embi","Test-negative case-control",996,2021-12-30,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"14+",">= 18 years","general pop","included","~33 weeks","hospitalization","severe","severe","other combinations",88,86,89,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"955",118,"Embi","Test-negative case-control",997,2021-12-30,"Moderna mRNA-1273","mRNA","2","final",NA,"14+","immunocompromised, >= 18 years","immunocompromised adults","included","~33 weeks","hospitalization","severe","severe","other combinations",81,76,85,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"956",118,"Embi","Test-negative case-control",998,2021-12-30,"Moderna mRNA-1273","mRNA","2","final",NA,"14+",">= 18 years","general pop","included","~33 weeks","hospitalization","severe","severe","other combinations",93,92,94,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"957",118,"Embi","Test-negative case-control",999,2021-12-30,"Multiple or heterologous RNA","mRNA","2","final",NA,"14+","immunocompromised, >= 18 years","immunocompromised adults","included","~33 weeks","hospitalization","severe","severe","other combinations",76,69,81,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"958",118,"Embi","Test-negative case-control",1000,2021-12-30,"Multiple or heterologous RNA","mRNA","2","final",NA,"14+",">= 18 years","general pop","included","~33 weeks","hospitalization","severe","severe","other combinations",91,90,93,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"959",118,"Embi","Test-negative case-control",1001,2021-12-30,"Multiple or heterologous RNA","mRNA","2","final",NA,"14+","immunocompromised, >= 18 years","immunocompromised adults","included","~33 weeks","hospitalization","severe","severe","delta",79,74,83,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"960",118,"Embi","Test-negative case-control",1002,2021-12-30,"Multiple or heterologous RNA","mRNA","2","final",NA,"14+",">= 18 years","general pop","included","~33 weeks","hospitalization","severe","severe","delta",90,89,91,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"961",119,"Poukka","Retrospective cohort",1003,2022-01-31,"BioNTech/Pfizer BNT162b2","mRNA","1","1",NA,"42+","HCW","HCW aged 16-69 years","excluded",NA,"Infection","infection","infection","other combinations",40,33,46,"Finland","FIN","Europe","Europe & Central Asia",49950,2019,"Finland","High income",4,NA,NA,NA,NA,NA
"962",119,"Poukka","Retrospective cohort",1004,2022-01-31,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"14-90","HCW","HCW aged 16-69 years","excluded","~11 weeks","Infection","infection","infection","other combinations",83,80,85,"Finland","FIN","Europe","Europe & Central Asia",49950,2019,"Finland","High income",4,NA,NA,NA,NA,NA
"963",119,"Poukka","Retrospective cohort",1005,2022-01-31,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"181+","HCW","HCW aged 16-69 years","excluded","~29.5 weeks","Infection","infection","infection","other combinations",55,45,64,"Finland","FIN","Europe","Europe & Central Asia",49950,2019,"Finland","High income",4,NA,NA,NA,NA,NA
"964",119,"Poukka","Retrospective cohort",1006,2022-01-31,"BioNTech/Pfizer BNT162b2","mRNA","1","1",NA,"42+","HCW","HCW aged 16-69 years","excluded",NA,"Hospitalization","severe","severe","other combinations",82,68,90,"Finland","FIN","Europe","Europe & Central Asia",49950,2019,"Finland","High income",4,NA,NA,NA,NA,NA
"965",119,"Poukka","Retrospective cohort",1007,2022-01-31,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"14-90","HCW","HCW aged 16-69 years","excluded","~11 weeks","Hospitalization","severe","severe","other combinations",99,97,100,"Finland","FIN","Europe","Europe & Central Asia",49950,2019,"Finland","High income",4,NA,NA,NA,NA,NA
"966",119,"Poukka","Retrospective cohort",1008,2022-01-31,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"181+","HCW","HCW aged 16-69 years","excluded","~38 weeks","Hospitalization","severe","severe","other combinations",98,89,100,"Finland","FIN","Europe","Europe & Central Asia",49950,2019,"Finland","High income",4,NA,NA,NA,NA,NA
"967",119,"Poukka","Retrospective cohort",1009,2022-01-31,"Moderna mRNA-1273","mRNA","1","1",NA,"42+","HCW","HCW aged 16-69 years","excluded",NA,"Infection","infection","infection","other combinations",61,45,72,"Finland","FIN","Europe","Europe & Central Asia",49950,2019,"Finland","High income",4,NA,NA,NA,NA,NA
"968",119,"Poukka","Retrospective cohort",1010,2022-01-31,"Moderna mRNA-1273","mRNA","2","final",NA,"14-90","HCW","HCW aged 16-69 years","excluded","~11 weeks","Infection","infection","infection","other combinations",84,68,92,"Finland","FIN","Europe","Europe & Central Asia",49950,2019,"Finland","High income",4,NA,NA,NA,NA,NA
"969",119,"Poukka","Retrospective cohort",1011,2022-01-31,"Moderna mRNA-1273","mRNA","2","final",NA,"91-180","HCW","HCW aged 16-69 years","excluded","~24 weeks","Infection","infection","infection","other combinations",69,-124,96,"Finland","FIN","Europe","Europe & Central Asia",49950,2019,"Finland","High income",4,NA,NA,NA,NA,NA
"970",119,"Poukka","Retrospective cohort",1012,2022-01-31,"Moderna mRNA-1273","mRNA","1","1",NA,"42+","HCW","HCW aged 16-69 years","excluded",NA,"Hospitalization","severe","severe","other combinations",89,22,98,"Finland","FIN","Europe","Europe & Central Asia",49950,2019,"Finland","High income",4,NA,NA,NA,NA,NA
"971",119,"Poukka","Retrospective cohort",1013,2022-01-31,"Moderna mRNA-1273","mRNA","2","final",NA,"14-90","HCW","HCW aged 16-69 years","excluded","~11 weeks","Hospitalization","severe","severe","other combinations",100,NA,NA,"Finland","FIN","Europe","Europe & Central Asia",49950,2019,"Finland","High income",4,NA,NA,NA,NA,NA
"972",119,"Poukka","Retrospective cohort",1014,2022-01-31,"Moderna mRNA-1273","mRNA","2","final",NA,"181+","HCW","HCW aged 16-69 years","excluded","~34 weeks","Hospitalization","severe","severe","other combinations",100,NA,NA,"Finland","FIN","Europe","Europe & Central Asia",49950,2019,"Finland","High income",4,NA,NA,NA,NA,NA
"973",119,"Poukka","Retrospective cohort",1015,2022-01-31,"Multiple or heterologous RNA","mRNA","2","final",NA,"14-90","HCW","HCW aged 16-69 years","excluded","~11 weeks","Infection","infection","infection","other combinations",100,NA,NA,"Finland","FIN","Europe","Europe & Central Asia",49950,2019,"Finland","High income",4,NA,NA,NA,NA,NA
"974",119,"Poukka","Retrospective cohort",1016,2022-01-31,"Multiple or heterologous RNA","mRNA","2","final",NA,"181+","HCW","HCW aged 16-69 years","excluded","~29.5 weeks","Infection","infection","infection","other combinations",100,NA,NA,"Finland","FIN","Europe","Europe & Central Asia",49950,2019,"Finland","High income",4,NA,NA,NA,NA,NA
"975",119,"Poukka","Retrospective cohort",1017,2022-01-31,"Multiple or heterologous RNA","mRNA","2","final",NA,"14-90","HCW","HCW aged 16-69 years","excluded","~11 weeks","Hospitalization","severe","severe","other combinations",100,NA,NA,"Finland","FIN","Europe","Europe & Central Asia",49950,2019,"Finland","High income",4,NA,NA,NA,NA,NA
"976",119,"Poukka","Retrospective cohort",1018,2022-01-31,"Multiple or heterologous RNA","mRNA","2","final",NA,"181+","HCW","HCW aged 16-69 years","excluded","~38 weeks","Hospitalization","severe","severe","other combinations",100,NA,NA,"Finland","FIN","Europe","Europe & Central Asia",49950,2019,"Finland","High income",4,NA,NA,NA,NA,NA
"977",119,"Poukka","Retrospective cohort",1019,2022-01-31,"Oxford/AstraZeneca ChAdOx1-S","Vectored","1","1",NA,"42+","HCW","HCW aged 16-69 years","excluded",NA,"Infection","infection","infection","other combinations",22,-3,42,"Finland","FIN","Europe","Europe & Central Asia",49950,2019,"Finland","High income",4,NA,NA,NA,NA,NA
"978",119,"Poukka","Retrospective cohort",1020,2022-01-31,"Oxford/AstraZeneca ChAdOx1-S","Vectored","2","final",NA,"14-90","HCW","HCW aged 16-69 years","excluded","~11 weeks","Infection","infection","infection","other combinations",89,73,95,"Finland","FIN","Europe","Europe & Central Asia",49950,2019,"Finland","High income",4,NA,NA,NA,NA,NA
"979",119,"Poukka","Retrospective cohort",1021,2022-01-31,"Oxford/AstraZeneca ChAdOx1-S","Vectored","2","final",NA,"91-180","HCW","HCW aged 16-69 years","excluded","~24 weeks","Infection","infection","infection","other combinations",63,-166,95,"Finland","FIN","Europe","Europe & Central Asia",49950,2019,"Finland","High income",4,NA,NA,NA,NA,NA
"980",119,"Poukka","Retrospective cohort",1022,2022-01-31,"Oxford/AstraZeneca ChAdOx1-S","Vectored","1","1",NA,"42+","HCW","HCW aged 16-69 years","excluded",NA,"Hospitalization","severe","severe","other combinations",88,10,98,"Finland","FIN","Europe","Europe & Central Asia",49950,2019,"Finland","High income",4,NA,NA,NA,NA,NA
"981",119,"Poukka","Retrospective cohort",1023,2022-01-31,"Oxford/AstraZeneca ChAdOx1-S","Vectored","2","final",NA,"14-90","HCW","HCW aged 16-69 years","excluded","~11 weeks","Hospitalization","severe","severe","other combinations",100,NA,NA,"Finland","FIN","Europe","Europe & Central Asia",49950,2019,"Finland","High income",4,NA,NA,NA,NA,NA
"982",119,"Poukka","Retrospective cohort",1024,2022-01-31,"Oxford/AstraZeneca ChAdOx1-S","Vectored","2","final",NA,"181+","HCW","HCW aged 16-69 years","excluded","~25 weeks","Hospitalization","severe","severe","other combinations",100,NA,NA,"Finland","FIN","Europe","Europe & Central Asia",49950,2019,"Finland","High income",4,NA,NA,NA,NA,NA
"983",119,"Poukka","Retrospective cohort",1025,2022-01-31,"Heterologous platforms","Multiple","2","final",NA,"14-90","HCW","HCW aged 16-69 years","excluded","~11 weeks","Infection","infection","infection","other combinations",80,72,86,"Finland","FIN","Europe","Europe & Central Asia",49950,2019,"Finland","High income",4,NA,NA,NA,NA,NA
"984",119,"Poukka","Retrospective cohort",1026,2022-01-31,"Heterologous platforms","Multiple","2","final",NA,"91-180","HCW","HCW aged 16-69 years","excluded","~24 weeks","Infection","infection","infection","other combinations",62,30,79,"Finland","FIN","Europe","Europe & Central Asia",49950,2019,"Finland","High income",4,NA,NA,NA,NA,NA
"985",119,"Poukka","Retrospective cohort",1027,2022-01-31,"Heterologous platforms","Multiple","2","final",NA,"14-90","HCW","HCW aged 16-69 years","excluded","~11 weeks","Hospitalization","severe","severe","other combinations",100,NA,NA,"Finland","FIN","Europe","Europe & Central Asia",49950,2019,"Finland","High income",4,NA,NA,NA,NA,NA
"986",119,"Poukka","Retrospective cohort",1028,2022-01-31,"Heterologous platforms","Multiple","2","final",NA,"181+","HCW","HCW aged 16-69 years","excluded","~25 weeks","Hospitalization","severe","severe","other combinations",100,NA,NA,"Finland","FIN","Europe","Europe & Central Asia",49950,2019,"Finland","High income",4,NA,NA,NA,NA,NA
"987",119,"Poukka","Retrospective cohort",1029,2022-01-31,"Multiple or heterologous RNA","mRNA","1","1",NA,"42+","HCW","HCW aged 16-69 years","excluded",NA,"Infection","infection","infection","other combinations",38,23,50,"Finland","FIN","Europe","Europe & Central Asia",49950,2019,"Finland","High income",4,NA,NA,NA,NA,NA
"988",119,"Poukka","Retrospective cohort",1030,2022-01-31,"Multiple or heterologous RNA","mRNA","2","final",NA,"14-90","HCW","HCW aged 16-69 years","excluded","~11 weeks","Infection","infection","infection","other combinations",77,71,82,"Finland","FIN","Europe","Europe & Central Asia",49950,2019,"Finland","High income",4,NA,NA,NA,NA,NA
"989",119,"Poukka","Retrospective cohort",1031,2022-01-31,"Multiple or heterologous RNA","mRNA","2","final",NA,"91-180","HCW","HCW aged 16-69 years","excluded","~24 weeks","Infection","infection","infection","other combinations",55,34,69,"Finland","FIN","Europe","Europe & Central Asia",49950,2019,"Finland","High income",4,NA,NA,NA,NA,NA
"990",119,"Poukka","Retrospective cohort",1032,2022-01-31,"Multiple or heterologous RNA","mRNA","1","1",NA,"42+","HCW","HCW aged 16-69 years","excluded",NA,"hospitalization","severe","severe","other combinations",90,27,99,"Finland","FIN","Europe","Europe & Central Asia",49950,2019,"Finland","High income",4,NA,NA,NA,NA,NA
"991",119,"Poukka","Retrospective cohort",1033,2022-01-31,"Multiple or heterologous RNA","mRNA","2","final",NA,"14-90","HCW","HCW aged 16-69 years","excluded","~11 weeks","hospitalization","severe","severe","other combinations",95,64,99,"Finland","FIN","Europe","Europe & Central Asia",49950,2019,"Finland","High income",4,NA,NA,NA,NA,NA
"992",119,"Poukka","Retrospective cohort",1034,2022-01-31,"Multiple or heterologous RNA","mRNA","2","final",NA,"91-180","HCW","HCW aged 16-69 years","excluded","~24 weeks","hospitalization","severe","severe","other combinations",100,NA,NA,"Finland","FIN","Europe","Europe & Central Asia",49950,2019,"Finland","High income",4,NA,NA,NA,NA,NA
"993",119,"Poukka","Retrospective cohort",1035,2022-01-31,"Oxford/AstraZeneca ChAdOx1-S","Vectored","1","1",NA,"42+","HCW","HCW aged 16-69 years","excluded",NA,"Infection","infection","infection","other combinations",15,-15,37,"Finland","FIN","Europe","Europe & Central Asia",49950,2019,"Finland","High income",4,NA,NA,NA,NA,NA
"994",119,"Poukka","Retrospective cohort",1036,2022-01-31,"Oxford/AstraZeneca ChAdOx1-S","Vectored","2","final",NA,"14-90","HCW","HCW aged 16-69 years","excluded","~11 weeks","Infection","infection","infection","other combinations",100,NA,NA,"Finland","FIN","Europe","Europe & Central Asia",49950,2019,"Finland","High income",4,NA,NA,NA,NA,NA
"995",119,"Poukka","Retrospective cohort",1037,2022-01-31,"Oxford/AstraZeneca ChAdOx1-S","Vectored","2","final",NA,"91-180","HCW","HCW aged 16-69 years","excluded","~24 weeks","Infection","infection","infection","other combinations",100,NA,NA,"Finland","FIN","Europe","Europe & Central Asia",49950,2019,"Finland","High income",4,NA,NA,NA,NA,NA
"996",119,"Poukka","Retrospective cohort",1038,2022-01-31,"Oxford/AstraZeneca ChAdOx1-S","Vectored","1","1",NA,"42+","HCW","HCW aged 16-69 years","excluded",NA,"hospitalization","severe","severe","other combinations",100,-Inf,100,"Finland","FIN","Europe","Europe & Central Asia",49950,2019,"Finland","High income",4,NA,NA,NA,NA,NA
"997",119,"Poukka","Retrospective cohort",1039,2022-01-31,"Oxford/AstraZeneca ChAdOx1-S","Vectored","2","final",NA,"14-90","HCW","HCW aged 16-69 years","excluded","~11 weeks","hospitalization","severe","severe","other combinations",100,NA,NA,"Finland","FIN","Europe","Europe & Central Asia",49950,2019,"Finland","High income",4,NA,NA,NA,NA,NA
"998",119,"Poukka","Retrospective cohort",1040,2022-01-31,"Heterologous platforms","Multiple","2","final",NA,"14-90","HCW","HCW aged 16-69 years","excluded","~11 weeks","Infection","infection","infection","other combinations",100,NA,NA,"Finland","FIN","Europe","Europe & Central Asia",49950,2019,"Finland","High income",4,NA,NA,NA,NA,NA
"999",119,"Poukka","Retrospective cohort",1041,2022-01-31,"Heterologous platforms","Multiple","2","final",NA,"91-180","HCW","HCW aged 16-69 years","excluded","~24 weeks","Infection","infection","infection","other combinations",100,NA,NA,"Finland","FIN","Europe","Europe & Central Asia",49950,2019,"Finland","High income",4,NA,NA,NA,NA,NA
"1000",119,"Poukka","Retrospective cohort",1042,2022-01-31,"Heterologous platforms","Multiple","2","final",NA,"14-90","HCW","HCW aged 16-69 years","excluded","~11 weeks","Hospitalization","severe","severe","other combinations",100,NA,NA,"Finland","FIN","Europe","Europe & Central Asia",49950,2019,"Finland","High income",4,NA,NA,NA,NA,NA
"1001",119,"Poukka","Retrospective cohort",1043,2022-01-31,"Multiple or heterologous RNA","mRNA","1","1",NA,"42+","HCW","HCW aged 16-69 years","excluded",NA,"Infection","infection","infection","delta",45,37,51,"Finland","FIN","Europe","Europe & Central Asia",49950,2019,"Finland","High income",4,NA,NA,NA,NA,NA
"1002",119,"Poukka","Retrospective cohort",1044,2022-01-31,"Multiple or heterologous RNA","mRNA","2","final",NA,"14-90","HCW","HCW aged 16-69 years","excluded","~11 weeks","Infection","infection","infection","delta",85,81,88,"Finland","FIN","Europe","Europe & Central Asia",49950,2019,"Finland","High income",4,NA,NA,NA,NA,NA
"1003",119,"Poukka","Retrospective cohort",1045,2022-01-31,"Multiple or heterologous RNA","mRNA","2","final",NA,"181+","HCW","HCW aged 16-69 years","excluded","~29.5 weeks","Infection","infection","infection","delta",56,46,65,"Finland","FIN","Europe","Europe & Central Asia",49950,2019,"Finland","High income",4,NA,NA,NA,NA,NA
"1004",119,"Poukka","Retrospective cohort",1046,2022-01-31,"Multiple or heterologous RNA","mRNA","1","1",NA,"42+","HCW","HCW aged 16-69 years","excluded",NA,"Hospitalization","severe","severe","delta",83,68,91,"Finland","FIN","Europe","Europe & Central Asia",49950,2019,"Finland","High income",4,NA,NA,NA,NA,NA
"1005",119,"Poukka","Retrospective cohort",1047,2022-01-31,"Multiple or heterologous RNA","mRNA","2","final",NA,"14-90","HCW","HCW aged 16-69 years","excluded","~11 weeks","Hospitalization","severe","severe","delta",100,97,100,"Finland","FIN","Europe","Europe & Central Asia",49950,2019,"Finland","High income",4,NA,NA,NA,NA,NA
"1006",119,"Poukka","Retrospective cohort",1048,2022-01-31,"Multiple or heterologous RNA","mRNA","2","final",NA,"181+","HCW","HCW aged 16-69 years","excluded","~38 weeks","Hospitalization","severe","severe","delta",98,88,100,"Finland","FIN","Europe","Europe & Central Asia",49950,2019,"Finland","High income",4,NA,NA,NA,NA,NA
"1007",119,"Poukka","Retrospective cohort",1049,2022-01-31,"Oxford/AstraZeneca ChAdOx1-S","Vectored","1","1",NA,"42+","HCW","HCW aged 16-69 years","excluded",NA,"Infection","infection","infection","delta",49,-16,77,"Finland","FIN","Europe","Europe & Central Asia",49950,2019,"Finland","High income",4,NA,NA,NA,NA,NA
"1008",119,"Poukka","Retrospective cohort",1050,2022-01-31,"Oxford/AstraZeneca ChAdOx1-S","Vectored","2","final",NA,"14-90","HCW","HCW aged 16-69 years","excluded","~11 weeks","Infection","infection","infection","delta",88,71,95,"Finland","FIN","Europe","Europe & Central Asia",49950,2019,"Finland","High income",4,NA,NA,NA,NA,NA
"1009",119,"Poukka","Retrospective cohort",1051,2022-01-31,"Oxford/AstraZeneca ChAdOx1-S","Vectored","2","final",NA,"91-180","HCW","HCW aged 16-69 years","excluded","~24 weeks","Infection","infection","infection","delta",62,-177,95,"Finland","FIN","Europe","Europe & Central Asia",49950,2019,"Finland","High income",4,NA,NA,NA,NA,NA
"1010",119,"Poukka","Retrospective cohort",1052,2022-01-31,"Oxford/AstraZeneca ChAdOx1-S","Vectored","1","1",NA,"42+","HCW","HCW aged 16-69 years","excluded",NA,"Hospitalization","severe","severe","delta",42,-330,92,"Finland","FIN","Europe","Europe & Central Asia",49950,2019,"Finland","High income",4,NA,NA,NA,NA,NA
"1011",119,"Poukka","Retrospective cohort",1053,2022-01-31,"Oxford/AstraZeneca ChAdOx1-S","Vectored","2","final",NA,"14-90","HCW","HCW aged 16-69 years","excluded","~11 weeks","Hospitalization","severe","severe","delta",100,NA,NA,"Finland","FIN","Europe","Europe & Central Asia",49950,2019,"Finland","High income",4,NA,NA,NA,NA,NA
"1012",119,"Poukka","Retrospective cohort",1054,2022-01-31,"Oxford/AstraZeneca ChAdOx1-S","Vectored","2","final",NA,"181+","HCW","HCW aged 16-69 years","excluded","~25 weeks","Hospitalization","severe","severe","delta",100,NA,NA,"Finland","FIN","Europe","Europe & Central Asia",49950,2019,"Finland","High income",4,NA,NA,NA,NA,NA
"1013",119,"Poukka","Retrospective cohort",1055,2022-01-31,"Heterologous platforms","Multiple","2","final",NA,"14-90","HCW","HCW aged 16-69 years","excluded","~11 weeks","Infection","infection","infection","delta",80,72,86,"Finland","FIN","Europe","Europe & Central Asia",49950,2019,"Finland","High income",4,NA,NA,NA,NA,NA
"1014",119,"Poukka","Retrospective cohort",1056,2022-01-31,"Heterologous platforms","Multiple","2","final",NA,"91-180","HCW","HCW aged 16-69 years","excluded","~24 weeks","Infection","infection","infection","delta",63,33,80,"Finland","FIN","Europe","Europe & Central Asia",49950,2019,"Finland","High income",4,NA,NA,NA,NA,NA
"1015",119,"Poukka","Retrospective cohort",1057,2022-01-31,"Heterologous platforms","Multiple","2","final",NA,"14-90","HCW","HCW aged 16-69 years","excluded","~11 weeks","Hospitalization","severe","severe","delta",100,NA,NA,"Finland","FIN","Europe","Europe & Central Asia",49950,2019,"Finland","High income",4,NA,NA,NA,NA,NA
"1016",119,"Poukka","Retrospective cohort",1058,2022-01-31,"Heterologous platforms","Multiple","2","final",NA,"181+","HCW","HCW aged 16-69 years","excluded","~25 weeks","Hospitalization","severe","severe","delta",100,NA,NA,"Finland","FIN","Europe","Europe & Central Asia",49950,2019,"Finland","High income",4,NA,NA,NA,NA,NA
"1017",120,"Al Hosani","Retrospective cohort",1059,2022-03-18,"Beijing/Sinopharm BBIBP-CorV","Inactivated","1","1",NA,"14+",">= 15 years",">= 15 years","included",NA,"Hospitalization","severe","severe","other combinations",-20,-28.6,11.8,"United Arab Emirates","ARE","Asia","Middle East & North Africa",45070,2019,"United Arab Emirates","High income",4,NA,NA,NA,NA,NA
"1018",120,"Al Hosani","Retrospective cohort",1060,2022-03-18,"Beijing/Sinopharm BBIBP-CorV","Inactivated","2","final",NA,"14+",">= 15 years",">= 15 years","included","~34 weeks","Hospitalization","severe","severe","other combinations",79.8,78,81.4,"United Arab Emirates","ARE","Asia","Middle East & North Africa",45070,2019,"United Arab Emirates","High income",4,NA,NA,NA,NA,NA
"1019",120,"Al Hosani","Retrospective cohort",1061,2022-03-18,"Beijing/Sinopharm BBIBP-CorV","Inactivated","1","1",NA,"14+",">= 15 years",">= 15 years","included",NA,"ICU admission","severe","severe","other combinations",3.7,-12.8,18.1,"United Arab Emirates","ARE","Asia","Middle East & North Africa",45070,2019,"United Arab Emirates","High income",4,NA,NA,NA,NA,NA
"1020",120,"Al Hosani","Retrospective cohort",1062,2022-03-18,"Beijing/Sinopharm BBIBP-CorV","Inactivated","2","final",NA,"14+",">= 15 years",">= 15 years","included","~34 weeks","ICU admission","severe","severe","other combinations",92.2,89.7,94.1,"United Arab Emirates","ARE","Asia","Middle East & North Africa",45070,2019,"United Arab Emirates","High income",4,NA,NA,NA,NA,NA
"1021",120,"Al Hosani","Retrospective cohort",1063,2022-03-18,"Beijing/Sinopharm BBIBP-CorV","Inactivated","1","1",NA,"14+",">= 15 years",">= 15 years","included",NA,"death","death","death","other combinations",27.9,-61,72.6,"United Arab Emirates","ARE","Asia","Middle East & North Africa",45070,2019,"United Arab Emirates","High income",4,NA,NA,NA,NA,NA
"1022",120,"Al Hosani","Retrospective cohort",1064,2022-03-18,"Beijing/Sinopharm BBIBP-CorV","Inactivated","2","final",NA,"14+",">= 15 years",">= 15 years","included","~34 weeks","death","death","death","other combinations",97.1,83,99.9,"United Arab Emirates","ARE","Asia","Middle East & North Africa",45070,2019,"United Arab Emirates","High income",4,NA,NA,NA,NA,NA
"1023",121,"Ng","Retrospective cohort",1065,2021-11-01,"Multiple or heterologous RNA","mRNA","2","final",NA,"15+","contacts of SARS-CoV-2 index cases of all ages","contacts of index cases","unknown","~16.5 weeks","Infection","infection","infection","delta",61.6,37.5,80.4,"Singapore","SGP","Asia","East Asia & Pacific",58810,2019,"Singapore","High income",4,NA,NA,NA,NA,NA
"1024",121,"Ng","Retrospective cohort",1066,2021-11-01,"Multiple or heterologous RNA","mRNA","2","final",NA,"15+","contacts of SARS-CoV-2 index cases of all ages","contacts of index cases","unknown","~16.5 weeks","symptomatic disease","symptomatic","symptomatic","delta",67.9,41.3,87.8,"Singapore","SGP","Asia","East Asia & Pacific",58810,2019,"Singapore","High income",4,NA,NA,NA,NA,NA
"1025",121,"Ng","Retrospective cohort",1067,2021-11-01,"Multiple or heterologous RNA","mRNA","2","final",NA,"15+","contacts of SARS-CoV-2 index cases of all ages","contacts of index cases","unknown","~16.5 weeks","severe disease","severe","severe","delta",100,NA,NA,"Singapore","SGP","Asia","East Asia & Pacific",58810,2019,"Singapore","High income",4,NA,NA,NA,NA,NA
"1026",122,"Paixao","Test-negative case-control",1068,2022-04-05,"Sinovac CoronaVac","Inactivated","1","1",NA,"14+","pregnant women","pregnant persons","excluded",NA,"symptomatic disease","symptomatic","symptomatic","other combinations",5,-18.2,23.7,"Brazil","BRA","South America","Latin America & Caribbean",9410,2019,"Brazil","Upper middle income",3,NA,NA,NA,NA,NA
"1027",122,"Paixao","Test-negative case-control",1069,2022-04-05,"Sinovac CoronaVac","Inactivated","2","final",NA,"14+","pregnant women","pregnant persons","excluded","~25 weeks","symptomatic disease","symptomatic","symptomatic","other combinations",41,27,52.2,"Brazil","BRA","South America","Latin America & Caribbean",9410,2019,"Brazil","Upper middle income",3,NA,NA,NA,NA,NA
"1028",122,"Paixao","Test-negative case-control",1070,2022-04-05,"Sinovac CoronaVac","Inactivated","1","1",NA,"14+","pregnant women","pregnant persons","excluded",NA,"severe disease","severe","severe","other combinations",67.7,20,87,"Brazil","BRA","South America","Latin America & Caribbean",9410,2019,"Brazil","Upper middle income",3,NA,NA,NA,NA,NA
"1029",122,"Paixao","Test-negative case-control",1071,2022-04-05,"Sinovac CoronaVac","Inactivated","2","final",NA,"14+","pregnant women","pregnant persons","excluded","~25 weeks","severe disease","severe","severe","other combinations",85.4,59.4,94.8,"Brazil","BRA","South America","Latin America & Caribbean",9410,2019,"Brazil","Upper middle income",3,NA,NA,NA,NA,NA
"1030",123,"Desai","Test-negative case-control",1072,2021-11-23,"Bharat Covaxin/BBV152","Inactivated","1","1",NA,"21+","HCW","HCW","included",NA,"symptomatic disease","symptomatic","symptomatic","delta",-1,-51,33,"India","IND","Asia","South Asia",2070,2019,"India","Lower middle income",1,NA,NA,NA,NA,NA
"1031",123,"Desai","Test-negative case-control",1073,2021-11-23,"Bharat Covaxin/BBV152","Inactivated","2","final",NA,"14+","HCW","HCW","included","~4 weeks","symptomatic disease","symptomatic","symptomatic","delta",50,33,62,"India","IND","Asia","South Asia",2070,2019,"India","Lower middle income",1,NA,NA,NA,NA,NA
"1032",123,"Desai","Test-negative case-control",1074,2021-11-23,"Bharat Covaxin/BBV152","Inactivated","2","final",NA,"28+","HCW","HCW","included","~4 weeks","symptomatic disease","symptomatic","symptomatic","delta",46,22,62,"India","IND","Asia","South Asia",2070,2019,"India","Lower middle income",1,NA,NA,NA,NA,NA
"1033",123,"Desai","Test-negative case-control",1075,2021-11-23,"Bharat Covaxin/BBV152","Inactivated","2","final",NA,"42+","HCW","HCW","included","~4 weeks","symptomatic disease","symptomatic","symptomatic","delta",57,21,76,"India","IND","Asia","South Asia",2070,2019,"India","Lower middle income",1,NA,NA,NA,NA,NA
"1034",123,"Desai","Test-negative case-control",1076,2021-11-23,"Bharat Covaxin/BBV152","Inactivated","2","final",NA,"14+","HCW","HCW","excluded","~4 weeks","symptomatic disease","symptomatic","symptomatic","delta",47,29,61,"India","IND","Asia","South Asia",2070,2019,"India","Lower middle income",1,NA,NA,NA,NA,NA
"1035",124,"Thiruvengadam","Test-negative case-control",1077,2021-11-25,"Oxford/AstraZeneca ChAdOx1-S","Vectored","1","1",NA,"21+",">= 18 years","general pop","excluded",NA,"infection","infection","infection","delta",46.2,31.6,57.7,"India","IND","Asia","South Asia",2070,2019,"India","Lower middle income",1,NA,NA,NA,NA,NA
"1036",124,"Thiruvengadam","Test-negative case-control",1078,2021-11-25,"Oxford/AstraZeneca ChAdOx1-S","Vectored","2","final",NA,"14+",">= 18 years","general pop","excluded","~10 weeks","infection","infection","infection","delta",63.1,51.5,72.1,"India","IND","Asia","South Asia",2070,2019,"India","Lower middle income",1,NA,NA,NA,NA,NA
"1037",125,"Hall","Prospective cohort",1079,2022-02-16,"BioNTech/Pfizer BNT162b2","mRNA","1","1",NA,"21-27","HCW","HCW","excluded",NA,"Infection","infection","infection","other combinations",59,42,71,"UK","GBR","Europe","Europe & Central Asia",43240,2019,"United Kingdom","High income",4,NA,NA,NA,NA,NA
"1038",125,"Hall","Prospective cohort",1080,2022-02-16,"BioNTech/Pfizer BNT162b2","mRNA","2","final","<6 weeks","14-73","HCW","HCW","excluded","~8 weeks","Infection","infection","infection","other combinations",89,78,94,"UK","GBR","Europe","Europe & Central Asia",43240,2019,"United Kingdom","High income",4,NA,NA,NA,NA,NA
"1039",125,"Hall","Prospective cohort",1081,2022-02-16,"BioNTech/Pfizer BNT162b2","mRNA","2","final","<6 weeks","194-265","HCW","HCW","excluded","36 weeks","Infection","infection","infection","other combinations",53,28,69,"UK","GBR","Europe","Europe & Central Asia",43240,2019,"United Kingdom","High income",4,NA,NA,NA,NA,NA
"1040",125,"Hall","Prospective cohort",1082,2022-02-16,"BioNTech/Pfizer BNT162b2","mRNA","1","1",NA,"56-280","HCW","HCW","excluded",NA,"Infection","infection","infection","other combinations",63,46,75,"UK","GBR","Europe","Europe & Central Asia",43240,2019,"United Kingdom","High income",4,NA,NA,NA,NA,NA
"1041",125,"Hall","Prospective cohort",1083,2022-02-16,"BioNTech/Pfizer BNT162b2","mRNA","2","final","6+ weeks","14-73","HCW","HCW","excluded","~8 weeks","Infection","infection","infection","other combinations",85,72,92,"UK","GBR","Europe","Europe & Central Asia",43240,2019,"United Kingdom","High income",4,NA,NA,NA,NA,NA
"1042",125,"Hall","Prospective cohort",1084,2022-02-16,"BioNTech/Pfizer BNT162b2","mRNA","2","final","6+ weeks","194-239","HCW","HCW","excluded","~32 weeks","Infection","infection","infection","other combinations",51,22,69,"UK","GBR","Europe","Europe & Central Asia",43240,2019,"United Kingdom","High income",4,NA,NA,NA,NA,NA
"1043",125,"Hall","Prospective cohort",1085,2022-02-16,"Oxford/AstraZeneca ChAdOx1-S","Vectored","1","1",NA,"21-27","HCW","HCW","excluded",NA,"Infection","infection","infection","other combinations",63,-80,92,"UK","GBR","Europe","Europe & Central Asia",43240,2019,"United Kingdom","High income",4,NA,NA,NA,NA,NA
"1044",125,"Hall","Prospective cohort",1086,2022-02-16,"Oxford/AstraZeneca ChAdOx1-S","Vectored","2","final",NA,"14-73","HCW","HCW","excluded","~8 weeks","Infection","infection","infection","other combinations",58,23,77,"UK","GBR","Europe","Europe & Central Asia",43240,2019,"United Kingdom","High income",4,NA,NA,NA,NA,NA
"1045",125,"Hall","Prospective cohort",1087,2022-02-16,"Oxford/AstraZeneca ChAdOx1-S","Vectored","1","1",NA,"56-249","HCW","HCW","excluded",NA,"Infection","infection","infection","other combinations",9,-87,55,"UK","GBR","Europe","Europe & Central Asia",43240,2019,"United Kingdom","High income",4,NA,NA,NA,NA,NA
"1046",125,"Hall","Prospective cohort",1088,2022-02-16,"Oxford/AstraZeneca ChAdOx1-S","Vectored","2","final",NA,"134-220","HCW","HCW","excluded","~29 weeks","Infection","infection","infection","other combinations",72,39,87,"UK","GBR","Europe","Europe & Central Asia",43240,2019,"United Kingdom","High income",4,NA,NA,NA,NA,NA
"1047",126,"Voko","Retrospective cohort",1089,2021-11-24,"BioNTech/Pfizer BNT162b2","mRNA","1","1+",NA,"0+",">= 16 years","general pop","included",NA,"Infection","infection","infection","alpha",41,39.5,42.4,"Hungary","HUN","Europe","Europe & Central Asia",16570,2019,"Hungary","High income",3,NA,NA,NA,NA,NA
"1048",126,"Voko","Retrospective cohort",1090,2021-11-24,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"14+",">= 16 years","general pop","included","~19 weeks","Infection","infection","infection","alpha",84,83.3,84.7,"Hungary","HUN","Europe","Europe & Central Asia",16570,2019,"Hungary","High income",3,NA,NA,NA,NA,NA
"1049",126,"Voko","Retrospective cohort",1091,2021-11-24,"BioNTech/Pfizer BNT162b2","mRNA","1","1+",NA,"0+",">= 16 years","general pop","included",NA,"death","death","death","alpha",64.3,61.8,66.6,"Hungary","HUN","Europe","Europe & Central Asia",16570,2019,"Hungary","High income",3,NA,NA,NA,NA,NA
"1050",126,"Voko","Retrospective cohort",1092,2021-11-24,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"14+",">= 16 years","general pop","included","~19 weeks","death","death","death","alpha",90.3,88.9,91.5,"Hungary","HUN","Europe","Europe & Central Asia",16570,2019,"Hungary","High income",3,NA,NA,NA,NA,NA
"1051",126,"Voko","Retrospective cohort",1093,2021-11-24,"Beijing/Sinopharm BBIBP-CorV","Inactivated","1","1+",NA,"0+",">= 16 years","general pop","included",NA,"Infection","infection","infection","alpha",34,31.8,36.1,"Hungary","HUN","Europe","Europe & Central Asia",16570,2019,"Hungary","High income",3,NA,NA,NA,NA,NA
"1052",126,"Voko","Retrospective cohort",1094,2021-11-24,"Beijing/Sinopharm BBIBP-CorV","Inactivated","2","final",NA,"14+",">= 16 years","general pop","included","~10.5 weeks","Infection","infection","infection","alpha",72.8,71.2,74.4,"Hungary","HUN","Europe","Europe & Central Asia",16570,2019,"Hungary","High income",3,NA,NA,NA,NA,NA
"1053",126,"Voko","Retrospective cohort",1095,2021-11-24,"Beijing/Sinopharm BBIBP-CorV","Inactivated","1","1+",NA,"0+",">= 16 years","general pop","included",NA,"death","death","death","alpha",39.4,34.1,44.3,"Hungary","HUN","Europe","Europe & Central Asia",16570,2019,"Hungary","High income",3,NA,NA,NA,NA,NA
"1054",126,"Voko","Retrospective cohort",1096,2021-11-24,"Beijing/Sinopharm BBIBP-CorV","Inactivated","2","final",NA,"14+",">= 16 years","general pop","included","~10.5 weeks","death","death","death","alpha",86,83.7,87.9,"Hungary","HUN","Europe","Europe & Central Asia",16570,2019,"Hungary","High income",3,NA,NA,NA,NA,NA
"1055",126,"Voko","Retrospective cohort",1097,2021-11-24,"Gamaleya Gam-COVID-Vac/Sputnik V","Vectored","1","1+",NA,"0+",">= 16 years","general pop","included",NA,"Infection","infection","infection","alpha",48.7,47.1,50.2,"Hungary","HUN","Europe","Europe & Central Asia",16570,2019,"Hungary","High income",3,NA,NA,NA,NA,NA
"1056",126,"Voko","Retrospective cohort",1098,2021-11-24,"Gamaleya Gam-COVID-Vac/Sputnik V","Vectored","2","final",NA,"14+",">= 16 years","general pop","included","~11 weeks","Infection","infection","infection","alpha",88.1,86.5,89.4,"Hungary","HUN","Europe","Europe & Central Asia",16570,2019,"Hungary","High income",3,NA,NA,NA,NA,NA
"1057",126,"Voko","Retrospective cohort",1099,2021-11-24,"Gamaleya Gam-COVID-Vac/Sputnik V","Vectored","1","1+",NA,"0+",">= 16 years","general pop","included",NA,"death","death","death","alpha",78,74.3,81.2,"Hungary","HUN","Europe","Europe & Central Asia",16570,2019,"Hungary","High income",3,NA,NA,NA,NA,NA
"1058",126,"Voko","Retrospective cohort",1100,2021-11-24,"Gamaleya Gam-COVID-Vac/Sputnik V","Vectored","2","final",NA,"14+",">= 16 years","general pop","included","~11 weeks","death","death","death","alpha",97.8,95.5,98.9,"Hungary","HUN","Europe","Europe & Central Asia",16570,2019,"Hungary","High income",3,NA,NA,NA,NA,NA
"1059",126,"Voko","Retrospective cohort",1101,2021-11-24,"Oxford/AstraZeneca ChAdOx1-S","Vectored","1","1+",NA,"0+",">= 16 years","general pop","included",NA,"Infection","infection","infection","alpha",49.2,47.7,50.6,"Hungary","HUN","Europe","Europe & Central Asia",16570,2019,"Hungary","High income",3,NA,NA,NA,NA,NA
"1060",126,"Voko","Retrospective cohort",1102,2021-11-24,"Oxford/AstraZeneca ChAdOx1-S","Vectored","2","final",NA,"14+",">= 16 years","general pop","included","~11.5 weeks","Infection","infection","infection","alpha",73.3,71.1,76,"Hungary","HUN","Europe","Europe & Central Asia",16570,2019,"Hungary","High income",3,NA,NA,NA,NA,NA
"1061",126,"Voko","Retrospective cohort",1103,2021-11-24,"Oxford/AstraZeneca ChAdOx1-S","Vectored","1","1+",NA,"0+",">= 16 years","general pop","included",NA,"death","death","death","alpha",71.3,67.9,74.4,"Hungary","HUN","Europe","Europe & Central Asia",16570,2019,"Hungary","High income",3,NA,NA,NA,NA,NA
"1062",126,"Voko","Retrospective cohort",1104,2021-11-24,"Oxford/AstraZeneca ChAdOx1-S","Vectored","2","final",NA,"14+",">= 16 years","general pop","included","~11.5 weeks","death","death","death","alpha",85.8,73.5,92.4,"Hungary","HUN","Europe","Europe & Central Asia",16570,2019,"Hungary","High income",3,NA,NA,NA,NA,NA
"1063",126,"Voko","Retrospective cohort",1105,2021-11-24,"Moderna mRNA-1273","mRNA","1","1+",NA,"0+",">= 16 years","general pop","included",NA,"Infection","infection","infection","alpha",60.8,58.6,63,"Hungary","HUN","Europe","Europe & Central Asia",16570,2019,"Hungary","High income",3,NA,NA,NA,NA,NA
"1064",126,"Voko","Retrospective cohort",1106,2021-11-24,"Moderna mRNA-1273","mRNA","2","final",NA,"14+",">= 16 years","general pop","included","~15 weeks","Infection","infection","infection","alpha",88.2,85.8,90.3,"Hungary","HUN","Europe","Europe & Central Asia",16570,2019,"Hungary","High income",3,NA,NA,NA,NA,NA
"1065",126,"Voko","Retrospective cohort",1107,2021-11-24,"Moderna mRNA-1273","mRNA","1","1+",NA,"0+",">= 16 years","general pop","included",NA,"death","death","death","alpha",68.7,62.5,73.8,"Hungary","HUN","Europe","Europe & Central Asia",16570,2019,"Hungary","High income",3,NA,NA,NA,NA,NA
"1066",126,"Voko","Retrospective cohort",1108,2021-11-24,"Moderna mRNA-1273","mRNA","2","final",NA,"14+",">= 16 years","general pop","included","~15 weeks","death","death","death","alpha",93.8,90.3,96.1,"Hungary","HUN","Europe","Europe & Central Asia",16570,2019,"Hungary","High income",3,NA,NA,NA,NA,NA
"1067",127,"Wu","Retrospective cohort",1109,2021-12-02,"Multiple or heterologous RNA","mRNA","1","1",NA,"14+","cancer patients","immunocompromised adults","excluded",NA,"Infection","infection","infection","other combinations",45,8,66,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"1068",127,"Wu","Retrospective cohort",1110,2021-12-02,"Multiple or heterologous RNA","mRNA","2","final",NA,"14+","cancer patients","immunocompromised adults","excluded","15 weeks","Infection","infection","infection","other combinations",58,39,73,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"1069",128,"Muhsen","Prospective cohort",1111,2021-10-28,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"14+","HCW","HCW","excluded","~11 weeks","Infection","infection","infection","alpha",89,83,93,"Israel","ISR","Asia","Middle East & North Africa",43800,2019,"Israel","High income",4,NA,NA,NA,NA,NA
"1070",129,"Yassi","Retrospective cohort",1112,2021-12-06,"Multiple or heterologous RNA","mRNA","2","final",NA,"7+","HCW","HCW","unknown","~40.5 weeks","Infection","infection","infection","other combinations",74.1,62.5,82.1,"Canada","CAN","North America","North America",46580,2019,"Canada","High income",4,NA,NA,NA,NA,NA
"1071",129,"Yassi","Test-negative case-control",1113,2021-12-06,"Multiple or heterologous RNA","mRNA","2","final",NA,"7+","HCW","HCW","unknown","~40.5 weeks","Infection","infection","infection","other combinations",82.8,74,88.6,"Canada","CAN","North America","North America",46580,2019,"Canada","High income",4,NA,NA,NA,NA,NA
"1072",130,"UKHSA","Test-negative case-control",1114,2022-01-27,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"2-4 weeks",">= 18 years","general pop","excluded","~32 weeks","symptomatic disease","symptomatic","symptomatic","omicron",65.8,64.4,67.2,"UK","GBR","Europe","Europe & Central Asia",43240,2019,"United Kingdom","High income",4,NA,NA,NA,NA,NA
"1073",130,"UKHSA","Test-negative case-control",1115,2022-01-27,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"25+ weeks",">= 18 years","general pop","excluded","~32 weeks","symptomatic disease","symptomatic","symptomatic","omicron",9.4,7.8,11.1,"UK","GBR","Europe","Europe & Central Asia",43240,2019,"United Kingdom","High income",4,NA,NA,NA,NA,NA
"1074",130,"UKHSA","Test-negative case-control",1116,2022-01-27,"Oxford/AstraZeneca ChAdOx1-S","Vectored","2","final",NA,"2-4 weeks",">= 18 years","general pop","excluded","~32 weeks","symptomatic disease","symptomatic","symptomatic","omicron",49.8,40.7,57.5,"UK","GBR","Europe","Europe & Central Asia",43240,2019,"United Kingdom","High income",4,NA,NA,NA,NA,NA
"1075",130,"UKHSA","Test-negative case-control",1117,2022-01-27,"Oxford/AstraZeneca ChAdOx1-S","Vectored","2","final",NA,"25+ weeks",">= 18 years","general pop","excluded","~32 weeks","symptomatic disease","symptomatic","symptomatic","omicron",-1,-2.4,0.3,"UK","GBR","Europe","Europe & Central Asia",43240,2019,"United Kingdom","High income",4,NA,NA,NA,NA,NA
"1076",130,"UKHSA","Test-negative case-control",1118,2022-01-27,"Moderna mRNA-1273","mRNA","2","final",NA,"2-4 weeks",">= 18 years","general pop","excluded","~32 weeks","symptomatic disease","symptomatic","symptomatic","omicron",76,72,79,"UK","GBR","Europe","Europe & Central Asia",43240,2019,"United Kingdom","High income",4,NA,NA,NA,NA,NA
"1077",130,"UKHSA","Test-negative case-control",1119,2022-01-27,"Moderna mRNA-1273","mRNA","2","final",NA,"25+ weeks",">= 18 years","general pop","excluded","~32 weeks","symptomatic disease","symptomatic","symptomatic","omicron",13,3,22,"UK","GBR","Europe","Europe & Central Asia",43240,2019,"United Kingdom","High income",4,NA,NA,NA,NA,NA
"1078",130,"UKHSA","Test-negative case-control",1120,2022-01-27,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"2-4 weeks",">= 18 years","general pop","excluded","~32 weeks","symptomatic disease","symptomatic","symptomatic","delta",90.9,89.6,92,"UK","GBR","Europe","Europe & Central Asia",43240,2019,"United Kingdom","High income",4,NA,NA,NA,NA,NA
"1079",130,"UKHSA","Test-negative case-control",1121,2022-01-27,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"25+ weeks",">= 18 years","general pop","excluded","~32 weeks","symptomatic disease","symptomatic","symptomatic","delta",62.7,61.6,63.7,"UK","GBR","Europe","Europe & Central Asia",43240,2019,"United Kingdom","High income",4,NA,NA,NA,NA,NA
"1080",130,"UKHSA","Test-negative case-control",1122,2022-01-27,"Oxford/AstraZeneca ChAdOx1-S","Vectored","2","final",NA,"2-4 weeks",">= 18 years","general pop","excluded","~32 weeks","symptomatic disease","symptomatic","symptomatic","delta",82.8,74.5,88.4,"UK","GBR","Europe","Europe & Central Asia",43240,2019,"United Kingdom","High income",4,NA,NA,NA,NA,NA
"1081",130,"UKHSA","Test-negative case-control",1123,2022-01-27,"Oxford/AstraZeneca ChAdOx1-S","Vectored","2","final",NA,"25+ weeks",">= 18 years","general pop","excluded","~32 weeks","symptomatic disease","symptomatic","symptomatic","delta",43.5,42.4,44.5,"UK","GBR","Europe","Europe & Central Asia",43240,2019,"United Kingdom","High income",4,NA,NA,NA,NA,NA
"1082",130,"UKHSA","Test-negative case-control",1124,2022-01-27,"Moderna mRNA-1273","mRNA","2","final",NA,"2-4 weeks",">= 18 years","general pop","excluded","~32 weeks","symptomatic disease","symptomatic","symptomatic","delta",94.5,90.5,96.9,"UK","GBR","Europe","Europe & Central Asia",43240,2019,"United Kingdom","High income",4,NA,NA,NA,NA,NA
"1083",130,"UKHSA","Test-negative case-control",1125,2022-01-27,"Moderna mRNA-1273","mRNA","2","final",NA,"25+ weeks",">= 18 years","general pop","excluded","~32 weeks","symptomatic disease","symptomatic","symptomatic","delta",80.4,67.3,88.2,"UK","GBR","Europe","Europe & Central Asia",43240,2019,"United Kingdom","High income",4,NA,NA,NA,NA,NA
"1084",130,"UKHSA","Test-negative case-control",1126,2022-01-27,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"2-4 weeks",">= 18 years","general pop","excluded","~32 weeks","symptomatic disease","symptomatic","symptomatic","omicron",73.6,40.7,88.3,"UK","GBR","Europe","Europe & Central Asia",43240,2019,"United Kingdom","High income",4,NA,NA,NA,NA,NA
"1085",130,"UKHSA","Test-negative case-control",1127,2022-01-27,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"25+ weeks",">= 18 years","general pop","excluded","~32 weeks","symptomatic disease","symptomatic","symptomatic","omicron",34.9,17.7,48.4,"UK","GBR","Europe","Europe & Central Asia",43240,2019,"United Kingdom","High income",4,NA,NA,NA,NA,NA
"1086",130,"UKHSA","Test-negative case-control",1128,2022-01-27,"Oxford/AstraZeneca ChAdOx1-S","Vectored","2","final",NA,"20-24 weeks",">= 18 years","general pop","excluded","~32 weeks","symptomatic disease","symptomatic","symptomatic","omicron",55.8,34.1,70.3,"UK","GBR","Europe","Europe & Central Asia",43240,2019,"United Kingdom","High income",4,NA,NA,NA,NA,NA
"1087",130,"UKHSA","Test-negative case-control",1129,2022-01-27,"Oxford/AstraZeneca ChAdOx1-S","Vectored","2","final",NA,"25+ weeks",">= 18 years","general pop","excluded","~32 weeks","symptomatic disease","symptomatic","symptomatic","omicron",32.7,19.7,43.6,"UK","GBR","Europe","Europe & Central Asia",43240,2019,"United Kingdom","High income",4,NA,NA,NA,NA,NA
"1088",130,"UKHSA","Test-negative case-control",1130,2022-01-27,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"2-4 weeks",">= 18 years","general pop","excluded","~32 weeks","symptomatic disease","symptomatic","symptomatic","delta",94.1,81.6,98.1,"UK","GBR","Europe","Europe & Central Asia",43240,2019,"United Kingdom","High income",4,NA,NA,NA,NA,NA
"1089",130,"UKHSA","Test-negative case-control",1131,2022-01-27,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"25+ weeks",">= 18 years","general pop","excluded","~32 weeks","symptomatic disease","symptomatic","symptomatic","delta",95.3,93.9,96.5,"UK","GBR","Europe","Europe & Central Asia",43240,2019,"United Kingdom","High income",4,NA,NA,NA,NA,NA
"1090",130,"UKHSA","Test-negative case-control",1132,2022-01-27,"Oxford/AstraZeneca ChAdOx1-S","Vectored","2","final",NA,"20-24 weeks",">= 18 years","general pop","excluded","~32 weeks","symptomatic disease","symptomatic","symptomatic","delta",92.9,91.3,94.2,"UK","GBR","Europe","Europe & Central Asia",43240,2019,"United Kingdom","High income",4,NA,NA,NA,NA,NA
"1091",130,"UKHSA","Test-negative case-control",1133,2022-01-27,"Oxford/AstraZeneca ChAdOx1-S","Vectored","2","final",NA,"25+ weeks",">= 18 years","general pop","excluded","~32 weeks","symptomatic disease","symptomatic","symptomatic","delta",90.6,89.3,91.8,"UK","GBR","Europe","Europe & Central Asia",43240,2019,"United Kingdom","High income",4,NA,NA,NA,NA,NA
"1092",131,"Bajema","Test-negative case-control",1134,2021-12-10,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"14-119",">= 18 years","general pop","excluded","~36 weeks","Hospitalization","severe","severe","other combinations",86,77.6,91.3,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"1093",131,"Bajema","Test-negative case-control",1135,2021-12-10,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"120+",">= 18 years","general pop","excluded","~36 weeks","Hospitalization","severe","severe","other combinations",75.1,64.6,82.4,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"1094",131,"Bajema","Test-negative case-control",1136,2021-12-10,"Moderna mRNA-1273","mRNA","2","final",NA,"14-119",">= 18 years","general pop","excluded","~36 weeks","Hospitalization","severe","severe","other combinations",89.6,80.1,94.5,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"1095",131,"Bajema","Test-negative case-control",1137,2021-12-10,"Moderna mRNA-1273","mRNA","2","final",NA,"120+",">= 18 years","general pop","excluded","~36 weeks","Hospitalization","severe","severe","other combinations",86.1,77.7,91.3,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"1096",132,"Powell","Test-negative case-control",1138,2022-03-21,"BioNTech/Pfizer BNT162b2","mRNA","1","1",NA,"14-20","12-15 years","12-15 years","excluded",NA,"symptomatic disease","symptomatic","symptomatic","omicron",49.6,43.9,54.8,"UK","GBR","Europe","Europe & Central Asia",43240,2019,"United Kingdom","High income",4,NA,NA,NA,NA,NA
"1097",132,"Powell","Test-negative case-control",1139,2022-03-21,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"14+","12-15 years","12-15 years","excluded","~33 weeks","symptomatic disease","symptomatic","symptomatic","omicron",73,66.4,78.3,"UK","GBR","Europe","Europe & Central Asia",43240,2019,"United Kingdom","High income",4,NA,NA,NA,NA,NA
"1098",132,"Powell","Test-negative case-control",1140,2022-03-21,"BioNTech/Pfizer BNT162b2","mRNA","1","1",NA,"84+","12-15 years","12-15 years","excluded",NA,"symptomatic disease","symptomatic","symptomatic","omicron",17.2,12,22.1,"UK","GBR","Europe","Europe & Central Asia",43240,2019,"United Kingdom","High income",4,NA,NA,NA,NA,NA
"1099",132,"Powell","Test-negative case-control",1141,2022-03-21,"BioNTech/Pfizer BNT162b2","mRNA","1","1",NA,"14-20","16-17 years","16-17 years","excluded",NA,"symptomatic disease","symptomatic","symptomatic","omicron",51.4,42.7,58.8,"UK","GBR","Europe","Europe & Central Asia",43240,2019,"United Kingdom","High income",4,NA,NA,NA,NA,NA
"1100",132,"Powell","Test-negative case-control",1142,2022-03-21,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"14-34","16-17 years","16-17 years","excluded","~33 weeks","symptomatic disease","symptomatic","symptomatic","omicron",71.3,69.3,73.1,"UK","GBR","Europe","Europe & Central Asia",43240,2019,"United Kingdom","High income",4,NA,NA,NA,NA,NA
"1101",132,"Powell","Test-negative case-control",1143,2022-03-21,"BioNTech/Pfizer BNT162b2","mRNA","1","1",NA,"105+","16-17 years","16-17 years","excluded",NA,"symptomatic disease","symptomatic","symptomatic","omicron",12.5,6.9,17.8,"UK","GBR","Europe","Europe & Central Asia",43240,2019,"United Kingdom","High income",4,NA,NA,NA,NA,NA
"1102",132,"Powell","Test-negative case-control",1144,2022-03-21,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"70+","16-17 years","16-17 years","excluded","~33 weeks","symptomatic disease","symptomatic","symptomatic","omicron",22.6,14.5,29.9,"UK","GBR","Europe","Europe & Central Asia",43240,2019,"United Kingdom","High income",4,NA,NA,NA,NA,NA
"1103",132,"Powell","Test-negative case-control",1145,2022-03-21,"BioNTech/Pfizer BNT162b2","mRNA","1","1",NA,"14-20","12-15 years","12-15 years","excluded",NA,"symptomatic disease","symptomatic","symptomatic","delta",74.5,73.2,75.6,"UK","GBR","Europe","Europe & Central Asia",43240,2019,"United Kingdom","High income",4,NA,NA,NA,NA,NA
"1104",132,"Powell","Test-negative case-control",1146,2022-03-21,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"14+","12-15 years","12-15 years","excluded","~33 weeks","symptomatic disease","symptomatic","symptomatic","delta",87.2,73.7,93.8,"UK","GBR","Europe","Europe & Central Asia",43240,2019,"United Kingdom","High income",4,NA,NA,NA,NA,NA
"1105",132,"Powell","Test-negative case-control",1147,2022-03-21,"BioNTech/Pfizer BNT162b2","mRNA","1","1",NA,"84+","12-15 years","12-15 years","excluded",NA,"symptomatic disease","symptomatic","symptomatic","delta",53.1,41.6,62.4,"UK","GBR","Europe","Europe & Central Asia",43240,2019,"United Kingdom","High income",4,NA,NA,NA,NA,NA
"1106",132,"Powell","Test-negative case-control",1148,2022-03-21,"BioNTech/Pfizer BNT162b2","mRNA","1","1",NA,"14-20","16-17 years","16-17 years","excluded",NA,"symptomatic disease","symptomatic","symptomatic","delta",75.9,74.3,77.3,"UK","GBR","Europe","Europe & Central Asia",43240,2019,"United Kingdom","High income",4,NA,NA,NA,NA,NA
"1107",132,"Powell","Test-negative case-control",1149,2022-03-21,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"14-34","16-17 years","16-17 years","excluded","~33 weeks","symptomatic disease","symptomatic","symptomatic","delta",93.1,91.6,94.4,"UK","GBR","Europe","Europe & Central Asia",43240,2019,"United Kingdom","High income",4,NA,NA,NA,NA,NA
"1108",132,"Powell","Test-negative case-control",1150,2022-03-21,"BioNTech/Pfizer BNT162b2","mRNA","1","1",NA,"105+","16-17 years","16-17 years","excluded",NA,"symptomatic disease","symptomatic","symptomatic","delta",30.9,25.4,36,"UK","GBR","Europe","Europe & Central Asia",43240,2019,"United Kingdom","High income",4,NA,NA,NA,NA,NA
"1109",132,"Powell","Test-negative case-control",1151,2022-03-21,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"70+","16-17 years","16-17 years","excluded","~33 weeks","symptomatic disease","symptomatic","symptomatic","delta",83.7,72,90.5,"UK","GBR","Europe","Europe & Central Asia",43240,2019,"United Kingdom","High income",4,NA,NA,NA,NA,NA
"1110",132,"Powell","Test-negative case-control",1152,2022-03-21,"BioNTech/Pfizer BNT162b2","mRNA","1","1",NA,"28+","12-15 years","12-15 years","excluded",NA,"hospitalization","severe","severe","delta",83.4,54,94,"UK","GBR","Europe","Europe & Central Asia",43240,2019,"United Kingdom","High income",4,NA,NA,NA,NA,NA
"1111",132,"Powell","Test-negative case-control",1153,2022-03-21,"BioNTech/Pfizer BNT162b2","mRNA","1","1",NA,"28+","16-17 years","16-17 years","excluded",NA,"hospitalization","severe","severe","delta",76.3,61.1,85.6,"UK","GBR","Europe","Europe & Central Asia",43240,2019,"United Kingdom","High income",4,NA,NA,NA,NA,NA
"1112",133,"Berec","Retrospective cohort",1154,2022-07-08,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"0-2 months",">= 18 years","general pop","included","~35 weeks","Infection","infection","infection","other combinations",87,86,87,"Czech Republic","CZE","Europe","Europe & Central Asia",22100,2019,"Czechia","High income",3,NA,NA,NA,NA,NA
"1113",133,"Berec","Retrospective cohort",1155,2022-07-08,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"7-8 months",">= 18 years","general pop","included","~35 weeks","Infection","infection","infection","other combinations",53,52,54,"Czech Republic","CZE","Europe","Europe & Central Asia",22100,2019,"Czechia","High income",3,NA,NA,NA,NA,NA
"1114",133,"Berec","Retrospective cohort",1156,2022-07-08,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"0-2 months",">= 18 years","general pop","included","~35 weeks","Hospitalization","severe","severe","other combinations",90,89,91,"Czech Republic","CZE","Europe","Europe & Central Asia",22100,2019,"Czechia","High income",3,NA,NA,NA,NA,NA
"1115",133,"Berec","Retrospective cohort",1157,2022-07-08,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"7-8 months",">= 18 years","general pop","included","~35 weeks","Hospitalization","severe","severe","other combinations",75,73,76,"Czech Republic","CZE","Europe","Europe & Central Asia",22100,2019,"Czechia","High income",3,NA,NA,NA,NA,NA
"1116",133,"Berec","Retrospective cohort",1158,2022-07-08,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"0-2 months",">= 18 years","general pop","included","~35 weeks","death","death","death","other combinations",92,90,93,"Czech Republic","CZE","Europe","Europe & Central Asia",22100,2019,"Czechia","High income",3,NA,NA,NA,NA,NA
"1117",133,"Berec","Retrospective cohort",1159,2022-07-08,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"7-8 months",">= 18 years","general pop","included","~35 weeks","death","death","death","other combinations",83,81,86,"Czech Republic","CZE","Europe","Europe & Central Asia",22100,2019,"Czechia","High income",3,NA,NA,NA,NA,NA
"1118",133,"Berec","Retrospective cohort",1160,2022-07-08,"Moderna mRNA-1273","mRNA","2","final",NA,"0-2 months",">= 18 years","general pop","included","~35 weeks","Infection","infection","infection","other combinations",90,89,91,"Czech Republic","CZE","Europe","Europe & Central Asia",22100,2019,"Czechia","High income",3,NA,NA,NA,NA,NA
"1119",133,"Berec","Retrospective cohort",1161,2022-07-08,"Moderna mRNA-1273","mRNA","2","final",NA,"7-8 months",">= 18 years","general pop","included","~35 weeks","Infection","infection","infection","other combinations",65,63,67,"Czech Republic","CZE","Europe","Europe & Central Asia",22100,2019,"Czechia","High income",3,NA,NA,NA,NA,NA
"1120",133,"Berec","Retrospective cohort",1162,2022-07-08,"Moderna mRNA-1273","mRNA","2","final",NA,"0-2 months",">= 18 years","general pop","included","~35 weeks","Hospitalization","severe","severe","other combinations",94,92,96,"Czech Republic","CZE","Europe","Europe & Central Asia",22100,2019,"Czechia","High income",3,NA,NA,NA,NA,NA
"1121",133,"Berec","Retrospective cohort",1163,2022-07-08,"Moderna mRNA-1273","mRNA","2","final",NA,"7-8 months",">= 18 years","general pop","included","~35 weeks","Hospitalization","severe","severe","other combinations",81,78,84,"Czech Republic","CZE","Europe","Europe & Central Asia",22100,2019,"Czechia","High income",3,NA,NA,NA,NA,NA
"1122",133,"Berec","Retrospective cohort",1164,2022-07-08,"Moderna mRNA-1273","mRNA","2","final",NA,"0-2 months",">= 18 years","general pop","included","~35 weeks","death","death","death","other combinations",96,91,98,"Czech Republic","CZE","Europe","Europe & Central Asia",22100,2019,"Czechia","High income",3,NA,NA,NA,NA,NA
"1123",133,"Berec","Retrospective cohort",1165,2022-07-08,"Moderna mRNA-1273","mRNA","2","final",NA,"7-8 months",">= 18 years","general pop","included","~35 weeks","death","death","death","other combinations",88,82,92,"Czech Republic","CZE","Europe","Europe & Central Asia",22100,2019,"Czechia","High income",3,NA,NA,NA,NA,NA
"1124",133,"Berec","Retrospective cohort",1166,2022-07-08,"Oxford/AstraZeneca ChAdOx1-S","Vectored","2","final",NA,"0-2 months",">= 18 years","general pop","included","~35 weeks","Infection","infection","infection","other combinations",83,80,85,"Czech Republic","CZE","Europe","Europe & Central Asia",22100,2019,"Czechia","High income",3,NA,NA,NA,NA,NA
"1125",133,"Berec","Retrospective cohort",1167,2022-07-08,"Oxford/AstraZeneca ChAdOx1-S","Vectored","2","final",NA,"5-6 months",">= 18 years","general pop","included","~35 weeks","Infection","infection","infection","other combinations",55,54,56,"Czech Republic","CZE","Europe","Europe & Central Asia",22100,2019,"Czechia","High income",3,NA,NA,NA,NA,NA
"1126",133,"Berec","Retrospective cohort",1168,2022-07-08,"Oxford/AstraZeneca ChAdOx1-S","Vectored","2","final",NA,"0-2 months",">= 18 years","general pop","included","~35 weeks","Hospitalization","severe","severe","other combinations",87,81,91,"Czech Republic","CZE","Europe","Europe & Central Asia",22100,2019,"Czechia","High income",3,NA,NA,NA,NA,NA
"1127",133,"Berec","Retrospective cohort",1169,2022-07-08,"Oxford/AstraZeneca ChAdOx1-S","Vectored","2","final",NA,"5-6 months",">= 18 years","general pop","included","~35 weeks","Hospitalization","severe","severe","other combinations",70,68,72,"Czech Republic","CZE","Europe","Europe & Central Asia",22100,2019,"Czechia","High income",3,NA,NA,NA,NA,NA
"1128",133,"Berec","Retrospective cohort",1170,2022-07-08,"Oxford/AstraZeneca ChAdOx1-S","Vectored","2","final",NA,"0-2 months",">= 18 years","general pop","included","~35 weeks","death","death","death","other combinations",93,77,98,"Czech Republic","CZE","Europe","Europe & Central Asia",22100,2019,"Czechia","High income",3,NA,NA,NA,NA,NA
"1129",133,"Berec","Retrospective cohort",1171,2022-07-08,"Oxford/AstraZeneca ChAdOx1-S","Vectored","2","final",NA,"5-6 months",">= 18 years","general pop","included","~35 weeks","death","death","death","other combinations",82,78,85,"Czech Republic","CZE","Europe","Europe & Central Asia",22100,2019,"Czechia","High income",3,NA,NA,NA,NA,NA
"1130",133,"Berec","Retrospective cohort",1172,2022-07-08,"Janssen Ad26.COV2.S","Vectored","2","final",NA,"0-2 months",">= 18 years","general pop","included","~35 weeks","Infection","infection","infection","other combinations",68,66,70,"Czech Republic","CZE","Europe","Europe & Central Asia",22100,2019,"Czechia","High income",3,NA,NA,NA,NA,NA
"1131",133,"Berec","Retrospective cohort",1173,2022-07-08,"Janssen Ad26.COV2.S","Vectored","2","final",NA,"5-6 months",">= 18 years","general pop","included","~35 weeks","Infection","infection","infection","other combinations",67,65,69,"Czech Republic","CZE","Europe","Europe & Central Asia",22100,2019,"Czechia","High income",3,NA,NA,NA,NA,NA
"1132",133,"Berec","Retrospective cohort",1174,2022-07-08,"Janssen Ad26.COV2.S","Vectored","2","final",NA,"2 months",">= 18 years","general pop","included","~35 weeks","Hospitalization","severe","severe","other combinations",68,60,75,"Czech Republic","CZE","Europe","Europe & Central Asia",22100,2019,"Czechia","High income",3,NA,NA,NA,NA,NA
"1133",133,"Berec","Retrospective cohort",1175,2022-07-08,"Janssen Ad26.COV2.S","Vectored","2","final",NA,"5-6 months",">= 18 years","general pop","included","~35 weeks","Hospitalization","severe","severe","other combinations",67,62,72,"Czech Republic","CZE","Europe","Europe & Central Asia",22100,2019,"Czechia","High income",3,NA,NA,NA,NA,NA
"1134",133,"Berec","Retrospective cohort",1176,2022-07-08,"Janssen Ad26.COV2.S","Vectored","2","final",NA,"2 months",">= 18 years","general pop","included","~35 weeks","death","death","death","other combinations",68,42,82,"Czech Republic","CZE","Europe","Europe & Central Asia",22100,2019,"Czechia","High income",3,NA,NA,NA,NA,NA
"1135",133,"Berec","Retrospective cohort",1177,2022-07-08,"Janssen Ad26.COV2.S","Vectored","2","final",NA,"5-6 months",">= 18 years","general pop","included","~35 weeks","death","death","death","other combinations",68,53,78,"Czech Republic","CZE","Europe","Europe & Central Asia",22100,2019,"Czechia","High income",3,NA,NA,NA,NA,NA
"1136",134,"Machado","Retrospective cohort",1178,2021-09-13,"Multiple or heterologous RNA","mRNA","2","final",NA,"14-41","65-79 years","65-79 years","excluded","~29 weeks","symptomatic disease","symptomatic","symptomatic","other combinations",79,76,83,"Portugal","PRT","Europe","Europe & Central Asia",23180,2019,"Portugal","High income",4,NA,NA,NA,NA,NA
"1137",134,"Machado","Retrospective cohort",1179,2021-09-13,"Multiple or heterologous RNA","mRNA","2","final",NA,"98+","65-79 years","65-79 years","excluded","~29 weeks","symptomatic disease","symptomatic","symptomatic","other combinations",39,29,48,"Portugal","PRT","Europe","Europe & Central Asia",23180,2019,"Portugal","High income",4,NA,NA,NA,NA,NA
"1138",134,"Machado","Retrospective cohort",1180,2021-09-13,"Multiple or heterologous RNA","mRNA","2","final",NA,"14-41",">= 80 years",">= 80 years","excluded","~29 weeks","symptomatic disease","symptomatic","symptomatic","other combinations",72,61,79,"Portugal","PRT","Europe","Europe & Central Asia",23180,2019,"Portugal","High income",4,NA,NA,NA,NA,NA
"1139",134,"Machado","Retrospective cohort",1181,2021-09-13,"Multiple or heterologous RNA","mRNA","2","final",NA,"124+",">= 80 years",">= 80 years","excluded","~29 weeks","symptomatic disease","symptomatic","symptomatic","other combinations",34,29,48,"Portugal","PRT","Europe","Europe & Central Asia",23180,2019,"Portugal","High income",4,NA,NA,NA,NA,NA
"1140",134,"Machado","Retrospective cohort",1182,2021-09-13,"Multiple or heterologous RNA","mRNA","2","final",NA,"14-41","65-79 years","65-79 years","excluded","~29 weeks","Hospitalization","severe","severe","other combinations",95,90,97,"Portugal","PRT","Europe","Europe & Central Asia",23180,2019,"Portugal","High income",4,NA,NA,NA,NA,NA
"1141",134,"Machado","Retrospective cohort",1183,2021-09-13,"Multiple or heterologous RNA","mRNA","2","final",NA,"70+","65-79 years","65-79 years","excluded","~29 weeks","Hospitalization","severe","severe","other combinations",93,86,96,"Portugal","PRT","Europe","Europe & Central Asia",23180,2019,"Portugal","High income",4,NA,NA,NA,NA,NA
"1142",134,"Machado","Retrospective cohort",1184,2021-09-13,"Multiple or heterologous RNA","mRNA","2","final",NA,"14-41",">= 80 years",">= 80 years","excluded","~29 weeks","Hospitalization","severe","severe","other combinations",83,68,91,"Portugal","PRT","Europe","Europe & Central Asia",23180,2019,"Portugal","High income",4,NA,NA,NA,NA,NA
"1143",134,"Machado","Retrospective cohort",1185,2021-09-13,"Multiple or heterologous RNA","mRNA","2","final",NA,"124+",">= 80 years",">= 80 years","excluded","~29 weeks","Hospitalization","severe","severe","other combinations",63,37,78,"Portugal","PRT","Europe","Europe & Central Asia",23180,2019,"Portugal","High income",4,NA,NA,NA,NA,NA
"1144",134,"Machado","Retrospective cohort",1186,2021-09-13,"Multiple or heterologous RNA","mRNA","2","final",NA,"14-41","65-79 years","65-79 years","excluded","~29 weeks","death","death","death","other combinations",95,88,98,"Portugal","PRT","Europe","Europe & Central Asia",23180,2019,"Portugal","High income",4,NA,NA,NA,NA,NA
"1145",134,"Machado","Retrospective cohort",1187,2021-09-13,"Multiple or heterologous RNA","mRNA","2","final",NA,"70+","65-79 years","65-79 years","excluded","~29 weeks","death","death","death","other combinations",93,87,96,"Portugal","PRT","Europe","Europe & Central Asia",23180,2019,"Portugal","High income",4,NA,NA,NA,NA,NA
"1146",134,"Machado","Retrospective cohort",1188,2021-09-13,"Multiple or heterologous RNA","mRNA","2","final",NA,"14-41",">= 80 years",">= 80 years","excluded","~29 weeks","death","death","death","other combinations",87,71,93,"Portugal","PRT","Europe","Europe & Central Asia",23180,2019,"Portugal","High income",4,NA,NA,NA,NA,NA
"1147",134,"Machado","Retrospective cohort",1189,2021-09-13,"Multiple or heterologous RNA","mRNA","2","final",NA,"124+",">= 80 years",">= 80 years","excluded","~29 weeks","death","death","death","other combinations",75,64,82,"Portugal","PRT","Europe","Europe & Central Asia",23180,2019,"Portugal","High income",4,NA,NA,NA,NA,NA
"1148",134,"Machado","Retrospective cohort",1190,2021-09-13,"Oxford/AstraZeneca ChAdOx1-S","Vectored","2","final",NA,"14-41","65-79 years","65-79 years","excluded","~29 weeks","symptomatic disease","symptomatic","symptomatic","other combinations",95,90,97,"Portugal","PRT","Europe","Europe & Central Asia",23180,2019,"Portugal","High income",4,NA,NA,NA,NA,NA
"1149",134,"Machado","Retrospective cohort",1191,2021-09-13,"Oxford/AstraZeneca ChAdOx1-S","Vectored","2","final",NA,"70+","65-79 years","65-79 years","excluded","~29 weeks","symptomatic disease","symptomatic","symptomatic","other combinations",93,86,96,"Portugal","PRT","Europe","Europe & Central Asia",23180,2019,"Portugal","High income",4,NA,NA,NA,NA,NA
"1150",134,"Machado","Retrospective cohort",1192,2021-09-13,"Oxford/AstraZeneca ChAdOx1-S","Vectored","2","final",NA,"14+","65-79 years","65-79 years","excluded","~29 weeks","Hospitalization","severe","severe","other combinations",89,52,94,"Portugal","PRT","Europe","Europe & Central Asia",23180,2019,"Portugal","High income",4,NA,NA,NA,NA,NA
"1151",134,"Machado","Retrospective cohort",1193,2021-09-13,"Oxford/AstraZeneca ChAdOx1-S","Vectored","2","final",NA,"14+","65-79 years","65-79 years","excluded","~29 weeks","death","death","death","other combinations",95,90,97,"Portugal","PRT","Europe","Europe & Central Asia",23180,2019,"Portugal","High income",4,NA,NA,NA,NA,NA
"1152",135,"Florea","Prospective cohort",1194,2022-04-28,"Moderna mRNA-1273","mRNA","2","final",NA,"14+",">= 18 years","general pop","included","~35 weeks","Infection","infection","infection","other combinations",82.8,82.2,83.3,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"1153",135,"Florea","Prospective cohort",1195,2022-04-28,"Moderna mRNA-1273","mRNA","2","final",NA,"14-60",">= 18 years","general pop","included","~6.5 weeks","Infection","infection","infection","other combinations",88,86.8,89.1,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"1154",135,"Florea","Prospective cohort",1196,2022-04-28,"Moderna mRNA-1273","mRNA","2","final",NA,"180-240",">= 18 years","general pop","included","~35 weeks","Infection","infection","infection","other combinations",75.5,70.4,79.7,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"1155",135,"Florea","Prospective cohort",1197,2022-04-28,"Moderna mRNA-1273","mRNA","2","final",NA,"14+",">= 18 years","general pop","included","~35 weeks","Hospitalization","severe","severe","other combinations",96.1,95.5,96.6,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"1156",135,"Florea","Prospective cohort",1198,2022-04-28,"Moderna mRNA-1273","mRNA","2","final",NA,"14-60",">= 18 years","general pop","included","~6.5 weeks","Hospitalization","severe","severe","other combinations",95.9,93.5,97.4,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"1157",135,"Florea","Prospective cohort",1199,2022-04-28,"Moderna mRNA-1273","mRNA","2","final",NA,"180-240",">= 18 years","general pop","included","~35 weeks","Hospitalization","severe","severe","other combinations",94.5,90.9,96.7,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"1158",135,"Florea","Prospective cohort",1200,2022-04-28,"Moderna mRNA-1273","mRNA","2","final",NA,"14+",">= 18 years","general pop","included","~35 weeks","death","death","death","other combinations",97.2,94.8,98.4,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"1159",135,"Florea","Prospective cohort",1201,2022-04-28,"Moderna mRNA-1273","mRNA","2","final",NA,"14+",">= 18 years","general pop","included","~15 weeks","Infection","infection","infection","delta",86.5,84.8,88,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"1160",136,"Young-Xu","Test-negative case-control",1202,2021-12-15,"Multiple or heterologous RNA","mRNA","2","final",NA,"14-43","males 65+","males 65+","excluded","4 weeks","Infection","infection","infection","other combinations",94.5,90.7,96.7,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"1161",136,"Young-Xu","Test-negative case-control",1203,2021-12-15,"Multiple or heterologous RNA","mRNA","2","final",NA,"74-103","males 65+","males 65+","excluded","12 weeks","Infection","infection","infection","other combinations",87.9,85.9,89.5,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"1162",136,"Young-Xu","Test-negative case-control",1204,2021-12-15,"Multiple or heterologous RNA","mRNA","2","final",NA,"14-43","males 65+","males 65+","excluded","4 weeks","Infection","infection","infection","other combinations",92.1,87.2,95.1,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"1163",136,"Young-Xu","Test-negative case-control",1205,2021-12-15,"Multiple or heterologous RNA","mRNA","2","final",NA,"134-163","males 65+","males 65+","excluded","20 weeks","Infection","infection","infection","other combinations",67.3,63.2,70.9,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"1164",136,"Young-Xu","Test-negative case-control",1206,2021-12-15,"Multiple or heterologous RNA","mRNA","2","final",NA,"14-43","males 65+","males 65+","excluded","4 weeks","Infection","infection","infection","delta",62,45.6,73.5,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"1165",136,"Young-Xu","Test-negative case-control",1207,2021-12-15,"Multiple or heterologous RNA","mRNA","2","final",NA,"224-253","males 65+","males 65+","excluded","32 weeks","Infection","infection","infection","delta",24.8,18.8,30.4,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"1166",137,"Castillo-Arregoces","Retrospective matched cohort",1208,2021-12-16,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"14+",">= 60 years","60+ years","excluded","32 weeks","hospitalization","severe","severe","mu",83,78.4,86.6,"Colombia","COL","South America","Latin America & Caribbean",6630,2019,"Colombia","Upper middle income",3,NA,NA,NA,NA,NA
"1167",137,"Castillo-Arregoces","Retrospective matched cohort",1209,2021-12-16,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"14+",">= 60 years","60+ years","excluded","32 weeks","post-hospitalization death","death","death","mu",94.8,93.3,96,"Colombia","COL","South America","Latin America & Caribbean",6630,2019,"Colombia","Upper middle income",3,NA,NA,NA,NA,NA
"1168",137,"Castillo-Arregoces","Retrospective matched cohort",1210,2021-12-16,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"14+",">= 60 years","60+ years","excluded","32 weeks","death","death","death","mu",88.3,84.1,91.4,"Colombia","COL","South America","Latin America & Caribbean",6630,2019,"Colombia","Upper middle income",3,NA,NA,NA,NA,NA
"1169",137,"Castillo-Arregoces","Retrospective matched cohort",1211,2021-12-16,"Oxford/AstraZeneca ChAdOx1-S","Vectored","2","final",NA,"14+",">= 60 years","60+ years","excluded","32 weeks","hospitalization","severe","severe","mu",90.8,85.5,94.2,"Colombia","COL","South America","Latin America & Caribbean",6630,2019,"Colombia","Upper middle income",3,NA,NA,NA,NA,NA
"1170",137,"Castillo-Arregoces","Retrospective matched cohort",1212,2021-12-16,"Oxford/AstraZeneca ChAdOx1-S","Vectored","2","final",NA,"14+",">= 60 years","60+ years","excluded","32 weeks","post-hospitalization death","death","death","mu",97.5,95.8,98.5,"Colombia","COL","South America","Latin America & Caribbean",6630,2019,"Colombia","Upper middle income",3,NA,NA,NA,NA,NA
"1171",137,"Castillo-Arregoces","Retrospective matched cohort",1213,2021-12-16,"Oxford/AstraZeneca ChAdOx1-S","Vectored","2","final",NA,"14+",">= 60 years","60+ years","excluded","32 weeks","death","death","death","mu",93.9,89.3,96.6,"Colombia","COL","South America","Latin America & Caribbean",6630,2019,"Colombia","Upper middle income",3,NA,NA,NA,NA,NA
"1172",137,"Castillo-Arregoces","Retrospective matched cohort",1214,2021-12-16,"Janssen Ad26.COV2.S","Vectored","1","final",NA,"14+",">= 60 years","60+ years","excluded","32 weeks","hospitalization","severe","severe","mu",60.9,36.8,75.8,"Colombia","COL","South America","Latin America & Caribbean",6630,2019,"Colombia","Upper middle income",3,NA,NA,NA,NA,NA
"1173",137,"Castillo-Arregoces","Retrospective matched cohort",1215,2021-12-16,"Janssen Ad26.COV2.S","Vectored","1","final",NA,"14+",">= 60 years","60+ years","excluded","32 weeks","post-hospitalization death","death","death","mu",85.8,77.1,91.2,"Colombia","COL","South America","Latin America & Caribbean",6630,2019,"Colombia","Upper middle income",3,NA,NA,NA,NA,NA
"1174",137,"Castillo-Arregoces","Retrospective matched cohort",1216,2021-12-16,"Janssen Ad26.COV2.S","Vectored","1","final",NA,"14+",">= 60 years","60+ years","excluded","32 weeks","death","death","death","mu",95.5,82,98.9,"Colombia","COL","South America","Latin America & Caribbean",6630,2019,"Colombia","Upper middle income",3,NA,NA,NA,NA,NA
"1175",137,"Castillo-Arregoces","Retrospective matched cohort",1217,2021-12-16,"Sinovac CoronaVac","Inactivated","2","final",NA,"14+",">= 60 years",">= 60 years","excluded","32 weeks","hospitalization","severe","severe","mu",47.3,41.9,52.3,"Colombia","COL","South America","Latin America & Caribbean",6630,2019,"Colombia","Upper middle income",3,NA,NA,NA,NA,NA
"1176",137,"Castillo-Arregoces","Retrospective matched cohort",1218,2021-12-16,"Sinovac CoronaVac","Inactivated","2","final",NA,"14+",">= 60 years","60+ years","excluded","32 weeks","post-hospitalization death","death","death","mu",72.1,70.1,73.9,"Colombia","COL","South America","Latin America & Caribbean",6630,2019,"Colombia","Upper middle income",3,NA,NA,NA,NA,NA
"1177",137,"Castillo-Arregoces","Retrospective matched cohort",1219,2021-12-16,"Sinovac CoronaVac","Inactivated","2","final",NA,"14+",">= 60 years","60+ years","excluded","32 weeks","death","death","death","mu",64.9,61.2,68.9,"Colombia","COL","South America","Latin America & Caribbean",6630,2019,"Colombia","Upper middle income",3,NA,NA,NA,NA,NA
"1178",138,"McLean","Prospective cohort",1220,2022-02-18,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"14+",">= 12 years","general pop","included","~52 weeks","infection","infection","infection","other combinations",50,21,69,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"1179",138,"McLean","Prospective cohort",1221,2022-02-18,"Moderna mRNA-1273","mRNA","2","final",NA,"14+",">= 12 years","general pop","included","~52 weeks","Infection","infection","infection","other combinations",65,37,81,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"1180",138,"McLean","Prospective cohort",1222,2022-02-18,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"14+",">= 12 years","general pop","included","~52 weeks","symptomatic disease","symptomatic","symptomatic","other combinations",54,26,71,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"1181",138,"McLean","Prospective cohort",1223,2022-02-18,"Moderna mRNA-1273","mRNA","2","final",NA,"14+",">= 12 years","general pop","included","~52 weeks","symptomatic disease","symptomatic","symptomatic","other combinations",65,38,81,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"1182",138,"McLean","Prospective cohort",1224,2022-02-18,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"14+",">= 12 years","general pop","excluded","~52 weeks","Infection","infection","infection","other combinations",51,22,70,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"1183",138,"McLean","Prospective cohort",1225,2022-02-18,"Moderna mRNA-1273","mRNA","2","final",NA,"14+",">= 12 years","general pop","excluded","~52 weeks","Infection","infection","infection","other combinations",66,38,82,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"1184",138,"McLean","Prospective cohort",1226,2022-02-18,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"14+",">= 12 years","general pop","excluded","~52 weeks","Infection","infection","infection","delta",52,20,71,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"1185",138,"McLean","Prospective cohort",1227,2022-02-18,"Moderna mRNA-1273","mRNA","2","final",NA,"14+",">= 12 years","general pop","excluded","~52 weeks","Infection","infection","infection","delta",59,24,78,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"1186",139,"Abu-Raddad","Test-negative case-control",1228,2022-01-21,"Moderna mRNA-1273","mRNA","1","1",NA,"14+",">= 18 years","general pop","excluded",NA,"Infection","infection","infection","other combinations",60.3,57,63.3,"Qatar","QAT","Asia","Middle East & North Africa",65700,2019,"Qatar","High income",4,NA,NA,NA,NA,NA
"1187",139,"Abu-Raddad","Test-negative case-control",1229,2022-01-21,"Moderna mRNA-1273","mRNA","2","final",NA,"30+",">= 18 years","general pop","excluded","~35 weeks","Infection","infection","infection","other combinations",85.3,83.5,86.9,"Qatar","QAT","Asia","Middle East & North Africa",65700,2019,"Qatar","High income",4,NA,NA,NA,NA,NA
"1188",139,"Abu-Raddad","Test-negative case-control",1230,2022-01-21,"Moderna mRNA-1273","mRNA","2","final",NA,"240+",">= 18 years","general pop","excluded","~35 weeks","Infection","infection","infection","other combinations",-29.5,-84,8.8,"Qatar","QAT","Asia","Middle East & North Africa",65700,2019,"Qatar","High income",4,NA,NA,NA,NA,NA
"1189",139,"Abu-Raddad","Test-negative case-control",1231,2022-01-21,"Moderna mRNA-1273","mRNA","1","1",NA,"14+",">= 18 years","general pop","excluded",NA,"symptomatic disease","symptomatic","symptomatic","other combinations",78.3,75.2,81.1,"Qatar","QAT","Asia","Middle East & North Africa",65700,2019,"Qatar","High income",4,NA,NA,NA,NA,NA
"1190",139,"Abu-Raddad","Test-negative case-control",1232,2022-01-21,"Moderna mRNA-1273","mRNA","2","final",NA,"30+",">= 18 years","general pop","excluded","~35 weeks","symptomatic disease","symptomatic","symptomatic","other combinations",94.4,92.8,95.6,"Qatar","QAT","Asia","Middle East & North Africa",65700,2019,"Qatar","High income",4,NA,NA,NA,NA,NA
"1191",139,"Abu-Raddad","Test-negative case-control",1233,2022-01-21,"Moderna mRNA-1273","mRNA","2","final",NA,"240+",">= 18 years","general pop","excluded","~35 weeks","symptomatic disease","symptomatic","symptomatic","other combinations",20,-29,59.3,"Qatar","QAT","Asia","Middle East & North Africa",65700,2019,"Qatar","High income",4,NA,NA,NA,NA,NA
"1192",139,"Abu-Raddad","Test-negative case-control",1234,2022-01-21,"Moderna mRNA-1273","mRNA","1","1",NA,"14+",">= 18 years","general pop","excluded",NA,"asymptomatic infection","asymptomatic","infection","other combinations",54.6,47.7,60.6,"Qatar","QAT","Asia","Middle East & North Africa",65700,2019,"Qatar","High income",4,NA,NA,NA,NA,NA
"1193",139,"Abu-Raddad","Test-negative case-control",1235,2022-01-21,"Moderna mRNA-1273","mRNA","2","final",NA,"30+",">= 18 years","general pop","excluded","~35 weeks","asymptomatic infection","asymptomatic","infection","other combinations",79.9,75.5,83.4,"Qatar","QAT","Asia","Middle East & North Africa",65700,2019,"Qatar","High income",4,NA,NA,NA,NA,NA
"1194",139,"Abu-Raddad","Test-negative case-control",1236,2022-01-21,"Moderna mRNA-1273","mRNA","2","final",NA,"240+",">= 18 years","general pop","excluded","~35 weeks","asymptomatic infection","asymptomatic","infection","other combinations",-28.4,-129.3,28.1,"Qatar","QAT","Asia","Middle East & North Africa",65700,2019,"Qatar","High income",4,NA,NA,NA,NA,NA
"1195",139,"Abu-Raddad","Test-negative case-control",1237,2022-01-21,"Moderna mRNA-1273","mRNA","1","1",NA,"14+",">= 18 years","general pop","excluded",NA,"hospitalization or death","severe","severe","other combinations",82.1,73.1,88.1,"Qatar","QAT","Asia","Middle East & North Africa",65700,2019,"Qatar","High income",4,NA,NA,NA,NA,NA
"1196",139,"Abu-Raddad","Test-negative case-control",1238,2022-01-21,"Moderna mRNA-1273","mRNA","2","final",NA,"30+",">= 18 years","general pop","excluded","~35 weeks","hospitalization or death","severe","severe","other combinations",97.2,92.4,99,"Qatar","QAT","Asia","Middle East & North Africa",65700,2019,"Qatar","High income",4,NA,NA,NA,NA,NA
"1197",139,"Abu-Raddad","Test-negative case-control",1239,2022-01-21,"Moderna mRNA-1273","mRNA","2","final",NA,"180+",">= 18 years","general pop","excluded","~35 weeks","hospitalization or death","severe","severe","other combinations",61,-225.5,95.3,"Qatar","QAT","Asia","Middle East & North Africa",65700,2019,"Qatar","High income",4,NA,NA,NA,NA,NA
"1198",140,"Bekker","Retrospective matched cohort",1240,2022-03-19,"Janssen Ad26.COV2.S","Vectored","1","final",NA,"28+","HCW","HCW","included","12 weeks","hospitalization","severe","severe","other combinations",67,62,71,"South Africa","ZAF","Africa","Sub-Saharan Africa",6570,2019,"South Africa","Upper middle income",3,NA,NA,NA,NA,NA
"1199",140,"Bekker","Retrospective matched cohort",1241,2022-03-19,"Janssen Ad26.COV2.S","Vectored","1","final",NA,"28+","HCW","HCW","included","12 weeks","ICU admission","severe","severe","other combinations",75,69,82,"South Africa","ZAF","Africa","Sub-Saharan Africa",6570,2019,"South Africa","Upper middle income",3,NA,NA,NA,NA,NA
"1200",140,"Bekker","Retrospective matched cohort",1242,2022-03-19,"Janssen Ad26.COV2.S","Vectored","1","final",NA,"28+","HCW","HCW","included","12 weeks","death","death","death","other combinations",83,75,89,"South Africa","ZAF","Africa","Sub-Saharan Africa",6570,2019,"South Africa","Upper middle income",3,NA,NA,NA,NA,NA
"1201",140,"Bekker","Retrospective matched cohort",1243,2022-03-19,"Janssen Ad26.COV2.S","Vectored","1","final",NA,"28+","HCW","HCW","included","12 weeks","hospitalization","severe","severe","beta",62,42,76,"South Africa","ZAF","Africa","Sub-Saharan Africa",6570,2019,"South Africa","Upper middle income",3,NA,NA,NA,NA,NA
"1202",140,"Bekker","Retrospective matched cohort",1244,2022-03-19,"Janssen Ad26.COV2.S","Vectored","1","final",NA,"28+","HCW","HCW","included","12 weeks","ICU admission","severe","severe","beta",49,8,77,"South Africa","ZAF","Africa","Sub-Saharan Africa",6570,2019,"South Africa","Upper middle income",3,NA,NA,NA,NA,NA
"1203",140,"Bekker","Retrospective matched cohort",1245,2022-03-19,"Janssen Ad26.COV2.S","Vectored","1","final",NA,"28+","HCW","HCW","included","12 weeks","death","death","death","beta",86,57,100,"South Africa","ZAF","Africa","Sub-Saharan Africa",6570,2019,"South Africa","Upper middle income",3,NA,NA,NA,NA,NA
"1204",140,"Bekker","Retrospective matched cohort",1246,2022-03-19,"Janssen Ad26.COV2.S","Vectored","1","final",NA,"28+","HCW","HCW","included","12 weeks","hospitalization","severe","severe","delta",67,62,71,"South Africa","ZAF","Africa","Sub-Saharan Africa",6570,2019,"South Africa","Upper middle income",3,NA,NA,NA,NA,NA
"1205",140,"Bekker","Retrospective matched cohort",1247,2022-03-19,"Janssen Ad26.COV2.S","Vectored","1","final",NA,"28+","HCW","HCW","included","12 weeks","ICU admission","severe","severe","delta",78,71,88,"South Africa","ZAF","Africa","Sub-Saharan Africa",6570,2019,"South Africa","Upper middle income",3,NA,NA,NA,NA,NA
"1206",140,"Bekker","Retrospective matched cohort",1248,2022-03-19,"Janssen Ad26.COV2.S","Vectored","1","final",NA,"28+","HCW","HCW","included","12 weeks","death","death","death","delta",82,74,89,"South Africa","ZAF","Africa","Sub-Saharan Africa",6570,2019,"South Africa","Upper middle income",3,NA,NA,NA,NA,NA
"1207",141,"Tartof","Retrospective matched cohort",1249,2022-02-14,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"7-36",">= 18 years","general pop","included","~48 weeks","Infection","infection","infection","other combinations",85,83,86,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"1208",141,"Tartof","Retrospective matched cohort",1250,2022-02-14,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"217+",">= 18 years","general pop","included","~48 weeks","Infection","infection","infection","other combinations",49,46,51,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"1209",141,"Tartof","Retrospective matched cohort",1251,2022-02-14,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"7-36",">= 18 years","general pop","included","~48 weeks","hospitalization","severe","severe","other combinations",90,86,92,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"1210",141,"Tartof","Retrospective matched cohort",1252,2022-02-14,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"217+",">= 18 years","general pop","included","~48 weeks","hospitalization","severe","severe","other combinations",88,85,90,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"1211",142,"Lewis","Test-negative case-control",1253,2021-12-21,"Multiple or heterologous RNA","mRNA","2","final",NA,"14+",">= 18 years","general pop","included","~30 weeks","hospitalization","severe","severe","other combinations",96,93,98,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"1212",142,"Lewis","Test-negative case-control",1254,2021-12-21,"Multiple or heterologous RNA","mRNA","2","final",NA,"14+",">= 18 years","general pop","included","~30 weeks","hospitalization","severe","severe","other combinations",93,89,95,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"1213",142,"Lewis","Test-negative case-control",1255,2021-12-21,"Multiple or heterologous RNA","mRNA","2","final",NA,"14+",">= 18 years","general pop","included","~30 weeks","hospitalization","severe","severe","other combinations",87,82,91,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"1214",142,"Lewis","Test-negative case-control",1256,2021-12-21,"Multiple or heterologous RNA","mRNA","2","final",NA,"14+",">= 18 years","general pop","included","~30 weeks","hospitalization","severe","severe","other combinations",83,72,88,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"1215",143,"Ioannou","Target trial emulation",1257,2021-12-21,"Multiple or heterologous RNA","mRNA","1","1",NA,"14+",">= 18 years","general pop","excluded",NA,"infection (March 31 2021)","infection","infection","other combinations",31,26,35,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"1216",143,"Ioannou","Target trial emulation",1258,2021-12-21,"Multiple or heterologous RNA","mRNA","2","final",NA,"7+",">= 18 years","general pop","excluded","~28 weeks","infection (March 31 2021)","infection","infection","other combinations",65,63,68,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"1217",143,"Ioannou","Target trial emulation",1259,2021-12-21,"Multiple or heterologous RNA","mRNA","2","final",NA,"7+",">= 18 years","general pop","excluded","~28 weeks","infection (June 30 2021)","infection","infection","other combinations",69,67,70,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"1218",143,"Ioannou","Target trial emulation",1260,2021-12-21,"Multiple or heterologous RNA","mRNA","1","1",NA,"14+",">= 18 years","general pop","excluded",NA,"death (March 31 2021)","death","death","other combinations",55,42,64,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"1219",143,"Ioannou","Target trial emulation",1261,2021-12-21,"Multiple or heterologous RNA","mRNA","2","final",NA,"7+",">= 18 years","general pop","excluded","~28 weeks","death (March 31 2021)","death","death","other combinations",89,84,92,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"1220",143,"Ioannou","Target trial emulation",1262,2021-12-21,"Multiple or heterologous RNA","mRNA","2","final",NA,"7+",">= 18 years","general pop","excluded","~28 weeks","death (June 30 2021)","death","death","other combinations",86,82,89,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"1221",144,"Hansen","Retrospective cohort",1263,2021-12-23,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"15-44",">= 12 years","general pop","excluded","21 weeks","Infection","infection","infection","omicron",55.2,23.5,73.7,"Denmark","DNK","Europe","Europe & Central Asia",63020,2019,"Denmark","High income",4,NA,NA,NA,NA,NA
"1222",144,"Hansen","Retrospective cohort",1264,2021-12-23,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"105-164",">= 12 years","general pop","excluded","22 weeks","Infection","infection","infection","omicron",-76.5,-95.3,-59.5,"Denmark","DNK","Europe","Europe & Central Asia",63020,2019,"Denmark","High income",4,NA,NA,NA,NA,NA
"1223",144,"Hansen","Retrospective cohort",1265,2021-12-23,"Moderna mRNA-1273","mRNA","2","final",NA,"15-44",">= 12 years","general pop","excluded","23 weeks","Infection","infection","infection","omicron",36.7,-69.9,76.4,"Denmark","DNK","Europe","Europe & Central Asia",63020,2019,"Denmark","High income",4,NA,NA,NA,NA,NA
"1224",144,"Hansen","Retrospective cohort",1266,2021-12-23,"Moderna mRNA-1273","mRNA","2","final",NA,"105-164",">= 12 years","general pop","excluded","24 weeks","Infection","infection","infection","omicron",-39.3,-61.6,-20,"Denmark","DNK","Europe","Europe & Central Asia",63020,2019,"Denmark","High income",4,NA,NA,NA,NA,NA
"1225",144,"Hansen","Retrospective cohort",1267,2021-12-23,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"15-44",">= 12 years","general pop","excluded","25 weeks","Infection","infection","infection","delta",86.7,84.6,88.6,"Denmark","DNK","Europe","Europe & Central Asia",63020,2019,"Denmark","High income",4,NA,NA,NA,NA,NA
"1226",144,"Hansen","Retrospective cohort",1268,2021-12-23,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"105-164",">= 12 years","general pop","excluded","26 weeks","Infection","infection","infection","delta",53.8,52.9,54.6,"Denmark","DNK","Europe","Europe & Central Asia",63020,2019,"Denmark","High income",4,NA,NA,NA,NA,NA
"1227",144,"Hansen","Retrospective cohort",1269,2021-12-23,"Moderna mRNA-1273","mRNA","2","final",NA,"15-44",">= 12 years","general pop","excluded","27 weeks","Infection","infection","infection","delta",88.2,83.1,91.8,"Denmark","DNK","Europe","Europe & Central Asia",63020,2019,"Denmark","High income",4,NA,NA,NA,NA,NA
"1228",144,"Hansen","Retrospective cohort",1270,2021-12-23,"Moderna mRNA-1273","mRNA","2","final",NA,"105-164",">= 12 years","general pop","excluded","28 weeks","Infection","infection","infection","delta",65,63.6,66.3,"Denmark","DNK","Europe","Europe & Central Asia",63020,2019,"Denmark","High income",4,NA,NA,NA,NA,NA
"1229",146,"Katikireddi","Retrospective cohort",1281,2021-12-20,"Oxford/AstraZeneca ChAdOx1-S","Vectored","2","final",NA,"14-27",">= 18 years","general pop","excluded","~20 weeks","severe disease","severe","severe","delta",83.7,79.7,87,"UK","GBR","Europe","Europe & Central Asia",43240,2019,"United Kingdom","High income",4,14,27,"yes",NA,0
"1230",146,"Katikireddi","Retrospective cohort",1282,2021-12-20,"Oxford/AstraZeneca ChAdOx1-S","Vectored","2","final",NA,"140-153",">= 18 years","general pop","excluded","~20 weeks","severe disease","severe","severe","delta",53.6,48.4,58.3,"UK","GBR","Europe","Europe & Central Asia",43240,2019,"United Kingdom","High income",4,140,153,"no","sequential period",0
"1231",147,"Amir","Quasi-experimental",1283,2021-12-21,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"14-60","12-14 years","12-14 years","excluded","~6.5 weeks","Infection","infection","infection","delta",92,91.1,92.8,"Israel","ISR","Asia","Middle East & North Africa",43800,2019,"Israel","High income",4,NA,NA,NA,NA,NA
"1232",147,"Amir","Quasi-experimental",1284,2021-12-21,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"14-60","16-18 years","16-18 years","excluded","~6.5 weeks","Infection","infection","infection","delta",89.8,80,93.8,"Israel","ISR","Asia","Middle East & North Africa",43800,2019,"Israel","High income",4,NA,NA,NA,NA,NA
"1233",148,"Ostropolets","Retrospective cohort",1285,2022-08-23,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"14+",">= 18 years","general pop","excluded","52 weeks","Infection","infection","infection","other combinations",94,91,95,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"1234",148,"Ostropolets","Retrospective cohort",1286,2022-08-23,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"14+",">= 18 years","general pop","excluded","52 weeks","Hospitalization","severe","severe","other combinations",95,92,97,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"1235",148,"Ostropolets","Retrospective cohort",1287,2022-08-23,"Moderna mRNA-1273","mRNA","2","final",NA,"14+",">= 18 years","general pop","excluded","52 weeks","infection","infection","infection","other combinations",97,94,98,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"1236",148,"Ostropolets","Retrospective cohort",1288,2022-08-23,"Moderna mRNA-1273","mRNA","2","final",NA,"14+",">= 18 years","general pop","excluded","52 weeks","Hospitalization","severe","severe","other combinations",96,92,99,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"1237",148,"Ostropolets","Retrospective cohort",1289,2022-08-23,"Janssen Ad26.COV2.S","Vectored","1","final",NA,"14+",">= 18 years","general pop","excluded","52 weeks","Infection","infection","infection","other combinations",81,50,94,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"1238",148,"Ostropolets","Retrospective cohort",1290,2022-08-23,"Janssen Ad26.COV2.S","Vectored","1","final",NA,"14+",">= 18 years","general pop","excluded","52 weeks","hospitalization","severe","severe","other combinations",92,58,100,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"1239",149,"Alali","Retrospective cohort",1291,2021-12-07,"BioNTech/Pfizer BNT162b2","mRNA","1","1",NA,"14+","HCW","HCW","excluded",NA,"symptomatic disease","symptomatic","symptomatic","alpha",91.4,65.1,97.9,"Kuwait","KWT","Asia","Middle East & North Africa",35680,2019,"Kuwait","High income",4,NA,NA,NA,NA,NA
"1240",149,"Alali","Retrospective cohort",1292,2021-12-07,"Oxford/AstraZeneca ChAdOx1-S","Vectored","1","1",NA,"28+","HCW","HCW","excluded",NA,"symptomatic disease","symptomatic","symptomatic","alpha",75.4,67.2,81.6,"Kuwait","KWT","Asia","Middle East & North Africa",35680,2019,"Kuwait","High income",4,NA,NA,NA,NA,NA
"1241",149,"Alali","Retrospective cohort",1293,2021-12-07,"Oxford/AstraZeneca ChAdOx1-S","Vectored","2","final",NA,"14+","HCW","HCW","excluded","~20 weeks","symptomatic disease","symptomatic","symptomatic","alpha",94.5,89.4,97.2,"Kuwait","KWT","Asia","Middle East & North Africa",35680,2019,"Kuwait","High income",4,NA,NA,NA,NA,NA
"1242",150,"Mendola","Retrospective cohort",1294,2021-12-23,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"8-98","HCW","HCW","excluded","~12 weeks","infection","infection","infection","alpha",89,78,95,"Italy","ITA","Europe","Europe & Central Asia",34890,2019,"Italy","High income",4,NA,NA,NA,NA,NA
"1243",151,"Collie","Test-negative case-control",1295,2021-12-29,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"14+",">= 18 years","general pop","included","~24 weeks","Hospitalization","severe","severe","omicron",70,62,76,"South Africa","ZAF","Africa","Sub-Saharan Africa",6570,2019,"South Africa","Upper middle income",3,14,168,"yes",NA,0
"1244",151,"Collie","Test-negative case-control",1296,2021-12-29,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"14+",">= 18 years","general pop","included","~19 weeks","Hospitalization","severe","severe","delta",93,90,94,"South Africa","ZAF","Africa","Sub-Saharan Africa",6570,2019,"South Africa","Upper middle income",3,14,133,"yes",NA,0
"1245",152,"Lutrick","Prospective cohort",1297,2021-12-31,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"14+","12-17 years","12-17 years","excluded","~17 weeks","infection","infection","infection","delta",92,79,97,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"1246",153,"Chung","Test-negative case-control",1298,2022-01-01,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"14+",">= 12 years","general pop","included","~34 weeks","symptomatic disease","symptomatic","symptomatic","other combinations",66,56,73,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"1247",153,"Chung","Test-negative case-control",1299,2022-01-01,"Moderna mRNA-1273","mRNA","2","final",NA,"14+",">= 12 years","general pop","included","~34 weeks","symptomatic disease","symptomatic","symptomatic","other combinations",81,73,86,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"1248",155,"Cerqueira-Silva","Test-negative case-control",1300,2022-03-31,"Sinovac CoronaVac","Inactivated","1","1",NA,"14+",">= 18 years with prior SARS-CoV-2 infection","general pop with prior SARS-CoV-2 infection","confirmed prior infection",NA,"symptomatic reinfection","symptomatic","symptomatic","other combinations",18.8,10.7,26.1,"Brazil","BRA","South America","Latin America & Caribbean",9410,2019,"Brazil","Upper middle income",3,NA,NA,NA,NA,NA
"1249",155,"Cerqueira-Silva","Test-negative case-control",1301,2022-03-31,"Sinovac CoronaVac","Inactivated","2","final",NA,"14+",">= 18 years with prior SARS-CoV-2 infection","general pop with prior SARS-CoV-2 infection","confirmed prior infection","~37 weeks","symptomatic reinfection","symptomatic","symptomatic","other combinations",39.4,36.1,42.6,"Brazil","BRA","South America","Latin America & Caribbean",9410,2019,"Brazil","Upper middle income",3,NA,NA,NA,NA,NA
"1250",155,"Cerqueira-Silva","Test-negative case-control",1302,2022-03-31,"Sinovac CoronaVac","Inactivated","2","final",NA,"14-90",">= 18 years with prior SARS-CoV-2 infection","general pop with prior SARS-CoV-2 infection","confirmed prior infection","~11 weeks","symptomatic reinfection","symptomatic","symptomatic","other combinations",40.5,36.4,44.3,"Brazil","BRA","South America","Latin America & Caribbean",9410,2019,"Brazil","Upper middle income",3,NA,NA,NA,NA,NA
"1251",155,"Cerqueira-Silva","Test-negative case-control",1303,2022-03-31,"Sinovac CoronaVac","Inactivated","2","final",NA,"90+",">= 18 years with prior SARS-CoV-2 infection","general pop with prior SARS-CoV-2 infection","confirmed prior infection","~37 weeks","symptomatic reinfection","symptomatic","symptomatic","other combinations",38,33.1,42.5,"Brazil","BRA","South America","Latin America & Caribbean",9410,2019,"Brazil","Upper middle income",3,NA,NA,NA,NA,NA
"1252",155,"Cerqueira-Silva","Test-negative case-control",1304,2022-03-31,"Sinovac CoronaVac","Inactivated","1","1",NA,"14+",">= 18 years with prior SARS-CoV-2 infection","general pop with prior SARS-CoV-2 infection","confirmed prior infection",NA,"hospitalization or death","severe","severe","other combinations",35.3,7.9,54.5,"Brazil","BRA","South America","Latin America & Caribbean",9410,2019,"Brazil","Upper middle income",3,NA,NA,NA,NA,NA
"1253",155,"Cerqueira-Silva","Test-negative case-control",1305,2022-03-31,"Sinovac CoronaVac","Inactivated","2","final",NA,"14+",">= 18 years with prior SARS-CoV-2 infection","general pop with prior SARS-CoV-2 infection","confirmed prior infection","~37 weeks","hospitalization or death","severe","severe","other combinations",81.3,75.3,85.8,"Brazil","BRA","South America","Latin America & Caribbean",9410,2019,"Brazil","Upper middle income",3,NA,NA,NA,NA,NA
"1254",155,"Cerqueira-Silva","Test-negative case-control",1306,2022-03-31,"Sinovac CoronaVac","Inactivated","2","final",NA,"14-90",">= 18 years with prior SARS-CoV-2 infection","general pop with prior SARS-CoV-2 infection","confirmed prior infection","~11 weeks","hospitalization or death","severe","severe","other combinations",86.6,79.8,90.3,"Brazil","BRA","South America","Latin America & Caribbean",9410,2019,"Brazil","Upper middle income",3,NA,NA,NA,NA,NA
"1255",155,"Cerqueira-Silva","Test-negative case-control",1307,2022-03-31,"Sinovac CoronaVac","Inactivated","2","final",NA,"90+",">= 18 years with prior SARS-CoV-2 infection","general pop with prior SARS-CoV-2 infection","confirmed prior infection","~37 weeks","hospitalization or death","severe","severe","other combinations",74.4,63.3,82.2,"Brazil","BRA","South America","Latin America & Caribbean",9410,2019,"Brazil","Upper middle income",3,NA,NA,NA,NA,NA
"1256",155,"Cerqueira-Silva","Test-negative case-control",1308,2022-03-31,"Oxford/AstraZeneca ChAdOx1-S","Vectored","1","1",NA,"14+",">= 18 years with prior SARS-CoV-2 infection","general pop with prior SARS-CoV-2 infection","confirmed prior infection",NA,"symptomatic reinfection","symptomatic","symptomatic","other combinations",34.2,30.1,38.1,"Brazil","BRA","South America","Latin America & Caribbean",9410,2019,"Brazil","Upper middle income",3,NA,NA,NA,NA,NA
"1257",155,"Cerqueira-Silva","Test-negative case-control",1309,2022-03-31,"Oxford/AstraZeneca ChAdOx1-S","Vectored","2","final",NA,"14+",">= 18 years with prior SARS-CoV-2 infection","general pop with prior SARS-CoV-2 infection","confirmed prior infection","~37 weeks","symptomatic reinfection","symptomatic","symptomatic","other combinations",56,51.4,60.2,"Brazil","BRA","South America","Latin America & Caribbean",9410,2019,"Brazil","Upper middle income",3,NA,NA,NA,NA,NA
"1258",155,"Cerqueira-Silva","Test-negative case-control",1310,2022-03-31,"Oxford/AstraZeneca ChAdOx1-S","Vectored","2","final",NA,"14-90",">= 18 years with prior SARS-CoV-2 infection","general pop with prior SARS-CoV-2 infection","confirmed prior infection","~11 weeks","symptomatic reinfection","symptomatic","symptomatic","other combinations",55.5,50.5,60.1,"Brazil","BRA","South America","Latin America & Caribbean",9410,2019,"Brazil","Upper middle income",3,NA,NA,NA,NA,NA
"1259",155,"Cerqueira-Silva","Test-negative case-control",1311,2022-03-31,"Oxford/AstraZeneca ChAdOx1-S","Vectored","2","final",NA,"90+",">= 18 years with prior SARS-CoV-2 infection","general pop with prior SARS-CoV-2 infection","confirmed prior infection","~37 weeks","symptomatic reinfection","symptomatic","symptomatic","other combinations",56.8,46.6,65.1,"Brazil","BRA","South America","Latin America & Caribbean",9410,2019,"Brazil","Upper middle income",3,NA,NA,NA,NA,NA
"1260",155,"Cerqueira-Silva","Test-negative case-control",1312,2022-03-31,"Oxford/AstraZeneca ChAdOx1-S","Vectored","1","1",NA,"14+",">= 18 years with prior SARS-CoV-2 infection","general pop with prior SARS-CoV-2 infection","confirmed prior infection",NA,"hospitalization or death","severe","severe","other combinations",56.9,45.2,66.1,"Brazil","BRA","South America","Latin America & Caribbean",9410,2019,"Brazil","Upper middle income",3,NA,NA,NA,NA,NA
"1261",155,"Cerqueira-Silva","Test-negative case-control",1313,2022-03-31,"Oxford/AstraZeneca ChAdOx1-S","Vectored","2","final",NA,"14+",">= 18 years with prior SARS-CoV-2 infection","general pop with prior SARS-CoV-2 infection","confirmed prior infection","~37 weeks","hospitalization or death","severe","severe","other combinations",89.9,83.5,93.8,"Brazil","BRA","South America","Latin America & Caribbean",9410,2019,"Brazil","Upper middle income",3,NA,NA,NA,NA,NA
"1262",155,"Cerqueira-Silva","Test-negative case-control",1314,2022-03-31,"Oxford/AstraZeneca ChAdOx1-S","Vectored","2","final",NA,"14-90",">= 18 years with prior SARS-CoV-2 infection","general pop with prior SARS-CoV-2 infection","confirmed prior infection","~11 weeks","hospitalization or death","severe","severe","other combinations",86.6,77.6,92,"Brazil","BRA","South America","Latin America & Caribbean",9410,2019,"Brazil","Upper middle income",3,NA,NA,NA,NA,NA
"1263",155,"Cerqueira-Silva","Test-negative case-control",1315,2022-03-31,"Oxford/AstraZeneca ChAdOx1-S","Vectored","2","final",NA,"90+",">= 18 years with prior SARS-CoV-2 infection","general pop with prior SARS-CoV-2 infection","confirmed prior infection","~37 weeks","hospitalization or death","severe","severe","other combinations",95.1,84.8,98.4,"Brazil","BRA","South America","Latin America & Caribbean",9410,2019,"Brazil","Upper middle income",3,NA,NA,NA,NA,NA
"1264",155,"Cerqueira-Silva","Test-negative case-control",1316,2022-03-31,"BioNTech/Pfizer BNT162b2","mRNA","1","1",NA,"14+",">= 18 years with prior SARS-CoV-2 infection","general pop with prior SARS-CoV-2 infection","confirmed prior infection",NA,"symptomatic reinfection","symptomatic","symptomatic","other combinations",45,39.7,49.9,"Brazil","BRA","South America","Latin America & Caribbean",9410,2019,"Brazil","Upper middle income",3,NA,NA,NA,NA,NA
"1265",155,"Cerqueira-Silva","Test-negative case-control",1317,2022-03-31,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"14+",">= 18 years with prior SARS-CoV-2 infection","general pop with prior SARS-CoV-2 infection","confirmed prior infection","~37 weeks","symptomatic reinfection","symptomatic","symptomatic","other combinations",64.8,54.9,72.4,"Brazil","BRA","South America","Latin America & Caribbean",9410,2019,"Brazil","Upper middle income",3,NA,NA,NA,NA,NA
"1266",155,"Cerqueira-Silva","Test-negative case-control",1318,2022-03-31,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"14-90",">= 18 years with prior SARS-CoV-2 infection","general pop with prior SARS-CoV-2 infection","confirmed prior infection","~11 weeks","symptomatic reinfection","symptomatic","symptomatic","other combinations",64.2,54.2,72,"Brazil","BRA","South America","Latin America & Caribbean",9410,2019,"Brazil","Upper middle income",3,NA,NA,NA,NA,NA
"1267",155,"Cerqueira-Silva","Test-negative case-control",1319,2022-03-31,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"90+",">= 18 years with prior SARS-CoV-2 infection","general pop with prior SARS-CoV-2 infection","confirmed prior infection","~37 weeks","symptomatic reinfection","symptomatic","symptomatic","other combinations",100,NA,NA,"Brazil","BRA","South America","Latin America & Caribbean",9410,2019,"Brazil","Upper middle income",3,NA,NA,NA,NA,NA
"1268",155,"Cerqueira-Silva","Test-negative case-control",1320,2022-03-31,"BioNTech/Pfizer BNT162b2","mRNA","1","1",NA,"14+",">= 18 years with prior SARS-CoV-2 infection","general pop with prior SARS-CoV-2 infection","confirmed prior infection",NA,"hospitalization or death","severe","severe","other combinations",61.8,40.8,75.3,"Brazil","BRA","South America","Latin America & Caribbean",9410,2019,"Brazil","Upper middle income",3,NA,NA,NA,NA,NA
"1269",155,"Cerqueira-Silva","Test-negative case-control",1321,2022-03-31,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"14+",">= 18 years with prior SARS-CoV-2 infection","general pop with prior SARS-CoV-2 infection","confirmed prior infection","~37 weeks","hospitalization or death","severe","severe","other combinations",89.7,54.3,97.7,"Brazil","BRA","South America","Latin America & Caribbean",9410,2019,"Brazil","Upper middle income",3,NA,NA,NA,NA,NA
"1270",155,"Cerqueira-Silva","Test-negative case-control",1322,2022-03-31,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"14-90",">= 18 years with prior SARS-CoV-2 infection","general pop with prior SARS-CoV-2 infection","confirmed prior infection","~11 weeks","hospitalization or death","severe","severe","other combinations",88.8,50,97.5,"Brazil","BRA","South America","Latin America & Caribbean",9410,2019,"Brazil","Upper middle income",3,NA,NA,NA,NA,NA
"1271",155,"Cerqueira-Silva","Test-negative case-control",1323,2022-03-31,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"90+",">= 18 years with prior SARS-CoV-2 infection","general pop with prior SARS-CoV-2 infection","confirmed prior infection","~37 weeks","hospitalization or death","severe","severe","other combinations",100,NA,NA,"Brazil","BRA","South America","Latin America & Caribbean",9410,2019,"Brazil","Upper middle income",3,NA,NA,NA,NA,NA
"1272",155,"Cerqueira-Silva","Test-negative case-control",1324,2022-03-31,"Janssen Ad26.COV2.S","Vectored","1","final",NA,"14+",">= 18 years with prior SARS-CoV-2 infection","general pop with prior SARS-CoV-2 infection","confirmed prior infection","~37 weeks","symptomatic reinfection","symptomatic","symptomatic","other combinations",44,31.5,54.2,"Brazil","BRA","South America","Latin America & Caribbean",9410,2019,"Brazil","Upper middle income",3,NA,NA,NA,NA,NA
"1273",155,"Cerqueira-Silva","Test-negative case-control",1325,2022-03-31,"Janssen Ad26.COV2.S","Vectored","1","final",NA,"14-90",">= 18 years with prior SARS-CoV-2 infection","general pop with prior SARS-CoV-2 infection","confirmed prior infection","~11 weeks","symptomatic reinfection","symptomatic","symptomatic","other combinations",46.1,32.7,56.7,"Brazil","BRA","South America","Latin America & Caribbean",9410,2019,"Brazil","Upper middle income",3,NA,NA,NA,NA,NA
"1274",155,"Cerqueira-Silva","Test-negative case-control",1326,2022-03-31,"Janssen Ad26.COV2.S","Vectored","1","final",NA,"90+",">= 18 years with prior SARS-CoV-2 infection","general pop with prior SARS-CoV-2 infection","confirmed prior infection","~37 weeks","symptomatic reinfection","symptomatic","symptomatic","other combinations",30.6,-12.4,57.1,"Brazil","BRA","South America","Latin America & Caribbean",9410,2019,"Brazil","Upper middle income",3,NA,NA,NA,NA,NA
"1275",155,"Cerqueira-Silva","Test-negative case-control",1327,2022-03-31,"Janssen Ad26.COV2.S","Vectored","1","final",NA,"14+",">= 18 years with prior SARS-CoV-2 infection","general pop with prior SARS-CoV-2 infection","confirmed prior infection","~37 weeks","hospitalization or death","severe","severe","other combinations",57.7,-2.6,82.5,"Brazil","BRA","South America","Latin America & Caribbean",9410,2019,"Brazil","Upper middle income",3,NA,NA,NA,NA,NA
"1276",155,"Cerqueira-Silva","Test-negative case-control",1328,2022-03-31,"Janssen Ad26.COV2.S","Vectored","1","final",NA,"14-90",">= 18 years with prior SARS-CoV-2 infection","general pop with prior SARS-CoV-2 infection","confirmed prior infection","~11 weeks","hospitalization or death","severe","severe","other combinations",60.2,-10.8,85.7,"Brazil","BRA","South America","Latin America & Caribbean",9410,2019,"Brazil","Upper middle income",3,NA,NA,NA,NA,NA
"1277",155,"Cerqueira-Silva","Test-negative case-control",1329,2022-03-31,"Janssen Ad26.COV2.S","Vectored","1","final",NA,"90+",">= 18 years with prior SARS-CoV-2 infection","general pop with prior SARS-CoV-2 infection","confirmed prior infection","~37 weeks","hospitalization or death","severe","severe","other combinations",41,-240.9,89.9,"Brazil","BRA","South America","Latin America & Caribbean",9410,2019,"Brazil","Upper middle income",3,NA,NA,NA,NA,NA
"1278",156,"Petra","Retrospective cohort",1330,2021-12-22,"BioNTech/Pfizer BNT162b2","mRNA","1","1",NA,"14+","HCW","HCW","excluded",NA,"infection","infection","infection","other combinations",47.7,19.2,66.2,"Czech Republic","CZE","Europe","Europe & Central Asia",22100,2019,"Czechia","High income",3,NA,NA,NA,NA,NA
"1279",156,"Petra","Retrospective cohort",1331,2021-12-22,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"14+","HCW","HCW","excluded","~30 weeks","Infection","infection","infection","other combinations",88.3,83.2,91.8,"Czech Republic","CZE","Europe","Europe & Central Asia",22100,2019,"Czechia","High income",3,NA,NA,NA,NA,NA
"1280",156,"Petra","Retrospective cohort",1332,2021-12-22,"BioNTech/Pfizer BNT162b2","mRNA","1","1",NA,"14+","HCW","HCW","excluded",NA,"symptomatic disease","symptomatic","symptomatic","other combinations",76.4,46,89.7,"Czech Republic","CZE","Europe","Europe & Central Asia",22100,2019,"Czechia","High income",3,NA,NA,NA,NA,NA
"1281",156,"Petra","Retrospective cohort",1333,2021-12-22,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"14+","HCW","HCW","excluded","~30 weeks","symptomatic disease","symptomatic","symptomatic","other combinations",91.7,85.7,95.2,"Czech Republic","CZE","Europe","Europe & Central Asia",22100,2019,"Czechia","High income",3,NA,NA,NA,NA,NA
"1282",156,"Petra","Retrospective cohort",1334,2021-12-22,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"14+","HCW","HCW","excluded","4 weeks","infection (February 2021)","infection","infection","other combinations",96.2,91.6,98.7,"Czech Republic","CZE","Europe","Europe & Central Asia",22100,2019,"Czechia","High income",3,NA,NA,NA,NA,NA
"1283",156,"Petra","Retrospective cohort",1335,2021-12-22,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"14+","HCW","HCW","excluded","~30 weeks","infection (June-August 2021)","infection","infection","other combinations",65,NA,96.6,"Czech Republic","CZE","Europe","Europe & Central Asia",22100,2019,"Czechia","High income",3,NA,NA,NA,NA,NA
"1284",157,"Prunas","Matched case-control",1336,2022-12-09,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"14-89","12-16 years","12-16 years","excluded","~25 weeks","Infection","infection","infection","delta",85,84,86,"Israel","ISR","Asia","Middle East & North Africa",43800,2019,"Israel","High income",4,NA,NA,NA,NA,NA
"1285",157,"Prunas","Matched case-control",1337,2022-12-09,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"150-180","12-16 years","12-16 years","excluded","~25 weeks","Infection","infection","infection","delta",53,46,60,"Israel","ISR","Asia","Middle East & North Africa",43800,2019,"Israel","High income",4,NA,NA,NA,NA,NA
"1286",157,"Prunas","Matched case-control",1338,2022-12-09,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"14-89","12-16 years","12-16 years","excluded","~25 weeks","symptomatic disease","symptomatic","symptomatic","delta",90,89,91,"Israel","ISR","Asia","Middle East & North Africa",43800,2019,"Israel","High income",4,NA,NA,NA,NA,NA
"1287",157,"Prunas","Matched case-control",1339,2022-12-09,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"150-180","12-16 years","12-16 years","excluded","~25 weeks","symptomatic disease","symptomatic","symptomatic","delta",66,59,72,"Israel","ISR","Asia","Middle East & North Africa",43800,2019,"Israel","High income",4,NA,NA,NA,NA,NA
"1288",157,"Prunas","Test-negative case-control",1340,2022-12-09,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"14-89","12-16 years","12-16 years","excluded","~25 weeks","Infection","infection","infection","delta",84,82,85,"Israel","ISR","Asia","Middle East & North Africa",43800,2019,"Israel","High income",4,NA,NA,NA,NA,NA
"1289",157,"Prunas","Test-negative case-control",1341,2022-12-09,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"150-180","12-16 years","12-16 years","excluded","~25 weeks","Infection","infection","infection","delta",50,43,57,"Israel","ISR","Asia","Middle East & North Africa",43800,2019,"Israel","High income",4,NA,NA,NA,NA,NA
"1290",158,"Zambrano","Test-negative case-control",1342,2022-01-07,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"14+","12-18 years","12-18 years","included","~23 weeks","MIS-C","MIS-C","severe","delta",86,70,93,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"1291",158,"Zambrano","Test-negative case-control",1343,2022-01-07,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"28+","12-18 years","12-18 years","included","~23 weeks","MIS-C","MIS-C","severe","delta",91,78,97,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"1292",158,"Zambrano","Test-negative case-control",1344,2022-01-07,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"28+","12-18 years","12-18 years","excluded","~23 weeks","MIS-C","MIS-C","severe","delta",90,75,96,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"1293",159,"Tseng","Test-negative case-control",1345,2022-02-21,"Moderna mRNA-1273","mRNA","1","1",NA,"14+",">= 18 years","general pop","included",NA,"Infection","infection","infection","omicron",20.4,9.5,30,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"1294",159,"Tseng","Test-negative case-control",1346,2022-02-21,"Moderna mRNA-1273","mRNA","2","final",NA,"14+",">= 18 years","general pop","included","~47.5 weeks","Infection","infection","infection","omicron",13.9,10.5,17.1,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"1295",159,"Tseng","Test-negative case-control",1347,2022-02-21,"Moderna mRNA-1273","mRNA","2","final",NA,"14-90",">= 18 years","general pop","included","~11 weeks","Infection","infection","infection","omicron",44,35.1,51.6,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"1296",159,"Tseng","Test-negative case-control",1348,2022-02-21,"Moderna mRNA-1273","mRNA","2","final",NA,"270+",">= 18 years","general pop","included","~47.5 weeks","Infection","infection","infection","omicron",5.9,0.4,11,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"1297",159,"Tseng","Test-negative case-control",1349,2022-02-21,"Moderna mRNA-1273","mRNA","2","final",NA,"14+",">= 18 years","general pop","included","~47.5 weeks","Hospitalization","severe","severe","omicron",84.5,23,96.9,"USA","USA","North America","North America",66220,2019,"United States","High income",4,14,332.5,"yes",NA,0
"1298",159,"Tseng","Test-negative case-control",1350,2022-02-21,"Moderna mRNA-1273","mRNA","1","1",NA,"14+",">= 18 years","general pop","included",NA,"Infection","infection","infection","delta",56.7,40.7,68.4,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"1299",159,"Tseng","Test-negative case-control",1351,2022-02-21,"Moderna mRNA-1273","mRNA","2","final",NA,"14+",">= 18 years","general pop","included","~47.5 weeks","Infection","infection","infection","delta",63.6,59.9,66.9,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"1300",159,"Tseng","Test-negative case-control",1352,2022-02-21,"Moderna mRNA-1273","mRNA","2","final",NA,"14-90",">= 18 years","general pop","included","~11 weeks","Infection","infection","infection","delta",80.2,68.2,87.7,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"1301",159,"Tseng","Test-negative case-control",1353,2022-02-21,"Moderna mRNA-1273","mRNA","2","final",NA,"270+",">= 18 years","general pop","included","~47.5 weeks","Infection","infection","infection","delta",61.3,55,66.7,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"1302",159,"Tseng","Test-negative case-control",1354,2022-02-21,"Moderna mRNA-1273","mRNA","1","1",NA,"14+",">= 18 years","general pop","included",NA,"Hospitalization","severe","severe","delta",71.2,-68.7,97.4,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"1303",159,"Tseng","Test-negative case-control",1355,2022-02-21,"Moderna mRNA-1273","mRNA","2","final",NA,"14+",">= 18 years","general pop","included","~47.5 weeks","Hospitalization","severe","severe","delta",99,93.3,99.9,"USA","USA","North America","North America",66220,2019,"United States","High income",4,14,332.5,"yes",NA,0
"1304",160,"Chiew","Retrospective cohort",1356,2022-09-28,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"8+","12-17 years","12-17 years","excluded","~44 weeks","Infection","infection","infection","omicron",25,21,29,"Singapore","SGP","Asia","East Asia & Pacific",58810,2019,"Singapore","High income",4,NA,NA,NA,NA,NA
"1305",160,"Chiew","Retrospective cohort",1357,2022-09-28,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"8-59","12-17 years","12-17 years","excluded",NA,"Infection","infection","infection","omicron",38,32,43,"Singapore","SGP","Asia","East Asia & Pacific",58810,2019,"Singapore","High income",4,NA,NA,NA,NA,NA
"1306",160,"Chiew","Retrospective cohort",1358,2022-09-28,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"240+","12-17 years","12-17 years","excluded","~44 weeks","Infection","infection","infection","omicron",40,34,46,"Singapore","SGP","Asia","East Asia & Pacific",58810,2019,"Singapore","High income",4,NA,NA,NA,NA,NA
"1307",160,"Chiew","Retrospective cohort",1359,2022-09-28,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"8+","12-17 years","12-17 years","excluded","~44 weeks","Hospitalization","severe","severe","omicron",75,56,86,"Singapore","SGP","Asia","East Asia & Pacific",58810,2019,"Singapore","High income",4,NA,NA,NA,NA,NA
"1308",160,"Chiew","Retrospective cohort",1360,2022-09-28,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"8-59","12-17 years","12-17 years","excluded",NA,"Hospitalization","severe","severe","omicron",74,26,91,"Singapore","SGP","Asia","East Asia & Pacific",58810,2019,"Singapore","High income",4,NA,NA,NA,NA,NA
"1309",160,"Chiew","Retrospective cohort",1361,2022-09-28,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"240+","12-17 years","12-17 years","excluded","~44 weeks","Hospitalization","severe","severe","omicron",77,54,89,"Singapore","SGP","Asia","East Asia & Pacific",58810,2019,"Singapore","High income",4,NA,NA,NA,NA,NA
"1310",160,"Chiew","Retrospective cohort",1362,2022-09-28,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"8+","12-17 years","12-17 years","excluded","~24 weeks","Infection","infection","infection","delta",66,63,69,"Singapore","SGP","Asia","East Asia & Pacific",58810,2019,"Singapore","High income",4,NA,NA,NA,NA,NA
"1311",160,"Chiew","Retrospective cohort",1363,2022-09-28,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"8-59","12-17 years","12-17 years","excluded",NA,"Infection","infection","infection","delta",71,67,74,"Singapore","SGP","Asia","East Asia & Pacific",58810,2019,"Singapore","High income",4,NA,NA,NA,NA,NA
"1312",160,"Chiew","Retrospective cohort",1364,2022-09-28,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"240+","12-17 years","12-17 years","excluded","~24 weeks","Infection","infection","infection","delta",57,27,75,"Singapore","SGP","Asia","East Asia & Pacific",58810,2019,"Singapore","High income",4,NA,NA,NA,NA,NA
"1313",160,"Chiew","Retrospective cohort",1365,2022-09-28,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"8+","12-17 years","12-17 years","excluded","~24 weeks","Hospitalization","severe","severe","delta",83,74,89,"Singapore","SGP","Asia","East Asia & Pacific",58810,2019,"Singapore","High income",4,NA,NA,NA,NA,NA
"1314",160,"Chiew","Retrospective cohort",1366,2022-09-28,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"8-59","12-17 years","12-17 years","excluded",NA,"Hospitalization","severe","severe","delta",76,62,85,"Singapore","SGP","Asia","East Asia & Pacific",58810,2019,"Singapore","High income",4,NA,NA,NA,NA,NA
"1315",160,"Chiew","Retrospective cohort",1367,2022-09-28,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"240+","12-17 years","12-17 years","excluded","~24 weeks","Hospitalization","severe","severe","delta",89,64,94,"Singapore","SGP","Asia","East Asia & Pacific",58810,2019,"Singapore","High income",4,NA,NA,NA,NA,NA
"1316",161,"Olson","Case-control",1368,2022-01-12,"BioNTech/Pfizer BNT162b2","mRNA","1","1",NA,"14+","12-18 years","12-18 years","unknown",NA,"Hospitalization","severe","severe","delta",97,86,100,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"1317",161,"Olson","Case-control",1369,2022-01-12,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"14+","12-18 years","12-18 years","unknown","~18 weeks","Hospitalization","severe","severe","delta",94,90,96,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"1318",161,"Olson","Case-control",1370,2022-01-12,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"14+","12-18 years","12-18 years","unknown","~18 weeks","ICU admission","severe","severe","delta",98,93,99,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"1319",161,"Olson","Case-control",1371,2022-01-12,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"14+","12-18 years","12-18 years","unknown","~18 weeks","life support","severe","severe","delta",98,92,100,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"1320",161,"Olson","Test-negative case-control",1372,2022-01-12,"BioNTech/Pfizer BNT162b2","mRNA","1","1",NA,"14+","12-18 years","12-18 years","unknown",NA,"hospitalization","severe","severe","delta",98,88,100,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"1321",161,"Olson","Test-negative case-control",1373,2022-01-12,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"14+","12-18 years","12-18 years","unknown","~18 weeks","hospitalization","severe","severe","delta",95,91,97,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"1322",161,"Olson","Test-negative case-control",1374,2022-01-12,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"14+","12-18 years","12-18 years","unknown","~18 weeks","ICU admission","severe","severe","delta",98,94,100,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"1323",161,"Olson","Test-negative case-control",1375,2022-01-12,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"14+","12-18 years","12-18 years","unknown","~18 weeks","life support","severe","severe","delta",99,93,100,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"1324",162,"Gazit","Retrospective cohort",1376,2021-11-24,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"7+","adult contacts of SARS-CoV-2 index cases","contacts of index cases","excluded","~7.5 weeks","infection","infection","infection","alpha",80.3,73.5,85.4,"Israel","ISR","Asia","Middle East & North Africa",43800,2019,"Israel","High income",4,NA,NA,NA,NA,NA
"1325",163,"Suah","Retrospective cohort",1377,2022-03-21,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"9-26 weeks",">= 15 years","general pop","excluded","~26 weeks","infection (vaccinated April to June)","infection","infection","delta",79.3,76.1,82.1,"Malaysia","MYS","Asia","East Asia & Pacific",10750,2019,"Malaysia","Upper middle income",3,NA,NA,NA,NA,NA
"1326",163,"Suah","Retrospective cohort",1378,2022-03-21,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"2-13 weeks",">= 15 years","general pop","excluded","~26 weeks","infection (vaccinated July to August)","infection","infection","delta",90.8,89.4,92.1,"Malaysia","MYS","Asia","East Asia & Pacific",10750,2019,"Malaysia","Upper middle income",3,NA,NA,NA,NA,NA
"1327",163,"Suah","Retrospective cohort",1379,2022-03-21,"Sinovac CoronaVac","Inactivated","2","final",NA,"9-26 weeks",">= 15 years","general pop","excluded","~26 weeks","infection (vaccinated April to June)","infection","infection","delta",30.4,18.8,40.3,"Malaysia","MYS","Asia","East Asia & Pacific",10750,2019,"Malaysia","Upper middle income",3,NA,NA,NA,NA,NA
"1328",163,"Suah","Retrospective cohort",1380,2022-03-21,"Sinovac CoronaVac","Inactivated","2","final",NA,"2-13 weeks",">= 15 years","general pop","excluded","~26 weeks","infection (vaccinated July to August)","infection","infection","delta",74.5,70.6,78,"Malaysia","MYS","Asia","East Asia & Pacific",10750,2019,"Malaysia","Upper middle income",3,NA,NA,NA,NA,NA
"1329",164,"Young-Xu","Matched test-negative case-control",1381,2022-08-03,"Multiple or heterologous RNA","mRNA","2","final",NA,"14+","veterans 18+ years","veterans 18+ years","excluded","~48 weeks","infection","infection","infection","omicron",12,10,15,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"1330",164,"Young-Xu","Matched test-negative case-control",1382,2022-08-03,"Multiple or heterologous RNA","mRNA","2","final",NA,"14+","veterans 18+ years","veterans 18+ years","excluded","~48 weeks","hospitalization","severe","severe","omicron",63,58,67,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"1331",164,"Young-Xu","Matched test-negative case-control",1383,2022-08-03,"Multiple or heterologous RNA","mRNA","2","final",NA,"14+","veterans 18+ years","veterans 18+ years","excluded","~48 weeks","death","death","death","omicron",77,67,83,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"1332",164,"Young-Xu","Matched test-negative case-control",1384,2022-08-03,"Multiple or heterologous RNA","mRNA","2","final",NA,"14+","veterans 18+ years","veterans 18+ years","excluded","~48 weeks","infection","infection","infection","delta",54,50,57,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"1333",164,"Young-Xu","Matched test-negative case-control",1385,2022-08-03,"Multiple or heterologous RNA","mRNA","2","final",NA,"14+","veterans 18+ years","veterans 18+ years","excluded","~48 weeks","hospitalization","severe","severe","delta",75,69,80,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"1334",164,"Young-Xu","Matched test-negative case-control",1386,2022-08-03,"Multiple or heterologous RNA","mRNA","2","final",NA,"14+","veterans 18+ years","veterans 18+ years","excluded","~48 weeks","death","death","death","delta",92,83,96,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"1335",165,"Tartof","Test-negative case-control",1387,2022-04-22,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"7+","hospital admissions","general pop","excluded","~47 weeks","ED visits","symptomatic","symptomatic","omicron",47,40,54,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"1336",165,"Tartof","Test-negative case-control",1388,2022-04-22,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"7 to <3 months","hospital admissions","general pop","excluded","~47 weeks","ED visits","symptomatic","symptomatic","omicron",64,51,73,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"1337",165,"Tartof","Test-negative case-control",1389,2022-04-22,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,">=9 months","hospital admissions","general pop","excluded","~47 weeks","ED visits","symptomatic","symptomatic","omicron",31,16,43,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"1338",165,"Tartof","Test-negative case-control",1390,2022-04-22,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"7+","hospital admissions","general pop","excluded","~47 weeks","hospitalization","severe","severe","omicron",62,53,69,"USA","USA","North America","North America",66220,2019,"United States","High income",4,7,329,"yes",NA,0
"1339",165,"Tartof","Test-negative case-control",1391,2022-04-22,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"7 to <3 months","hospital admissions","general pop","excluded","~47 weeks","hospitalization","severe","severe","omicron",68,48,80,"USA","USA","North America","North America",66220,2019,"United States","High income",4,7,90,"no","nested period",0
"1340",165,"Tartof","Test-negative case-control",1392,2022-04-22,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,">=9 months","hospital admissions","general pop","excluded","~47 weeks","Hospitalization","severe","severe","omicron",41,21,55,"USA","USA","North America","North America",66220,2019,"United States","High income",4,270,329,"no","nested period",0
"1341",165,"Tartof","Test-negative case-control",1393,2022-04-22,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"7+","hospital admissions","general pop","excluded","~47 weeks","ED visits","symptomatic","symptomatic","delta",61,55,66,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"1342",165,"Tartof","Test-negative case-control",1394,2022-04-22,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"7 to <3 months","hospital admissions","general pop","excluded","~47 weeks","ED visits","symptomatic","symptomatic","delta",78,69,85,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"1343",165,"Tartof","Test-negative case-control",1395,2022-04-22,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,">=9 months","hospital admissions","general pop","excluded","~47 weeks","ED visits","symptomatic","symptomatic","delta",57,45,66,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"1344",165,"Tartof","Test-negative case-control",1396,2022-04-22,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"7+","hospital admissions","general pop","excluded","~47 weeks","hospitalization","severe","severe","delta",76,69,82,"USA","USA","North America","North America",66220,2019,"United States","High income",4,7,329,"yes",NA,0
"1345",165,"Tartof","Test-negative case-control",1397,2022-04-22,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"7 to <3 months","hospital admissions","general pop","excluded","~47 weeks","hospitalization","severe","severe","delta",78,55,89,"USA","USA","North America","North America",66220,2019,"United States","High income",4,7,90,"no","nested period",0
"1346",165,"Tartof","Test-negative case-control",1398,2022-04-22,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,">=9 months","hospital admissions","general pop","excluded","~47 weeks","hospitalization","severe","severe","delta",73,58,83,"USA","USA","North America","North America",66220,2019,"United States","High income",4,270,329,"no","nested period",0
"1347",166,"Amodio","Retrospective cohort",1399,2022-03-11,"Multiple or heterologous RNA","mRNA","2","final",NA,"2 months",">= 18 years","general pop","excluded","~37 weeks","Infection","infection","infection","other combinations",81.3,80.3,82.3,"Italy","ITA","Europe","Europe & Central Asia",34890,2019,"Italy","High income",4,NA,NA,NA,NA,NA
"1348",166,"Amodio","Retrospective cohort",1400,2022-03-11,"Multiple or heterologous RNA","mRNA","2","final",NA,"8 months",">= 18 years","general pop","excluded","~37 weeks","infection","infection","infection","other combinations",57.8,55.4,60.2,"Italy","ITA","Europe","Europe & Central Asia",34890,2019,"Italy","High income",4,NA,NA,NA,NA,NA
"1349",166,"Amodio","Retrospective cohort",1401,2022-03-11,"Multiple or heterologous RNA","mRNA","2","final",NA,"2 months",">= 18 years","general pop","excluded","~37 weeks","severe disease","severe","severe","other combinations",96.1,94.5,97.7,"Italy","ITA","Europe","Europe & Central Asia",34890,2019,"Italy","High income",4,NA,NA,NA,NA,NA
"1350",166,"Amodio","Retrospective cohort",1402,2022-03-11,"Multiple or heterologous RNA","mRNA","2","final",NA,"8 months",">= 18 years","general pop","excluded","~37 weeks","severe disease","severe","severe","other combinations",90.3,86.2,94.4,"Italy","ITA","Europe","Europe & Central Asia",34890,2019,"Italy","High income",4,NA,NA,NA,NA,NA
"1351",166,"Amodio","Retrospective cohort",1403,2022-03-11,"Multiple or heterologous RNA","mRNA","2","final",NA,"2 months",">= 18 years","general pop","excluded","~37 weeks","death or intubation","severe","severe","other combinations",93.4,91.2,95.6,"Italy","ITA","Europe","Europe & Central Asia",34890,2019,"Italy","High income",4,NA,NA,NA,NA,NA
"1352",166,"Amodio","Retrospective cohort",1404,2022-03-11,"Multiple or heterologous RNA","mRNA","2","final",NA,"8 months",">= 18 years","general pop","excluded","~37 weeks","death or intubation","severe","severe","other combinations",83.7,75.1,92.3,"Italy","ITA","Europe","Europe & Central Asia",34890,2019,"Italy","High income",4,NA,NA,NA,NA,NA
"1353",167,"Thompson","Test-negative case-control",1405,2022-01-21,"Multiple or heterologous RNA","mRNA","2","final",NA,"14-179","ED encounters and hospital admissions","general pop","unknown","~50 weeks","ED or UC visit","symptomatic","symptomatic","omicron",52,46,58,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"1354",167,"Thompson","Test-negative case-control",1406,2022-01-21,"Multiple or heterologous RNA","mRNA","2","final",NA,"180+","ED encounters and hospital admissions","general pop","unknown","~50 weeks","ED or UC visit","symptomatic","symptomatic","omicron",38,32,43,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"1355",167,"Thompson","Test-negative case-control",1407,2022-01-21,"Multiple or heterologous RNA","mRNA","2","final",NA,"14-179","ED encounters and hospital admissions","general pop","unknown","~50 weeks","hospitalization","severe","severe","omicron",81,65,90,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"1356",167,"Thompson","Test-negative case-control",1408,2022-01-21,"Multiple or heterologous RNA","mRNA","2","final",NA,"180+","ED encounters and hospital admissions","general pop","unknown","~50 weeks","hospitalization","severe","severe","omicron",57,39,70,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"1357",167,"Thompson","Test-negative case-control",1409,2022-01-21,"Multiple or heterologous RNA","mRNA","2","final",NA,"14-179","ED encounters and hospital admissions","general pop","unknown","~32 weeks","ED or UC visit","symptomatic","symptomatic","delta",86,85,87,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"1358",167,"Thompson","Test-negative case-control",1410,2022-01-21,"Multiple or heterologous RNA","mRNA","2","final",NA,"180+","ED encounters and hospital admissions","general pop","unknown","~32 weeks","ED or UC visit","symptomatic","symptomatic","delta",76,75,77,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"1359",167,"Thompson","Test-negative case-control",1411,2022-01-21,"Multiple or heterologous RNA","mRNA","2","final",NA,"14-179","ED encounters and hospital admissions","general pop","unknown","~32 weeks","hospitalization","severe","severe","delta",90,89,90,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"1360",167,"Thompson","Test-negative case-control",1412,2022-01-21,"Multiple or heterologous RNA","mRNA","2","final",NA,"180+","ED encounters and hospital admissions","general pop","unknown","~32 weeks","hospitalization","severe","severe","delta",81,80,82,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"1361",168,"Bedston","Prospective cohort",1413,2022-01-21,"BioNTech/Pfizer BNT162b2","mRNA","1","1",NA,"3-6 weeks","HCW","HCW","excluded",NA,"infection","infection","infection","alpha",52,45,58,"UK","GBR","Europe","Europe & Central Asia",43240,2019,"United Kingdom","High income",4,NA,NA,NA,NA,NA
"1362",168,"Bedston","Prospective cohort",1414,2022-01-21,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"2-5 weeks","HCW","HCW","excluded","~37 weeks","infection","infection","infection","alpha",86,74,91,"UK","GBR","Europe","Europe & Central Asia",43240,2019,"United Kingdom","High income",4,NA,NA,NA,NA,NA
"1363",168,"Bedston","Prospective cohort",1415,2022-01-21,"BioNTech/Pfizer BNT162b2","mRNA","1","1",NA,"7+ weeks","HCW","HCW","excluded",NA,"infection","infection","infection","alpha",39,24,50,"UK","GBR","Europe","Europe & Central Asia",43240,2019,"United Kingdom","High income",4,NA,NA,NA,NA,NA
"1364",168,"Bedston","Prospective cohort",1416,2022-01-21,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"26+ weeks","HCW","HCW","excluded","~37 weeks","infection","infection","infection","alpha",45,39,51,"UK","GBR","Europe","Europe & Central Asia",43240,2019,"United Kingdom","High income",4,NA,NA,NA,NA,NA
"1365",169,"Botton","Retrospective cohort",1417,2022-01-24,"Multiple or heterologous RNA","mRNA","1","1",NA,"14+",">= 75 years",">= 75 years","unknown",NA,"hospitalization","severe","severe","other combinations",34,28,40,"France","FRA","Europe","Europe & Central Asia",42470,2019,"France","High income",4,NA,NA,NA,NA,NA
"1366",169,"Botton","Retrospective cohort",1418,2022-01-24,"Multiple or heterologous RNA","mRNA","2","final",NA,"7+",">= 75 years",">= 75 years","unknown","~7 weeks","hospitalization","severe","severe","other combinations",86,83,89,"France","FRA","Europe","Europe & Central Asia",42470,2019,"France","High income",4,NA,NA,NA,NA,NA
"1367",170,"Spensley","Prospective cohort",1419,2022-01-26,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"14+","end stage kidney disease patients","end stage kidney disease patients","included","~52.5 weeks","infection","infection","infection","omicron",17,-62,57,"UK","GBR","Europe","Europe & Central Asia",43240,2019,"United Kingdom","High income",4,NA,NA,NA,NA,NA
"1368",170,"Spensley","Prospective cohort",1420,2022-01-26,"Oxford/AstraZeneca ChAdOx1-S","Vectored","2","final",NA,"14+","end stage kidney disease patients","end stage kidney disease patients","included","~52.5 weeks","infection","infection","infection","omicron",-4,-97,43,"UK","GBR","Europe","Europe & Central Asia",43240,2019,"United Kingdom","High income",4,NA,NA,NA,NA,NA
"1369",171,"Willet","Test-negative case-control",1421,2022-01-26,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"14+",">= 18 years","general pop","included","~11 weeks","infection","infection","infection","omicron",26,13.9,36.4,"UK","GBR","Europe","Europe & Central Asia",43240,2019,"United Kingdom","High income",4,NA,NA,NA,NA,NA
"1370",171,"Willet","Test-negative case-control",1422,2022-01-26,"Moderna mRNA-1273","mRNA","2","final",NA,"14+",">= 18 years","general pop","included","~11 weeks","infection","infection","infection","omicron",23.7,4.4,39.4,"UK","GBR","Europe","Europe & Central Asia",43240,2019,"United Kingdom","High income",4,NA,NA,NA,NA,NA
"1371",171,"Willet","Test-negative case-control",1423,2022-01-26,"Oxford/AstraZeneca ChAdOx1-S","Vectored","2","final",NA,"14+",">= 18 years","general pop","included","~11 weeks","infection","infection","infection","omicron",11.4,-18.8,34.6,"UK","GBR","Europe","Europe & Central Asia",43240,2019,"United Kingdom","High income",4,NA,NA,NA,NA,NA
"1372",171,"Willet","Test-negative case-control",1424,2022-01-26,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"14+",">= 18 years","general pop","included","~11 weeks","infection","infection","infection","delta",83.5,78.6,87.3,"UK","GBR","Europe","Europe & Central Asia",43240,2019,"United Kingdom","High income",4,NA,NA,NA,NA,NA
"1373",171,"Willet","Test-negative case-control",1425,2022-01-26,"Moderna mRNA-1273","mRNA","2","final",NA,"14+",">= 18 years","general pop","included","~11 weeks","infection","infection","infection","delta",87.8,79.8,92.7,"UK","GBR","Europe","Europe & Central Asia",43240,2019,"United Kingdom","High income",4,NA,NA,NA,NA,NA
"1374",171,"Willet","Test-negative case-control",1426,2022-01-26,"Oxford/AstraZeneca ChAdOx1-S","Vectored","2","final",NA,"14+",">= 18 years","general pop","included","~11 weeks","infection","infection","infection","delta",78.9,66.6,86.7,"UK","GBR","Europe","Europe & Central Asia",43240,2019,"United Kingdom","High income",4,NA,NA,NA,NA,NA
"1375",172,"Belayachi","Test-negative case-control",1427,2022-12-07,"Beijing/Sinopharm BBIBP-CorV","Inactivated","2","final",NA,"1-273","hospital patients","general pop","included","~39 weeks","severe hospitalization","severe","severe","other combinations",73,71,76,"Morocco","MAR","Africa","Middle East & North Africa",3510,2019,"Morocco","Lower middle income",2,NA,NA,NA,NA,NA
"1376",172,"Belayachi","Test-negative case-control",1428,2022-12-07,"Beijing/Sinopharm BBIBP-CorV","Inactivated","2","final",NA,"1-30","hospital patients","general pop","included","~39 weeks","severe hospitalization","severe","severe","other combinations",88,84,91,"Morocco","MAR","Africa","Middle East & North Africa",3510,2019,"Morocco","Lower middle income",2,NA,NA,NA,NA,NA
"1377",172,"Belayachi","Test-negative case-control",1429,2022-12-07,"Beijing/Sinopharm BBIBP-CorV","Inactivated","2","final",NA,"150+","hospital patients","general pop","included","~39 weeks","severe hospitalization","severe","severe","other combinations",64,59,69,"Morocco","MAR","Africa","Middle East & North Africa",3510,2019,"Morocco","Lower middle income",2,NA,NA,NA,NA,NA
"1378",173,"Tenforde","Test-negative case-control",1430,2022-01-28,"Multiple or heterologous RNA","mRNA","2","final",NA,"14+","hospital patients 18+ years","general pop","included","~47 weeks","hospitalization","severe","severe","delta",69,57,78,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"1379",173,"Tenforde","Test-negative case-control",1431,2022-01-28,"Multiple or heterologous RNA","mRNA","2","final",NA,"14+","hospital patients 18+ years","general pop","included","~47 weeks","hospitalization","severe","severe","delta",82,77,86,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"1380",174,"Lytras","Retrospective cohort",1432,2022-06-14,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"14+","15-59 years","15-59 years","included","~48 weeks","intubation","severe","severe","delta",98.1,97.5,98.6,"Greece","GRC","Europe","Europe & Central Asia",19690,2019,"Greece","High income",3,14,336,"yes",NA,0
"1381",174,"Lytras","Retrospective cohort",1433,2022-06-14,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"6 months","15-59 years","15-59 years","included","~48 weeks","intubation","severe","severe","delta",95.5,94.3,96.5,"Greece","GRC","Europe","Europe & Central Asia",19690,2019,"Greece","High income",3,180,336,"no","nested period",0
"1382",174,"Lytras","Retrospective cohort",1434,2022-06-14,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"14+","60-79 years","60-79 years","included","~48 weeks","intubation","severe","severe","delta",96.7,95.9,97.4,"Greece","GRC","Europe","Europe & Central Asia",19690,2019,"Greece","High income",3,14,336,"yes",NA,1
"1383",174,"Lytras","Retrospective cohort",1435,2022-06-14,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"6 months","60-79 years","60-79 years","included","~48 weeks","intubation","severe","severe","delta",92,91,92.9,"Greece","GRC","Europe","Europe & Central Asia",19690,2019,"Greece","High income",3,180,336,"no","nested period",1
"1384",174,"Lytras","Retrospective cohort",1436,2022-06-14,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"14+",">= 80 years",">= 80 years","included","~48 weeks","intubation","severe","severe","delta",94.2,92,95.7,"Greece","GRC","Europe","Europe & Central Asia",19690,2019,"Greece","High income",3,14,336,"yes",NA,1
"1385",174,"Lytras","Retrospective cohort",1437,2022-06-14,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"6 months",">= 80 years",">= 80 years","included","~48 weeks","intubation","severe","severe","delta",85.9,83.5,88,"Greece","GRC","Europe","Europe & Central Asia",19690,2019,"Greece","High income",3,180,336,"no","nested period",1
"1386",174,"Lytras","Retrospective cohort",1438,2022-06-14,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"14+","15-59 years","15-59 years","included","~48 weeks","death","death","death","delta",96.5,94.8,97.6,"Greece","GRC","Europe","Europe & Central Asia",19690,2019,"Greece","High income",3,NA,NA,NA,NA,NA
"1387",174,"Lytras","Retrospective cohort",1439,2022-06-14,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"6 months","15-59 years","15-59 years","included","~48 weeks","death","death","death","delta",93.8,91,95.7,"Greece","GRC","Europe","Europe & Central Asia",19690,2019,"Greece","High income",3,NA,NA,NA,NA,NA
"1388",174,"Lytras","Retrospective cohort",1440,2022-06-14,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"14+","60-79 years","60-79 years","included","~48 weeks","death","death","death","delta",94.1,92.7,95.2,"Greece","GRC","Europe","Europe & Central Asia",19690,2019,"Greece","High income",3,NA,NA,NA,NA,NA
"1389",174,"Lytras","Retrospective cohort",1441,2022-06-14,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"6 months","60-79 years","60-79 years","included","~48 weeks","death","death","death","delta",89.4,87.9,90.8,"Greece","GRC","Europe","Europe & Central Asia",19690,2019,"Greece","High income",3,NA,NA,NA,NA,NA
"1390",174,"Lytras","Retrospective cohort",1442,2022-06-14,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"14+",">= 80 years",">= 80 years","included","~48 weeks","death","death","death","delta",91,88.4,93,"Greece","GRC","Europe","Europe & Central Asia",19690,2019,"Greece","High income",3,NA,NA,NA,NA,NA
"1391",174,"Lytras","Retrospective cohort",1443,2022-06-14,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"6 months",">= 80 years",">= 80 years","included","~48 weeks","death","death","death","delta",84,82.2,85.6,"Greece","GRC","Europe","Europe & Central Asia",19690,2019,"Greece","High income",3,NA,NA,NA,NA,NA
"1392",174,"Lytras","Retrospective cohort",1444,2022-06-14,"Moderna mRNA-1273","mRNA","2","final",NA,"14+","15-59 years","15-59 years","included","~48 weeks","intubation","severe","severe","delta",99.4,98.2,99.8,"Greece","GRC","Europe","Europe & Central Asia",19690,2019,"Greece","High income",3,14,336,"yes",NA,0
"1393",174,"Lytras","Retrospective cohort",1445,2022-06-14,"Moderna mRNA-1273","mRNA","2","final",NA,"6 months","15-59 years","15-59 years","included","~48 weeks","intubation","severe","severe","delta",97.3,93.1,98.9,"Greece","GRC","Europe","Europe & Central Asia",19690,2019,"Greece","High income",3,180,336,"no","nested period",0
"1394",174,"Lytras","Retrospective cohort",1446,2022-06-14,"Moderna mRNA-1273","mRNA","2","final",NA,"14+","60-79 years","60-79 years","included","~48 weeks","intubation","severe","severe","delta",98.9,97.3,99.5,"Greece","GRC","Europe","Europe & Central Asia",19690,2019,"Greece","High income",3,14,336,"yes",NA,1
"1395",174,"Lytras","Retrospective cohort",1447,2022-06-14,"Moderna mRNA-1273","mRNA","2","final",NA,"6 months","60-79 years","60-79 years","included","~48 weeks","intubation","severe","severe","delta",95.1,93,96.5,"Greece","GRC","Europe","Europe & Central Asia",19690,2019,"Greece","High income",3,180,336,"no","nested period",1
"1396",174,"Lytras","Retrospective cohort",1448,2022-06-14,"Moderna mRNA-1273","mRNA","2","final",NA,"14+",">= 80 years",">= 80 years","included","~48 weeks","intubation","severe","severe","delta",97.9,90.2,99.5,"Greece","GRC","Europe","Europe & Central Asia",19690,2019,"Greece","High income",3,14,336,"yes",NA,1
"1397",174,"Lytras","Retrospective cohort",1449,2022-06-14,"Moderna mRNA-1273","mRNA","2","final",NA,"6 months",">= 80 years",">= 80 years","included","~48 weeks","intubation","severe","severe","delta",90.6,67,97.3,"Greece","GRC","Europe","Europe & Central Asia",19690,2019,"Greece","High income",3,180,336,"no","nested period",1
"1398",174,"Lytras","Retrospective cohort",1450,2022-06-14,"Moderna mRNA-1273","mRNA","2","final",NA,"14+","15-59 years","15-59 years","included","~48 weeks","death","death","death","delta",99.3,94.7,99.9,"Greece","GRC","Europe","Europe & Central Asia",19690,2019,"Greece","High income",3,NA,NA,NA,NA,NA
"1399",174,"Lytras","Retrospective cohort",1451,2022-06-14,"Moderna mRNA-1273","mRNA","2","final",NA,"6 months","15-59 years","15-59 years","included","~48 weeks","death","death","death","delta",98.3,88.3,99.8,"Greece","GRC","Europe","Europe & Central Asia",19690,2019,"Greece","High income",3,NA,NA,NA,NA,NA
"1400",174,"Lytras","Retrospective cohort",1452,2022-06-14,"Moderna mRNA-1273","mRNA","2","final",NA,"14+","60-79 years","60-79 years","included","~48 weeks","death","death","death","delta",98.4,95.5,99.5,"Greece","GRC","Europe","Europe & Central Asia",19690,2019,"Greece","High income",3,NA,NA,NA,NA,NA
"1401",174,"Lytras","Retrospective cohort",1453,2022-06-14,"Moderna mRNA-1273","mRNA","2","final",NA,"6 months","60-79 years","60-79 years","included","~48 weeks","death","death","death","delta",96.2,93.6,97.7,"Greece","GRC","Europe","Europe & Central Asia",19690,2019,"Greece","High income",3,NA,NA,NA,NA,NA
"1402",174,"Lytras","Retrospective cohort",1454,2022-06-14,"Moderna mRNA-1273","mRNA","2","final",NA,"14+",">= 80 years",">= 80 years","included","~48 weeks","death","death","death","delta",96.7,87.9,99.1,"Greece","GRC","Europe","Europe & Central Asia",19690,2019,"Greece","High income",3,NA,NA,NA,NA,NA
"1403",174,"Lytras","Retrospective cohort",1455,2022-06-14,"Moderna mRNA-1273","mRNA","2","final",NA,"6 months",">= 80 years",">= 80 years","included","~48 weeks","death","death","death","delta",92,80,96.8,"Greece","GRC","Europe","Europe & Central Asia",19690,2019,"Greece","High income",3,NA,NA,NA,NA,NA
"1404",174,"Lytras","Retrospective cohort",1456,2022-06-14,"Oxford/AstraZeneca ChAdOx1-S","Vectored","2","final",NA,"14+","15-59 years","15-59 years","included","~48 weeks","intubation","severe","severe","delta",97.8,95.3,99,"Greece","GRC","Europe","Europe & Central Asia",19690,2019,"Greece","High income",3,14,336,"yes",NA,0
"1405",174,"Lytras","Retrospective cohort",1457,2022-06-14,"Oxford/AstraZeneca ChAdOx1-S","Vectored","2","final",NA,"6 months","15-59 years","15-59 years","included","~48 weeks","intubation","severe","severe","delta",92.4,84,96.4,"Greece","GRC","Europe","Europe & Central Asia",19690,2019,"Greece","High income",3,180,336,"no","nested period",0
"1406",174,"Lytras","Retrospective cohort",1458,2022-06-14,"Oxford/AstraZeneca ChAdOx1-S","Vectored","2","final",NA,"14+","60-79 years","60-79 years","included","~48 weeks","intubation","severe","severe","delta",97.2,95.3,98.3,"Greece","GRC","Europe","Europe & Central Asia",19690,2019,"Greece","High income",3,14,336,"yes",NA,1
"1407",174,"Lytras","Retrospective cohort",1459,2022-06-14,"Oxford/AstraZeneca ChAdOx1-S","Vectored","2","final",NA,"6 months","60-79 years","60-79 years","included","~48 weeks","intubation","severe","severe","delta",90.3,87.4,92.5,"Greece","GRC","Europe","Europe & Central Asia",19690,2019,"Greece","High income",3,180,336,"no","nested period",1
"1408",174,"Lytras","Retrospective cohort",1460,2022-06-14,"Oxford/AstraZeneca ChAdOx1-S","Vectored","2","final",NA,"14+",">= 80 years",">= 80 years","included","~48 weeks","intubation","severe","severe","delta",97.8,91.7,99.4,"Greece","GRC","Europe","Europe & Central Asia",19690,2019,"Greece","High income",3,14,336,"yes",NA,1
"1409",174,"Lytras","Retrospective cohort",1461,2022-06-14,"Oxford/AstraZeneca ChAdOx1-S","Vectored","2","final",NA,"6 months",">= 80 years",">= 80 years","included","~48 weeks","intubation","severe","severe","delta",92.4,72.7,97.9,"Greece","GRC","Europe","Europe & Central Asia",19690,2019,"Greece","High income",3,180,336,"no","nested period",1
"1410",174,"Lytras","Retrospective cohort",1462,2022-06-14,"Oxford/AstraZeneca ChAdOx1-S","Vectored","2","final",NA,"14+","15-59 years","15-59 years","included","~48 weeks","death","death","death","delta",97.5,89.7,99.4,"Greece","GRC","Europe","Europe & Central Asia",19690,2019,"Greece","High income",3,NA,NA,NA,NA,NA
"1411",174,"Lytras","Retrospective cohort",1463,2022-06-14,"Oxford/AstraZeneca ChAdOx1-S","Vectored","2","final",NA,"6 months","15-59 years","15-59 years","included","~48 weeks","death","death","death","delta",94.5,77.2,98.7,"Greece","GRC","Europe","Europe & Central Asia",19690,2019,"Greece","High income",3,NA,NA,NA,NA,NA
"1412",174,"Lytras","Retrospective cohort",1464,2022-06-14,"Oxford/AstraZeneca ChAdOx1-S","Vectored","2","final",NA,"14+","60-79 years","60-79 years","included","~48 weeks","death","death","death","delta",95.4,91.2,97.6,"Greece","GRC","Europe","Europe & Central Asia",19690,2019,"Greece","High income",3,NA,NA,NA,NA,NA
"1413",174,"Lytras","Retrospective cohort",1465,2022-06-14,"Oxford/AstraZeneca ChAdOx1-S","Vectored","2","final",NA,"6 months","60-79 years","60-79 years","included","~48 weeks","death","death","death","delta",89.8,85.2,93,"Greece","GRC","Europe","Europe & Central Asia",19690,2019,"Greece","High income",3,NA,NA,NA,NA,NA
"1414",174,"Lytras","Retrospective cohort",1466,2022-06-14,"Oxford/AstraZeneca ChAdOx1-S","Vectored","2","final",NA,"14+",">= 80 years",">= 80 years","included","~48 weeks","death","death","death","delta",92.6,84.2,96.5,"Greece","GRC","Europe","Europe & Central Asia",19690,2019,"Greece","High income",3,NA,NA,NA,NA,NA
"1415",174,"Lytras","Retrospective cohort",1467,2022-06-14,"Oxford/AstraZeneca ChAdOx1-S","Vectored","2","final",NA,"6 months",">= 80 years",">= 80 years","included","~48 weeks","death","death","death","delta",83.4,69.6,90.9,"Greece","GRC","Europe","Europe & Central Asia",19690,2019,"Greece","High income",3,NA,NA,NA,NA,NA
"1416",174,"Lytras","Retrospective cohort",1468,2022-06-14,"Janssen Ad26.COV2.S","Vectored","1","final",NA,"14+","15-59 years","15-59 years","included","~48 weeks","intubation","severe","severe","delta",85,73.9,91.4,"Greece","GRC","Europe","Europe & Central Asia",19690,2019,"Greece","High income",3,NA,NA,NA,NA,NA
"1417",174,"Lytras","Retrospective cohort",1469,2022-06-14,"Janssen Ad26.COV2.S","Vectored","1","final",NA,"6 months","15-59 years","15-59 years","included","~48 weeks","intubation","severe","severe","delta",91.7,84.4,95.6,"Greece","GRC","Europe","Europe & Central Asia",19690,2019,"Greece","High income",3,NA,NA,NA,NA,NA
"1418",174,"Lytras","Retrospective cohort",1470,2022-06-14,"Janssen Ad26.COV2.S","Vectored","1","final",NA,"14+","60-79 years","60-79 years","included","~48 weeks","intubation","severe","severe","delta",79.6,65.2,88,"Greece","GRC","Europe","Europe & Central Asia",19690,2019,"Greece","High income",3,NA,NA,NA,NA,NA
"1419",174,"Lytras","Retrospective cohort",1471,2022-06-14,"Janssen Ad26.COV2.S","Vectored","1","final",NA,"6 months","60-79 years","60-79 years","included","~48 weeks","intubation","severe","severe","delta",88.7,78.7,94,"Greece","GRC","Europe","Europe & Central Asia",19690,2019,"Greece","High income",3,NA,NA,NA,NA,NA
"1420",174,"Lytras","Retrospective cohort",1472,2022-06-14,"Janssen Ad26.COV2.S","Vectored","1","final",NA,"14+",">= 80 years",">= 80 years","included","~48 weeks","intubation","severe","severe","delta",85,62.3,94,"Greece","GRC","Europe","Europe & Central Asia",19690,2019,"Greece","High income",3,NA,NA,NA,NA,NA
"1421",174,"Lytras","Retrospective cohort",1473,2022-06-14,"Janssen Ad26.COV2.S","Vectored","1","final",NA,"6 months",">= 80 years",">= 80 years","included","~48 weeks","intubation","severe","severe","delta",91.7,75.5,97.2,"Greece","GRC","Europe","Europe & Central Asia",19690,2019,"Greece","High income",3,NA,NA,NA,NA,NA
"1422",174,"Lytras","Retrospective cohort",1474,2022-06-14,"Janssen Ad26.COV2.S","Vectored","1","final",NA,"14+","15-59 years","15-59 years","included","~48 weeks","death","death","death","delta",81.7,57.5,92.1,"Greece","GRC","Europe","Europe & Central Asia",19690,2019,"Greece","High income",3,NA,NA,NA,NA,NA
"1423",174,"Lytras","Retrospective cohort",1475,2022-06-14,"Janssen Ad26.COV2.S","Vectored","1","final",NA,"6 months","15-59 years","15-59 years","included","~48 weeks","death","death","death","delta",90.7,77.2,96.2,"Greece","GRC","Europe","Europe & Central Asia",19690,2019,"Greece","High income",3,NA,NA,NA,NA,NA
"1424",174,"Lytras","Retrospective cohort",1476,2022-06-14,"Janssen Ad26.COV2.S","Vectored","1","final",NA,"14+","60-79 years","60-79 years","included","~48 weeks","death","death","death","delta",69.1,43.2,83.2,"Greece","GRC","Europe","Europe & Central Asia",19690,2019,"Greece","High income",3,NA,NA,NA,NA,NA
"1425",174,"Lytras","Retrospective cohort",1477,2022-06-14,"Janssen Ad26.COV2.S","Vectored","1","final",NA,"6 months","60-79 years","60-79 years","included","~48 weeks","death","death","death","delta",84.3,67.9,92.3,"Greece","GRC","Europe","Europe & Central Asia",19690,2019,"Greece","High income",3,NA,NA,NA,NA,NA
"1426",174,"Lytras","Retrospective cohort",1478,2022-06-14,"Janssen Ad26.COV2.S","Vectored","1","final",NA,"14+",">= 80 years",">= 80 years","included","~48 weeks","death","death","death","delta",61.9,43.2,74.4,"Greece","GRC","Europe","Europe & Central Asia",19690,2019,"Greece","High income",3,NA,NA,NA,NA,NA
"1427",174,"Lytras","Retrospective cohort",1479,2022-06-14,"Janssen Ad26.COV2.S","Vectored","1","final",NA,"6 months",">= 80 years",">= 80 years","included","~48 weeks","death","death","death","delta",80.6,59.7,90.7,"Greece","GRC","Europe","Europe & Central Asia",19690,2019,"Greece","High income",3,NA,NA,NA,NA,NA
"1428",175,"Roberts","Test-negative case-control",1480,2022-07-26,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"<3 months",">= 18 years","general pop","included","~48 weeks","infection","infection","infection","other combinations",83,81,84,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"1429",175,"Roberts","Test-negative case-control",1481,2022-07-26,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,">=3 months",">= 18 years","general pop","included","~48 weeks","infection","infection","infection","other combinations",60,58,62,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"1430",175,"Roberts","Test-negative case-control",1482,2022-07-26,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"<3 months",">= 18 years","general pop","included","~48 weeks","infection (Jan-March)","infection","infection","other combinations",80,74,85,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"1431",175,"Roberts","Test-negative case-control",1483,2022-07-26,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,">=3 months",">= 18 years","general pop","included","~48 weeks","infection (Jan-March)","infection","infection","other combinations",80.5,74,86,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"1432",175,"Roberts","Test-negative case-control",1484,2022-07-26,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"<3 months",">= 18 years","general pop","included","~48 weeks","infection (Oct-Dec)","infection","infection","other combinations",75,64,81,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"1433",175,"Roberts","Test-negative case-control",1485,2022-07-26,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,">=3 months",">= 18 years","general pop","included","~48 weeks","infection (Oct-Dec)","infection","infection","other combinations",60,55,62,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"1434",175,"Roberts","Test-negative case-control",1486,2022-07-26,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"<3 months",">= 18 years","general pop","included","~48 weeks","severe disease","severe","severe","other combinations",88,80,91,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"1435",175,"Roberts","Test-negative case-control",1487,2022-07-26,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,">=3 months",">= 18 years","general pop","included","~48 weeks","severe disease","severe","severe","other combinations",75,70,80,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"1436",175,"Roberts","Test-negative case-control",1488,2022-07-26,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"<3 months",">= 18 years","general pop","included","~48 weeks","severe disease (Jan-March)","severe","severe","other combinations",90,49,99,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"1437",175,"Roberts","Test-negative case-control",1489,2022-07-26,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,">=3 months",">= 18 years","general pop","included","~48 weeks","severe disease (Jan-March)","severe","severe","other combinations",90,50,99,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"1438",175,"Roberts","Test-negative case-control",1490,2022-07-26,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"<3 months",">= 18 years","general pop","included","~48 weeks","severe disease (Oct-Dec)","severe","severe","other combinations",69,22,88,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"1439",175,"Roberts","Test-negative case-control",1491,2022-07-26,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,">=3 months",">= 18 years","general pop","included","~48 weeks","severe disease (Oct-Dec)","severe","severe","other combinations",78,70,82,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"1440",175,"Roberts","Test-negative case-control",1492,2022-07-26,"Moderna mRNA-1273","mRNA","2","final",NA,"<3 months",">= 18 years","general pop","included","~48 weeks","infection","infection","infection","other combinations",88,85,90,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"1441",175,"Roberts","Test-negative case-control",1493,2022-07-26,"Moderna mRNA-1273","mRNA","2","final",NA,">=3 months",">= 18 years","general pop","included","~48 weeks","infection","infection","infection","other combinations",65,62,68,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"1442",175,"Roberts","Test-negative case-control",1494,2022-07-26,"Moderna mRNA-1273","mRNA","2","final",NA,"<3 months",">= 18 years","general pop","included","~48 weeks","infection (Jan-March)","infection","infection","other combinations",89,73,95,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"1443",175,"Roberts","Test-negative case-control",1495,2022-07-26,"Moderna mRNA-1273","mRNA","2","final",NA,">=3 months",">= 18 years","general pop","included","~48 weeks","infection (Jan-March)","infection","infection","other combinations",89,74,93,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"1444",175,"Roberts","Test-negative case-control",1496,2022-07-26,"Moderna mRNA-1273","mRNA","2","final",NA,"<3 months",">= 18 years","general pop","included","~48 weeks","infection (Oct-Dec)","infection","infection","other combinations",82,69,91,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"1445",175,"Roberts","Test-negative case-control",1497,2022-07-26,"Moderna mRNA-1273","mRNA","2","final",NA,">=3 months",">= 18 years","general pop","included","~48 weeks","infection (Oct-Dec)","infection","infection","other combinations",68,64,69,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"1446",175,"Roberts","Test-negative case-control",1498,2022-07-26,"Moderna mRNA-1273","mRNA","2","final",NA,"<3 months",">= 18 years","general pop","included","~48 weeks","severe disease","severe","severe","other combinations",85,75,90,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"1447",175,"Roberts","Test-negative case-control",1499,2022-07-26,"Moderna mRNA-1273","mRNA","2","final",NA,">=3 months",">= 18 years","general pop","included","~48 weeks","severe disease","severe","severe","other combinations",72,65,78,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"1448",175,"Roberts","Test-negative case-control",1500,2022-07-26,"Moderna mRNA-1273","mRNA","2","final",NA,"<3 months",">= 18 years","general pop","included","~48 weeks","severe disease (Jan-March)","severe","severe","other combinations",70,0,95,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"1449",175,"Roberts","Test-negative case-control",1501,2022-07-26,"Moderna mRNA-1273","mRNA","2","final",NA,">=3 months",">= 18 years","general pop","included","~48 weeks","severe disease (Jan-March)","severe","severe","other combinations",70,0,93,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"1450",175,"Roberts","Test-negative case-control",1502,2022-07-26,"Moderna mRNA-1273","mRNA","2","final",NA,"<3 months",">= 18 years","general pop","included","~48 weeks","severe disease (Oct-Dec)","severe","severe","other combinations",91,5,99,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"1451",175,"Roberts","Test-negative case-control",1503,2022-07-26,"Moderna mRNA-1273","mRNA","2","final",NA,">=3 months",">= 18 years","general pop","included","~48 weeks","severe disease (Oct-Dec)","severe","severe","other combinations",80,72,88,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"1452",176,"Sritipsukho","Test-negative case-control",1504,2022-02-03,"Oxford/AstraZeneca ChAdOx1-S","Vectored","1","1",NA,"21+",">= 18 years","general pop","excluded",NA,"Infection","infection","infection","delta",49,36,58,"Thailand","THA","Asia","East Asia & Pacific",7060,2019,"Thailand","Upper middle income",3,NA,NA,NA,NA,NA
"1453",176,"Sritipsukho","Test-negative case-control",1505,2022-02-03,"Oxford/AstraZeneca ChAdOx1-S","Vectored","2","final",NA,"14+",">= 18 years","general pop","excluded","~13 weeks","Infection","infection","infection","delta",83,70,90,"Thailand","THA","Asia","East Asia & Pacific",7060,2019,"Thailand","Upper middle income",3,NA,NA,NA,NA,NA
"1454",176,"Sritipsukho","Test-negative case-control",1506,2022-02-03,"Sinovac CoronaVac","Inactivated","1","1",NA,"21+",">= 18 years","general pop","excluded",NA,"Infection","infection","infection","delta",-15,-45,15,"Thailand","THA","Asia","East Asia & Pacific",7060,2019,"Thailand","Upper middle income",3,NA,NA,NA,NA,NA
"1455",176,"Sritipsukho","Test-negative case-control",1507,2022-02-03,"Sinovac CoronaVac","Inactivated","2","final",NA,"14+",">= 18 years","general pop","excluded","~13 weeks","Infection","infection","infection","delta",60,49,69,"Thailand","THA","Asia","East Asia & Pacific",7060,2019,"Thailand","Upper middle income",3,NA,NA,NA,NA,NA
"1456",176,"Sritipsukho","Test-negative case-control",1508,2022-02-03,"Heterologous platforms","Multiple","2","final",NA,"14+",">= 18 years","general pop","excluded","~13 weeks","Infection","infection","infection","delta",74,43,88,"Thailand","THA","Asia","East Asia & Pacific",7060,2019,"Thailand","Upper middle income",3,NA,NA,NA,NA,NA
"1457",177,"Suryatma","Test-negative case-control",1509,2022-02-04,"Sinovac CoronaVac","Inactivated","1","1",NA,"14+",">= 18 years","general pop","excluded",NA,"infection","infection","infection","other combinations",10.5,-12,28.6,"Indonesia","IDN","Asia","East Asia & Pacific",4020,2019,"Indonesia","Upper middle income",2,NA,NA,NA,NA,NA
"1458",177,"Suryatma","Test-negative case-control",1510,2022-02-04,"Sinovac CoronaVac","Inactivated","2","final",NA,"14+",">= 18 years","general pop","excluded","~24 weeks","infection","infection","infection","other combinations",66.7,58.1,73.5,"Indonesia","IDN","Asia","East Asia & Pacific",4020,2019,"Indonesia","Upper middle income",2,NA,NA,NA,NA,NA
"1459",177,"Suryatma","Test-negative case-control",1511,2022-02-04,"Sinovac CoronaVac","Inactivated","1","1",NA,"14+",">= 18 years","general pop","excluded",NA,"hospitalization","severe","severe","other combinations",34.1,16.4,48.1,"Indonesia","IDN","Asia","East Asia & Pacific",4020,2019,"Indonesia","Upper middle income",2,NA,NA,NA,NA,NA
"1460",177,"Suryatma","Test-negative case-control",1512,2022-02-04,"Sinovac CoronaVac","Inactivated","2","final",NA,"14+",">= 18 years","general pop","excluded","~24 weeks","hospitalization","severe","severe","other combinations",71.1,62.9,77.6,"Indonesia","IDN","Asia","East Asia & Pacific",4020,2019,"Indonesia","Upper middle income",2,NA,NA,NA,NA,NA
"1461",177,"Suryatma","Test-negative case-control",1513,2022-02-04,"Sinovac CoronaVac","Inactivated","1","1",NA,"14+",">= 18 years","general pop","excluded",NA,"death","death","death","other combinations",58.6,28.3,76.1,"Indonesia","IDN","Asia","East Asia & Pacific",4020,2019,"Indonesia","Upper middle income",2,NA,NA,NA,NA,NA
"1462",177,"Suryatma","Test-negative case-control",1514,2022-02-04,"Sinovac CoronaVac","Inactivated","2","final",NA,"14+",">= 18 years","general pop","excluded","~24 weeks","death","death","death","other combinations",87.4,65.1,95.4,"Indonesia","IDN","Asia","East Asia & Pacific",4020,2019,"Indonesia","Upper middle income",2,NA,NA,NA,NA,NA
"1463",178,"Lauring","Test-negative case-control",1515,2022-03-09,"Multiple or heterologous RNA","mRNA","2","final",NA,"14+",">= 18 years","general pop","excluded","~3 weeks","hospitalization","severe","severe","omicron",65,51,75,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"1464",178,"Lauring","Test-negative case-control",1516,2022-03-09,"Multiple or heterologous RNA","mRNA","2","final",NA,"150+",">= 18 years","general pop","excluded","~27 weeks","hospitalization","severe","severe","delta",85,83,87,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"1465",178,"Lauring","Test-negative case-control",1517,2022-03-09,"Multiple or heterologous RNA","mRNA","2","final",NA,">150",">= 18 years","general pop","excluded","~27 weeks","hospitalization","severe","severe","delta",90,85,93,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"1466",178,"Lauring","Test-negative case-control",1518,2022-03-09,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"14+",">= 18 years","general pop","excluded","~27 weeks","hospitalization","severe","severe","delta",82,80,84,"USA","USA","North America","North America",66220,2019,"United States","High income",4,14,189,"yes",NA,0
"1467",178,"Lauring","Test-negative case-control",1519,2022-03-09,"Moderna mRNA-1273","mRNA","2","final",NA,"14+",">= 18 years","general pop","excluded","~27 weeks","hospitalization","severe","severe","delta",88,86,90,"USA","USA","North America","North America",66220,2019,"United States","High income",4,14,189,"yes",NA,0
"1468",178,"Lauring","Test-negative case-control",1520,2022-03-09,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"14+",">= 18 years","general pop","excluded","~44 weeks","hospitalization","severe","severe","alpha",82,77,86,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"1469",178,"Lauring","Test-negative case-control",1521,2022-03-09,"Moderna mRNA-1273","mRNA","2","final",NA,"14+",">= 18 years","general pop","excluded","~44 weeks","hospitalization","severe","severe","alpha",90,85,93,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"1470",178,"Lauring","Test-negative case-control",1522,2022-03-09,"Multiple or heterologous RNA","mRNA","1","1",NA,"14+",">= 18 years","general pop","excluded",NA,"hospitalization","severe","severe","other combinations",77,71,81,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"1471",179,"Chemaitelly","Test-negative case-control",1523,2022-06-02,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"1-3 months",">= 18 years","general pop","included","~58 weeks","symptomatic disease","symptomatic","symptomatic","omicron",46.6,33.4,57.2,"Qatar","QAT","Asia","Middle East & North Africa",65700,2019,"Qatar","High income",4,NA,NA,NA,NA,NA
"1472",179,"Chemaitelly","Test-negative case-control",1524,2022-06-02,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"7+ months",">= 18 years","general pop","included","~58 weeks","symptomatic disease","symptomatic","symptomatic","omicron",-17.8,-28.2,-8.2,"Qatar","QAT","Asia","Middle East & North Africa",65700,2019,"Qatar","High income",4,NA,NA,NA,NA,NA
"1473",179,"Chemaitelly","Test-negative case-control",1525,2022-06-02,"Moderna mRNA-1273","mRNA","2","final",NA,"1-3 months",">= 18 years","general pop","included","~58 weeks","symptomatic disease","symptomatic","symptomatic","omicron",71,24,89,"Qatar","QAT","Asia","Middle East & North Africa",65700,2019,"Qatar","High income",4,NA,NA,NA,NA,NA
"1474",179,"Chemaitelly","Test-negative case-control",1526,2022-06-02,"Moderna mRNA-1273","mRNA","2","final",NA,"7+ months",">= 18 years","general pop","included","~58 weeks","symptomatic disease","symptomatic","symptomatic","omicron",-10.2,-23.1,1.3,"Qatar","QAT","Asia","Middle East & North Africa",65700,2019,"Qatar","High income",4,NA,NA,NA,NA,NA
"1475",179,"Chemaitelly","Test-negative case-control",1527,2022-06-02,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"1-3 months",">= 18 years","general pop","included","~58 weeks","symptomatic disease","symptomatic","symptomatic","omicron",51.7,43.2,58.9,"Qatar","QAT","Asia","Middle East & North Africa",65700,2019,"Qatar","High income",4,NA,NA,NA,NA,NA
"1476",179,"Chemaitelly","Test-negative case-control",1528,2022-06-02,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"7+ months",">= 18 years","general pop","included","~58 weeks","symptomatic disease","symptomatic","symptomatic","omicron",-12.1,-19.1,5.5,"Qatar","QAT","Asia","Middle East & North Africa",65700,2019,"Qatar","High income",4,NA,NA,NA,NA,NA
"1477",179,"Chemaitelly","Test-negative case-control",1529,2022-06-02,"Moderna mRNA-1273","mRNA","2","final",NA,"1-3 months",">= 18 years","general pop","included","~58 weeks","symptomatic disease","symptomatic","symptomatic","omicron",35.9,-5.9,61.2,"Qatar","QAT","Asia","Middle East & North Africa",65700,2019,"Qatar","High income",4,NA,NA,NA,NA,NA
"1478",179,"Chemaitelly","Test-negative case-control",1530,2022-06-02,"Moderna mRNA-1273","mRNA","2","final",NA,"7+ months",">= 18 years","general pop","included","~58 weeks","symptomatic disease","symptomatic","symptomatic","omicron",-20.4,-30.2,1.2,"Qatar","QAT","Asia","Middle East & North Africa",65700,2019,"Qatar","High income",4,NA,NA,NA,NA,NA
"1479",179,"Chemaitelly","Test-negative case-control",1531,2022-06-02,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"1-3 months",">= 18 years","general pop","included","~58 weeks","symptomatic disease","symptomatic","symptomatic","omicron",51.7,43.2,58.9,"Qatar","QAT","Asia","Middle East & North Africa",65700,2019,"Qatar","High income",4,NA,NA,NA,NA,NA
"1480",179,"Chemaitelly","Test-negative case-control",1532,2022-06-02,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"7+ months",">= 18 years","general pop","included","~58 weeks","symptomatic disease","symptomatic","symptomatic","omicron",-9,-14.5,-3.7,"Qatar","QAT","Asia","Middle East & North Africa",65700,2019,"Qatar","High income",4,NA,NA,NA,NA,NA
"1481",179,"Chemaitelly","Test-negative case-control",1533,2022-06-02,"Moderna mRNA-1273","mRNA","2","final",NA,"1-3 months",">= 18 years","general pop","included","~58 weeks","symptomatic disease","symptomatic","symptomatic","omicron",43.2,15,62.1,"Qatar","QAT","Asia","Middle East & North Africa",65700,2019,"Qatar","High income",4,NA,NA,NA,NA,NA
"1482",179,"Chemaitelly","Test-negative case-control",1534,2022-06-02,"Moderna mRNA-1273","mRNA","2","final",NA,"7+ months",">= 18 years","general pop","included","~58 weeks","symptomatic disease","symptomatic","symptomatic","omicron",-13.7,-21.3,-6.6,"Qatar","QAT","Asia","Middle East & North Africa",65700,2019,"Qatar","High income",4,NA,NA,NA,NA,NA
"1483",179,"Chemaitelly","Test-negative case-control",1535,2022-06-02,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"1-6 months",">= 18 years","general pop","included","~58 weeks","severe, critical or fatal disease","severe","severe","omicron",70.4,45,85,"Qatar","QAT","Asia","Middle East & North Africa",65700,2019,"Qatar","High income",4,30,180,"yes",NA,0
"1484",179,"Chemaitelly","Test-negative case-control",1536,2022-06-02,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,">=7 months",">= 18 years","general pop","included","~58 weeks","severe, critical or fatal disease","severe","severe","omicron",77.5,67.8,84.3,"Qatar","QAT","Asia","Middle East & North Africa",65700,2019,"Qatar","High income",4,210,406,"no","sequential period",0
"1485",179,"Chemaitelly","Test-negative case-control",1537,2022-06-02,"Moderna mRNA-1273","mRNA","2","final",NA,"1-6 months",">= 18 years","general pop","included","~58 weeks","severe, critical or fatal disease","severe","severe","omicron",87.1,40.2,97.2,"Qatar","QAT","Asia","Middle East & North Africa",65700,2019,"Qatar","High income",4,30,180,"yes",NA,0
"1486",179,"Chemaitelly","Test-negative case-control",1538,2022-06-02,"Moderna mRNA-1273","mRNA","2","final",NA,">=7 months",">= 18 years","general pop","included","~58 weeks","severe, critical or fatal disease","severe","severe","omicron",68.4,46.1,81.5,"Qatar","QAT","Asia","Middle East & North Africa",65700,2019,"Qatar","High income",4,210,406,"no","sequential period",0
"1487",180,"Cerqueira-Silva","Test-negative case-control",1539,2022-02-09,"Sinovac CoronaVac","Inactivated","2","final",NA,"14-30",">= 18 years","general pop","excluded","~30 weeks","infection","infection","infection","other combinations",55,54.3,55.7,"Brazil","BRA","South America","Latin America & Caribbean",9410,2019,"Brazil","Upper middle income",3,NA,NA,NA,NA,NA
"1488",180,"Cerqueira-Silva","Test-negative case-control",1540,2022-02-09,"Sinovac CoronaVac","Inactivated","2","final",NA,"180+",">= 18 years","general pop","excluded","~30 weeks","infection","infection","infection","other combinations",34.7,33.1,36.3,"Brazil","BRA","South America","Latin America & Caribbean",9410,2019,"Brazil","Upper middle income",3,NA,NA,NA,NA,NA
"1489",180,"Cerqueira-Silva","Test-negative case-control",1541,2022-02-09,"Sinovac CoronaVac","Inactivated","2","final",NA,"14-30",">= 18 years","general pop","excluded","~30 weeks","severe disease","severe","severe","other combinations",82.1,81.4,82.8,"Brazil","BRA","South America","Latin America & Caribbean",9410,2019,"Brazil","Upper middle income",3,NA,NA,NA,NA,NA
"1490",180,"Cerqueira-Silva","Test-negative case-control",1542,2022-02-09,"Sinovac CoronaVac","Inactivated","2","final",NA,"180+",">= 18 years","general pop","excluded","~30 weeks","severe disease","severe","severe","other combinations",72.6,71,74.2,"Brazil","BRA","South America","Latin America & Caribbean",9410,2019,"Brazil","Upper middle income",3,NA,NA,NA,NA,NA
"1491",180,"Cerqueira-Silva","Test-negative case-control",1543,2022-02-09,"Sinovac CoronaVac","Inactivated","2","final",NA,"14-30",">= 18 years","general pop","excluded","~30 weeks","hospitalization","severe","severe","other combinations",82.1,81.4,82.8,"Brazil","BRA","South America","Latin America & Caribbean",9410,2019,"Brazil","Upper middle income",3,NA,NA,NA,NA,NA
"1492",180,"Cerqueira-Silva","Test-negative case-control",1544,2022-02-09,"Sinovac CoronaVac","Inactivated","2","final",NA,"180+",">= 18 years","general pop","excluded","~30 weeks","hospitalization","severe","severe","other combinations",72.4,70.7,73.9,"Brazil","BRA","South America","Latin America & Caribbean",9410,2019,"Brazil","Upper middle income",3,NA,NA,NA,NA,NA
"1493",180,"Cerqueira-Silva","Test-negative case-control",1545,2022-02-09,"Sinovac CoronaVac","Inactivated","2","final",NA,"14-30",">= 18 years","general pop","excluded","~30 weeks","death","death","death","other combinations",82.7,81.7,83.6,"Brazil","BRA","South America","Latin America & Caribbean",9410,2019,"Brazil","Upper middle income",3,NA,NA,NA,NA,NA
"1494",180,"Cerqueira-Silva","Test-negative case-control",1546,2022-02-09,"Sinovac CoronaVac","Inactivated","2","final",NA,"180+",">= 18 years","general pop","excluded","~30 weeks","death","death","death","other combinations",74.8,72.2,77.2,"Brazil","BRA","South America","Latin America & Caribbean",9410,2019,"Brazil","Upper middle income",3,NA,NA,NA,NA,NA
"1495",181,"Butt","Test-negative case-control",1547,2022-02-09,"BioNTech/Pfizer BNT162b2","mRNA","1","1",NA,"14+","haemodialysis patients","haemodialysis patients","excluded",NA,"infection","infection","infection","delta",60.6,25.5,79.2,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"1496",181,"Butt","Test-negative case-control",1548,2022-02-09,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"14+","haemodialysis patients","haemodialysis patients","excluded","~31 weeks","infection","infection","infection","delta",68.9,61.9,74.7,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"1497",181,"Butt","Test-negative case-control",1549,2022-02-09,"Moderna mRNA-1273","mRNA","1","1",NA,"14+","haemodialysis patients","haemodialysis patients","excluded",NA,"infection","infection","infection","delta",37.2,27.1,69,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"1498",181,"Butt","Test-negative case-control",1550,2022-02-09,"Moderna mRNA-1273","mRNA","2","final",NA,"14+","haemodialysis patients","haemodialysis patients","excluded","~31 weeks","infection","infection","infection","delta",66.7,58.9,73,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"1499",183,"Hayek","Retrospective cohort",1553,2022-01-27,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"7+","households with children","households with children","excluded","~12 weeks","infection","infection","infection","alpha",94.4,93.2,95.4,"Israel","ISR","Asia","Middle East & North Africa",43800,2019,"Israel","High income",4,NA,NA,NA,NA,NA
"1500",184,"Goldin","Retrospective cohort",1554,2022-02-08,"BioNTech/Pfizer BNT162b2","mRNA","1","1",NA,"10+","LTCF residents","LTCF residents","excluded",NA,"infection","infection","infection","other combinations",61.8,58.2,65.1,"Israel","ISR","Asia","Middle East & North Africa",43800,2019,"Israel","High income",4,NA,NA,NA,NA,NA
"1501",184,"Goldin","Retrospective cohort",1555,2022-02-08,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"7+","LTCF residents","LTCF residents","excluded","~16.5 weeks","infection","infection","infection","other combinations",81.2,78.6,83.5,"Israel","ISR","Asia","Middle East & North Africa",43800,2019,"Israel","High income",4,NA,NA,NA,NA,NA
"1502",184,"Goldin","Retrospective cohort",1556,2022-02-08,"BioNTech/Pfizer BNT162b2","mRNA","1","1",NA,"10+","LTCF residents","LTCF residents","excluded",NA,"death","death","death","other combinations",72.3,66.9,76.8,"Israel","ISR","Asia","Middle East & North Africa",43800,2019,"Israel","High income",4,NA,NA,NA,NA,NA
"1503",184,"Goldin","Retrospective cohort",1557,2022-02-08,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"7+","LTCF residents","LTCF residents","excluded","~16.5 weeks","death","death","death","other combinations",85.3,80.4,88.9,"Israel","ISR","Asia","Middle East & North Africa",43800,2019,"Israel","High income",4,NA,NA,NA,NA,NA
"1504",185,"Ferdinands","Test-negative case-control",1558,2022-02-11,"Multiple or heterologous RNA","mRNA","2","final",NA,"<2 months","ED encounters and hospital admissions","general pop","included","~53 weeks","ED or UC visit","symptomatic","symptomatic","omicron",69,62,75,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"1505",185,"Ferdinands","Test-negative case-control",1559,2022-02-11,"Multiple or heterologous RNA","mRNA","2","final",NA,">=5 months","ED encounters and hospital admissions","general pop","included","~53 weeks","ED or UC visit","symptomatic","symptomatic","omicron",37,34,40,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"1506",185,"Ferdinands","Test-negative case-control",1560,2022-02-11,"Multiple or heterologous RNA","mRNA","2","final",NA,"<2 months","ED encounters and hospital admissions","general pop","included","~53 weeks","hospitalization","severe","severe","omicron",71,51,83,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"1507",185,"Ferdinands","Test-negative case-control",1561,2022-02-11,"Multiple or heterologous RNA","mRNA","2","final",NA,">=5 months","ED encounters and hospital admissions","general pop","included","~53 weeks","hospitalization","severe","severe","omicron",54,48,59,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"1508",185,"Ferdinands","Test-negative case-control",1562,2022-02-11,"Multiple or heterologous RNA","mRNA","2","final",NA,"<2 months","ED encounters and hospital admissions","general pop","included","~25 weeks","ED or UC visit","symptomatic","symptomatic","delta",92,91,94,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"1509",185,"Ferdinands","Test-negative case-control",1563,2022-02-11,"Multiple or heterologous RNA","mRNA","2","final",NA,">=5 months","ED encounters and hospital admissions","general pop","included","~25 weeks","ED or UC visit","symptomatic","symptomatic","delta",77,76,78,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"1510",185,"Ferdinands","Test-negative case-control",1564,2022-02-11,"Multiple or heterologous RNA","mRNA","2","final",NA,"<2 months","ED encounters and hospital admissions","general pop","included","~25 weeks","hospitalization","severe","severe","delta",94,92,96,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"1511",185,"Ferdinands","Test-negative case-control",1565,2022-02-11,"Multiple or heterologous RNA","mRNA","2","final",NA,">=5 months","ED encounters and hospital admissions","general pop","included","~25 weeks","hospitalization","severe","severe","delta",82,82,83,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"1512",186,"Jara","Prospective cohort",1566,2023-04-20,"Sinovac CoronaVac","Inactivated","2","final",NA,"14+","6-16 years","6-16 years","excluded","~28 weeks","infection","infection","infection","delta",74.8,74.1,75.5,"Chile","CHL","South America","Latin America & Caribbean",14690,2019,"Chile","High income",3,NA,NA,NA,NA,NA
"1513",186,"Jara","Prospective cohort",1567,2023-04-20,"Sinovac CoronaVac","Inactivated","2","final",NA,"14+","6-16 years","6-16 years","excluded","~28 weeks","hospitalization","severe","severe","delta",91.3,88.1,93.6,"Chile","CHL","South America","Latin America & Caribbean",14690,2019,"Chile","High income",3,NA,NA,NA,NA,NA
"1514",186,"Jara","Prospective cohort",1568,2023-04-20,"Sinovac CoronaVac","Inactivated","2","final",NA,"14+","6-16 years","6-16 years","excluded","~28 weeks","ICU admission","severe","severe","delta",93.8,85.7,97.3,"Chile","CHL","South America","Latin America & Caribbean",14690,2019,"Chile","High income",3,NA,NA,NA,NA,NA
"1515",186,"Jara","Prospective cohort",1569,2023-04-20,"Sinovac CoronaVac","Inactivated","2","final",NA,"14+","6-11 years","6-11 years","excluded","~28 weeks","infection","infection","infection","delta",75.8,74.8,76.8,"Chile","CHL","South America","Latin America & Caribbean",14690,2019,"Chile","High income",3,NA,NA,NA,NA,NA
"1516",186,"Jara","Prospective cohort",1570,2023-04-20,"Sinovac CoronaVac","Inactivated","2","final",NA,"14+","6-11 years","6-11 years","excluded","~28 weeks","hospitalization","severe","severe","delta",78.5,62.8,87.6,"Chile","CHL","South America","Latin America & Caribbean",14690,2019,"Chile","High income",3,NA,NA,NA,NA,NA
"1517",186,"Jara","Prospective cohort",1571,2023-04-20,"Sinovac CoronaVac","Inactivated","2","final",NA,"14+","12-16 years","12-16 years","excluded","~28 weeks","infection","infection","infection","delta",73.6,72.5,74.6,"Chile","CHL","South America","Latin America & Caribbean",14690,2019,"Chile","High income",3,NA,NA,NA,NA,NA
"1518",186,"Jara","Prospective cohort",1572,2023-04-20,"Sinovac CoronaVac","Inactivated","2","final",NA,"14+","12-16 years","12-16 years","excluded","~28 weeks","hospitalization","severe","severe","delta",93.4,90.4,95.5,"Chile","CHL","South America","Latin America & Caribbean",14690,2019,"Chile","High income",3,NA,NA,NA,NA,NA
"1519",186,"Jara","Prospective cohort",1573,2023-04-20,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"14+","12-16 years","12-16 years","excluded","~30 weeks","infection","infection","infection","delta",84.4,83.7,85,"Chile","CHL","South America","Latin America & Caribbean",14690,2019,"Chile","High income",3,NA,NA,NA,NA,NA
"1520",186,"Jara","Prospective cohort",1574,2023-04-20,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"14+","12-16 years","12-16 years","excluded","~30 weeks","hospitalization","severe","severe","delta",93.5,90.4,95.6,"Chile","CHL","South America","Latin America & Caribbean",14690,2019,"Chile","High income",3,NA,NA,NA,NA,NA
"1521",186,"Jara","Prospective cohort",1575,2023-04-20,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"14+","12-16 years","12-16 years","excluded","~30 weeks","ICU admission","severe","severe","delta",98,89.9,99.6,"Chile","CHL","South America","Latin America & Caribbean",14690,2019,"Chile","High income",3,NA,NA,NA,NA,NA
"1522",187,"Halasa","Test-negative case-control",1576,2022-06-22,"Multiple or heterologous RNA","mRNA","2","final",NA,"14+","infants <6 months when timing of maternal vaccination was anytime up to 14 days before delivery","infants <6 months when timing of maternal vaccination was anytime up to 14 days before delivery","included","~33 weeks","hospitalization","severe","severe","delta/omicron",52,33,65,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"1523",187,"Halasa","Test-negative case-control",1577,2022-06-22,"Multiple or heterologous RNA","mRNA","2","final",NA,"14+","infants <6 months when timing of maternal vaccination was in first 20 weeks","infants <6 months when timing of maternal vaccination was in first 20 weeks","included","~33 weeks","hospitalization","severe","severe","delta/omicron",38,3,60,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"1524",187,"Halasa","Test-negative case-control",1578,2022-06-22,"Multiple or heterologous RNA","mRNA","2","final",NA,"14+","infants <6 months when timing of maternal vaccination was from 21 weeks' gestation up to 14 days before delivery","infants <6 months when timing of maternal vaccination was from 21 weeks' gestation up to 14 days before delivery","included","~33 weeks","hospitalization","severe","severe","delta/omicron",69,50,80,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"1525",187,"Halasa","Test-negative case-control",1579,2022-06-22,"Multiple or heterologous RNA","mRNA","2","final",NA,"14+","infants <6 months when timing of maternal vaccination was anytime up to 14 days before delivery","infants <6 months when timing of maternal vaccination was anytime up to 14 days before delivery","included","~33 weeks","hospitalization","severe","severe","omicron",38,8,58,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"1526",187,"Halasa","Test-negative case-control",1580,2022-06-22,"Multiple or heterologous RNA","mRNA","2","final",NA,"14+","infants <6 months when timing of maternal vaccination was in first 20 weeks","infants <6 months when timing of maternal vaccination was in first 20 weeks","included","~33 weeks","hospitalization","severe","severe","omicron",25,-26,56,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"1527",187,"Halasa","Test-negative case-control",1581,2022-06-22,"Multiple or heterologous RNA","mRNA","2","final",NA,"14+","infants <6 months when timing of maternal vaccination was from 21 weeks' gestation up to 14 days before delivery","infants <6 months when timing of maternal vaccination was from 21 weeks' gestation up to 14 days before delivery","included","~33 weeks","hospitalization","severe","severe","omicron",57,25,75,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"1528",187,"Halasa","Test-negative case-control",1582,2022-06-22,"Multiple or heterologous RNA","mRNA","2","final",NA,"14+","infants <6 months when timing of maternal vaccination was anytime up to 14 days before delivery","infants <6 months when timing of maternal vaccination was anytime up to 14 days before delivery","included","~33 weeks","hospitalization","severe","severe","delta",80,60,90,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"1529",187,"Halasa","Test-negative case-control",1583,2022-06-22,"Multiple or heterologous RNA","mRNA","2","final",NA,"14+","infants <6 months when timing of maternal vaccination was in first 20 weeks","infants <6 months when timing of maternal vaccination was in first 20 weeks","included","~33 weeks","hospitalization","severe","severe","delta",68,19,87,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"1530",187,"Halasa","Test-negative case-control",1584,2022-06-22,"Multiple or heterologous RNA","mRNA","2","final",NA,"14+","infants <6 months when timing of maternal vaccination was from 21 weeks' gestation up to 14 days before delivery","infants <6 months when timing of maternal vaccination was from 21 weeks' gestation up to 14 days before delivery","included","~33 weeks","hospitalization","severe","severe","delta",88,68,96,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"1531",188,"Gazit","Retrospective cohort",1585,2022-02-15,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"14+",">= 18 years","general pop","included","~40 weeks","infection","infection","infection","other combinations",82,80,85,"Israel","ISR","Asia","Middle East & North Africa",43800,2019,"Israel","High income",4,NA,NA,NA,NA,NA
"1532",188,"Gazit","Retrospective cohort",1586,2022-02-15,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"14+",">= 18 years","general pop","included","~40 weeks","symptomatic disease","symptomatic","symptomatic","other combinations",76,71,80,"Israel","ISR","Asia","Middle East & North Africa",43800,2019,"Israel","High income",4,NA,NA,NA,NA,NA
"1533",189,"Filon","Retrospective cohort",1587,2022-02-15,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"14+","HCW","HCW","excluded","~16 weeks","infection (March)","infection","infection","other combinations",95,92,98,"Italy","ITA","Europe","Europe & Central Asia",34890,2019,"Italy","High income",4,NA,NA,NA,NA,NA
"1534",189,"Filon","Retrospective cohort",1588,2022-02-15,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"14+","HCW","HCW","excluded","~16 weeks","infection (April)","infection","infection","other combinations",95,92,98,"Italy","ITA","Europe","Europe & Central Asia",34890,2019,"Italy","High income",4,NA,NA,NA,NA,NA
"1535",189,"Filon","Retrospective cohort",1589,2022-02-15,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"14+","HCW","HCW","excluded","~16 weeks","infection (May)","infection","infection","other combinations",80,70,84,"Italy","ITA","Europe","Europe & Central Asia",34890,2019,"Italy","High income",4,NA,NA,NA,NA,NA
"1536",190,"Wu","Retrospective cohort",1590,2022-01-10,"Beijing/Sinopharm BBIBP-CorV","Inactivated","1+","1+",NA,"14+","close contacts","Contacts of index cases","excluded",NA,"symptomatic disease","symptomatic","symptomatic","delta",24.7,-98.8,71.4,"China","CHN","Asia","East Asia & Pacific",10310,2019,"China","Upper middle income",3,NA,NA,NA,NA,NA
"1537",190,"Wu","Retrospective cohort",1591,2022-01-10,"Beijing/Sinopharm BBIBP-CorV","Inactivated","2","final",NA,"14+","close contacts","Contacts of index cases","excluded","~24 weeks","symptomatic disease","symptomatic","symptomatic","delta",50.5,3.8,74.6,"China","CHN","Asia","East Asia & Pacific",10310,2019,"China","Upper middle income",3,NA,NA,NA,NA,NA
"1538",190,"Wu","Retrospective cohort",1592,2022-01-10,"Beijing/Sinopharm BBIBP-CorV","Inactivated","2","final",NA,">=3 months","close contacts","Contacts of index cases","excluded","~24 weeks","symptomatic disease","symptomatic","symptomatic","delta",39.3,-20.4,69.4,"China","CHN","Asia","East Asia & Pacific",10310,2019,"China","Upper middle income",3,NA,NA,NA,NA,NA
"1539",190,"Wu","Retrospective cohort",1593,2022-01-10,"Beijing/Sinopharm BBIBP-CorV","Inactivated","2","final",NA,"4-6 months","close contacts","Contacts of index cases","excluded","~24 weeks","symptomatic disease","symptomatic","symptomatic","delta",82,-25.7,97.4,"China","CHN","Asia","East Asia & Pacific",10310,2019,"China","Upper middle income",3,NA,NA,NA,NA,NA
"1540",190,"Wu","Retrospective cohort",1594,2022-01-10,"Beijing/Sinopharm BBIBP-CorV","Inactivated","1+","1+",NA,"14+","close contacts","Contacts of index cases","excluded",NA,"pneumonia","severe","severe","delta",16.3,-164.3,73.2,"China","CHN","Asia","East Asia & Pacific",10310,2019,"China","Upper middle income",3,NA,NA,NA,NA,NA
"1541",190,"Wu","Retrospective cohort",1595,2022-01-10,"Beijing/Sinopharm BBIBP-CorV","Inactivated","2","final",NA,"14+","close contacts","Contacts of index cases","excluded","~24 weeks","pneumonia","severe","severe","delta",54.7,-3.4,80.2,"China","CHN","Asia","East Asia & Pacific",10310,2019,"China","Upper middle income",3,NA,NA,NA,NA,NA
"1542",190,"Wu","Retrospective cohort",1596,2022-01-10,"Beijing/Sinopharm BBIBP-CorV","Inactivated","2","final",NA,">=3 months","close contacts","Contacts of index cases","excluded","~24 weeks","pneumonia","severe","severe","delta",39.6,-35.4,73.1,"China","CHN","Asia","East Asia & Pacific",10310,2019,"China","Upper middle income",3,NA,NA,NA,NA,NA
"1543",190,"Wu","Retrospective cohort",1597,2022-01-10,"Beijing/Sinopharm BBIBP-CorV","Inactivated","1+","1+",NA,"14+","close contacts","Contacts of index cases","excluded",NA,"severe disease","severe","severe","delta",7.5,-655.6,88.7,"China","CHN","Asia","East Asia & Pacific",10310,2019,"China","Upper middle income",3,NA,NA,NA,NA,NA
"1544",190,"Wu","Retrospective cohort",1598,2022-01-10,"Sinovac CoronaVac","Inactivated","1+","1+",NA,"14+","close contacts","Contacts of index cases","excluded",NA,"symptomatic disease","symptomatic","symptomatic","delta",29.9,-44.3,66,"China","CHN","Asia","East Asia & Pacific",10310,2019,"China","Upper middle income",3,NA,NA,NA,NA,NA
"1545",190,"Wu","Retrospective cohort",1599,2022-01-10,"Sinovac CoronaVac","Inactivated","2","final",NA,"14+","close contacts","Contacts of index cases","excluded","~24 weeks","symptomatic disease","symptomatic","symptomatic","delta",39.1,-0.9,63.3,"China","CHN","Asia","East Asia & Pacific",10310,2019,"China","Upper middle income",3,NA,NA,NA,NA,NA
"1546",190,"Wu","Retrospective cohort",1600,2022-01-10,"Sinovac CoronaVac","Inactivated","2","final",NA,">=3 months","close contacts","Contacts of index cases","excluded","~24 weeks","symptomatic disease","symptomatic","symptomatic","delta",45.5,-5.9,71.9,"China","CHN","Asia","East Asia & Pacific",10310,2019,"China","Upper middle income",3,NA,NA,NA,NA,NA
"1547",190,"Wu","Retrospective cohort",1601,2022-01-10,"Sinovac CoronaVac","Inactivated","2","final",NA,"4-6 months","close contacts","Contacts of index cases","excluded","~24 weeks","symptomatic disease","symptomatic","symptomatic","delta",29.8,-41.1,65.1,"China","CHN","Asia","East Asia & Pacific",10310,2019,"China","Upper middle income",3,NA,NA,NA,NA,NA
"1548",190,"Wu","Retrospective cohort",1602,2022-01-10,"Sinovac CoronaVac","Inactivated","1","1",NA,"14+","close contacts","Contacts of index cases","excluded",NA,"pneumonia","severe","severe","delta",52.6,-25.2,82.1,"China","CHN","Asia","East Asia & Pacific",10310,2019,"China","Upper middle income",3,NA,NA,NA,NA,NA
"1549",190,"Wu","Retrospective cohort",1603,2022-01-10,"Sinovac CoronaVac","Inactivated","2","final",NA,"14+","close contacts","Contacts of index cases","excluded","~24 weeks","pneumonia","severe","severe","delta",64.9,22.8,84,"China","CHN","Asia","East Asia & Pacific",10310,2019,"China","Upper middle income",3,NA,NA,NA,NA,NA
"1550",190,"Wu","Retrospective cohort",1604,2022-01-10,"Sinovac CoronaVac","Inactivated","2","final",NA,">=3 months","close contacts","Contacts of index cases","excluded","~24 weeks","pneumonia","severe","severe","delta",73.8,17.9,91.6,"China","CHN","Asia","East Asia & Pacific",10310,2019,"China","Upper middle income",3,NA,NA,NA,NA,NA
"1551",190,"Wu","Retrospective cohort",1605,2022-01-10,"Sinovac CoronaVac","Inactivated","2","final",NA,"4-6 months","close contacts","Contacts of index cases","excluded","~24 weeks","pneumonia","severe","severe","delta",47.4,-44.3,80.8,"China","CHN","Asia","East Asia & Pacific",10310,2019,"China","Upper middle income",3,NA,NA,NA,NA,NA
"1552",190,"Wu","Retrospective cohort",1606,2022-01-10,"Sinovac CoronaVac","Inactivated","1","1",NA,"14+","close contacts","Contacts of index cases","excluded",NA,"severe disease","severe","severe","delta",59.7,-209.9,94.7,"China","CHN","Asia","East Asia & Pacific",10310,2019,"China","Upper middle income",3,NA,NA,NA,NA,NA
"1553",191,"Mallow","Test-negative case-control",1607,2022-02-09,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"14+","ED patients (aged 18+)","general pop","unknown","~31 weeks","ED visits","symptomatic","symptomatic","other combinations",73.9,66.3,79.8,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"1554",191,"Mallow","Test-negative case-control",1608,2022-02-09,"Moderna mRNA-1273","mRNA","2","final",NA,"14+","ED patients (aged 18+)","general pop","unknown","~31 weeks","ED visits","symptomatic","symptomatic","other combinations",78,68.1,84.9,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"1555",192,"Shen","Retrospective cohort",1609,2022-02-23,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"14+","immunocompromised","immunocompromised adults","excluded","~36 weeks","Infection","infection","infection","other combinations",41,9,62,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"1556",192,"Shen","Retrospective cohort",1610,2022-02-23,"Moderna mRNA-1273","mRNA","2","final",NA,"14+","immunocompromised","immunocompromised adults","excluded","~36 weeks","Infection","infection","infection","other combinations",48,18,67,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"1557",192,"Shen","Retrospective cohort",1611,2022-02-23,"Janssen Ad26.COV2.S","Vectored","1","final",NA,"14+","immunocompromised","immunocompromised adults","excluded","~36 weeks","Infection","infection","infection","other combinations",66,-30,91,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"1558",193,"Cura-Bilbao","Prospective cohort",1612,2022-02-02,"BioNTech/Pfizer BNT162b2","mRNA","1","1",NA,"12+",">= 18 years","general pop","excluded",NA,"Infection","infection","infection","other combinations",20.8,11.6,29,"Spain","ESP","Europe","Europe & Central Asia",30370,2019,"Spain","High income",4,NA,NA,NA,NA,NA
"1559",193,"Cura-Bilbao","Prospective cohort",1613,2022-02-02,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"7+",">= 18 years","general pop","excluded","~16 weeks","Infection","infection","infection","other combinations",70,65.3,74.1,"Spain","ESP","Europe","Europe & Central Asia",30370,2019,"Spain","High income",4,NA,NA,NA,NA,NA
"1560",193,"Cura-Bilbao","Prospective cohort",1614,2022-02-02,"Moderna mRNA-1273","mRNA","1","1",NA,"14+",">= 18 years","general pop","excluded",NA,"Infection","infection","infection","other combinations",52.8,30.7,67.8,"Spain","ESP","Europe","Europe & Central Asia",30370,2019,"Spain","High income",4,NA,NA,NA,NA,NA
"1561",193,"Cura-Bilbao","Prospective cohort",1615,2022-02-02,"Moderna mRNA-1273","mRNA","2","final",NA,"14+",">= 18 years","general pop","excluded","~16 weeks","Infection","infection","infection","other combinations",70.3,52.2,81.5,"Spain","ESP","Europe","Europe & Central Asia",30370,2019,"Spain","High income",4,NA,NA,NA,NA,NA
"1562",193,"Cura-Bilbao","Prospective cohort",1616,2022-02-02,"Oxford/AstraZeneca ChAdOx1-S","Vectored","1","1",NA,"21+",">= 18 years","general pop","excluded",NA,"Infection","infection","infection","other combinations",40.3,31.8,47.7,"Spain","ESP","Europe","Europe & Central Asia",30370,2019,"Spain","High income",4,NA,NA,NA,NA,NA
"1563",194,"Smid","Retrospective cohort",1617,2022-10-15,"BioNTech/Pfizer BNT162b2","mRNA","1","1",NA,"14-74","all ages","general pop","included",NA,"Infection","infection","infection","omicron",31,28,34,"Czech Republic","CZE","Europe","Europe & Central Asia",22100,2019,"Czechia","High income",3,NA,NA,NA,NA,NA
"1564",194,"Smid","Retrospective cohort",1618,2022-10-15,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"14-74","all ages","general pop","included","~54 weeks","Infection","infection","infection","omicron",49,48,50,"Czech Republic","CZE","Europe","Europe & Central Asia",22100,2019,"Czechia","High income",3,NA,NA,NA,NA,NA
"1565",194,"Smid","Retrospective cohort",1619,2022-10-15,"BioNTech/Pfizer BNT162b2","mRNA","1","1",NA,"75+","all ages","general pop","included",NA,"Infection","infection","infection","omicron",53,46,59,"Czech Republic","CZE","Europe","Europe & Central Asia",22100,2019,"Czechia","High income",3,NA,NA,NA,NA,NA
"1566",194,"Smid","Retrospective cohort",1620,2022-10-15,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"135+","all ages","general pop","included","~54 weeks","Infection","infection","infection","omicron",11,10,12,"Czech Republic","CZE","Europe","Europe & Central Asia",22100,2019,"Czechia","High income",3,NA,NA,NA,NA,NA
"1567",194,"Smid","Retrospective cohort",1621,2022-10-15,"BioNTech/Pfizer BNT162b2","mRNA","1","1",NA,"14-74","all ages","general pop","included",NA,"hospitalization","severe","severe","omicron",41,-3,66,"Czech Republic","CZE","Europe","Europe & Central Asia",22100,2019,"Czechia","High income",3,NA,NA,NA,NA,NA
"1568",194,"Smid","Retrospective cohort",1622,2022-10-15,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"14-74","all ages","general pop","included","~54 weeks","hospitalization","severe","severe","omicron",46,28,60,"Czech Republic","CZE","Europe","Europe & Central Asia",22100,2019,"Czechia","High income",3,14,74,"yes",NA,0
"1569",194,"Smid","Retrospective cohort",1623,2022-10-15,"BioNTech/Pfizer BNT162b2","mRNA","1","1",NA,"75+","all ages","general pop","included",NA,"hospitalization","severe","severe","omicron",4,-287,76,"Czech Republic","CZE","Europe","Europe & Central Asia",22100,2019,"Czechia","High income",3,NA,NA,NA,NA,NA
"1570",194,"Smid","Retrospective cohort",1624,2022-10-15,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"135+","all ages","general pop","included","~54 weeks","hospitalization","severe","severe","omicron",34,24,42,"Czech Republic","CZE","Europe","Europe & Central Asia",22100,2019,"Czechia","High income",3,135,378,"no","sequential period",0
"1571",194,"Smid","Retrospective cohort",1625,2022-10-15,"Moderna mRNA-1273","mRNA","1","1",NA,"14-74","all ages","general pop","included",NA,"Infection","infection","infection","omicron",49,42,55,"Czech Republic","CZE","Europe","Europe & Central Asia",22100,2019,"Czechia","High income",3,NA,NA,NA,NA,NA
"1572",194,"Smid","Retrospective cohort",1626,2022-10-15,"Moderna mRNA-1273","mRNA","2","final",NA,"14-74","all ages","general pop","included","~54 weeks","Infection","infection","infection","omicron",48,44,52,"Czech Republic","CZE","Europe","Europe & Central Asia",22100,2019,"Czechia","High income",3,NA,NA,NA,NA,NA
"1573",194,"Smid","Retrospective cohort",1627,2022-10-15,"Moderna mRNA-1273","mRNA","1","1",NA,"75+","all ages","general pop","included",NA,"Infection","infection","infection","omicron",60,36,75,"Czech Republic","CZE","Europe","Europe & Central Asia",22100,2019,"Czechia","High income",3,NA,NA,NA,NA,NA
"1574",194,"Smid","Retrospective cohort",1628,2022-10-15,"Moderna mRNA-1273","mRNA","2","final",NA,"135+","all ages","general pop","included","~54 weeks","Infection","infection","infection","omicron",20,17,22,"Czech Republic","CZE","Europe","Europe & Central Asia",22100,2019,"Czechia","High income",3,NA,NA,NA,NA,NA
"1575",194,"Smid","Retrospective cohort",1629,2022-10-15,"Moderna mRNA-1273","mRNA","1","1",NA,"14-74","all ages","general pop","included",NA,"hospitalization","severe","severe","omicron",56,-78,89,"Czech Republic","CZE","Europe","Europe & Central Asia",22100,2019,"Czechia","High income",3,NA,NA,NA,NA,NA
"1576",194,"Smid","Retrospective cohort",1630,2022-10-15,"Moderna mRNA-1273","mRNA","2","final",NA,"14-74","all ages","general pop","included","~54 weeks","hospitalization","severe","severe","omicron",51,-20,80,"Czech Republic","CZE","Europe","Europe & Central Asia",22100,2019,"Czechia","High income",3,14,74,"yes",NA,0
"1577",194,"Smid","Retrospective cohort",1631,2022-10-15,"Moderna mRNA-1273","mRNA","1","1",NA,"75+","all ages","general pop","included",NA,"hospitalization","severe","severe","omicron",-160,-1743,64,"Czech Republic","CZE","Europe","Europe & Central Asia",22100,2019,"Czechia","High income",3,NA,NA,NA,NA,NA
"1578",194,"Smid","Retrospective cohort",1632,2022-10-15,"Moderna mRNA-1273","mRNA","2","final",NA,"135+","all ages","general pop","included","~54 weeks","hospitalization","severe","severe","omicron",31,9,49,"Czech Republic","CZE","Europe","Europe & Central Asia",22100,2019,"Czechia","High income",3,135,378,"no","sequential period",0
"1579",194,"Smid","Retrospective cohort",1633,2022-10-15,"Oxford/AstraZeneca ChAdOx1-S","Vectored","2","final",NA,"75-135","all ages","general pop","included","~54 weeks","Infection","infection","infection","omicron",51,23,69,"Czech Republic","CZE","Europe","Europe & Central Asia",22100,2019,"Czechia","High income",3,NA,NA,NA,NA,NA
"1580",194,"Smid","Retrospective cohort",1634,2022-10-15,"Oxford/AstraZeneca ChAdOx1-S","Vectored","2","final",NA,"135+","all ages","general pop","included","~54 weeks","Infection","infection","infection","omicron",5,1,9,"Czech Republic","CZE","Europe","Europe & Central Asia",22100,2019,"Czechia","High income",3,NA,NA,NA,NA,NA
"1581",194,"Smid","Retrospective cohort",1635,2022-10-15,"Oxford/AstraZeneca ChAdOx1-S","Vectored","2","final",NA,"75-135","all ages","general pop","included","~54 weeks","hospitalization","severe","severe","omicron",-139,-861,41,"Czech Republic","CZE","Europe","Europe & Central Asia",22100,2019,"Czechia","High income",3,75,135,"yes",NA,0
"1582",194,"Smid","Retrospective cohort",1636,2022-10-15,"Oxford/AstraZeneca ChAdOx1-S","Vectored","2","final",NA,"135+","all ages","general pop","included","~54 weeks","hospitalization","severe","severe","omicron",13,-8,30,"Czech Republic","CZE","Europe","Europe & Central Asia",22100,2019,"Czechia","High income",3,135,378,"no","sequential period",0
"1583",194,"Smid","Retrospective cohort",1637,2022-10-15,"Janssen Ad26.COV2.S","Vectored","1","final",NA,"14-74","all ages","general pop","included","~54 weeks","Infection","infection","infection","omicron",47,45,49,"Czech Republic","CZE","Europe","Europe & Central Asia",22100,2019,"Czechia","High income",3,NA,NA,NA,NA,NA
"1584",194,"Smid","Retrospective cohort",1638,2022-10-15,"Janssen Ad26.COV2.S","Vectored","1","final",NA,"135+","all ages","general pop","included","~54 weeks","Infection","infection","infection","omicron",35,33,38,"Czech Republic","CZE","Europe","Europe & Central Asia",22100,2019,"Czechia","High income",3,NA,NA,NA,NA,NA
"1585",194,"Smid","Retrospective cohort",1639,2022-10-15,"Janssen Ad26.COV2.S","Vectored","1","final",NA,"14-74","all ages","general pop","included","~54 weeks","hospitalization","severe","severe","omicron",28,-22,57,"Czech Republic","CZE","Europe","Europe & Central Asia",22100,2019,"Czechia","High income",3,NA,NA,NA,NA,NA
"1586",194,"Smid","Retrospective cohort",1640,2022-10-15,"Janssen Ad26.COV2.S","Vectored","1","final",NA,"135+","all ages","general pop","included","~54 weeks","hospitalization","severe","severe","omicron",38,8,58,"Czech Republic","CZE","Europe","Europe & Central Asia",22100,2019,"Czechia","High income",3,NA,NA,NA,NA,NA
"1587",194,"Smid","Retrospective cohort",1641,2022-10-15,"BioNTech/Pfizer BNT162b2","mRNA","1","1",NA,"14-74","all ages","general pop","included",NA,"Infection","infection","infection","delta",67,65,69,"Czech Republic","CZE","Europe","Europe & Central Asia",22100,2019,"Czechia","High income",3,NA,NA,NA,NA,NA
"1588",194,"Smid","Retrospective cohort",1642,2022-10-15,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"14-74","all ages","general pop","included","~54 weeks","Infection","infection","infection","delta",82,81,83,"Czech Republic","CZE","Europe","Europe & Central Asia",22100,2019,"Czechia","High income",3,NA,NA,NA,NA,NA
"1589",194,"Smid","Retrospective cohort",1643,2022-10-15,"BioNTech/Pfizer BNT162b2","mRNA","1","1",NA,"75+","all ages","general pop","included",NA,"Infection","infection","infection","delta",61,51,69,"Czech Republic","CZE","Europe","Europe & Central Asia",22100,2019,"Czechia","High income",3,NA,NA,NA,NA,NA
"1590",194,"Smid","Retrospective cohort",1644,2022-10-15,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"135+","all ages","general pop","included","~54 weeks","Infection","infection","infection","delta",54,53,55,"Czech Republic","CZE","Europe","Europe & Central Asia",22100,2019,"Czechia","High income",3,NA,NA,NA,NA,NA
"1591",194,"Smid","Retrospective cohort",1645,2022-10-15,"BioNTech/Pfizer BNT162b2","mRNA","1","1",NA,"14-74","all ages","general pop","included",NA,"hospitalization","severe","severe","delta",53,40,63,"Czech Republic","CZE","Europe","Europe & Central Asia",22100,2019,"Czechia","High income",3,NA,NA,NA,NA,NA
"1592",194,"Smid","Retrospective cohort",1646,2022-10-15,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"14-74","all ages","general pop","included","~54 weeks","hospitalization","severe","severe","delta",80,72,85,"Czech Republic","CZE","Europe","Europe & Central Asia",22100,2019,"Czechia","High income",3,14,74,"yes",NA,0
"1593",194,"Smid","Retrospective cohort",1647,2022-10-15,"BioNTech/Pfizer BNT162b2","mRNA","1","1",NA,"75+","all ages","general pop","included",NA,"hospitalization","severe","severe","delta",61,-20,87,"Czech Republic","CZE","Europe","Europe & Central Asia",22100,2019,"Czechia","High income",3,NA,NA,NA,NA,NA
"1594",194,"Smid","Retrospective cohort",1648,2022-10-15,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"135+","all ages","general pop","included","~54 weeks","hospitalization","severe","severe","delta",82,77,86,"Czech Republic","CZE","Europe","Europe & Central Asia",22100,2019,"Czechia","High income",3,135,378,"no","sequential period",0
"1595",194,"Smid","Retrospective cohort",1649,2022-10-15,"Moderna mRNA-1273","mRNA","1","1",NA,"14-74","all ages","general pop","included",NA,"Infection","infection","infection","delta",68,61,74,"Czech Republic","CZE","Europe","Europe & Central Asia",22100,2019,"Czechia","High income",3,NA,NA,NA,NA,NA
"1596",194,"Smid","Retrospective cohort",1650,2022-10-15,"Moderna mRNA-1273","mRNA","2","final",NA,"14-74","all ages","general pop","included","~54 weeks","Infection","infection","infection","delta",71,65,76,"Czech Republic","CZE","Europe","Europe & Central Asia",22100,2019,"Czechia","High income",3,NA,NA,NA,NA,NA
"1597",194,"Smid","Retrospective cohort",1651,2022-10-15,"Moderna mRNA-1273","mRNA","1","1",NA,"75+","all ages","general pop","included",NA,"Infection","infection","infection","delta",67,34,84,"Czech Republic","CZE","Europe","Europe & Central Asia",22100,2019,"Czechia","High income",3,NA,NA,NA,NA,NA
"1598",194,"Smid","Retrospective cohort",1652,2022-10-15,"Moderna mRNA-1273","mRNA","2","final",NA,"135+","all ages","general pop","included","~54 weeks","Infection","infection","infection","delta",68,66,69,"Czech Republic","CZE","Europe","Europe & Central Asia",22100,2019,"Czechia","High income",3,NA,NA,NA,NA,NA
"1599",194,"Smid","Retrospective cohort",1653,2022-10-15,"Moderna mRNA-1273","mRNA","1","1",NA,"14-74","all ages","general pop","included",NA,"hospitalization","severe","severe","delta",49,13,71,"Czech Republic","CZE","Europe","Europe & Central Asia",22100,2019,"Czechia","High income",3,NA,NA,NA,NA,NA
"1600",194,"Smid","Retrospective cohort",1654,2022-10-15,"Moderna mRNA-1273","mRNA","2","final",NA,"14-74","all ages","general pop","included","~54 weeks","hospitalization","severe","severe","delta",100,NA,NA,"Czech Republic","CZE","Europe","Europe & Central Asia",22100,2019,"Czechia","High income",3,14,74,"yes",NA,0
"1601",194,"Smid","Retrospective cohort",1655,2022-10-15,"Moderna mRNA-1273","mRNA","1","1",NA,"75+","all ages","general pop","included",NA,"hospitalization","severe","severe","delta",100,NA,NA,"Czech Republic","CZE","Europe","Europe & Central Asia",22100,2019,"Czechia","High income",3,NA,NA,NA,NA,NA
"1602",194,"Smid","Retrospective cohort",1656,2022-10-15,"Moderna mRNA-1273","mRNA","2","final",NA,"135+","all ages","general pop","included","~54 weeks","hospitalization","severe","severe","delta",82,78,85,"Czech Republic","CZE","Europe","Europe & Central Asia",22100,2019,"Czechia","High income",3,135,378,"no","sequential period",0
"1603",194,"Smid","Retrospective cohort",1657,2022-10-15,"Oxford/AstraZeneca ChAdOx1-S","Vectored","2","final",NA,"75-135","all ages","general pop","included","~54 weeks","Infection","infection","infection","delta",65,57,72,"Czech Republic","CZE","Europe","Europe & Central Asia",22100,2019,"Czechia","High income",3,NA,NA,NA,NA,NA
"1604",194,"Smid","Retrospective cohort",1658,2022-10-15,"Oxford/AstraZeneca ChAdOx1-S","Vectored","2","final",NA,"135+","all ages","general pop","included","~54 weeks","Infection","infection","infection","delta",45,43,48,"Czech Republic","CZE","Europe","Europe & Central Asia",22100,2019,"Czechia","High income",3,NA,NA,NA,NA,NA
"1605",194,"Smid","Retrospective cohort",1659,2022-10-15,"Oxford/AstraZeneca ChAdOx1-S","Vectored","2","final",NA,"75-135","all ages","general pop","included","~54 weeks","hospitalization","severe","severe","delta",80,62,89,"Czech Republic","CZE","Europe","Europe & Central Asia",22100,2019,"Czechia","High income",3,75,135,"yes",NA,0
"1606",194,"Smid","Retrospective cohort",1660,2022-10-15,"Oxford/AstraZeneca ChAdOx1-S","Vectored","2","final",NA,"135+","all ages","general pop","included","~54 weeks","hospitalization","severe","severe","delta",68,64,71,"Czech Republic","CZE","Europe","Europe & Central Asia",22100,2019,"Czechia","High income",3,135,378,"no","sequential period",0
"1607",194,"Smid","Retrospective cohort",1661,2022-10-15,"Janssen Ad26.COV2.S","Vectored","1","final",NA,"14-74","all ages","general pop","included","~54 weeks","Infection","infection","infection","delta",60,57,63,"Czech Republic","CZE","Europe","Europe & Central Asia",22100,2019,"Czechia","High income",3,NA,NA,NA,NA,NA
"1608",194,"Smid","Retrospective cohort",1662,2022-10-15,"Janssen Ad26.COV2.S","Vectored","1","final",NA,"135+","all ages","general pop","included","~54 weeks","Infection","infection","infection","delta",54,50,57,"Czech Republic","CZE","Europe","Europe & Central Asia",22100,2019,"Czechia","High income",3,NA,NA,NA,NA,NA
"1609",194,"Smid","Retrospective cohort",1663,2022-10-15,"Janssen Ad26.COV2.S","Vectored","1","final",NA,"14-74","all ages","general pop","included","~54 weeks","hospitalization","severe","severe","delta",54,39,65,"Czech Republic","CZE","Europe","Europe & Central Asia",22100,2019,"Czechia","High income",3,NA,NA,NA,NA,NA
"1610",194,"Smid","Retrospective cohort",1664,2022-10-15,"Janssen Ad26.COV2.S","Vectored","1","final",NA,"135+","all ages","general pop","included","~54 weeks","hospitalization","severe","severe","delta",61,51,69,"Czech Republic","CZE","Europe","Europe & Central Asia",22100,2019,"Czechia","High income",3,NA,NA,NA,NA,NA
"1611",195,"Klein","Test-negative case-control",1665,2022-03-01,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"14-67","5-11 years","5-11 years","unknown","~33 weeks","ED or UC visit","symptomatic","symptomatic","omicron",51,30,65,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"1612",195,"Klein","Test-negative case-control",1666,2022-03-01,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"14-149","12-15 years","12-15 years","unknown","~33 weeks","ED or UC visit","symptomatic","symptomatic","omicron",45,30,57,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"1613",195,"Klein","Test-negative case-control",1667,2022-03-01,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"150+","12-15 years","12-15 years","unknown","~33 weeks","ED or UC visit","symptomatic","symptomatic","omicron",-2,-25,17,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"1614",195,"Klein","Test-negative case-control",1668,2022-03-01,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"14-149","16-17 years","16-17 years","unknown","~33 weeks","ED or UC visit","symptomatic","symptomatic","omicron",34,8,53,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"1615",195,"Klein","Test-negative case-control",1669,2022-03-01,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"150+","16-17 years","16-17 years","unknown","~33 weeks","ED or UC visit","symptomatic","symptomatic","omicron",-3,-30,18,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"1616",195,"Klein","Test-negative case-control",1670,2022-03-01,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"14-149","12-15 years","12-15 years","unknown","~33 weeks","ED or UC visit","symptomatic","symptomatic","delta",92,89,94,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"1617",195,"Klein","Test-negative case-control",1671,2022-03-01,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"150+","12-15 years","12-15 years","unknown","~33 weeks","ED or UC visit","symptomatic","symptomatic","delta",79,68,86,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"1618",195,"Klein","Test-negative case-control",1672,2022-03-01,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"14-149","16-17 years","16-17 years","unknown","~33 weeks","ED or UC visit","symptomatic","symptomatic","delta",85,81,89,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"1619",195,"Klein","Test-negative case-control",1673,2022-03-01,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"150+","16-17 years","16-17 years","unknown","~33 weeks","ED or UC visit","symptomatic","symptomatic","delta",77,67,84,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"1620",195,"Klein","Test-negative case-control",1674,2022-03-01,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"14-67","5-11 years","5-11 years","unknown","~33 weeks","hospitalization","severe","severe","delta/omicron",74,-35,95,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"1621",195,"Klein","Test-negative case-control",1675,2022-03-01,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"14-149","12-15 years","12-15 years","unknown","~33 weeks","hospitalization","severe","severe","delta/omicron",92,79,97,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"1622",195,"Klein","Test-negative case-control",1676,2022-03-01,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"150+","12-15 years","12-15 years","unknown","~33 weeks","hospitalization","severe","severe","delta/omicron",73,43,88,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"1623",195,"Klein","Test-negative case-control",1677,2022-03-01,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"14-149","16-17 years","16-17 years","unknown","~33 weeks","hospitalization","severe","severe","delta/omicron",94,87,97,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"1624",195,"Klein","Test-negative case-control",1678,2022-03-01,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"150+","16-17 years","16-17 years","unknown","~33 weeks","hospitalization","severe","severe","delta/omicron",88,72,95,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"1625",196,"Wright","Case-control",1679,2022-02-25,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"14+",">= 18 years","general pop","included","~40 weeks","severe disease","severe","severe","other combinations",87.9,86.7,89,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"1626",196,"Wright","Case-control",1680,2022-02-25,"Moderna mRNA-1273","mRNA","2","final",NA,"14+",">= 18 years","general pop","included","~40 weeks","severe disease","severe","severe","other combinations",92.9,92,93.7,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"1627",196,"Wright","Case-control",1681,2022-02-25,"Janssen Ad26.COV2.S","Vectored","1","final",NA,"14+",">= 18 years","general pop","included","~40 weeks","severe disease","severe","severe","other combinations",73,68.8,76.6,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"1628",197,"Perry","Retrospective cohort",1682,2022-03-03,"BioNTech/Pfizer BNT162b2","mRNA","1","1",NA,"14-20",">= 50 years",">= 50 years","included",NA,"infection","infection","infection","other combinations",19,9,28,"UK","GBR","Europe","Europe & Central Asia",43240,2019,"United Kingdom","High income",4,NA,NA,NA,NA,NA
"1629",197,"Perry","Retrospective cohort",1683,2022-03-03,"BioNTech/Pfizer BNT162b2","mRNA","1","1",NA,">27",">= 50 years",">= 50 years","included",NA,"infection","infection","infection","other combinations",16,8,24,"UK","GBR","Europe","Europe & Central Asia",43240,2019,"United Kingdom","High income",4,NA,NA,NA,NA,NA
"1630",197,"Perry","Retrospective cohort",1684,2022-03-03,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,">6",">= 50 years",">= 50 years","included","~26.5 weeks","infection","infection","infection","other combinations",50,44,55,"UK","GBR","Europe","Europe & Central Asia",43240,2019,"United Kingdom","High income",4,NA,NA,NA,NA,NA
"1631",197,"Perry","Retrospective cohort",1685,2022-03-03,"BioNTech/Pfizer BNT162b2","mRNA","1","1",NA,"14-20",">= 50 years",">= 50 years","included",NA,"hospitalization","severe","severe","other combinations",69,43,83,"UK","GBR","Europe","Europe & Central Asia",43240,2019,"United Kingdom","High income",4,NA,NA,NA,NA,NA
"1632",197,"Perry","Retrospective cohort",1686,2022-03-03,"BioNTech/Pfizer BNT162b2","mRNA","1","1",NA,">27",">= 50 years",">= 50 years","included",NA,"hospitalization","severe","severe","other combinations",75,56,85,"UK","GBR","Europe","Europe & Central Asia",43240,2019,"United Kingdom","High income",4,NA,NA,NA,NA,NA
"1633",197,"Perry","Retrospective cohort",1687,2022-03-03,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,">6",">= 50 years",">= 50 years","included","~26.5 weeks","hospitalization","severe","severe","other combinations",88,81,93,"UK","GBR","Europe","Europe & Central Asia",43240,2019,"United Kingdom","High income",4,NA,NA,NA,NA,NA
"1634",197,"Perry","Retrospective cohort",1688,2022-03-03,"Oxford/AstraZeneca ChAdOx1-S","Vectored","1","1",NA,"14-20",">= 50 years",">= 50 years","included",NA,"infection","infection","infection","other combinations",7,-5,19,"UK","GBR","Europe","Europe & Central Asia",43240,2019,"United Kingdom","High income",4,NA,NA,NA,NA,NA
"1635",197,"Perry","Retrospective cohort",1689,2022-03-03,"Oxford/AstraZeneca ChAdOx1-S","Vectored","1","1",NA,">27",">= 50 years",">= 50 years","included",NA,"infection","infection","infection","other combinations",17,9,25,"UK","GBR","Europe","Europe & Central Asia",43240,2019,"United Kingdom","High income",4,NA,NA,NA,NA,NA
"1636",197,"Perry","Retrospective cohort",1690,2022-03-03,"Oxford/AstraZeneca ChAdOx1-S","Vectored","2","final",NA,">6",">= 50 years",">= 50 years","included","~18 weeks","infection","infection","infection","other combinations",25,15,33,"UK","GBR","Europe","Europe & Central Asia",43240,2019,"United Kingdom","High income",4,NA,NA,NA,NA,NA
"1637",197,"Perry","Retrospective cohort",1691,2022-03-03,"Oxford/AstraZeneca ChAdOx1-S","Vectored","1","1",NA,"14-20",">= 50 years",">= 50 years","included",NA,"hospitalization","severe","severe","other combinations",48,26,64,"UK","GBR","Europe","Europe & Central Asia",43240,2019,"United Kingdom","High income",4,NA,NA,NA,NA,NA
"1638",197,"Perry","Retrospective cohort",1692,2022-03-03,"Oxford/AstraZeneca ChAdOx1-S","Vectored","1","1",NA,">27",">= 50 years",">= 50 years","included",NA,"hospitalization","severe","severe","other combinations",72,62,80,"UK","GBR","Europe","Europe & Central Asia",43240,2019,"United Kingdom","High income",4,NA,NA,NA,NA,NA
"1639",197,"Perry","Retrospective cohort",1693,2022-03-03,"Oxford/AstraZeneca ChAdOx1-S","Vectored","2","final",NA,">6",">= 50 years",">= 50 years","included","~18 weeks","hospitalization","severe","severe","other combinations",81,71,88,"UK","GBR","Europe","Europe & Central Asia",43240,2019,"United Kingdom","High income",4,NA,NA,NA,NA,NA
"1640",198,"Oliver","Retrospective cohort",1694,2022-03-09,"Multiple or heterologous RNA","mRNA","1","1",NA,"14+","hemodialysis patients","hemodialysis patients","included",NA,"infection","infection","infection","alpha",41,24,54,"Canada","CAN","North America","North America",46580,2019,"Canada","High income",4,NA,NA,NA,NA,NA
"1641",198,"Oliver","Retrospective cohort",1695,2022-03-09,"Multiple or heterologous RNA","mRNA","2","final",NA,"7+","hemodialysis patients","hemodialysis patients","included","~22 weeks","infection","infection","infection","alpha",69,58,78,"Canada","CAN","North America","North America",46580,2019,"Canada","High income",4,NA,NA,NA,NA,NA
"1642",198,"Oliver","Retrospective cohort",1696,2022-03-09,"Multiple or heterologous RNA","mRNA","1","1",NA,"14+","hemodialysis patients","hemodialysis patients","included",NA,"severe disease","severe","severe","alpha",46,23,63,"Canada","CAN","North America","North America",46580,2019,"Canada","High income",4,NA,NA,NA,NA,NA
"1643",198,"Oliver","Retrospective cohort",1697,2022-03-09,"Multiple or heterologous RNA","mRNA","2","final",NA,"7+","hemodialysis patients","hemodialysis patients","included","~22 weeks","severe disease","severe","severe","alpha",83,70,90,"Canada","CAN","North America","North America",46580,2019,"Canada","High income",4,NA,NA,NA,NA,NA
"1644",198,"Oliver","Retrospective cohort",1698,2022-03-09,"Multiple or heterologous RNA","mRNA","1","1",NA,"14+","hemodialysis patients","hemodialysis patients","included",NA,"hospitalization","severe","severe","alpha",40,13,58,"Canada","CAN","North America","North America",46580,2019,"Canada","High income",4,NA,NA,NA,NA,NA
"1645",198,"Oliver","Retrospective cohort",1699,2022-03-09,"Multiple or heterologous RNA","mRNA","2","final",NA,"7+","hemodialysis patients","hemodialysis patients","included","~22 weeks","hospitalization","severe","severe","alpha",82,69,90,"Canada","CAN","North America","North America",46580,2019,"Canada","High income",4,NA,NA,NA,NA,NA
"1646",198,"Oliver","Retrospective cohort",1700,2022-03-09,"Multiple or heterologous RNA","mRNA","1","1",NA,"14+","hemodialysis patients","hemodialysis patients","included",NA,"death","death","death","alpha",71,40,86,"Canada","CAN","North America","North America",46580,2019,"Canada","High income",4,NA,NA,NA,NA,NA
"1647",198,"Oliver","Retrospective cohort",1701,2022-03-09,"Multiple or heterologous RNA","mRNA","2","final",NA,"7+","hemodialysis patients","hemodialysis patients","included","~22 weeks","death","death","death","alpha",85,59,95,"Canada","CAN","North America","North America",46580,2019,"Canada","High income",4,NA,NA,NA,NA,NA
"1648",199,"Oliveira","Matched case-control",1702,2022-03-03,"BioNTech/Pfizer BNT162b2","mRNA","1","1",NA,"14+","12-18 years","12-18 years","excluded",NA,"infection","infection","infection","delta",74,18,92,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"1649",199,"Oliveira","Matched case-control",1703,2022-03-03,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"1-4 weeks","12-18 years","12-18 years","excluded","~11 weeks","infection","infection","infection","delta",91,33,99,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"1650",199,"Oliveira","Matched case-control",1704,2022-03-03,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"13-17 weeks","12-18 years","12-18 years","excluded","~11 weeks","infection","infection","infection","delta",83,34,95,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"1651",199,"Oliveira","Matched case-control",1705,2022-03-03,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"14+","12-18 years","12-18 years","excluded","~11 weeks","symptomatic disease","symptomatic","symptomatic","delta",93,81,97,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"1652",199,"Oliveira","Matched case-control",1706,2022-03-03,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"14+","12-18 years","12-18 years","excluded","~11 weeks","asymptomatic infection","asymptomatic","infection","delta",85,57,95,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"1653",200,"Ashmawy","Ambispective cohort",1707,2023-04-24,"Beijing/Sinopharm BBIBP-CorV","Inactivated","2","final",NA,"14+","HCW","HCW","included","~29 weeks","symptomatic disease","symptomatic","symptomatic","delta",67,43,80,"Egypt","EGY","Africa","Middle East & North Africa",2640,2019,"Egypt, Arab Rep.","Lower middle income",2,NA,NA,NA,NA,NA
"1654",200,"Ashmawy","Ambispective cohort",1708,2023-04-24,"Beijing/Sinopharm BBIBP-CorV","Inactivated","2","final",NA,"14+","HCW","HCW","included","~29 weeks","infection","infection","infection","delta",46,24,62,"Egypt","EGY","Africa","Middle East & North Africa",2640,2019,"Egypt, Arab Rep.","Lower middle income",2,NA,NA,NA,NA,NA
"1655",200,"Ashmawy","Ambispective cohort",1709,2023-04-24,"Beijing/Sinopharm BBIBP-CorV","Inactivated","2","final",NA,"14+","HCW","HCW","included","~29 weeks","hospitalization","severe","severe","delta",65,-8,88,"Egypt","EGY","Africa","Middle East & North Africa",2640,2019,"Egypt, Arab Rep.","Lower middle income",2,NA,NA,NA,NA,NA
"1656",201,"Fowlkes","Prospective cohort",1710,2022-03-11,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"14-82","5-11 years","5-11 years","excluded","~29 weeks","infection","infection","infection","omicron",31,9,48,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"1657",201,"Fowlkes","Prospective cohort",1711,2022-03-11,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"14+","12-15 years","12-15 years","excluded","~29 weeks","infection","infection","infection","omicron",59,24,78,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"1658",201,"Fowlkes","Prospective cohort",1712,2022-03-11,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"14-149","12-15 years","12-15 years","excluded",NA,"infection","infection","infection","omicron",59,22,79,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"1659",201,"Fowlkes","Prospective cohort",1713,2022-03-11,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"150+","12-15 years","12-15 years","excluded","~29 weeks","infection","infection","infection","omicron",62,-28,29,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"1660",201,"Fowlkes","Prospective cohort",1714,2022-03-11,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"14+","12-15 years","12-15 years","excluded","~29 weeks","infection","infection","infection","delta",81,51,93,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"1661",201,"Fowlkes","Prospective cohort",1715,2022-03-11,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"14-149","12-15 years","12-15 years","excluded",NA,"infection","infection","infection","delta",87,49,97,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"1662",201,"Fowlkes","Prospective cohort",1716,2022-03-11,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"150+","12-15 years","12-15 years","excluded","~29 weeks","infection","infection","infection","delta",60,-35,88,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"1663",202,"Shrotri","Prospective cohort",1717,2022-03-12,"Multiple or heterologous RNA","mRNA","1","1",NA,"28+","LTCF residents","LTCF residents","excluded",NA,"infection","infection","infection","other combinations",31.7,-14.2,59.1,"UK","GBR","Europe","Europe & Central Asia",43240,2019,"United Kingdom","High income",4,NA,NA,NA,NA,NA
"1664",202,"Shrotri","Prospective cohort",1718,2022-03-12,"Multiple or heterologous RNA","mRNA","2","final",NA,"14-83","LTCF residents","LTCF residents","excluded","45 weeks","Infection","infection","infection","other combinations",25.5,-57.5,64.7,"UK","GBR","Europe","Europe & Central Asia",43240,2019,"United Kingdom","High income",4,NA,NA,NA,NA,NA
"1665",202,"Shrotri","Prospective cohort",1719,2022-03-12,"Multiple or heterologous RNA","mRNA","2","final",NA,"84+","LTCF residents","LTCF residents","excluded","45 weeks","Infection","infection","infection","other combinations",26.3,-21.7,55.4,"UK","GBR","Europe","Europe & Central Asia",43240,2019,"United Kingdom","High income",4,NA,NA,NA,NA,NA
"1666",202,"Shrotri","Prospective cohort",1720,2022-03-12,"Multiple or heterologous RNA","mRNA","1","1",NA,"28+","LTCF residents","LTCF residents","excluded",NA,"hospitalization","severe","severe","other combinations",40.8,-16,69.7,"UK","GBR","Europe","Europe & Central Asia",43240,2019,"United Kingdom","High income",4,NA,NA,NA,NA,NA
"1667",202,"Shrotri","Prospective cohort",1721,2022-03-12,"Multiple or heterologous RNA","mRNA","2","final",NA,"14-83","LTCF residents","LTCF residents","excluded","45 weeks","hospitalization","severe","severe","other combinations",88.8,16.8,98.5,"UK","GBR","Europe","Europe & Central Asia",43240,2019,"United Kingdom","High income",4,NA,NA,NA,NA,NA
"1668",202,"Shrotri","Prospective cohort",1722,2022-03-12,"Multiple or heterologous RNA","mRNA","2","final",NA,"84+","LTCF residents","LTCF residents","excluded","45 weeks","hospitalization","severe","severe","other combinations",65.1,33.6,81.6,"UK","GBR","Europe","Europe & Central Asia",43240,2019,"United Kingdom","High income",4,NA,NA,NA,NA,NA
"1669",202,"Shrotri","Prospective cohort",1723,2022-03-12,"Multiple or heterologous RNA","mRNA","1","1",NA,"28+","LTCF residents","LTCF residents","excluded",NA,"death","death","death","other combinations",58.6,25.3,77,"UK","GBR","Europe","Europe & Central Asia",43240,2019,"United Kingdom","High income",4,NA,NA,NA,NA,NA
"1670",202,"Shrotri","Prospective cohort",1724,2022-03-12,"Multiple or heterologous RNA","mRNA","2","final",NA,"14-83","LTCF residents","LTCF residents","excluded","45 weeks","death","death","death","other combinations",100,NA,NA,"UK","GBR","Europe","Europe & Central Asia",43240,2019,"United Kingdom","High income",4,NA,NA,NA,NA,NA
"1671",202,"Shrotri","Prospective cohort",1725,2022-03-12,"Multiple or heterologous RNA","mRNA","2","final",NA,"84+","LTCF residents","LTCF residents","excluded","45 weeks","death","death","death","other combinations",66.1,26,84.4,"UK","GBR","Europe","Europe & Central Asia",43240,2019,"United Kingdom","High income",4,NA,NA,NA,NA,NA
"1672",202,"Shrotri","Prospective cohort",1726,2022-03-12,"Oxford/AstraZeneca ChAdOx1-S","Vectored","1","1",NA,"28+","LTCF residents","LTCF residents","excluded",NA,"Infection","infection","infection","other combinations",41.3,8.8,62.2,"UK","GBR","Europe","Europe & Central Asia",43240,2019,"United Kingdom","High income",4,NA,NA,NA,NA,NA
"1673",202,"Shrotri","Prospective cohort",1727,2022-03-12,"Oxford/AstraZeneca ChAdOx1-S","Vectored","2","final",NA,"14-83","LTCF residents","LTCF residents","excluded","45 weeks","Infection","infection","infection","other combinations",62.1,12.1,83.6,"UK","GBR","Europe","Europe & Central Asia",43240,2019,"United Kingdom","High income",4,NA,NA,NA,NA,NA
"1674",202,"Shrotri","Prospective cohort",1728,2022-03-12,"Oxford/AstraZeneca ChAdOx1-S","Vectored","2","final",NA,"84+","LTCF residents","LTCF residents","excluded","45 weeks","Infection","infection","infection","other combinations",13.6,-33.2,43.9,"UK","GBR","Europe","Europe & Central Asia",43240,2019,"United Kingdom","High income",4,NA,NA,NA,NA,NA
"1675",202,"Shrotri","Prospective cohort",1729,2022-03-12,"Oxford/AstraZeneca ChAdOx1-S","Vectored","1","1",NA,"28+","LTCF residents","LTCF residents","excluded",NA,"hospitalization","severe","severe","other combinations",44.9,7.9,67.1,"UK","GBR","Europe","Europe & Central Asia",43240,2019,"United Kingdom","High income",4,NA,NA,NA,NA,NA
"1676",202,"Shrotri","Prospective cohort",1730,2022-03-12,"Oxford/AstraZeneca ChAdOx1-S","Vectored","2","final",NA,"14-83","LTCF residents","LTCF residents","excluded","45 weeks","hospitalization","severe","severe","other combinations",82.7,46.4,94.4,"UK","GBR","Europe","Europe & Central Asia",43240,2019,"United Kingdom","High income",4,NA,NA,NA,NA,NA
"1677",202,"Shrotri","Prospective cohort",1731,2022-03-12,"Oxford/AstraZeneca ChAdOx1-S","Vectored","2","final",NA,"84+","LTCF residents","LTCF residents","excluded","45 weeks","hospitalization","severe","severe","other combinations",48.7,12.5,70,"UK","GBR","Europe","Europe & Central Asia",43240,2019,"United Kingdom","High income",4,NA,NA,NA,NA,NA
"1678",202,"Shrotri","Prospective cohort",1732,2022-03-12,"Oxford/AstraZeneca ChAdOx1-S","Vectored","1","1",NA,"28+","LTCF residents","LTCF residents","excluded",NA,"death","death","death","other combinations",52.7,16.4,73.2,"UK","GBR","Europe","Europe & Central Asia",43240,2019,"United Kingdom","High income",4,NA,NA,NA,NA,NA
"1679",202,"Shrotri","Prospective cohort",1733,2022-03-12,"Oxford/AstraZeneca ChAdOx1-S","Vectored","2","final",NA,"14-83","LTCF residents","LTCF residents","excluded","45 weeks","death","death","death","other combinations",91.7,65.1,98,"UK","GBR","Europe","Europe & Central Asia",43240,2019,"United Kingdom","High income",4,NA,NA,NA,NA,NA
"1680",202,"Shrotri","Prospective cohort",1734,2022-03-12,"Oxford/AstraZeneca ChAdOx1-S","Vectored","2","final",NA,"84+","LTCF residents","LTCF residents","excluded","45 weeks","death","death","death","other combinations",61.1,26.2,79.5,"UK","GBR","Europe","Europe & Central Asia",43240,2019,"United Kingdom","High income",4,NA,NA,NA,NA,NA
"1681",202,"Shrotri","Prospective cohort",1735,2022-03-12,"Multiple or heterologous RNA","mRNA","1","1",NA,"28+","LTCF staff","LTCF staff","excluded",NA,"Infection","infection","infection","other combinations",27,4.4,44.3,"UK","GBR","Europe","Europe & Central Asia",43240,2019,"United Kingdom","High income",4,NA,NA,NA,NA,NA
"1682",202,"Shrotri","Prospective cohort",1736,2022-03-12,"Multiple or heterologous RNA","mRNA","2","final",NA,"14-83","LTCF staff","LTCF staff","excluded","45 weeks","infection","infection","infection","other combinations",60.7,44.2,72.4,"UK","GBR","Europe","Europe & Central Asia",43240,2019,"United Kingdom","High income",4,NA,NA,NA,NA,NA
"1683",202,"Shrotri","Prospective cohort",1737,2022-03-12,"Multiple or heterologous RNA","mRNA","2","final",NA,"84+","LTCF staff","LTCF staff","excluded","45 weeks","Infection","infection","infection","other combinations",45.1,31.3,56.2,"UK","GBR","Europe","Europe & Central Asia",43240,2019,"United Kingdom","High income",4,NA,NA,NA,NA,NA
"1684",202,"Shrotri","Prospective cohort",1738,2022-03-12,"Multiple or heterologous RNA","mRNA","1","1",NA,"28+","LTCF staff","LTCF staff","excluded",NA,"hospitalization","severe","severe","other combinations",100,NA,NA,"UK","GBR","Europe","Europe & Central Asia",43240,2019,"United Kingdom","High income",4,NA,NA,NA,NA,NA
"1685",202,"Shrotri","Prospective cohort",1739,2022-03-12,"Multiple or heterologous RNA","mRNA","2","final",NA,"14-83","LTCF staff","LTCF staff","excluded","45 weeks","hospitalization","severe","severe","other combinations",100,NA,NA,"UK","GBR","Europe","Europe & Central Asia",43240,2019,"United Kingdom","High income",4,NA,NA,NA,NA,NA
"1686",202,"Shrotri","Prospective cohort",1740,2022-03-12,"Multiple or heterologous RNA","mRNA","2","final",NA,"84+","LTCF staff","LTCF staff","excluded","45 weeks","hospitalization","severe","severe","other combinations",92.1,69.3,97.9,"UK","GBR","Europe","Europe & Central Asia",43240,2019,"United Kingdom","High income",4,NA,NA,NA,NA,NA
"1687",202,"Shrotri","Prospective cohort",1741,2022-03-12,"Oxford/AstraZeneca ChAdOx1-S","Vectored","1","1",NA,"28+","LTCF staff","LTCF staff","excluded",NA,"Infection","infection","infection","other combinations",19.6,-10.7,41.6,"UK","GBR","Europe","Europe & Central Asia",43240,2019,"United Kingdom","High income",4,NA,NA,NA,NA,NA
"1688",202,"Shrotri","Prospective cohort",1742,2022-03-12,"Oxford/AstraZeneca ChAdOx1-S","Vectored","2","final",NA,"14-83","LTCF staff","LTCF staff","excluded","45 weeks","Infection","infection","infection","other combinations",29,-10.3,54.3,"UK","GBR","Europe","Europe & Central Asia",43240,2019,"United Kingdom","High income",4,NA,NA,NA,NA,NA
"1689",202,"Shrotri","Prospective cohort",1743,2022-03-12,"Oxford/AstraZeneca ChAdOx1-S","Vectored","2","final",NA,"84+","LTCF staff","LTCF staff","excluded","45 weeks","Infection","infection","infection","other combinations",36.9,20.6,49.9,"UK","GBR","Europe","Europe & Central Asia",43240,2019,"United Kingdom","High income",4,NA,NA,NA,NA,NA
"1690",202,"Shrotri","Prospective cohort",1744,2022-03-12,"Oxford/AstraZeneca ChAdOx1-S","Vectored","1","1",NA,"28+","LTCF staff","LTCF staff","excluded",NA,"hospitalization","severe","severe","other combinations",19.6,-121.6,70.8,"UK","GBR","Europe","Europe & Central Asia",43240,2019,"United Kingdom","High income",4,NA,NA,NA,NA,NA
"1691",202,"Shrotri","Prospective cohort",1745,2022-03-12,"Oxford/AstraZeneca ChAdOx1-S","Vectored","2","final",NA,"14-83","LTCF staff","LTCF staff","excluded","45 weeks","hospitalization","severe","severe","other combinations",100,NA,NA,"UK","GBR","Europe","Europe & Central Asia",43240,2019,"United Kingdom","High income",4,NA,NA,NA,NA,NA
"1692",202,"Shrotri","Prospective cohort",1746,2022-03-12,"Oxford/AstraZeneca ChAdOx1-S","Vectored","2","final",NA,"84+","LTCF staff","LTCF staff","excluded","45 weeks","hospitalization","severe","severe","other combinations",89.6,64.4,96.9,"UK","GBR","Europe","Europe & Central Asia",43240,2019,"United Kingdom","High income",4,NA,NA,NA,NA,NA
"1693",203,"Baum","Retrospective cohort",1747,2022-11-05,"BioNTech/Pfizer BNT162b2","mRNA","1","1",NA,"21-83",">= 70 years",">= 70 years","excluded",NA,"hospitalization","severe","severe","other combinations",61,49,71,"Finland","FIN","Europe","Europe & Central Asia",49950,2019,"Finland","High income",4,NA,NA,NA,NA,NA
"1694",203,"Baum","Retrospective cohort",1748,2022-11-05,"BioNTech/Pfizer BNT162b2","mRNA","1","1",NA,"84+",">= 70 years",">= 70 years","excluded",NA,"hospitalization","severe","severe","other combinations",64,49,75,"Finland","FIN","Europe","Europe & Central Asia",49950,2019,"Finland","High income",4,NA,NA,NA,NA,NA
"1695",203,"Baum","Retrospective cohort",1749,2022-11-05,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"14-90",">= 70 years",">= 70 years","excluded",NA,"hospitalization","severe","severe","other combinations",93,89,95,"Finland","FIN","Europe","Europe & Central Asia",49950,2019,"Finland","High income",4,NA,NA,NA,NA,NA
"1696",203,"Baum","Retrospective cohort",1750,2022-11-05,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"181+",">= 70 years",">= 70 years","excluded","~56 weeks","hospitalization","severe","severe","other combinations",69,63,74,"Finland","FIN","Europe","Europe & Central Asia",49950,2019,"Finland","High income",4,NA,NA,NA,NA,NA
"1697",203,"Baum","Retrospective cohort",1751,2022-11-05,"BioNTech/Pfizer BNT162b2","mRNA","1","1",NA,"21-83",">= 70 years",">= 70 years","excluded",NA,"ICU admission","severe","severe","other combinations",84,63,93,"Finland","FIN","Europe","Europe & Central Asia",49950,2019,"Finland","High income",4,NA,NA,NA,NA,NA
"1698",203,"Baum","Retrospective cohort",1752,2022-11-05,"BioNTech/Pfizer BNT162b2","mRNA","1","1",NA,"84+",">= 70 years",">= 70 years","excluded",NA,"ICU admission","severe","severe","other combinations",69,15,89,"Finland","FIN","Europe","Europe & Central Asia",49950,2019,"Finland","High income",4,NA,NA,NA,NA,NA
"1699",203,"Baum","Retrospective cohort",1753,2022-11-05,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"14-90",">= 70 years",">= 70 years","excluded",NA,"ICU admission","severe","severe","other combinations",98,92,99,"Finland","FIN","Europe","Europe & Central Asia",49950,2019,"Finland","High income",4,NA,NA,NA,NA,NA
"1700",203,"Baum","Retrospective cohort",1754,2022-11-05,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"181+",">= 70 years",">= 70 years","excluded","~56 weeks","ICU admission","severe","severe","other combinations",79,65,87,"Finland","FIN","Europe","Europe & Central Asia",49950,2019,"Finland","High income",4,NA,NA,NA,NA,NA
"1701",203,"Baum","Retrospective cohort",1755,2022-11-05,"Moderna mRNA-1273","mRNA","1","1",NA,"21-83",">= 70 years",">= 70 years","excluded",NA,"hospitalization","severe","severe","other combinations",70,43,84,"Finland","FIN","Europe","Europe & Central Asia",49950,2019,"Finland","High income",4,NA,NA,NA,NA,NA
"1702",203,"Baum","Retrospective cohort",1756,2022-11-05,"Moderna mRNA-1273","mRNA","1","1",NA,"84+",">= 70 years",">= 70 years","excluded",NA,"hospitalization","severe","severe","other combinations",63,26,82,"Finland","FIN","Europe","Europe & Central Asia",49950,2019,"Finland","High income",4,NA,NA,NA,NA,NA
"1703",203,"Baum","Retrospective cohort",1757,2022-11-05,"Moderna mRNA-1273","mRNA","2","final",NA,"14-90",">= 70 years",">= 70 years","excluded","~56 weeks","hospitalization","severe","severe","other combinations",93,82,97,"Finland","FIN","Europe","Europe & Central Asia",49950,2019,"Finland","High income",4,NA,NA,NA,NA,NA
"1704",203,"Baum","Retrospective cohort",1758,2022-11-05,"Moderna mRNA-1273","mRNA","2","final",NA,"181+",">= 70 years",">= 70 years","excluded","~56 weeks","hospitalization","severe","severe","other combinations",73,59,83,"Finland","FIN","Europe","Europe & Central Asia",49950,2019,"Finland","High income",4,NA,NA,NA,NA,NA
"1705",203,"Baum","Retrospective cohort",1759,2022-11-05,"Moderna mRNA-1273","mRNA","1","1",NA,"21-83",">= 70 years",">= 70 years","excluded",NA,"ICU admission","severe","severe","other combinations",70,-29,93,"Finland","FIN","Europe","Europe & Central Asia",49950,2019,"Finland","High income",4,NA,NA,NA,NA,NA
"1706",203,"Baum","Retrospective cohort",1760,2022-11-05,"Moderna mRNA-1273","mRNA","1","1",NA,"84+",">= 70 years",">= 70 years","excluded",NA,"ICU admission","severe","severe","other combinations",100,NA,NA,"Finland","FIN","Europe","Europe & Central Asia",49950,2019,"Finland","High income",4,NA,NA,NA,NA,NA
"1707",203,"Baum","Retrospective cohort",1761,2022-11-05,"Moderna mRNA-1273","mRNA","2","final",NA,"14-90",">= 70 years",">= 70 years","excluded","~56 weeks","ICU admission","severe","severe","other combinations",100,NA,NA,"Finland","FIN","Europe","Europe & Central Asia",49950,2019,"Finland","High income",4,NA,NA,NA,NA,NA
"1708",203,"Baum","Retrospective cohort",1762,2022-11-05,"Moderna mRNA-1273","mRNA","2","final",NA,"181+",">= 70 years",">= 70 years","excluded","~56 weeks","ICU admission","severe","severe","other combinations",93,46,99,"Finland","FIN","Europe","Europe & Central Asia",49950,2019,"Finland","High income",4,NA,NA,NA,NA,NA
"1709",203,"Baum","Retrospective cohort",1763,2022-11-05,"Oxford/AstraZeneca ChAdOx1-S","Vectored","1","1",NA,"21-83",">= 70 years",">= 70 years","excluded",NA,"hospitalization","severe","severe","other combinations",68,-3,90,"Finland","FIN","Europe","Europe & Central Asia",49950,2019,"Finland","High income",4,NA,NA,NA,NA,NA
"1710",203,"Baum","Retrospective cohort",1764,2022-11-05,"Oxford/AstraZeneca ChAdOx1-S","Vectored","1","1",NA,"84+",">= 70 years",">= 70 years","excluded",NA,"hospitalization","severe","severe","other combinations",37,-95,80,"Finland","FIN","Europe","Europe & Central Asia",49950,2019,"Finland","High income",4,NA,NA,NA,NA,NA
"1711",203,"Baum","Retrospective cohort",1765,2022-11-05,"Oxford/AstraZeneca ChAdOx1-S","Vectored","2","final",NA,"14-90",">= 70 years",">= 70 years","excluded","~56 weeks","hospitalization","severe","severe","other combinations",81,49,93,"Finland","FIN","Europe","Europe & Central Asia",49950,2019,"Finland","High income",4,NA,NA,NA,NA,NA
"1712",203,"Baum","Retrospective cohort",1766,2022-11-05,"Oxford/AstraZeneca ChAdOx1-S","Vectored","2","final",NA,"181+",">= 70 years",">= 70 years","excluded","~56 weeks","hospitalization","severe","severe","other combinations",48,17,68,"Finland","FIN","Europe","Europe & Central Asia",49950,2019,"Finland","High income",4,NA,NA,NA,NA,NA
"1713",203,"Baum","Retrospective cohort",1767,2022-11-05,"Oxford/AstraZeneca ChAdOx1-S","Vectored","1","1",NA,"21-83",">= 70 years",">= 70 years","excluded",NA,"ICU admission","severe","severe","other combinations",68,-151,96,"Finland","FIN","Europe","Europe & Central Asia",49950,2019,"Finland","High income",4,NA,NA,NA,NA,NA
"1714",203,"Baum","Retrospective cohort",1768,2022-11-05,"Oxford/AstraZeneca ChAdOx1-S","Vectored","1","1",NA,"84+",">= 70 years",">= 70 years","excluded",NA,"ICU admission","severe","severe","other combinations",100,NA,NA,"Finland","FIN","Europe","Europe & Central Asia",49950,2019,"Finland","High income",4,NA,NA,NA,NA,NA
"1715",203,"Baum","Retrospective cohort",1769,2022-11-05,"Oxford/AstraZeneca ChAdOx1-S","Vectored","2","final",NA,"14-90",">= 70 years",">= 70 years","excluded","~56 weeks","ICU admission","severe","severe","other combinations",78,2,95,"Finland","FIN","Europe","Europe & Central Asia",49950,2019,"Finland","High income",4,NA,NA,NA,NA,NA
"1716",203,"Baum","Retrospective cohort",1770,2022-11-05,"Oxford/AstraZeneca ChAdOx1-S","Vectored","2","final",NA,"181+",">= 70 years",">= 70 years","excluded","~56 weeks","ICU admission","severe","severe","other combinations",64,-14,89,"Finland","FIN","Europe","Europe & Central Asia",49950,2019,"Finland","High income",4,NA,NA,NA,NA,NA
"1717",203,"Baum","Retrospective cohort",1771,2022-11-05,"BioNTech/Pfizer BNT162b2","mRNA","1","1",NA,"21-83",">= 70 years",">= 70 years","excluded",NA,"hospitalization","severe","severe","delta",53,-16,81,"Finland","FIN","Europe","Europe & Central Asia",49950,2019,"Finland","High income",4,NA,NA,NA,NA,NA
"1718",203,"Baum","Retrospective cohort",1772,2022-11-05,"BioNTech/Pfizer BNT162b2","mRNA","1","1",NA,"84+",">= 70 years",">= 70 years","excluded",NA,"hospitalization","severe","severe","delta",68,45,81,"Finland","FIN","Europe","Europe & Central Asia",49950,2019,"Finland","High income",4,NA,NA,NA,NA,NA
"1719",203,"Baum","Retrospective cohort",1773,2022-11-05,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"14-90",">= 70 years",">= 70 years","excluded","~48.5 weeks","hospitalization","severe","severe","delta",90,78,96,"Finland","FIN","Europe","Europe & Central Asia",49950,2019,"Finland","High income",4,14,90,"yes",NA,1
"1720",203,"Baum","Retrospective cohort",1774,2022-11-05,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"181+",">= 70 years",">= 70 years","excluded","~48.5 weeks","hospitalization","severe","severe","delta",79,71,84,"Finland","FIN","Europe","Europe & Central Asia",49950,2019,"Finland","High income",4,181,339.5,"no","sequential period",1
"1721",203,"Baum","Retrospective cohort",1775,2022-11-05,"Moderna mRNA-1273","mRNA","1","1",NA,"21-83",">= 70 years",">= 70 years","excluded",NA,"hospitalization","severe","severe","delta",60,-189,94,"Finland","FIN","Europe","Europe & Central Asia",49950,2019,"Finland","High income",4,NA,NA,NA,NA,NA
"1722",203,"Baum","Retrospective cohort",1776,2022-11-05,"Moderna mRNA-1273","mRNA","1","1",NA,"84+",">= 70 years",">= 70 years","excluded",NA,"hospitalization","severe","severe","delta",91,35,99,"Finland","FIN","Europe","Europe & Central Asia",49950,2019,"Finland","High income",4,NA,NA,NA,NA,NA
"1723",203,"Baum","Retrospective cohort",1777,2022-11-05,"Moderna mRNA-1273","mRNA","2","final",NA,"14-90",">= 70 years",">= 70 years","excluded","~48.5 weeks","hospitalization","severe","severe","delta",92,42,99,"Finland","FIN","Europe","Europe & Central Asia",49950,2019,"Finland","High income",4,14,90,"yes",NA,1
"1724",203,"Baum","Retrospective cohort",1778,2022-11-05,"Moderna mRNA-1273","mRNA","2","final",NA,"181+",">= 70 years",">= 70 years","excluded","~48.5 weeks","hospitalization","severe","severe","delta",87,70,94,"Finland","FIN","Europe","Europe & Central Asia",49950,2019,"Finland","High income",4,181,339.5,"no","sequential period",1
"1725",203,"Baum","Retrospective cohort",1779,2022-11-05,"Oxford/AstraZeneca ChAdOx1-S","Vectored","1","1",NA,"84+",">= 70 years",">= 70 years","excluded",NA,"hospitalization","severe","severe","delta",62,-171,95,"Finland","FIN","Europe","Europe & Central Asia",49950,2019,"Finland","High income",4,NA,NA,NA,NA,NA
"1726",203,"Baum","Retrospective cohort",1780,2022-11-05,"Oxford/AstraZeneca ChAdOx1-S","Vectored","2","final",NA,"91-180",">= 70 years",">= 70 years","excluded","~48.5 weeks","hospitalization","severe","severe","delta",79,67,87,"Finland","FIN","Europe","Europe & Central Asia",49950,2019,"Finland","High income",4,91,180,"yes",NA,1
"1727",203,"Baum","Retrospective cohort",1781,2022-11-05,"Oxford/AstraZeneca ChAdOx1-S","Vectored","2","final",NA,"181+",">= 70 years",">= 70 years","excluded","~48.5 weeks","hospitalization","severe","severe","delta",23,-76,67,"Finland","FIN","Europe","Europe & Central Asia",49950,2019,"Finland","High income",4,181,339.5,"no","sequential period",1
"1728",203,"Baum","Retrospective cohort",1782,2022-11-05,"BioNTech/Pfizer BNT162b2","mRNA","1","1",NA,"21-83",">= 70 years",">= 70 years","excluded",NA,"hospitalization","severe","severe","omicron",22,-38,56,"Finland","FIN","Europe","Europe & Central Asia",49950,2019,"Finland","High income",4,NA,NA,NA,NA,NA
"1729",203,"Baum","Retrospective cohort",1783,2022-11-05,"BioNTech/Pfizer BNT162b2","mRNA","1","1",NA,"84+",">= 70 years",">= 70 years","excluded",NA,"hospitalization","severe","severe","omicron",61,34,77,"Finland","FIN","Europe","Europe & Central Asia",49950,2019,"Finland","High income",4,NA,NA,NA,NA,NA
"1730",203,"Baum","Retrospective cohort",1784,2022-11-05,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"14-90",">= 70 years",">= 70 years","excluded","~56 weeks","hospitalization","severe","severe","omicron",91,83,95,"Finland","FIN","Europe","Europe & Central Asia",49950,2019,"Finland","High income",4,14,90,"yes",NA,1
"1731",203,"Baum","Retrospective cohort",1785,2022-11-05,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"181+",">= 70 years",">= 70 years","excluded","~56 weeks","hospitalization","severe","severe","omicron",58,48,66,"Finland","FIN","Europe","Europe & Central Asia",49950,2019,"Finland","High income",4,181,392,"no","sequential period",1
"1732",203,"Baum","Retrospective cohort",1786,2022-11-05,"Moderna mRNA-1273","mRNA","1","1",NA,"21-83",">= 70 years",">= 70 years","excluded",NA,"hospitalization","severe","severe","omicron",81,-33,97,"Finland","FIN","Europe","Europe & Central Asia",49950,2019,"Finland","High income",4,NA,NA,NA,NA,NA
"1733",203,"Baum","Retrospective cohort",1787,2022-11-05,"Moderna mRNA-1273","mRNA","1","1",NA,"84+",">= 70 years",">= 70 years","excluded",NA,"hospitalization","severe","severe","omicron",23,-63,64,"Finland","FIN","Europe","Europe & Central Asia",49950,2019,"Finland","High income",4,NA,NA,NA,NA,NA
"1734",203,"Baum","Retrospective cohort",1788,2022-11-05,"Moderna mRNA-1273","mRNA","2","final",NA,"14-90",">= 70 years",">= 70 years","excluded","~56 weeks","hospitalization","severe","severe","omicron",79,43,92,"Finland","FIN","Europe","Europe & Central Asia",49950,2019,"Finland","High income",4,14,90,"yes",NA,1
"1735",203,"Baum","Retrospective cohort",1789,2022-11-05,"Moderna mRNA-1273","mRNA","2","final",NA,"181+",">= 70 years",">= 70 years","excluded","~56 weeks","hospitalization","severe","severe","omicron",60,34,75,"Finland","FIN","Europe","Europe & Central Asia",49950,2019,"Finland","High income",4,181,392,"no","sequential period",1
"1736",203,"Baum","Retrospective cohort",1790,2022-11-05,"Oxford/AstraZeneca ChAdOx1-S","Vectored","1","1",NA,"84+",">= 70 years",">= 70 years","excluded",NA,"hospitalization","severe","severe","omicron",100,NA,NA,"Finland","FIN","Europe","Europe & Central Asia",49950,2019,"Finland","High income",4,NA,NA,NA,NA,NA
"1737",203,"Baum","Retrospective cohort",1791,2022-11-05,"Oxford/AstraZeneca ChAdOx1-S","Vectored","2","final",NA,"91-180",">= 70 years",">= 70 years","excluded",NA,"hospitalization","severe","severe","omicron",37,-154,85,"Finland","FIN","Europe","Europe & Central Asia",49950,2019,"Finland","High income",4,91,180,"yes",NA,1
"1738",203,"Baum","Retrospective cohort",1792,2022-11-05,"Oxford/AstraZeneca ChAdOx1-S","Vectored","2","final",NA,"181+",">= 70 years",">= 70 years","excluded","~56 weeks","hospitalization","severe","severe","omicron",51,12,73,"Finland","FIN","Europe","Europe & Central Asia",49950,2019,"Finland","High income",4,181,392,"no","sequential period",1
"1739",204,"Jara","Retrospective cohort",1793,2022-05-23,"Sinovac CoronaVac","Inactivated","2","final",NA,"14+","3-5 years","3-5 years","excluded","~12 weeks","infection","infection","infection","omicron",37.9,36.1,39.6,"Chile","CHL","South America","Latin America & Caribbean",14690,2019,"Chile","High income",3,NA,NA,NA,NA,NA
"1740",204,"Jara","Retrospective cohort",1794,2022-05-23,"Sinovac CoronaVac","Inactivated","2","final",NA,"14+","3-5 years","3-5 years","excluded","~12 weeks","hospitalization","severe","severe","omicron",65.2,50.4,75.6,"Chile","CHL","South America","Latin America & Caribbean",14690,2019,"Chile","High income",3,NA,NA,NA,NA,NA
"1741",204,"Jara","Retrospective cohort",1795,2022-05-23,"Sinovac CoronaVac","Inactivated","2","final",NA,"14+","3-5 years","3-5 years","excluded","~12 weeks","ICU admission","severe","severe","omicron",68.8,18,88.1,"Chile","CHL","South America","Latin America & Caribbean",14690,2019,"Chile","High income",3,NA,NA,NA,NA,NA
"1742",205,"Rearte","Test-negative case-control",1796,2022-03-15,"Oxford/AstraZeneca ChAdOx1-S","Vectored","1","1",NA,"21+",">= 18 years","general pop","excluded",NA,"infection","infection","infection","other combinations",39.9,39,41,"Argentina","ARG","South America","Latin America & Caribbean",11210,2019,"Argentina","Upper middle income",3,NA,NA,NA,NA,NA
"1743",205,"Rearte","Test-negative case-control",1797,2022-03-15,"Oxford/AstraZeneca ChAdOx1-S","Vectored","2","final",NA,"21+",">= 18 years","general pop","excluded","~26 weeks","infection","infection","infection","other combinations",68.5,67,69,"Argentina","ARG","South America","Latin America & Caribbean",11210,2019,"Argentina","Upper middle income",3,NA,NA,NA,NA,NA
"1744",205,"Rearte","Test-negative case-control",1798,2022-03-15,"Oxford/AstraZeneca ChAdOx1-S","Vectored","1","1",NA,"21+",">= 18 years","general pop","excluded",NA,"death","death","death","other combinations",83.1,82.3,83.9,"Argentina","ARG","South America","Latin America & Caribbean",11210,2019,"Argentina","Upper middle income",3,NA,NA,NA,NA,NA
"1745",205,"Rearte","Test-negative case-control",1799,2022-03-15,"Oxford/AstraZeneca ChAdOx1-S","Vectored","2","final",NA,"21+",">= 18 years","general pop","excluded","~26 weeks","death","death","death","other combinations",93.7,93.2,94.3,"Argentina","ARG","South America","Latin America & Caribbean",11210,2019,"Argentina","Upper middle income",3,NA,NA,NA,NA,NA
"1746",205,"Rearte","Test-negative case-control",1800,2022-03-15,"Beijing/Sinopharm BBIBP-CorV","Inactivated","1","1",NA,"21+",">= 18 years","general pop","excluded",NA,"infection","infection","infection","other combinations",22.6,20,25,"Argentina","ARG","South America","Latin America & Caribbean",11210,2019,"Argentina","Upper middle income",3,NA,NA,NA,NA,NA
"1747",205,"Rearte","Test-negative case-control",1801,2022-03-15,"Beijing/Sinopharm BBIBP-CorV","Inactivated","2","final",NA,"21+",">= 18 years","general pop","excluded","~26 weeks","infection","infection","infection","other combinations",43.6,42,45,"Argentina","ARG","South America","Latin America & Caribbean",11210,2019,"Argentina","Upper middle income",3,NA,NA,NA,NA,NA
"1748",205,"Rearte","Test-negative case-control",1802,2022-03-15,"Beijing/Sinopharm BBIBP-CorV","Inactivated","1","1",NA,"21+",">= 18 years","general pop","excluded",NA,"death","death","death","other combinations",70.4,68.1,72.8,"Argentina","ARG","South America","Latin America & Caribbean",11210,2019,"Argentina","Upper middle income",3,NA,NA,NA,NA,NA
"1749",205,"Rearte","Test-negative case-control",1803,2022-03-15,"Beijing/Sinopharm BBIBP-CorV","Inactivated","2","final",NA,"21+",">= 18 years","general pop","excluded","~26 weeks","death","death","death","other combinations",85,84,86,"Argentina","ARG","South America","Latin America & Caribbean",11210,2019,"Argentina","Upper middle income",3,NA,NA,NA,NA,NA
"1750",205,"Rearte","Test-negative case-control",1804,2022-03-15,"Gamaleya Gam-COVID-Vac/Sputnik V","Vectored","1","1",NA,"21+",">= 18 years","general pop","excluded",NA,"infection","infection","infection","other combinations",39.5,39,40,"Argentina","ARG","South America","Latin America & Caribbean",11210,2019,"Argentina","Upper middle income",3,NA,NA,NA,NA,NA
"1751",205,"Rearte","Test-negative case-control",1805,2022-03-15,"Gamaleya Gam-COVID-Vac/Sputnik V","Vectored","2","final",NA,"21+",">= 18 years","general pop","excluded","~26 weeks","infection","infection","infection","other combinations",64,63,65,"Argentina","ARG","South America","Latin America & Caribbean",11210,2019,"Argentina","Upper middle income",3,NA,NA,NA,NA,NA
"1752",205,"Rearte","Test-negative case-control",1806,2022-03-15,"Gamaleya Gam-COVID-Vac/Sputnik V","Vectored","1","1",NA,"21+",">= 18 years","general pop","excluded",NA,"death","death","death","other combinations",81.1,80.5,81.7,"Argentina","ARG","South America","Latin America & Caribbean",11210,2019,"Argentina","Upper middle income",3,NA,NA,NA,NA,NA
"1753",205,"Rearte","Test-negative case-control",1807,2022-03-15,"Gamaleya Gam-COVID-Vac/Sputnik V","Vectored","2","final",NA,"21+",">= 18 years","general pop","excluded","~26 weeks","death","death","death","other combinations",93.1,92.6,93.5,"Argentina","ARG","South America","Latin America & Caribbean",11210,2019,"Argentina","Upper middle income",3,NA,NA,NA,NA,NA
"1754",206,"Can","Retrospective cohort",1808,2022-03-19,"Sinovac CoronaVac","Inactivated","2","final",NA,"14+","HCW","HCW","excluded","13 weeks","infection","infection","infection","alpha",39,20,54,"Turkey","TUR","Asia","Europe & Central Asia",9800,2019,"Trkiye","Upper middle income",3,NA,NA,NA,NA,NA
"1755",207,"Altarawneh","Test-negative case-control",1809,2022-06-15,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"14+",">= 18 years","general pop","previously infected only","44 weeks","symptomatic disease","symptomatic","symptomatic","omicron",51.7,43.5,58.7,"Qatar","QAT","Asia","Middle East & North Africa",65700,2019,"Qatar","High income",4,NA,NA,NA,NA,NA
"1756",207,"Altarawneh","Test-negative case-control",1810,2022-06-15,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"14+",">= 18 years","general pop","previously infected only","44 weeks","hospitalization or death","severe","severe","omicron",96.2,37.7,99.8,"Qatar","QAT","Asia","Middle East & North Africa",65700,2019,"Qatar","High income",4,NA,NA,NA,NA,NA
"1757",207,"Altarawneh","Test-negative case-control",1811,2022-06-15,"Moderna mRNA-1273","mRNA","2","final",NA,"14+",">= 18 years","general pop","previously infected only","44 weeks","symptomatic disease","symptomatic","symptomatic","omicron",44.3,30.4,55.4,"Qatar","QAT","Asia","Middle East & North Africa",65700,2019,"Qatar","High income",4,NA,NA,NA,NA,NA
"1758",207,"Altarawneh","Test-negative case-control",1812,2022-06-15,"Moderna mRNA-1273","mRNA","2","final",NA,"14+",">= 18 years","general pop","previously infected only","44 weeks","hospitalization or death","severe","severe","omicron",100,-51.5,100,"Qatar","QAT","Asia","Middle East & North Africa",65700,2019,"Qatar","High income",4,NA,NA,NA,NA,NA
"1759",207,"Altarawneh","Test-negative case-control",1813,2022-06-15,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"14+",">= 18 years","general pop","excluded","44 weeks","symptomatic disease","symptomatic","symptomatic","omicron",-4.9,-16.4,5.4,"Qatar","QAT","Asia","Middle East & North Africa",65700,2019,"Qatar","High income",4,NA,NA,NA,NA,NA
"1760",207,"Altarawneh","Test-negative case-control",1814,2022-06-15,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"14+",">= 18 years","general pop","excluded","44 weeks","hospitalization or death","severe","severe","omicron",96.8,71.1,99.6,"Qatar","QAT","Asia","Middle East & North Africa",65700,2019,"Qatar","High income",4,14,308,"no","nested endpoint",0
"1761",207,"Altarawneh","Test-negative case-control",1815,2022-06-15,"Moderna mRNA-1273","mRNA","2","final",NA,"14+",">= 18 years","general pop","excluded","44 weeks","symptomatic disease","symptomatic","symptomatic","omicron",-2.7,-16.8,9.7,"Qatar","QAT","Asia","Middle East & North Africa",65700,2019,"Qatar","High income",4,NA,NA,NA,NA,NA
"1762",207,"Altarawneh","Test-negative case-control",1816,2022-06-15,"Moderna mRNA-1273","mRNA","2","final",NA,"14+",">= 18 years","general pop","excluded","44 weeks","hospitalization or death","severe","severe","omicron",88.8,-1.7,98.8,"Qatar","QAT","Asia","Middle East & North Africa",65700,2019,"Qatar","High income",4,14,308,"no","nested endpoint",0
"1763",207,"Altarawneh","Test-negative case-control",1817,2022-06-15,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"14+",">= 18 years","general pop","previously infected only","44 weeks","symptomatic disease","symptomatic","symptomatic","omicron",55.1,50.9,58.9,"Qatar","QAT","Asia","Middle East & North Africa",65700,2019,"Qatar","High income",4,NA,NA,NA,NA,NA
"1764",207,"Altarawneh","Test-negative case-control",1818,2022-06-15,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"14+",">= 18 years","general pop","previously infected only","44 weeks","hospitalization or death","severe","severe","omicron",97.8,82.6,99.7,"Qatar","QAT","Asia","Middle East & North Africa",65700,2019,"Qatar","High income",4,NA,NA,NA,NA,NA
"1765",207,"Altarawneh","Test-negative case-control",1819,2022-06-15,"Moderna mRNA-1273","mRNA","2","final",NA,"14+",">= 18 years","general pop","previously infected only","44 weeks","symptomatic disease","symptomatic","symptomatic","omicron",47.9,40.8,54.1,"Qatar","QAT","Asia","Middle East & North Africa",65700,2019,"Qatar","High income",4,NA,NA,NA,NA,NA
"1766",207,"Altarawneh","Test-negative case-control",1820,2022-06-15,"Moderna mRNA-1273","mRNA","2","final",NA,"14+",">= 18 years","general pop","previously infected only","44 weeks","hospitalization or death","severe","severe","omicron",100,55.4,100,"Qatar","QAT","Asia","Middle East & North Africa",65700,2019,"Qatar","High income",4,NA,NA,NA,NA,NA
"1767",207,"Altarawneh","Test-negative case-control",1821,2022-06-15,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"14+",">= 18 years","general pop","excluded","44 weeks","symptomatic disease","symptomatic","symptomatic","omicron",-1.1,-7.1,4.6,"Qatar","QAT","Asia","Middle East & North Africa",65700,2019,"Qatar","High income",4,NA,NA,NA,NA,NA
"1768",207,"Altarawneh","Test-negative case-control",1822,2022-06-15,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"14+",">= 18 years","general pop","excluded","44 weeks","hospitalization or death","severe","severe","omicron",76.8,58,87.1,"Qatar","QAT","Asia","Middle East & North Africa",65700,2019,"Qatar","High income",4,14,308,"no","nested endpoint",0
"1769",207,"Altarawneh","Test-negative case-control",1823,2022-06-15,"Moderna mRNA-1273","mRNA","2","final",NA,"14+",">= 18 years","general pop","excluded","44 weeks","symptomatic disease","symptomatic","symptomatic","omicron",-7.3,-15.6,0.3,"Qatar","QAT","Asia","Middle East & North Africa",65700,2019,"Qatar","High income",4,NA,NA,NA,NA,NA
"1770",207,"Altarawneh","Test-negative case-control",1824,2022-06-15,"Moderna mRNA-1273","mRNA","2","final",NA,"14+",">= 18 years","general pop","excluded","44 weeks","hospitalization or death","severe","severe","omicron",84.8,47.9,95.6,"Qatar","QAT","Asia","Middle East & North Africa",65700,2019,"Qatar","High income",4,14,308,"no","nested endpoint",0
"1771",207,"Altarawneh","Test-negative case-control",1825,2022-06-15,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"14+",">= 18 years","general pop","previously infected only","44 weeks","symptomatic disease","symptomatic","symptomatic","omicron",55.5,51.8,59,"Qatar","QAT","Asia","Middle East & North Africa",65700,2019,"Qatar","High income",4,NA,NA,NA,NA,NA
"1772",207,"Altarawneh","Test-negative case-control",1826,2022-06-15,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"14+",">= 18 years","general pop","previously infected only","44 weeks","hospitalization or death","severe","severe","omicron",94.3,81.3,98.3,"Qatar","QAT","Asia","Middle East & North Africa",65700,2019,"Qatar","High income",4,NA,NA,NA,NA,NA
"1773",207,"Altarawneh","Test-negative case-control",1827,2022-06-15,"Moderna mRNA-1273","mRNA","2","final",NA,"14+",">= 18 years","general pop","previously infected only","44 weeks","symptomatic disease","symptomatic","symptomatic","omicron",52,45.8,57.4,"Qatar","QAT","Asia","Middle East & North Africa",65700,2019,"Qatar","High income",4,NA,NA,NA,NA,NA
"1774",207,"Altarawneh","Test-negative case-control",1828,2022-06-15,"Moderna mRNA-1273","mRNA","2","final",NA,"14+",">= 18 years","general pop","previously infected only","44 weeks","hospitalization or death","severe","severe","omicron",100,NA,NA,"Qatar","QAT","Asia","Middle East & North Africa",65700,2019,"Qatar","High income",4,NA,NA,NA,NA,NA
"1775",207,"Altarawneh","Test-negative case-control",1829,2022-06-15,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"14+",">= 18 years","general pop","excluded","44 weeks","symptomatic disease","symptomatic","symptomatic","omicron",-0.2,-5.5,4.9,"Qatar","QAT","Asia","Middle East & North Africa",65700,2019,"Qatar","High income",4,NA,NA,NA,NA,NA
"1776",207,"Altarawneh","Test-negative case-control",1830,2022-06-15,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"14+",">= 18 years","general pop","excluded","44 weeks","hospitalization or death","severe","severe","omicron",73.5,60.5,82.2,"Qatar","QAT","Asia","Middle East & North Africa",65700,2019,"Qatar","High income",4,14,308,"yes",NA,0
"1777",207,"Altarawneh","Test-negative case-control",1831,2022-06-15,"Moderna mRNA-1273","mRNA","2","final",NA,"14+",">= 18 years","general pop","excluded","44 weeks","symptomatic disease","symptomatic","symptomatic","omicron",2.2,-4.6,8.5,"Qatar","QAT","Asia","Middle East & North Africa",65700,2019,"Qatar","High income",4,NA,NA,NA,NA,NA
"1778",207,"Altarawneh","Test-negative case-control",1832,2022-06-15,"Moderna mRNA-1273","mRNA","2","final",NA,"14+",">= 18 years","general pop","excluded","44 weeks","hospitalization or death","severe","severe","omicron",66.3,38.3,81.6,"Qatar","QAT","Asia","Middle East & North Africa",65700,2019,"Qatar","High income",4,14,308,"yes",NA,0
"1779",208,"Kaura","Retrospective cohort",1833,2022-03-12,"BioNTech/Pfizer BNT162b2","mRNA","1","1",NA,"14-84",">= 16 years","general pop","excluded",NA,"Infection","infection","infection","alpha",31,14,45,"UK","GBR","Europe","Europe & Central Asia",43240,2019,"United Kingdom","High income",4,NA,NA,NA,NA,NA
"1780",208,"Kaura","Retrospective cohort",1834,2022-03-12,"BioNTech/Pfizer BNT162b2","mRNA","1","1",NA,"14-84",">= 16 years","general pop","excluded",NA,"hospitalization","severe","severe","alpha",75,45,91,"UK","GBR","Europe","Europe & Central Asia",43240,2019,"United Kingdom","High income",4,NA,NA,NA,NA,NA
"1781",208,"Kaura","Retrospective cohort",1835,2022-03-12,"BioNTech/Pfizer BNT162b2","mRNA","1","1",NA,"14-84",">= 16 years","general pop","excluded",NA,"death","death","death","alpha",86,42,98,"UK","GBR","Europe","Europe & Central Asia",43240,2019,"United Kingdom","High income",4,NA,NA,NA,NA,NA
"1782",208,"Kaura","Retrospective cohort",1836,2022-03-12,"Oxford/AstraZeneca ChAdOx1-S","Vectored","1","1",NA,"14-84",">= 16 years","general pop","excluded",NA,"Infection","infection","infection","alpha",15,-5,31,"UK","GBR","Europe","Europe & Central Asia",43240,2019,"United Kingdom","High income",4,NA,NA,NA,NA,NA
"1783",208,"Kaura","Retrospective cohort",1837,2022-03-12,"Oxford/AstraZeneca ChAdOx1-S","Vectored","1","1",NA,"14-84",">= 16 years","general pop","excluded",NA,"hospitalization","severe","severe","alpha",75,45,91,"UK","GBR","Europe","Europe & Central Asia",43240,2019,"United Kingdom","High income",4,NA,NA,NA,NA,NA
"1784",208,"Kaura","Retrospective cohort",1838,2022-03-12,"Oxford/AstraZeneca ChAdOx1-S","Vectored","1","1",NA,"14-84",">= 16 years","general pop","excluded",NA,"death","death","death","alpha",86,42,98,"UK","GBR","Europe","Europe & Central Asia",43240,2019,"United Kingdom","High income",4,NA,NA,NA,NA,NA
"1785",209,"Horne","Retrospective cohort",1839,2022-07-20,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"21-42","18-39 years","18-39 years","excluded","~30 weeks","infection","infection","infection","other combinations",76,75,77,"UK","GBR","Europe","Europe & Central Asia",43240,2019,"United Kingdom","High income",4,NA,NA,NA,NA,NA
"1786",209,"Horne","Retrospective cohort",1840,2022-07-20,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"161-182","18-39 years","18-39 years","excluded","~30 weeks","infection","infection","infection","other combinations",-53,-118,-7,"UK","GBR","Europe","Europe & Central Asia",43240,2019,"United Kingdom","High income",4,NA,NA,NA,NA,NA
"1787",209,"Horne","Retrospective cohort",1841,2022-07-20,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"21-42","18-39 years","18-39 years","excluded","~30 weeks","hospitalization","severe","severe","other combinations",96,94,98,"UK","GBR","Europe","Europe & Central Asia",43240,2019,"United Kingdom","High income",4,NA,NA,NA,NA,NA
"1788",209,"Horne","Retrospective cohort",1842,2022-07-20,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"133-154","18-39 years","18-39 years","excluded","~30 weeks","hospitalization","severe","severe","other combinations",82,71,90,"UK","GBR","Europe","Europe & Central Asia",43240,2019,"United Kingdom","High income",4,NA,NA,NA,NA,NA
"1789",209,"Horne","Retrospective cohort",1843,2022-07-20,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"21-42","40-64 years","40-64 years","excluded","~30 weeks","infection","infection","infection","other combinations",73,69,77,"UK","GBR","Europe","Europe & Central Asia",43240,2019,"United Kingdom","High income",4,NA,NA,NA,NA,NA
"1790",209,"Horne","Retrospective cohort",1844,2022-07-20,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"161-182","40-64 years","40-64 years","excluded","~30 weeks","infection","infection","infection","other combinations",-3,-15,7,"UK","GBR","Europe","Europe & Central Asia",43240,2019,"United Kingdom","High income",4,NA,NA,NA,NA,NA
"1791",209,"Horne","Retrospective cohort",1845,2022-07-20,"Oxford/AstraZeneca ChAdOx1-S","Vectored","2","final",NA,"21-42","40-64 years","40-64 years","excluded","~30 weeks","infection","infection","infection","other combinations",21,18,24,"UK","GBR","Europe","Europe & Central Asia",43240,2019,"United Kingdom","High income",4,NA,NA,NA,NA,NA
"1792",209,"Horne","Retrospective cohort",1846,2022-07-20,"Oxford/AstraZeneca ChAdOx1-S","Vectored","2","final",NA,"161-182","40-64 years","40-64 years","excluded","~30 weeks","infection","infection","infection","other combinations",-99,-105,-94,"UK","GBR","Europe","Europe & Central Asia",43240,2019,"United Kingdom","High income",4,NA,NA,NA,NA,NA
"1793",209,"Horne","Retrospective cohort",1847,2022-07-20,"Oxford/AstraZeneca ChAdOx1-S","Vectored","2","final",NA,"21-42","40-64 years","40-64 years","excluded","~30 weeks","hospitalization","severe","severe","other combinations",95,93,96,"UK","GBR","Europe","Europe & Central Asia",43240,2019,"United Kingdom","High income",4,NA,NA,NA,NA,NA
"1794",209,"Horne","Retrospective cohort",1848,2022-07-20,"Oxford/AstraZeneca ChAdOx1-S","Vectored","2","final",NA,"161-182","40-64 years","40-64 years","excluded","~30 weeks","hospitalization","severe","severe","other combinations",86,83,88,"UK","GBR","Europe","Europe & Central Asia",43240,2019,"United Kingdom","High income",4,NA,NA,NA,NA,NA
"1795",209,"Horne","Retrospective cohort",1849,2022-07-20,"Oxford/AstraZeneca ChAdOx1-S","Vectored","2","final",NA,"105-126","40-64 years","40-64 years","excluded","~30 weeks","death","death","death","other combinations",55,-5,81,"UK","GBR","Europe","Europe & Central Asia",43240,2019,"United Kingdom","High income",4,NA,NA,NA,NA,NA
"1796",209,"Horne","Retrospective cohort",1850,2022-07-20,"Oxford/AstraZeneca ChAdOx1-S","Vectored","2","final",NA,"161-182","40-64 years","40-64 years","excluded","~30 weeks","death","death","death","other combinations",41,-7,68,"UK","GBR","Europe","Europe & Central Asia",43240,2019,"United Kingdom","High income",4,NA,NA,NA,NA,NA
"1797",209,"Horne","Retrospective cohort",1851,2022-07-20,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"21-42","clinically vulnerable 16-64 years","clinically vulnerable 16-64 years","excluded","~30 weeks","infection","infection","infection","other combinations",34,30,39,"UK","GBR","Europe","Europe & Central Asia",43240,2019,"United Kingdom","High income",4,NA,NA,NA,NA,NA
"1798",209,"Horne","Retrospective cohort",1852,2022-07-20,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"161-182","clinically vulnerable 16-64 years","clinically vulnerable 16-64 years","excluded","~30 weeks","infection","infection","infection","other combinations",4,-1,8,"UK","GBR","Europe","Europe & Central Asia",43240,2019,"United Kingdom","High income",4,NA,NA,NA,NA,NA
"1799",209,"Horne","Retrospective cohort",1853,2022-07-20,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"49-70","clinically vulnerable 16-64 years","clinically vulnerable 16-64 years","excluded","~30 weeks","hospitalization","severe","severe","other combinations",95,94,97,"UK","GBR","Europe","Europe & Central Asia",43240,2019,"United Kingdom","High income",4,NA,NA,NA,NA,NA
"1800",209,"Horne","Retrospective cohort",1854,2022-07-20,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"161-182","clinically vulnerable 16-64 years","clinically vulnerable 16-64 years","excluded","~30 weeks","hospitalization","severe","severe","other combinations",91,88,93,"UK","GBR","Europe","Europe & Central Asia",43240,2019,"United Kingdom","High income",4,NA,NA,NA,NA,NA
"1801",209,"Horne","Retrospective cohort",1855,2022-07-20,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"77-98","clinically vulnerable 16-64 years","clinically vulnerable 16-64 years","excluded","~30 weeks","death","death","death","other combinations",96,91,98,"UK","GBR","Europe","Europe & Central Asia",43240,2019,"United Kingdom","High income",4,NA,NA,NA,NA,NA
"1802",209,"Horne","Retrospective cohort",1856,2022-07-20,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"161-182","clinically vulnerable 16-64 years","clinically vulnerable 16-64 years","excluded","~30 weeks","death","death","death","other combinations",92,86,96,"UK","GBR","Europe","Europe & Central Asia",43240,2019,"United Kingdom","High income",4,NA,NA,NA,NA,NA
"1803",209,"Horne","Retrospective cohort",1857,2022-07-20,"Oxford/AstraZeneca ChAdOx1-S","Vectored","2","final",NA,"21-42","clinically vulnerable 16-64 years","clinically vulnerable 16-64 years","excluded","~30 weeks","infection","infection","infection","other combinations",34,30,39,"UK","GBR","Europe","Europe & Central Asia",43240,2019,"United Kingdom","High income",4,NA,NA,NA,NA,NA
"1804",209,"Horne","Retrospective cohort",1858,2022-07-20,"Oxford/AstraZeneca ChAdOx1-S","Vectored","2","final",NA,"161-182","clinically vulnerable 16-64 years","clinically vulnerable 16-64 years","excluded","~30 weeks","infection","infection","infection","other combinations",-45,-50,-40,"UK","GBR","Europe","Europe & Central Asia",43240,2019,"United Kingdom","High income",4,NA,NA,NA,NA,NA
"1805",209,"Horne","Retrospective cohort",1859,2022-07-20,"Oxford/AstraZeneca ChAdOx1-S","Vectored","2","final",NA,"21-42","clinically vulnerable 16-64 years","clinically vulnerable 16-64 years","excluded","~30 weeks","hospitalization","severe","severe","other combinations",92,88,95,"UK","GBR","Europe","Europe & Central Asia",43240,2019,"United Kingdom","High income",4,NA,NA,NA,NA,NA
"1806",209,"Horne","Retrospective cohort",1860,2022-07-20,"Oxford/AstraZeneca ChAdOx1-S","Vectored","2","final",NA,"161-182","clinically vulnerable 16-64 years","clinically vulnerable 16-64 years","excluded","~30 weeks","hospitalization","severe","severe","other combinations",75,71,78,"UK","GBR","Europe","Europe & Central Asia",43240,2019,"United Kingdom","High income",4,NA,NA,NA,NA,NA
"1807",209,"Horne","Retrospective cohort",1861,2022-07-20,"Oxford/AstraZeneca ChAdOx1-S","Vectored","2","final",NA,"77-98","clinically vulnerable 16-64 years","clinically vulnerable 16-64 years","excluded","~30 weeks","death","death","death","other combinations",92,88,95,"UK","GBR","Europe","Europe & Central Asia",43240,2019,"United Kingdom","High income",4,NA,NA,NA,NA,NA
"1808",209,"Horne","Retrospective cohort",1862,2022-07-20,"Oxford/AstraZeneca ChAdOx1-S","Vectored","2","final",NA,"161-182","clinically vulnerable 16-64 years","clinically vulnerable 16-64 years","excluded","~30 weeks","death","death","death","other combinations",87,81,92,"UK","GBR","Europe","Europe & Central Asia",43240,2019,"United Kingdom","High income",4,NA,NA,NA,NA,NA
"1809",209,"Horne","Retrospective cohort",1863,2022-07-20,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"21-42",">= 65 years",">= 65 years","excluded","~30 weeks","infection","infection","infection","other combinations",81,74,86,"UK","GBR","Europe","Europe & Central Asia",43240,2019,"United Kingdom","High income",4,NA,NA,NA,NA,NA
"1810",209,"Horne","Retrospective cohort",1864,2022-07-20,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"161-182",">= 65 years",">= 65 years","excluded","~30 weeks","infection","infection","infection","other combinations",15,8,22,"UK","GBR","Europe","Europe & Central Asia",43240,2019,"United Kingdom","High income",4,NA,NA,NA,NA,NA
"1811",209,"Horne","Retrospective cohort",1865,2022-07-20,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"21-42",">= 65 years",">= 65 years","excluded","~30 weeks","hospitalization","severe","severe","other combinations",91,86,95,"UK","GBR","Europe","Europe & Central Asia",43240,2019,"United Kingdom","High income",4,NA,NA,NA,NA,NA
"1812",209,"Horne","Retrospective cohort",1866,2022-07-20,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"161-182",">= 65 years",">= 65 years","excluded","~30 weeks","hospitalization","severe","severe","other combinations",80,76,82,"UK","GBR","Europe","Europe & Central Asia",43240,2019,"United Kingdom","High income",4,NA,NA,NA,NA,NA
"1813",209,"Horne","Retrospective cohort",1867,2022-07-20,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"21-42",">= 65 years",">= 65 years","excluded","~30 weeks","death","death","death","other combinations",98,93,99,"UK","GBR","Europe","Europe & Central Asia",43240,2019,"United Kingdom","High income",4,NA,NA,NA,NA,NA
"1814",209,"Horne","Retrospective cohort",1868,2022-07-20,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"161-182",">= 65 years",">= 65 years","excluded","~30 weeks","death","death","death","other combinations",88,84,91,"UK","GBR","Europe","Europe & Central Asia",43240,2019,"United Kingdom","High income",4,NA,NA,NA,NA,NA
"1815",209,"Horne","Retrospective cohort",1869,2022-07-20,"Oxford/AstraZeneca ChAdOx1-S","Vectored","2","final",NA,"21-42",">= 65 years",">= 65 years","excluded","~30 weeks","infection","infection","infection","other combinations",53,41,62,"UK","GBR","Europe","Europe & Central Asia",43240,2019,"United Kingdom","High income",4,NA,NA,NA,NA,NA
"1816",209,"Horne","Retrospective cohort",1870,2022-07-20,"Oxford/AstraZeneca ChAdOx1-S","Vectored","2","final",NA,"161-182",">= 65 years",">= 65 years","excluded","~30 weeks","infection","infection","infection","other combinations",-21,-30,-13,"UK","GBR","Europe","Europe & Central Asia",43240,2019,"United Kingdom","High income",4,NA,NA,NA,NA,NA
"1817",209,"Horne","Retrospective cohort",1871,2022-07-20,"Oxford/AstraZeneca ChAdOx1-S","Vectored","2","final",NA,"21-42",">= 65 years",">= 65 years","excluded","~30 weeks","hospitalization","severe","severe","other combinations",88,85,90,"UK","GBR","Europe","Europe & Central Asia",43240,2019,"United Kingdom","High income",4,NA,NA,NA,NA,NA
"1818",209,"Horne","Retrospective cohort",1872,2022-07-20,"Oxford/AstraZeneca ChAdOx1-S","Vectored","2","final",NA,"161-182",">= 65 years",">= 65 years","excluded","~30 weeks","hospitalization","severe","severe","other combinations",75,71,79,"UK","GBR","Europe","Europe & Central Asia",43240,2019,"United Kingdom","High income",4,NA,NA,NA,NA,NA
"1819",209,"Horne","Retrospective cohort",1873,2022-07-20,"Oxford/AstraZeneca ChAdOx1-S","Vectored","2","final",NA,"21-42",">= 65 years",">= 65 years","excluded","~30 weeks","death","death","death","other combinations",90,84,94,"UK","GBR","Europe","Europe & Central Asia",43240,2019,"United Kingdom","High income",4,NA,NA,NA,NA,NA
"1820",209,"Horne","Retrospective cohort",1874,2022-07-20,"Oxford/AstraZeneca ChAdOx1-S","Vectored","2","final",NA,"161-182",">= 65 years",">= 65 years","excluded","~30 weeks","death","death","death","other combinations",83,77,88,"UK","GBR","Europe","Europe & Central Asia",43240,2019,"United Kingdom","High income",4,NA,NA,NA,NA,NA
"1821",210,"Stowe","Test-negative case-control",1875,2022-09-30,"BioNTech/Pfizer BNT162b2","mRNA","1","1",NA,"28+","18-64 years","18-64 years","included",NA,"hospitalization with ARI","severe","severe","omicron",31.7,-3.1,54.8,"UK","GBR","Europe","Europe & Central Asia",43240,2019,"United Kingdom","High income",4,NA,NA,NA,NA,NA
"1822",210,"Stowe","Test-negative case-control",1876,2022-09-30,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"14-174","18-64 years","18-64 years","included","~43 weeks","hospitalization with ARI","severe","severe","omicron",73.8,62.5,81.7,"UK","GBR","Europe","Europe & Central Asia",43240,2019,"United Kingdom","High income",4,14,174,"yes",NA,0
"1823",210,"Stowe","Test-negative case-control",1877,2022-09-30,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"175+","18-64 years","18-64 years","included","~43 weeks","hospitalization with ARI","severe","severe","omicron",65.1,51.3,74.9,"UK","GBR","Europe","Europe & Central Asia",43240,2019,"United Kingdom","High income",4,175,301,"no","sequential period",0
"1824",210,"Stowe","Test-negative case-control",1878,2022-09-30,"BioNTech/Pfizer BNT162b2","mRNA","1","1",NA,"0-27",">= 65 years",">= 65 years","included",NA,"hospitalization with ARI","severe","severe","omicron",54.8,-25.3,83.7,"UK","GBR","Europe","Europe & Central Asia",43240,2019,"United Kingdom","High income",4,NA,NA,NA,NA,NA
"1825",210,"Stowe","Test-negative case-control",1879,2022-09-30,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"14-174",">= 65 years",">= 65 years","included","~43 weeks","hospitalization with ARI","severe","severe","omicron",87.6,79.4,92.5,"UK","GBR","Europe","Europe & Central Asia",43240,2019,"United Kingdom","High income",4,14,174,"yes",NA,1
"1826",210,"Stowe","Test-negative case-control",1880,2022-09-30,"BioNTech/Pfizer BNT162b2","mRNA","1","1",NA,"28+",">= 65 years",">= 65 years","included",NA,"hospitalization with ARI","severe","severe","omicron",59.5,35.5,74.6,"UK","GBR","Europe","Europe & Central Asia",43240,2019,"United Kingdom","High income",4,NA,NA,NA,NA,NA
"1827",210,"Stowe","Test-negative case-control",1881,2022-09-30,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"175+",">= 65 years",">= 65 years","included","~43 weeks","hospitalization with ARI","severe","severe","omicron",65.4,56.6,72.5,"UK","GBR","Europe","Europe & Central Asia",43240,2019,"United Kingdom","High income",4,175,301,"no","sequential period",1
"1828",210,"Stowe","Test-negative case-control",1882,2022-09-30,"Oxford/AstraZeneca ChAdOx1-S","Vectored","1","1",NA,"28+","18-64 years","18-64 years","included",NA,"hospitalization with ARI","severe","severe","omicron",48.5,25.7,64.3,"UK","GBR","Europe","Europe & Central Asia",43240,2019,"United Kingdom","High income",4,NA,NA,NA,NA,NA
"1829",210,"Stowe","Test-negative case-control",1883,2022-09-30,"Oxford/AstraZeneca ChAdOx1-S","Vectored","2","final",NA,"14-174","18-64 years","18-64 years","included","~43 weeks","hospitalization with ARI","severe","severe","omicron",59,31.9,75.3,"UK","GBR","Europe","Europe & Central Asia",43240,2019,"United Kingdom","High income",4,14,174,"yes",NA,0
"1830",210,"Stowe","Test-negative case-control",1884,2022-09-30,"Oxford/AstraZeneca ChAdOx1-S","Vectored","2","final",NA,"175+","18-64 years","18-64 years","included","~43 weeks","hospitalization with ARI","severe","severe","omicron",53,41.7,62,"UK","GBR","Europe","Europe & Central Asia",43240,2019,"United Kingdom","High income",4,175,301,"no","sequential period",0
"1831",210,"Stowe","Test-negative case-control",1885,2022-09-30,"Oxford/AstraZeneca ChAdOx1-S","Vectored","1","1",NA,"28+",">= 65 years",">= 65 years","included",NA,"hospitalization with ARI","severe","severe","omicron",48.1,23.5,64.8,"UK","GBR","Europe","Europe & Central Asia",43240,2019,"United Kingdom","High income",4,NA,NA,NA,NA,NA
"1832",210,"Stowe","Test-negative case-control",1886,2022-09-30,"Oxford/AstraZeneca ChAdOx1-S","Vectored","2","final",NA,"14-174",">= 65 years",">= 65 years","included","~43 weeks","hospitalization with ARI","severe","severe","omicron",71.2,50,83.4,"UK","GBR","Europe","Europe & Central Asia",43240,2019,"United Kingdom","High income",4,14,174,"yes",NA,1
"1833",210,"Stowe","Test-negative case-control",1887,2022-09-30,"Oxford/AstraZeneca ChAdOx1-S","Vectored","2","final",NA,"175+",">= 65 years",">= 65 years","included","~43 weeks","hospitalization with ARI","severe","severe","omicron",53.1,43.4,61.2,"UK","GBR","Europe","Europe & Central Asia",43240,2019,"United Kingdom","High income",4,175,301,"no","sequential period",1
"1834",211,"Tenforde","Case-control",1888,2022-03-25,"Multiple or heterologous RNA","mRNA","2","final",NA,"14+","hospitalized patients","general pop","included","~45 weeks","invasive mechanical ventilation or in-hospital death","severe","severe","omicron",79,66,87,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"1835",211,"Tenforde","Case-control",1889,2022-03-25,"Multiple or heterologous RNA","mRNA","2","final",NA,"14+","hospitalized patients","general pop","included","~45 weeks","invasive mechanical ventilation or in-hospital death","severe","severe","delta",88,86,90,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"1836",211,"Tenforde","Case-control",1890,2022-03-25,"Multiple or heterologous RNA","mRNA","2","final",NA,"14-150","hospitalized patients","general pop","included","~45 weeks","invasive mechanical ventilation or in-hospital death","severe","severe","alpha",92,90,94,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"1837",211,"Tenforde","Case-control",1891,2022-03-25,"Multiple or heterologous RNA","mRNA","2","final",NA,">150","hospitalized patients","general pop","included","~45 weeks","invasive mechanical ventilation or in-hospital death","severe","severe","alpha",84,80,87,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"1838",212,"Veneti","Retrospective cohort",1892,2023-03-07,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"7-34","16-17 years","16-17 years","excluded","~12 weeks","infection","infection","infection","omicron",53.1,42.6,61.7,"Norway","NOR","Europe","Europe & Central Asia",82430,2019,"Norway","High income",4,NA,NA,NA,NA,NA
"1839",212,"Veneti","Retrospective cohort",1893,2023-03-07,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"63+","16-17 years","16-17 years","excluded","~12 weeks","infection","infection","infection","omicron",23.3,2.7,39.5,"Norway","NOR","Europe","Europe & Central Asia",82430,2019,"Norway","High income",4,NA,NA,NA,NA,NA
"1840",212,"Veneti","Retrospective cohort",1894,2023-03-07,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"7-34","16-17 years","16-17 years","excluded","~12 weeks","infection","infection","infection","delta",90.8,89.1,92.3,"Norway","NOR","Europe","Europe & Central Asia",82430,2019,"Norway","High income",4,NA,NA,NA,NA,NA
"1841",212,"Veneti","Retrospective cohort",1895,2023-03-07,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"63+","16-17 years","16-17 years","excluded","~12 weeks","infection","infection","infection","delta",83.7,75.9,89,"Norway","NOR","Europe","Europe & Central Asia",82430,2019,"Norway","High income",4,NA,NA,NA,NA,NA
"1842",213,"Wang","Test-negative case-control",1896,2022-11-23,"Multiple or heterologous RNA","mRNA","2","final",NA,"14-179","patients","general pop","included","~23.5 weeks","infection","infection","infection","omicron",26,22,30,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"1843",213,"Wang","Test-negative case-control",1897,2022-11-23,"Multiple or heterologous RNA","mRNA","2","final",NA,"180+","patients","general pop","included","54 weeks","infection","infection","infection","omicron",7,4,10,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"1844",213,"Wang","Test-negative case-control",1898,2022-11-23,"Multiple or heterologous RNA","mRNA","2","final",NA,"14-179","patients","general pop","included","~23.5 weeks","infection","infection","infection","delta",70,68,72,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"1845",213,"Wang","Test-negative case-control",1899,2022-11-23,"Multiple or heterologous RNA","mRNA","2","final",NA,"180+","patients","general pop","included","54 weeks","infection","infection","infection","delta",53,52,55,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"1846",214,"Natarajan","Test-negative case-control",1900,2022-03-29,"Janssen Ad26.COV2.S","Vectored","1","final",NA,"14+","ED/UC encounters or hospitalization among adults with COVID-19 like illness","ED/UC encounters or hospitalization among adults with COVID-19 like illness","included","40 weeks","ED or UC visit","symptomatic","symptomatic","omicron",24,18,29,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"1847",214,"Natarajan","Test-negative case-control",1901,2022-03-29,"Janssen Ad26.COV2.S","Vectored","1","final",NA,"14+","ED/UC encounters or hospitalization among adults with COVID-19 like illness","ED/UC encounters or hospitalization among adults with COVID-19 like illness","included","40 weeks","hospitalization","severe","severe","omicron",31,21,40,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"1848",215,"Hansen","Retrospective cohort",1902,2022-03-30,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"14-30",">= 12 years","general pop","excluded","~2 weeks","infection","infection","infection","omicron",37,35.6,38.3,"Denmark","DNK","Europe","Europe & Central Asia",63020,2019,"Denmark","High income",4,NA,NA,NA,NA,NA
"1849",215,"Hansen","Retrospective cohort",1903,2022-03-30,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"121+",">= 12 years","general pop","excluded","~30 weeks","infection","infection","infection","omicron",9.8,9.2,10.4,"Denmark","DNK","Europe","Europe & Central Asia",63020,2019,"Denmark","High income",4,NA,NA,NA,NA,NA
"1850",215,"Hansen","Retrospective cohort",1904,2022-03-30,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"14-30",">= 12 years","general pop","excluded","~2 weeks","hospitalization","severe","severe","omicron",50.5,33.9,63,"Denmark","DNK","Europe","Europe & Central Asia",63020,2019,"Denmark","High income",4,14,30,"yes",NA,0
"1851",215,"Hansen","Retrospective cohort",1905,2022-03-30,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"121+",">= 12 years","general pop","excluded","~30 weeks","hospitalization","severe","severe","omicron",51.6,47.2,55.6,"Denmark","DNK","Europe","Europe & Central Asia",63020,2019,"Denmark","High income",4,121,210,"no","sequential period",0
"1852",215,"Hansen","Retrospective cohort",1906,2022-03-30,"Moderna mRNA-1273","mRNA","2","final",NA,"14-30",">= 12 years","general pop","excluded","~2 weeks","infection","infection","infection","omicron",37.9,34.4,41.2,"Denmark","DNK","Europe","Europe & Central Asia",63020,2019,"Denmark","High income",4,NA,NA,NA,NA,NA
"1853",215,"Hansen","Retrospective cohort",1907,2022-03-30,"Moderna mRNA-1273","mRNA","2","final",NA,"121+",">= 12 years","general pop","excluded","~30 weeks","infection","infection","infection","omicron",13.2,12.3,14.2,"Denmark","DNK","Europe","Europe & Central Asia",63020,2019,"Denmark","High income",4,NA,NA,NA,NA,NA
"1854",216,"Price","Test-negative case-control",1908,2022-03-30,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"14+","12-18 years","12-18 years","included","~42 weeks","hospitalization","severe","severe","omicron",40,9,60,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"1855",216,"Price","Test-negative case-control",1909,2022-03-30,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"14-160","12-18 years","12-18 years","included","~20 weeks","hospitalization","severe","severe","omicron",43,-1,68,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"1856",216,"Price","Test-negative case-control",1910,2022-03-30,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"161-314","12-18 years","12-18 years","included","~42 weeks","hospitalization","severe","severe","omicron",38,-3,62,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"1857",216,"Price","Test-negative case-control",1911,2022-03-30,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"14+","5-11 years","5-11 years","included","~11 weeks","hospitalization","severe","severe","omicron",68,42,82,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"1858",216,"Price","Test-negative case-control",1912,2022-03-30,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"14+","12-18 years","12-18 years","included","~42 weeks","hospitalization","severe","severe","delta",92,89,95,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"1859",216,"Price","Test-negative case-control",1913,2022-03-30,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"14-160","12-18 years","12-18 years","included","~20 weeks","hospitalization","severe","severe","delta",93,89,95,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"1860",216,"Price","Test-negative case-control",1914,2022-03-30,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"161-314","12-18 years","12-18 years","included","~42 weeks","hospitalization","severe","severe","delta",92,80,97,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"1861",217,"Marra","Retrospective cohort",1915,2022-03-30,"Sinovac CoronaVac","Inactivated","2","final",NA,"14+","HCW","HCW","excluded","~23 weeks","Infection","infection","infection","gamma",51.3,34.6,63.7,"Brazil","BRA","South America","Latin America & Caribbean",9410,2019,"Brazil","Upper middle income",3,NA,NA,NA,NA,NA
"1862",217,"Marra","Retrospective cohort",1916,2022-03-30,"Oxford/AstraZeneca ChAdOx1-S","Vectored","2","final",NA,"14+","HCW","HCW","excluded","~15 weeks","Infection","infection","infection","gamma",88.1,82.8,91.7,"Brazil","BRA","South America","Latin America & Caribbean",9410,2019,"Brazil","Upper middle income",3,NA,NA,NA,NA,NA
"1863",218,"Starrfelt","Retrospective cohort",1917,2022-03-30,"BioNTech/Pfizer BNT162b2","mRNA","1","1",NA,"21+",">= 18 years","general pop","excluded",NA,"Infection","infection","infection","delta",15.5,12.9,18,"Norway","NOR","Europe","Europe & Central Asia",82430,2019,"Norway","High income",4,NA,NA,NA,NA,NA
"1864",218,"Starrfelt","Retrospective cohort",1918,2022-03-30,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"2-9 weeks",">= 18 years","general pop","excluded","~7 weeks","Infection","infection","infection","delta",77.7,76.8,78.5,"Norway","NOR","Europe","Europe & Central Asia",82430,2019,"Norway","High income",4,NA,NA,NA,NA,NA
"1865",218,"Starrfelt","Retrospective cohort",1919,2022-03-30,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,">33 weeks",">= 18 years","general pop","excluded","~43 weeks","Infection","infection","infection","delta",8.2,3.4,12.8,"Norway","NOR","Europe","Europe & Central Asia",82430,2019,"Norway","High income",4,NA,NA,NA,NA,NA
"1866",218,"Starrfelt","Retrospective cohort",1920,2022-03-30,"BioNTech/Pfizer BNT162b2","mRNA","1","1",NA,"21+",">= 18 years","general pop","excluded",NA,"hospitalization","severe","severe","delta",75.3,66.4,81.9,"Norway","NOR","Europe","Europe & Central Asia",82430,2019,"Norway","High income",4,NA,NA,NA,NA,NA
"1867",218,"Starrfelt","Retrospective cohort",1921,2022-03-30,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"2-9 weeks",">= 18 years","general pop","excluded","~7 weeks","hospitalization","severe","severe","delta",97.5,95.6,98.6,"Norway","NOR","Europe","Europe & Central Asia",82430,2019,"Norway","High income",4,14,63,"yes",NA,0
"1868",218,"Starrfelt","Retrospective cohort",1922,2022-03-30,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,">33 weeks",">= 18 years","general pop","excluded","~43 weeks","hospitalization","severe","severe","delta",63.9,54.3,71.5,"Norway","NOR","Europe","Europe & Central Asia",82430,2019,"Norway","High income",4,231,301,"no","sequential period",0
"1869",218,"Starrfelt","Retrospective cohort",1923,2022-03-30,"Moderna mRNA-1273","mRNA","1","1",NA,"21+",">= 18 years","general pop","excluded",NA,"Infection","infection","infection","delta",38.1,34.7,41.3,"Norway","NOR","Europe","Europe & Central Asia",82430,2019,"Norway","High income",4,NA,NA,NA,NA,NA
"1870",218,"Starrfelt","Retrospective cohort",1924,2022-03-30,"Moderna mRNA-1273","mRNA","2","final",NA,"2-9 weeks",">= 18 years","general pop","excluded","~7 weeks","Infection","infection","infection","delta",86.6,85.6,87.6,"Norway","NOR","Europe","Europe & Central Asia",82430,2019,"Norway","High income",4,NA,NA,NA,NA,NA
"1871",218,"Starrfelt","Retrospective cohort",1925,2022-03-30,"Moderna mRNA-1273","mRNA","2","final",NA,">33 weeks",">= 18 years","general pop","excluded","~43 weeks","Infection","infection","infection","delta",28.6,9.6,43.6,"Norway","NOR","Europe","Europe & Central Asia",82430,2019,"Norway","High income",4,NA,NA,NA,NA,NA
"1872",218,"Starrfelt","Retrospective cohort",1926,2022-03-30,"Moderna mRNA-1273","mRNA","1","1",NA,"21+",">= 18 years","general pop","excluded",NA,"hospitalization","severe","severe","delta",77.1,58.9,87.3,"Norway","NOR","Europe","Europe & Central Asia",82430,2019,"Norway","High income",4,NA,NA,NA,NA,NA
"1873",218,"Starrfelt","Retrospective cohort",1927,2022-03-30,"Moderna mRNA-1273","mRNA","2","final",NA,"18-25 weeks",">= 18 years","general pop","excluded","~23 weeks","hospitalization","severe","severe","delta",95.3,91.5,97.4,"Norway","NOR","Europe","Europe & Central Asia",82430,2019,"Norway","High income",4,126,175,"yes",NA,0
"1874",218,"Starrfelt","Retrospective cohort",1928,2022-03-30,"Moderna mRNA-1273","mRNA","2","final",NA,"26-33 weeks",">= 18 years","general pop","excluded","~31 weeks","hospitalization","severe","severe","delta",91.1,84.9,94.8,"Norway","NOR","Europe","Europe & Central Asia",82430,2019,"Norway","High income",4,182,231,"no","sequential period",0
"1875",218,"Starrfelt","Retrospective cohort",1929,2022-03-30,"Multiple or heterologous RNA","mRNA","2","final",NA,"2-9 weeks",">= 18 years","general pop","excluded","~7 weeks","Infection","infection","infection","delta",84.1,83.2,85,"Norway","NOR","Europe","Europe & Central Asia",82430,2019,"Norway","High income",4,NA,NA,NA,NA,NA
"1876",218,"Starrfelt","Retrospective cohort",1930,2022-03-30,"Multiple or heterologous RNA","mRNA","2","final",NA,"18-25 weeks",">= 18 years","general pop","excluded","~23 weeks","Infection","infection","infection","delta",40.7,23.9,53.8,"Norway","NOR","Europe","Europe & Central Asia",82430,2019,"Norway","High income",4,NA,NA,NA,NA,NA
"1877",219,"Pardo-Seco","Test-negative case-control",1931,2022-03-29,"BioNTech/Pfizer BNT162b2","mRNA","1","1",NA,"14-20",">= 18 years","general pop","excluded",NA,"Infection","infection","infection","other combinations",67.7,64.6,70.6,"Spain","ESP","Europe","Europe & Central Asia",30370,2019,"Spain","High income",4,NA,NA,NA,NA,NA
"1878",219,"Pardo-Seco","Test-negative case-control",1932,2022-03-29,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"14+",">= 18 years","general pop","excluded","~7.5 weeks","Infection","infection","infection","other combinations",90.8,88.6,92.7,"Spain","ESP","Europe","Europe & Central Asia",30370,2019,"Spain","High income",4,NA,NA,NA,NA,NA
"1879",220,"Nordstrom","Retrospective cohort",1933,2022-03-31,"Multiple or heterologous RNA","mRNA","2","final",NA,"14+",">= 18 years","general pop","previously infected only","~38 weeks","Infection","infection","infection","other combinations",68,63,72,"Sweden","SWE","Europe","Europe & Central Asia",56230,2019,"Sweden","High income",4,NA,NA,NA,NA,NA
"1880",220,"Nordstrom","Retrospective cohort",1934,2022-03-31,"Oxford/AstraZeneca ChAdOx1-S","Vectored","2","final",NA,"14+",">= 18 years","general pop","previously infected only","~38 weeks","Infection","infection","infection","other combinations",25,-37,59,"Sweden","SWE","Europe","Europe & Central Asia",56230,2019,"Sweden","High income",4,NA,NA,NA,NA,NA
"1881",221,"Ranzani","Test-negative case-control",1935,2022-08-16,"Sinovac CoronaVac","Inactivated","2","final",NA,"14-59",">= 18 years","general pop","included","~10 weeks","symptomatic disease","symptomatic","symptomatic","omicron",28.1,26.5,29.6,"Brazil","BRA","South America","Latin America & Caribbean",9410,2019,"Brazil","Upper middle income",3,NA,NA,NA,NA,NA
"1882",221,"Ranzani","Test-negative case-control",1936,2022-08-16,"Sinovac CoronaVac","Inactivated","2","final",NA,"180+",">= 18 years","general pop","included","~59 weeks","symptomatic disease","symptomatic","symptomatic","omicron",6.3,5.3,7.3,"Brazil","BRA","South America","Latin America & Caribbean",9410,2019,"Brazil","Upper middle income",3,NA,NA,NA,NA,NA
"1883",221,"Ranzani","Test-negative case-control",1937,2022-08-16,"Sinovac CoronaVac","Inactivated","2","final",NA,"14-59",">= 18 years","general pop","included","~10 weeks","hospitalization or death","severe","severe","omicron",56.1,40.6,67.5,"Brazil","BRA","South America","Latin America & Caribbean",9410,2019,"Brazil","Upper middle income",3,NA,NA,NA,NA,NA
"1884",221,"Ranzani","Test-negative case-control",1938,2022-08-16,"Sinovac CoronaVac","Inactivated","2","final",NA,"180+",">= 18 years","general pop","included","~59 weeks","hospitalization or death","severe","severe","omicron",57.6,54.4,60.6,"Brazil","BRA","South America","Latin America & Caribbean",9410,2019,"Brazil","Upper middle income",3,NA,NA,NA,NA,NA
"1885",221,"Ranzani","Test-negative case-control",1939,2022-08-16,"Sinovac CoronaVac","Inactivated","2","final",NA,"14-59",">= 18 years","general pop","included","~10 weeks","symptomatic disease","symptomatic","symptomatic","delta",51.3,49.9,52.7,"Brazil","BRA","South America","Latin America & Caribbean",9410,2019,"Brazil","Upper middle income",3,NA,NA,NA,NA,NA
"1886",221,"Ranzani","Test-negative case-control",1940,2022-08-16,"Sinovac CoronaVac","Inactivated","2","final",NA,"180+",">= 18 years","general pop","included","~59 weeks","symptomatic disease","symptomatic","symptomatic","delta",34,49.9,52.7,"Brazil","BRA","South America","Latin America & Caribbean",9410,2019,"Brazil","Upper middle income",3,NA,NA,NA,NA,NA
"1887",221,"Ranzani","Test-negative case-control",1941,2022-08-16,"Sinovac CoronaVac","Inactivated","2","final",NA,"14-59",">= 18 years","general pop","included","~10 weeks","hospitalization or death","severe","severe","delta",86.5,83.4,88.9,"Brazil","BRA","South America","Latin America & Caribbean",9410,2019,"Brazil","Upper middle income",3,NA,NA,NA,NA,NA
"1888",221,"Ranzani","Test-negative case-control",1942,2022-08-16,"Sinovac CoronaVac","Inactivated","2","final",NA,"180+",">= 18 years","general pop","included","~59 weeks","hospitalization or death","severe","severe","delta",60.9,57.3,64.2,"Brazil","BRA","South America","Latin America & Caribbean",9410,2019,"Brazil","Upper middle income",3,NA,NA,NA,NA,NA
"1889",222,"Florentino","Test-negative case-control",1943,2022-08-08,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"14-27","12-17 years","12-17 years","included","2 weeks","symptomatic disease","symptomatic","symptomatic","omicron",64.7,63,66.3,"Brazil","BRA","South America","Latin America & Caribbean",9410,2019,"Brazil","Upper middle income",3,NA,NA,NA,NA,NA
"1890",222,"Florentino","Test-negative case-control",1944,2022-08-08,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"98+","12-17 years","12-17 years","included","~21 weeks","symptomatic disease","symptomatic","symptomatic","omicron",5.9,2.2,9.4,"Brazil","BRA","South America","Latin America & Caribbean",9410,2019,"Brazil","Upper middle income",3,NA,NA,NA,NA,NA
"1891",222,"Florentino","Test-negative case-control",1945,2022-08-08,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"14-27","12-17 years","12-17 years","included","2 weeks","severe disease","severe","severe","omicron",75.6,58.1,85.8,"Brazil","BRA","South America","Latin America & Caribbean",9410,2019,"Brazil","Upper middle income",3,NA,NA,NA,NA,NA
"1892",222,"Florentino","Test-negative case-control",1946,2022-08-08,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"98+","12-17 years","12-17 years","included","~21 weeks","severe disease","severe","severe","omicron",82.7,68.8,90.4,"Brazil","BRA","South America","Latin America & Caribbean",9410,2019,"Brazil","Upper middle income",3,NA,NA,NA,NA,NA
"1893",222,"Florentino","Test-negative case-control",1947,2022-08-08,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"14-27","12-17 years","12-17 years","included","2 weeks","symptomatic disease","symptomatic","symptomatic","delta",80.7,77.8,83.3,"Brazil","BRA","South America","Latin America & Caribbean",9410,2019,"Brazil","Upper middle income",3,NA,NA,NA,NA,NA
"1894",222,"Florentino","Test-negative case-control",1948,2022-08-08,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"56-69","12-17 years","12-17 years","included","~8 weeks","symptomatic disease","symptomatic","symptomatic","delta",26.6,4.1,43.9,"Brazil","BRA","South America","Latin America & Caribbean",9410,2019,"Brazil","Upper middle income",3,NA,NA,NA,NA,NA
"1895",501,"Florentino","Test-negative case-control",1949,2022-08-08,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"14-27","12-17 years","12-17 years","included","2 weeks","symptomatic disease","symptomatic","symptomatic","omicron",82.6,80.6,84.5,"UK","GBR","Europe","Europe & Central Asia",43240,2019,"United Kingdom","High income",4,NA,NA,NA,NA,NA
"1896",501,"Florentino","Test-negative case-control",1950,2022-08-08,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"98+","12-17 years","12-17 years","included","~15.5 weeks","symptomatic disease","symptomatic","symptomatic","omicron",50.6,42.7,57.4,"UK","GBR","Europe","Europe & Central Asia",43240,2019,"United Kingdom","High income",4,NA,NA,NA,NA,NA
"1897",501,"Florentino","Test-negative case-control",1951,2022-08-08,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"14-27","12-17 years","12-17 years","included","2 weeks","symptomatic disease","symptomatic","symptomatic","delta",92.8,85.7,96.4,"UK","GBR","Europe","Europe & Central Asia",43240,2019,"United Kingdom","High income",4,NA,NA,NA,NA,NA
"1898",501,"Florentino","Test-negative case-control",1952,2022-08-08,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"56-69","12-17 years","12-17 years","included","~8 weeks","symptomatic disease","symptomatic","symptomatic","delta",86.5,72.2,93.4,"UK","GBR","Europe","Europe & Central Asia",43240,2019,"United Kingdom","High income",4,NA,NA,NA,NA,NA
"1899",223,"Yoon","Prospective cohort",1953,2022-04-06,"Multiple or heterologous RNA","mRNA","2","final",NA,"14+","HCW","HCW","excluded","~21 weeks","infection","infection","infection","omicron",46,25,61,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"1900",223,"Yoon","Prospective cohort",1954,2022-04-06,"Multiple or heterologous RNA","mRNA","2","final",NA,"14+","HCW","HCW","excluded","~21 weeks","infection","infection","infection","delta",65,49,76,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"1901",224,"Kwon","Test-negative case-control",1955,2022-04-06,"Multiple or heterologous RNA","mRNA","2","final",NA,"14+","transplant recipients","transplant recipients","included","~37 weeks","hospitalization","severe","severe","other combinations",29,-19,58,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"1902",224,"Kwon","Test-negative case-control",1956,2022-04-06,"Multiple or heterologous RNA","mRNA","2","final",NA,"14+","immunocompromised","immunocompromised adults","included","~37 weeks","hospitalization","severe","severe","other combinations",72,64,79,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"1903",224,"Kwon","Test-negative case-control",1957,2022-04-06,"Multiple or heterologous RNA","mRNA","2","final",NA,"14+","immunocompetent adults","immunocompetent adults","included","~37 weeks","hospitalization","severe","severe","other combinations",88,87,90,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"1904",224,"Kwon","Test-negative case-control",1958,2022-04-06,"Multiple or heterologous RNA","mRNA","2","final",NA,"14+","transplant recipients","transplant recipients","included","~37 weeks","supplemental oxygen/oxygen support","severe","severe","other combinations",31,-27,63,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"1905",224,"Kwon","Test-negative case-control",1959,2022-04-06,"Multiple or heterologous RNA","mRNA","2","final",NA,"14+","immunocompromised","immunocompromised adults","included","~37 weeks","supplemental oxygen/oxygen support","severe","severe","other combinations",73,64,80,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"1906",224,"Kwon","Test-negative case-control",1960,2022-04-06,"Multiple or heterologous RNA","mRNA","2","final",NA,"14+","immunocompetent adults","immunocompetent adults","included","~37 weeks","supplemental oxygen/oxygen support","severe","severe","other combinations",90,89,92,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"1907",225,"Paraguay Ministry of Health and Social Welfare","Test-negative case-control",1961,2022-03-22,"Bharat Covaxin/BBV152","Inactivated","2","final",NA,"14+","patients >=16 years with severe acute respiratory infection","general pop","excluded","~38 weeks","hospitalization with SARI","severe","severe","other combinations",27.7,-10.2,52.6,"Paraguay","PRY","South America","Latin America & Caribbean",5950,2019,"Paraguay","Upper middle income",2,NA,NA,NA,NA,NA
"1908",225,"Paraguay Ministry of Health and Social Welfare","Test-negative case-control",1962,2022-03-22,"Oxford/AstraZeneca ChAdOx1-S","Vectored","2","final",NA,"14+","patients >=16 years with severe acute respiratory infection","general pop","excluded","~38 weeks","hospitalization with SARI","severe","severe","other combinations",85.8,70.6,93.1,"Paraguay","PRY","South America","Latin America & Caribbean",5950,2019,"Paraguay","Upper middle income",2,NA,NA,NA,NA,NA
"1909",225,"Paraguay Ministry of Health and Social Welfare","Test-negative case-control",1963,2022-03-22,"Beijing/Sinopharm BBIBP-CorV","Inactivated","2","final",NA,"14+","patients >=16 years with severe acute respiratory infection","general pop","excluded","~38 weeks","hospitalization with SARI","severe","severe","other combinations",56.4,15.5,77.6,"Paraguay","PRY","South America","Latin America & Caribbean",5950,2019,"Paraguay","Upper middle income",2,NA,NA,NA,NA,NA
"1910",225,"Paraguay Ministry of Health and Social Welfare","Test-negative case-control",1964,2022-03-22,"Gamaleya Gam-COVID-Vac/Sputnik V","Vectored","2","final",NA,"14+","patients >=16 years with severe acute respiratory infection","general pop","excluded","~38 weeks","hospitalization with SARI","severe","severe","other combinations",77,30.8,92.3,"Paraguay","PRY","South America","Latin America & Caribbean",5950,2019,"Paraguay","Upper middle income",2,NA,NA,NA,NA,NA
"1911",225,"Paraguay Ministry of Health and Social Welfare","Test-negative case-control",1965,2022-03-22,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"14+","patients >=16 years with severe acute respiratory infection","general pop","excluded","~38 weeks","hospitalization with SARI","severe","severe","other combinations",95.4,65.7,99.4,"Paraguay","PRY","South America","Latin America & Caribbean",5950,2019,"Paraguay","Upper middle income",2,NA,NA,NA,NA,NA
"1912",226,"Buchan","Test-negative case-control",1966,2022-04-07,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"7-59","12-17 years","12-17 years","included","~41 weeks","symptomatic disease","symptomatic","symptomatic","omicron",51,38,61,"Canada","CAN","North America","North America",46580,2019,"Canada","High income",4,NA,NA,NA,NA,NA
"1913",226,"Buchan","Test-negative case-control",1967,2022-04-07,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"180+","12-17 years","12-17 years","included","~41 weeks","symptomatic disease","symptomatic","symptomatic","omicron",29,17,38,"Canada","CAN","North America","North America",46580,2019,"Canada","High income",4,NA,NA,NA,NA,NA
"1914",226,"Buchan","Test-negative case-control",1968,2022-04-07,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"7-59","12-17 years","12-17 years","included","~41 weeks","hospitalization or death","severe","severe","omicron",76,-10,95,"Canada","CAN","North America","North America",46580,2019,"Canada","High income",4,NA,NA,NA,NA,NA
"1915",226,"Buchan","Test-negative case-control",1969,2022-04-07,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"180+","12-17 years","12-17 years","included","~32 weeks","hospitalization or death","severe","severe","omicron",88,77,94,"Canada","CAN","North America","North America",46580,2019,"Canada","High income",4,NA,NA,NA,NA,NA
"1916",226,"Buchan","Test-negative case-control",1970,2022-04-07,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"7-59","12-17 years","12-17 years","included","~32 weeks","symptomatic disease","symptomatic","symptomatic","delta",97,94,99,"Canada","CAN","North America","North America",46580,2019,"Canada","High income",4,NA,NA,NA,NA,NA
"1917",226,"Buchan","Test-negative case-control",1971,2022-04-07,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"180+","12-17 years","12-17 years","included","~32 weeks","symptomatic disease","symptomatic","symptomatic","delta",90,79,95,"Canada","CAN","North America","North America",46580,2019,"Canada","High income",4,NA,NA,NA,NA,NA
"1918",227,"Kim","Test-negative case-control",1972,2022-07-29,"Multiple or heterologous RNA","mRNA","2","final",NA,"14-149",">= 18 years","general pop","included","~58 weeks","symptomatic disease","symptomatic","symptomatic","omicron",45,14,66,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"1919",227,"Kim","Test-negative case-control",1973,2022-07-29,"Multiple or heterologous RNA","mRNA","2","final",NA,"150+",">= 18 years","general pop","included","~58 weeks","symptomatic disease","symptomatic","symptomatic","omicron",11,-21,35,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"1920",227,"Kim","Test-negative case-control",1974,2022-07-29,"Multiple or heterologous RNA","mRNA","2","final",NA,"14-149",">= 18 years","general pop","included","~48 weeks","symptomatic disease","symptomatic","symptomatic","delta",89,78,94,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"1921",227,"Kim","Test-negative case-control",1975,2022-07-29,"Multiple or heterologous RNA","mRNA","2","final",NA,"150+",">= 18 years","general pop","included","~48 weeks","symptomatic disease","symptomatic","symptomatic","delta",58,44,68,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"1922",228,"Kildegard","Retrospective cohort",1976,2022-04-11,"BioNTech/Pfizer BNT162b2","mRNA","1","1",NA,"0-20","12-17 years","12-17 years","excluded",NA,"infection","infection","infection","delta",62,59,65,"Denmark","DNK","Europe","Europe & Central Asia",63020,2019,"Denmark","High income",4,NA,NA,NA,NA,NA
"1923",228,"Kildegard","Retrospective cohort",1977,2022-04-11,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"0-59","12-17 years","12-17 years","excluded","~13 weeks","infection","infection","infection","delta",93,93,94,"Denmark","DNK","Europe","Europe & Central Asia",63020,2019,"Denmark","High income",4,NA,NA,NA,NA,NA
"1924",229,"Institute of Public Health","Test-negative case-control",1978,2022-04-12,"BioNTech/Pfizer BNT162b2","mRNA","1","1",NA,"14+",">= 18 years","general pop","included",NA,"hospitalization","severe","severe","other combinations",53.5,-27.3,83,"Chile","CHL","South America","Latin America & Caribbean",14690,2019,"Chile","High income",3,NA,NA,NA,NA,NA
"1925",229,"Institute of Public Health","Test-negative case-control",1979,2022-04-12,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"14+",">= 18 years","general pop","included","~53 weeks","hospitalization","severe","severe","other combinations",85.3,73.5,91.8,"Chile","CHL","South America","Latin America & Caribbean",14690,2019,"Chile","High income",3,NA,NA,NA,NA,NA
"1926",229,"Institute of Public Health","Test-negative case-control",1980,2022-04-12,"Sinovac CoronaVac","Inactivated","1","1",NA,"14+",">= 18 years","general pop","included",NA,"hospitalization","severe","severe","other combinations",36.6,6,57.2,"Chile","CHL","South America","Latin America & Caribbean",14690,2019,"Chile","High income",3,NA,NA,NA,NA,NA
"1927",229,"Institute of Public Health","Test-negative case-control",1981,2022-04-12,"Sinovac CoronaVac","Inactivated","2","final",NA,"14+",">= 18 years","general pop","included","~53 weeks","hospitalization","severe","severe","other combinations",59.5,49,67.9,"Chile","CHL","South America","Latin America & Caribbean",14690,2019,"Chile","High income",3,NA,NA,NA,NA,NA
"1928",230,"Plumb","Test-negative case-control",1982,2022-04-12,"Multiple or heterologous RNA","mRNA","1","1",NA,"14+","hospitalized adults","general pop","included",NA,"hospitalization","severe","severe","omicron",33,15,47.2,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"1929",230,"Plumb","Test-negative case-control",1983,2022-04-12,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"14+","hospitalized adults","general pop","included","~55 weeks","hospitalization","severe","severe","omicron",37.3,25.8,46.9,"USA","USA","North America","North America",66220,2019,"United States","High income",4,14,385,"yes",NA,0
"1930",230,"Plumb","Test-negative case-control",1984,2022-04-12,"Moderna mRNA-1273","mRNA","2","final",NA,"14+","hospitalized adults","general pop","included","~55 weeks","hospitalization","severe","severe","omicron",35.9,21.7,47.4,"USA","USA","North America","North America",66220,2019,"United States","High income",4,14,385,"yes",NA,0
"1931",230,"Plumb","Test-negative case-control",1985,2022-04-12,"Multiple or heterologous RNA","mRNA","1","1",NA,"14+","hospitalized adults","general pop","included",NA,"hospitalization","severe","severe","delta",58.8,41.3,71.1,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"1932",230,"Plumb","Test-negative case-control",1986,2022-04-12,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"14+","hospitalized adults","general pop","included","~55 weeks","hospitalization","severe","severe","delta",50,39,59,"USA","USA","North America","North America",66220,2019,"United States","High income",4,14,385,"yes",NA,0
"1933",230,"Plumb","Test-negative case-control",1987,2022-04-12,"Moderna mRNA-1273","mRNA","2","final",NA,"14+","hospitalized adults","general pop","included","~55 weeks","hospitalization","severe","severe","delta",44,29.9,55.2,"USA","USA","North America","North America",66220,2019,"United States","High income",4,14,385,"yes",NA,0
"1934",231,"Dale","Outbreak investigation",1988,2022-04-12,"Multiple or heterologous RNA","mRNA","2","final",NA,"14+",">= 18 years","general pop","excluded","~25 weeks","infection","infection","infection","delta",51,-27,81,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"1935",231,"Dale","Outbreak investigation",1989,2022-04-12,"Multiple or heterologous RNA","mRNA","2","final",NA,"14+",">= 18 years","general pop","excluded","~25 weeks","symptomatic disease","symptomatic","symptomatic","delta",67,-7,90,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"1936",231,"Dale","Outbreak investigation",1990,2022-04-12,"Multiple or heterologous RNA","mRNA","2","final",NA,"14+",">= 18 years","general pop","excluded","~25 weeks","hospitalization","severe","severe","delta",61,-59,90,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"1937",231,"Dale","Outbreak investigation",1991,2022-04-12,"Multiple or heterologous RNA","mRNA","2","final",NA,"14+",">= 18 years","general pop","excluded","~25 weeks","death","death","death","delta",80,-10,96,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"1938",232,"Cerqueira-Silva","Test-negative case-control",1992,2022-07-01,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"14-69",">= 18 years","general pop","previously infected only","~59 weeks","symptomatic disease","symptomatic","symptomatic","omicron",51.9,50,53.8,"Brazil","BRA","South America","Latin America & Caribbean",9410,2019,"Brazil","Upper middle income",3,NA,NA,NA,NA,NA
"1939",232,"Cerqueira-Silva","Test-negative case-control",1993,2022-07-01,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"140+",">= 18 years","general pop","previously infected only","~59 weeks","symptomatic disease","symptomatic","symptomatic","omicron",26.2,22.8,29.4,"Brazil","BRA","South America","Latin America & Caribbean",9410,2019,"Brazil","Upper middle income",3,NA,NA,NA,NA,NA
"1940",232,"Cerqueira-Silva","Test-negative case-control",1994,2022-07-01,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"14-69",">= 18 years","general pop","previously infected only","~59 weeks","hospitalization or death","severe","severe","omicron",59.6,36.6,74.2,"Brazil","BRA","South America","Latin America & Caribbean",9410,2019,"Brazil","Upper middle income",3,NA,NA,NA,NA,NA
"1941",232,"Cerqueira-Silva","Test-negative case-control",1995,2022-07-01,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"140+",">= 18 years","general pop","previously infected only","~59 weeks","hospitalization or death","severe","severe","omicron",53.6,30.2,69.1,"Brazil","BRA","South America","Latin America & Caribbean",9410,2019,"Brazil","Upper middle income",3,NA,NA,NA,NA,NA
"1942",232,"Cerqueira-Silva","Test-negative case-control",1996,2022-07-01,"Oxford/AstraZeneca ChAdOx1-S","Vectored","2","final",NA,"14-69",">= 18 years","general pop","previously infected only","~59 weeks","symptomatic disease","symptomatic","symptomatic","omicron",25.5,1,29.7,"Brazil","BRA","South America","Latin America & Caribbean",9410,2019,"Brazil","Upper middle income",3,NA,NA,NA,NA,NA
"1943",232,"Cerqueira-Silva","Test-negative case-control",1997,2022-07-01,"Oxford/AstraZeneca ChAdOx1-S","Vectored","2","final",NA,"140+",">= 18 years","general pop","previously infected only","~59 weeks","symptomatic disease","symptomatic","symptomatic","omicron",17,14.4,19.6,"Brazil","BRA","South America","Latin America & Caribbean",9410,2019,"Brazil","Upper middle income",3,NA,NA,NA,NA,NA
"1944",232,"Cerqueira-Silva","Test-negative case-control",1998,2022-07-01,"Oxford/AstraZeneca ChAdOx1-S","Vectored","2","final",NA,"14-69",">= 18 years","general pop","previously infected only","~59 weeks","hospitalization or death","severe","severe","omicron",41,-8.1,67.8,"Brazil","BRA","South America","Latin America & Caribbean",9410,2019,"Brazil","Upper middle income",3,NA,NA,NA,NA,NA
"1945",232,"Cerqueira-Silva","Test-negative case-control",1999,2022-07-01,"Oxford/AstraZeneca ChAdOx1-S","Vectored","2","final",NA,"140+",">= 18 years","general pop","previously infected only","~59 weeks","hospitalization or death","severe","severe","omicron",55.4,44.6,64.1,"Brazil","BRA","South America","Latin America & Caribbean",9410,2019,"Brazil","Upper middle income",3,NA,NA,NA,NA,NA
"1946",232,"Cerqueira-Silva","Test-negative case-control",2000,2022-07-01,"Janssen Ad26.COV2.S","Vectored","1","final",NA,"14+",">= 18 years","general pop","previously infected only","~59 weeks","symptomatic disease","symptomatic","symptomatic","omicron",16.2,12.4,19.8,"Brazil","BRA","South America","Latin America & Caribbean",9410,2019,"Brazil","Upper middle income",3,NA,NA,NA,NA,NA
"1947",232,"Cerqueira-Silva","Test-negative case-control",2001,2022-07-01,"Janssen Ad26.COV2.S","Vectored","1","final",NA,"14+",">= 18 years","general pop","previously infected only","~59 weeks","hospitalization or death","severe","severe","omicron",39.5,8.3,69,"Brazil","BRA","South America","Latin America & Caribbean",9410,2019,"Brazil","Upper middle income",3,NA,NA,NA,NA,NA
"1948",232,"Cerqueira-Silva","Test-negative case-control",2002,2022-07-01,"Sinovac CoronaVac","Inactivated","2","final",NA,"14-69",">= 18 years","general pop","previously infected only","~59 weeks","symptomatic disease","symptomatic","symptomatic","omicron",23.4,18.2,28.3,"Brazil","BRA","South America","Latin America & Caribbean",9410,2019,"Brazil","Upper middle income",3,NA,NA,NA,NA,NA
"1949",232,"Cerqueira-Silva","Test-negative case-control",2003,2022-07-01,"Sinovac CoronaVac","Inactivated","2","final",NA,"140+",">= 18 years","general pop","previously infected only","~59 weeks","symptomatic disease","symptomatic","symptomatic","omicron",12.3,9.4,15.1,"Brazil","BRA","South America","Latin America & Caribbean",9410,2019,"Brazil","Upper middle income",3,NA,NA,NA,NA,NA
"1950",232,"Cerqueira-Silva","Test-negative case-control",2004,2022-07-01,"Sinovac CoronaVac","Inactivated","2","final",NA,"14-69",">= 18 years","general pop","previously infected only","~59 weeks","hospitalization or death","severe","severe","omicron",34.1,-28.9,66.3,"Brazil","BRA","South America","Latin America & Caribbean",9410,2019,"Brazil","Upper middle income",3,NA,NA,NA,NA,NA
"1951",232,"Cerqueira-Silva","Test-negative case-control",2005,2022-07-01,"Sinovac CoronaVac","Inactivated","2","final",NA,"140+",">= 18 years","general pop","previously infected only","~59 weeks","hospitalization or death","severe","severe","omicron",34.4,18.3,47.3,"Brazil","BRA","South America","Latin America & Caribbean",9410,2019,"Brazil","Upper middle income",3,NA,NA,NA,NA,NA
"1952",232,"Cerqueira-Silva","Matched case-control",2006,2022-07-01,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"14-69",">= 18 years","general pop","previously infected only","~59 weeks","symptomatic disease","symptomatic","symptomatic","omicron",54.1,52.1,55.9,"Brazil","BRA","South America","Latin America & Caribbean",9410,2019,"Brazil","Upper middle income",3,NA,NA,NA,NA,NA
"1953",232,"Cerqueira-Silva","Matched case-control",2007,2022-07-01,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"140+",">= 18 years","general pop","previously infected only","~59 weeks","symptomatic disease","symptomatic","symptomatic","omicron",30.6,27.3,33.7,"Brazil","BRA","South America","Latin America & Caribbean",9410,2019,"Brazil","Upper middle income",3,NA,NA,NA,NA,NA
"1954",232,"Cerqueira-Silva","Matched case-control",2008,2022-07-01,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"14-69",">= 18 years","general pop","previously infected only","~59 weeks","hospitalization or death","severe","severe","omicron",53.6,-6.4,79.8,"Brazil","BRA","South America","Latin America & Caribbean",9410,2019,"Brazil","Upper middle income",3,NA,NA,NA,NA,NA
"1955",232,"Cerqueira-Silva","Matched case-control",2009,2022-07-01,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"140+",">= 18 years","general pop","previously infected only","~59 weeks","hospitalization or death","severe","severe","omicron",55.1,-1.9,80.2,"Brazil","BRA","South America","Latin America & Caribbean",9410,2019,"Brazil","Upper middle income",3,NA,NA,NA,NA,NA
"1956",232,"Cerqueira-Silva","Matched case-control",2010,2022-07-01,"Oxford/AstraZeneca ChAdOx1-S","Vectored","2","final",NA,"14-69",">= 18 years","general pop","previously infected only","~59 weeks","symptomatic disease","symptomatic","symptomatic","omicron",27.2,22.9,31.3,"Brazil","BRA","South America","Latin America & Caribbean",9410,2019,"Brazil","Upper middle income",3,NA,NA,NA,NA,NA
"1957",232,"Cerqueira-Silva","Matched case-control",2011,2022-07-01,"Oxford/AstraZeneca ChAdOx1-S","Vectored","2","final",NA,"140+",">= 18 years","general pop","previously infected only","~59 weeks","symptomatic disease","symptomatic","symptomatic","omicron",15.9,13.2,18.5,"Brazil","BRA","South America","Latin America & Caribbean",9410,2019,"Brazil","Upper middle income",3,NA,NA,NA,NA,NA
"1958",232,"Cerqueira-Silva","Matched case-control",2012,2022-07-01,"Oxford/AstraZeneca ChAdOx1-S","Vectored","2","final",NA,"14-69",">= 18 years","general pop","previously infected only","~59 weeks","hospitalization or death","severe","severe","omicron",67.5,-7.9,90.2,"Brazil","BRA","South America","Latin America & Caribbean",9410,2019,"Brazil","Upper middle income",3,NA,NA,NA,NA,NA
"1959",232,"Cerqueira-Silva","Matched case-control",2013,2022-07-01,"Oxford/AstraZeneca ChAdOx1-S","Vectored","2","final",NA,"140+",">= 18 years","general pop","previously infected only","~59 weeks","hospitalization or death","severe","severe","omicron",63.2,39,77.8,"Brazil","BRA","South America","Latin America & Caribbean",9410,2019,"Brazil","Upper middle income",3,NA,NA,NA,NA,NA
"1960",232,"Cerqueira-Silva","Matched case-control",2014,2022-07-01,"Janssen Ad26.COV2.S","Vectored","1","final",NA,"14+",">= 18 years","general pop","previously infected only","~59 weeks","symptomatic disease","symptomatic","symptomatic","omicron",16.9,13.2,20.5,"Brazil","BRA","South America","Latin America & Caribbean",9410,2019,"Brazil","Upper middle income",3,NA,NA,NA,NA,NA
"1961",232,"Cerqueira-Silva","Matched case-control",2015,2022-07-01,"Janssen Ad26.COV2.S","Vectored","1","final",NA,"14+",">= 18 years","general pop","previously infected only","~59 weeks","hospitalization or death","severe","severe","omicron",45.4,-19.6,75.1,"Brazil","BRA","South America","Latin America & Caribbean",9410,2019,"Brazil","Upper middle income",3,NA,NA,NA,NA,NA
"1962",232,"Cerqueira-Silva","Matched case-control",2016,2022-07-01,"Sinovac CoronaVac","Inactivated","2","final",NA,"14-69",">= 18 years","general pop","previously infected only","~59 weeks","symptomatic disease","symptomatic","symptomatic","omicron",27.3,22.3,31.9,"Brazil","BRA","South America","Latin America & Caribbean",9410,2019,"Brazil","Upper middle income",3,NA,NA,NA,NA,NA
"1963",232,"Cerqueira-Silva","Matched case-control",2017,2022-07-01,"Sinovac CoronaVac","Inactivated","2","final",NA,"140+",">= 18 years","general pop","previously infected only","~59 weeks","symptomatic disease","symptomatic","symptomatic","omicron",14.3,11.4,17,"Brazil","BRA","South America","Latin America & Caribbean",9410,2019,"Brazil","Upper middle income",3,NA,NA,NA,NA,NA
"1964",232,"Cerqueira-Silva","Matched case-control",2018,2022-07-01,"Sinovac CoronaVac","Inactivated","2","final",NA,"14-69",">= 18 years","general pop","previously infected only","~59 weeks","hospitalization or death","severe","severe","omicron",21.4,-148.4,75.1,"Brazil","BRA","South America","Latin America & Caribbean",9410,2019,"Brazil","Upper middle income",3,NA,NA,NA,NA,NA
"1965",232,"Cerqueira-Silva","Matched case-control",2019,2022-07-01,"Sinovac CoronaVac","Inactivated","2","final",NA,"140+",">= 18 years","general pop","previously infected only","~59 weeks","hospitalization or death","severe","severe","omicron",66.4,37.6,81.9,"Brazil","BRA","South America","Latin America & Caribbean",9410,2019,"Brazil","Upper middle income",3,NA,NA,NA,NA,NA
"1966",233,"Nasreen","Test-negative case-control",2020,2022-08-17,"Multiple or heterologous RNA","mRNA","2","final",NA,"7-55",">= 18 years","general pop","excluded","~32 weeks","hospitalization or death","severe","severe","other combinations",98,95,99,"Canada","CAN","North America","North America",46580,2019,"Canada","High income",4,NA,NA,NA,NA,NA
"1967",233,"Nasreen","Test-negative case-control",2021,2022-08-17,"Multiple or heterologous RNA","mRNA","2","final",NA,"112+",">= 18 years","general pop","excluded","~32 weeks","hospitalization or death","severe","severe","other combinations",98,95,99,"Canada","CAN","North America","North America",46580,2019,"Canada","High income",4,NA,NA,NA,NA,NA
"1968",233,"Nasreen","Test-negative case-control",2022,2022-08-17,"Oxford/AstraZeneca ChAdOx1-S","Vectored","2","final",NA,"7-55",">= 18 years","general pop","excluded","~7 weeks","hospitalization or death","severe","severe","other combinations",96,88,96,"Canada","CAN","North America","North America",46580,2019,"Canada","High income",4,NA,NA,NA,NA,NA
"1969",233,"Nasreen","Test-negative case-control",2023,2022-08-17,"Oxford/AstraZeneca ChAdOx1-S","Vectored","2","final",NA,"56+",">= 18 years","general pop","excluded","~7 weeks","hospitalization or death","severe","severe","other combinations",97,91,99,"Canada","CAN","North America","North America",46580,2019,"Canada","High income",4,NA,NA,NA,NA,NA
"1970",233,"Nasreen","Test-negative case-control",2024,2022-08-17,"Heterologous platforms","Multiple","2","final",NA,"14+",">= 18 years","general pop","excluded","~7 weeks","hospitalization or death","severe","severe","other combinations",99,98,100,"Canada","CAN","North America","North America",46580,2019,"Canada","High income",4,NA,NA,NA,NA,NA
"1971",234,"Richardson","Prospective cohort",2025,2022-06-19,"Cansino Ad5-nCoV","Vectored","1","final",NA,"14-60","childcare workers","childcare workers","excluded","~33 weeks","infection","infection","infection","other combinations",48,32,61,"Mexico","MEX","North America","Latin America & Caribbean",9860,2019,"Mexico","Upper middle income",3,NA,NA,NA,NA,NA
"1972",234,"Richardson","Prospective cohort",2026,2022-06-19,"Cansino Ad5-nCoV","Vectored","1","final",NA,"120+","childcare workers","childcare workers","excluded","~33 weeks","infection","infection","infection","other combinations",-3,-26,16,"Mexico","MEX","North America","Latin America & Caribbean",9860,2019,"Mexico","Upper middle income",3,NA,NA,NA,NA,NA
"1973",234,"Richardson","Prospective cohort",2027,2022-06-19,"Cansino Ad5-nCoV","Vectored","1","final",NA,"14-60","childcare workers","childcare workers","excluded","~33 weeks","hospitalization","severe","severe","other combinations",92,23,99,"Mexico","MEX","North America","Latin America & Caribbean",9860,2019,"Mexico","Upper middle income",3,NA,NA,NA,NA,NA
"1974",234,"Richardson","Prospective cohort",2028,2022-06-19,"Cansino Ad5-nCoV","Vectored","1","final",NA,"120+","childcare workers","childcare workers","excluded","~33 weeks","hospitalization","severe","severe","other combinations",24,-263,84,"Mexico","MEX","North America","Latin America & Caribbean",9860,2019,"Mexico","Upper middle income",3,NA,NA,NA,NA,NA
"1975",234,"Richardson","Prospective cohort",2029,2022-06-19,"Cansino Ad5-nCoV","Vectored","1","final",NA,"61-120","childcare workers","childcare workers","excluded","~33 weeks","death","death","death","other combinations",95,53,100,"Mexico","MEX","North America","Latin America & Caribbean",9860,2019,"Mexico","Upper middle income",3,NA,NA,NA,NA,NA
"1976",234,"Richardson","Prospective cohort",2030,2022-06-19,"Cansino Ad5-nCoV","Vectored","1","final",NA,"120+","childcare workers","childcare workers","excluded","~33 weeks","death","death","death","other combinations",93,22,99,"Mexico","MEX","North America","Latin America & Caribbean",9860,2019,"Mexico","Upper middle income",3,NA,NA,NA,NA,NA
"1977",234,"Richardson","Prospective cohort",2031,2022-06-19,"Cansino Ad5-nCoV","Vectored","1","final",NA,"14+","childcare workers","childcare workers","excluded","~33 weeks","infection","infection","infection","other combinations",53,23,71,"Mexico","MEX","North America","Latin America & Caribbean",9860,2019,"Mexico","Upper middle income",3,NA,NA,NA,NA,NA
"1978",234,"Richardson","Prospective cohort",2032,2022-06-19,"Cansino Ad5-nCoV","Vectored","1","final",NA,"14+","childcare workers","childcare workers","excluded","~33 weeks","infection","infection","infection","delta",18,8,28,"Mexico","MEX","North America","Latin America & Caribbean",9860,2019,"Mexico","Upper middle income",3,NA,NA,NA,NA,NA
"1979",234,"Richardson","Prospective cohort",2033,2022-06-19,"Cansino Ad5-nCoV","Vectored","1","final",NA,"14+","childcare workers","childcare workers","excluded","~33 weeks","hospitalization","severe","severe","delta",74,38,89,"Mexico","MEX","North America","Latin America & Caribbean",9860,2019,"Mexico","Upper middle income",3,NA,NA,NA,NA,NA
"1980",234,"Richardson","Prospective cohort",2034,2022-06-19,"Cansino Ad5-nCoV","Vectored","1","final",NA,"14+","childcare workers","childcare workers","excluded","~33 weeks","death","death","death","delta",94,67,99,"Mexico","MEX","North America","Latin America & Caribbean",9860,2019,"Mexico","Upper middle income",3,NA,NA,NA,NA,NA
"1981",235,"Voko","Retrospective cohort",2035,2022-07-22,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"14-120","18-64 years","18-64 years","included","~47 weeks","infection","infection","infection","delta",70.3,69.2,71.3,"Hungary","HUN","Europe","Europe & Central Asia",16570,2019,"Hungary","High income",3,NA,NA,NA,NA,NA
"1982",235,"Voko","Retrospective cohort",2036,2022-07-22,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"240+","18-64 years","18-64 years","included","~47 weeks","infection","infection","infection","delta",0.6,-2.3,3.4,"Hungary","HUN","Europe","Europe & Central Asia",16570,2019,"Hungary","High income",3,NA,NA,NA,NA,NA
"1983",235,"Voko","Retrospective cohort",2037,2022-07-22,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"14-120","18-64 years","18-64 years","included","~47 weeks","hospitalization","severe","severe","delta",82.6,80.1,84.7,"Hungary","HUN","Europe","Europe & Central Asia",16570,2019,"Hungary","High income",3,14,120,"yes",NA,0
"1984",235,"Voko","Retrospective cohort",2038,2022-07-22,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"240+","18-64 years","18-64 years","included","~47 weeks","hospitalization","severe","severe","delta",69.6,64.9,73.6,"Hungary","HUN","Europe","Europe & Central Asia",16570,2019,"Hungary","High income",3,240,329,"no","sequential period",0
"1985",235,"Voko","Retrospective cohort",2039,2022-07-22,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"14-120","18-64 years","18-64 years","included","~47 weeks","death","death","death","delta",87.4,81.5,91.5,"Hungary","HUN","Europe","Europe & Central Asia",16570,2019,"Hungary","High income",3,NA,NA,NA,NA,NA
"1986",235,"Voko","Retrospective cohort",2040,2022-07-22,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"240+","18-64 years","18-64 years","included","~47 weeks","death","death","death","delta",73.6,61.1,82.1,"Hungary","HUN","Europe","Europe & Central Asia",16570,2019,"Hungary","High income",3,NA,NA,NA,NA,NA
"1987",235,"Voko","Retrospective cohort",2041,2022-07-22,"Moderna mRNA-1273","mRNA","2","final",NA,"14-120","18-64 years","18-64 years","included","~47 weeks","infection","infection","infection","delta",76.9,73.3,80,"Hungary","HUN","Europe","Europe & Central Asia",16570,2019,"Hungary","High income",3,NA,NA,NA,NA,NA
"1988",235,"Voko","Retrospective cohort",2042,2022-07-22,"Moderna mRNA-1273","mRNA","2","final",NA,"240+","18-64 years","18-64 years","included","~47 weeks","infection","infection","infection","delta",22.6,6.1,36.2,"Hungary","HUN","Europe","Europe & Central Asia",16570,2019,"Hungary","High income",3,NA,NA,NA,NA,NA
"1989",235,"Voko","Retrospective cohort",2043,2022-07-22,"Moderna mRNA-1273","mRNA","2","final",NA,"14-120","18-64 years","18-64 years","included","~47 weeks","hospitalization","severe","severe","delta",84.9,75.4,90.8,"Hungary","HUN","Europe","Europe & Central Asia",16570,2019,"Hungary","High income",3,14,120,"yes",NA,0
"1990",235,"Voko","Retrospective cohort",2044,2022-07-22,"Moderna mRNA-1273","mRNA","2","final",NA,"240+","18-64 years","18-64 years","included","~47 weeks","hospitalization","severe","severe","delta",42.5,-4,68.2,"Hungary","HUN","Europe","Europe & Central Asia",16570,2019,"Hungary","High income",3,240,329,"no","sequential period",0
"1991",235,"Voko","Retrospective cohort",2045,2022-07-22,"Moderna mRNA-1273","mRNA","2","final",NA,"14-120","18-64 years","18-64 years","included","~47 weeks","death","death","death","delta",77.7,30.7,92.8,"Hungary","HUN","Europe","Europe & Central Asia",16570,2019,"Hungary","High income",3,NA,NA,NA,NA,NA
"1992",235,"Voko","Retrospective cohort",2046,2022-07-22,"Moderna mRNA-1273","mRNA","2","final",NA,"240+","18-64 years","18-64 years","included","~47 weeks","death","death","death","delta",100,NA,NA,"Hungary","HUN","Europe","Europe & Central Asia",16570,2019,"Hungary","High income",3,NA,NA,NA,NA,NA
"1993",235,"Voko","Retrospective cohort",2047,2022-07-22,"Oxford/AstraZeneca ChAdOx1-S","Vectored","2","final",NA,"14-120","18-64 years","18-64 years","included","~47 weeks","infection","infection","infection","delta",39.2,36.4,41.9,"Hungary","HUN","Europe","Europe & Central Asia",16570,2019,"Hungary","High income",3,NA,NA,NA,NA,NA
"1994",235,"Voko","Retrospective cohort",2048,2022-07-22,"Oxford/AstraZeneca ChAdOx1-S","Vectored","2","final",NA,"240+","18-64 years","18-64 years","included","~47 weeks","infection","infection","infection","delta",-14,-20.5,-7.9,"Hungary","HUN","Europe","Europe & Central Asia",16570,2019,"Hungary","High income",3,NA,NA,NA,NA,NA
"1995",235,"Voko","Retrospective cohort",2049,2022-07-22,"Oxford/AstraZeneca ChAdOx1-S","Vectored","2","final",NA,"14-120","18-64 years","18-64 years","included","~47 weeks","hospitalization","severe","severe","delta",76.2,70.6,80.7,"Hungary","HUN","Europe","Europe & Central Asia",16570,2019,"Hungary","High income",3,14,120,"yes",NA,0
"1996",235,"Voko","Retrospective cohort",2050,2022-07-22,"Oxford/AstraZeneca ChAdOx1-S","Vectored","2","final",NA,"240+","18-64 years","18-64 years","included","~47 weeks","hospitalization","severe","severe","delta",48.8,38.2,57.6,"Hungary","HUN","Europe","Europe & Central Asia",16570,2019,"Hungary","High income",3,240,329,"no","sequential period",0
"1997",235,"Voko","Retrospective cohort",2051,2022-07-22,"Oxford/AstraZeneca ChAdOx1-S","Vectored","2","final",NA,"14-120","18-64 years","18-64 years","included","~47 weeks","death","death","death","delta",90.1,73.5,96.3,"Hungary","HUN","Europe","Europe & Central Asia",16570,2019,"Hungary","High income",3,NA,NA,NA,NA,NA
"1998",235,"Voko","Retrospective cohort",2052,2022-07-22,"Oxford/AstraZeneca ChAdOx1-S","Vectored","2","final",NA,"240+","18-64 years","18-64 years","included","~47 weeks","death","death","death","delta",57.1,35.2,71.6,"Hungary","HUN","Europe","Europe & Central Asia",16570,2019,"Hungary","High income",3,NA,NA,NA,NA,NA
"1999",235,"Voko","Retrospective cohort",2053,2022-07-22,"Gamaleya Gam-COVID-Vac/Sputnik V","Vectored","2","final",NA,"14-120","18-64 years","18-64 years","included","~47 weeks","infection","infection","infection","delta",38.3,31.8,44.3,"Hungary","HUN","Europe","Europe & Central Asia",16570,2019,"Hungary","High income",3,NA,NA,NA,NA,NA
"2000",235,"Voko","Retrospective cohort",2054,2022-07-22,"Gamaleya Gam-COVID-Vac/Sputnik V","Vectored","2","final",NA,"240+","18-64 years","18-64 years","included","~47 weeks","infection","infection","infection","delta",-4.6,-12.5,2.9,"Hungary","HUN","Europe","Europe & Central Asia",16570,2019,"Hungary","High income",3,NA,NA,NA,NA,NA
"2001",235,"Voko","Retrospective cohort",2055,2022-07-22,"Gamaleya Gam-COVID-Vac/Sputnik V","Vectored","2","final",NA,"14-120","18-64 years","18-64 years","included","~47 weeks","hospitalization","severe","severe","delta",90.4,78.5,95.7,"Hungary","HUN","Europe","Europe & Central Asia",16570,2019,"Hungary","High income",3,NA,NA,NA,NA,NA
"2002",235,"Voko","Retrospective cohort",2056,2022-07-22,"Gamaleya Gam-COVID-Vac/Sputnik V","Vectored","2","final",NA,"240+","18-64 years","18-64 years","included","~47 weeks","hospitalization","severe","severe","delta",78.7,69.1,85.4,"Hungary","HUN","Europe","Europe & Central Asia",16570,2019,"Hungary","High income",3,NA,NA,NA,NA,NA
"2003",235,"Voko","Retrospective cohort",2057,2022-07-22,"Gamaleya Gam-COVID-Vac/Sputnik V","Vectored","2","final",NA,"121-180","18-64 years","18-64 years","included","~47 weeks","death","death","death","delta",89.3,79.9,94.3,"Hungary","HUN","Europe","Europe & Central Asia",16570,2019,"Hungary","High income",3,NA,NA,NA,NA,NA
"2004",235,"Voko","Retrospective cohort",2058,2022-07-22,"Gamaleya Gam-COVID-Vac/Sputnik V","Vectored","2","final",NA,"240+","18-64 years","18-64 years","included","~47 weeks","death","death","death","delta",79.1,59.8,89.2,"Hungary","HUN","Europe","Europe & Central Asia",16570,2019,"Hungary","High income",3,NA,NA,NA,NA,NA
"2005",235,"Voko","Retrospective cohort",2059,2022-07-22,"Janssen Ad26.COV2.S","Vectored","1","final",NA,"14-120","18-64 years","18-64 years","included","~47 weeks","infection","infection","infection","delta",39.3,36.1,42.4,"Hungary","HUN","Europe","Europe & Central Asia",16570,2019,"Hungary","High income",3,NA,NA,NA,NA,NA
"2006",235,"Voko","Retrospective cohort",2060,2022-07-22,"Janssen Ad26.COV2.S","Vectored","1","final",NA,"181-240","18-64 years","18-64 years","included","~47 weeks","infection","infection","infection","delta",35.9,32.5,39.2,"Hungary","HUN","Europe","Europe & Central Asia",16570,2019,"Hungary","High income",3,NA,NA,NA,NA,NA
"2007",235,"Voko","Retrospective cohort",2061,2022-07-22,"Janssen Ad26.COV2.S","Vectored","1","final",NA,"14-120","18-64 years","18-64 years","included","~47 weeks","hospitalization","severe","severe","delta",43.2,32.9,52,"Hungary","HUN","Europe","Europe & Central Asia",16570,2019,"Hungary","High income",3,NA,NA,NA,NA,NA
"2008",235,"Voko","Retrospective cohort",2062,2022-07-22,"Janssen Ad26.COV2.S","Vectored","1","final",NA,"181-240","18-64 years","18-64 years","included","~47 weeks","hospitalization","severe","severe","delta",59.4,50.1,67,"Hungary","HUN","Europe","Europe & Central Asia",16570,2019,"Hungary","High income",3,NA,NA,NA,NA,NA
"2009",235,"Voko","Retrospective cohort",2063,2022-07-22,"Janssen Ad26.COV2.S","Vectored","1","final",NA,"14-120","18-64 years","18-64 years","included","~47 weeks","death","death","death","delta",59.8,35.2,75.1,"Hungary","HUN","Europe","Europe & Central Asia",16570,2019,"Hungary","High income",3,NA,NA,NA,NA,NA
"2010",235,"Voko","Retrospective cohort",2064,2022-07-22,"Janssen Ad26.COV2.S","Vectored","1","final",NA,"181-240","18-64 years","18-64 years","included","~47 weeks","death","death","death","delta",76.1,56.7,86.8,"Hungary","HUN","Europe","Europe & Central Asia",16570,2019,"Hungary","High income",3,NA,NA,NA,NA,NA
"2011",235,"Voko","Retrospective cohort",2065,2022-07-22,"Beijing/Sinopharm BBIBP-CorV","Inactivated","2","final",NA,"14-120","18-64 years","18-64 years","included","~47 weeks","infection","infection","infection","delta",10.9,6.7,15,"Hungary","HUN","Europe","Europe & Central Asia",16570,2019,"Hungary","High income",3,NA,NA,NA,NA,NA
"2012",235,"Voko","Retrospective cohort",2066,2022-07-22,"Beijing/Sinopharm BBIBP-CorV","Inactivated","2","final",NA,"240+","18-64 years","18-64 years","included","~47 weeks","infection","infection","infection","delta",-19.9,-31.9,-9,"Hungary","HUN","Europe","Europe & Central Asia",16570,2019,"Hungary","High income",3,NA,NA,NA,NA,NA
"2013",235,"Voko","Retrospective cohort",2067,2022-07-22,"Beijing/Sinopharm BBIBP-CorV","Inactivated","2","final",NA,"14-120","18-64 years","18-64 years","included","~47 weeks","hospitalization","severe","severe","delta",53.8,43.9,61.9,"Hungary","HUN","Europe","Europe & Central Asia",16570,2019,"Hungary","High income",3,NA,NA,NA,NA,NA
"2014",235,"Voko","Retrospective cohort",2068,2022-07-22,"Beijing/Sinopharm BBIBP-CorV","Inactivated","2","final",NA,"240+","18-64 years","18-64 years","included","~47 weeks","hospitalization","severe","severe","delta",40.9,24.4,53.8,"Hungary","HUN","Europe","Europe & Central Asia",16570,2019,"Hungary","High income",3,NA,NA,NA,NA,NA
"2015",235,"Voko","Retrospective cohort",2069,2022-07-22,"Beijing/Sinopharm BBIBP-CorV","Inactivated","2","final",NA,"14-120","18-64 years","18-64 years","included","~47 weeks","death","death","death","delta",67.4,39.2,82.5,"Hungary","HUN","Europe","Europe & Central Asia",16570,2019,"Hungary","High income",3,NA,NA,NA,NA,NA
"2016",235,"Voko","Retrospective cohort",2070,2022-07-22,"Beijing/Sinopharm BBIBP-CorV","Inactivated","2","final",NA,"240+","18-64 years","18-64 years","included","~47 weeks","death","death","death","delta",50.7,21.4,69.1,"Hungary","HUN","Europe","Europe & Central Asia",16570,2019,"Hungary","High income",3,NA,NA,NA,NA,NA
"2017",236,"Gram","Retrospective cohort",2071,2022-09-01,"Multiple or heterologous RNA","mRNA","2","final",NA,"14-30","12-59 years","12-59 years","excluded","~56 weeks","infection","infection","infection","omicron",40,38.6,41.3,"Denmark","DNK","Europe","Europe & Central Asia",63020,2019,"Denmark","High income",4,NA,NA,NA,NA,NA
"2018",236,"Gram","Retrospective cohort",2072,2022-09-01,"Multiple or heterologous RNA","mRNA","2","final",NA,"120+","12-59 years","12-59 years","excluded","~56 weeks","infection","infection","infection","omicron",12.6,12,13.3,"Denmark","DNK","Europe","Europe & Central Asia",63020,2019,"Denmark","High income",4,NA,NA,NA,NA,NA
"2019",236,"Gram","Retrospective cohort",2073,2022-09-01,"Multiple or heterologous RNA","mRNA","2","final",NA,"14-30","12-59 years","12-59 years","excluded","~56 weeks","hospitalization","severe","severe","omicron",96.2,72.9,99.5,"Denmark","DNK","Europe","Europe & Central Asia",63020,2019,"Denmark","High income",4,NA,NA,NA,NA,NA
"2020",236,"Gram","Retrospective cohort",2074,2022-09-01,"Multiple or heterologous RNA","mRNA","2","final",NA,"120+","12-59 years","12-59 years","excluded","~56 weeks","hospitalization","severe","severe","omicron",77.6,72.6,81.6,"Denmark","DNK","Europe","Europe & Central Asia",63020,2019,"Denmark","High income",4,NA,NA,NA,NA,NA
"2021",236,"Gram","Retrospective cohort",2075,2022-09-01,"Multiple or heterologous RNA","mRNA","2","final",NA,"14-30","12-59 years","12-59 years","excluded","~56 weeks","infection","infection","infection","delta",92.2,91.8,92.6,"Denmark","DNK","Europe","Europe & Central Asia",63020,2019,"Denmark","High income",4,NA,NA,NA,NA,NA
"2022",236,"Gram","Retrospective cohort",2076,2022-09-01,"Multiple or heterologous RNA","mRNA","2","final",NA,"120+","12-59 years","12-59 years","excluded","~56 weeks","infection","infection","infection","delta",64.8,64,65.8,"Denmark","DNK","Europe","Europe & Central Asia",63020,2019,"Denmark","High income",4,NA,NA,NA,NA,NA
"2023",236,"Gram","Retrospective cohort",2077,2022-09-01,"Multiple or heterologous RNA","mRNA","2","final",NA,"14-30","12-59 years","12-59 years","excluded","~56 weeks","hospitalization","severe","severe","delta",99.5,98.4,99.8,"Denmark","DNK","Europe","Europe & Central Asia",63020,2019,"Denmark","High income",4,NA,NA,NA,NA,NA
"2024",236,"Gram","Retrospective cohort",2078,2022-09-01,"Multiple or heterologous RNA","mRNA","2","final",NA,"120+","12-59 years","12-59 years","excluded","~56 weeks","hospitalization","severe","severe","delta",93.5,91.6,95,"Denmark","DNK","Europe","Europe & Central Asia",63020,2019,"Denmark","High income",4,NA,NA,NA,NA,NA
"2025",236,"Gram","Retrospective cohort",2079,2022-09-01,"Multiple or heterologous RNA","mRNA","2","final",NA,"14-30",">= 60 years",">= 60 years","excluded","~56 weeks","infection","infection","infection","omicron",39.9,26.3,50.9,"Denmark","DNK","Europe","Europe & Central Asia",63020,2019,"Denmark","High income",4,NA,NA,NA,NA,NA
"2026",236,"Gram","Retrospective cohort",2080,2022-09-01,"Multiple or heterologous RNA","mRNA","2","final",NA,"120+",">= 60 years",">= 60 years","excluded","~56 weeks","infection","infection","infection","omicron",4.4,-0.1,8.7,"Denmark","DNK","Europe","Europe & Central Asia",63020,2019,"Denmark","High income",4,NA,NA,NA,NA,NA
"2027",236,"Gram","Retrospective cohort",2081,2022-09-01,"Multiple or heterologous RNA","mRNA","2","final",NA,"14-30",">= 60 years",">= 60 years","excluded","~56 weeks","infection","infection","infection","delta",82.3,75.5,87.2,"Denmark","DNK","Europe","Europe & Central Asia",63020,2019,"Denmark","High income",4,NA,NA,NA,NA,NA
"2028",236,"Gram","Retrospective cohort",2082,2022-09-01,"Multiple or heterologous RNA","mRNA","2","final",NA,"120+",">= 60 years",">= 60 years","excluded","~56 weeks","infection","infection","infection","delta",50,46.7,53,"Denmark","DNK","Europe","Europe & Central Asia",63020,2019,"Denmark","High income",4,NA,NA,NA,NA,NA
"2029",236,"Gram","Retrospective cohort",2083,2022-09-01,"Multiple or heterologous RNA","mRNA","2","final",NA,"31-60",">= 60 years",">= 60 years","excluded","~56 weeks","hospitalization","severe","severe","delta",97.7,94.8,98.8,"Denmark","DNK","Europe","Europe & Central Asia",63020,2019,"Denmark","High income",4,NA,NA,NA,NA,NA
"2030",236,"Gram","Retrospective cohort",2084,2022-09-01,"Multiple or heterologous RNA","mRNA","2","final",NA,"120+",">= 60 years",">= 60 years","excluded","~56 weeks","hospitalization","severe","severe","delta",87.5,85.6,89.2,"Denmark","DNK","Europe","Europe & Central Asia",63020,2019,"Denmark","High income",4,NA,NA,NA,NA,NA
"2031",236,"Gram","Retrospective cohort",2085,2022-09-01,"Multiple or heterologous RNA","mRNA","2","final",NA,"14-30",">= 60 years",">= 60 years","excluded","~56 weeks","infection","infection","infection","alpha",90.7,88.2,92.7,"Denmark","DNK","Europe","Europe & Central Asia",63020,2019,"Denmark","High income",4,NA,NA,NA,NA,NA
"2032",236,"Gram","Retrospective cohort",2086,2022-09-01,"Multiple or heterologous RNA","mRNA","2","final",NA,"120+",">= 60 years",">= 60 years","excluded","~56 weeks","infection","infection","infection","alpha",73.2,57.1,83.3,"Denmark","DNK","Europe","Europe & Central Asia",63020,2019,"Denmark","High income",4,NA,NA,NA,NA,NA
"2033",236,"Gram","Retrospective cohort",2087,2022-09-01,"Multiple or heterologous RNA","mRNA","2","final",NA,"14-30",">= 60 years",">= 60 years","excluded","~56 weeks","hospitalization","severe","severe","alpha",98.1,94.7,99.3,"Denmark","DNK","Europe","Europe & Central Asia",63020,2019,"Denmark","High income",4,NA,NA,NA,NA,NA
"2034",236,"Gram","Retrospective cohort",2088,2022-09-01,"Multiple or heterologous RNA","mRNA","2","final",NA,"120+",">= 60 years",">= 60 years","excluded","~56 weeks","hospitalization","severe","severe","alpha",96.5,73.4,99.5,"Denmark","DNK","Europe","Europe & Central Asia",63020,2019,"Denmark","High income",4,NA,NA,NA,NA,NA
"2035",237,"Lind","Test-negative case-control",2089,2022-04-25,"Multiple or heterologous RNA","mRNA","2","final",NA,"14-140",">= 18 years","general pop","excluded","~67 weeks","infection","infection","infection","omicron",28.5,20,36.2,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"2036",237,"Lind","Test-negative case-control",2090,2022-04-25,"Multiple or heterologous RNA","mRNA","2","final",NA,"150+",">= 18 years","general pop","excluded","~67 weeks","infection","infection","infection","omicron",15.3,10.4,20,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"2037",237,"Lind","Test-negative case-control",2091,2022-04-25,"Multiple or heterologous RNA","mRNA","2","final",NA,"14-140",">= 18 years","general pop","included","~67 weeks","infection","infection","infection","omicron",36.1,7.1,56.1,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"2038",237,"Lind","Test-negative case-control",2092,2022-04-25,"Multiple or heterologous RNA","mRNA","2","final",NA,"150+",">= 18 years","general pop","included","~67 weeks","infection","infection","infection","omicron",34,18.5,46.5,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"2039",237,"Lind","1:1 Matched case control",2093,2022-04-25,"Multiple or heterologous RNA","mRNA","2","final",NA,"14-140",">= 18 years","general pop","excluded","~67 weeks","infection","infection","infection","omicron",30.7,20.6,39.6,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"2040",237,"Lind","1:1 Matched case control",2094,2022-04-25,"Multiple or heterologous RNA","mRNA","2","final",NA,"150+",">= 18 years","general pop","excluded","~67 weeks","infection","infection","infection","omicron",20,14,25.6,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"2041",237,"Lind","1:1 Matched case control",2095,2022-04-25,"Multiple or heterologous RNA","mRNA","2","final",NA,"14-140",">= 18 years","general pop","included","~67 weeks","infection","infection","infection","omicron",14.3,-43.1,48.7,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"2042",237,"Lind","1:1 Matched case control",2096,2022-04-25,"Multiple or heterologous RNA","mRNA","2","final",NA,"150+",">= 18 years","general pop","included","~67 weeks","infection","infection","infection","omicron",18.8,-9,39.5,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"2043",238,"Sanchez Ruiz","Retrospective cohort",2097,2022-04-01,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"14+","LTCF residents","LTCF residents","excluded",NA,"infection","infection","infection","delta",11.2,0,61.1,"France","FRA","Europe","Europe & Central Asia",42470,2019,"France","High income",4,NA,NA,NA,NA,NA
"2044",238,"Sanchez Ruiz","Retrospective cohort",2098,2022-04-01,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"14+","LTCF residents","LTCF residents","excluded",NA,"symptomatic disease","symptomatic","symptomatic","delta",88.4,59.9,96.7,"France","FRA","Europe","Europe & Central Asia",42470,2019,"France","High income",4,NA,NA,NA,NA,NA
"2045",238,"Sanchez Ruiz","Retrospective cohort",2099,2022-04-01,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"14+","LTCF residents","LTCF residents","excluded",NA,"severe disease","severe","severe","delta",93.5,67.2,98.7,"France","FRA","Europe","Europe & Central Asia",42470,2019,"France","High income",4,NA,NA,NA,NA,NA
"2046",239,"Widdifield","Test-negative case-control",2100,2022-04-14,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"7+","individuals with rheumatoid arthritis","individuals with rheumatoid arthritis","included","~44 weeks","infection","infection","infection","other combinations",82,78,85,"Canada","CAN","North America","North America",46580,2019,"Canada","High income",4,NA,NA,NA,NA,NA
"2047",239,"Widdifield","Test-negative case-control",2101,2022-04-14,"Moderna mRNA-1273","mRNA","2","final",NA,"7+","individuals with rheumatoid arthritis","individuals with rheumatoid arthritis","included","~44 weeks","infection","infection","infection","other combinations",86,80,90,"Canada","CAN","North America","North America",46580,2019,"Canada","High income",4,NA,NA,NA,NA,NA
"2048",239,"Widdifield","Test-negative case-control",2102,2022-04-14,"Multiple or heterologous RNA","mRNA","2","final",NA,"7+","individuals with rheumatoid arthritis","individuals with rheumatoid arthritis","included","~44 weeks","infection","infection","infection","other combinations",83,80,86,"Canada","CAN","North America","North America",46580,2019,"Canada","High income",4,NA,NA,NA,NA,NA
"2049",239,"Widdifield","Test-negative case-control",2103,2022-04-14,"Multiple or heterologous RNA","mRNA","2","final",NA,"7+","individuals with rheumatoid arthritis","individuals with rheumatoid arthritis","included","~44 weeks","severe disease","severe","severe","other combinations",92,88,95,"Canada","CAN","North America","North America",46580,2019,"Canada","High income",4,NA,NA,NA,NA,NA
"2050",239,"Widdifield","Test-negative case-control",2104,2022-04-14,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"7+","individuals with ankylosing spondylitis","individuals with ankylosing spondylitis","included","~44 weeks","infection","infection","infection","other combinations",88,82,93,"Canada","CAN","North America","North America",46580,2019,"Canada","High income",4,NA,NA,NA,NA,NA
"2051",239,"Widdifield","Test-negative case-control",2105,2022-04-14,"Moderna mRNA-1273","mRNA","2","final",NA,"7+","individuals with ankylosing spondylitis","individuals with ankylosing spondylitis","included","~44 weeks","infection","infection","infection","other combinations",93,83,97,"Canada","CAN","North America","North America",46580,2019,"Canada","High income",4,NA,NA,NA,NA,NA
"2052",239,"Widdifield","Test-negative case-control",2106,2022-04-14,"Multiple or heterologous RNA","mRNA","2","final",NA,"7+","individuals with ankylosing spondylitis","individuals with ankylosing spondylitis","included","~44 weeks","infection","infection","infection","other combinations",89,83,93,"Canada","CAN","North America","North America",46580,2019,"Canada","High income",4,NA,NA,NA,NA,NA
"2053",239,"Widdifield","Test-negative case-control",2107,2022-04-14,"Multiple or heterologous RNA","mRNA","2","final",NA,"7+","individuals with ankylosing spondylitis","individuals with ankylosing spondylitis","included","~44 weeks","severe disease","severe","severe","other combinations",97,83,99,"Canada","CAN","North America","North America",46580,2019,"Canada","High income",4,NA,NA,NA,NA,NA
"2054",239,"Widdifield","Test-negative case-control",2108,2022-04-14,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"7+","individuals with psoriasis","individuals with psoriasis","included","~44 weeks","infection","infection","infection","other combinations",82,79,85,"Canada","CAN","North America","North America",46580,2019,"Canada","High income",4,NA,NA,NA,NA,NA
"2055",239,"Widdifield","Test-negative case-control",2109,2022-04-14,"Moderna mRNA-1273","mRNA","2","final",NA,"7+","individuals with psoriasis","individuals with psoriasis","included","~44 weeks","infection","infection","infection","other combinations",87,82,91,"Canada","CAN","North America","North America",46580,2019,"Canada","High income",4,NA,NA,NA,NA,NA
"2056",239,"Widdifield","Test-negative case-control",2110,2022-04-14,"Multiple or heterologous RNA","mRNA","2","final",NA,"7+","individuals with psoriasis","individuals with psoriasis","included","~44 weeks","infection","infection","infection","other combinations",84,81,86,"Canada","CAN","North America","North America",46580,2019,"Canada","High income",4,NA,NA,NA,NA,NA
"2057",239,"Widdifield","Test-negative case-control",2111,2022-04-14,"Multiple or heterologous RNA","mRNA","2","final",NA,"7+","individuals with psoriasis","individuals with psoriasis","included","~44 weeks","severe disease","severe","severe","other combinations",92,86,95,"Canada","CAN","North America","North America",46580,2019,"Canada","High income",4,NA,NA,NA,NA,NA
"2058",239,"Widdifield","Test-negative case-control",2112,2022-04-14,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"7+","individuals with inflammatory bowel disease","individuals with inflammatory bowel disease","included","~44 weeks","infection","infection","infection","other combinations",82,79,85,"Canada","CAN","North America","North America",46580,2019,"Canada","High income",4,NA,NA,NA,NA,NA
"2059",239,"Widdifield","Test-negative case-control",2113,2022-04-14,"Moderna mRNA-1273","mRNA","2","final",NA,"7+","individuals with inflammatory bowel disease","individuals with inflammatory bowel disease","included","~44 weeks","infection","infection","infection","other combinations",87,82,91,"Canada","CAN","North America","North America",46580,2019,"Canada","High income",4,NA,NA,NA,NA,NA
"2060",239,"Widdifield","Test-negative case-control",2114,2022-04-14,"Multiple or heterologous RNA","mRNA","2","final",NA,"7+","individuals with inflammatory bowel disease","individuals with inflammatory bowel disease","included","~44 weeks","infection","infection","infection","other combinations",79,74,82,"Canada","CAN","North America","North America",46580,2019,"Canada","High income",4,NA,NA,NA,NA,NA
"2061",239,"Widdifield","Test-negative case-control",2115,2022-04-14,"Multiple or heterologous RNA","mRNA","2","final",NA,"7+","individuals with inflammatory bowel disease","individuals with inflammatory bowel disease","included","~44 weeks","severe disease","severe","severe","other combinations",94,88,97,"Canada","CAN","North America","North America",46580,2019,"Canada","High income",4,NA,NA,NA,NA,NA
"2062",240,"Cerqueira-Silva","Test-negative case-control",2116,2023-01-11,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"14-59",">= 18 years","general pop","included","~7 weeks","symptomatic disease","symptomatic","symptomatic","omicron",49.2,48.5,49.9,"Brazil","BRA","South America","Latin America & Caribbean",9410,2019,"Brazil","Upper middle income",3,NA,NA,NA,NA,NA
"2063",240,"Cerqueira-Silva","Test-negative case-control",2117,2023-01-11,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"150+",">= 18 years","general pop","included","~33 weeks","symptomatic disease","symptomatic","symptomatic","omicron",9.6,8.1,11,"Brazil","BRA","South America","Latin America & Caribbean",9410,2019,"Brazil","Upper middle income",3,NA,NA,NA,NA,NA
"2064",240,"Cerqueira-Silva","Test-negative case-control",2118,2023-01-11,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"14-59",">= 18 years","general pop","included","~7 weeks","severe disease","severe","severe","omicron",82.9,80.6,85,"Brazil","BRA","South America","Latin America & Caribbean",9410,2019,"Brazil","Upper middle income",3,14,59,"yes",NA,0
"2065",240,"Cerqueira-Silva","Test-negative case-control",2119,2023-01-11,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"150+",">= 18 years","general pop","included","~33 weeks","severe disease","severe","severe","omicron",82.6,80.7,84.3,"Brazil","BRA","South America","Latin America & Caribbean",9410,2019,"Brazil","Upper middle income",3,150,231,"no","sequential period",0
"2066",240,"Cerqueira-Silva","Test-negative case-control",2120,2023-01-11,"Oxford/AstraZeneca ChAdOx1-S","Vectored","2","final",NA,"14-59",">= 18 years","general pop","included","~7 weeks","symptomatic disease","symptomatic","symptomatic","omicron",26.7,25.2,28.2,"Brazil","BRA","South America","Latin America & Caribbean",9410,2019,"Brazil","Upper middle income",3,NA,NA,NA,NA,NA
"2067",240,"Cerqueira-Silva","Test-negative case-control",2121,2023-01-11,"Oxford/AstraZeneca ChAdOx1-S","Vectored","2","final",NA,"150+",">= 18 years","general pop","included","~36 weeks","symptomatic disease","symptomatic","symptomatic","omicron",0.9,0,1.9,"Brazil","BRA","South America","Latin America & Caribbean",9410,2019,"Brazil","Upper middle income",3,NA,NA,NA,NA,NA
"2068",240,"Cerqueira-Silva","Test-negative case-control",2122,2023-01-11,"Oxford/AstraZeneca ChAdOx1-S","Vectored","2","final",NA,"14-59",">= 18 years","general pop","included","~7 weeks","severe disease","severe","severe","omicron",77.1,72.9,80.6,"Brazil","BRA","South America","Latin America & Caribbean",9410,2019,"Brazil","Upper middle income",3,14,59,"yes",NA,0
"2069",240,"Cerqueira-Silva","Test-negative case-control",2123,2023-01-11,"Oxford/AstraZeneca ChAdOx1-S","Vectored","2","final",NA,"150+",">= 18 years","general pop","included","~36 weeks","severe disease","severe","severe","omicron",67.8,66.7,69,"Brazil","BRA","South America","Latin America & Caribbean",9410,2019,"Brazil","Upper middle income",3,150,252,"no","sequential period",0
"2070",500,"Cerqueira-Silva","Test-negative case-control",2124,2023-01-11,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"14-59",">= 18 years","general pop","included","~7 weeks","symptomatic disease","symptomatic","symptomatic","omicron",57.7,54.5,60.6,"UK","GBR","Europe","Europe & Central Asia",43240,2019,"United Kingdom","High income",4,NA,NA,NA,NA,NA
"2071",500,"Cerqueira-Silva","Test-negative case-control",2125,2023-01-11,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"150+",">= 18 years","general pop","included","~38.5 weeks","symptomatic disease","symptomatic","symptomatic","omicron",17.8,15.1,20.5,"UK","GBR","Europe","Europe & Central Asia",43240,2019,"United Kingdom","High income",4,NA,NA,NA,NA,NA
"2072",500,"Cerqueira-Silva","Test-negative case-control",2126,2023-01-11,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"14-59",">= 18 years","general pop","included","~7 weeks","severe disease","severe","severe","omicron",90.4,30.4,98.7,"UK","GBR","Europe","Europe & Central Asia",43240,2019,"United Kingdom","High income",4,14,59,"yes",NA,0
"2073",500,"Cerqueira-Silva","Test-negative case-control",2127,2023-01-11,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"150+",">= 18 years","general pop","included","~38.5 weeks","severe disease","severe","severe","omicron",72.9,57.9,82.5,"UK","GBR","Europe","Europe & Central Asia",43240,2019,"United Kingdom","High income",4,150,269.5,"no","sequential period",0
"2074",500,"Cerqueira-Silva","Test-negative case-control",2128,2023-01-11,"Oxford/AstraZeneca ChAdOx1-S","Vectored","2","final",NA,"14-59",">= 18 years","general pop","included","~7 weeks","symptomatic disease","symptomatic","symptomatic","omicron",40.7,26.6,52.1,"UK","GBR","Europe","Europe & Central Asia",43240,2019,"United Kingdom","High income",4,NA,NA,NA,NA,NA
"2075",500,"Cerqueira-Silva","Test-negative case-control",2129,2023-01-11,"Oxford/AstraZeneca ChAdOx1-S","Vectored","2","final",NA,"150+",">= 18 years","general pop","included","~35.5 weeks","symptomatic disease","symptomatic","symptomatic","omicron",9.6,6.3,12.9,"UK","GBR","Europe","Europe & Central Asia",43240,2019,"United Kingdom","High income",4,NA,NA,NA,NA,NA
"2076",500,"Cerqueira-Silva","Test-negative case-control",2130,2023-01-11,"Oxford/AstraZeneca ChAdOx1-S","Vectored","2","final",NA,"60-149",">= 18 years","general pop","included","~19 weeks","severe disease","severe","severe","omicron",78.8,31.8,93.4,"UK","GBR","Europe","Europe & Central Asia",43240,2019,"United Kingdom","High income",4,60,149,"yes",NA,0
"2077",500,"Cerqueira-Silva","Test-negative case-control",2131,2023-01-11,"Oxford/AstraZeneca ChAdOx1-S","Vectored","2","final",NA,"150+",">= 18 years","general pop","included","~35.5 weeks","severe disease","severe","severe","omicron",52.8,33.3,66.7,"UK","GBR","Europe","Europe & Central Asia",43240,2019,"United Kingdom","High income",4,150,248.5,"no","sequential period",0
"2078",241,"Gonzalez","Retrospective cohort",2132,2022-04-19,"Multiple or heterologous RNA","mRNA","2","final",NA,"14+","12-17 years","12-17 years","included","~17 weeks","hospitalization","severe","severe","delta/omicron",81,59.9,90.1,"Argentina","ARG","South America","Latin America & Caribbean",11210,2019,"Argentina","Upper middle income",3,NA,NA,NA,NA,NA
"2079",241,"Gonzalez","Retrospective cohort",2133,2022-04-19,"Beijing/Sinopharm BBIBP-CorV","Inactivated","2","final",NA,"14+","3-11 years","3-11 years","included","~9 weeks","hospitalization","severe","severe","delta/omicron",83.4,70.9,90.2,"Argentina","ARG","South America","Latin America & Caribbean",11210,2019,"Argentina","Upper middle income",3,NA,NA,NA,NA,NA
"2080",241,"Gonzalez","Retrospective cohort",2134,2022-04-19,"Multiple or heterologous RNA","mRNA","2","final",NA,"14+","12-17 years","12-17 years","included","~25 weeks","hospitalization","severe","severe","omicron",78.2,42,90.3,"Argentina","ARG","South America","Latin America & Caribbean",11210,2019,"Argentina","Upper middle income",3,NA,NA,NA,NA,NA
"2081",241,"Gonzalez","Retrospective cohort",2135,2022-04-19,"Beijing/Sinopharm BBIBP-CorV","Inactivated","2","final",NA,"14+","3-11 years","3-11 years","included","16 weeks","hospitalization","severe","severe","omicron",58.6,4.1,79.7,"Argentina","ARG","South America","Latin America & Caribbean",11210,2019,"Argentina","Upper middle income",3,NA,NA,NA,NA,NA
"2082",242,"Eick-Cost","Case-control",2136,2022-04-20,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"14+","military personnel","military personnel","excluded","~19 weeks","infection","infection","infection","other combinations",87.6,86.2,88.9,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"2083",242,"Eick-Cost","Case-control",2137,2022-04-20,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"14+","military personnel","military personnel","excluded","~19 weeks","asymptomatic infection","asymptomatic","infection","other combinations",80.3,76.5,83.5,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"2084",242,"Eick-Cost","Case-control",2138,2022-04-20,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"14+","military personnel","military personnel","excluded","~19 weeks","symptomatic disease","symptomatic","symptomatic","other combinations",89.9,88.4,91.2,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"2085",242,"Eick-Cost","Case-control",2139,2022-04-20,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"14+","military personnel","military personnel","excluded","~19 weeks","hospitalization","severe","severe","other combinations",88,75.4,94.1,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"2086",242,"Eick-Cost","Case-control",2140,2022-04-20,"Moderna mRNA-1273","mRNA","2","final",NA,"14+","military personnel","military personnel","excluded","~19 weeks","infection","infection","infection","other combinations",93.5,91.9,94.7,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"2087",242,"Eick-Cost","Case-control",2141,2022-04-20,"Moderna mRNA-1273","mRNA","2","final",NA,"14+","military personnel","military personnel","excluded","~19 weeks","asymptomatic infection","asymptomatic","infection","other combinations",94.7,91.9,96.6,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"2088",242,"Eick-Cost","Case-control",2142,2022-04-20,"Moderna mRNA-1273","mRNA","2","final",NA,"14+","military personnel","military personnel","excluded","~19 weeks","symptomatic disease","symptomatic","symptomatic","other combinations",93.1,91.2,94.6,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"2089",242,"Eick-Cost","Case-control",2143,2022-04-20,"Moderna mRNA-1273","mRNA","2","final",NA,"14+","military personnel","military personnel","excluded","~19 weeks","hospitalization","severe","severe","other combinations",89.6,57.5,97.4,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"2090",242,"Eick-Cost","Case-control",2144,2022-04-20,"Janssen Ad26.COV2.S","Vectored","1","final",NA,"14+","military personnel","military personnel","excluded","~19 weeks","infection","infection","infection","other combinations",81.8,74.2,87.1,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"2091",242,"Eick-Cost","Case-control",2145,2022-04-20,"Janssen Ad26.COV2.S","Vectored","1","final",NA,"14+","military personnel","military personnel","excluded","~19 weeks","asymptomatic infection","asymptomatic","infection","other combinations",81.4,62.6,90.8,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"2092",242,"Eick-Cost","Case-control",2146,2022-04-20,"Janssen Ad26.COV2.S","Vectored","1","final",NA,"14+","military personnel","military personnel","excluded","~19 weeks","symptomatic disease","symptomatic","symptomatic","other combinations",82.4,73.9,88.2,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"2093",242,"Eick-Cost","Case-control",2147,2022-04-20,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"14+","military personnel","military personnel","excluded","~35 weeks","infection","infection","infection","delta",69.3,68.2,70.3,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"2094",242,"Eick-Cost","Case-control",2148,2022-04-20,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"14+","military personnel","military personnel","excluded","~35 weeks","asymptomatic infection","asymptomatic","infection","delta",66,64,67.8,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"2095",242,"Eick-Cost","Case-control",2149,2022-04-20,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"14+","military personnel","military personnel","excluded","~35 weeks","symptomatic disease","symptomatic","symptomatic","delta",71,69.7,72.1,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"2096",242,"Eick-Cost","Case-control",2150,2022-04-20,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"14+","military personnel","military personnel","excluded","~35 weeks","hospitalization","severe","severe","delta",88.4,82.1,92.5,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"2097",242,"Eick-Cost","Case-control",2151,2022-04-20,"Moderna mRNA-1273","mRNA","2","final",NA,"14+","military personnel","military personnel","excluded","~35 weeks","infection","infection","infection","delta",79.4,78.3,80.4,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"2098",242,"Eick-Cost","Case-control",2152,2022-04-20,"Moderna mRNA-1273","mRNA","2","final",NA,"14+","military personnel","military personnel","excluded","~35 weeks","asymptomatic infection","asymptomatic","infection","delta",77,75.1,78.8,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"2099",242,"Eick-Cost","Case-control",2153,2022-04-20,"Moderna mRNA-1273","mRNA","2","final",NA,"14+","military personnel","military personnel","excluded","~35 weeks","symptomatic disease","symptomatic","symptomatic","delta",80.6,79.4,81.8,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"2100",242,"Eick-Cost","Case-control",2154,2022-04-20,"Moderna mRNA-1273","mRNA","2","final",NA,"14+","military personnel","military personnel","excluded","~35 weeks","hospitalization","severe","severe","delta",88.1,75.7,94.2,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"2101",242,"Eick-Cost","Case-control",2155,2022-04-20,"Janssen Ad26.COV2.S","Vectored","1","final",NA,"14+","military personnel","military personnel","excluded","~35 weeks","infection","infection","infection","delta",38.3,34.5,41.9,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"2102",242,"Eick-Cost","Case-control",2156,2022-04-20,"Janssen Ad26.COV2.S","Vectored","1","final",NA,"14+","military personnel","military personnel","excluded","~35 weeks","asymptomatic infection","asymptomatic","infection","delta",19.6,12.2,26.4,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"2103",242,"Eick-Cost","Case-control",2157,2022-04-20,"Janssen Ad26.COV2.S","Vectored","1","final",NA,"14+","military personnel","military personnel","excluded","~35 weeks","symptomatic disease","symptomatic","symptomatic","delta",48.9,45,52.7,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"2104",242,"Eick-Cost","Case-control",2158,2022-04-20,"Janssen Ad26.COV2.S","Vectored","1","final",NA,"14+","military personnel","military personnel","excluded","~35 weeks","hospitalization","severe","severe","delta",57.7,2.6,81.6,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"2105",243,"Castillo","Test-negative case-control",2159,2022-04-21,"Multiple or heterologous RNA","mRNA","2","final",NA,"0-30",">= 18 years","general pop","included","~48 weeks","symptomatic disease","symptomatic","symptomatic","omicron",43,41,45,"France","FRA","Europe","Europe & Central Asia",42470,2019,"France","High income",4,NA,NA,NA,NA,NA
"2106",243,"Castillo","Test-negative case-control",2160,2022-04-21,"Multiple or heterologous RNA","mRNA","2","final",NA,"180+",">= 18 years","general pop","included","~48 weeks","symptomatic disease","symptomatic","symptomatic","omicron",11,10,13,"France","FRA","Europe","Europe & Central Asia",42470,2019,"France","High income",4,NA,NA,NA,NA,NA
"2107",243,"Castillo","Test-negative case-control",2161,2022-04-21,"Multiple or heterologous RNA","mRNA","2","final",NA,"0-30",">= 18 years","general pop","included","~48 weeks","hospitalization","severe","severe","omicron",59,49,70,"France","FRA","Europe","Europe & Central Asia",42470,2019,"France","High income",4,NA,NA,NA,NA,NA
"2108",243,"Castillo","Test-negative case-control",2162,2022-04-21,"Multiple or heterologous RNA","mRNA","2","final",NA,"180+",">= 18 years","general pop","included","~48 weeks","hospitalization","severe","severe","omicron",56,51,62,"France","FRA","Europe","Europe & Central Asia",42470,2019,"France","High income",4,NA,NA,NA,NA,NA
"2109",243,"Castillo","Test-negative case-control",2163,2022-04-21,"Multiple or heterologous RNA","mRNA","2","final",NA,"0-30",">= 18 years","general pop","included","~48 weeks","ICU admission","severe","severe","omicron",70,40,97,"France","FRA","Europe","Europe & Central Asia",42470,2019,"France","High income",4,NA,NA,NA,NA,NA
"2110",243,"Castillo","Test-negative case-control",2164,2022-04-21,"Multiple or heterologous RNA","mRNA","2","final",NA,"180+",">= 18 years","general pop","included","~48 weeks","ICU admission","severe","severe","omicron",72,63,81,"France","FRA","Europe","Europe & Central Asia",42470,2019,"France","High income",4,NA,NA,NA,NA,NA
"2111",243,"Castillo","Test-negative case-control",2165,2022-04-21,"Multiple or heterologous RNA","mRNA","2","final",NA,"0-30",">= 18 years","general pop","included","~48 weeks","death","death","death","omicron",60,24,92,"France","FRA","Europe","Europe & Central Asia",42470,2019,"France","High income",4,NA,NA,NA,NA,NA
"2112",243,"Castillo","Test-negative case-control",2166,2022-04-21,"Multiple or heterologous RNA","mRNA","2","final",NA,"180+",">= 18 years","general pop","included","~48 weeks","death","death","death","omicron",54,41,69,"France","FRA","Europe","Europe & Central Asia",42470,2019,"France","High income",4,NA,NA,NA,NA,NA
"2113",243,"Castillo","Test-negative case-control",2167,2022-04-21,"Multiple or heterologous RNA","mRNA","2","final",NA,"0-30",">= 18 years","general pop","included","~48 weeks","symptomatic disease","symptomatic","symptomatic","delta",78,77,80,"France","FRA","Europe","Europe & Central Asia",42470,2019,"France","High income",4,NA,NA,NA,NA,NA
"2114",243,"Castillo","Test-negative case-control",2168,2022-04-21,"Multiple or heterologous RNA","mRNA","2","final",NA,"180+",">= 18 years","general pop","included","~48 weeks","symptomatic disease","symptomatic","symptomatic","delta",63,62,64,"France","FRA","Europe","Europe & Central Asia",42470,2019,"France","High income",4,NA,NA,NA,NA,NA
"2115",243,"Castillo","Test-negative case-control",2169,2022-04-21,"Multiple or heterologous RNA","mRNA","2","final",NA,"0-30",">= 18 years","general pop","included","~48 weeks","hospitalization","severe","severe","delta",91,87,95,"France","FRA","Europe","Europe & Central Asia",42470,2019,"France","High income",4,NA,NA,NA,NA,NA
"2116",243,"Castillo","Test-negative case-control",2170,2022-04-21,"Multiple or heterologous RNA","mRNA","2","final",NA,"180+",">= 18 years","general pop","included","~48 weeks","hospitalization","severe","severe","delta",90,89,91,"France","FRA","Europe","Europe & Central Asia",42470,2019,"France","High income",4,NA,NA,NA,NA,NA
"2117",243,"Castillo","Test-negative case-control",2171,2022-04-21,"Multiple or heterologous RNA","mRNA","2","final",NA,"0-30",">= 18 years","general pop","included","~48 weeks","ICU admission","severe","severe","delta",93,86,99,"France","FRA","Europe","Europe & Central Asia",42470,2019,"France","High income",4,NA,NA,NA,NA,NA
"2118",243,"Castillo","Test-negative case-control",2172,2022-04-21,"Multiple or heterologous RNA","mRNA","2","final",NA,"180+",">= 18 years","general pop","included","~48 weeks","ICU admission","severe","severe","delta",95,93,97,"France","FRA","Europe","Europe & Central Asia",42470,2019,"France","High income",4,NA,NA,NA,NA,NA
"2119",243,"Castillo","Test-negative case-control",2173,2022-04-21,"Multiple or heterologous RNA","mRNA","2","final",NA,"0-30",">= 18 years","general pop","included","~48 weeks","death","death","death","delta",90,79,100,"France","FRA","Europe","Europe & Central Asia",42470,2019,"France","High income",4,NA,NA,NA,NA,NA
"2120",243,"Castillo","Test-negative case-control",2174,2022-04-21,"Multiple or heterologous RNA","mRNA","2","final",NA,"180+",">= 18 years","general pop","included","~48 weeks","death","death","death","delta",87,83,91,"France","FRA","Europe","Europe & Central Asia",42470,2019,"France","High income",4,NA,NA,NA,NA,NA
"2121",244,"Sharma","Matched case-control",2175,2022-04-27,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"14+","veterans","veterans","excluded","~42 weeks","infection","infection","infection","omicron",25.3,21.8,28.7,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"2122",244,"Sharma","Matched case-control",2176,2022-04-27,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"14+","veterans","veterans","excluded","~42 weeks","hospitalization","severe","severe","omicron",52.9,47.8,57.6,"USA","USA","North America","North America",66220,2019,"United States","High income",4,14,294,"yes",NA,0
"2123",244,"Sharma","Matched case-control",2177,2022-04-27,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"14+","veterans","veterans","excluded","~42 weeks","death","death","death","omicron",50.7,37.9,61.6,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"2124",244,"Sharma","Matched case-control",2178,2022-04-27,"Moderna mRNA-1273","mRNA","2","final",NA,"14+","veterans","veterans","excluded","~42 weeks","infection","infection","infection","omicron",39.5,35.8,43,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"2125",244,"Sharma","Matched case-control",2179,2022-04-27,"Moderna mRNA-1273","mRNA","2","final",NA,"14+","veterans","veterans","excluded","~42 weeks","hospitalization","severe","severe","omicron",66.7,61.4,71.6,"USA","USA","North America","North America",66220,2019,"United States","High income",4,14,294,"yes",NA,0
"2126",244,"Sharma","Matched case-control",2180,2022-04-27,"Moderna mRNA-1273","mRNA","2","final",NA,"14+","veterans","veterans","excluded","~42 weeks","death","death","death","omicron",65.6,52.8,76.3,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"2127",246,"Florentino","Test-negative case-control",2181,2022-08-13,"Sinovac CoronaVac","Inactivated","2","final",NA,"14+","6-11 years","6-11 years","included","~12 weeks","symptomatic disease","symptomatic","symptomatic","omicron",39.8,33.7,45.4,"Brazil","BRA","South America","Latin America & Caribbean",9410,2019,"Brazil","Upper middle income",3,NA,NA,NA,NA,NA
"2128",246,"Florentino","Test-negative case-control",2182,2022-08-13,"Sinovac CoronaVac","Inactivated","2","final",NA,"14+","6-11 years","6-11 years","included","~12 weeks","hospitalization","severe","severe","omicron",59.2,11.3,84.5,"Brazil","BRA","South America","Latin America & Caribbean",9410,2019,"Brazil","Upper middle income",3,NA,NA,NA,NA,NA
"2129",247,"Kirsebom","Test-negative case-control",2183,2022-12-12,"Oxford/AstraZeneca ChAdOx1-S","Vectored","2","final",NA,"175+","40-64 years","40-64 years","included","~44.5 weeks","symptomatic disease","symptomatic","symptomatic","omicron",8,6,9.9,"UK","GBR","Europe","Europe & Central Asia",43240,2019,"United Kingdom","High income",4,NA,NA,NA,NA,NA
"2130",247,"Kirsebom","Test-negative case-control",2184,2022-12-12,"Oxford/AstraZeneca ChAdOx1-S","Vectored","2","final",NA,"175+","40-64 years","40-64 years","included","~44.5 weeks","symptomatic disease","symptomatic","symptomatic","omicron",19.5,11.7,26.6,"UK","GBR","Europe","Europe & Central Asia",43240,2019,"United Kingdom","High income",4,NA,NA,NA,NA,NA
"2131",247,"Kirsebom","Test-negative case-control",2185,2022-12-12,"Oxford/AstraZeneca ChAdOx1-S","Vectored","2","final",NA,"175+",">= 65 years",">= 65 years","included","~44.5 weeks","hospitalization","severe","severe","omicron",61,49.8,69.7,"UK","GBR","Europe","Europe & Central Asia",43240,2019,"United Kingdom","High income",4,175,311.5,"yes",NA,1
"2132",247,"Kirsebom","Test-negative case-control",2186,2022-12-12,"Oxford/AstraZeneca ChAdOx1-S","Vectored","2","final",NA,"175+",">= 65 years",">= 65 years","included","~44.5 weeks","hospitalization","severe","severe","delta",73.4,70.4,76.2,"UK","GBR","Europe","Europe & Central Asia",43240,2019,"United Kingdom","High income",4,175,311.5,"yes",NA,1
"2133",248,"Carazo","Test-negative case-control",2187,2022-10-14,"Multiple or heterologous RNA","mRNA","2","final",NA,"7+",">= 12 years","general pop","excluded","~51 weeks","infection","infection","infection","omicron",42,41,44,"Canada","CAN","North America","North America",46580,2019,"Canada","High income",4,NA,NA,NA,NA,NA
"2134",248,"Carazo","Test-negative case-control",2188,2022-10-14,"Multiple or heterologous RNA","mRNA","2","final",NA,"7+",">= 12 years","general pop","excluded","~51 weeks","hospitalization","severe","severe","omicron",76,74,78,"Canada","CAN","North America","North America",46580,2019,"Canada","High income",4,NA,NA,NA,NA,NA
"2135",248,"Carazo","Test-negative case-control",2189,2022-10-14,"Multiple or heterologous RNA","mRNA","2","final",NA,"7+",">= 12 years","general pop","previously infected only","~51 weeks","infection","infection","infection","omicron",23.2,21.2,27.4,"Canada","CAN","North America","North America",46580,2019,"Canada","High income",4,NA,NA,NA,NA,NA
"2136",248,"Carazo","Test-negative case-control",2190,2022-10-14,"Multiple or heterologous RNA","mRNA","2","final",NA,"7+",">= 12 years","general pop","previously infected only","~51 weeks","hospitalization","severe","severe","omicron",68.4,63.6,73.5,"Canada","CAN","North America","North America",46580,2019,"Canada","High income",4,NA,NA,NA,NA,NA
"2137",249,"Ma","Retrospective cohort/Outbreak investigation",2191,2022-05-03,"Beijing/Sinopharm BBIBP-CorV","Inactivated","2","final",NA,"14+","close contacts","close contacts","included","~8 weeks","symptomatic disease","symptomatic","symptomatic","delta",75.5,63,93.6,"China","CHN","Asia","East Asia & Pacific",10310,2019,"China","Upper middle income",3,NA,NA,NA,NA,NA
"2138",249,"Ma","Retrospective cohort/Outbreak investigation",2192,2022-05-03,"Beijing/Sinopharm BBIBP-CorV","Inactivated","2","final",NA,"14+","close contacts","close contacts","included","~8 weeks","pneumonia","severe","severe","delta",56.5,-95.9,90.4,"China","CHN","Asia","East Asia & Pacific",10310,2019,"China","Upper middle income",3,NA,NA,NA,NA,NA
"2139",249,"Ma","Retrospective cohort/Outbreak investigation",2193,2022-05-03,"Sinovac CoronaVac","Inactivated","2","final",NA,"14+","close contacts","close contacts","included","~8 weeks","symptomatic disease","symptomatic","symptomatic","delta",73,22.3,96,"China","CHN","Asia","East Asia & Pacific",10310,2019,"China","Upper middle income",3,NA,NA,NA,NA,NA
"2140",249,"Ma","Retrospective cohort/Outbreak investigation",2194,2022-05-03,"Sinovac CoronaVac","Inactivated","2","final",NA,"14+","close contacts","close contacts","included","~8 weeks","pneumonia","severe","severe","delta",84.6,18.8,97.1,"China","CHN","Asia","East Asia & Pacific",10310,2019,"China","Upper middle income",3,NA,NA,NA,NA,NA
"2141",249,"Ma","Retrospective cohort/Outbreak investigation",2195,2022-05-03,"Cansino Ad5-nCoV","Vectored","1","final",NA,"14+","close contacts","close contacts","included","~8 weeks","symptomatic disease","symptomatic","symptomatic","delta",61.5,9.5,83.6,"China","CHN","Asia","East Asia & Pacific",10310,2019,"China","Upper middle income",3,NA,NA,NA,NA,NA
"2142",249,"Ma","Retrospective cohort/Outbreak investigation",2196,2022-05-03,"Cansino Ad5-nCoV","Vectored","1","final",NA,"14+","close contacts","close contacts","included","~8 weeks","pneumonia","severe","severe","delta",67.9,1.7,89.9,"China","CHN","Asia","East Asia & Pacific",10310,2019,"China","Upper middle income",3,NA,NA,NA,NA,NA
"2143",249,"Ma","Retrospective cohort/Outbreak investigation",2197,2022-05-03,"Cansino Ad5-nCoV","Vectored","1","final",NA,"14+","close contacts","close contacts","included","~8 weeks","severe disease","severe","severe","delta",100,NA,NA,"China","CHN","Asia","East Asia & Pacific",10310,2019,"China","Upper middle income",3,NA,NA,NA,NA,NA
"2144",250,"Rennert","Propensity matched case control",2198,2023-01-10,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"14+","students 18-64 years","students 18-64 years","included","~23 weeks","infection","infection","infection","omicron",2.1,-21.2,21,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"2145",250,"Rennert","Propensity matched case control",2199,2023-01-10,"Moderna mRNA-1273","mRNA","2","final",NA,"14+","students 18-64 years","students 18-64 years","included","~23 weeks","infection","infection","infection","omicron",17.3,-10.8,38.3,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"2146",250,"Rennert","Propensity matched case control",2200,2023-01-10,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"14+","employees 18-65 years","employees 18-65 years","included","~23 weeks","infection","infection","infection","omicron",30.1,-24.5,60.8,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"2147",250,"Rennert","Propensity matched case control",2201,2023-01-10,"Moderna mRNA-1273","mRNA","2","final",NA,"14+","employees 18-65 years","employees 18-65 years","included","~23 weeks","infection","infection","infection","omicron",14.4,-64.2,55.4,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"2148",251,"Simwanza","Case-control",2202,2022-09-12,"Janssen Ad26.COV2.S","Vectored","1","final",NA,"14+",">= 18 years in a correctional facility","18+ years in a correctional facility","included","~13 weeks","infection","infection","infection","omicron",63.6,33.6,80.5,"Zambia","ZMB","Africa","Sub-Saharan Africa",1380,2019,"Zambia","Lower middle income",1,NA,NA,NA,NA,NA
"2149",251,"Simwanza","Case-control",2203,2022-09-12,"Janssen Ad26.COV2.S","Vectored","1","final",NA,"14+",">= 18 years in a correctional facility","18+ years in a correctional facility","included","~13 weeks","symptomatic disease","symptomatic","symptomatic","omicron",73,41.6,87.7,"Zambia","ZMB","Africa","Sub-Saharan Africa",1380,2019,"Zambia","Lower middle income",1,NA,NA,NA,NA,NA
"2150",251,"Simwanza","Case-control",2204,2022-09-12,"Oxford/AstraZeneca ChAdOx1-S","Vectored","2","final",NA,"14+",">= 18 years in a correctional facility","18+ years in a correctional facility","included","~13 weeks","infection","infection","infection","omicron",89.4,59.5,97.8,"Zambia","ZMB","Africa","Sub-Saharan Africa",1380,2019,"Zambia","Lower middle income",1,NA,NA,NA,NA,NA
"2151",251,"Simwanza","Case-control",2205,2022-09-12,"Oxford/AstraZeneca ChAdOx1-S","Vectored","2","final",NA,"14+",">= 18 years in a correctional facility","18+ years in a correctional facility","included","~13 weeks","symptomatic disease","symptomatic","symptomatic","omicron",85.1,19.5,98,"Zambia","ZMB","Africa","Sub-Saharan Africa",1380,2019,"Zambia","Lower middle income",1,NA,NA,NA,NA,NA
"2152",252,"Zahradka","Retrospective cohort",2206,2022-05-03,"Multiple or heterologous RNA","mRNA","2","final",NA,"14+","kidney transplant recipients","transplant recipients","excluded","~12.5 weeks","infection","infection","infection","alpha",45.6,12.4,67.6,"Czech Republic","CZE","Europe","Europe & Central Asia",22100,2019,"Czechia","High income",3,NA,NA,NA,NA,NA
"2153",253,"Martellucci","Retrospective cohort",2207,2022-04-22,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"14+",">= 18 years","general pop","excluded","~53 weeks","infection","infection","infection","other combinations",24,23,25,"Italy","ITA","Europe","Europe & Central Asia",34890,2019,"Italy","High income",4,NA,NA,NA,NA,NA
"2154",253,"Martellucci","Retrospective cohort",2208,2022-04-22,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"14+",">= 18 years","general pop","excluded","~53 weeks","hospitalization","severe","severe","other combinations",86,84,88,"Italy","ITA","Europe","Europe & Central Asia",34890,2019,"Italy","High income",4,NA,NA,NA,NA,NA
"2155",253,"Martellucci","Retrospective cohort",2209,2022-04-22,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"14+",">= 18 years","general pop","excluded","~53 weeks","death","death","death","other combinations",92,90,94,"Italy","ITA","Europe","Europe & Central Asia",34890,2019,"Italy","High income",4,NA,NA,NA,NA,NA
"2156",253,"Martellucci","Retrospective cohort",2210,2022-04-22,"Moderna mRNA-1273","mRNA","2","final",NA,"14+",">= 18 years","general pop","excluded","~53 weeks","infection","infection","infection","other combinations",32,31,34,"Italy","ITA","Europe","Europe & Central Asia",34890,2019,"Italy","High income",4,NA,NA,NA,NA,NA
"2157",253,"Martellucci","Retrospective cohort",2211,2022-04-22,"Moderna mRNA-1273","mRNA","2","final",NA,"14+",">= 18 years","general pop","excluded","~53 weeks","hospitalization","severe","severe","other combinations",90,86,93,"Italy","ITA","Europe","Europe & Central Asia",34890,2019,"Italy","High income",4,NA,NA,NA,NA,NA
"2158",253,"Martellucci","Retrospective cohort",2212,2022-04-22,"Moderna mRNA-1273","mRNA","2","final",NA,"14+",">= 18 years","general pop","excluded","~53 weeks","death","death","death","other combinations",96,92,98,"Italy","ITA","Europe","Europe & Central Asia",34890,2019,"Italy","High income",4,NA,NA,NA,NA,NA
"2159",253,"Martellucci","Retrospective cohort",2213,2022-04-22,"Oxford/AstraZeneca ChAdOx1-S","Vectored","2","final",NA,"14+",">= 18 years","general pop","excluded","~53 weeks","infection","infection","infection","other combinations",4,1,6,"Italy","ITA","Europe","Europe & Central Asia",34890,2019,"Italy","High income",4,NA,NA,NA,NA,NA
"2160",253,"Martellucci","Retrospective cohort",2214,2022-04-22,"Oxford/AstraZeneca ChAdOx1-S","Vectored","2","final",NA,"14+",">= 18 years","general pop","excluded","~53 weeks","hospitalization","severe","severe","other combinations",93,92,95,"Italy","ITA","Europe","Europe & Central Asia",34890,2019,"Italy","High income",4,NA,NA,NA,NA,NA
"2161",253,"Martellucci","Retrospective cohort",2215,2022-04-22,"Oxford/AstraZeneca ChAdOx1-S","Vectored","2","final",NA,"14+",">= 18 years","general pop","excluded","~53 weeks","death","death","death","other combinations",98,96,99,"Italy","ITA","Europe","Europe & Central Asia",34890,2019,"Italy","High income",4,NA,NA,NA,NA,NA
"2162",253,"Martellucci","Retrospective cohort",2216,2022-04-22,"Janssen Ad26.COV2.S","Vectored","1","final",NA,"14+",">= 18 years","general pop","excluded","~53 weeks","infection","infection","infection","other combinations",12,7,17,"Italy","ITA","Europe","Europe & Central Asia",34890,2019,"Italy","High income",4,NA,NA,NA,NA,NA
"2163",253,"Martellucci","Retrospective cohort",2217,2022-04-22,"Janssen Ad26.COV2.S","Vectored","1","final",NA,"14+",">= 18 years","general pop","excluded","~53 weeks","hospitalization","severe","severe","other combinations",87,73,94,"Italy","ITA","Europe","Europe & Central Asia",34890,2019,"Italy","High income",4,NA,NA,NA,NA,NA
"2164",254,"Braeye","Retrospective cohort",2218,2022-05-11,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"7-57","contacts of index cases among women aged 45-64","contacts of index cases among women aged 45-64","excluded","~28.5 weeks","infection","infection","infection","alpha",72,70,74,"Belgium","BEL","Europe","Europe & Central Asia",48050,2019,"Belgium","High income",4,NA,NA,NA,NA,NA
"2165",254,"Braeye","Retrospective cohort",2219,2022-05-11,"Moderna mRNA-1273","mRNA","2","final",NA,"14-64","contacts of index cases among women aged 45-64","contacts of index cases among women aged 45-64","excluded","~28.5 weeks","infection","infection","infection","alpha",82,79,84,"Belgium","BEL","Europe","Europe & Central Asia",48050,2019,"Belgium","High income",4,NA,NA,NA,NA,NA
"2166",254,"Braeye","Retrospective cohort",2220,2022-05-11,"Janssen Ad26.COV2.S","Vectored","1","final",NA,"21-71","contacts of index cases among women aged 45-64","contacts of index cases among women aged 45-64","excluded","~28.5 weeks","infection","infection","infection","alpha",38,34,44,"Belgium","BEL","Europe","Europe & Central Asia",48050,2019,"Belgium","High income",4,NA,NA,NA,NA,NA
"2167",254,"Braeye","Retrospective cohort",2221,2022-05-11,"Oxford/AstraZeneca ChAdOx1-S","Vectored","2","final",NA,"14-64","contacts of index cases among women aged 45-64","contacts of index cases among women aged 45-64","excluded","~28.5 weeks","infection","infection","infection","alpha",56,51,59,"Belgium","BEL","Europe","Europe & Central Asia",48050,2019,"Belgium","High income",4,NA,NA,NA,NA,NA
"2168",254,"Braeye","Retrospective cohort",2222,2022-05-11,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"7-57","contacts of index cases among women aged 45-64","contacts of index cases among women aged 45-64","excluded","~28.5 weeks","infection","infection","infection","delta",64,63,66,"Belgium","BEL","Europe","Europe & Central Asia",48050,2019,"Belgium","High income",4,NA,NA,NA,NA,NA
"2169",254,"Braeye","Retrospective cohort",2223,2022-05-11,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"157-207","contacts of index cases among women aged 45-64","contacts of index cases among women aged 45-64","excluded","~28.5 weeks","infection","infection","infection","delta",44,43,44,"Belgium","BEL","Europe","Europe & Central Asia",48050,2019,"Belgium","High income",4,NA,NA,NA,NA,NA
"2170",254,"Braeye","Retrospective cohort",2224,2022-05-11,"Moderna mRNA-1273","mRNA","2","final",NA,"14-64","contacts of index cases among women aged 45-64","contacts of index cases among women aged 45-64","excluded","~28.5 weeks","infection","infection","infection","delta",75,71,77,"Belgium","BEL","Europe","Europe & Central Asia",48050,2019,"Belgium","High income",4,NA,NA,NA,NA,NA
"2171",254,"Braeye","Retrospective cohort",2225,2022-05-11,"Moderna mRNA-1273","mRNA","2","final",NA,"164-214","contacts of index cases among women aged 45-64","contacts of index cases among women aged 45-64","excluded","~28.5 weeks","infection","infection","infection","delta",56,55,58,"Belgium","BEL","Europe","Europe & Central Asia",48050,2019,"Belgium","High income",4,NA,NA,NA,NA,NA
"2172",254,"Braeye","Retrospective cohort",2226,2022-05-11,"Janssen Ad26.COV2.S","Vectored","1","final",NA,"21-71","contacts of index cases among women aged 45-64","contacts of index cases among women aged 45-64","excluded","~28.5 weeks","infection","infection","infection","delta",33,28,38,"Belgium","BEL","Europe","Europe & Central Asia",48050,2019,"Belgium","High income",4,NA,NA,NA,NA,NA
"2173",254,"Braeye","Retrospective cohort",2227,2022-05-11,"Janssen Ad26.COV2.S","Vectored","1","final",NA,"171-221","contacts of index cases among women aged 45-64","contacts of index cases among women aged 45-64","excluded","~28.5 weeks","infection","infection","infection","delta",22,19,25,"Belgium","BEL","Europe","Europe & Central Asia",48050,2019,"Belgium","High income",4,NA,NA,NA,NA,NA
"2174",254,"Braeye","Retrospective cohort",2228,2022-05-11,"Oxford/AstraZeneca ChAdOx1-S","Vectored","2","final",NA,"14-64","contacts of index cases among women aged 45-64","contacts of index cases among women aged 45-64","excluded","~28.5 weeks","infection","infection","infection","delta",49,45,52,"Belgium","BEL","Europe","Europe & Central Asia",48050,2019,"Belgium","High income",4,NA,NA,NA,NA,NA
"2175",254,"Braeye","Retrospective cohort",2229,2022-05-11,"Oxford/AstraZeneca ChAdOx1-S","Vectored","2","final",NA,"164-214","contacts of index cases among women aged 45-64","contacts of index cases among women aged 45-64","excluded","~28.5 weeks","infection","infection","infection","delta",35,33,37,"Belgium","BEL","Europe","Europe & Central Asia",48050,2019,"Belgium","High income",4,NA,NA,NA,NA,NA
"2176",254,"Braeye","Retrospective cohort",2230,2022-05-11,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"7-57","contacts of index cases among women aged 45-64","contacts of index cases among women aged 45-64","previously infected only","~28.5 weeks","infection","infection","infection","delta",87,84,88,"Belgium","BEL","Europe","Europe & Central Asia",48050,2019,"Belgium","High income",4,NA,NA,NA,NA,NA
"2177",254,"Braeye","Retrospective cohort",2231,2022-05-11,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"157-207","contacts of index cases among women aged 45-64","contacts of index cases among women aged 45-64","previously infected only","~28.5 weeks","infection","infection","infection","delta",82,81,83,"Belgium","BEL","Europe","Europe & Central Asia",48050,2019,"Belgium","High income",4,NA,NA,NA,NA,NA
"2178",254,"Braeye","Retrospective cohort",2232,2022-05-11,"Moderna mRNA-1273","mRNA","2","final",NA,"14-64","contacts of index cases among women aged 45-64","contacts of index cases among women aged 45-64","previously infected only","~28.5 weeks","infection","infection","infection","delta",87,83,92,"Belgium","BEL","Europe","Europe & Central Asia",48050,2019,"Belgium","High income",4,NA,NA,NA,NA,NA
"2179",254,"Braeye","Retrospective cohort",2233,2022-05-11,"Moderna mRNA-1273","mRNA","2","final",NA,"164-214","contacts of index cases among women aged 45-64","contacts of index cases among women aged 45-64","previously infected only","~28.5 weeks","infection","infection","infection","delta",85,80,89,"Belgium","BEL","Europe","Europe & Central Asia",48050,2019,"Belgium","High income",4,NA,NA,NA,NA,NA
"2180",254,"Braeye","Retrospective cohort",2234,2022-05-11,"Janssen Ad26.COV2.S","Vectored","1","final",NA,"21-71","contacts of index cases among women aged 45-64","contacts of index cases among women aged 45-64","previously infected only","~28.5 weeks","infection","infection","infection","delta",88,85,91,"Belgium","BEL","Europe","Europe & Central Asia",48050,2019,"Belgium","High income",4,NA,NA,NA,NA,NA
"2181",254,"Braeye","Retrospective cohort",2235,2022-05-11,"Janssen Ad26.COV2.S","Vectored","1","final",NA,"171-221","contacts of index cases among women aged 45-64","contacts of index cases among women aged 45-64","previously infected only","~28.5 weeks","infection","infection","infection","delta",87,84,89,"Belgium","BEL","Europe","Europe & Central Asia",48050,2019,"Belgium","High income",4,NA,NA,NA,NA,NA
"2182",254,"Braeye","Retrospective cohort",2236,2022-05-11,"Oxford/AstraZeneca ChAdOx1-S","Vectored","2","final",NA,"14-64","contacts of index cases among women aged 45-64","contacts of index cases among women aged 45-64","previously infected only","~28.5 weeks","infection","infection","infection","delta",88,84,94,"Belgium","BEL","Europe","Europe & Central Asia",48050,2019,"Belgium","High income",4,NA,NA,NA,NA,NA
"2183",254,"Braeye","Retrospective cohort",2237,2022-05-11,"Oxford/AstraZeneca ChAdOx1-S","Vectored","2","final",NA,"164-214","contacts of index cases among women aged 45-64","contacts of index cases among women aged 45-64","previously infected only","~28.5 weeks","infection","infection","infection","delta",83,81,85,"Belgium","BEL","Europe","Europe & Central Asia",48050,2019,"Belgium","High income",4,NA,NA,NA,NA,NA
"2184",255,"Lan","Retrospective cohort",2238,2022-05-12,"Multiple or heterologous RNA","mRNA","2","final",NA,"14+","HCW","HCW","excluded","~36 weeks","infection","infection","infection","other combinations",82.3,75.1,87.4,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"2185",255,"Lan","Retrospective cohort",2239,2022-05-12,"Multiple or heterologous RNA","mRNA","2","final",NA,"14+","HCW","HCW","excluded","~36 weeks","infection","infection","infection","other combinations",76.5,40.9,90.6,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"2186",256,"Tenforde","Case-control",2240,2022-05-17,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"14-179","hospitalized adults","hospitalized adults","included","~23.5 weeks","hospitalization","severe","severe","other combinations",88,86,90,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"2187",256,"Tenforde","Case-control",2241,2022-05-17,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"180+","hospitalized adults","hospitalized adults","included","~47 weeks","hospitalization","severe","severe","other combinations",79,74,83,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"2188",256,"Tenforde","Case-control",2242,2022-05-17,"Moderna mRNA-1273","mRNA","2","final",NA,"14-179","hospitalized adults","hospitalized adults","included","~23.5 weeks","hospitalization","severe","severe","other combinations",93,91,94,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"2189",256,"Tenforde","Case-control",2243,2022-05-17,"Moderna mRNA-1273","mRNA","2","final",NA,"180+","hospitalized adults","hospitalized adults","included","~47 weeks","hospitalization","severe","severe","other combinations",87,83,90,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"2190",256,"Tenforde","Case-control",2244,2022-05-17,"Multiple or heterologous RNA","mRNA","2","final",NA,"14-179","immunocompetent adults","immunocompetent adults","included","~23.5 weeks","hospitalization","severe","severe","other combinations",90,88,91,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"2191",256,"Tenforde","Case-control",2245,2022-05-17,"Multiple or heterologous RNA","mRNA","2","final",NA,"180+","immunocompetent adults","immunocompetent adults","included","~47 weeks","hospitalization","severe","severe","other combinations",82,79,85,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"2192",256,"Tenforde","Case-control",2246,2022-05-17,"Multiple or heterologous RNA","mRNA","2","final",NA,"14+","hospitalized immunocompromised adults","immunocompromised adults","included","~47 weeks","hospitalization","severe","severe","other combinations",63,55,69,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"2193",256,"Tenforde","Case-control",2247,2022-05-17,"Multiple or heterologous RNA","mRNA","2","final",NA,"14-179","hospitalized immunocompromised adults","immunocompromised adults","included","~23.5 weeks","hospitalization","severe","severe","other combinations",65,57,72,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"2194",256,"Tenforde","Case-control",2248,2022-05-17,"Multiple or heterologous RNA","mRNA","2","final",NA,"180+","hospitalized immunocompromised adults","immunocompromised adults","included","~47 weeks","hospitalization","severe","severe","other combinations",53,38,65,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"2195",256,"Tenforde","Case-control",2249,2022-05-17,"Multiple or heterologous RNA","mRNA","2","final",NA,"14-179","hospitalized adults","hospitalized adults","included","~23.5 weeks","hospitalization","severe","severe","delta",90,88,91,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"2196",256,"Tenforde","Case-control",2250,2022-05-17,"Multiple or heterologous RNA","mRNA","2","final",NA,"180+","hospitalized adults","hospitalized adults","included","~47 weeks","hospitalization","severe","severe","delta",83,80,86,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"2197",257,"Fano","Retrospective cohort",2251,2022-05-18,"Multiple or heterologous RNA","mRNA","2","final",NA,"40-44",">= 12 years","general pop","excluded","~48 weeks","infection","infection","infection","other combinations",70.9,69.3,72.4,"Italy","ITA","Europe","Europe & Central Asia",34890,2019,"Italy","High income",4,NA,NA,NA,NA,NA
"2198",257,"Fano","Retrospective cohort",2252,2022-05-18,"Multiple or heterologous RNA","mRNA","2","final",NA,"200+",">= 12 years","general pop","excluded","~48 weeks","infection","infection","infection","other combinations",22.7,18.5,26.8,"Italy","ITA","Europe","Europe & Central Asia",34890,2019,"Italy","High income",4,NA,NA,NA,NA,NA
"2199",257,"Fano","Retrospective cohort",2253,2022-05-18,"Oxford/AstraZeneca ChAdOx1-S","Vectored","2","final",NA,"40-44",">= 12 years","general pop","excluded","~48 weeks","infection","infection","infection","other combinations",76.3,71.9,80,"Italy","ITA","Europe","Europe & Central Asia",34890,2019,"Italy","High income",4,NA,NA,NA,NA,NA
"2200",257,"Fano","Retrospective cohort",2254,2022-05-18,"Oxford/AstraZeneca ChAdOx1-S","Vectored","2","final",NA,"125+",">= 12 years","general pop","excluded","~48 weeks","infection","infection","infection","other combinations",3.8,0,9.2,"Italy","ITA","Europe","Europe & Central Asia",34890,2019,"Italy","High income",4,NA,NA,NA,NA,NA
"2201",257,"Fano","Retrospective cohort",2255,2022-05-18,"Janssen Ad26.COV2.S","Vectored","1","final",NA,"40-44",">= 12 years","general pop","excluded","~48 weeks","infection","infection","infection","other combinations",39.4,28.3,48.8,"Italy","ITA","Europe","Europe & Central Asia",34890,2019,"Italy","High income",4,NA,NA,NA,NA,NA
"2202",257,"Fano","Retrospective cohort",2256,2022-05-18,"Janssen Ad26.COV2.S","Vectored","1","final",NA,"150+",">= 12 years","general pop","excluded","~48 weeks","infection","infection","infection","other combinations",2.5,0,9.1,"Italy","ITA","Europe","Europe & Central Asia",34890,2019,"Italy","High income",4,NA,NA,NA,NA,NA
"2203",257,"Fano","Retrospective cohort",2257,2022-05-18,"Heterologous platforms","Multiple","2","final",NA,"40-44",">= 12 years","general pop","excluded","~48 weeks","infection","infection","infection","other combinations",81.6,75.3,86.3,"Italy","ITA","Europe","Europe & Central Asia",34890,2019,"Italy","High income",4,NA,NA,NA,NA,NA
"2204",257,"Fano","Retrospective cohort",2258,2022-05-18,"Heterologous platforms","Multiple","2","final",NA,"125+",">= 12 years","general pop","excluded","~48 weeks","infection","infection","infection","other combinations",3.1,0,12,"Italy","ITA","Europe","Europe & Central Asia",34890,2019,"Italy","High income",4,NA,NA,NA,NA,NA
"2205",258,"Paranthaman","Retrospective cohort",2259,2022-05-20,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"7-34","LTCF residents","LTCF residents","excluded","~3 weeks","infection","infection","infection","other combinations",62,46,73,"UK","GBR","Europe","Europe & Central Asia",43240,2019,"United Kingdom","High income",4,NA,NA,NA,NA,NA
"2206",258,"Paranthaman","Retrospective cohort",2260,2022-05-20,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"147+","LTCF residents","LTCF residents","excluded","~37 weeks","infection","infection","infection","other combinations",47,32,58,"UK","GBR","Europe","Europe & Central Asia",43240,2019,"United Kingdom","High income",4,NA,NA,NA,NA,NA
"2207",258,"Paranthaman","Retrospective cohort",2261,2022-05-20,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"7-34","LTCF residents","LTCF residents","excluded","~3 weeks","death","death","death","other combinations",86,67,94,"UK","GBR","Europe","Europe & Central Asia",43240,2019,"United Kingdom","High income",4,NA,NA,NA,NA,NA
"2208",258,"Paranthaman","Retrospective cohort",2262,2022-05-20,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"147+","LTCF residents","LTCF residents","excluded","~37 weeks","death","death","death","other combinations",69,51,80,"UK","GBR","Europe","Europe & Central Asia",43240,2019,"United Kingdom","High income",4,NA,NA,NA,NA,NA
"2209",258,"Paranthaman","Retrospective cohort",2263,2022-05-20,"Oxford/AstraZeneca ChAdOx1-S","Vectored","2","final",NA,"7-34","LTCF residents","LTCF residents","excluded","~3 weeks","infection","infection","infection","other combinations",61,40,74,"UK","GBR","Europe","Europe & Central Asia",43240,2019,"United Kingdom","High income",4,NA,NA,NA,NA,NA
"2210",258,"Paranthaman","Retrospective cohort",2264,2022-05-20,"Oxford/AstraZeneca ChAdOx1-S","Vectored","2","final",NA,"147+","LTCF residents","LTCF residents","excluded","~24.5 weeks","infection","infection","infection","other combinations",29,10,43,"UK","GBR","Europe","Europe & Central Asia",43240,2019,"United Kingdom","High income",4,NA,NA,NA,NA,NA
"2211",258,"Paranthaman","Retrospective cohort",2265,2022-05-20,"Oxford/AstraZeneca ChAdOx1-S","Vectored","2","final",NA,"7-34","LTCF residents","LTCF residents","excluded","~3 weeks","death","death","death","other combinations",83,58,94,"UK","GBR","Europe","Europe & Central Asia",43240,2019,"United Kingdom","High income",4,NA,NA,NA,NA,NA
"2212",258,"Paranthaman","Retrospective cohort",2266,2022-05-20,"Oxford/AstraZeneca ChAdOx1-S","Vectored","2","final",NA,"147+","LTCF residents","LTCF residents","excluded","~24.5 weeks","death","death","death","other combinations",56,33,70,"UK","GBR","Europe","Europe & Central Asia",43240,2019,"United Kingdom","High income",4,NA,NA,NA,NA,NA
"2213",258,"Paranthaman","Retrospective cohort",2267,2022-05-20,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"7-34","LTCF residents","LTCF residents","previously infected only","~3 weeks","infection","infection","infection","other combinations",79,15,95,"UK","GBR","Europe","Europe & Central Asia",43240,2019,"United Kingdom","High income",4,NA,NA,NA,NA,NA
"2214",258,"Paranthaman","Retrospective cohort",2268,2022-05-20,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"147+","LTCF residents","LTCF residents","previously infected only","~37 weeks","infection","infection","infection","other combinations",80,43,93,"UK","GBR","Europe","Europe & Central Asia",43240,2019,"United Kingdom","High income",4,NA,NA,NA,NA,NA
"2215",258,"Paranthaman","Retrospective cohort",2269,2022-05-20,"Oxford/AstraZeneca ChAdOx1-S","Vectored","2","final",NA,"7-34","LTCF residents","LTCF residents","previously infected only","~3 weeks","infection","infection","infection","other combinations",37,-50,73,"UK","GBR","Europe","Europe & Central Asia",43240,2019,"United Kingdom","High income",4,NA,NA,NA,NA,NA
"2216",258,"Paranthaman","Retrospective cohort",2270,2022-05-20,"Oxford/AstraZeneca ChAdOx1-S","Vectored","2","final",NA,"147+","LTCF residents","LTCF residents","previously infected only","~24.5 weeks","infection","infection","infection","other combinations",65,14,86,"UK","GBR","Europe","Europe & Central Asia",43240,2019,"United Kingdom","High income",4,NA,NA,NA,NA,NA
"2217",259,"Tsundue","Prospective cohort",2271,2022-05-24,"Oxford/AstraZeneca ChAdOx1-S","Vectored","2","final",NA,"14+","residents of congregate living facilities","general pop","included","13 weeks","infection","infection","infection","delta",98,85,99.8,"India","IND","Asia","South Asia",2070,2019,"India","Lower middle income",1,NA,NA,NA,NA,NA
"2218",259,"Tsundue","Prospective cohort",2272,2022-05-24,"Oxford/AstraZeneca ChAdOx1-S","Vectored","2","final",NA,"14+","residents of congregate living facilities","general pop","included","13 weeks","shortness of breath/use of supplemental oxygen, hospitalization or death","severe","severe","delta",99,90,99.8,"India","IND","Asia","South Asia",2070,2019,"India","Lower middle income",1,14,91,"yes",NA,0
"2219",260,"Amir","Retrospective cohort",2273,2022-09-09,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"14-35","5-10 years","5-10 years","included","~2 weeks","infection","infection","infection","omicron",58.3,54.6,61.5,"Israel","ISR","Asia","Middle East & North Africa",43800,2019,"Israel","High income",4,NA,NA,NA,NA,NA
"2220",261,"Chin","Retrospective cohort",2274,2022-10-26,"Multiple or heterologous RNA","mRNA","2","final",NA,"14+","prison residents >= 18 years","prison residents","excluded","~65 weeks","infection","infection","infection","omicron",18.6,7.7,28.1,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"2221",261,"Chin","Retrospective cohort",2275,2022-10-26,"Multiple or heterologous RNA","mRNA","2","final",NA,"14+","prison staff >= 18 years","prison staff","excluded","~65 weeks","infection","infection","infection","omicron",40.1,34,45.6,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"2222",261,"Chin","Retrospective cohort",2276,2022-10-26,"Multiple or heterologous RNA","mRNA","2","final",NA,"14+","prison residents >= 18 years","prison residents","previously infected before July 1, 2021","~65 weeks","infection","infection","infection","omicron",51.2,41.5,59.2,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"2223",261,"Chin","Retrospective cohort",2277,2022-10-26,"Multiple or heterologous RNA","mRNA","2","final",NA,"14+","prison staff >= 18 years","prison staff","previously infected before July 1, 2021","~65 weeks","infection","infection","infection","omicron",55.8,49.6,61.2,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"2224",261,"Chin","Retrospective cohort",2278,2022-10-26,"Multiple or heterologous RNA","mRNA","2","final",NA,"14+","prison residents >= 18 years","prison residents","previously infected between July 1 and November 30, 2021","~65 weeks","infection","infection","infection","omicron",68.7,38.5,84.1,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"2225",261,"Chin","Retrospective cohort",2279,2022-10-26,"Multiple or heterologous RNA","mRNA","2","final",NA,"14+","prison staff >= 18 years","prison staff","previously infected between July 1 and November 30, 2021","~65 weeks","infection","infection","infection","omicron",83.2,77.7,87.4,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"2226",261,"Chin","Retrospective test-negative case control",2280,2022-10-26,"Multiple or heterologous RNA","mRNA","2","final",NA,"14+","prison residents and staff >= 18 years","prison residents and staff","excluded","~65 weeks","infection","infection","infection","omicron",14.9,12.3,19.7,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"2227",261,"Chin","Retrospective test-negative case control",2281,2022-10-26,"Multiple or heterologous RNA","mRNA","2","final",NA,"14+","prison residents and staff >= 18 years","prison residents and staff","previously infected before July 1, 2021","~65 weeks","infection","infection","infection","omicron",47.8,46.6,52.8,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"2228",261,"Chin","Retrospective test-negative case control",2282,2022-10-26,"Multiple or heterologous RNA","mRNA","2","final",NA,"14+","prison residents and staff >= 18 years","prison residents and staff","previously infected between July 1 and November 30, 2021","~65 weeks","infection","infection","infection","omicron",73.1,69.8,80.1,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"2229",262,"Carlsen","Retrospective cohort",2283,2022-06-01,"Multiple or heterologous RNA","mRNA","2","final",NA,"14+","newborns","newborns","excluded","~45 weeks","infection during an infant's first 4 months of life (born to unvaccinated mothers and mothers vaccinated in 2nd or 3rd trimester)","infection during an infant's first 4 months of life","infection","omicron",30,17,41,"Norway","NOR","Europe","Europe & Central Asia",82430,2019,"Norway","High income",4,NA,NA,NA,NA,NA
"2230",262,"Carlsen","Retrospective cohort",2284,2022-06-01,"Multiple or heterologous RNA","mRNA","2","final",NA,"14+","newborns","newborns","excluded","~45 weeks","infection during an infant's first 4 months of life (born to unvaccinated mothers and mothers vaccinated in 2nd or 3rd trimester)","infection during an infant's first 4 months of life","infection","delta",71,56,81,"Norway","NOR","Europe","Europe & Central Asia",82430,2019,"Norway","High income",4,NA,NA,NA,NA,NA
"2231",263,"Grewal","Test-negative case-control",2285,2022-07-06,"Multiple or heterologous RNA","mRNA","2","final",NA,"0+","LTCF residents","LTCF residents","included","~66 weeks","infection","infection","infection","omicron",6,-5,15,"Canada","CAN","North America","North America",46580,2019,"Canada","High income",4,NA,NA,NA,NA,NA
"2232",263,"Grewal","Test-negative case-control",2286,2022-07-06,"Multiple or heterologous RNA","mRNA","2","final",NA,"0+","LTCF residents","LTCF residents","included","~66 weeks","symptomatic disease","symptomatic","symptomatic","omicron",23,1,40,"Canada","CAN","North America","North America",46580,2019,"Canada","High income",4,NA,NA,NA,NA,NA
"2233",263,"Grewal","Test-negative case-control",2287,2022-07-06,"Multiple or heterologous RNA","mRNA","2","final",NA,"0+","LTCF residents","LTCF residents","included","~66 weeks","hospitalization or death","severe","severe","omicron",52,33,65,"Canada","CAN","North America","North America",46580,2019,"Canada","High income",4,NA,NA,NA,NA,NA
"2234",264,"Spicer","Test-negative case-control",2288,2022-05-26,"Multiple or heterologous RNA","mRNA","2","final",NA,"14+","12-17 years","12-17 years","excluded","~36.5 weeks","infection","infection","infection","delta",81,79.7,82.3,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"2235",264,"Spicer","Test-negative case-control",2289,2022-05-26,"Multiple or heterologous RNA","mRNA","2","final",NA,"14+","12-17 years","12-17 years","previously infected only","~36.5 weeks","infection","infection","infection","delta",78.3,66.7,86.5,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"2236",265,"Richterman","Test-negative case-control",2290,2022-06-06,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"14+","HCW","HCW","excluded","~63 weeks","symptomatic disease","symptomatic","symptomatic","omicron",41,-17,87,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"2237",265,"Richterman","Test-negative case-control",2291,2022-06-06,"Moderna mRNA-1273","mRNA","2","final",NA,"14+","HCW","HCW","excluded","~63 weeks","symptomatic disease","symptomatic","symptomatic","omicron",5,-69,47,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"2238",265,"Richterman","Test-negative case-control",2292,2022-06-06,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"14+","HCW","HCW","excluded","~63 weeks","symptomatic disease","symptomatic","symptomatic","delta",75,52,87,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"2239",265,"Richterman","Test-negative case-control",2293,2022-06-06,"Moderna mRNA-1273","mRNA","2","final",NA,"14+","HCW","HCW","excluded","~63 weeks","symptomatic disease","symptomatic","symptomatic","delta",73,56,84,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"2240",266,"Lin","RCT crossover",2294,2022-06-08,"Moderna mRNA-1273","mRNA","2","final",NA,"12 days",">= 18 years","general pop","excluded","~0 weeks","symptomatic disease","symptomatic","symptomatic","other combinations",92.6,80.5,97.2,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"2241",266,"Lin","RCT crossover",2295,2022-06-08,"Moderna mRNA-1273","mRNA","2","final",NA,"172 days",">= 18 years","general pop","excluded","~22.5 weeks","symptomatic disease","symptomatic","symptomatic","other combinations",89.6,41.7,98.2,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"2242",267,"Lewis","Test-negative case-control",2296,2022-06-08,"Janssen Ad26.COV2.S","Vectored","1","final",NA,"14+","hospitalized adults","general pop","included","~39.5 weeks","hospitalization","severe","severe","other combinations",70,63,75,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"2243",267,"Lewis","Test-negative case-control",2297,2022-06-08,"Janssen Ad26.COV2.S","Vectored","1","final",NA,"14-90","hospitalized adults","general pop","included","~39.5 weeks","hospitalization","severe","severe","other combinations",73,60,82,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"2244",267,"Lewis","Test-negative case-control",2298,2022-06-08,"Janssen Ad26.COV2.S","Vectored","1","final",NA,"180+","hospitalized adults","general pop","included","~39.5 weeks","hospitalization","severe","severe","other combinations",70,54,81,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"2245",267,"Lewis","Test-negative case-control",2299,2022-06-08,"Janssen Ad26.COV2.S","Vectored","1","final",NA,"14+","hospitalized immunocompromised adults","immunocompromised adults","included","~39.5 weeks","hospitalization","severe","severe","other combinations",55,31,72,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"2246",267,"Lewis","Test-negative case-control",2300,2022-06-08,"Janssen Ad26.COV2.S","Vectored","1","final",NA,"14+","hospitalized adults","general pop","included","~39.5 weeks","hospitalization","severe","severe","alpha",68,43,83,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"2247",267,"Lewis","Test-negative case-control",2301,2022-06-08,"Janssen Ad26.COV2.S","Vectored","1","final",NA,"14+","hospitalized adults","general pop","included","~39.5 weeks","hospitalization","severe","severe","delta",72,64,78,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"2248",270,"Al Kaabi","Retrospective cohort",2306,2022-06-09,"Beijing/Sinopharm BBIBP-CorV","Inactivated","2","final",NA,"14+",">= 18 years","general pop","excluded","~39 weeks","hospitalization","severe","severe","original",97.3,95.7,98.3,"United Arab Emirates","ARE","Asia","Middle East & North Africa",45070,2019,"United Arab Emirates","High income",4,NA,NA,NA,NA,NA
"2249",270,"Al Kaabi","Retrospective cohort",2307,2022-06-09,"Beijing/Sinopharm BBIBP-CorV","Inactivated","2","final",NA,"14+",">= 18 years","general pop","excluded","~39 weeks","critical care admission","severe","severe","original",98.8,95.3,99.7,"United Arab Emirates","ARE","Asia","Middle East & North Africa",45070,2019,"United Arab Emirates","High income",4,NA,NA,NA,NA,NA
"2250",270,"Al Kaabi","Retrospective cohort",2308,2022-06-09,"Beijing/Sinopharm BBIBP-CorV","Inactivated","2","final",NA,"14+",">= 18 years","general pop","excluded","~39 weeks","death","death","death","original",100,100,100,"United Arab Emirates","ARE","Asia","Middle East & North Africa",45070,2019,"United Arab Emirates","High income",4,NA,NA,NA,NA,NA
"2251",270,"Al Kaabi","Retrospective cohort",2309,2022-06-09,"Beijing/Sinopharm BBIBP-CorV","Inactivated","2","final",NA,"14+",">= 18 years","general pop","excluded","~39 weeks","hospitalization","severe","severe","alpha",73.3,70.6,75.7,"United Arab Emirates","ARE","Asia","Middle East & North Africa",45070,2019,"United Arab Emirates","High income",4,NA,NA,NA,NA,NA
"2252",270,"Al Kaabi","Retrospective cohort",2310,2022-06-09,"Beijing/Sinopharm BBIBP-CorV","Inactivated","2","final",NA,"14+",">= 18 years","general pop","excluded","~39 weeks","critical care admission","severe","severe","alpha",79.1,73.1,83.7,"United Arab Emirates","ARE","Asia","Middle East & North Africa",45070,2019,"United Arab Emirates","High income",4,NA,NA,NA,NA,NA
"2253",270,"Al Kaabi","Retrospective cohort",2311,2022-06-09,"Beijing/Sinopharm BBIBP-CorV","Inactivated","2","final",NA,"14+",">= 18 years","general pop","excluded","~39 weeks","death","death","death","alpha",81.9,66.9,90.1,"United Arab Emirates","ARE","Asia","Middle East & North Africa",45070,2019,"United Arab Emirates","High income",4,NA,NA,NA,NA,NA
"2254",270,"Al Kaabi","Retrospective cohort",2312,2022-06-09,"Beijing/Sinopharm BBIBP-CorV","Inactivated","2","final",NA,"14+",">= 18 years","general pop","excluded","~39 weeks","hospitalization","severe","severe","delta",34.6,14.2,50.2,"United Arab Emirates","ARE","Asia","Middle East & North Africa",45070,2019,"United Arab Emirates","High income",4,NA,NA,NA,NA,NA
"2255",270,"Al Kaabi","Retrospective cohort",2313,2022-06-09,"Beijing/Sinopharm BBIBP-CorV","Inactivated","2","final",NA,"14+",">= 18 years","general pop","excluded","~39 weeks","critical care admission","severe","severe","delta",49.6,0,76.4,"United Arab Emirates","ARE","Asia","Middle East & North Africa",45070,2019,"United Arab Emirates","High income",4,NA,NA,NA,NA,NA
"2256",270,"Al Kaabi","Retrospective cohort",2314,2022-06-09,"Beijing/Sinopharm BBIBP-CorV","Inactivated","2","final",NA,"14+",">= 18 years","general pop","excluded","~39 weeks","death","death","death","delta",62.5,31.4,79.5,"United Arab Emirates","ARE","Asia","Middle East & North Africa",45070,2019,"United Arab Emirates","High income",4,NA,NA,NA,NA,NA
"2257",271,"Gray","Test-negative case-control",2315,2022-06-09,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"14-27","HCW","HCW","excluded","~30 weeks","hospitalization","severe","severe","omicron",88,62,96,"South Africa","ZAF","Africa","Sub-Saharan Africa",6570,2019,"South Africa","Upper middle income",3,NA,NA,NA,NA,NA
"2258",271,"Gray","Test-negative case-control",2316,2022-06-09,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"148-207","HCW","HCW","excluded","~30 weeks","hospitalization","severe","severe","omicron",67,63,71,"South Africa","ZAF","Africa","Sub-Saharan Africa",6570,2019,"South Africa","Upper middle income",3,NA,NA,NA,NA,NA
"2259",271,"Gray","Test-negative case-control",2317,2022-06-09,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"14-27","HCW","HCW","excluded","~30 weeks","ICU admission","severe","severe","omicron",69,56,79,"South Africa","ZAF","Africa","Sub-Saharan Africa",6570,2019,"South Africa","Upper middle income",3,NA,NA,NA,NA,NA
"2260",271,"Gray","Test-negative case-control",2318,2022-06-09,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"148-207","HCW","HCW","excluded","~30 weeks","ICU admission","severe","severe","omicron",71,65,76,"South Africa","ZAF","Africa","Sub-Saharan Africa",6570,2019,"South Africa","Upper middle income",3,NA,NA,NA,NA,NA
"2261",272,"Adams","Prospective test-negative case control",2319,2022-10-11,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"14+",">= 18 years","general pop","included","~72 weeks","hospitalization","severe","severe","omicron",36,21,48,"USA","USA","North America","North America",66220,2019,"United States","High income",4,14,504,"yes",NA,0
"2262",272,"Adams","Prospective test-negative case control",2320,2022-10-11,"Moderna mRNA-1273","mRNA","2","final",NA,"14+",">= 18 years","general pop","included","~72 weeks","hospitalization","severe","severe","omicron",41,25,54,"USA","USA","North America","North America",66220,2019,"United States","High income",4,14,504,"yes",NA,0
"2263",272,"Adams","Prospective test-negative case control",2321,2022-10-11,"Janssen Ad26.COV2.S","Vectored","2","final",NA,"14+",">= 18 years","general pop","included","~72 weeks","hospitalization","severe","severe","omicron",32,9,62,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"2264",273,"Magro","Matched case-control",2322,2022-06-22,"Multiple or heterologous RNA","mRNA","2","final",NA,"14+","SNF personnel 18+ years","SNF employees","included","~10 weeks","infection","infection","infection","other combinations",1,55.9,81.8,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"2265",273,"Magro","Matched case-control",2323,2022-06-22,"Multiple or heterologous RNA","mRNA","2","final",NA,"14+","SNF personnel 18+ years","SNF employees","excluded","~10 weeks","infection","infection","infection","other combinations",32,1,54,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"2266",274,"Moline","Outbreak investigation",2324,2022-06-27,"Multiple or heterologous RNA","mRNA","2","final",NA,"14+","SNF residents","SNF residents","excluded","~12 weeks","infection","infection","infection","beta",65,25,84,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"2267",275,"Carazo","Test-negative case-control",2325,2022-09-21,"Multiple or heterologous RNA","mRNA","2","final",NA,"14+","HCW","HCW","excluded","~70 weeks","infection","infection","infection","omicron",35,27,42,"Canada","CAN","North America","North America",46580,2019,"Canada","High income",4,NA,NA,NA,NA,NA
"2268",275,"Carazo","Test-negative case-control",2326,2022-09-21,"Multiple or heterologous RNA","mRNA","2","final",NA,"14+","HCW","HCW","excluded","~70 weeks","symptomatic disease","symptomatic","symptomatic","omicron",61,52,69,"Canada","CAN","North America","North America",46580,2019,"Canada","High income",4,NA,NA,NA,NA,NA
"2269",276,"Cohen-Stavi","Taget trial emulation study",2327,2022-06-29,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"7-21","5-11 years","5-11 years","excluded","1 week","infection","infection","infection","omicron",51,39,61,"Israel","ISR","Asia","Middle East & North Africa",43800,2019,"Israel","High income",4,NA,NA,NA,NA,NA
"2270",276,"Cohen-Stavi","Taget trial emulation study",2328,2022-06-29,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"7-21","5-11 years","5-11 years","excluded","1 week","symptomatic disease","symptomatic","symptomatic","omicron",48,29,63,"Israel","ISR","Asia","Middle East & North Africa",43800,2019,"Israel","High income",4,NA,NA,NA,NA,NA
"2271",277,"Ionescu","Test-negative case-control",2329,2023-01-16,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"14+","12-17 years","12-17 years","excluded","~26 weeks","infection","infection","infection","omicron",41.9,37.7,45.8,"Canada","CAN","North America","North America",46580,2019,"Canada","High income",4,NA,NA,NA,NA,NA
"2272",277,"Ionescu","Test-negative case-control",2330,2023-01-16,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"14-27","12-17 years","12-17 years","excluded","2 weeks","infection","infection","infection","omicron",75.6,65.8,82.6,"Canada","CAN","North America","North America",46580,2019,"Canada","High income",4,NA,NA,NA,NA,NA
"2273",277,"Ionescu","Test-negative case-control",2331,2023-01-16,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"168-195","12-17 years","12-17 years","excluded","~26 weeks","infection","infection","infection","omicron",33.9,27.4,39.9,"Canada","CAN","North America","North America",46580,2019,"Canada","High income",4,NA,NA,NA,NA,NA
"2274",277,"Ionescu","Test-negative case-control",2332,2023-01-16,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"14+","12-17 years","12-17 years","excluded","~26 weeks","symptomatic disease","symptomatic","symptomatic","omicron",55.2,49.5,60.3,"Canada","CAN","North America","North America",46580,2019,"Canada","High income",4,NA,NA,NA,NA,NA
"2275",277,"Ionescu","Test-negative case-control",2333,2023-01-16,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"14+","12-17 years","12-17 years","excluded","~22 weeks","infection","infection","infection","delta/omicron",82.8,81,94.4,"Canada","CAN","North America","North America",46580,2019,"Canada","High income",4,NA,NA,NA,NA,NA
"2276",277,"Ionescu","Test-negative case-control",2334,2023-01-16,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"14-27","12-17 years","12-17 years","excluded","2 weeks","infection","infection","infection","delta/omicron",83.1,68.9,90.8,"Canada","CAN","North America","North America",46580,2019,"Canada","High income",4,NA,NA,NA,NA,NA
"2277",277,"Ionescu","Test-negative case-control",2335,2023-01-16,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"140-167","12-17 years","12-17 years","excluded","~22 weeks","infection","infection","infection","delta/omicron",75.4,72.1,78.4,"Canada","CAN","North America","North America",46580,2019,"Canada","High income",4,NA,NA,NA,NA,NA
"2278",277,"Ionescu","Test-negative case-control",2336,2023-01-16,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"14+","12-17 years","12-17 years","excluded","~22 weeks","symptomatic disease","symptomatic","symptomatic","delta/omicron",87.9,86.1,89.5,"Canada","CAN","North America","North America",46580,2019,"Canada","High income",4,NA,NA,NA,NA,NA
"2279",277,"Ionescu","Test-negative case-control",2337,2023-01-16,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"14+","12-17 years","12-17 years","excluded","~18 weeks","infection","infection","infection","delta",95.5,95,96,"Canada","CAN","North America","North America",46580,2019,"Canada","High income",4,NA,NA,NA,NA,NA
"2280",277,"Ionescu","Test-negative case-control",2338,2023-01-16,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"14-27","12-17 years","12-17 years","excluded","2 weeks","infection","infection","infection","delta",97.7,96.2,98.6,"Canada","CAN","North America","North America",46580,2019,"Canada","High income",4,NA,NA,NA,NA,NA
"2281",277,"Ionescu","Test-negative case-control",2339,2023-01-16,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"112-139","12-17 years","12-17 years","excluded","~18 weeks","infection","infection","infection","delta",92.4,90.4,94,"Canada","CAN","North America","North America",46580,2019,"Canada","High income",4,NA,NA,NA,NA,NA
"2282",277,"Ionescu","Test-negative case-control",2340,2023-01-16,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"14+","12-17 years","12-17 years","excluded","~18 weeks","symptomatic disease","symptomatic","symptomatic","delta",97.3,96.8,97.7,"Canada","CAN","North America","North America",46580,2019,"Canada","High income",4,NA,NA,NA,NA,NA
"2283",277,"Ionescu","Test-negative case-control",2341,2023-01-16,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"14+","12-17 years","12-17 years","excluded","~26 weeks","infection","infection","infection","omicron",33.9,25.7,41.1,"Canada","CAN","North America","North America",46580,2019,"Canada","High income",4,NA,NA,NA,NA,NA
"2284",277,"Ionescu","Test-negative case-control",2342,2023-01-16,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"14-27","12-17 years","12-17 years","excluded","2 weeks","infection","infection","infection","omicron",63.4,21.4,83,"Canada","CAN","North America","North America",46580,2019,"Canada","High income",4,NA,NA,NA,NA,NA
"2285",277,"Ionescu","Test-negative case-control",2343,2023-01-16,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"168-195","12-17 years","12-17 years","excluded","~26 weeks","infection","infection","infection","omicron",22.2,8.4,33.9,"Canada","CAN","North America","North America",46580,2019,"Canada","High income",4,NA,NA,NA,NA,NA
"2286",277,"Ionescu","Test-negative case-control",2344,2023-01-16,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"14+","12-17 years","12-17 years","excluded","~22 weeks","infection","infection","infection","delta/omicron",88,85.1,90.3,"Canada","CAN","North America","North America",46580,2019,"Canada","High income",4,NA,NA,NA,NA,NA
"2287",277,"Ionescu","Test-negative case-control",2345,2023-01-16,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"28-55","12-17 years","12-17 years","excluded","2 weeks","infection","infection","infection","delta/omicron",94.8,83.7,98.4,"Canada","CAN","North America","North America",46580,2019,"Canada","High income",4,NA,NA,NA,NA,NA
"2288",277,"Ionescu","Test-negative case-control",2346,2023-01-16,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"140-167","12-17 years","12-17 years","excluded","~22 weeks","infection","infection","infection","delta/omicron",84.2,77.8,88.8,"Canada","CAN","North America","North America",46580,2019,"Canada","High income",4,NA,NA,NA,NA,NA
"2289",277,"Ionescu","Test-negative case-control",2347,2023-01-16,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"14+","12-17 years","12-17 years","excluded","~18 weeks","infection","infection","infection","delta",95.7,95.1,96.2,"Canada","CAN","North America","North America",46580,2019,"Canada","High income",4,NA,NA,NA,NA,NA
"2290",277,"Ionescu","Test-negative case-control",2348,2023-01-16,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"14-27","12-17 years","12-17 years","excluded","2 weeks","infection","infection","infection","delta",96.8,94.4,98.2,"Canada","CAN","North America","North America",46580,2019,"Canada","High income",4,NA,NA,NA,NA,NA
"2291",277,"Ionescu","Test-negative case-control",2349,2023-01-16,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"112-139","12-17 years","12-17 years","excluded","~18 weeks","infection","infection","infection","delta",90.9,87.7,93.2,"Canada","CAN","North America","North America",46580,2019,"Canada","High income",4,NA,NA,NA,NA,NA
"2292",278,"Tartof","Test-negative case-control",2350,2022-10-07,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"<6 months",">= 18 years","general pop","included","~70 weeks","hospitalization","severe","severe","omicron",54,38,65,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,180,"yes",NA,0
"2293",278,"Tartof","Test-negative case-control",2351,2022-10-07,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,">=6 months",">= 18 years","general pop","included","~70 weeks","hospitalization","severe","severe","omicron",32,16,45,"USA","USA","North America","North America",66220,2019,"United States","High income",4,180,490,"no","sequential period",0
"2294",278,"Tartof","Test-negative case-control",2352,2022-10-07,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"<6 months",">= 18 years","general pop","included","~70 weeks","ED admissions","symptomatic","symptomatic","omicron",42,31,52,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"2295",278,"Tartof","Test-negative case-control",2353,2022-10-07,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,">=6 months",">= 18 years","general pop","included","~70 weeks","ED admissions","symptomatic","symptomatic","omicron",19,6,31,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"2296",278,"Tartof","Test-negative case-control",2354,2022-10-07,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"<6 months",">= 18 years","general pop","included","~70 weeks","hospitalization","severe","severe","omicron",56,-2,81,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,180,"yes",NA,0
"2297",278,"Tartof","Test-negative case-control",2355,2022-10-07,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,">=6 months",">= 18 years","general pop","included","~70 weeks","hospitalization","severe","severe","omicron",56,28,73,"USA","USA","North America","North America",66220,2019,"United States","High income",4,180,490,"no","sequential period",0
"2298",278,"Tartof","Test-negative case-control",2356,2022-10-07,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"<6 months",">= 18 years","general pop","included","~70 weeks","ED admissions","symptomatic","symptomatic","omicron",27,-11,52,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"2299",278,"Tartof","Test-negative case-control",2357,2022-10-07,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,">=6 months",">= 18 years","general pop","included","~70 weeks","ED admissions","symptomatic","symptomatic","omicron",12,-10,31,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"2300",279,"Paternina-Caicedo","Retrospective cohort",2358,2022-07-01,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"14+",">= 40 years",">= 40 years","included","~25 weeks","symptomatic disease","symptomatic","symptomatic","mu",13,5.3,20,"Colombia","COL","South America","Latin America & Caribbean",6630,2019,"Colombia","Upper middle income",3,NA,NA,NA,NA,NA
"2301",279,"Paternina-Caicedo","Retrospective cohort",2359,2022-07-01,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"14+",">= 40 years",">= 40 years","included","~25 weeks","hospitalization","severe","severe","mu",45.5,29.4,58,"Colombia","COL","South America","Latin America & Caribbean",6630,2019,"Colombia","Upper middle income",3,NA,NA,NA,NA,NA
"2302",279,"Paternina-Caicedo","Retrospective cohort",2360,2022-07-01,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"14+",">= 40 years",">= 40 years","included","~25 weeks","critical care admission","severe","severe","mu",82.2,60.1,92.1,"Colombia","COL","South America","Latin America & Caribbean",6630,2019,"Colombia","Upper middle income",3,NA,NA,NA,NA,NA
"2303",279,"Paternina-Caicedo","Retrospective cohort",2361,2022-07-01,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"14+",">= 40 years",">= 40 years","included","~25 weeks","death","death","death","mu",94.1,76.4,98.5,"Colombia","COL","South America","Latin America & Caribbean",6630,2019,"Colombia","Upper middle income",3,NA,NA,NA,NA,NA
"2304",279,"Paternina-Caicedo","Retrospective cohort",2362,2022-07-01,"Sinovac CoronaVac","Inactivated","2","final",NA,"14+",">= 40 years",">= 40 years","included","~25 weeks","symptomatic disease","symptomatic","symptomatic","mu",-45.1,-53.6,-37.1,"Colombia","COL","South America","Latin America & Caribbean",6630,2019,"Colombia","Upper middle income",3,NA,NA,NA,NA,NA
"2305",279,"Paternina-Caicedo","Retrospective cohort",2363,2022-07-01,"Sinovac CoronaVac","Inactivated","2","final",NA,"14+",">= 40 years",">= 40 years","included","~25 weeks","hospitalization","severe","severe","mu",-3,-18,10.2,"Colombia","COL","South America","Latin America & Caribbean",6630,2019,"Colombia","Upper middle income",3,NA,NA,NA,NA,NA
"2306",279,"Paternina-Caicedo","Retrospective cohort",2364,2022-07-01,"Sinovac CoronaVac","Inactivated","2","final",NA,"14+",">= 40 years",">= 40 years","included","~25 weeks","critical care admission","severe","severe","mu",13.6,-13.2,34,"Colombia","COL","South America","Latin America & Caribbean",6630,2019,"Colombia","Upper middle income",3,NA,NA,NA,NA,NA
"2307",279,"Paternina-Caicedo","Retrospective cohort",2365,2022-07-01,"Sinovac CoronaVac","Inactivated","2","final",NA,"14+",">= 40 years",">= 40 years","included","~25 weeks","death","death","death","mu",20.6,-0.5,37.3,"Colombia","COL","South America","Latin America & Caribbean",6630,2019,"Colombia","Upper middle income",3,NA,NA,NA,NA,NA
"2308",280,"Tonnara","Retrospective cohort",2366,2022-07-04,"Gamaleya Gam-COVID-Vac/Sputnik V","Vectored","2","final",NA,"7-59",">= 18 years","general pop","excluded","~27 weeks","infection","infection","infection","other combinations",91.8,86.3,95.1,"Republic of San Marino","SMR","Europe","Europe & Central Asia",43770,2019,"San Marino","High income",4,NA,NA,NA,NA,NA
"2309",280,"Tonnara","Retrospective cohort",2367,2022-07-04,"Gamaleya Gam-COVID-Vac/Sputnik V","Vectored","2","final",NA,"120+",">= 18 years","general pop","excluded","~27 weeks","infection","infection","infection","other combinations",57.8,42.2,69.2,"Republic of San Marino","SMR","Europe","Europe & Central Asia",43770,2019,"San Marino","High income",4,NA,NA,NA,NA,NA
"2310",280,"Tonnara","Retrospective cohort",2368,2022-07-04,"Gamaleya Gam-COVID-Vac/Sputnik V","Vectored","2","final",NA,"7-59",">= 18 years","general pop","excluded","~27 weeks","hospitalization","severe","severe","other combinations",95.2,79.1,98.9,"Republic of San Marino","SMR","Europe","Europe & Central Asia",43770,2019,"San Marino","High income",4,NA,NA,NA,NA,NA
"2311",280,"Tonnara","Retrospective cohort",2369,2022-07-04,"Gamaleya Gam-COVID-Vac/Sputnik V","Vectored","2","final",NA,"120+",">= 18 years","general pop","excluded","~27 weeks","hospitalization","severe","severe","other combinations",89.7,52.7,97.7,"Republic of San Marino","SMR","Europe","Europe & Central Asia",43770,2019,"San Marino","High income",4,NA,NA,NA,NA,NA
"2312",280,"Tonnara","Retrospective cohort",2370,2022-07-04,"Gamaleya Gam-COVID-Vac/Sputnik V","Vectored","2","final",NA,"7+",">= 18 years","general pop","excluded","~15 weeks","infection","infection","infection","alpha",97.3,94.2,98.7,"Republic of San Marino","SMR","Europe","Europe & Central Asia",43770,2019,"San Marino","High income",4,NA,NA,NA,NA,NA
"2313",280,"Tonnara","Retrospective cohort",2371,2022-07-04,"Gamaleya Gam-COVID-Vac/Sputnik V","Vectored","2","final",NA,"7+",">= 18 years","general pop","excluded","~15 weeks","hospitalization","severe","severe","alpha",96.9,86.5,99.3,"Republic of San Marino","SMR","Europe","Europe & Central Asia",43770,2019,"San Marino","High income",4,NA,NA,NA,NA,NA
"2314",281,"Kerr","Test-negative case-control",2372,2022-07-09,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"14+",">= 18 years","general pop","unknown","~38 weeks","symptomatic disease","symptomatic","symptomatic","delta",78.7,69.9,85,"UK","GBR","Europe","Europe & Central Asia",43240,2019,"United Kingdom","High income",4,NA,NA,NA,NA,NA
"2315",281,"Kerr","Test-negative case-control",2373,2022-07-09,"Moderna mRNA-1273","mRNA","2","final",NA,"14+",">= 18 years","general pop","unknown","~38 weeks","symptomatic disease","symptomatic","symptomatic","delta",93.7,86.4,97.1,"UK","GBR","Europe","Europe & Central Asia",43240,2019,"United Kingdom","High income",4,NA,NA,NA,NA,NA
"2316",281,"Kerr","Test-negative case-control",2374,2022-07-09,"Oxford/AstraZeneca ChAdOx1-S","Vectored","2","final",NA,"14+",">= 18 years","general pop","unknown","~38 weeks","symptomatic disease","symptomatic","symptomatic","delta",54.5,35.7,67.8,"UK","GBR","Europe","Europe & Central Asia",43240,2019,"United Kingdom","High income",4,NA,NA,NA,NA,NA
"2317",282,"Stephenson","Retrospective cohort",2375,2022-07-11,"Multiple or heterologous RNA","mRNA","2","final",NA,"14+",">= 18 years","general pop","included","~18 weeks","hospitalization","severe","severe","other combinations",85,81,89,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"2318",283,"Guedalia","Retrospective cohort",2376,2022-11-15,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"0+","pregnant women aged 16+","pregnant persons","excluded","~60 weeks","hospitalization","severe","severe","omicron",-12,-36,8,"Israel","ISR","Asia","Middle East & North Africa",43800,2019,"Israel","High income",4,NA,NA,NA,NA,NA
"2319",283,"Guedalia","Retrospective cohort",2377,2022-11-15,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"0+","pregnant women aged 16+","pregnant persons","excluded","~60 weeks","hospitalization with moderate disease","severe","severe","omicron",51,-47,84,"Israel","ISR","Asia","Middle East & North Africa",43800,2019,"Israel","High income",4,NA,NA,NA,NA,NA
"2320",283,"Guedalia","Retrospective cohort",2378,2022-11-15,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"0+","pregnant women aged 16+","pregnant persons","excluded","~60 weeks","severe disease","severe","severe","omicron",83,-47,98,"Israel","ISR","Asia","Middle East & North Africa",43800,2019,"Israel","High income",4,NA,NA,NA,NA,NA
"2321",283,"Guedalia","Retrospective cohort",2379,2022-11-15,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"0+","pregnant women aged 16+","pregnant persons","excluded","~44 weeks","hospitalization","severe","severe","delta",61,51,69,"Israel","ISR","Asia","Middle East & North Africa",43800,2019,"Israel","High income",4,NA,NA,NA,NA,NA
"2322",283,"Guedalia","Retrospective cohort",2380,2022-11-15,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"0+","pregnant women aged 16+","pregnant persons","excluded","~44 weeks","hospitalization with moderate disease","severe","severe","delta",97,92,99,"Israel","ISR","Asia","Middle East & North Africa",43800,2019,"Israel","High income",4,NA,NA,NA,NA,NA
"2323",283,"Guedalia","Retrospective cohort",2381,2022-11-15,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"0+","pregnant women aged 16+","pregnant persons","excluded","~44 weeks","severe disease","severe","severe","delta",96,86,99,"Israel","ISR","Asia","Middle East & North Africa",43800,2019,"Israel","High income",4,NA,NA,NA,NA,NA
"2324",284,"Link-Gelles","Test-negative case-control",2382,2022-07-15,"Multiple or heterologous RNA","mRNA","2","final",NA,"14-140",">= 18 years","general pop","excluded","~44 weeks","ED or UC visit","symptomatic","symptomatic","omicron",47,44,50,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"2325",284,"Link-Gelles","Test-negative case-control",2383,2022-07-15,"Multiple or heterologous RNA","mRNA","2","final",NA,"150+",">= 18 years","general pop","excluded","~44 weeks","ED or UC visit","symptomatic","symptomatic","omicron",39,37,41,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"2326",284,"Link-Gelles","Test-negative case-control",2384,2022-07-15,"Multiple or heterologous RNA","mRNA","2","final",NA,"14-140",">= 18 years","general pop","excluded","~44 weeks","hospitalization","severe","severe","omicron",68,63,73,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"2327",284,"Link-Gelles","Test-negative case-control",2385,2022-07-15,"Multiple or heterologous RNA","mRNA","2","final",NA,"150+",">= 18 years","general pop","excluded","~44 weeks","hospitalization","severe","severe","omicron",61,58,63,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"2328",284,"Link-Gelles","Test-negative case-control",2386,2022-07-15,"Multiple or heterologous RNA","mRNA","2","final",NA,"14-140",">= 18 years","general pop","excluded","~44 weeks","ED or UC visit","symptomatic","symptomatic","omicron",59,40,71,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"2329",284,"Link-Gelles","Test-negative case-control",2387,2022-07-15,"Multiple or heterologous RNA","mRNA","2","final",NA,"150+",">= 18 years","general pop","excluded","~44 weeks","ED or UC visit","symptomatic","symptomatic","omicron",18,10,26,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"2330",284,"Link-Gelles","Test-negative case-control",2388,2022-07-15,"Multiple or heterologous RNA","mRNA","2","final",NA,"14-140",">= 18 years","general pop","excluded","~44 weeks","hospitalization","severe","severe","omicron",57,19,77,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"2331",284,"Link-Gelles","Test-negative case-control",2389,2022-07-15,"Multiple or heterologous RNA","mRNA","2","final",NA,"150+",">= 18 years","general pop","excluded","~44 weeks","hospitalization","severe","severe","omicron",24,12,35,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"2332",285,"Cerqueira-Silva","Test-negative case-control",2390,2022-07-18,"Sinovac CoronaVac","Inactivated","2","final",NA,"14-180",">= 18 years","general pop","included","~59 weeks","infection","infection","infection","omicron",-0.7,-1.6,0.2,"Brazil","BRA","South America","Latin America & Caribbean",9410,2019,"Brazil","Upper middle income",3,NA,NA,NA,NA,NA
"2333",285,"Cerqueira-Silva","Test-negative case-control",2391,2022-07-18,"Sinovac CoronaVac","Inactivated","2","final",NA,"180+",">= 18 years","general pop","included","~59 weeks","infection","infection","infection","omicron",3.2,2.1,4.2,"Brazil","BRA","South America","Latin America & Caribbean",9410,2019,"Brazil","Upper middle income",3,NA,NA,NA,NA,NA
"2334",285,"Cerqueira-Silva","Test-negative case-control",2392,2022-07-18,"Sinovac CoronaVac","Inactivated","2","final",NA,"14-180",">= 18 years","general pop","included","~59 weeks","hospitalization or death","severe","severe","omicron",64.5,62.6,66.3,"Brazil","BRA","South America","Latin America & Caribbean",9410,2019,"Brazil","Upper middle income",3,NA,NA,NA,NA,NA
"2335",285,"Cerqueira-Silva","Test-negative case-control",2393,2022-07-18,"Sinovac CoronaVac","Inactivated","2","final",NA,"180+",">= 18 years","general pop","included","~59 weeks","hospitalization or death","severe","severe","omicron",61.8,60.3,63.2,"Brazil","BRA","South America","Latin America & Caribbean",9410,2019,"Brazil","Upper middle income",3,NA,NA,NA,NA,NA
"2336",285,"Cerqueira-Silva","Test-negative case-control",2394,2022-07-18,"Sinovac CoronaVac","Inactivated","2","final",NA,"14-180",">= 18 years","general pop","included","~59 weeks","death","death","death","omicron",67.8,64,71.3,"Brazil","BRA","South America","Latin America & Caribbean",9410,2019,"Brazil","Upper middle income",3,NA,NA,NA,NA,NA
"2337",285,"Cerqueira-Silva","Test-negative case-control",2395,2022-07-18,"Sinovac CoronaVac","Inactivated","2","final",NA,"180+",">= 18 years","general pop","included","~59 weeks","death","death","death","omicron",63.1,60.9,65.1,"Brazil","BRA","South America","Latin America & Caribbean",9410,2019,"Brazil","Upper middle income",3,NA,NA,NA,NA,NA
"2338",286,"Hatfield","Retrospective cohort",2396,2022-07-20,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"7-157","nursing home residents","nursing home residents","excluded","~44 weeks","infection","infection","infection","other combinations",67,40,82,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"2339",286,"Hatfield","Retrospective cohort",2397,2022-07-20,"Moderna mRNA-1273","mRNA","2","final",NA,"7-157","nursing home residents","nursing home residents","excluded","~44 weeks","infection","infection","infection","other combinations",75,32,91,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"2340",286,"Hatfield","Retrospective cohort",2398,2022-07-20,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"157+","nursing home residents","nursing home residents","excluded","~44 weeks","infection","infection","infection","delta",33,-2,56,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"2341",286,"Hatfield","Retrospective cohort",2399,2022-07-20,"Moderna mRNA-1273","mRNA","2","final",NA,"157+","nursing home residents","nursing home residents","excluded","~44 weeks","infection","infection","infection","delta",77,48,91,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"2342",287,"Tan","Retrospective cohort",2400,2022-07-20,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"7-14","5-11 years","5-11 years","excluded","~9 weeks","infection (PCR or antigen)","infection","infection","omicron",48.8,46.9,50.8,"Singapore","SGP","Asia","East Asia & Pacific",58810,2019,"Singapore","High income",4,NA,NA,NA,NA,NA
"2343",287,"Tan","Retrospective cohort",2401,2022-07-20,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"60+","5-11 years","5-11 years","excluded","~9 weeks","infection (PCR or antigen)","infection","infection","omicron",25.6,19.3,31.5,"Singapore","SGP","Asia","East Asia & Pacific",58810,2019,"Singapore","High income",4,NA,NA,NA,NA,NA
"2344",287,"Tan","Retrospective cohort",2402,2022-07-20,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"7-14","5-11 years","5-11 years","excluded","~9 weeks","infection (PCR only)","infection","infection","omicron",70.6,65.9,74.7,"Singapore","SGP","Asia","East Asia & Pacific",58810,2019,"Singapore","High income",4,NA,NA,NA,NA,NA
"2345",287,"Tan","Retrospective cohort",2403,2022-07-20,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"60+","5-11 years","5-11 years","excluded","~9 weeks","infection (PCR only)","infection","infection","omicron",42.7,12,62.7,"Singapore","SGP","Asia","East Asia & Pacific",58810,2019,"Singapore","High income",4,NA,NA,NA,NA,NA
"2346",287,"Tan","Retrospective cohort",2404,2022-07-20,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"7-14","5-11 years","5-11 years","excluded","~9 weeks","hospitalization","severe","severe","omicron",87.8,72.2,94.7,"Singapore","SGP","Asia","East Asia & Pacific",58810,2019,"Singapore","High income",4,NA,NA,NA,NA,NA
"2347",287,"Tan","Retrospective cohort",2405,2022-07-20,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"30-59","5-11 years","5-11 years","excluded","~9 weeks","hospitalization","severe","severe","omicron",80.4,67,88.4,"Singapore","SGP","Asia","East Asia & Pacific",58810,2019,"Singapore","High income",4,NA,NA,NA,NA,NA
"2348",288,"Mazagatos","Test-negative case-control",2406,2022-07-26,"Multiple or heterologous RNA","mRNA","2","final",NA,"14+","20-59 years","20-59 years","included","~19 weeks","hospitalization with SARI","severe","severe","other combinations",92,78,97,"Spain","ESP","Europe","Europe & Central Asia",30370,2019,"Spain","High income",4,NA,NA,NA,NA,NA
"2349",288,"Mazagatos","Test-negative case-control",2407,2022-07-26,"Multiple or heterologous RNA","mRNA","2","final",NA,"<90","20-59 years","20-59 years","included","~19 weeks","hospitalization with SARI","severe","severe","other combinations",95,82,98,"Spain","ESP","Europe","Europe & Central Asia",30370,2019,"Spain","High income",4,NA,NA,NA,NA,NA
"2350",288,"Mazagatos","Test-negative case-control",2408,2022-07-26,"Multiple or heterologous RNA","mRNA","2","final",NA,"152+","20-59 years","20-59 years","included","~19 weeks","hospitalization with SARI","severe","severe","other combinations",91,50,98,"Spain","ESP","Europe","Europe & Central Asia",30370,2019,"Spain","High income",4,NA,NA,NA,NA,NA
"2351",288,"Mazagatos","Test-negative case-control",2409,2022-07-26,"Multiple or heterologous RNA","mRNA","2","final",NA,"14+","60-69 years","60-69 years","included","~19 weeks","hospitalization with SARI","severe","severe","other combinations",97,86,99,"Spain","ESP","Europe","Europe & Central Asia",30370,2019,"Spain","High income",4,NA,NA,NA,NA,NA
"2352",288,"Mazagatos","Test-negative case-control",2410,2022-07-26,"Multiple or heterologous RNA","mRNA","2","final",NA,"<90","60-69 years","60-69 years","included","~19 weeks","hospitalization with SARI","severe","severe","other combinations",97,87,99,"Spain","ESP","Europe","Europe & Central Asia",30370,2019,"Spain","High income",4,NA,NA,NA,NA,NA
"2353",288,"Mazagatos","Test-negative case-control",2411,2022-07-26,"Multiple or heterologous RNA","mRNA","2","final",NA,"152+","60-69 years","60-69 years","included","~19 weeks","hospitalization with SARI","severe","severe","other combinations",96,47,100,"Spain","ESP","Europe","Europe & Central Asia",30370,2019,"Spain","High income",4,NA,NA,NA,NA,NA
"2354",288,"Mazagatos","Test-negative case-control",2412,2022-07-26,"Multiple or heterologous RNA","mRNA","2","final",NA,"<90","70-79 years","70-79 years","included","~23 weeks","hospitalization with SARI","severe","severe","other combinations",98,90,100,"Spain","ESP","Europe","Europe & Central Asia",30370,2019,"Spain","High income",4,NA,NA,NA,NA,NA
"2355",288,"Mazagatos","Test-negative case-control",2413,2022-07-26,"Multiple or heterologous RNA","mRNA","2","final",NA,"152+","70-79 years","70-79 years","included","~23 weeks","hospitalization with SARI","severe","severe","other combinations",91,24,99,"Spain","ESP","Europe","Europe & Central Asia",30370,2019,"Spain","High income",4,NA,NA,NA,NA,NA
"2356",288,"Mazagatos","Test-negative case-control",2414,2022-07-26,"Multiple or heterologous RNA","mRNA","2","final",NA,"<90",">= 80 years",">= 80 years","included","~33 weeks","hospitalization with SARI","severe","severe","other combinations",86,70,94,"Spain","ESP","Europe","Europe & Central Asia",30370,2019,"Spain","High income",4,NA,NA,NA,NA,NA
"2357",288,"Mazagatos","Test-negative case-control",2415,2022-07-26,"Multiple or heterologous RNA","mRNA","2","final",NA,"152+",">= 80 years",">= 80 years","included","~33 weeks","hospitalization with SARI","severe","severe","other combinations",48,-51,82,"Spain","ESP","Europe","Europe & Central Asia",30370,2019,"Spain","High income",4,NA,NA,NA,NA,NA
"2358",288,"Mazagatos","Test-negative case-control",2416,2022-07-26,"Janssen Ad26.COV2.S","Vectored","1","final",NA,"14+","20-59 years","20-59 years","included","~19 weeks","hospitalization with SARI","severe","severe","other combinations",71,-3,92,"Spain","ESP","Europe","Europe & Central Asia",30370,2019,"Spain","High income",4,NA,NA,NA,NA,NA
"2359",288,"Mazagatos","Test-negative case-control",2417,2022-07-26,"Janssen Ad26.COV2.S","Vectored","1","final",NA,"14+","60-69 years","60-69 years","included","~19 weeks","hospitalization with SARI","severe","severe","other combinations",82,-78,98,"Spain","ESP","Europe","Europe & Central Asia",30370,2019,"Spain","High income",4,NA,NA,NA,NA,NA
"2360",288,"Mazagatos","Test-negative case-control",2418,2022-07-26,"Oxford/AstraZeneca ChAdOx1-S","Vectored","2","final",NA,"14+","60-69 years","60-69 years","included","~19 weeks","hospitalization with SARI","severe","severe","other combinations",89,25,98,"Spain","ESP","Europe","Europe & Central Asia",30370,2019,"Spain","High income",4,NA,NA,NA,NA,NA
"2361",289,"Chemaitelly","Retrospective cohort",2419,2022-11-02,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"14+","12-17 years","12-17 years","excluded","~68 weeks","infection","infection","infection","omicron",51.3,34.9,63.6,"Qatar","QAT","Asia","Middle East & North Africa",65700,2019,"Qatar","High income",4,NA,NA,NA,NA,NA
"2362",289,"Chemaitelly","Retrospective cohort",2420,2022-11-02,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"172+","12-17 years","12-17 years","excluded","~68 weeks","infection","infection","infection","omicron",-1.7,-20,10,"Qatar","QAT","Asia","Middle East & North Africa",65700,2019,"Qatar","High income",4,NA,NA,NA,NA,NA
"2363",289,"Chemaitelly","Retrospective cohort",2421,2022-11-02,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"14-30","5-11 years","5-11 years","excluded","~68 weeks","infection","infection","infection","omicron",49.6,28.5,64.5,"Qatar","QAT","Asia","Middle East & North Africa",65700,2019,"Qatar","High income",4,NA,NA,NA,NA,NA
"2364",289,"Chemaitelly","Retrospective cohort",2422,2022-11-02,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"120+","5-11 years","5-11 years","excluded","~68 weeks","infection","infection","infection","omicron",-9.5,-30,35,"Qatar","QAT","Asia","Middle East & North Africa",65700,2019,"Qatar","High income",4,NA,NA,NA,NA,NA
"2365",289,"Chemaitelly","Retrospective cohort",2423,2022-11-02,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"14-30","12-17 years","12-17 years","excluded","~68 weeks","infection","infection","infection","other combinations",95.3,92,97.2,"Qatar","QAT","Asia","Middle East & North Africa",65700,2019,"Qatar","High income",4,NA,NA,NA,NA,NA
"2366",289,"Chemaitelly","Retrospective cohort",2424,2022-11-02,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"152+","12-17 years","12-17 years","excluded","~68 weeks","infection","infection","infection","other combinations",70.6,18,92,"Qatar","QAT","Asia","Middle East & North Africa",65700,2019,"Qatar","High income",4,NA,NA,NA,NA,NA
"2367",290,"Mayr","Test-negative case-control",2425,2022-06-22,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"14 days-1 month","veterans","veterans","excluded","2 weeks","symptomatic disease","symptomatic","symptomatic","other combinations",76.1,71.1,80.2,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"2368",290,"Mayr","Test-negative case-control",2426,2022-06-22,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"7 months","veterans","veterans","excluded","~26 weeks","symptomatic disease","symptomatic","symptomatic","other combinations",0.1,-10.9,10.1,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"2369",290,"Mayr","Test-negative case-control",2427,2022-06-22,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"14 days-1 month","veterans < 65 years","veterans < 65 years","excluded","2 weeks","symptomatic disease","symptomatic","symptomatic","other combinations",81.6,75.9,85.9,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"2370",290,"Mayr","Test-negative case-control",2428,2022-06-22,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"7 months","veterans < 65 years","veterans < 65 years","excluded","~26 weeks","symptomatic disease","symptomatic","symptomatic","other combinations",22.5,7.2,35.2,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"2371",290,"Mayr","Test-negative case-control",2429,2022-06-22,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"14 days-1 month","veterans >= 65 years","veterans >= 65 years","excluded","2 weeks","symptomatic disease","symptomatic","symptomatic","other combinations",66.3,55.7,74.4,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"2372",290,"Mayr","Test-negative case-control",2430,2022-06-22,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"7 months","veterans >= 65 years","veterans >= 65 years","excluded","~26 weeks","symptomatic disease","symptomatic","symptomatic","other combinations",-23.3,-40.5,-8.2,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"2373",290,"Mayr","Test-negative case-control",2431,2022-06-22,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"14 days-1 month","veterans","veterans","excluded","2 weeks","hospitalization","severe","severe","other combinations",72.9,61.7,80.7,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"2374",290,"Mayr","Test-negative case-control",2432,2022-06-22,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"7 months","veterans","veterans","excluded","~26 weeks","hospitalization","severe","severe","other combinations",19.8,2.5,34.1,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"2375",290,"Mayr","Test-negative case-control",2433,2022-06-22,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"14 days-1 month","veterans < 65 years","veterans < 65 years","excluded","2 weeks","hospitalization","severe","severe","other combinations",85.6,72.6,92.4,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"2376",290,"Mayr","Test-negative case-control",2434,2022-06-22,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"7 months","veterans < 65 years","veterans < 65 years","excluded","~26 weeks","hospitalization","severe","severe","other combinations",57,31.2,73.2,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"2377",290,"Mayr","Test-negative case-control",2435,2022-06-22,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"14 days-1 month","veterans >= 65 years","veterans >= 65 years","excluded","2 weeks","hospitalization","severe","severe","other combinations",61,41.3,74.2,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"2378",290,"Mayr","Test-negative case-control",2436,2022-06-22,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"7 months","veterans >= 65 years","veterans >= 65 years","excluded","~26 weeks","hospitalization","severe","severe","other combinations",1.7,-22,20.8,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"2379",290,"Mayr","Test-negative case-control",2437,2022-06-22,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"14 days-1 month","veterans","veterans","excluded","2 weeks","ICU admission or death","severe","severe","other combinations",74.7,54.2,86,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"2380",290,"Mayr","Test-negative case-control",2438,2022-06-22,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"7 months","veterans","veterans","excluded","~26 weeks","ICU admission or death","severe","severe","other combinations",39.5,17.6,55.6,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"2381",290,"Mayr","Test-negative case-control",2439,2022-06-22,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"14 days-1 month","veterans < 65 years","veterans < 65 years","excluded","2 weeks","ICU admission or death","severe","severe","other combinations",87.6,61,96.1,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"2382",290,"Mayr","Test-negative case-control",2440,2022-06-22,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"7 months","veterans < 65 years","veterans < 65 years","excluded","~26 weeks","ICU admission or death","severe","severe","other combinations",66.4,7.7,87.8,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"2383",290,"Mayr","Test-negative case-control",2441,2022-06-22,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"14 days-1 month","veterans >= 65 years","veterans >= 65 years","excluded","2 weeks","ICU admission or death","severe","severe","other combinations",67.4,32.6,84.3,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"2384",290,"Mayr","Test-negative case-control",2442,2022-06-22,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"7 months","veterans >= 65 years","veterans >= 65 years","excluded","~26 weeks","ICU admission or death","severe","severe","other combinations",29.3,2.3,48.9,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"2385",290,"Mayr","Test-negative case-control",2443,2022-06-22,"Moderna mRNA-1273","mRNA","2","final",NA,"14 days-1 month","veterans","veterans","excluded","2 weeks","symptomatic disease","symptomatic","symptomatic","other combinations",84.6,80.5,87.8,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"2386",290,"Mayr","Test-negative case-control",2444,2022-06-22,"Moderna mRNA-1273","mRNA","2","final",NA,"7 months","veterans","veterans","excluded","~26 weeks","symptomatic disease","symptomatic","symptomatic","other combinations",46.6,40.8,51.9,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"2387",290,"Mayr","Test-negative case-control",2445,2022-06-22,"Moderna mRNA-1273","mRNA","2","final",NA,"14 days-1 month","veterans < 65 years","veterans < 65 years","excluded","2 weeks","symptomatic disease","symptomatic","symptomatic","other combinations",89.7,84.8,93,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"2388",290,"Mayr","Test-negative case-control",2446,2022-06-22,"Moderna mRNA-1273","mRNA","2","final",NA,"7 months","veterans < 65 years","veterans < 65 years","excluded","~26 weeks","symptomatic disease","symptomatic","symptomatic","other combinations",57.3,48.4,64.7,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"2389",290,"Mayr","Test-negative case-control",2447,2022-06-22,"Moderna mRNA-1273","mRNA","2","final",NA,"14 days-1 month","veterans >= 65 years","veterans >= 65 years","excluded","2 weeks","symptomatic disease","symptomatic","symptomatic","other combinations",78.4,71.1,83.9,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"2390",290,"Mayr","Test-negative case-control",2448,2022-06-22,"Moderna mRNA-1273","mRNA","2","final",NA,"7 months","veterans >= 65 years","veterans >= 65 years","excluded","~26 weeks","symptomatic disease","symptomatic","symptomatic","other combinations",36.2,27.7,43.6,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"2391",290,"Mayr","Test-negative case-control",2449,2022-06-22,"Moderna mRNA-1273","mRNA","2","final",NA,"14 days-1 month","veterans","veterans","excluded","2 weeks","hospitalization","severe","severe","other combinations",76.6,63.9,84.8,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"2392",290,"Mayr","Test-negative case-control",2450,2022-06-22,"Moderna mRNA-1273","mRNA","2","final",NA,"7 months","veterans","veterans","excluded","~26 weeks","hospitalization","severe","severe","other combinations",71.3,64,77.1,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"2393",290,"Mayr","Test-negative case-control",2451,2022-06-22,"Moderna mRNA-1273","mRNA","2","final",NA,"14 days-1 month","veterans < 65 years","veterans < 65 years","excluded","2 weeks","hospitalization","severe","severe","other combinations",92,76.1,97.3,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"2394",290,"Mayr","Test-negative case-control",2452,2022-06-22,"Moderna mRNA-1273","mRNA","2","final",NA,"7 months","veterans < 65 years","veterans < 65 years","excluded","~26 weeks","hospitalization","severe","severe","other combinations",83.1,66.8,91.4,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"2395",290,"Mayr","Test-negative case-control",2453,2022-06-22,"Moderna mRNA-1273","mRNA","2","final",NA,"14 days-1 month","veterans >= 65 years","veterans >= 65 years","excluded","2 weeks","hospitalization","severe","severe","other combinations",66.1,45.3,79,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"2396",290,"Mayr","Test-negative case-control",2454,2022-06-22,"Moderna mRNA-1273","mRNA","2","final",NA,"7 months","veterans >= 65 years","veterans >= 65 years","excluded","~26 weeks","hospitalization","severe","severe","other combinations",64.7,55.2,72.3,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"2397",290,"Mayr","Test-negative case-control",2455,2022-06-22,"Moderna mRNA-1273","mRNA","2","final",NA,"14 days-1 month","veterans","veterans","excluded","2 weeks","ICU admission or death","severe","severe","other combinations",80.5,64.1,89.4,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"2398",290,"Mayr","Test-negative case-control",2456,2022-06-22,"Moderna mRNA-1273","mRNA","2","final",NA,"7 months","veterans","veterans","excluded","~26 weeks","ICU admission or death","severe","severe","other combinations",77.2,68.4,83.5,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"2399",290,"Mayr","Test-negative case-control",2457,2022-06-22,"Moderna mRNA-1273","mRNA","2","final",NA,"14 days-1 month","veterans < 65 years","veterans < 65 years","excluded","2 weeks","ICU admission or death","severe","severe","other combinations",89.2,49.5,97.7,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"2400",290,"Mayr","Test-negative case-control",2458,2022-06-22,"Moderna mRNA-1273","mRNA","2","final",NA,"7 months","veterans < 65 years","veterans < 65 years","excluded","~26 weeks","ICU admission or death","severe","severe","other combinations",84.4,59,94.1,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"2401",290,"Mayr","Test-negative case-control",2459,2022-06-22,"Moderna mRNA-1273","mRNA","2","final",NA,"14 days-1 month","veterans >= 65 years","veterans >= 65 years","excluded","2 weeks","ICU admission or death","severe","severe","other combinations",75.4,51.7,87.5,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"2402",290,"Mayr","Test-negative case-control",2460,2022-06-22,"Moderna mRNA-1273","mRNA","2","final",NA,"7 months","veterans >= 65 years","veterans >= 65 years","excluded","~26 weeks","ICU admission or death","severe","severe","other combinations",73.8,62.9,81.5,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"2403",290,"Mayr","Test-negative case-control",2461,2022-06-22,"Janssen Ad26.COV2.S","Vectored","1","final",NA,"14 days-1 month","veterans","veterans","excluded","2 weeks","symptomatic disease","symptomatic","symptomatic","other combinations",25.4,2.9,42.6,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"2404",290,"Mayr","Test-negative case-control",2462,2022-06-22,"Janssen Ad26.COV2.S","Vectored","1","final",NA,"7 months","veterans","veterans","excluded","~26 weeks","symptomatic disease","symptomatic","symptomatic","other combinations",25.5,-2.2,45.6,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"2405",290,"Mayr","Test-negative case-control",2463,2022-06-22,"Janssen Ad26.COV2.S","Vectored","1","final",NA,"14 days-1 month","veterans","veterans","excluded","2 weeks","hospitalization","severe","severe","other combinations",55.8,20.6,75.4,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"2406",290,"Mayr","Test-negative case-control",2464,2022-06-22,"Janssen Ad26.COV2.S","Vectored","1","final",NA,"7 months","veterans","veterans","excluded","~26 weeks","hospitalization","severe","severe","other combinations",16.9,-90.9,63.8,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"2407",290,"Mayr","Test-negative case-control",2465,2022-06-22,"Janssen Ad26.COV2.S","Vectored","1","final",NA,"14 days-1 month","veterans","veterans","excluded","2 weeks","ICU admission or death","severe","severe","other combinations",61.1,11.9,82.8,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"2408",290,"Mayr","Test-negative case-control",2466,2022-06-22,"Janssen Ad26.COV2.S","Vectored","1","final",NA,"7 months","veterans","veterans","excluded","~26 weeks","ICU admission or death","severe","severe","other combinations",63.3,-15.5,88.3,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"2409",291,"Piche-Renaud","Test-negative case-control",2467,2023-03-03,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"7+","5-11 years","5-11 years","included","~29 weeks","symptomatic disease","symptomatic","symptomatic","omicron",49,43,54,"Canada","CAN","North America","North America",46580,2019,"Canada","High income",4,NA,NA,NA,NA,NA
"2410",291,"Piche-Renaud","Test-negative case-control",2468,2023-03-03,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"7-29","5-11 years","5-11 years","included","~29 weeks","symptomatic disease","symptomatic","symptomatic","omicron",66,60,71,"Canada","CAN","North America","North America",46580,2019,"Canada","High income",4,NA,NA,NA,NA,NA
"2411",291,"Piche-Renaud","Test-negative case-control",2469,2023-03-03,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"120+","5-11 years","5-11 years","included","~29 weeks","symptomatic disease","symptomatic","symptomatic","omicron",-4,-30,46,"Canada","CAN","North America","North America",46580,2019,"Canada","High income",4,NA,NA,NA,NA,NA
"2412",291,"Piche-Renaud","Test-negative case-control",2470,2023-03-03,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"7+","5-11 years","5-11 years","included","~29 weeks","hospitalization or death","severe","severe","omicron",79,63,88,"Canada","CAN","North America","North America",46580,2019,"Canada","High income",4,NA,NA,NA,NA,NA
"2413",291,"Piche-Renaud","Test-negative case-control",2471,2023-03-03,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"7-29","5-11 years","5-11 years","included","~29 weeks","hospitalization or death","severe","severe","omicron",94,57,99,"Canada","CAN","North America","North America",46580,2019,"Canada","High income",4,NA,NA,NA,NA,NA
"2414",291,"Piche-Renaud","Test-negative case-control",2472,2023-03-03,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"120+","5-11 years","5-11 years","included","~29 weeks","hospitalization or death","severe","severe","omicron",57,-20,85,"Canada","CAN","North America","North America",46580,2019,"Canada","High income",4,NA,NA,NA,NA,NA
"2415",292,"Arashiro","Case-control",2473,2022-08-03,"Multiple or heterologous RNA","mRNA","2","final",NA,"14-89",">= 20 years","general pop","included","~54 weeks","symptomatic disease","symptomatic","symptomatic","omicron",55,34,69,"Japan","JPN","Asia","East Asia & Pacific",41970,2019,"Japan","High income",4,NA,NA,NA,NA,NA
"2416",292,"Arashiro","Case-control",2474,2022-08-03,"Multiple or heterologous RNA","mRNA","2","final",NA,"180+",">= 20 years","general pop","included","~54 weeks","symptomatic disease","symptomatic","symptomatic","omicron",52,37,63,"Japan","JPN","Asia","East Asia & Pacific",41970,2019,"Japan","High income",4,NA,NA,NA,NA,NA
"2417",292,"Arashiro","Case-control",2475,2022-08-03,"Multiple or heterologous RNA","mRNA","2","final",NA,"14-89",">= 20 years","general pop","included","~54 weeks","symptomatic disease","symptomatic","symptomatic","delta",88,80,92,"Japan","JPN","Asia","East Asia & Pacific",41970,2019,"Japan","High income",4,NA,NA,NA,NA,NA
"2418",292,"Arashiro","Case-control",2476,2022-08-03,"Multiple or heterologous RNA","mRNA","2","final",NA,"90-179",">= 20 years","general pop","included","~54 weeks","symptomatic disease","symptomatic","symptomatic","delta",86,35,97,"Japan","JPN","Asia","East Asia & Pacific",41970,2019,"Japan","High income",4,NA,NA,NA,NA,NA
"2419",293,"Tartof","Test-negative case-control",2477,2022-08-03,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"<60","12-17 years","12-17 years","included","~44 weeks","ED or UC visit","symptomatic","symptomatic","omicron",73,54,84,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"2420",293,"Tartof","Test-negative case-control",2478,2022-08-03,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"180+","12-17 years","12-17 years","included","~44 weeks","ED or UC visit","symptomatic","symptomatic","omicron",16,-7,34,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"2421",293,"Tartof","Test-negative case-control",2479,2022-08-03,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"<60","12-17 years","12-17 years","excluded","~44 weeks","ED or UC visit","symptomatic","symptomatic","omicron",72,52,84,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"2422",293,"Tartof","Test-negative case-control",2480,2022-08-03,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"180+","12-17 years","12-17 years","excluded","~44 weeks","ED or UC visit","symptomatic","symptomatic","omicron",18,-6,36,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"2423",293,"Tartof","Test-negative case-control",2481,2022-08-03,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"<60","12-17 years","12-17 years","included","~44 weeks","ED or UC visit","symptomatic","symptomatic","delta",89,69,96,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"2424",293,"Tartof","Test-negative case-control",2482,2022-08-03,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"180+","12-17 years","12-17 years","included","~44 weeks","ED or UC visit","symptomatic","symptomatic","delta",49,27,65,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"2425",293,"Tartof","Test-negative case-control",2483,2022-08-03,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"<60","12-17 years","12-17 years","excluded","~44 weeks","ED or UC visit","symptomatic","symptomatic","delta",88,68,96,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"2426",293,"Tartof","Test-negative case-control",2484,2022-08-03,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"180+","12-17 years","12-17 years","excluded","~44 weeks","ED or UC visit","symptomatic","symptomatic","delta",47,23,63,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"2427",294,"Pinto-Alvarez","Nested cohort",2485,2022-10-13,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"15+",">= 16 years","general pop","excluded","~56 weeks","infection","infection","infection","other combinations",73.4,68.6,77.5,"Colombia","COL","South America","Latin America & Caribbean",6630,2019,"Colombia","Upper middle income",3,NA,NA,NA,NA,NA
"2428",294,"Pinto-Alvarez","Nested cohort",2486,2022-10-13,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"15+",">= 16 years","general pop","excluded","~56 weeks","hospitalization","severe","severe","other combinations",85.4,80.1,89.3,"Colombia","COL","South America","Latin America & Caribbean",6630,2019,"Colombia","Upper middle income",3,NA,NA,NA,NA,NA
"2429",294,"Pinto-Alvarez","Nested cohort",2487,2022-10-13,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"15+",">= 16 years","general pop","excluded","~56 weeks","death","death","death","other combinations",93.4,89.8,95.7,"Colombia","COL","South America","Latin America & Caribbean",6630,2019,"Colombia","Upper middle income",3,NA,NA,NA,NA,NA
"2430",294,"Pinto-Alvarez","Nested cohort",2488,2022-10-13,"Moderna mRNA-1273","mRNA","2","final",NA,"15+",">= 16 years","general pop","excluded","~56 weeks","infection","infection","infection","other combinations",28.1,0,48.9,"Colombia","COL","South America","Latin America & Caribbean",6630,2019,"Colombia","Upper middle income",3,NA,NA,NA,NA,NA
"2431",294,"Pinto-Alvarez","Nested cohort",2489,2022-10-13,"Moderna mRNA-1273","mRNA","2","final",NA,"15+",">= 16 years","general pop","excluded","~56 weeks","hospitalization","severe","severe","other combinations",85.2,64.6,93.8,"Colombia","COL","South America","Latin America & Caribbean",6630,2019,"Colombia","Upper middle income",3,NA,NA,NA,NA,NA
"2432",294,"Pinto-Alvarez","Nested cohort",2490,2022-10-13,"Moderna mRNA-1273","mRNA","2","final",NA,"15+",">= 16 years","general pop","excluded","~56 weeks","death","death","death","other combinations",96.9,76.5,99.6,"Colombia","COL","South America","Latin America & Caribbean",6630,2019,"Colombia","Upper middle income",3,NA,NA,NA,NA,NA
"2433",294,"Pinto-Alvarez","Nested cohort",2491,2022-10-13,"Oxford/AstraZeneca ChAdOx1-S","Vectored","2","final",NA,"15+",">= 16 years","general pop","excluded","~56 weeks","infection","infection","infection","other combinations",67.9,57.9,75.5,"Colombia","COL","South America","Latin America & Caribbean",6630,2019,"Colombia","Upper middle income",3,NA,NA,NA,NA,NA
"2434",294,"Pinto-Alvarez","Nested cohort",2492,2022-10-13,"Oxford/AstraZeneca ChAdOx1-S","Vectored","2","final",NA,"15+",">= 16 years","general pop","excluded","~56 weeks","hospitalization","severe","severe","other combinations",82.5,70.9,89.5,"Colombia","COL","South America","Latin America & Caribbean",6630,2019,"Colombia","Upper middle income",3,NA,NA,NA,NA,NA
"2435",294,"Pinto-Alvarez","Nested cohort",2493,2022-10-13,"Oxford/AstraZeneca ChAdOx1-S","Vectored","2","final",NA,"15+",">= 16 years","general pop","excluded","~56 weeks","death","death","death","other combinations",93.8,86.4,97.1,"Colombia","COL","South America","Latin America & Caribbean",6630,2019,"Colombia","Upper middle income",3,NA,NA,NA,NA,NA
"2436",294,"Pinto-Alvarez","Nested cohort",2494,2022-10-13,"Sinovac CoronaVac","Inactivated","2","final",NA,"15+",">= 16 years","general pop","excluded","~56 weeks","infection","infection","infection","other combinations",74.2,68.3,79.1,"Colombia","COL","South America","Latin America & Caribbean",6630,2019,"Colombia","Upper middle income",3,NA,NA,NA,NA,NA
"2437",294,"Pinto-Alvarez","Nested cohort",2495,2022-10-13,"Sinovac CoronaVac","Inactivated","2","final",NA,"15+",">= 16 years","general pop","excluded","~56 weeks","hospitalization","severe","severe","other combinations",83.3,75.3,88.7,"Colombia","COL","South America","Latin America & Caribbean",6630,2019,"Colombia","Upper middle income",3,NA,NA,NA,NA,NA
"2438",294,"Pinto-Alvarez","Nested cohort",2496,2022-10-13,"Sinovac CoronaVac","Inactivated","2","final",NA,"15+",">= 16 years","general pop","excluded","~56 weeks","death","death","death","other combinations",92.6,87.5,95.6,"Colombia","COL","South America","Latin America & Caribbean",6630,2019,"Colombia","Upper middle income",3,NA,NA,NA,NA,NA
"2439",294,"Pinto-Alvarez","Nested cohort",2497,2022-10-13,"Janssen Ad26.COV2.S","Vectored","1","final",NA,"15+",">= 16 years","general pop","excluded","~56 weeks","infection","infection","infection","other combinations",73.7,65.2,80.1,"Colombia","COL","South America","Latin America & Caribbean",6630,2019,"Colombia","Upper middle income",3,NA,NA,NA,NA,NA
"2440",294,"Pinto-Alvarez","Nested cohort",2498,2022-10-13,"Janssen Ad26.COV2.S","Vectored","1","final",NA,"15+",">= 16 years","general pop","excluded","~56 weeks","hospitalization","severe","severe","other combinations",88.4,77.4,94,"Colombia","COL","South America","Latin America & Caribbean",6630,2019,"Colombia","Upper middle income",3,NA,NA,NA,NA,NA
"2441",294,"Pinto-Alvarez","Nested cohort",2499,2022-10-13,"Janssen Ad26.COV2.S","Vectored","1","final",NA,"15+",">= 16 years","general pop","excluded","~56 weeks","death","death","death","other combinations",97.1,87.9,99.3,"Colombia","COL","South America","Latin America & Caribbean",6630,2019,"Colombia","Upper middle income",3,NA,NA,NA,NA,NA
"2442",295,"Zambrano","Test-negative case-control",2500,2022-08-04,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"28+","12-18 years","12-18 years","included","~40 weeks","hospitalization with MIS-C","hospitalization with MIS-C","severe","omicron",92,71,98,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"2443",295,"Zambrano","Test-negative case-control",2501,2022-08-04,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"28+","12-18 years","12-18 years","included","~40 weeks","hospitalization with MIS-C","hospitalization with MIS-C","severe","delta",94,83,98,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"2444",295,"Zambrano","Test-negative case-control",2502,2022-08-04,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"28-120","12-18 years","12-18 years","included","~40 weeks","hospitalization with MIS-C","hospitalization with MIS-C","severe","delta/omicron",90,75,96,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"2445",295,"Zambrano","Test-negative case-control",2503,2022-08-04,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"120+","12-18 years","12-18 years","included","~40 weeks","hospitalization with MIS-C","hospitalization with MIS-C","severe","delta/omicron",92,78,97,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"2446",295,"Zambrano","Test-negative case-control",2504,2022-08-04,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"28+","5-11 years","5-11 years","included","~16 weeks","hospitalization with MIS-C","hospitalization with MIS-C","severe","delta/omicron",78,48,90,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"2447",296,"El Adam","Test-negative case-control",2505,2022-04-15,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"14+","HCW","HCW","excluded","~34 weeks","infection","infection","infection","other combinations",89,87,91,"Canada","CAN","North America","North America",46580,2019,"Canada","High income",4,NA,NA,NA,NA,NA
"2448",296,"El Adam","Test-negative case-control",2506,2022-04-15,"Moderna mRNA-1273","mRNA","2","final",NA,"14+","HCW","HCW","excluded","~34 weeks","infection","infection","infection","other combinations",93,90,95,"Canada","CAN","North America","North America",46580,2019,"Canada","High income",4,NA,NA,NA,NA,NA
"2449",296,"El Adam","Test-negative case-control",2507,2022-04-15,"Multiple or heterologous RNA","mRNA","2","final",NA,"14+","HCW","HCW","excluded","~34 weeks","infection","infection","infection","other combinations",92,86,95,"Canada","CAN","North America","North America",46580,2019,"Canada","High income",4,NA,NA,NA,NA,NA
"2450",296,"El Adam","Test-negative case-control",2508,2022-04-15,"Multiple or heterologous RNA","mRNA","2","final",NA,"14+","HCW","HCW","excluded","~34 weeks","infection","infection","infection","other combinations",90,88,92,"Canada","CAN","North America","North America",46580,2019,"Canada","High income",4,NA,NA,NA,NA,NA
"2451",296,"El Adam","Test-negative case-control",2509,2022-04-15,"Multiple or heterologous RNA","mRNA","2","final",NA,"14-20","HCW","HCW","excluded","~34 weeks","infection","infection","infection","other combinations",99,90,100,"Canada","CAN","North America","North America",46580,2019,"Canada","High income",4,NA,NA,NA,NA,NA
"2452",296,"El Adam","Test-negative case-control",2510,2022-04-15,"Multiple or heterologous RNA","mRNA","2","final",NA,"196+","HCW","HCW","excluded","~34 weeks","infection","infection","infection","other combinations",82,75,87,"Canada","CAN","North America","North America",46580,2019,"Canada","High income",4,NA,NA,NA,NA,NA
"2453",297,"Lewis","Retrospective cohort",2511,2022-07-27,"Multiple or heterologous RNA","mRNA","2","final",NA,"14+",">= 12 years",">= 12 years","previously infected only","~46 weeks","infection","infection","infection","other combinations",64,58,69,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"2454",297,"Lewis","Retrospective cohort",2512,2022-07-27,"Janssen Ad26.COV2.S","Vectored","1","final",NA,"14+",">= 12 years",">= 12 years","previously infected only","~46 weeks","infection","infection","infection","other combinations",48,26,63,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"2455",297,"Lewis","Retrospective cohort",2513,2022-07-27,"Multiple or heterologous RNA","mRNA","2","final",NA,"14+","LTCF residents","LTCF residents","previously infected only","~46 weeks","infection","infection","infection","other combinations",49,26,65,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"2456",297,"Lewis","Retrospective cohort",2514,2022-07-27,"Janssen Ad26.COV2.S","Vectored","1","final",NA,"14+","LTCF residents","LTCF residents","previously infected only","~46 weeks","infection","infection","infection","other combinations",57,-211,94,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"2457",297,"Lewis","Retrospective cohort",2515,2022-07-27,"Multiple or heterologous RNA","mRNA","2","final",NA,"14+","LTCF employees","LTCF employees","previously infected only","~46 weeks","infection","infection","infection","other combinations",52,26,68,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"2458",297,"Lewis","Retrospective cohort",2516,2022-07-27,"Janssen Ad26.COV2.S","Vectored","1","final",NA,"14+","LTCF employees","LTCF employees","previously infected only","~46 weeks","infection","infection","infection","other combinations",-68,-415,45,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"2459",298,"Cheng","Retrospective cohort",2517,2022-08-11,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"14+","patients with chronic kidney disease","patients with chronic kidney disease","excluded","~51 weeks","infection","infection","infection","omicron",38,34,41,"Hong Kong","HKG","Asia","East Asia & Pacific",50480,2019,"Hong Kong SAR, China","High income",4,NA,NA,NA,NA,NA
"2460",298,"Cheng","Retrospective cohort",2518,2022-08-11,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"14+","patients with chronic kidney disease","patients with chronic kidney disease","excluded","~51 weeks","hospitalization","severe","severe","omicron",64,57,69,"Hong Kong","HKG","Asia","East Asia & Pacific",50480,2019,"Hong Kong SAR, China","High income",4,NA,NA,NA,NA,NA
"2461",298,"Cheng","Retrospective cohort",2519,2022-08-11,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"14+","patients with chronic kidney disease","patients with chronic kidney disease","excluded","~51 weeks","death","death","death","omicron",86,80,90,"Hong Kong","HKG","Asia","East Asia & Pacific",50480,2019,"Hong Kong SAR, China","High income",4,NA,NA,NA,NA,NA
"2462",298,"Cheng","Retrospective cohort",2520,2022-08-11,"Sinovac CoronaVac","Inactivated","2","final",NA,"14+","patients with chronic kidney disease","patients with chronic kidney disease","excluded","~51 weeks","infection","infection","infection","omicron",4,0,8,"Hong Kong","HKG","Asia","East Asia & Pacific",50480,2019,"Hong Kong SAR, China","High income",4,NA,NA,NA,NA,NA
"2463",298,"Cheng","Retrospective cohort",2521,2022-08-11,"Sinovac CoronaVac","Inactivated","2","final",NA,"14+","patients with chronic kidney disease","patients with chronic kidney disease","excluded","~51 weeks","hospitalization","severe","severe","omicron",44,37,91,"Hong Kong","HKG","Asia","East Asia & Pacific",50480,2019,"Hong Kong SAR, China","High income",4,NA,NA,NA,NA,NA
"2464",298,"Cheng","Retrospective cohort",2522,2022-08-11,"Sinovac CoronaVac","Inactivated","2","final",NA,"14+","patients with chronic kidney disease","patients with chronic kidney disease","excluded","~51 weeks","death","death","death","omicron",70,64,75,"Hong Kong","HKG","Asia","East Asia & Pacific",50480,2019,"Hong Kong SAR, China","High income",4,NA,NA,NA,NA,NA
"2465",299,"Risk","Retrospective cohort",2523,2022-08-16,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"14+","immunocompromised adults","immunocompromised adults","included","~56 weeks","infection","infection","infection","omicron",13,-23,39,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"2466",299,"Risk","Retrospective cohort",2524,2022-08-16,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"14+","immunocompetent adults","immunocompetent adults","included","~56 weeks","infection","infection","infection","omicron",-6,-16,4,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"2467",299,"Risk","Retrospective cohort",2525,2022-08-16,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"14+",">= 18 years","general pop","included","~56 weeks","hospitalization","severe","severe","omicron",67,51,78,"USA","USA","North America","North America",66220,2019,"United States","High income",4,14,392,"yes",NA,0
"2468",299,"Risk","Retrospective cohort",2526,2022-08-16,"Moderna mRNA-1273","mRNA","2","final",NA,"14+","immunocompromised adults","immunocompromised adults","included","~56 weeks","infection","infection","infection","omicron",57,29,74,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"2469",299,"Risk","Retrospective cohort",2527,2022-08-16,"Moderna mRNA-1273","mRNA","2","final",NA,"14+","immunocompetent adults","immunocompetent adults","included","~56 weeks","infection","infection","infection","omicron",16,5,26,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"2470",299,"Risk","Retrospective cohort",2528,2022-08-16,"Moderna mRNA-1273","mRNA","2","final",NA,"14+",">= 18 years","general pop","included","~56 weeks","hospitalization","severe","severe","omicron",79,63,88,"USA","USA","North America","North America",66220,2019,"United States","High income",4,14,392,"yes",NA,0
"2471",299,"Risk","Retrospective cohort",2529,2022-08-16,"Multiple or heterologous RNA","mRNA","2","final",NA,"14+","immunocompromised adults","immunocompromised adults","included","~56 weeks","hospitalization","severe","severe","omicron",85,62,94,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"2472",299,"Risk","Retrospective cohort",2530,2022-08-16,"Multiple or heterologous RNA","mRNA","2","final",NA,"14+","immunocompetent adults","immunocompetent adults","included","~56 weeks","hospitalization","severe","severe","omicron",68,53,78,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"2473",299,"Risk","Retrospective cohort",2531,2022-08-16,"Multiple or heterologous RNA","mRNA","2","final",NA,"14+",">= 18 years","general pop","included","~56 weeks","ICU admission","severe","severe","omicron",92,66,98,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"2474",300,"Kim","Retrospective cohort",2532,2022-08-17,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"14-29","12-18 years","12-18 years","excluded","~6 weeks","infection","infection","infection","delta/omicron",76.6,74.3,78.6,"South Korea","KOR","Asia","East Asia & Pacific",33830,2019,"Korea, Rep.","High income",4,NA,NA,NA,NA,NA
"2475",300,"Kim","Retrospective cohort",2533,2022-08-17,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"30-59","12-18 years","12-18 years","excluded","~6 weeks","infection","infection","infection","delta/omicron",49.6,45.9,53.2,"South Korea","KOR","Asia","East Asia & Pacific",33830,2019,"Korea, Rep.","High income",4,NA,NA,NA,NA,NA
"2476",300,"Kim","Retrospective cohort",2534,2022-08-17,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"14-29","12-18 years","12-18 years","excluded","~11 weeks","infection","infection","infection","delta/omicron",83.5,81.3,85.4,"South Korea","KOR","Asia","East Asia & Pacific",33830,2019,"Korea, Rep.","High income",4,NA,NA,NA,NA,NA
"2477",300,"Kim","Retrospective cohort",2535,2022-08-17,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"60-89","12-18 years","12-18 years","excluded","~11 weeks","infection","infection","infection","delta/omicron",41.8,35.3,47.6,"South Korea","KOR","Asia","East Asia & Pacific",33830,2019,"Korea, Rep.","High income",4,NA,NA,NA,NA,NA
"2478",300,"Kim","Retrospective cohort",2536,2022-08-17,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"14-29","12-18 years","12-18 years","excluded","~22 weeks","infection","infection","infection","delta/omicron",82.8,75.1,88.1,"South Korea","KOR","Asia","East Asia & Pacific",33830,2019,"Korea, Rep.","High income",4,NA,NA,NA,NA,NA
"2479",300,"Kim","Retrospective cohort",2537,2022-08-17,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"90+","12-18 years","12-18 years","excluded","~22 weeks","infection","infection","infection","delta/omicron",28.9,20.6,36.4,"South Korea","KOR","Asia","East Asia & Pacific",33830,2019,"Korea, Rep.","High income",4,NA,NA,NA,NA,NA
"2480",301,"Yan","Case-control",2538,2022-08-18,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"14+","18-50 years","18-50 years","excluded","~52 weeks","severe disease","severe","severe","omicron",73.7,54.2,84.9,"Hong Kong","HKG","Asia","East Asia & Pacific",50480,2019,"Hong Kong SAR, China","High income",4,14,364,"yes",NA,0
"2481",301,"Yan","Case-control",2539,2022-08-18,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"14+","51-64 years","51-64 years","excluded","~52 weeks","severe disease","severe","severe","omicron",84.5,72.2,91.4,"Hong Kong","HKG","Asia","East Asia & Pacific",50480,2019,"Hong Kong SAR, China","High income",4,14,364,"yes",NA,0
"2482",301,"Yan","Case-control",2540,2022-08-18,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"14+",">= 65 years",">= 65 years","excluded","~52 weeks","severe disease","severe","severe","omicron",81.9,74.4,87.2,"Hong Kong","HKG","Asia","East Asia & Pacific",50480,2019,"Hong Kong SAR, China","High income",4,14,364,"yes",NA,1
"2483",301,"Yan","Case-control",2541,2022-08-18,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"14+","18-50 years","18-50 years","excluded","~52 weeks","death","death","death","omicron",84.2,67.3,92.4,"Hong Kong","HKG","Asia","East Asia & Pacific",50480,2019,"Hong Kong SAR, China","High income",4,NA,NA,NA,NA,NA
"2484",301,"Yan","Case-control",2542,2022-08-18,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"14+","51-64 years","51-64 years","excluded","~52 weeks","death","death","death","omicron",86.9,80.3,91.3,"Hong Kong","HKG","Asia","East Asia & Pacific",50480,2019,"Hong Kong SAR, China","High income",4,NA,NA,NA,NA,NA
"2485",301,"Yan","Case-control",2543,2022-08-18,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"14+",">= 65 years",">= 65 years","excluded","~52 weeks","death","death","death","omicron",90.6,88.5,92.4,"Hong Kong","HKG","Asia","East Asia & Pacific",50480,2019,"Hong Kong SAR, China","High income",4,NA,NA,NA,NA,NA
"2486",301,"Yan","Case-control",2544,2022-08-18,"Sinovac CoronaVac","Inactivated","2","final",NA,"14+","18-50 years","18-50 years","excluded","~52 weeks","severe disease","severe","severe","omicron",72.6,40.1,87.5,"Hong Kong","HKG","Asia","East Asia & Pacific",50480,2019,"Hong Kong SAR, China","High income",4,NA,NA,NA,NA,NA
"2487",301,"Yan","Case-control",2545,2022-08-18,"Sinovac CoronaVac","Inactivated","2","final",NA,"14+","51-64 years","51-64 years","excluded","~52 weeks","severe disease","severe","severe","omicron",67.8,48.7,79.7,"Hong Kong","HKG","Asia","East Asia & Pacific",50480,2019,"Hong Kong SAR, China","High income",4,NA,NA,NA,NA,NA
"2488",301,"Yan","Case-control",2546,2022-08-18,"Sinovac CoronaVac","Inactivated","2","final",NA,"14+",">= 65 years",">= 65 years","excluded","~52 weeks","severe disease","severe","severe","omicron",56.7,47.4,64.4,"Hong Kong","HKG","Asia","East Asia & Pacific",50480,2019,"Hong Kong SAR, China","High income",4,NA,NA,NA,NA,NA
"2489",301,"Yan","Case-control",2547,2022-08-18,"Sinovac CoronaVac","Inactivated","2","final",NA,"14+","18-50 years","18-50 years","excluded","~52 weeks","death","death","death","omicron",83.7,57.9,93.7,"Hong Kong","HKG","Asia","East Asia & Pacific",50480,2019,"Hong Kong SAR, China","High income",4,NA,NA,NA,NA,NA
"2490",301,"Yan","Case-control",2548,2022-08-18,"Sinovac CoronaVac","Inactivated","2","final",NA,"14+","51-64 years","51-64 years","excluded","~52 weeks","death","death","death","omicron",78.1,69.4,84.3,"Hong Kong","HKG","Asia","East Asia & Pacific",50480,2019,"Hong Kong SAR, China","High income",4,NA,NA,NA,NA,NA
"2491",301,"Yan","Case-control",2549,2022-08-18,"Sinovac CoronaVac","Inactivated","2","final",NA,"14+",">= 65 years",">= 65 years","excluded","~52 weeks","death","death","death","omicron",72.5,69.9,74.9,"Hong Kong","HKG","Asia","East Asia & Pacific",50480,2019,"Hong Kong SAR, China","High income",4,NA,NA,NA,NA,NA
"2492",302,"Powell","Test-negative case-control",2550,2022-08-22,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"14-104","11-17 years","11-17 years","excluded","~38 weeks","symptomatic disease","symptomatic","symptomatic","omicron",64.5,63.6,65.4,"UK","GBR","Europe","Europe & Central Asia",43240,2019,"United Kingdom","High income",4,NA,NA,NA,NA,NA
"2493",302,"Powell","Test-negative case-control",2551,2022-08-22,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"280-286","11-17 years","11-17 years","excluded","~38 weeks","symptomatic disease","symptomatic","symptomatic","omicron",25.7,-4.2,47,"UK","GBR","Europe","Europe & Central Asia",43240,2019,"United Kingdom","High income",4,NA,NA,NA,NA,NA
"2494",302,"Powell","Test-negative case-control",2552,2022-08-22,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"14-104","11-17 years","11-17 years","excluded","~38 weeks","symptomatic disease","symptomatic","symptomatic","delta",91.8,91.2,92.3,"UK","GBR","Europe","Europe & Central Asia",43240,2019,"United Kingdom","High income",4,NA,NA,NA,NA,NA
"2495",302,"Powell","Test-negative case-control",2553,2022-08-22,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"175-279","11-17 years","11-17 years","excluded","~38 weeks","symptomatic disease","symptomatic","symptomatic","delta",71.9,67.9,75.4,"UK","GBR","Europe","Europe & Central Asia",43240,2019,"United Kingdom","High income",4,NA,NA,NA,NA,NA
"2496",303,"Wan","Case-control",2554,2022-08-17,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"14+",">=12 years with diabetes mellitus",">=12 years with diabetes mellitus","excluded","~53 weeks","infection","infection","infection","omicron",22.1,20,24.2,"Hong Kong","HKG","Asia","East Asia & Pacific",50480,2019,"Hong Kong SAR, China","High income",4,NA,NA,NA,NA,NA
"2497",303,"Wan","Case-control",2555,2022-08-17,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"14+",">=12 years with diabetes mellitus",">=12 years with diabetes mellitus","excluded","~53 weeks","hospitalization","severe","severe","omicron",74.2,71.7,76.4,"Hong Kong","HKG","Asia","East Asia & Pacific",50480,2019,"Hong Kong SAR, China","High income",4,NA,NA,NA,NA,NA
"2498",303,"Wan","Case-control",2556,2022-08-17,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"14+",">=12 years with diabetes mellitus",">=12 years with diabetes mellitus","excluded","~53 weeks","ICU admission","severe","severe","omicron",82.3,72.1,88.8,"Hong Kong","HKG","Asia","East Asia & Pacific",50480,2019,"Hong Kong SAR, China","High income",4,NA,NA,NA,NA,NA
"2499",303,"Wan","Case-control",2557,2022-08-17,"Sinovac CoronaVac","Inactivated","2","final",NA,"14+",">=12 years with diabetes mellitus",">=12 years with diabetes mellitus","excluded","~53 weeks","infection","infection","infection","omicron",-0.3,-2.7,2.1,"Hong Kong","HKG","Asia","East Asia & Pacific",50480,2019,"Hong Kong SAR, China","High income",4,NA,NA,NA,NA,NA
"2500",303,"Wan","Case-control",2558,2022-08-17,"Sinovac CoronaVac","Inactivated","2","final",NA,"14+",">=12 years with diabetes mellitus",">=12 years with diabetes mellitus","excluded","~53 weeks","hospitalization","severe","severe","omicron",64.2,61.8,66.4,"Hong Kong","HKG","Asia","East Asia & Pacific",50480,2019,"Hong Kong SAR, China","High income",4,NA,NA,NA,NA,NA
"2501",303,"Wan","Case-control",2559,2022-08-17,"Sinovac CoronaVac","Inactivated","2","final",NA,"14+",">=12 years with diabetes mellitus",">=12 years with diabetes mellitus","excluded","~53 weeks","ICU admission","severe","severe","omicron",58.1,45,68.1,"Hong Kong","HKG","Asia","East Asia & Pacific",50480,2019,"Hong Kong SAR, China","High income",4,NA,NA,NA,NA,NA
"2502",304,"Tsang","Prospective cohort",2560,2022-12-12,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"14-89",">=5 years","general pop","excluded","~55 weeks","infection","infection","infection","omicron",27.6,-6.3,50.7,"Hong Kong","HKG","Asia","East Asia & Pacific",50480,2019,"Hong Kong SAR, China","High income",4,NA,NA,NA,NA,NA
"2503",304,"Tsang","Prospective cohort",2561,2022-12-12,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"90+",">=5 years","general pop","excluded","~55 weeks","infection","infection","infection","omicron",1.1,-22.4,20.1,"Hong Kong","HKG","Asia","East Asia & Pacific",50480,2019,"Hong Kong SAR, China","High income",4,NA,NA,NA,NA,NA
"2504",304,"Tsang","Prospective cohort",2562,2022-12-12,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"14-89",">=5 years","general pop","excluded","~55 weeks","symptomatic disease","symptomatic","symptomatic","omicron",31.6,-9.3,57.2,"Hong Kong","HKG","Asia","East Asia & Pacific",50480,2019,"Hong Kong SAR, China","High income",4,NA,NA,NA,NA,NA
"2505",304,"Tsang","Prospective cohort",2563,2022-12-12,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"90+",">=5 years","general pop","excluded","~55 weeks","symptomatic disease","symptomatic","symptomatic","omicron",4.7,-23.5,26.6,"Hong Kong","HKG","Asia","East Asia & Pacific",50480,2019,"Hong Kong SAR, China","High income",4,NA,NA,NA,NA,NA
"2506",304,"Tsang","Prospective cohort",2564,2022-12-12,"Sinovac CoronaVac","Inactivated","2","final",NA,"14-89",">=5 years","general pop","excluded","~55 weeks","infection","infection","infection","omicron",22.7,-15.2,48.2,"Hong Kong","HKG","Asia","East Asia & Pacific",50480,2019,"Hong Kong SAR, China","High income",4,NA,NA,NA,NA,NA
"2507",304,"Tsang","Prospective cohort",2565,2022-12-12,"Sinovac CoronaVac","Inactivated","2","final",NA,"90+",">=5 years","general pop","excluded","~55 weeks","infection","infection","infection","omicron",5.4,-25.6,28.8,"Hong Kong","HKG","Asia","East Asia & Pacific",50480,2019,"Hong Kong SAR, China","High income",4,NA,NA,NA,NA,NA
"2508",304,"Tsang","Prospective cohort",2566,2022-12-12,"Sinovac CoronaVac","Inactivated","2","final",NA,"14-89",">=5 years","general pop","excluded","~55 weeks","symptomatic disease","symptomatic","symptomatic","omicron",12.2,-40,44.9,"Hong Kong","HKG","Asia","East Asia & Pacific",50480,2019,"Hong Kong SAR, China","High income",4,NA,NA,NA,NA,NA
"2509",304,"Tsang","Prospective cohort",2567,2022-12-12,"Sinovac CoronaVac","Inactivated","2","final",NA,"90+",">=5 years","general pop","excluded","~55 weeks","symptomatic disease","symptomatic","symptomatic","omicron",6.4,-32.1,33.7,"Hong Kong","HKG","Asia","East Asia & Pacific",50480,2019,"Hong Kong SAR, China","High income",4,NA,NA,NA,NA,NA
"2510",305,"Cocchio","Retrospective cohort",2568,2022-08-20,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"14-34","5-11 years","5-11 years","excluded","~16 weeks","infection","infection","infection","omicron",53,51,55,"Italy","ITA","Europe","Europe & Central Asia",34890,2019,"Italy","High income",4,NA,NA,NA,NA,NA
"2511",305,"Cocchio","Retrospective cohort",2569,2022-08-20,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"70+","5-11 years","5-11 years","excluded","~16 weeks","infection","infection","infection","omicron",23,20,26,"Italy","ITA","Europe","Europe & Central Asia",34890,2019,"Italy","High income",4,NA,NA,NA,NA,NA
"2512",305,"Cocchio","Retrospective cohort",2570,2022-08-20,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"14-34","12-17 years","12-17 years","excluded","~53 weeks","infection","infection","infection","omicron",59,55,62,"Italy","ITA","Europe","Europe & Central Asia",34890,2019,"Italy","High income",4,NA,NA,NA,NA,NA
"2513",305,"Cocchio","Retrospective cohort",2571,2022-08-20,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"70+","12-17 years","12-17 years","excluded","~53 weeks","infection","infection","infection","omicron",8,5,11,"Italy","ITA","Europe","Europe & Central Asia",34890,2019,"Italy","High income",4,NA,NA,NA,NA,NA
"2514",305,"Cocchio","Retrospective cohort",2572,2022-08-20,"Moderna mRNA-1273","mRNA","2","final",NA,"14-34","12-17 years","12-17 years","excluded","~33 weeks","infection","infection","infection","omicron",55,49,61,"Italy","ITA","Europe","Europe & Central Asia",34890,2019,"Italy","High income",4,NA,NA,NA,NA,NA
"2515",305,"Cocchio","Retrospective cohort",2573,2022-08-20,"Moderna mRNA-1273","mRNA","2","final",NA,"70+","12-17 years","12-17 years","excluded","~33 weeks","infection","infection","infection","omicron",20,15,24,"Italy","ITA","Europe","Europe & Central Asia",34890,2019,"Italy","High income",4,NA,NA,NA,NA,NA
"2516",305,"Cocchio","Retrospective cohort",2574,2022-08-20,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"14-34","12-17 years","12-17 years","excluded","~28 weeks","infection","infection","infection","delta",88,85,91,"Italy","ITA","Europe","Europe & Central Asia",34890,2019,"Italy","High income",4,NA,NA,NA,NA,NA
"2517",305,"Cocchio","Retrospective cohort",2575,2022-08-20,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"70+","12-17 years","12-17 years","excluded","~28 weeks","infection","infection","infection","delta",82,74,88,"Italy","ITA","Europe","Europe & Central Asia",34890,2019,"Italy","High income",4,NA,NA,NA,NA,NA
"2518",305,"Cocchio","Retrospective cohort",2576,2022-08-20,"Moderna mRNA-1273","mRNA","2","final",NA,"14-34","12-17 years","12-17 years","excluded","~7 weeks","infection","infection","infection","delta",90,68,97,"Italy","ITA","Europe","Europe & Central Asia",34890,2019,"Italy","High income",4,NA,NA,NA,NA,NA
"2519",305,"Cocchio","Retrospective cohort",2577,2022-08-20,"Moderna mRNA-1273","mRNA","2","final",NA,"35-69","12-17 years","12-17 years","excluded","~7 weeks","infection","infection","infection","delta",96,86,99,"Italy","ITA","Europe","Europe & Central Asia",34890,2019,"Italy","High income",4,NA,NA,NA,NA,NA
"2520",306,"Lim","Test-negative case-control",2578,2022-08-24,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"14-27",">=18 years","general pop","excluded","~28 weeks","infection","infection","infection","other combinations",58.9,40.7,71.9,"Malaysia","MYS","Asia","East Asia & Pacific",10750,2019,"Malaysia","Upper middle income",3,NA,NA,NA,NA,NA
"2521",306,"Lim","Test-negative case-control",2579,2022-08-24,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"98-111",">=18 years","general pop","excluded","~28 weeks","infection","infection","infection","other combinations",31.3,10.8,47.2,"Malaysia","MYS","Asia","East Asia & Pacific",10750,2019,"Malaysia","Upper middle income",3,NA,NA,NA,NA,NA
"2522",306,"Lim","Test-negative case-control",2580,2022-08-24,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"14+",">=18 years","general pop","excluded","~28 weeks","ICU admission","severe","severe","other combinations",92.5,72.3,98.8,"Malaysia","MYS","Asia","East Asia & Pacific",10750,2019,"Malaysia","Upper middle income",3,NA,NA,NA,NA,NA
"2523",306,"Lim","Test-negative case-control",2581,2022-08-24,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"14+",">=18 years","general pop","excluded","~28 weeks","death","death","death","other combinations",96.5,82.3,99.8,"Malaysia","MYS","Asia","East Asia & Pacific",10750,2019,"Malaysia","Upper middle income",3,NA,NA,NA,NA,NA
"2524",306,"Lim","Retrospective cohort",2582,2022-08-24,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"14+",">=18 years","general pop","excluded","~28 weeks","infection","infection","infection","other combinations",87.9,86.3,89.4,"Malaysia","MYS","Asia","East Asia & Pacific",10750,2019,"Malaysia","Upper middle income",3,NA,NA,NA,NA,NA
"2525",306,"Lim","Retrospective cohort",2583,2022-08-24,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"14+",">=18 years","general pop","excluded","~28 weeks","ICU admission","severe","severe","other combinations",97.5,81.2,99.6,"Malaysia","MYS","Asia","East Asia & Pacific",10750,2019,"Malaysia","Upper middle income",3,NA,NA,NA,NA,NA
"2526",306,"Lim","Retrospective cohort",2584,2022-08-24,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"14+",">=18 years","general pop","excluded","~28 weeks","death","death","death","other combinations",99.3,96.3,100,"Malaysia","MYS","Asia","East Asia & Pacific",10750,2019,"Malaysia","Upper middle income",3,NA,NA,NA,NA,NA
"2527",307,"Lind","Test-negative case-control",2585,2022-11-21,"Multiple or heterologous RNA","mRNA","2","final",NA,"14-89",">=16 years","general pop","excluded","~29 weeks","infection","infection","infection","alpha",84.4,75.5,90,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"2528",307,"Lind","Test-negative case-control",2586,2022-11-21,"Multiple or heterologous RNA","mRNA","2","final",NA,"90-149",">=16 years","general pop","excluded","~29 weeks","infection","infection","infection","alpha",96.5,75.1,99.5,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"2529",307,"Lind","Test-negative case-control",2587,2022-11-21,"Multiple or heterologous RNA","mRNA","2","final",NA,"14-89",">=16 years","general pop","excluded","~29 weeks","symptomatic disease","symptomatic","symptomatic","alpha",86.6,75.5,92.7,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"2530",307,"Lind","Test-negative case-control",2588,2022-11-21,"Multiple or heterologous RNA","mRNA","2","final",NA,"90-149",">=16 years","general pop","excluded","~29 weeks","symptomatic disease","symptomatic","symptomatic","alpha",93.8,55,99.1,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"2531",307,"Lind","Test-negative case-control",2589,2022-11-21,"Multiple or heterologous RNA","mRNA","2","final",NA,"14-89",">=16 years","general pop","excluded","~29 weeks","hospitalization","severe","severe","alpha",85.5,65.5,93.9,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"2532",307,"Lind","Test-negative case-control",2590,2022-11-21,"Multiple or heterologous RNA","mRNA","2","final",NA,"90-149",">=16 years","general pop","excluded","~29 weeks","hospitalization","severe","severe","alpha",82.2,-34.5,97.7,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"2533",307,"Lind","Test-negative case-control",2591,2022-11-21,"Multiple or heterologous RNA","mRNA","2","final",NA,"14-89",">=16 years","general pop","excluded","~29 weeks","infection","infection","infection","delta",68.9,58,77.1,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"2534",307,"Lind","Test-negative case-control",2592,2022-11-21,"Multiple or heterologous RNA","mRNA","2","final",NA,"150+",">=16 years","general pop","excluded","~29 weeks","infection","infection","infection","delta",37.1,24,48.1,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"2535",307,"Lind","Test-negative case-control",2593,2022-11-21,"Multiple or heterologous RNA","mRNA","2","final",NA,"14-89",">=16 years","general pop","excluded","~29 weeks","symptomatic disease","symptomatic","symptomatic","delta",74.8,62.9,82.9,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"2536",307,"Lind","Test-negative case-control",2594,2022-11-21,"Multiple or heterologous RNA","mRNA","2","final",NA,"150+",">=16 years","general pop","excluded","~29 weeks","symptomatic disease","symptomatic","symptomatic","delta",48.4,32.8,60.4,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"2537",307,"Lind","Test-negative case-control",2595,2022-11-21,"Multiple or heterologous RNA","mRNA","2","final",NA,"14-89",">=16 years","general pop","excluded","~29 weeks","hospitalization","severe","severe","delta",85.4,60.2,94.6,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"2538",307,"Lind","Test-negative case-control",2596,2022-11-21,"Multiple or heterologous RNA","mRNA","2","final",NA,"150+",">=16 years","general pop","excluded","~29 weeks","hospitalization","severe","severe","delta",66.2,42.5,80.1,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"2539",308,"Suphanchaimat","Test-negative case-control",2597,2022-07-05,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"15-29",">=18 years","general pop","included","~2 weeks","infection","infection","infection","delta",74.2,71.8,76.3,"Thailand","THA","Asia","East Asia & Pacific",7060,2019,"Thailand","Upper middle income",3,NA,NA,NA,NA,NA
"2540",308,"Suphanchaimat","Test-negative case-control",2598,2022-07-05,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"90+",">=18 years","general pop","included","~15 weeks","infection","infection","infection","delta",57,43.6,57.2,"Thailand","THA","Asia","East Asia & Pacific",7060,2019,"Thailand","Upper middle income",3,NA,NA,NA,NA,NA
"2541",308,"Suphanchaimat","Test-negative case-control",2599,2022-07-05,"Oxford/AstraZeneca ChAdOx1-S","Vectored","2","final",NA,"15-29",">=18 years","general pop","included","~2 weeks","infection","infection","infection","delta",61.4,59.6,63.2,"Thailand","THA","Asia","East Asia & Pacific",7060,2019,"Thailand","Upper middle income",3,NA,NA,NA,NA,NA
"2542",308,"Suphanchaimat","Test-negative case-control",2600,2022-07-05,"Oxford/AstraZeneca ChAdOx1-S","Vectored","2","final",NA,"90+",">=18 years","general pop","included","~31 weeks","infection","infection","infection","delta",25.8,19.1,31.9,"Thailand","THA","Asia","East Asia & Pacific",7060,2019,"Thailand","Upper middle income",3,NA,NA,NA,NA,NA
"2543",308,"Suphanchaimat","Test-negative case-control",2601,2022-07-05,"Sinovac CoronaVac","Inactivated","2","final",NA,"15-29",">=18 years","general pop","included","~2 weeks","infection","infection","infection","delta",27.9,0.3,47.9,"Thailand","THA","Asia","East Asia & Pacific",7060,2019,"Thailand","Upper middle income",3,NA,NA,NA,NA,NA
"2544",308,"Suphanchaimat","Test-negative case-control",2602,2022-07-05,"Sinovac CoronaVac","Inactivated","2","final",NA,"90+",">=18 years","general pop","included","~40 weeks","infection","infection","infection","delta",49.8,47.8,51.6,"Thailand","THA","Asia","East Asia & Pacific",7060,2019,"Thailand","Upper middle income",3,NA,NA,NA,NA,NA
"2545",308,"Suphanchaimat","Test-negative case-control",2603,2022-07-05,"Heterologous platforms","Multiple","2","final",NA,"15-29",">=18 years","general pop","included","~2 weeks","infection","infection","infection","delta",79.9,74,84.5,"Thailand","THA","Asia","East Asia & Pacific",7060,2019,"Thailand","Upper middle income",3,NA,NA,NA,NA,NA
"2546",308,"Suphanchaimat","Test-negative case-control",2604,2022-07-05,"Heterologous platforms","Multiple","2","final",NA,"90+",">=18 years","general pop","included","~19 weeks","infection","infection","infection","delta",77.4,68.2,84,"Thailand","THA","Asia","East Asia & Pacific",7060,2019,"Thailand","Upper middle income",3,NA,NA,NA,NA,NA
"2547",308,"Suphanchaimat","Test-negative case-control",2605,2022-07-05,"Heterologous platforms","Multiple","2","final",NA,"15-29",">=18 years","general pop","included","~2 weeks","infection","infection","infection","delta",57.8,56.3,59.2,"Thailand","THA","Asia","East Asia & Pacific",7060,2019,"Thailand","Upper middle income",3,NA,NA,NA,NA,NA
"2548",308,"Suphanchaimat","Test-negative case-control",2606,2022-07-05,"Heterologous platforms","Multiple","2","final",NA,"90+",">=18 years","general pop","included","~39 weeks","infection","infection","infection","delta",36.6,33.6,39.4,"Thailand","THA","Asia","East Asia & Pacific",7060,2019,"Thailand","Upper middle income",3,NA,NA,NA,NA,NA
"2549",308,"Suphanchaimat","Test-negative case-control",2607,2022-07-05,"Heterologous platforms","Multiple","2","final",NA,"15-29",">=18 years","general pop","included","~2 weeks","infection","infection","infection","delta",74.7,62.8,82.8,"Thailand","THA","Asia","East Asia & Pacific",7060,2019,"Thailand","Upper middle income",3,NA,NA,NA,NA,NA
"2550",308,"Suphanchaimat","Test-negative case-control",2608,2022-07-05,"Heterologous platforms","Multiple","2","final",NA,"90+",">=18 years","general pop","included","~19 weeks","infection","infection","infection","delta",84.6,64.9,89.3,"Thailand","THA","Asia","East Asia & Pacific",7060,2019,"Thailand","Upper middle income",3,NA,NA,NA,NA,NA
"2551",309,"Barraza","Retrospective cohort",2609,2022-08-05,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"14+",">=18 years","general pop","included","~77 weeks","hospitalization with SARI","severe","severe","other combinations",80.3,68.9,87.5,"Chile","CHL","South America","Latin America & Caribbean",14690,2019,"Chile","High income",3,NA,NA,NA,NA,NA
"2552",309,"Barraza","Retrospective cohort",2610,2022-08-05,"Oxford/AstraZeneca ChAdOx1-S","Vectored","2","final",NA,"14+",">=18 years","general pop","included","~71 weeks","hospitalization with SARI","severe","severe","other combinations",72.4,32.8,88.6,"Chile","CHL","South America","Latin America & Caribbean",14690,2019,"Chile","High income",3,NA,NA,NA,NA,NA
"2553",309,"Barraza","Retrospective cohort",2611,2022-08-05,"Sinovac CoronaVac","Inactivated","2","final",NA,"14+",">=18 years","general pop","included","~72 weeks","hospitalization with SARI","severe","severe","other combinations",54.5,45.2,62.3,"Chile","CHL","South America","Latin America & Caribbean",14690,2019,"Chile","High income",3,NA,NA,NA,NA,NA
"2554",310,"Penayo","Test-negative case-control",2612,2022-06-01,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"14+",">=18 years","general pop","included","~38 weeks","hospitalization with SARI","severe","severe","delta",91.9,72.2,97.6,"Paraguay","PRY","South America","Latin America & Caribbean",5950,2019,"Paraguay","Upper middle income",2,14,266,"yes",NA,0
"2555",310,"Penayo","Test-negative case-control",2613,2022-06-01,"Moderna mRNA-1273","mRNA","2","final",NA,"14+",">=18 years","general pop","included","~37 weeks","hospitalization with SARI","severe","severe","delta",76.1,-127.4,97.5,"Paraguay","PRY","South America","Latin America & Caribbean",5950,2019,"Paraguay","Upper middle income",2,14,259,"yes",NA,0
"2556",310,"Penayo","Test-negative case-control",2614,2022-06-01,"Oxford/AstraZeneca ChAdOx1-S","Vectored","2","final",NA,"14+",">=18 years","general pop","included","~33 weeks","hospitalization with SARI","severe","severe","delta",83,66.3,91.5,"Paraguay","PRY","South America","Latin America & Caribbean",5950,2019,"Paraguay","Upper middle income",2,14,231,"yes",NA,0
"2557",310,"Penayo","Test-negative case-control",2615,2022-06-01,"Gamaleya Gam-COVID-Vac/Sputnik V","Vectored","2","final",NA,"14+",">=18 years","general pop","included","~38 weeks","hospitalization with SARI","severe","severe","delta",83.2,48.9,94.5,"Paraguay","PRY","South America","Latin America & Caribbean",5950,2019,"Paraguay","Upper middle income",2,NA,NA,NA,NA,NA
"2558",310,"Penayo","Test-negative case-control",2616,2022-06-01,"Beijing/Sinopharm BBIBP-CorV","Inactivated","2","final",NA,"14+",">=18 years","general pop","included","~39 weeks","hospitalization with SARI","severe","severe","delta",31.8,-41.2,67.1,"Paraguay","PRY","South America","Latin America & Caribbean",5950,2019,"Paraguay","Upper middle income",2,NA,NA,NA,NA,NA
"2559",310,"Penayo","Test-negative case-control",2617,2022-06-01,"Bharat Covaxin/BBV152","Inactivated","2","final",NA,"14+",">=18 years","general pop","included","~37 weeks","hospitalization with SARI","severe","severe","delta",25.8,-37.1,59.9,"Paraguay","PRY","South America","Latin America & Caribbean",5950,2019,"Paraguay","Upper middle income",2,NA,NA,NA,NA,NA
"2560",310,"Penayo","Test-negative case-control",2618,2022-06-01,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"14+",">=18 years","general pop","included","~53 weeks","hospitalization with SARI","severe","severe","omicron",49.5,9.9,71.7,"Paraguay","PRY","South America","Latin America & Caribbean",5950,2019,"Paraguay","Upper middle income",2,14,371,"yes",NA,0
"2561",310,"Penayo","Test-negative case-control",2619,2022-06-01,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"14-89",">=18 years","general pop","included","~11 weeks","hospitalization with SARI","severe","severe","omicron",78,-97,97.5,"Paraguay","PRY","South America","Latin America & Caribbean",5950,2019,"Paraguay","Upper middle income",2,14,89,"no","nested endpoint",0
"2562",310,"Penayo","Test-negative case-control",2620,2022-06-01,"Moderna mRNA-1273","mRNA","2","final",NA,"14+",">=18 years","general pop","included","~52 weeks","hospitalization with SARI","severe","severe","omicron",42.1,-105.4,83.7,"Paraguay","PRY","South America","Latin America & Caribbean",5950,2019,"Paraguay","Upper middle income",2,14,364,"yes",NA,0
"2563",310,"Penayo","Test-negative case-control",2621,2022-06-01,"Oxford/AstraZeneca ChAdOx1-S","Vectored","2","final",NA,"14+",">=18 years","general pop","included","~48 weeks","hospitalization with SARI","severe","severe","omicron",10.1,-31,38.3,"Paraguay","PRY","South America","Latin America & Caribbean",5950,2019,"Paraguay","Upper middle income",2,14,336,"yes",NA,0
"2564",310,"Penayo","Test-negative case-control",2622,2022-06-01,"Gamaleya Gam-COVID-Vac/Sputnik V","Vectored","2","final",NA,"14+",">=18 years","general pop","included","~53 weeks","hospitalization with SARI","severe","severe","omicron",25.7,-29.9,57.5,"Paraguay","PRY","South America","Latin America & Caribbean",5950,2019,"Paraguay","Upper middle income",2,NA,NA,NA,NA,NA
"2565",310,"Penayo","Test-negative case-control",2623,2022-06-01,"Gamaleya Gam-COVID-Vac/Sputnik V","Vectored","2","final",NA,"14-89",">=18 years","general pop","included","~11 weeks","hospitalization with SARI","severe","severe","omicron",64.4,-44.6,92.2,"Paraguay","PRY","South America","Latin America & Caribbean",5950,2019,"Paraguay","Upper middle income",2,NA,NA,NA,NA,NA
"2566",310,"Penayo","Test-negative case-control",2624,2022-06-01,"Beijing/Sinopharm BBIBP-CorV","Inactivated","2","final",NA,"14+",">=18 years","general pop","included","~54 weeks","hospitalization with SARI","severe","severe","omicron",40.4,-5.1,66.2,"Paraguay","PRY","South America","Latin America & Caribbean",5950,2019,"Paraguay","Upper middle income",2,NA,NA,NA,NA,NA
"2567",310,"Penayo","Test-negative case-control",2625,2022-06-01,"Bharat Covaxin/BBV152","Inactivated","2","final",NA,"14+",">=18 years","general pop","included","~52 weeks","hospitalization with SARI","severe","severe","omicron",13,-45.8,48,"Paraguay","PRY","South America","Latin America & Caribbean",5950,2019,"Paraguay","Upper middle income",2,NA,NA,NA,NA,NA
"2568",311,"Monge","Case cohort",2626,2022-09-02,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"14+","50-59 years","50-59 years","included","~21 weeks","infection","infection","infection","delta",77,76,77,"Spain","ESP","Europe","Europe & Central Asia",30370,2019,"Spain","High income",4,NA,NA,NA,NA,NA
"2569",311,"Monge","Case cohort",2627,2022-09-02,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"14+","50-59 years","50-59 years","included","~21 weeks","symptomatic disease","symptomatic","symptomatic","delta",77,76,78,"Spain","ESP","Europe","Europe & Central Asia",30370,2019,"Spain","High income",4,NA,NA,NA,NA,NA
"2570",311,"Monge","Case cohort",2628,2022-09-02,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"14+","50-59 years","50-59 years","included","~21 weeks","hospitalization","severe","severe","delta",97,97,98,"Spain","ESP","Europe","Europe & Central Asia",30370,2019,"Spain","High income",4,14,147,"yes",NA,0
"2571",311,"Monge","Case cohort",2629,2022-09-02,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"14+","50-59 years","50-59 years","included","~21 weeks","death","death","death","delta",97,93,99,"Spain","ESP","Europe","Europe & Central Asia",30370,2019,"Spain","High income",4,NA,NA,NA,NA,NA
"2572",311,"Monge","Case cohort",2630,2022-09-02,"Moderna mRNA-1273","mRNA","2","final",NA,"14+","50-59 years","50-59 years","included","~21 weeks","infection","infection","infection","delta",87,86,87,"Spain","ESP","Europe","Europe & Central Asia",30370,2019,"Spain","High income",4,NA,NA,NA,NA,NA
"2573",311,"Monge","Case cohort",2631,2022-09-02,"Moderna mRNA-1273","mRNA","2","final",NA,"14+","50-59 years","50-59 years","included","~21 weeks","symptomatic disease","symptomatic","symptomatic","delta",89,88,90,"Spain","ESP","Europe","Europe & Central Asia",30370,2019,"Spain","High income",4,NA,NA,NA,NA,NA
"2574",311,"Monge","Case cohort",2632,2022-09-02,"Moderna mRNA-1273","mRNA","2","final",NA,"14+","50-59 years","50-59 years","included","~21 weeks","hospitalization","severe","severe","delta",98,97,99,"Spain","ESP","Europe","Europe & Central Asia",30370,2019,"Spain","High income",4,14,147,"yes",NA,0
"2575",311,"Monge","Case cohort",2633,2022-09-02,"Moderna mRNA-1273","mRNA","2","final",NA,"14+","50-59 years","50-59 years","included","~21 weeks","death","death","death","delta",94,75,99,"Spain","ESP","Europe","Europe & Central Asia",30370,2019,"Spain","High income",4,NA,NA,NA,NA,NA
"2576",311,"Monge","Case cohort",2634,2022-09-02,"Oxford/AstraZeneca ChAdOx1-S","Vectored","2","final",NA,"14+","50-59 years","50-59 years","included","~21 weeks","infection","infection","infection","delta",59,56,61,"Spain","ESP","Europe","Europe & Central Asia",30370,2019,"Spain","High income",4,NA,NA,NA,NA,NA
"2577",311,"Monge","Case cohort",2635,2022-09-02,"Oxford/AstraZeneca ChAdOx1-S","Vectored","2","final",NA,"14+","50-59 years","50-59 years","included","~21 weeks","symptomatic disease","symptomatic","symptomatic","delta",59,55,62,"Spain","ESP","Europe","Europe & Central Asia",30370,2019,"Spain","High income",4,NA,NA,NA,NA,NA
"2578",311,"Monge","Case cohort",2636,2022-09-02,"Oxford/AstraZeneca ChAdOx1-S","Vectored","2","final",NA,"14+","50-59 years","50-59 years","included","~21 weeks","hospitalization","severe","severe","delta",96,93,98,"Spain","ESP","Europe","Europe & Central Asia",30370,2019,"Spain","High income",4,14,147,"yes",NA,0
"2579",311,"Monge","Case cohort",2637,2022-09-02,"Janssen Ad26.COV2.S","Vectored","1","final",NA,"14+","50-59 years","50-59 years","included","~21 weeks","infection","infection","infection","delta",64,62,66,"Spain","ESP","Europe","Europe & Central Asia",30370,2019,"Spain","High income",4,NA,NA,NA,NA,NA
"2580",311,"Monge","Case cohort",2638,2022-09-02,"Janssen Ad26.COV2.S","Vectored","1","final",NA,"14+","50-59 years","50-59 years","included","~21 weeks","symptomatic disease","symptomatic","symptomatic","delta",56,53,59,"Spain","ESP","Europe","Europe & Central Asia",30370,2019,"Spain","High income",4,NA,NA,NA,NA,NA
"2581",311,"Monge","Case cohort",2639,2022-09-02,"Janssen Ad26.COV2.S","Vectored","1","final",NA,"14+","50-59 years","50-59 years","included","~21 weeks","hospitalization","severe","severe","delta",86,83,89,"Spain","ESP","Europe","Europe & Central Asia",30370,2019,"Spain","High income",4,NA,NA,NA,NA,NA
"2582",311,"Monge","Case cohort",2640,2022-09-02,"Janssen Ad26.COV2.S","Vectored","1","final",NA,"14+","50-59 years","50-59 years","included","~21 weeks","death","death","death","delta",89,64,97,"Spain","ESP","Europe","Europe & Central Asia",30370,2019,"Spain","High income",4,NA,NA,NA,NA,NA
"2583",311,"Monge","Case cohort",2641,2022-09-02,"Heterologous platforms","Multiple","2","final",NA,"14+","50-59 years","50-59 years","included","~21 weeks","infection","infection","infection","delta",88,85,91,"Spain","ESP","Europe","Europe & Central Asia",30370,2019,"Spain","High income",4,NA,NA,NA,NA,NA
"2584",311,"Monge","Case cohort",2642,2022-09-02,"Heterologous platforms","Multiple","2","final",NA,"14+","50-59 years","50-59 years","included","~21 weeks","symptomatic disease","symptomatic","symptomatic","delta",82,75,87,"Spain","ESP","Europe","Europe & Central Asia",30370,2019,"Spain","High income",4,NA,NA,NA,NA,NA
"2585",311,"Monge","Case cohort",2643,2022-09-02,"Heterologous platforms","Multiple","2","final",NA,"14+","50-59 years","50-59 years","included","~21 weeks","hospitalization","severe","severe","delta",98,84,100,"Spain","ESP","Europe","Europe & Central Asia",30370,2019,"Spain","High income",4,NA,NA,NA,NA,NA
"2586",312,"Huang","Matched case-control",2644,2022-10-20,"Cansino Ad5-nCoV","Vectored","1","final",NA,"14+",">=3 years","general pop","excluded","~62 weeks","infection","infection","infection","omicron",13.2,10.9,15.5,"China","CHN","Asia","East Asia & Pacific",10310,2019,"China","Upper middle income",3,NA,NA,NA,NA,NA
"2587",312,"Huang","Matched case-control",2645,2022-10-20,"Cansino Ad5-nCoV","Vectored","1","final",NA,"14+",">=3 years","general pop","excluded","~62 weeks","severe/critical illness","severe","severe","omicron",77.9,15.6,94.2,"China","CHN","Asia","East Asia & Pacific",10310,2019,"China","Upper middle income",3,NA,NA,NA,NA,NA
"2588",313,"Chico-Sanchez","Test-negative case-control",2646,2022-08-31,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"12-120","HCW","HCW","included","~22 weeks","infection","infection","infection","other combinations",91.6,89.6,93.2,"Spain","ESP","Europe","Europe & Central Asia",30370,2019,"Spain","High income",4,NA,NA,NA,NA,NA
"2589",313,"Chico-Sanchez","Test-negative case-control",2647,2022-08-31,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"120+","HCW","HCW","included","~22 weeks","infection","infection","infection","other combinations",71.5,67,75.5,"Spain","ESP","Europe","Europe & Central Asia",30370,2019,"Spain","High income",4,NA,NA,NA,NA,NA
"2590",313,"Chico-Sanchez","Test-negative case-control",2648,2022-08-31,"Moderna mRNA-1273","mRNA","2","final",NA,"12-120","HCW","HCW","included","~22 weeks","infection","infection","infection","other combinations",95.2,88.3,98.1,"Spain","ESP","Europe","Europe & Central Asia",30370,2019,"Spain","High income",4,NA,NA,NA,NA,NA
"2591",313,"Chico-Sanchez","Test-negative case-control",2649,2022-08-31,"Moderna mRNA-1273","mRNA","2","final",NA,"120+","HCW","HCW","included","~22 weeks","infection","infection","infection","other combinations",88.3,75.7,94.4,"Spain","ESP","Europe","Europe & Central Asia",30370,2019,"Spain","High income",4,NA,NA,NA,NA,NA
"2592",313,"Chico-Sanchez","Test-negative case-control",2650,2022-08-31,"Multiple or heterologous RNA","mRNA","2","final",NA,"12+","HCW","HCW","included","~22 weeks","hospitalization","severe","severe","other combinations",96.8,76.1,99.6,"Spain","ESP","Europe","Europe & Central Asia",30370,2019,"Spain","High income",4,NA,NA,NA,NA,NA
"2593",314,"Mallah","Test-negative case-control",2651,2022-09-10,"Multiple or heterologous RNA","mRNA","2","final",NA,"7+",">=11 years","general pop","excluded","~42 weeks","infection","infection","infection","other combinations",72,71,73,"Spain","ESP","Europe","Europe & Central Asia",30370,2019,"Spain","High income",4,NA,NA,NA,NA,NA
"2594",314,"Mallah","Test-negative case-control",2652,2022-09-10,"Multiple or heterologous RNA","mRNA","2","final",NA,"7+",">=11 years","general pop","excluded","~42 weeks","hospitalization","severe","severe","other combinations",74,70,77,"Spain","ESP","Europe","Europe & Central Asia",30370,2019,"Spain","High income",4,NA,NA,NA,NA,NA
"2595",315,"Chatzilena","Test-negative case-control",2653,2022-12-07,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"7+",">=18 years","general pop","excluded","~56 weeks","hospitalization","severe","severe","delta",82.5,76.2,87.2,"UK","GBR","Europe","Europe & Central Asia",43240,2019,"United Kingdom","High income",4,7,392,"yes",NA,0
"2596",315,"Chatzilena","Test-negative case-control",2654,2022-12-07,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,">=3 months",">=18 years","general pop","excluded","~56 weeks","hospitalization","severe","severe","delta",91.5,83.1,96.2,"UK","GBR","Europe","Europe & Central Asia",43240,2019,"United Kingdom","High income",4,90,392,"no","nested period (should be <=3 months)",0
"2597",315,"Chatzilena","Test-negative case-control",2655,2022-12-07,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,">3 months",">=18 years","general pop","excluded","~56 weeks","hospitalization","severe","severe","delta",79.5,71.5,85.3,"UK","GBR","Europe","Europe & Central Asia",43240,2019,"United Kingdom","High income",4,90,392,"no","nested period",0
"2598",316,"Collie","Test-negative case-control",2656,2022-09-14,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"14-27",">=18 years","general pop","included","~36 weeks","hospitalization","severe","severe","omicron",80.3,62.8,89.5,"South Africa","ZAF","Africa","Sub-Saharan Africa",6570,2019,"South Africa","Upper middle income",3,14,27,"yes",NA,0
"2599",316,"Collie","Test-negative case-control",2657,2022-09-14,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"7-8 months",">=18 years","general pop","included","~36 weeks","hospitalization","severe","severe","omicron",38.4,16.9,54.4,"South Africa","ZAF","Africa","Sub-Saharan Africa",6570,2019,"South Africa","Upper middle income",3,210,240,"no","sequential period",0
"2600",316,"Collie","Test-negative case-control",2658,2022-09-14,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"3-4 months",">=18 years","general pop","included","~53 weeks","hospitalization","severe","severe","omicron",47.4,19.9,65.5,"South Africa","ZAF","Africa","Sub-Saharan Africa",6570,2019,"South Africa","Upper middle income",3,90,120,"no","sequential period",0
"2601",316,"Collie","Test-negative case-control",2659,2022-09-14,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"9+ months",">=18 years","general pop","included","~53 weeks","hospitalization","severe","severe","omicron",19.3,6.3,30.5,"South Africa","ZAF","Africa","Sub-Saharan Africa",6570,2019,"South Africa","Upper middle income",3,270,371,"no","sequential period",0
"2602",317,"Martin","Prospective cohort",2660,2022-09-10,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"14+","patients with end-stage kidney disease undergoing hemodialysis","immunocompromised adults","included","~46 weeks","infection","infection","infection","other combinations",62,18,82,"UK","GBR","Europe","Europe & Central Asia",43240,2019,"United Kingdom","High income",4,NA,NA,NA,NA,NA
"2603",317,"Martin","Prospective cohort",2661,2022-09-10,"Oxford/AstraZeneca ChAdOx1-S","Vectored","2","final",NA,"14+","patients with end-stage kidney disease undergoing hemodialysis","immunocompromised adults","included","~46 weeks","infection","infection","infection","other combinations",42,-22,70,"UK","GBR","Europe","Europe & Central Asia",43240,2019,"United Kingdom","High income",4,NA,NA,NA,NA,NA
"2604",318,"Chung","Test-negative case-control",2662,2022-09-07,"Multiple or heterologous RNA","mRNA","2","final",NA,"7-59",">=16 years","general pop","excluded","~6 weeks","infection","infection","infection","other combinations",89,88,90,"Canada","CAN","North America","North America",46580,2019,"Canada","High income",4,NA,NA,NA,NA,NA
"2605",318,"Chung","Test-negative case-control",2663,2022-09-07,"Multiple or heterologous RNA","mRNA","2","final",NA,"60-119",">=16 years","general pop","excluded","~15 weeks","infection","infection","infection","other combinations",80,75,85,"Canada","CAN","North America","North America",46580,2019,"Canada","High income",4,NA,NA,NA,NA,NA
"2606",318,"Chung","Test-negative case-control",2664,2022-09-07,"Multiple or heterologous RNA","mRNA","2","final",NA,"7-59",">=16 years","general pop","excluded","~6 weeks","symptomatic disease","symptomatic","symptomatic","other combinations",94,91,96,"Canada","CAN","North America","North America",46580,2019,"Canada","High income",4,NA,NA,NA,NA,NA
"2607",318,"Chung","Test-negative case-control",2665,2022-09-07,"Multiple or heterologous RNA","mRNA","2","final",NA,"60-119",">=16 years","general pop","excluded","~15 weeks","symptomatic disease","symptomatic","symptomatic","other combinations",93,79,98,"Canada","CAN","North America","North America",46580,2019,"Canada","High income",4,NA,NA,NA,NA,NA
"2608",318,"Chung","Test-negative case-control",2666,2022-09-07,"Multiple or heterologous RNA","mRNA","2","final",NA,"7-59",">=16 years","general pop","excluded","~6 weeks","severe disease","severe","severe","other combinations",95,90,97,"Canada","CAN","North America","North America",46580,2019,"Canada","High income",4,NA,NA,NA,NA,NA
"2609",318,"Chung","Test-negative case-control",2667,2022-09-07,"Multiple or heterologous RNA","mRNA","2","final",NA,"7-59",">=16 years","general pop","excluded","~6 weeks","infection","infection","infection","alpha",92,91,93,"Canada","CAN","North America","North America",46580,2019,"Canada","High income",4,NA,NA,NA,NA,NA
"2610",318,"Chung","Test-negative case-control",2668,2022-09-07,"Multiple or heterologous RNA","mRNA","2","final",NA,"120-179",">=16 years","general pop","excluded","~24 weeks","infection","infection","infection","alpha",82,79,85,"Canada","CAN","North America","North America",46580,2019,"Canada","High income",4,NA,NA,NA,NA,NA
"2611",318,"Chung","Test-negative case-control",2669,2022-09-07,"Multiple or heterologous RNA","mRNA","2","final",NA,"7-59",">=16 years","general pop","excluded","~6 weeks","symptomatic disease","symptomatic","symptomatic","alpha",92,91,94,"Canada","CAN","North America","North America",46580,2019,"Canada","High income",4,NA,NA,NA,NA,NA
"2612",318,"Chung","Test-negative case-control",2670,2022-09-07,"Multiple or heterologous RNA","mRNA","2","final",NA,"120-179",">=16 years","general pop","excluded","~24 weeks","symptomatic disease","symptomatic","symptomatic","alpha",86,78,91,"Canada","CAN","North America","North America",46580,2019,"Canada","High income",4,NA,NA,NA,NA,NA
"2613",318,"Chung","Test-negative case-control",2671,2022-09-07,"Multiple or heterologous RNA","mRNA","2","final",NA,"7-59",">=16 years","general pop","excluded","~6 weeks","severe disease","severe","severe","alpha",94,92,95,"Canada","CAN","North America","North America",46580,2019,"Canada","High income",4,NA,NA,NA,NA,NA
"2614",318,"Chung","Test-negative case-control",2672,2022-09-07,"Multiple or heterologous RNA","mRNA","2","final",NA,"120-179",">=16 years","general pop","excluded","~24 weeks","severe disease","severe","severe","alpha",97,95,98,"Canada","CAN","North America","North America",46580,2019,"Canada","High income",4,NA,NA,NA,NA,NA
"2615",318,"Chung","Test-negative case-control",2673,2022-09-07,"Multiple or heterologous RNA","mRNA","2","final",NA,"7-59",">=16 years","general pop","excluded","~6 weeks","infection","infection","infection","delta",90,90,90,"Canada","CAN","North America","North America",46580,2019,"Canada","High income",4,NA,NA,NA,NA,NA
"2616",318,"Chung","Test-negative case-control",2674,2022-09-07,"Multiple or heterologous RNA","mRNA","2","final",NA,"240+",">=16 years","general pop","excluded","~42 weeks","infection","infection","infection","delta",78,76,80,"Canada","CAN","North America","North America",46580,2019,"Canada","High income",4,NA,NA,NA,NA,NA
"2617",318,"Chung","Test-negative case-control",2675,2022-09-07,"Multiple or heterologous RNA","mRNA","2","final",NA,"7-59",">=16 years","general pop","excluded","~6 weeks","symptomatic disease","symptomatic","symptomatic","delta",94,94,95,"Canada","CAN","North America","North America",46580,2019,"Canada","High income",4,NA,NA,NA,NA,NA
"2618",318,"Chung","Test-negative case-control",2676,2022-09-07,"Multiple or heterologous RNA","mRNA","2","final",NA,"240+",">=16 years","general pop","excluded","~42 weeks","symptomatic disease","symptomatic","symptomatic","delta",88,86,90,"Canada","CAN","North America","North America",46580,2019,"Canada","High income",4,NA,NA,NA,NA,NA
"2619",318,"Chung","Test-negative case-control",2677,2022-09-07,"Multiple or heterologous RNA","mRNA","2","final",NA,"7-59",">=16 years","general pop","excluded","~6 weeks","severe disease","severe","severe","delta",98,98,99,"Canada","CAN","North America","North America",46580,2019,"Canada","High income",4,NA,NA,NA,NA,NA
"2620",318,"Chung","Test-negative case-control",2678,2022-09-07,"Multiple or heterologous RNA","mRNA","2","final",NA,"240+",">=16 years","general pop","excluded","~42 weeks","severe disease","severe","severe","delta",98,95,99,"Canada","CAN","North America","North America",46580,2019,"Canada","High income",4,NA,NA,NA,NA,NA
"2621",319,"Xu","Retrospective cohort",2679,2022-12-05,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"28+",">=65 years",">=65 years","included","~51 weeks","infection","infection","infection","other combinations",85.8,83.8,88.2,"Sweden","SWE","Europe","Europe & Central Asia",56230,2019,"Sweden","High income",4,NA,NA,NA,NA,NA
"2622",319,"Xu","Retrospective cohort",2680,2022-12-05,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"350-371",">=65 years",">=65 years","included",NA,"infection","infection","infection","other combinations",18.2,2.2,31.6,"Sweden","SWE","Europe","Europe & Central Asia",56230,2019,"Sweden","High income",4,NA,NA,NA,NA,NA
"2623",319,"Xu","Retrospective cohort",2681,2022-12-05,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"28+",">=65 years",">=65 years","included","~51 weeks","hospitalization","severe","severe","other combinations",87.2,83.6,90,"Sweden","SWE","Europe","Europe & Central Asia",56230,2019,"Sweden","High income",4,NA,NA,NA,NA,NA
"2624",319,"Xu","Retrospective cohort",2682,2022-12-05,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"350-371",">=65 years",">=65 years","included",NA,"hospitalization","severe","severe","other combinations",68.5,45.5,81.8,"Sweden","SWE","Europe","Europe & Central Asia",56230,2019,"Sweden","High income",4,NA,NA,NA,NA,NA
"2625",319,"Xu","Retrospective cohort",2683,2022-12-05,"Moderna mRNA-1273","mRNA","2","final",NA,"28+",">=65 years",">=65 years","included","~51 weeks","infection","infection","infection","other combinations",94.6,89.6,97.2,"Sweden","SWE","Europe","Europe & Central Asia",56230,2019,"Sweden","High income",4,NA,NA,NA,NA,NA
"2626",319,"Xu","Retrospective cohort",2684,2022-12-05,"Moderna mRNA-1273","mRNA","2","final",NA,"350-371",">=65 years",">=65 years","included",NA,"infection","infection","infection","other combinations",11.8,-55.5,50,"Sweden","SWE","Europe","Europe & Central Asia",56230,2019,"Sweden","High income",4,NA,NA,NA,NA,NA
"2627",319,"Xu","Retrospective cohort",2685,2022-12-05,"Moderna mRNA-1273","mRNA","2","final",NA,"28+",">=65 years",">=65 years","included","~51 weeks","hospitalization","severe","severe","other combinations",96,89.5,98.5,"Sweden","SWE","Europe","Europe & Central Asia",56230,2019,"Sweden","High income",4,NA,NA,NA,NA,NA
"2628",319,"Xu","Retrospective cohort",2686,2022-12-05,"Moderna mRNA-1273","mRNA","2","final",NA,"350-371",">=65 years",">=65 years","included",NA,"hospitalization","severe","severe","other combinations",21.5,-89.2,67.4,"Sweden","SWE","Europe","Europe & Central Asia",56230,2019,"Sweden","High income",4,NA,NA,NA,NA,NA
"2629",319,"Xu","Retrospective cohort",2687,2022-12-05,"Oxford/AstraZeneca ChAdOx1-S","Vectored","2","final",NA,"28+",">=65 years",">=65 years","included","~39 weeks","infection","infection","infection","other combinations",43.6,1.9,67.6,"Sweden","SWE","Europe","Europe & Central Asia",56230,2019,"Sweden","High income",4,NA,NA,NA,NA,NA
"2630",319,"Xu","Retrospective cohort",2688,2022-12-05,"Oxford/AstraZeneca ChAdOx1-S","Vectored","2","final",NA,"266-287",">=65 years",">=65 years","included",NA,"infection","infection","infection","other combinations",-2.3,-627.9,85.6,"Sweden","SWE","Europe","Europe & Central Asia",56230,2019,"Sweden","High income",4,NA,NA,NA,NA,NA
"2631",319,"Xu","Retrospective cohort",2689,2022-12-05,"Oxford/AstraZeneca ChAdOx1-S","Vectored","2","final",NA,"28+",">=65 years",">=65 years","included","~39 weeks","hospitalization","severe","severe","other combinations",74.6,-5,93.9,"Sweden","SWE","Europe","Europe & Central Asia",56230,2019,"Sweden","High income",4,NA,NA,NA,NA,NA
"2632",319,"Xu","Retrospective cohort",2690,2022-12-05,"Oxford/AstraZeneca ChAdOx1-S","Vectored","2","final",NA,"238-259",">=65 years",">=65 years","included",NA,"hospitalization","severe","severe","other combinations",28.7,-37.6,63,"Sweden","SWE","Europe","Europe & Central Asia",56230,2019,"Sweden","High income",4,NA,NA,NA,NA,NA
"2633",320,"Mas-Bermejo","Retrospective cohort",2691,2022-09-28,"Abdala (CIBG)","Protein subunit","3","final",NA,"14+",">=19 years","general pop","excluded","~20 weeks","severe disease","severe","severe","delta",98.2,97.9,98.5,"Cuba","CUB","North America","Latin America & Caribbean",9010,2019,"Cuba","Upper middle income",3,NA,NA,NA,NA,NA
"2634",320,"Mas-Bermejo","Retrospective cohort",2692,2022-09-28,"Abdala (CIBG)","Protein subunit","3","final",NA,"14+",">=19 years","general pop","excluded","~20 weeks","death","death","death","delta",98.7,98.3,99,"Cuba","CUB","North America","Latin America & Caribbean",9010,2019,"Cuba","Upper middle income",3,NA,NA,NA,NA,NA
"2635",321,"Copur","Retrospective cohort",2693,2022-09-28,"Sinovac CoronaVac","Inactivated","2","final",NA,"14+","HCW","HCW","excluded","~15 weeks","infection","infection","infection","alpha",65,50,75,"Turkey","TUR","Asia","Europe & Central Asia",9800,2019,"Trkiye","Upper middle income",3,NA,NA,NA,NA,NA
"2636",322,"Schrag","Test-negative case-control",2694,2022-09-26,"Multiple or heterologous RNA","mRNA","2","final",NA,"14+","pregnant persons 18-49 years","pregnant persons","included","~55 weeks","ED or UC visit","symptomatic","symptomatic","omicron",16,-22,42,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"2637",322,"Schrag","Test-negative case-control",2695,2022-09-26,"Multiple or heterologous RNA","mRNA","2","final",NA,"14-149","pregnant persons 18-49 years","pregnant persons","included",NA,"ED or UC visit","symptomatic","symptomatic","omicron",3,-49,37,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"2638",322,"Schrag","Test-negative case-control",2696,2022-09-26,"Multiple or heterologous RNA","mRNA","2","final",NA,"150+","pregnant persons 18-49 years","pregnant persons","included","~55 weeks","ED or UC visit","symptomatic","symptomatic","omicron",42,-16,72,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"2639",322,"Schrag","Test-negative case-control",2697,2022-09-26,"Multiple or heterologous RNA","mRNA","2","final",NA,"14+","pregnant persons 18-49 years","pregnant persons","included","~55 weeks","hospitalization","severe","severe","omicron",77,28,93,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"2640",322,"Schrag","Test-negative case-control",2698,2022-09-26,"Multiple or heterologous RNA","mRNA","2","final",NA,"14-149","pregnant persons 18-49 years","pregnant persons","included",NA,"hospitalization","severe","severe","omicron",86,41,97,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"2641",322,"Schrag","Test-negative case-control",2699,2022-09-26,"Multiple or heterologous RNA","mRNA","2","final",NA,"150+","pregnant persons 18-49 years","pregnant persons","included","~55 weeks","hospitalization","severe","severe","omicron",64,-102,93,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"2642",322,"Schrag","Test-negative case-control",2700,2022-09-26,"Multiple or heterologous RNA","mRNA","2","final",NA,"14+","pregnant persons 18-49 years","pregnant persons","included","~55 weeks","ED or UC visit","symptomatic","symptomatic","delta",83,68,91,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"2643",322,"Schrag","Test-negative case-control",2701,2022-09-26,"Multiple or heterologous RNA","mRNA","2","final",NA,"14-149","pregnant persons 18-49 years","pregnant persons","included",NA,"ED or UC visit","symptomatic","symptomatic","delta",84,69,92,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"2644",322,"Schrag","Test-negative case-control",2702,2022-09-26,"Multiple or heterologous RNA","mRNA","2","final",NA,"150+","pregnant persons 18-49 years","pregnant persons","included","~55 weeks","ED or UC visit","symptomatic","symptomatic","delta",75,5,93,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"2645",322,"Schrag","Test-negative case-control",2703,2022-09-26,"Multiple or heterologous RNA","mRNA","2","final",NA,"14+","pregnant persons 18-49 years","pregnant persons","included",NA,"hospitalization","severe","severe","delta",98,96,99,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"2646",322,"Schrag","Test-negative case-control",2704,2022-09-26,"Multiple or heterologous RNA","mRNA","2","final",NA,"14-149","pregnant persons 18-49 years","pregnant persons","included",NA,"hospitalization","severe","severe","delta",99,96,100,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"2647",322,"Schrag","Test-negative case-control",2705,2022-09-26,"Multiple or heterologous RNA","mRNA","2","final",NA,"150+","pregnant persons 18-49 years","pregnant persons","included","~55 weeks","hospitalization","severe","severe","delta",96,86,99,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"2648",323,"Ferdinands","Test-negative case-control",2706,2022-10-03,"Multiple or heterologous RNA","mRNA","2","final",NA,"<2 months",">=18 years","general pop","excluded",NA,"ED or UC visit","symptomatic","symptomatic","omicron",63,57,68,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"2649",323,"Ferdinands","Test-negative case-control",2707,2022-10-03,"Multiple or heterologous RNA","mRNA","2","final",NA,"16-<18 months",">=18 years","general pop","excluded",NA,"ED or UC visit","symptomatic","symptomatic","omicron",22,5,36,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"2650",323,"Ferdinands","Test-negative case-control",2708,2022-10-03,"Multiple or heterologous RNA","mRNA","2","final",NA,"<2 months",">=18 years","general pop","excluded",NA,"hospitalization","severe","severe","omicron",73,63,80,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"2651",323,"Ferdinands","Test-negative case-control",2709,2022-10-03,"Multiple or heterologous RNA","mRNA","2","final",NA,"14+ months",">=18 years","general pop","excluded","~67 weeks","hospitalization","severe","severe","omicron",19,6,30,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"2652",323,"Ferdinands","Test-negative case-control",2710,2022-10-03,"Multiple or heterologous RNA","mRNA","2","final",NA,"<4 months","immunocompromised, >=18 years","immunocompromised adults","excluded",NA,"hospitalization","severe","severe","omicron",34,13,51,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"2653",323,"Ferdinands","Test-negative case-control",2711,2022-10-03,"Multiple or heterologous RNA","mRNA","2","final",NA,"6+ months","immunocompromised, >=18 years","immunocompromised adults","excluded","~67 weeks","hospitalization","severe","severe","omicron",20,1,36,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"2654",323,"Ferdinands","Test-negative case-control",2712,2022-10-03,"Multiple or heterologous RNA","mRNA","2","final",NA,"<2 months",">=18 years","general pop","excluded",NA,"ED or UC visit","symptomatic","symptomatic","delta",93,92,94,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"2655",323,"Ferdinands","Test-negative case-control",2713,2022-10-03,"Multiple or heterologous RNA","mRNA","2","final",NA,"10-<12 months",">=18 years","general pop","excluded",NA,"ED or UC visit","symptomatic","symptomatic","delta",66,60,72,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"2656",323,"Ferdinands","Test-negative case-control",2714,2022-10-03,"Multiple or heterologous RNA","mRNA","2","final",NA,"<2 months",">=18 years","general pop","excluded",NA,"hospitalization","severe","severe","delta",96,95,97,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"2657",323,"Ferdinands","Test-negative case-control",2715,2022-10-03,"Multiple or heterologous RNA","mRNA","2","final",NA,"10-<12 months",">=18 years","general pop","excluded",NA,"hospitalization","severe","severe","delta",68,59,75,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"2658",323,"Ferdinands","Test-negative case-control",2716,2022-10-03,"Multiple or heterologous RNA","mRNA","2","final",NA,"<2 months",">=18 years","general pop","excluded","~19 weeks","ED or UC visit","symptomatic","symptomatic","alpha",95,94,96,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"2659",323,"Ferdinands","Test-negative case-control",2717,2022-10-03,"Multiple or heterologous RNA","mRNA","2","final",NA,"4-<6 months",">=18 years","general pop","excluded","~19 weeks","ED or UC visit","symptomatic","symptomatic","alpha",86,78,91,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"2660",323,"Ferdinands","Test-negative case-control",2718,2022-10-03,"Multiple or heterologous RNA","mRNA","2","final",NA,"<2 months",">=18 years","general pop","excluded","~19 weeks","hospitalization","severe","severe","alpha",94,93,95,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"2661",323,"Ferdinands","Test-negative case-control",2719,2022-10-03,"Multiple or heterologous RNA","mRNA","2","final",NA,"4-<6 months",">=18 years","general pop","excluded","~19 weeks","hospitalization","severe","severe","alpha",87,77,93,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"2662",324,"Link-Gelles","Test-negative case-control",2720,2022-10-05,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"14-159",">=18 years","general pop","included",NA,"ED or UC visit","symptomatic","symptomatic","omicron",45,27,59,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"2663",324,"Link-Gelles","Test-negative case-control",2721,2022-10-05,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"150+",">=18 years","general pop","included","~82 weeks","ED or UC visit","symptomatic","symptomatic","omicron",24,19,27,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"2664",324,"Link-Gelles","Test-negative case-control",2722,2022-10-05,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"150+",">=18 years","general pop","included","~82 weeks","hospitalization","severe","severe","omicron",17,7,27,"USA","USA","North America","North America",66220,2019,"United States","High income",4,150,574,"yes",NA,0
"2665",324,"Link-Gelles","Test-negative case-control",2723,2022-10-05,"Moderna mRNA-1273","mRNA","2","final",NA,"14-159",">=18 years","general pop","included",NA,"ED or UC visit","symptomatic","symptomatic","omicron",51,30,66,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"2666",324,"Link-Gelles","Test-negative case-control",2724,2022-10-05,"Moderna mRNA-1273","mRNA","2","final",NA,"150+",">=18 years","general pop","included","~82 weeks","ED or UC visit","symptomatic","symptomatic","omicron",30,25,34,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"2667",324,"Link-Gelles","Test-negative case-control",2725,2022-10-05,"Moderna mRNA-1273","mRNA","2","final",NA,"150+",">=18 years","general pop","included","~82 weeks","hospitalization","severe","severe","omicron",28,17,38,"USA","USA","North America","North America",66220,2019,"United States","High income",4,150,574,"yes",NA,0
"2668",324,"Link-Gelles","Test-negative case-control",2726,2022-10-05,"Multiple or heterologous RNA","mRNA","2","final",NA,"14-159",">=18 years","general pop","included",NA,"ED or UC visit","symptomatic","symptomatic","omicron",70,52,81,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"2669",324,"Link-Gelles","Test-negative case-control",2727,2022-10-05,"Multiple or heterologous RNA","mRNA","2","final",NA,"150+",">=18 years","general pop","included","~82 weeks","ED or UC visit","symptomatic","symptomatic","omicron",38,29,46,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"2670",325,"Grewal","Test-negative case-control",2728,2022-12-03,"Multiple or heterologous RNA","mRNA","2","final",NA,"0+","LTCF residents, >=60 years","LTCF residents","included","~80 weeks","infection","infection","infection","omicron",3,-7,12,"Canada","CAN","North America","North America",46580,2019,"Canada","High income",4,NA,NA,NA,NA,NA
"2671",325,"Grewal","Test-negative case-control",2729,2022-12-03,"Multiple or heterologous RNA","mRNA","2","final",NA,"0+","LTCF residents, >=60 years","LTCF residents","included","~80 weeks","symptomatic disease","symptomatic","symptomatic","omicron",21,1,38,"Canada","CAN","North America","North America",46580,2019,"Canada","High income",4,NA,NA,NA,NA,NA
"2672",325,"Grewal","Test-negative case-control",2730,2022-12-03,"Multiple or heterologous RNA","mRNA","2","final",NA,"0+","LTCF residents, >=60 years","LTCF residents","included","~80 weeks","severe disease","severe","severe","omicron",43,24,58,"Canada","CAN","North America","North America",46580,2019,"Canada","High income",4,NA,NA,NA,NA,NA
"2673",326,"Lin","Retrospective cohort",2731,2022-09-26,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"~47 weeks",">=5 years","general pop","included","~47 weeks","infection","infection","infection","omicron",37.5,36,39,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"2674",326,"Lin","Retrospective cohort",2732,2022-09-26,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"~60 weeks",">=5 years","general pop","included","~60 weeks","infection","infection","infection","omicron",0.8,-1.5,3,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"2675",326,"Lin","Retrospective cohort",2733,2022-09-26,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"~47 weeks",">=5 years","general pop","included","~47 weeks","hospitalization","severe","severe","omicron",58.8,49.3,66.5,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,329,"yes",NA,0
"2676",326,"Lin","Retrospective cohort",2734,2022-09-26,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"~60 weeks",">=5 years","general pop","included","~60 weeks","hospitalization","severe","severe","omicron",29.4,50.4,76.9,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,420,"no","sequential period",0
"2677",326,"Lin","Retrospective cohort",2735,2022-09-26,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"~47 weeks",">=5 years","general pop","included","~47 weeks","death","death","death","omicron",75.2,67.7,81,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"2678",326,"Lin","Retrospective cohort",2736,2022-09-26,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"~60 weeks",">=5 years","general pop","included","~60 weeks","death","death","death","omicron",59.1,27.2,77,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"2679",326,"Lin","Retrospective cohort",2737,2022-09-26,"Moderna mRNA-1273","mRNA","2","final",NA,"~46 weeks",">=5 years","general pop","included","~46 weeks","infection","infection","infection","omicron",47.2,45.8,48.5,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"2680",326,"Lin","Retrospective cohort",2738,2022-09-26,"Moderna mRNA-1273","mRNA","2","final",NA,"~59 weeks",">=5 years","general pop","included","~59 weeks","infection","infection","infection","omicron",30.3,28.9,32.9,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"2681",326,"Lin","Retrospective cohort",2739,2022-09-26,"Moderna mRNA-1273","mRNA","2","final",NA,"~46 weeks",">=5 years","general pop","included","~46 weeks","hospitalization","severe","severe","omicron",64.7,57.2,70.9,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,322,"yes",NA,0
"2682",326,"Lin","Retrospective cohort",2740,2022-09-26,"Moderna mRNA-1273","mRNA","2","final",NA,"~59 weeks",">=5 years","general pop","included","~59 weeks","hospitalization","severe","severe","omicron",61.5,49.6,70.6,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,413,"no","sequential period",0
"2683",326,"Lin","Retrospective cohort",2741,2022-09-26,"Moderna mRNA-1273","mRNA","2","final",NA,"~46 weeks",">=5 years","general pop","included","~46 weeks","death","death","death","omicron",69.6,62.3,75.5,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"2684",326,"Lin","Retrospective cohort",2742,2022-09-26,"Moderna mRNA-1273","mRNA","2","final",NA,"~59 weeks",">=5 years","general pop","included","~59 weeks","death","death","death","omicron",48.3,22.6,65.4,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"2685",326,"Lin","Retrospective cohort",2743,2022-09-26,"Janssen Ad26.COV2.S","Vectored","2","final",NA,"~41 weeks",">=5 years","general pop","included","~41 weeks","infection","infection","infection","omicron",48.8,47.2,50.4,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"2686",326,"Lin","Retrospective cohort",2744,2022-09-26,"Janssen Ad26.COV2.S","Vectored","2","final",NA,"~54 weeks",">=5 years","general pop","included","~54 weeks","infection","infection","infection","omicron",49,46.4,51.4,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"2687",326,"Lin","Retrospective cohort",2745,2022-09-26,"Janssen Ad26.COV2.S","Vectored","2","final",NA,"~41 weeks",">=5 years","general pop","included","~41 weeks","hospitalization","severe","severe","omicron",65.3,58.3,71.1,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"2688",326,"Lin","Retrospective cohort",2746,2022-09-26,"Janssen Ad26.COV2.S","Vectored","2","final",NA,"~54 weeks",">=5 years","general pop","included","~54 weeks","hospitalization","severe","severe","omicron",53.3,26.7,70.2,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"2689",326,"Lin","Retrospective cohort",2747,2022-09-26,"Janssen Ad26.COV2.S","Vectored","2","final",NA,"~41 weeks",">=5 years","general pop","included","~41 weeks","death","death","death","omicron",76.1,69.2,81.4,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"2690",326,"Lin","Retrospective cohort",2748,2022-09-26,"Janssen Ad26.COV2.S","Vectored","2","final",NA,"~54 weeks",">=5 years","general pop","included","~54 weeks","death","death","death","omicron",77.5,19.6,93.7,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"2691",326,"Lin","Retrospective cohort",2749,2022-09-26,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"~25 weeks",">=5 years","general pop","included","~25 weeks","infection","infection","infection","delta",54.3,53.6,55,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"2692",326,"Lin","Retrospective cohort",2750,2022-09-26,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"~38 weeks",">=5 years","general pop","included","~38 weeks","infection","infection","infection","delta",47.4,46.6,48.2,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"2693",326,"Lin","Retrospective cohort",2751,2022-09-26,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"~25 weeks",">=5 years","general pop","included","~25 weeks","hospitalization","severe","severe","delta",85.8,83.4,87.8,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,175,"yes",NA,0
"2694",326,"Lin","Retrospective cohort",2752,2022-09-26,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"~38 weeks",">=5 years","general pop","included","~38 weeks","hospitalization","severe","severe","delta",70.9,65.3,75.6,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,266,"no","sequential period",0
"2695",326,"Lin","Retrospective cohort",2753,2022-09-26,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"~25 weeks",">=5 years","general pop","included","~25 weeks","death","death","death","delta",89.6,87,91.6,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"2696",326,"Lin","Retrospective cohort",2754,2022-09-26,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"~38 weeks",">=5 years","general pop","included","~38 weeks","death","death","death","delta",77.4,70.6,82.6,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"2697",326,"Lin","Retrospective cohort",2755,2022-09-26,"Moderna mRNA-1273","mRNA","2","final",NA,"~24 weeks",">=5 years","general pop","included","~24 weeks","infection","infection","infection","delta",69.2,68.5,69.9,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"2698",326,"Lin","Retrospective cohort",2756,2022-09-26,"Moderna mRNA-1273","mRNA","2","final",NA,"~37 weeks",">=5 years","general pop","included","~37 weeks","infection","infection","infection","delta",48.4,47.5,49.3,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"2699",326,"Lin","Retrospective cohort",2757,2022-09-26,"Moderna mRNA-1273","mRNA","2","final",NA,"~24 weeks",">=5 years","general pop","included","~24 weeks","hospitalization","severe","severe","delta",89.8,88.1,91.3,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,168,"yes",NA,0
"2700",326,"Lin","Retrospective cohort",2758,2022-09-26,"Moderna mRNA-1273","mRNA","2","final",NA,"~37 weeks",">=5 years","general pop","included","~37 weeks","hospitalization","severe","severe","delta",72.7,67.8,77,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,259,"no","sequential period",0
"2701",326,"Lin","Retrospective cohort",2759,2022-09-26,"Moderna mRNA-1273","mRNA","2","final",NA,"~24 weeks",">=5 years","general pop","included","~24 weeks","death","death","death","delta",93,91.1,94.5,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"2702",326,"Lin","Retrospective cohort",2760,2022-09-26,"Moderna mRNA-1273","mRNA","2","final",NA,"~37 weeks",">=5 years","general pop","included","~37 weeks","death","death","death","delta",85.1,80.1,88.8,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"2703",326,"Lin","Retrospective cohort",2761,2022-09-26,"Janssen Ad26.COV2.S","Vectored","2","final",NA,"~20 weeks",">=5 years","general pop","included","~20 weeks","infection","infection","infection","delta",59.2,57.7,60.7,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"2704",326,"Lin","Retrospective cohort",2762,2022-09-26,"Janssen Ad26.COV2.S","Vectored","2","final",NA,"~33 weeks",">=5 years","general pop","included","~33 weeks","infection","infection","infection","delta",60.5,58.9,62.1,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"2705",326,"Lin","Retrospective cohort",2763,2022-09-26,"Janssen Ad26.COV2.S","Vectored","2","final",NA,"~20 weeks",">=5 years","general pop","included","~20 weeks","hospitalization","severe","severe","delta",77.9,72.2,82.4,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"2706",326,"Lin","Retrospective cohort",2764,2022-09-26,"Janssen Ad26.COV2.S","Vectored","2","final",NA,"~33 weeks",">=5 years","general pop","included","~33 weeks","hospitalization","severe","severe","delta",70,64.8,74.5,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"2707",326,"Lin","Retrospective cohort",2765,2022-09-26,"Janssen Ad26.COV2.S","Vectored","2","final",NA,"~20 weeks",">=5 years","general pop","included","~20 weeks","death","death","death","delta",83.8,76.1,89,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"2708",326,"Lin","Retrospective cohort",2766,2022-09-26,"Janssen Ad26.COV2.S","Vectored","2","final",NA,"~33 weeks",">=5 years","general pop","included","~33 weeks","death","death","death","delta",79.2,73.1,84,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"2709",326,"Lin","Retrospective cohort",2767,2022-09-26,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"~3 weeks",">=5 years","general pop","included","~3 weeks","infection","infection","infection","alpha",67.6,66.9,68.3,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"2710",326,"Lin","Retrospective cohort",2768,2022-09-26,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"~21 weeks",">=5 years","general pop","included","~21 weeks","infection","infection","infection","alpha",58.6,58,59.2,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"2711",326,"Lin","Retrospective cohort",2769,2022-09-26,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"~3 weeks",">=5 years","general pop","included","~3 weeks","hospitalization","severe","severe","alpha",94.1,92.2,95.5,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"2712",326,"Lin","Retrospective cohort",2770,2022-09-26,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"~21 weeks",">=5 years","general pop","included","~21 weeks","hospitalization","severe","severe","alpha",87.1,85,88.9,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"2713",326,"Lin","Retrospective cohort",2771,2022-09-26,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"~3 weeks",">=5 years","general pop","included","~3 weeks","death","death","death","alpha",97.1,94.7,98.4,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"2714",326,"Lin","Retrospective cohort",2772,2022-09-26,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"~21 weeks",">=5 years","general pop","included","~21 weeks","death","death","death","alpha",91.9,89.4,93.8,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"2715",326,"Lin","Retrospective cohort",2773,2022-09-26,"Moderna mRNA-1273","mRNA","2","final",NA,"~2 weeks",">=5 years","general pop","included","~2 weeks","infection","infection","infection","alpha",90.1,89.6,90.7,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"2716",326,"Lin","Retrospective cohort",2774,2022-09-26,"Moderna mRNA-1273","mRNA","2","final",NA,"~20 weeks",">=5 years","general pop","included","~20 weeks","infection","infection","infection","alpha",71.9,71.3,72.6,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"2717",326,"Lin","Retrospective cohort",2775,2022-09-26,"Moderna mRNA-1273","mRNA","2","final",NA,"~2 weeks",">=5 years","general pop","included","~2 weeks","hospitalization","severe","severe","alpha",96.5,95.1,97.6,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"2718",326,"Lin","Retrospective cohort",2776,2022-09-26,"Moderna mRNA-1273","mRNA","2","final",NA,"~20 weeks",">=5 years","general pop","included","~20 weeks","hospitalization","severe","severe","alpha",90.4,88.6,91.9,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"2719",326,"Lin","Retrospective cohort",2777,2022-09-26,"Moderna mRNA-1273","mRNA","2","final",NA,"~2 weeks",">=5 years","general pop","included","~2 weeks","death","death","death","alpha",97.2,95.1,98.4,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"2720",326,"Lin","Retrospective cohort",2778,2022-09-26,"Moderna mRNA-1273","mRNA","2","final",NA,"~20 weeks",">=5 years","general pop","included","~20 weeks","death","death","death","alpha",92.8,90.3,94.6,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"2721",326,"Lin","Retrospective cohort",2779,2022-09-26,"Janssen Ad26.COV2.S","Vectored","2","final",NA,"~2 weeks",">=5 years","general pop","included","~2 weeks","infection","infection","infection","alpha",70.6,68.8,72.3,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"2722",326,"Lin","Retrospective cohort",2780,2022-09-26,"Janssen Ad26.COV2.S","Vectored","2","final",NA,"~10 weeks",">=5 years","general pop","included","~10 weeks","infection","infection","infection","alpha",63,60.8,65,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"2723",326,"Lin","Retrospective cohort",2781,2022-09-26,"Janssen Ad26.COV2.S","Vectored","2","final",NA,"~2 weeks",">=5 years","general pop","included","~2 weeks","hospitalization","severe","severe","alpha",67.9,56.5,76.3,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"2724",326,"Lin","Retrospective cohort",2782,2022-09-26,"Janssen Ad26.COV2.S","Vectored","2","final",NA,"~10 weeks",">=5 years","general pop","included","~10 weeks","hospitalization","severe","severe","alpha",79.3,71.7,84.8,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"2725",326,"Lin","Retrospective cohort",2783,2022-09-26,"Janssen Ad26.COV2.S","Vectored","2","final",NA,"~2 weeks",">=5 years","general pop","included","~2 weeks","death","death","death","alpha",85.7,74.6,91.9,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"2726",326,"Lin","Retrospective cohort",2784,2022-09-26,"Janssen Ad26.COV2.S","Vectored","2","final",NA,"~10 weeks",">=5 years","general pop","included","~10 weeks","death","death","death","alpha",80.5,75.7,84.4,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"2727",327,"Rudan","Test-negative case-control",2785,2022-09-28,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"14-35","12-15 years","12-15 years","included",NA,"symptomatic disease","symptomatic","symptomatic","omicron",81.2,77.7,84.2,"UK","GBR","Europe","Europe & Central Asia",43240,2019,"United Kingdom","High income",4,NA,NA,NA,NA,NA
"2728",327,"Rudan","Test-negative case-control",2786,2022-09-28,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"98+","12-15 years","12-15 years","included","~21 weeks","symptomatic disease","symptomatic","symptomatic","omicron",48.7,22,66.3,"UK","GBR","Europe","Europe & Central Asia",43240,2019,"United Kingdom","High income",4,NA,NA,NA,NA,NA
"2729",327,"Rudan","Test-negative case-control",2787,2022-09-28,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"14-35","12-15 years","12-15 years","included",NA,"symptomatic disease","symptomatic","symptomatic","delta",100,NA,100,"UK","GBR","Europe","Europe & Central Asia",43240,2019,"United Kingdom","High income",4,NA,NA,NA,NA,NA
"2730",327,"Rudan","Test-negative case-control",2788,2022-09-28,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"42-63","12-15 years","12-15 years","included","~10 weeks","symptomatic disease","symptomatic","symptomatic","delta",92.9,42.5,99.1,"UK","GBR","Europe","Europe & Central Asia",43240,2019,"United Kingdom","High income",4,NA,NA,NA,NA,NA
"2731",327,"Rudan","Test-negative case-control",2789,2022-09-28,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"14-35","16-17 years","16-17 years","included",NA,"symptomatic disease","symptomatic","symptomatic","omicron",65.5,56,73,"UK","GBR","Europe","Europe & Central Asia",43240,2019,"United Kingdom","High income",4,NA,NA,NA,NA,NA
"2732",327,"Rudan","Test-negative case-control",2790,2022-09-28,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"98+","16-17 years","16-17 years","included","~27 weeks","symptomatic disease","symptomatic","symptomatic","omicron",1.2,-49.3,34.6,"UK","GBR","Europe","Europe & Central Asia",43240,2019,"United Kingdom","High income",4,NA,NA,NA,NA,NA
"2733",327,"Rudan","Test-negative case-control",2791,2022-09-28,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"14-35","16-17 years","16-17 years","included",NA,"symptomatic disease","symptomatic","symptomatic","delta",95.6,77,99.1,"UK","GBR","Europe","Europe & Central Asia",43240,2019,"United Kingdom","High income",4,NA,NA,NA,NA,NA
"2734",327,"Rudan","Test-negative case-control",2792,2022-09-28,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"42-63","16-17 years","16-17 years","included","~17 weeks","symptomatic disease","symptomatic","symptomatic","delta",96.7,51.3,99.8,"UK","GBR","Europe","Europe & Central Asia",43240,2019,"United Kingdom","High income",4,NA,NA,NA,NA,NA
"2735",328,"Lewis","Outbreak investigation",2793,2022-09-28,"Multiple or heterologous RNA","mRNA","2","final",NA,"14+",">=60 years",">=60 years","unknown","~14 weeks","infection","infection","infection","gamma",80,46.4,92.6,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"2736",329,"Buchan","Test-negative case-control",2794,2022-09-22,"Multiple or heterologous RNA","mRNA","2","final",NA,"7-59",">=18 years","general pop","included",NA,"symptomatic disease","symptomatic","symptomatic","omicron",36,24,45,"Canada","CAN","North America","North America",46580,2019,"Canada","High income",4,NA,NA,NA,NA,NA
"2737",329,"Buchan","Test-negative case-control",2795,2022-09-22,"Multiple or heterologous RNA","mRNA","2","final",NA,"240+",">=18 years","general pop","included","~49 weeks","symptomatic disease","symptomatic","symptomatic","omicron",2,-17,17,"Canada","CAN","North America","North America",46580,2019,"Canada","High income",4,NA,NA,NA,NA,NA
"2738",329,"Buchan","Test-negative case-control",2796,2022-09-22,"Multiple or heterologous RNA","mRNA","2","final",NA,"120-179",">=18 years","general pop","included",NA,"severe disease","severe","severe","omicron",75,51,87,"Canada","CAN","North America","North America",46580,2019,"Canada","High income",4,NA,NA,NA,NA,NA
"2739",329,"Buchan","Test-negative case-control",2797,2022-09-22,"Multiple or heterologous RNA","mRNA","2","final",NA,"180-239",">=18 years","general pop","included","~32 weeks","severe disease","severe","severe","omicron",82,62,91,"Canada","CAN","North America","North America",46580,2019,"Canada","High income",4,NA,NA,NA,NA,NA
"2740",329,"Buchan","Test-negative case-control",2798,2022-09-22,"Multiple or heterologous RNA","mRNA","2","final",NA,"7-59",">=18 years","general pop","included",NA,"symptomatic disease","symptomatic","symptomatic","delta",89,86,92,"Canada","CAN","North America","North America",46580,2019,"Canada","High income",4,NA,NA,NA,NA,NA
"2741",329,"Buchan","Test-negative case-control",2799,2022-09-22,"Multiple or heterologous RNA","mRNA","2","final",NA,"240+",">=18 years","general pop","included","~49 weeks","symptomatic disease","symptomatic","symptomatic","delta",80,74,84,"Canada","CAN","North America","North America",46580,2019,"Canada","High income",4,NA,NA,NA,NA,NA
"2742",329,"Buchan","Test-negative case-control",2800,2022-09-22,"Multiple or heterologous RNA","mRNA","2","final",NA,"7-59",">=18 years","general pop","included",NA,"severe disease","severe","severe","delta",94,84,98,"Canada","CAN","North America","North America",46580,2019,"Canada","High income",4,NA,NA,NA,NA,NA
"2743",329,"Buchan","Test-negative case-control",2801,2022-09-22,"Multiple or heterologous RNA","mRNA","2","final",NA,"240+",">=18 years","general pop","included","~49 weeks","severe disease","severe","severe","delta",95,85,99,"Canada","CAN","North America","North America",46580,2019,"Canada","High income",4,NA,NA,NA,NA,NA
"2744",330,"Risk","Test-negative case-control",2802,2022-10-08,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"0-3 months","12-17 years","12-17 years","included",NA,"infection","infection","infection","omicron",54.5,17.8,76.9,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"2745",330,"Risk","Test-negative case-control",2803,2022-10-08,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,">=6 months","12-17 years","12-17 years","included","~58 weeks","infection","infection","infection","omicron",4.2,-20.2,23.6,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"2746",330,"Risk","Test-negative case-control",2804,2022-10-08,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"0-3 months","12-17 years","12-17 years","included",NA,"infection","infection","infection","delta",81.9,67.9,90.8,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"2747",330,"Risk","Test-negative case-control",2805,2022-10-08,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,">=6 months","12-17 years","12-17 years","included","~44 weeks","infection","infection","infection","delta",65.3,34.6,83.8,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"2748",331,"Mimura","Retrospective cohort",2806,2022-10-08,"Multiple or heterologous RNA","mRNA","2","final",NA,"14+ (includes up to 13 days post booster dose)","16-64 years","16-64 years","excluded","~43 weeks","infection","infection","infection","omicron",15.8,7.9,23.1,"Japan","JPN","Asia","East Asia & Pacific",41970,2019,"Japan","High income",4,NA,NA,NA,NA,NA
"2749",331,"Mimura","Retrospective cohort",2807,2022-10-08,"Multiple or heterologous RNA","mRNA","2","final",NA,"14+ (includes up to 13 days post booster dose)","16-64 years","16-64 years","excluded","~43 weeks","symptomatic disease","symptomatic","symptomatic","omicron",21.2,11,30.3,"Japan","JPN","Asia","East Asia & Pacific",41970,2019,"Japan","High income",4,NA,NA,NA,NA,NA
"2750",331,"Mimura","Retrospective cohort",2808,2022-10-08,"Multiple or heterologous RNA","mRNA","2","final",NA,"14+ (includes up to 13 days post booster dose)","16-64 years","16-64 years","excluded","~31 weeks","infection","infection","infection","delta",82.9,69.4,90.4,"Japan","JPN","Asia","East Asia & Pacific",41970,2019,"Japan","High income",4,NA,NA,NA,NA,NA
"2751",331,"Mimura","Retrospective cohort",2809,2022-10-08,"Multiple or heterologous RNA","mRNA","2","final",NA,"14+ (includes up to 13 days post booster dose)","16-64 years","16-64 years","excluded","~31 weeks","symptomatic disease","symptomatic","symptomatic","delta",95.7,82.5,98.9,"Japan","JPN","Asia","East Asia & Pacific",41970,2019,"Japan","High income",4,NA,NA,NA,NA,NA
"2752",332,"Wan","Case-control",2810,2022-10-17,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"14-180","60-79 years","60-79 years","excluded","~24 weeks","infection","infection","infection","omicron",17.3,15.2,19.3,"Hong Kong","HKG","Asia","East Asia & Pacific",50480,2019,"Hong Kong SAR, China","High income",4,NA,NA,NA,NA,NA
"2753",332,"Wan","Case-control",2811,2022-10-17,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"14-180","60-79 years","60-79 years","excluded","~24 weeks","hospitalization","severe","severe","omicron",74.6,72.1,76.8,"Hong Kong","HKG","Asia","East Asia & Pacific",50480,2019,"Hong Kong SAR, China","High income",4,14,168,"yes",NA,1
"2754",332,"Wan","Case-control",2812,2022-10-17,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"14-180","60-79 years","60-79 years","excluded","~24 weeks","severe disease","severe","severe","omicron",77.5,65.7,85.2,"Hong Kong","HKG","Asia","East Asia & Pacific",50480,2019,"Hong Kong SAR, China","High income",4,14,168,"no","duplicated endpoint (use hospitalisation)",1
"2755",332,"Wan","Case-control",2813,2022-10-17,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"14-180","60-79 years","60-79 years","excluded","~24 weeks","death","death","death","omicron",92.1,88.7,94.5,"Hong Kong","HKG","Asia","East Asia & Pacific",50480,2019,"Hong Kong SAR, China","High income",4,NA,NA,NA,NA,NA
"2756",332,"Wan","Case-control",2814,2022-10-17,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"14-180",">=80 years",">=80 years","excluded","~24 weeks","infection","infection","infection","omicron",54.2,51.4,56.9,"Hong Kong","HKG","Asia","East Asia & Pacific",50480,2019,"Hong Kong SAR, China","High income",4,NA,NA,NA,NA,NA
"2757",332,"Wan","Case-control",2815,2022-10-17,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"14-180",">=80 years",">=80 years","excluded","~24 weeks","hospitalization","severe","severe","omicron",81,78.2,83.5,"Hong Kong","HKG","Asia","East Asia & Pacific",50480,2019,"Hong Kong SAR, China","High income",4,14,168,"yes",NA,1
"2758",332,"Wan","Case-control",2816,2022-10-17,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"14-180",">=80 years",">=80 years","excluded","~24 weeks","severe disease","severe","severe","omicron",82.7,62.7,92,"Hong Kong","HKG","Asia","East Asia & Pacific",50480,2019,"Hong Kong SAR, China","High income",4,14,168,"no","duplicated endpoint (use hospitalisation)",1
"2759",332,"Wan","Case-control",2817,2022-10-17,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"14-180",">=80 years",">=80 years","excluded","~24 weeks","death","death","death","omicron",92.5,89.3,94.8,"Hong Kong","HKG","Asia","East Asia & Pacific",50480,2019,"Hong Kong SAR, China","High income",4,NA,NA,NA,NA,NA
"2760",332,"Wan","Case-control",2818,2022-10-17,"Sinovac CoronaVac","Inactivated","2","final",NA,"14-180","60-79 years","60-79 years","excluded","~24 weeks","infection","infection","infection","omicron",-23.1,-25.8,-20.5,"Hong Kong","HKG","Asia","East Asia & Pacific",50480,2019,"Hong Kong SAR, China","High income",4,NA,NA,NA,NA,NA
"2761",332,"Wan","Case-control",2819,2022-10-17,"Sinovac CoronaVac","Inactivated","2","final",NA,"14-180","60-79 years","60-79 years","excluded","~24 weeks","hospitalization","severe","severe","omicron",59.4,56.6,62,"Hong Kong","HKG","Asia","East Asia & Pacific",50480,2019,"Hong Kong SAR, China","High income",4,NA,NA,NA,NA,NA
"2762",332,"Wan","Case-control",2820,2022-10-17,"Sinovac CoronaVac","Inactivated","2","final",NA,"14-180","60-79 years","60-79 years","excluded","~24 weeks","severe disease","severe","severe","omicron",57.7,43.8,68.2,"Hong Kong","HKG","Asia","East Asia & Pacific",50480,2019,"Hong Kong SAR, China","High income",4,NA,NA,NA,NA,NA
"2763",332,"Wan","Case-control",2821,2022-10-17,"Sinovac CoronaVac","Inactivated","2","final",NA,"14-180","60-79 years","60-79 years","excluded","~24 weeks","death","death","death","omicron",79.6,75,83.3,"Hong Kong","HKG","Asia","East Asia & Pacific",50480,2019,"Hong Kong SAR, China","High income",4,NA,NA,NA,NA,NA
"2764",332,"Wan","Case-control",2822,2022-10-17,"Sinovac CoronaVac","Inactivated","2","final",NA,"14-180",">=80 years",">=80 years","excluded","~24 weeks","infection","infection","infection","omicron",31.2,28.7,33.6,"Hong Kong","HKG","Asia","East Asia & Pacific",50480,2019,"Hong Kong SAR, China","High income",4,NA,NA,NA,NA,NA
"2765",332,"Wan","Case-control",2823,2022-10-17,"Sinovac CoronaVac","Inactivated","2","final",NA,"14-180",">=80 years",">=80 years","excluded","~24 weeks","hospitalization","severe","severe","omicron",58.4,55.8,60.9,"Hong Kong","HKG","Asia","East Asia & Pacific",50480,2019,"Hong Kong SAR, China","High income",4,NA,NA,NA,NA,NA
"2766",332,"Wan","Case-control",2824,2022-10-17,"Sinovac CoronaVac","Inactivated","2","final",NA,"14-180",">=80 years",">=80 years","excluded","~24 weeks","severe disease","severe","severe","omicron",55,38.6,67,"Hong Kong","HKG","Asia","East Asia & Pacific",50480,2019,"Hong Kong SAR, China","High income",4,NA,NA,NA,NA,NA
"2767",332,"Wan","Case-control",2825,2022-10-17,"Sinovac CoronaVac","Inactivated","2","final",NA,"14-180",">=80 years",">=80 years","excluded","~24 weeks","death","death","death","omicron",69.4,65.6,72.8,"Hong Kong","HKG","Asia","East Asia & Pacific",50480,2019,"Hong Kong SAR, China","High income",4,NA,NA,NA,NA,NA
"2768",333,"Chambers","Test-negative case-control",2826,2022-10-19,"Multiple or heterologous RNA","mRNA","2","final",NA,"7+",">=19 years","general pop","excluded","~44 weeks","infection","infection","infection","other combinations",82,74,88,"Canada","CAN","North America","North America",46580,2019,"Canada","High income",4,NA,NA,NA,NA,NA
"2769",333,"Chambers","Test-negative case-control",2827,2022-10-19,"Multiple or heterologous RNA","mRNA","2","final",NA,"7+",">=19 years","general pop","excluded","~44 weeks","symptomatic disease","symptomatic","symptomatic","other combinations",93,79,98,"Canada","CAN","North America","North America",46580,2019,"Canada","High income",4,NA,NA,NA,NA,NA
"2770",333,"Chambers","Test-negative case-control",2828,2022-10-19,"Multiple or heterologous RNA","mRNA","2","final",NA,"7+",">=19 years","general pop","excluded","~44 weeks","severe disease","severe","severe","other combinations",97,80,99,"Canada","CAN","North America","North America",46580,2019,"Canada","High income",4,NA,NA,NA,NA,NA
"2771",333,"Chambers","Test-negative case-control",2829,2022-10-19,"Oxford/AstraZeneca ChAdOx1-S","Vectored","2","final",NA,"7+",">=19 years","general pop","excluded","~44 weeks","infection","infection","infection","other combinations",77,34,92,"Canada","CAN","North America","North America",46580,2019,"Canada","High income",4,NA,NA,NA,NA,NA
"2772",333,"Chambers","Test-negative case-control",2830,2022-10-19,"Heterologous platforms","Multiple","2","final",NA,"7+",">=19 years","general pop","excluded","~44 weeks","infection","infection","infection","other combinations",80,49,92,"Canada","CAN","North America","North America",46580,2019,"Canada","High income",4,NA,NA,NA,NA,NA
"2773",334,"Consonni","Retrospective cohort",2831,2022-10-19,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"7-119","HCW","HCW","excluded","~67 weeks","infection","infection","infection","omicron",70,54,80,"Italy","ITA","Europe","Europe & Central Asia",34890,2019,"Italy","High income",4,NA,NA,NA,NA,NA
"2774",334,"Consonni","Retrospective cohort",2832,2022-10-19,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"120+","HCW","HCW","excluded","~67 weeks","infection","infection","infection","omicron",16,0,43,"Italy","ITA","Europe","Europe & Central Asia",34890,2019,"Italy","High income",4,NA,NA,NA,NA,NA
"2775",334,"Consonni","Retrospective cohort",2833,2022-10-19,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"7-119","HCW","HCW","previously infected only","~67 weeks","infection","infection","infection","omicron",25,0,69,"Italy","ITA","Europe","Europe & Central Asia",34890,2019,"Italy","High income",4,NA,NA,NA,NA,NA
"2776",334,"Consonni","Retrospective cohort",2834,2022-10-19,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"120+","HCW","HCW","previously infected only","~67 weeks","infection","infection","infection","omicron",88,66,96,"Italy","ITA","Europe","Europe & Central Asia",34890,2019,"Italy","High income",4,NA,NA,NA,NA,NA
"2777",335,"Zerbo","Cohort study",2835,2023-02-28,"Multiple or heterologous RNA","mRNA","2","final",NA,"7+","infants born to mothers 16-50 years of age","infants","excluded","~11 months","infection in the first 2 months of life","infection in the first 2 months of life","infection","omicron",26,-22,56,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"2778",335,"Zerbo","Cohort study",2836,2023-02-28,"Multiple or heterologous RNA","mRNA","2","final",NA,"7+","infants born to mothers 16-50 years of age","infants","excluded","~13 months","infection in the first 4 months of life","infection in the first 4 months of life","infection","omicron",23,-6,44,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"2779",335,"Zerbo","Cohort study",2837,2023-02-28,"Multiple or heterologous RNA","mRNA","2","final",NA,"7+","infants born to mothers 16-50 years of age","infants","excluded","~15 months","infection in the first 6 months of life","infection in the first 6 months of life","infection","omicron",19,-3,37,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"2780",335,"Zerbo","Cohort study",2838,2023-02-28,"Multiple or heterologous RNA","mRNA","2","final",NA,"7+","infants born to mothers 16-50 years of age","infants","excluded","~8 months","infection in the first 2 months of life","infection in the first 2 months of life","infection","omicron",37,-21,67,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"2781",335,"Zerbo","Cohort study",2839,2023-02-28,"Multiple or heterologous RNA","mRNA","2","final",NA,"7+","infants born to mothers 16-50 years of age","infants","excluded","~10 months","infection in the first 4 months of life","infection in the first 4 months of life","infection","omicron",5,-28,29,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"2782",335,"Zerbo","Cohort study",2840,2023-02-28,"Multiple or heterologous RNA","mRNA","2","final",NA,"7+","infants born to mothers 16-50 years of age","infants","excluded","~12 months","infection in the first 6 months of life","infection in the first 6 months of life","infection","omicron",3,-19,21,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"2783",335,"Zerbo","Cohort study",2841,2023-02-28,"Multiple or heterologous RNA","mRNA","2","final",NA,"7+","infants born to mothers 16-50 years of age","infants","excluded","~5 months","infection in the first 2 months of life","infection in the first 2 months of life","infection","omicron",-4,-84,41,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"2784",335,"Zerbo","Cohort study",2842,2023-02-28,"Multiple or heterologous RNA","mRNA","2","final",NA,"7+","infants born to mothers 16-50 years of age","infants","excluded","~7 months","infection in the first 4 months of life","infection in the first 4 months of life","infection","omicron",12,-23,37,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"2785",335,"Zerbo","Cohort study",2843,2023-02-28,"Multiple or heterologous RNA","mRNA","2","final",NA,"7+","infants born to mothers 16-50 years of age","infants","excluded","~9 months","infection in the first 6 months of life","infection in the first 6 months of life","infection","omicron",18,-4,36,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"2786",335,"Zerbo","Cohort study",2844,2023-02-28,"Multiple or heterologous RNA","mRNA","2","final",NA,"7+","infants born to mothers 16-50 years of age","infants","excluded","~11 months","infection in the first 2 months of life","infection in the first 2 months of life","infection","delta",61,-31,89,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"2787",335,"Zerbo","Cohort study",2845,2023-02-28,"Multiple or heterologous RNA","mRNA","2","final",NA,"7+","infants born to mothers 16-50 years of age","infants","excluded","~13 months","infection in the first 4 months of life","infection in the first 4 months of life","infection","delta",48,-54,82,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"2788",335,"Zerbo","Cohort study",2846,2023-02-28,"Multiple or heterologous RNA","mRNA","2","final",NA,"7+","infants born to mothers 16-50 years of age","infants","excluded","~15 months","infection in the first 6 months of life","infection in the first 6 months of life","infection","delta",49,-46,82,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"2789",335,"Zerbo","Cohort study",2847,2023-02-28,"Multiple or heterologous RNA","mRNA","2","final",NA,"7+","infants born to mothers 16-50 years of age","infants","excluded","~8 months","infection in the first 2 months of life","infection in the first 2 months of life","infection","delta",91,63,98,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"2790",335,"Zerbo","Cohort study",2848,2023-02-28,"Multiple or heterologous RNA","mRNA","2","final",NA,"7+","infants born to mothers 16-50 years of age","infants","excluded","~10 months","infection in the first 4 months of life","infection in the first 4 months of life","infection","delta",60,23,79,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"2791",335,"Zerbo","Cohort study",2849,2023-02-28,"Multiple or heterologous RNA","mRNA","2","final",NA,"7+","infants born to mothers 16-50 years of age","infants","excluded","~12 months","infection in the first 6 months of life","infection in the first 6 months of life","infection","delta",65,33,81,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"2792",335,"Zerbo","Cohort study",2850,2023-02-28,"Multiple or heterologous RNA","mRNA","2","final",NA,"7+","infants born to mothers 16-50 years of age","infants","excluded","~5 months","infection in the first 2 months of life","infection in the first 2 months of life","infection","delta",87,55,96,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"2793",335,"Zerbo","Cohort study",2851,2023-02-28,"Multiple or heterologous RNA","mRNA","2","final",NA,"7+","infants born to mothers 16-50 years of age","infants","excluded","~7 months","infection in the first 4 months of life","infection in the first 4 months of life","infection","delta",70,43,84,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"2794",335,"Zerbo","Cohort study",2852,2023-02-28,"Multiple or heterologous RNA","mRNA","2","final",NA,"7+","infants born to mothers 16-50 years of age","infants","excluded","~9 months","infection in the first 6 months of life","infection in the first 6 months of life","infection","delta",54,27,71,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"2795",336,"Embi","Test-negative case-control",2853,2023-05-22,"Moderna mRNA-1273","mRNA","2","final",NA,"14-149","immunocompetent adults >=18 years","immunocompetent adults","included","~46 weeks","ED or UC visits with COVID-like illness","symptomatic","symptomatic","delta",90,89,91,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"2796",336,"Embi","Test-negative case-control",2854,2023-05-22,"Moderna mRNA-1273","mRNA","2","final",NA,"150+","immunocompetent adults >=18 years","immunocompetent adults","included","~46 weeks","ED or UC visits with COVID-like illness","symptomatic","symptomatic","delta",84,83,85,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"2797",336,"Embi","Test-negative case-control",2855,2023-05-22,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"14-149","immunocompetent adults >=18 years","immunocompetent adults","included","~46 weeks","ED or UC visits with COVID-like illness","symptomatic","symptomatic","delta",85,84,86,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"2798",336,"Embi","Test-negative case-control",2856,2023-05-22,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"150+","immunocompetent adults >=18 years","immunocompetent adults","included","~46 weeks","ED or UC visits with COVID-like illness","symptomatic","symptomatic","delta",73,72,74,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"2799",336,"Embi","Test-negative case-control",2857,2023-05-22,"Moderna mRNA-1273","mRNA","2","final",NA,"14-149","immunocompetent adults >=18 years","immunocompetent adults","included","~46 weeks","hospitalization with COVID-like illness","severe","severe","delta",95,92,95,"USA","USA","North America","North America",66220,2019,"United States","High income",4,14,149,"yes",NA,0
"2800",336,"Embi","Test-negative case-control",2858,2023-05-22,"Moderna mRNA-1273","mRNA","2","final",NA,"150+","immunocompetent adults >=18 years","immunocompetent adults","included","~46 weeks","hospitalization with COVID-like illness","severe","severe","delta",89,88,90,"USA","USA","North America","North America",66220,2019,"United States","High income",4,150,322,"no","sequential period",0
"2801",336,"Embi","Test-negative case-control",2859,2023-05-22,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"14-149","immunocompetent adults >=18 years","immunocompetent adults","included","~46 weeks","hospitalization with COVID-like illness","severe","severe","delta",90,88,91,"USA","USA","North America","North America",66220,2019,"United States","High income",4,14,149,"yes",NA,0
"2802",336,"Embi","Test-negative case-control",2860,2023-05-22,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"150+","immunocompetent adults >=18 years","immunocompetent adults","included","~46 weeks","hospitalization with COVID-like illness","severe","severe","delta",80,79,82,"USA","USA","North America","North America",66220,2019,"United States","High income",4,150,322,"no","sequential period",0
"2803",336,"Embi","Test-negative case-control",2861,2023-05-22,"Moderna mRNA-1273","mRNA","2","final",NA,"14-149","immunocompromised adults >=18 years","immunocompromised adults","included","~46 weeks","ED or UC visits with COVID-like illness","symptomatic","symptomatic","delta",79,64,88,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"2804",336,"Embi","Test-negative case-control",2862,2023-05-22,"Moderna mRNA-1273","mRNA","2","final",NA,"150+","immunocompromised adults >=18 years","immunocompromised adults","included","~46 weeks","ED or UC visits with COVID-like illness","symptomatic","symptomatic","delta",64,54,72,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"2805",336,"Embi","Test-negative case-control",2863,2023-05-22,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"14-149","immunocompromised adults >=18 years","immunocompromised adults","included","~46 weeks","ED or UC visits with COVID-like illness","symptomatic","symptomatic","delta",62,45,73,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"2806",336,"Embi","Test-negative case-control",2864,2023-05-22,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"150+","immunocompromised adults >=18 years","immunocompromised adults","included","~46 weeks","ED or UC visits with COVID-like illness","symptomatic","symptomatic","delta",56,46,64,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"2807",336,"Embi","Test-negative case-control",2865,2023-05-22,"Moderna mRNA-1273","mRNA","2","final",NA,"14-149","immunocompromised adults >=18 years","immunocompromised adults","included","~46 weeks","hospitalization with COVID-like illness","severe","severe","delta",81,69,88,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"2808",336,"Embi","Test-negative case-control",2866,2023-05-22,"Moderna mRNA-1273","mRNA","2","final",NA,"150+","immunocompromised adults >=18 years","immunocompromised adults","included","~46 weeks","hospitalization with COVID-like illness","severe","severe","delta",73,68,77,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"2809",336,"Embi","Test-negative case-control",2867,2023-05-22,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"14-149","immunocompromised adults >=18 years","immunocompromised adults","included","~46 weeks","hospitalization with COVID-like illness","severe","severe","delta",68,58,75,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"2810",336,"Embi","Test-negative case-control",2868,2023-05-22,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"150+","immunocompromised adults >=18 years","immunocompromised adults","included","~46 weeks","hospitalization with COVID-like illness","severe","severe","delta",64,58,69,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"2811",336,"Embi","Test-negative case-control",2869,2023-05-22,"Janssen Ad26.COV2.S","Vectored","1","final",NA,"14-149","immunocompetent adults >=18 years","immunocompetent adults","included","~46 weeks","ED or UC visits with COVID-like illness","symptomatic","symptomatic","delta",67,63,71,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"2812",336,"Embi","Test-negative case-control",2870,2023-05-22,"Janssen Ad26.COV2.S","Vectored","1","final",NA,"150+","immunocompetent adults >=18 years","immunocompetent adults","included","~46 weeks","ED or UC visits with COVID-like illness","symptomatic","symptomatic","delta",62,58,65,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"2813",336,"Embi","Test-negative case-control",2871,2023-05-22,"Janssen Ad26.COV2.S","Vectored","1","final",NA,"14-149","immunocompetent adults >=18 years","immunocompetent adults","included","~46 weeks","hospitalization with COVID-like illness","severe","severe","delta",77,71,82,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"2814",336,"Embi","Test-negative case-control",2872,2023-05-22,"Janssen Ad26.COV2.S","Vectored","1","final",NA,"150+","immunocompetent adults >=18 years","immunocompetent adults","included","~46 weeks","hospitalization with COVID-like illness","severe","severe","delta",69,65,73,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"2815",336,"Embi","Test-negative case-control",2873,2023-05-22,"Janssen Ad26.COV2.S","Vectored","1","final",NA,"14-149","immunocompromised adults >=18 years","immunocompromised adults","included","~46 weeks","ED or UC visits with COVID-like illness","symptomatic","symptomatic","delta",9,-66,50,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"2816",336,"Embi","Test-negative case-control",2874,2023-05-22,"Janssen Ad26.COV2.S","Vectored","1","final",NA,"150+","immunocompromised adults >=18 years","immunocompromised adults","included","~46 weeks","ED or UC visits with COVID-like illness","symptomatic","symptomatic","delta",-6,-49,25,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"2817",336,"Embi","Test-negative case-control",2875,2023-05-22,"Janssen Ad26.COV2.S","Vectored","1","final",NA,"14-149","immunocompromised adults >=18 years","immunocompromised adults","included","~46 weeks","hospitalization with COVID-like illness","severe","severe","delta",35,-3,60,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"2818",336,"Embi","Test-negative case-control",2876,2023-05-22,"Janssen Ad26.COV2.S","Vectored","1","final",NA,"150+","immunocompromised adults >=18 years","immunocompromised adults","included","~46 weeks","hospitalization with COVID-like illness","severe","severe","delta",43,23,58,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"2819",337,"Britton","Test-negative case-control",2877,2022-10-21,"Multiple or heterologous RNA","mRNA","2","final",NA,"14+","immunocompromised adults >=18 years","immunocompromised adults","included","~56 weeks","hospitalization with COVID-like illness","severe","severe","omicron",40,34,46,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"2820",337,"Britton","Test-negative case-control",2878,2022-10-21,"Multiple or heterologous RNA","mRNA","2","final",NA,"14+","immunocompromised adults >=18 years","immunocompromised adults","included","~69 weeks","hospitalization with COVID-like illness","severe","severe","omicron",7,-16,25,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"2821",337,"Britton","Test-negative case-control",2879,2022-10-21,"Multiple or heterologous RNA","mRNA","2","final",NA,"14+","immunocompromised adults >=18 years","immunocompromised adults","included","~77 weeks","hospitalization with COVID-like illness","severe","severe","omicron",38,23,50,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"2822",337,"Britton","Test-negative case-control",2880,2022-10-21,"Multiple or heterologous RNA","mRNA","2","final",NA,"14+","immunocompromised adults >=18 years","immunocompromised adults","included","~77 weeks","hospitalization with COVID-like illness","severe","severe","omicron",22,10,33,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"2823",338,"Surie","Test-negative case-control",2881,2022-10-21,"Multiple or heterologous RNA","mRNA","2","final",NA,"14-150",">=18 years","general pop","included","~74 weeks","hospitalization with COVID-like illness","severe","severe","omicron",63,46,75,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"2824",338,"Surie","Test-negative case-control",2882,2022-10-21,"Multiple or heterologous RNA","mRNA","2","final",NA,"150+",">=18 years","general pop","included","~74 weeks","hospitalization with COVID-like illness","severe","severe","omicron",34,20,46,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"2825",338,"Surie","Test-negative case-control",2883,2022-10-21,"Multiple or heterologous RNA","mRNA","2","final",NA,"14-150",">=18 years","general pop","included","~82 weeks","hospitalization with COVID-like illness","severe","severe","omicron",83,35,96,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"2826",338,"Surie","Test-negative case-control",2884,2022-10-21,"Multiple or heterologous RNA","mRNA","2","final",NA,"150+",">=18 years","general pop","included","~82 weeks","hospitalization with COVID-like illness","severe","severe","omicron",37,12,55,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"2827",339,"Collie","Test-negative case-control",2885,2022-10-24,"Janssen Ad26.COV2.S","Vectored","1","final",NA,"14-20","HCW >=18 years with low physical activity","HCW with low physical activity","included","~34 weeks","infection","infection","infection","other combinations",48,9.7,70.1,"South Africa","ZAF","Africa","Sub-Saharan Africa",6570,2019,"South Africa","Upper middle income",3,NA,NA,NA,NA,NA
"2828",339,"Collie","Test-negative case-control",2886,2022-10-24,"Janssen Ad26.COV2.S","Vectored","1","final",NA,"28+","HCW >=18 years with low physical activity","HCW with low physical activity","included","~34 weeks","infection","infection","infection","other combinations",39.8,34,45.1,"South Africa","ZAF","Africa","Sub-Saharan Africa",6570,2019,"South Africa","Upper middle income",3,NA,NA,NA,NA,NA
"2829",339,"Collie","Test-negative case-control",2887,2022-10-24,"Janssen Ad26.COV2.S","Vectored","1","final",NA,"28+","HCW >=18 years with low physical activity","HCW with low physical activity","included","~34 weeks","hospitalization","severe","severe","other combinations",60,39,73.8,"South Africa","ZAF","Africa","Sub-Saharan Africa",6570,2019,"South Africa","Upper middle income",3,NA,NA,NA,NA,NA
"2830",339,"Collie","Test-negative case-control",2888,2022-10-24,"Janssen Ad26.COV2.S","Vectored","1","final",NA,"14-20","HCW >=18 years with moderate physical activity","HCW years with moderate physical activity","included","~34 weeks","infection","infection","infection","other combinations",39,-4.9,64.5,"South Africa","ZAF","Africa","Sub-Saharan Africa",6570,2019,"South Africa","Upper middle income",3,NA,NA,NA,NA,NA
"2831",339,"Collie","Test-negative case-control",2889,2022-10-24,"Janssen Ad26.COV2.S","Vectored","1","final",NA,"28+","HCW >=18 years with moderate physical activity","HCW years with moderate physical activity","included","~34 weeks","infection","infection","infection","other combinations",36.3,31.3,41,"South Africa","ZAF","Africa","Sub-Saharan Africa",6570,2019,"South Africa","Upper middle income",3,NA,NA,NA,NA,NA
"2832",339,"Collie","Test-negative case-control",2890,2022-10-24,"Janssen Ad26.COV2.S","Vectored","1","final",NA,"28+","HCW >=18 years with moderate physical activity","HCW years with moderate physical activity","included","~34 weeks","hospitalization","severe","severe","other combinations",72.1,55.2,82.6,"South Africa","ZAF","Africa","Sub-Saharan Africa",6570,2019,"South Africa","Upper middle income",3,NA,NA,NA,NA,NA
"2833",339,"Collie","Test-negative case-control",2891,2022-10-24,"Janssen Ad26.COV2.S","Vectored","1","final",NA,"14-20","HCW >=18 years with high physical activity","HCW years with high physical activity","included","~34 weeks","infection","infection","infection","other combinations",51,16.8,71.1,"South Africa","ZAF","Africa","Sub-Saharan Africa",6570,2019,"South Africa","Upper middle income",3,NA,NA,NA,NA,NA
"2834",339,"Collie","Test-negative case-control",2892,2022-10-24,"Janssen Ad26.COV2.S","Vectored","1","final",NA,"28+","HCW >=18 years with high physical activity","HCW years with high physical activity","included","~34 weeks","infection","infection","infection","other combinations",41.2,37.5,44.7,"South Africa","ZAF","Africa","Sub-Saharan Africa",6570,2019,"South Africa","Upper middle income",3,NA,NA,NA,NA,NA
"2835",339,"Collie","Test-negative case-control",2893,2022-10-24,"Janssen Ad26.COV2.S","Vectored","1","final",NA,"28+","HCW >=18 years with high physical activity","HCW years with high physical activity","included","~34 weeks","hospitalization","severe","severe","other combinations",85.8,74.1,92.2,"South Africa","ZAF","Africa","Sub-Saharan Africa",6570,2019,"South Africa","Upper middle income",3,NA,NA,NA,NA,NA
"2836",340,"Nordstrom","Case-control",2894,2023-02-21,"Multiple or heterologous RNA","mRNA","2","final",NA,"7+","adolescents vaccinated on or after January 1, 2022","adolescents","included","~6 weeks","infection","infection","infection","omicron",51,48,55,"Sweden","SWE","Europe","Europe & Central Asia",56230,2019,"Sweden","High income",4,NA,NA,NA,NA,NA
"2837",340,"Nordstrom","Case-control",2895,2023-02-21,"Multiple or heterologous RNA","mRNA","2","final",NA,"7+","adolescents vaccinated on or after September 1, 2021","adolescents","included","~24 weeks","infection","infection","infection","omicron",12,10,13,"Sweden","SWE","Europe","Europe & Central Asia",56230,2019,"Sweden","High income",4,NA,NA,NA,NA,NA
"2838",340,"Nordstrom","Case-control",2896,2023-02-21,"Multiple or heterologous RNA","mRNA","2","final",NA,"7+","adolescents vaccinated on or after November 15, 2021","adolescents","included","~27 weeks","hospitalization with COVID-19 as the main diagnosis","severe","severe","omicron",87,66,95,"Sweden","SWE","Europe","Europe & Central Asia",56230,2019,"Sweden","High income",4,NA,NA,NA,NA,NA
"2839",340,"Nordstrom","Case-control",2897,2023-02-21,"Multiple or heterologous RNA","mRNA","2","final",NA,"48+","adolescents vaccinated before November 15, 2021","adolescents","included","~45 weeks","hospitalization with COVID-19 as the main diagnosis","severe","severe","omicron",69,29,87,"Sweden","SWE","Europe","Europe & Central Asia",56230,2019,"Sweden","High income",4,NA,NA,NA,NA,NA
"2840",341,"Tartof","Test-negative case-control",2898,2022-10-25,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"<6 months",">=18 years","general pop","included","~84 weeks","ED visit for ARI","symptomatic","symptomatic","omicron",30,-86,74,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"2841",341,"Tartof","Test-negative case-control",2899,2022-10-25,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,">=6 months",">=18 years","general pop","included","~84 weeks","ED visit for ARI","symptomatic","symptomatic","omicron",44,20,61,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"2842",341,"Tartof","Test-negative case-control",2900,2022-10-25,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"<6 months",">=18 years","general pop","included","~84 weeks","UC visit for ARI","symptomatic","symptomatic","omicron",50,10,72,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"2843",341,"Tartof","Test-negative case-control",2901,2022-10-25,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,">=6 months",">=18 years","general pop","included","~84 weeks","UC visit for ARI","symptomatic","symptomatic","omicron",7,-11,22,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"2844",341,"Tartof","Test-negative case-control",2902,2022-10-25,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"<6 months",">=18 years","general pop","included","~84 weeks","outpatient care visit for ARI","symptomatic","symptomatic","omicron",30,4,49,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"2845",341,"Tartof","Test-negative case-control",2903,2022-10-25,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,">=6 months",">=18 years","general pop","included","~84 weeks","outpatient care visit for ARI","symptomatic","symptomatic","omicron",19,9,29,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"2846",341,"Tartof","Test-negative case-control",2904,2022-10-25,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,">=6 months",">=18 years","general pop","included","~84 weeks","hospitalization for ARI","severe","severe","omicron",-4,-118,50,"USA","USA","North America","North America",66220,2019,"United States","High income",4,180,588,"yes",NA,0
"2847",342,"Moghnieh","Retrospective cohort",2905,2022-09-22,"Gamaleya Gam-COVID-Vac/Sputnik V","Vectored","2","final",NA,"3-5 months",">=18 years","general pop","included","~30 weeks","infection","infection","infection","delta",52.3,-27.4,78.7,"Lebanon","LBN","Asia","Middle East & North Africa",8630,2019,"Lebanon","Lower middle income",3,NA,NA,NA,NA,NA
"2848",342,"Moghnieh","Retrospective cohort",2906,2022-09-22,"Gamaleya Gam-COVID-Vac/Sputnik V","Vectored","2","final",NA,"7-9 months",">=18 years","general pop","included","~30 weeks","infection","infection","infection","delta",23.7,-84.7,62.8,"Lebanon","LBN","Asia","Middle East & North Africa",8630,2019,"Lebanon","Lower middle income",3,NA,NA,NA,NA,NA
"2849",342,"Moghnieh","Retrospective cohort",2907,2022-09-22,"Gamaleya Gam-COVID-Vac/Sputnik V","Vectored","2","final",NA,"7-9 months",">=18 years","general pop","excluded","~30 weeks","infection","infection","infection","delta",20.1,-94.7,61.6,"Lebanon","LBN","Asia","Middle East & North Africa",8630,2019,"Lebanon","Lower middle income",3,NA,NA,NA,NA,NA
"2850",342,"Moghnieh","Retrospective cohort",2908,2022-09-22,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"<3 months",">=18 years","general pop","included","~30 weeks","infection","infection","infection","delta",95.1,78.4,99.3,"Lebanon","LBN","Asia","Middle East & North Africa",8630,2019,"Lebanon","Lower middle income",3,NA,NA,NA,NA,NA
"2851",342,"Moghnieh","Retrospective cohort",2909,2022-09-22,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"<7 months",">=18 years","general pop","included","~30 weeks","infection","infection","infection","delta",67.5,12.8,87.2,"Lebanon","LBN","Asia","Middle East & North Africa",8630,2019,"Lebanon","Lower middle income",3,NA,NA,NA,NA,NA
"2852",342,"Moghnieh","Retrospective cohort",2910,2022-09-22,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"<7 months",">=18 years","general pop","excluded","~30 weeks","infection","infection","infection","delta",71.8,22.3,89.1,"Lebanon","LBN","Asia","Middle East & North Africa",8630,2019,"Lebanon","Lower middle income",3,NA,NA,NA,NA,NA
"2853",342,"Moghnieh","Retrospective cohort",2911,2022-09-22,"Gamaleya Gam-COVID-Vac/Sputnik V","Vectored","2","final",NA,">6 months",">=18 years","general pop","included","~43 weeks","infection","infection","infection","omicron",-54.1,-151,0.84,"Lebanon","LBN","Asia","Middle East & North Africa",8630,2019,"Lebanon","Lower middle income",3,NA,NA,NA,NA,NA
"2854",342,"Moghnieh","Retrospective cohort",2912,2022-09-22,"Gamaleya Gam-COVID-Vac/Sputnik V","Vectored","2","final",NA,">6 months",">=18 years","general pop","excluded","~43 weeks","infection","infection","infection","omicron",-46,-149.7,10.1,"Lebanon","LBN","Asia","Middle East & North Africa",8630,2019,"Lebanon","Lower middle income",3,NA,NA,NA,NA,NA
"2855",342,"Moghnieh","Retrospective cohort",2913,2022-09-22,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"3-5 months",">=18 years","general pop","included","~43 weeks","infection","infection","infection","omicron",23.1,-28.7,52.1,"Lebanon","LBN","Asia","Middle East & North Africa",8630,2019,"Lebanon","Lower middle income",3,NA,NA,NA,NA,NA
"2856",342,"Moghnieh","Retrospective cohort",2914,2022-09-22,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"3-5 months",">=18 years","general pop","excluded","~43 weeks","infection","infection","infection","omicron",21.9,-38.9,54.1,"Lebanon","LBN","Asia","Middle East & North Africa",8630,2019,"Lebanon","Lower middle income",3,NA,NA,NA,NA,NA
"2857",343,"Grewal","Test-negative case-control",2915,2023-03-07,"Multiple or heterologous RNA","mRNA","2","final",NA,"240-299","50-59 years","50-59 years","included","~74 weeks","severe disease","severe","severe","omicron",83,76,88,"Canada","CAN","North America","North America",46580,2019,"Canada","High income",4,NA,NA,NA,NA,NA
"2858",343,"Grewal","Test-negative case-control",2916,2023-03-07,"Multiple or heterologous RNA","mRNA","2","final",NA,"300+","50-59 years","50-59 years","included","~74 weeks","severe disease","severe","severe","omicron",83,74,89,"Canada","CAN","North America","North America",46580,2019,"Canada","High income",4,NA,NA,NA,NA,NA
"2859",343,"Grewal","Test-negative case-control",2917,2023-03-07,"Multiple or heterologous RNA","mRNA","2","final",NA,"300+","60-69 years","60-69 years","included","~74 weeks","severe disease","severe","severe","omicron",79,71,86,"Canada","CAN","North America","North America",46580,2019,"Canada","High income",4,NA,NA,NA,NA,NA
"2860",343,"Grewal","Test-negative case-control",2918,2023-03-07,"Multiple or heterologous RNA","mRNA","2","final",NA,"300+","70-79 years","70-79 years","included","~74 weeks","severe disease","severe","severe","omicron",80,72,86,"Canada","CAN","North America","North America",46580,2019,"Canada","High income",4,NA,NA,NA,NA,NA
"2861",343,"Grewal","Test-negative case-control",2919,2023-03-07,"Multiple or heterologous RNA","mRNA","2","final",NA,"300+",">=80 years",">=80 years","included","~74 weeks","severe disease","severe","severe","omicron",72,62,79,"Canada","CAN","North America","North America",46580,2019,"Canada","High income",4,NA,NA,NA,NA,NA
"2862",343,"Grewal","Test-negative case-control",2920,2023-03-07,"Multiple or heterologous RNA","mRNA","2","final",NA,"240-299","50-59 years","50-59 years","included","~86 weeks","severe disease","severe","severe","omicron",87,43,97,"Canada","CAN","North America","North America",46580,2019,"Canada","High income",4,NA,NA,NA,NA,NA
"2863",343,"Grewal","Test-negative case-control",2921,2023-03-07,"Multiple or heterologous RNA","mRNA","2","final",NA,"300+","50-59 years","50-59 years","included","~86 weeks","severe disease","severe","severe","omicron",56,30,72,"Canada","CAN","North America","North America",46580,2019,"Canada","High income",4,NA,NA,NA,NA,NA
"2864",343,"Grewal","Test-negative case-control",2922,2023-03-07,"Multiple or heterologous RNA","mRNA","2","final",NA,"300+","60-69 years","60-69 years","included","~86 weeks","severe disease","severe","severe","omicron",43,16,61,"Canada","CAN","North America","North America",46580,2019,"Canada","High income",4,NA,NA,NA,NA,NA
"2865",343,"Grewal","Test-negative case-control",2923,2023-03-07,"Multiple or heterologous RNA","mRNA","2","final",NA,"300+","70-79 years","70-79 years","included","~86 weeks","severe disease","severe","severe","omicron",48,25,64,"Canada","CAN","North America","North America",46580,2019,"Canada","High income",4,NA,NA,NA,NA,NA
"2866",343,"Grewal","Test-negative case-control",2924,2023-03-07,"Multiple or heterologous RNA","mRNA","2","final",NA,"300+",">=80 years",">=80 years","included","~86 weeks","severe disease","severe","severe","omicron",40,18,56,"Canada","CAN","North America","North America",46580,2019,"Canada","High income",4,NA,NA,NA,NA,NA
"2867",344,"Chemaitelly","Retrospective cohort",2925,2023-03-07,"Multiple or heterologous RNA","mRNA","2","final",NA,"91+ (90+ days post primary Omicron infection)",">=18 years with prior breakthrough Omicron infection",">=18 years with prior breakthrough Omicron infection","previously infected only","~85 weeks","reinfection","reinfection","infection","omicron",57,52,62,"Qatar","QAT","Asia","Middle East & North Africa",65700,2019,"Qatar","High income",4,NA,NA,NA,NA,NA
"2868",345,"Clemens","Test-negative case-control",2926,2022-10-13,"Oxford/AstraZeneca ChAdOx1-S","Vectored","2","final",NA,"14+","18-60 years","18-60 years","included","~12.5 weeks","infection","infection","infection","delta",76,49.5,87.8,"Brazil","BRA","South America","Latin America & Caribbean",9410,2019,"Brazil","Upper middle income",3,NA,NA,NA,NA,NA
"2869",345,"Clemens","Test-negative case-control",2927,2022-10-13,"Oxford/AstraZeneca ChAdOx1-S","Vectored","2","final",NA,"14+","18-60 years","18-60 years","included","~12.5 weeks","severe disease","severe","severe","delta",100,44.3,100,"Brazil","BRA","South America","Latin America & Caribbean",9410,2019,"Brazil","Upper middle income",3,14,87.5,"yes",NA,0
"2870",345,"Clemens","Test-negative case-control",2928,2022-10-13,"Oxford/AstraZeneca ChAdOx1-S","Vectored","2","final",NA,"14+","18-60 years","18-60 years","included","~12.5 weeks","infection","infection","infection","gamma",81.3,-298,97.9,"Brazil","BRA","South America","Latin America & Caribbean",9410,2019,"Brazil","Upper middle income",3,NA,NA,NA,NA,NA
"2871",346,"Jorgensen","Test-negative case-control",2929,2023-02-08,"Multiple or heterologous RNA","mRNA","2","final",NA,"14+","infants < 6 months","mothers of infants < 6 months","included","~66 weeks","infection","infection","infection","omicron",45,37,53,"Canada","CAN","North America","North America",46580,2019,"Canada","High income",4,NA,NA,NA,NA,NA
"2872",346,"Jorgensen","Test-negative case-control",2930,2023-02-08,"Multiple or heterologous RNA","mRNA","2","final",NA,"14+","infants < 6 months of mothers receiving second dose in first trimester","infants < 6 months of mothers receiving second dose in first trimester","included","~66 weeks","infection","infection","infection","omicron",47,31,59,"Canada","CAN","North America","North America",46580,2019,"Canada","High income",4,NA,NA,NA,NA,NA
"2873",346,"Jorgensen","Test-negative case-control",2931,2023-02-08,"Multiple or heterologous RNA","mRNA","2","final",NA,"14+","infants < 6 months of mothers receiving second dose in second trimester","infants < 6 months of mothers receiving second dose in second trimester","included","~66 weeks","infection","infection","infection","omicron",37,24,47,"Canada","CAN","North America","North America",46580,2019,"Canada","High income",4,NA,NA,NA,NA,NA
"2874",346,"Jorgensen","Test-negative case-control",2932,2023-02-08,"Multiple or heterologous RNA","mRNA","2","final",NA,"14+","infants < 6 months of mothers receiving second dose in third trimester","infants < 6 months of mothers receiving second dose in third trimester","included","~66 weeks","infection","infection","infection","omicron",53,42,62,"Canada","CAN","North America","North America",46580,2019,"Canada","High income",4,NA,NA,NA,NA,NA
"2875",346,"Jorgensen","Test-negative case-control",2933,2023-02-08,"Multiple or heterologous RNA","mRNA","2","final",NA,"14+","infants 0-8 weeks","infants 0-8 weeks","included","~66 weeks","infection","infection","infection","omicron",57,44,66,"Canada","CAN","North America","North America",46580,2019,"Canada","High income",4,NA,NA,NA,NA,NA
"2876",346,"Jorgensen","Test-negative case-control",2934,2023-02-08,"Multiple or heterologous RNA","mRNA","2","final",NA,"14+","infants 9-16 weeks","infants 9-16 weeks","included","~66 weeks","infection","infection","infection","omicron",47,31,60,"Canada","CAN","North America","North America",46580,2019,"Canada","High income",4,NA,NA,NA,NA,NA
"2877",346,"Jorgensen","Test-negative case-control",2935,2023-02-08,"Multiple or heterologous RNA","mRNA","2","final",NA,"14+","infants >16 weeks and < 6 months","infants >16 weeks and < 6 months","included","~66 weeks","infection","infection","infection","omicron",40,21,54,"Canada","CAN","North America","North America",46580,2019,"Canada","High income",4,NA,NA,NA,NA,NA
"2878",346,"Jorgensen","Test-negative case-control",2936,2023-02-08,"Multiple or heterologous RNA","mRNA","2","final",NA,"14+","infants < 6 months","infants < 6 months","included","~66 weeks","hospitalization","severe","severe","omicron",58,44,69,"Canada","CAN","North America","North America",46580,2019,"Canada","High income",4,NA,NA,NA,NA,NA
"2879",346,"Jorgensen","Test-negative case-control",2937,2023-02-08,"Multiple or heterologous RNA","mRNA","2","final",NA,"14+","infants < 6 months","infants < 6 months","excluded","~28 weeks","infection","infection","infection","delta",95,88,98,"Canada","CAN","North America","North America",46580,2019,"Canada","High income",4,NA,NA,NA,NA,NA
"2880",346,"Jorgensen","Test-negative case-control",2938,2023-02-08,"Multiple or heterologous RNA","mRNA","2","final",NA,"14+","infants < 6 months","infants < 6 months","excluded","~28 weeks","hospitalization","severe","severe","delta",97,74,100,"Canada","CAN","North America","North America",46580,2019,"Canada","High income",4,NA,NA,NA,NA,NA
"2881",347,"Van Ewijk","Test-negative case-control",2939,2022-11-10,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"14+",">=18 years","general pop","excluded","~41 weeks","infection","infection","infection","delta",64,51,74,"Netherlands","NLD","Europe","Europe & Central Asia",51920,2019,"Netherlands","High income",4,NA,NA,NA,NA,NA
"2882",347,"Van Ewijk","Test-negative case-control",2940,2022-11-10,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"14+",">=18 years","general pop","excluded","~41 weeks","symptomatic disease","symptomatic","symptomatic","delta",64,49,75,"Netherlands","NLD","Europe","Europe & Central Asia",51920,2019,"Netherlands","High income",4,NA,NA,NA,NA,NA
"2883",347,"Van Ewijk","Test-negative case-control",2941,2022-11-10,"Moderna mRNA-1273","mRNA","2","final",NA,"14+",">=18 years","general pop","excluded","~41 weeks","infection","infection","infection","delta",76,62,85,"Netherlands","NLD","Europe","Europe & Central Asia",51920,2019,"Netherlands","High income",4,NA,NA,NA,NA,NA
"2884",347,"Van Ewijk","Test-negative case-control",2942,2022-11-10,"Moderna mRNA-1273","mRNA","2","final",NA,"14+",">=18 years","general pop","excluded","~41 weeks","symptomatic disease","symptomatic","symptomatic","delta",75,58,85,"Netherlands","NLD","Europe","Europe & Central Asia",51920,2019,"Netherlands","High income",4,NA,NA,NA,NA,NA
"2885",347,"Van Ewijk","Test-negative case-control",2943,2022-11-10,"Oxford/AstraZeneca ChAdOx1-S","Vectored","2","final",NA,"14+",">=18 years","general pop","excluded","~41 weeks","infection","infection","infection","delta",53,37,68,"Netherlands","NLD","Europe","Europe & Central Asia",51920,2019,"Netherlands","High income",4,NA,NA,NA,NA,NA
"2886",347,"Van Ewijk","Test-negative case-control",2944,2022-11-10,"Oxford/AstraZeneca ChAdOx1-S","Vectored","2","final",NA,"14+",">=18 years","general pop","excluded","~41 weeks","symptomatic disease","symptomatic","symptomatic","delta",52,26,69,"Netherlands","NLD","Europe","Europe & Central Asia",51920,2019,"Netherlands","High income",4,NA,NA,NA,NA,NA
"2887",347,"Van Ewijk","Test-negative case-control",2945,2022-11-10,"Janssen Ad26.COV2.S","Vectored","1","final",NA,"28+",">=18 years","general pop","excluded","~36 weeks","infection","infection","infection","delta",55,32,70,"Netherlands","NLD","Europe","Europe & Central Asia",51920,2019,"Netherlands","High income",4,NA,NA,NA,NA,NA
"2888",347,"Van Ewijk","Test-negative case-control",2946,2022-11-10,"Janssen Ad26.COV2.S","Vectored","1","final",NA,"28+",">=18 years","general pop","excluded","~36 weeks","symptomatic disease","symptomatic","symptomatic","delta",59,35,74,"Netherlands","NLD","Europe","Europe & Central Asia",51920,2019,"Netherlands","High income",4,NA,NA,NA,NA,NA
"2889",347,"Van Ewijk","Test-negative case-control",2947,2022-11-10,"Multiple or heterologous RNA","mRNA","2","final",NA,"<120",">=18 years","general pop","excluded",NA,"infection","infection","infection","delta",74,63,81,"Netherlands","NLD","Europe","Europe & Central Asia",51920,2019,"Netherlands","High income",4,NA,NA,NA,NA,NA
"2890",347,"Van Ewijk","Test-negative case-control",2948,2022-11-10,"Multiple or heterologous RNA","mRNA","2","final",NA,">120",">=18 years","general pop","excluded","~41 weeks","infection","infection","infection","delta",56,36,69,"Netherlands","NLD","Europe","Europe & Central Asia",51920,2019,"Netherlands","High income",4,NA,NA,NA,NA,NA
"2891",347,"Van Ewijk","Test-negative case-control",2949,2022-11-10,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"14+",">=18 years","general pop","included","~41 weeks","infection","infection","infection","delta",59,25,70,"Netherlands","NLD","Europe","Europe & Central Asia",51920,2019,"Netherlands","High income",4,NA,NA,NA,NA,NA
"2892",347,"Van Ewijk","Test-negative case-control",2950,2022-11-10,"Moderna mRNA-1273","mRNA","2","final",NA,"14+",">=18 years","general pop","included","~41 weeks","infection","infection","infection","delta",73,59,83,"Netherlands","NLD","Europe","Europe & Central Asia",51920,2019,"Netherlands","High income",4,NA,NA,NA,NA,NA
"2893",347,"Van Ewijk","Test-negative case-control",2951,2022-11-10,"Oxford/AstraZeneca ChAdOx1-S","Vectored","2","final",NA,"14+",">=18 years","general pop","included","~36 weeks","infection","infection","infection","delta",48,25,64,"Netherlands","NLD","Europe","Europe & Central Asia",51920,2019,"Netherlands","High income",4,NA,NA,NA,NA,NA
"2894",347,"Van Ewijk","Test-negative case-control",2952,2022-11-10,"Janssen Ad26.COV2.S","Vectored","1","final",NA,"14+",">=18 years","general pop","included","~36 weeks","infection","infection","infection","delta",50,24,66,"Netherlands","NLD","Europe","Europe & Central Asia",51920,2019,"Netherlands","High income",4,NA,NA,NA,NA,NA
"2895",348,"Turbyfill","Test-negative case-control",2953,2022-11-15,"Multiple or heterologous RNA","mRNA","2","final",NA,"14+","immunocompetent adults >=18 years","immunocompetent adults","included","~30 weeks","hospitalization","severe","severe","other combinations",91,88,93,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"2896",348,"Turbyfill","Test-negative case-control",2954,2022-11-15,"Multiple or heterologous RNA","mRNA","2","final",NA,"14+","immunocompetent adults >=18 years","immunocompetent adults","included","~30 weeks","hospitalization","severe","severe","other combinations",84,80,88,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"2897",348,"Turbyfill","Test-negative case-control",2955,2022-11-15,"Multiple or heterologous RNA","mRNA","2","final",NA,"14+","immunocompromised, >=18 years","immunocompromised adults","included","~30 weeks","hospitalization","severe","severe","other combinations",64,48,75,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"2898",348,"Turbyfill","Test-negative case-control",2956,2022-11-15,"Multiple or heterologous RNA","mRNA","2","final",NA,"14+","immunocompromised, >=18 years","immunocompromised adults","included","~30 weeks","hospitalization","severe","severe","other combinations",53,22,72,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"2899",349,"Castelli","Test-negative case-control",2957,2022-11-30,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"14+","12-17 years","12-17 years","included","~32.5 weeks","infection","infection","infection","omicron",28.1,25.2,30.8,"Argentina","ARG","South America","Latin America & Caribbean",11210,2019,"Argentina","Upper middle income",3,NA,NA,NA,NA,NA
"2900",349,"Castelli","Test-negative case-control",2958,2022-11-30,"Moderna mRNA-1273","mRNA","2","final",NA,"14+","12-17 years","12-17 years","included","~32.5 weeks","infection","infection","infection","omicron",17.9,14,21.5,"Argentina","ARG","South America","Latin America & Caribbean",11210,2019,"Argentina","Upper middle income",3,NA,NA,NA,NA,NA
"2901",349,"Castelli","Test-negative case-control",2959,2022-11-30,"Multiple or heterologous RNA","mRNA","2","final",NA,"14+","12-17 years","12-17 years","included","~32.5 weeks","infection","infection","infection","omicron",40.6,29.4,50,"Argentina","ARG","South America","Latin America & Caribbean",11210,2019,"Argentina","Upper middle income",3,NA,NA,NA,NA,NA
"2902",349,"Castelli","Test-negative case-control",2960,2022-11-30,"Multiple or heterologous RNA","mRNA","2","final",NA,"14+","12-17 years","12-17 years","included","~32.5 weeks","infection","infection","infection","omicron",31.5,26.3,36.4,"Argentina","ARG","South America","Latin America & Caribbean",11210,2019,"Argentina","Upper middle income",3,NA,NA,NA,NA,NA
"2903",349,"Castelli","Test-negative case-control",2961,2022-11-30,"Multiple or heterologous RNA","mRNA","2","final",NA,"15-30","12-17 years","12-17 years","included","~32.5 weeks","infection","infection","infection","omicron",55.8,52.4,59,"Argentina","ARG","South America","Latin America & Caribbean",11210,2019,"Argentina","Upper middle income",3,NA,NA,NA,NA,NA
"2904",349,"Castelli","Test-negative case-control",2962,2022-11-30,"Multiple or heterologous RNA","mRNA","2","final",NA,"61+","12-17 years","12-17 years","included","~32.5 weeks","infection","infection","infection","omicron",12.4,8.6,16.1,"Argentina","ARG","South America","Latin America & Caribbean",11210,2019,"Argentina","Upper middle income",3,NA,NA,NA,NA,NA
"2905",349,"Castelli","Test-negative case-control",2963,2022-11-30,"Multiple or heterologous RNA","mRNA","2","final",NA,"14+","12-17 years","12-17 years","included","~32.5 weeks","death","death","death","omicron",97.6,81,99.7,"Argentina","ARG","South America","Latin America & Caribbean",11210,2019,"Argentina","Upper middle income",3,NA,NA,NA,NA,NA
"2906",349,"Castelli","Test-negative case-control",2964,2022-11-30,"Beijing/Sinopharm BBIBP-CorV","Inactivated","2","final",NA,"14+","3-11 years","3-11 years","included","~22.5 weeks","infection","infection","infection","omicron",26,23.2,28.8,"Argentina","ARG","South America","Latin America & Caribbean",11210,2019,"Argentina","Upper middle income",3,NA,NA,NA,NA,NA
"2907",349,"Castelli","Test-negative case-control",2965,2022-11-30,"Beijing/Sinopharm BBIBP-CorV","Inactivated","2","final",NA,"15-30","3-11 years","3-11 years","included","~22.5 weeks","infection","infection","infection","omicron",37.6,34.2,40.8,"Argentina","ARG","South America","Latin America & Caribbean",11210,2019,"Argentina","Upper middle income",3,NA,NA,NA,NA,NA
"2908",349,"Castelli","Test-negative case-control",2966,2022-11-30,"Beijing/Sinopharm BBIBP-CorV","Inactivated","2","final",NA,"61+","3-11 years","3-11 years","included","~22.5 weeks","infection","infection","infection","omicron",2,1.8,5.6,"Argentina","ARG","South America","Latin America & Caribbean",11210,2019,"Argentina","Upper middle income",3,NA,NA,NA,NA,NA
"2909",349,"Castelli","Test-negative case-control",2967,2022-11-30,"Beijing/Sinopharm BBIBP-CorV","Inactivated","2","final",NA,"14+","3-11 years","3-11 years","included","~22.5 weeks","death","death","death","omicron",66.9,6.4,89.8,"Argentina","ARG","South America","Latin America & Caribbean",11210,2019,"Argentina","Upper middle income",3,NA,NA,NA,NA,NA
"2910",349,"Castelli","Test-negative case-control",2968,2022-11-30,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"14+","12-17 years","12-17 years","included","~15.5 weeks","infection","infection","infection","delta",64.1,60.5,67.3,"Argentina","ARG","South America","Latin America & Caribbean",11210,2019,"Argentina","Upper middle income",3,NA,NA,NA,NA,NA
"2911",349,"Castelli","Test-negative case-control",2969,2022-11-30,"Moderna mRNA-1273","mRNA","2","final",NA,"14+","12-17 years","12-17 years","included","~15.5 weeks","infection","infection","infection","delta",70.2,66.8,73.1,"Argentina","ARG","South America","Latin America & Caribbean",11210,2019,"Argentina","Upper middle income",3,NA,NA,NA,NA,NA
"2912",349,"Castelli","Test-negative case-control",2970,2022-11-30,"Multiple or heterologous RNA","mRNA","2","final",NA,"14+","12-17 years","12-17 years","included","~15.5 weeks","infection","infection","infection","delta",88.9,66.1,96.4,"Argentina","ARG","South America","Latin America & Caribbean",11210,2019,"Argentina","Upper middle income",3,NA,NA,NA,NA,NA
"2913",349,"Castelli","Test-negative case-control",2971,2022-11-30,"Multiple or heterologous RNA","mRNA","2","final",NA,"14+","12-17 years","12-17 years","included","~15.5 weeks","infection","infection","infection","delta",66.3,54,75.4,"Argentina","ARG","South America","Latin America & Caribbean",11210,2019,"Argentina","Upper middle income",3,NA,NA,NA,NA,NA
"2914",349,"Castelli","Test-negative case-control",2972,2022-11-30,"Multiple or heterologous RNA","mRNA","2","final",NA,"15-30","12-17 years","12-17 years","included","~15.5 weeks","infection","infection","infection","delta",74.8,71.3,77.9,"Argentina","ARG","South America","Latin America & Caribbean",11210,2019,"Argentina","Upper middle income",3,NA,NA,NA,NA,NA
"2915",349,"Castelli","Test-negative case-control",2973,2022-11-30,"Multiple or heterologous RNA","mRNA","2","final",NA,"61+","12-17 years","12-17 years","included","~15.5 weeks","infection","infection","infection","delta",56.3,50.2,61.7,"Argentina","ARG","South America","Latin America & Caribbean",11210,2019,"Argentina","Upper middle income",3,NA,NA,NA,NA,NA
"2916",349,"Castelli","Test-negative case-control",2974,2022-11-30,"Beijing/Sinopharm BBIBP-CorV","Inactivated","2","final",NA,"14+","3-11 years","3-11 years","included","~5.5 weeks","infection","infection","infection","delta",61.2,56.4,65.5,"Argentina","ARG","South America","Latin America & Caribbean",11210,2019,"Argentina","Upper middle income",3,NA,NA,NA,NA,NA
"2917",349,"Castelli","Test-negative case-control",2975,2022-11-30,"Beijing/Sinopharm BBIBP-CorV","Inactivated","2","final",NA,"15-30","3-11 years","3-11 years","included","~5.5 weeks","infection","infection","infection","delta",68.4,64.1,72.2,"Argentina","ARG","South America","Latin America & Caribbean",11210,2019,"Argentina","Upper middle income",3,NA,NA,NA,NA,NA
"2918",349,"Castelli","Test-negative case-control",2976,2022-11-30,"Beijing/Sinopharm BBIBP-CorV","Inactivated","2","final",NA,"61+","3-11 years","3-11 years","included","~5.5 weeks","infection","infection","infection","delta",65.2,44,78.4,"Argentina","ARG","South America","Latin America & Caribbean",11210,2019,"Argentina","Upper middle income",3,NA,NA,NA,NA,NA
"2919",350,"Fu","Retrospective cohort",2977,2023-09-22,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"14+",">=18 years","general pop","included","~75.5 weeks","infection","infection","infection","omicron",-122.3,-124.2,120.3,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"2920",350,"Fu","Retrospective cohort",2978,2023-09-22,"Moderna mRNA-1273","mRNA","2","final",NA,"14+",">=18 years","general pop","included","~73.5 weeks","infection","infection","infection","omicron",-163.5,-166.6,-160.5,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"2921",350,"Fu","Retrospective cohort",2979,2023-09-22,"Multiple or heterologous RNA","mRNA","2","final",NA,"14+",">=18 years","general pop","included","~75.5 weeks","infection","infection","infection","omicron",-19,-27.4,-11,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"2922",350,"Fu","Retrospective cohort",2980,2023-09-22,"Janssen Ad26.COV2.S","Vectored","1","final",NA,"14+",">=18 years","general pop","included","~69.5 weeks","infection","infection","infection","omicron",-38.1,-44.2,32.2,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"2923",350,"Fu","Retrospective cohort",2981,2023-09-22,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"14+",">=18 years","general pop","included","~48.5 weeks","infection","infection","infection","delta",-25,-26.2,-23.8,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"2924",350,"Fu","Retrospective cohort",2982,2023-09-22,"Moderna mRNA-1273","mRNA","2","final",NA,"14+",">=18 years","general pop","included","~46.5 weeks","infection","infection","infection","delta",-11.3,-12.9,-9.8,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"2925",350,"Fu","Retrospective cohort",2983,2023-09-22,"Multiple or heterologous RNA","mRNA","2","final",NA,"14+",">=18 years","general pop","included","~48.5 weeks","infection","infection","infection","delta",-13.6,-22.7,-5.2,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"2926",350,"Fu","Retrospective cohort",2984,2023-09-22,"Janssen Ad26.COV2.S","Vectored","1","final",NA,"14+",">=18 years","general pop","included","~42.5 weeks","infection","infection","infection","delta",33,29.2,36.5,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"2927",350,"Fu","Retrospective cohort",2985,2023-09-22,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"14+",">=18 years","general pop","included","~23 weeks","infection","infection","infection","other combinations",77.9,77.2,78.5,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"2928",350,"Fu","Retrospective cohort",2986,2023-09-22,"Moderna mRNA-1273","mRNA","2","final",NA,"14+",">=18 years","general pop","included","~21 weeks","infection","infection","infection","other combinations",85.9,85.1,86.5,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"2929",350,"Fu","Retrospective cohort",2987,2023-09-22,"Multiple or heterologous RNA","mRNA","2","final",NA,"14+",">=18 years","general pop","included","~23 weeks","infection","infection","infection","other combinations",78.9,66.6,87.7,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"2930",350,"Fu","Retrospective cohort",2988,2023-09-22,"Janssen Ad26.COV2.S","Vectored","1","final",NA,"14+",">=18 years","general pop","included","~17 weeks","infection","infection","infection","other combinations",81.4,78.4,84.2,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"2931",350,"Fu","Retrospective cohort",2989,2023-09-22,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"1st month",">=18 years","general pop","included",NA,"infection","infection","infection","other combinations",47.3,46,48.5,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"2932",350,"Fu","Retrospective cohort",2990,2023-09-22,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"6th month",">=18 years","general pop","included","~50 weeks","infection","infection","infection","other combinations",-77,-80.6,-73.5,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"2933",350,"Fu","Retrospective cohort",2991,2023-09-22,"Moderna mRNA-1273","mRNA","2","final",NA,"1st month",">=18 years","general pop","included",NA,"infection","infection","infection","other combinations",64.7,63.3,66,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"2934",350,"Fu","Retrospective cohort",2992,2023-09-22,"Moderna mRNA-1273","mRNA","2","final",NA,"6th month",">=18 years","general pop","included","~50 weeks","infection","infection","infection","other combinations",-62.6,-67.2,-58.1,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"2935",350,"Fu","Retrospective cohort",2993,2023-09-22,"Multiple or heterologous RNA","mRNA","2","final",NA,"1st month",">=18 years","general pop","included",NA,"infection","infection","infection","other combinations",-35.5,-48.6,-23.6,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"2936",350,"Fu","Retrospective cohort",2994,2023-09-22,"Multiple or heterologous RNA","mRNA","2","final",NA,"6th month",">=18 years","general pop","included","~34 weeks","infection","infection","infection","other combinations",-4.2,-27.4,14.8,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"2937",350,"Fu","Retrospective cohort",2995,2023-09-22,"Janssen Ad26.COV2.S","Vectored","1","final",NA,"1st month",">=18 years","general pop","included",NA,"infection","infection","infection","other combinations",30.8,23.5,37.4,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"2938",350,"Fu","Retrospective cohort",2996,2023-09-22,"Janssen Ad26.COV2.S","Vectored","1","final",NA,"6th month",">=18 years","general pop","included","~50 weeks","infection","infection","infection","other combinations",-1.2,-13.2,9.5,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"2939",351,"Cegolon","Retrospective cohort",2997,2022-11-30,"Multiple or heterologous RNA","mRNA","2","final",NA,"7+","HCW","HCW","excluded","~69 weeks","infection","infection","infection","omicron",41,-49,77,"Italy","ITA","Europe","Europe & Central Asia",34890,2019,"Italy","High income",4,NA,NA,NA,NA,NA
"2940",351,"Cegolon","Retrospective cohort",2998,2022-11-30,"Multiple or heterologous RNA","mRNA","2","final",NA,"7+","HCW","HCW","previously infected only","~69 weeks","infection","infection","infection","omicron",-4,-43,24,"Italy","ITA","Europe","Europe & Central Asia",34890,2019,"Italy","High income",4,NA,NA,NA,NA,NA
"2941",352,"Khanam","Test-negative case-control",2999,2022-12-02,"Oxford/AstraZeneca ChAdOx1-S","Vectored","2","final",NA,"14+",">=18 years","general pop","excluded","~36 weeks","symptomatic disease","symptomatic","symptomatic","delta",-45,-119,4,"Bangladesh","BGD","Asia","South Asia",2220,2019,"Bangladesh","Lower middle income",2,NA,NA,NA,NA,NA
"2942",352,"Khanam","Test-negative case-control",3000,2022-12-02,"Oxford/AstraZeneca ChAdOx1-S","Vectored","2","final",NA,"<19 weeks",">=18 years","general pop","excluded","~36 weeks","symptomatic disease","symptomatic","symptomatic","delta",3,-129,59,"Bangladesh","BGD","Asia","South Asia",2220,2019,"Bangladesh","Lower middle income",2,NA,NA,NA,NA,NA
"2943",352,"Khanam","Test-negative case-control",3001,2022-12-02,"Oxford/AstraZeneca ChAdOx1-S","Vectored","2","final",NA,">19 weeks",">=18 years","general pop","excluded","~36 weeks","symptomatic disease","symptomatic","symptomatic","delta",-35,-112,14,"Bangladesh","BGD","Asia","South Asia",2220,2019,"Bangladesh","Lower middle income",2,NA,NA,NA,NA,NA
"2944",352,"Khanam","Test-negative case-control",3002,2022-12-02,"Oxford/AstraZeneca ChAdOx1-S","Vectored","2","final",NA,"14+",">=18 years","general pop","excluded","~36 weeks","death","death","death","delta",86,-23,98,"Bangladesh","BGD","Asia","South Asia",2220,2019,"Bangladesh","Lower middle income",2,NA,NA,NA,NA,NA
"2945",352,"Khanam","Test-negative case-control",3003,2022-12-02,"Beijing/Sinopharm BBIBP-CorV","Inactivated","2","final",NA,"14+",">=18 years","general pop","excluded","~36 weeks","symptomatic disease","symptomatic","symptomatic","delta",29,-22,58,"Bangladesh","BGD","Asia","South Asia",2220,2019,"Bangladesh","Lower middle income",2,NA,NA,NA,NA,NA
"2946",352,"Khanam","Test-negative case-control",3004,2022-12-02,"Beijing/Sinopharm BBIBP-CorV","Inactivated","2","final",NA,"<19 weeks",">=18 years","general pop","excluded","~36 weeks","symptomatic disease","symptomatic","symptomatic","delta",34,-16,62,"Bangladesh","BGD","Asia","South Asia",2220,2019,"Bangladesh","Lower middle income",2,NA,NA,NA,NA,NA
"2947",352,"Khanam","Test-negative case-control",3005,2022-12-02,"Beijing/Sinopharm BBIBP-CorV","Inactivated","2","final",NA,">19 weeks",">=18 years","general pop","excluded","~36 weeks","symptomatic disease","symptomatic","symptomatic","delta",-36,-886,81,"Bangladesh","BGD","Asia","South Asia",2220,2019,"Bangladesh","Lower middle income",2,NA,NA,NA,NA,NA
"2948",352,"Khanam","Test-negative case-control",3006,2022-12-02,"Beijing/Sinopharm BBIBP-CorV","Inactivated","2","final",NA,"14+",">=18 years","general pop","excluded","~36 weeks","death","death","death","delta",75,-124,97,"Bangladesh","BGD","Asia","South Asia",2220,2019,"Bangladesh","Lower middle income",2,NA,NA,NA,NA,NA
"2949",352,"Khanam","Test-negative case-control",3007,2022-12-02,"Moderna mRNA-1273","mRNA","2","final",NA,"14+",">=18 years","general pop","excluded","~36 weeks","symptomatic disease","symptomatic","symptomatic","delta",64,10,86,"Bangladesh","BGD","Asia","South Asia",2220,2019,"Bangladesh","Lower middle income",2,NA,NA,NA,NA,NA
"2950",353,"Nittayasoot","Test-negative case-control",3008,2022-12-12,"Beijing/Sinopharm BBIBP-CorV","Inactivated","2","final",NA,"14+",">=18 years","general pop","included","~54 weeks","pneumonia requiring invasive ventilation","severe","severe","delta/omicron",65.8,39.4,80.7,"Thailand","THA","Asia","East Asia & Pacific",7060,2019,"Thailand","Upper middle income",3,NA,NA,NA,NA,NA
"2951",353,"Nittayasoot","Test-negative case-control",3009,2022-12-12,"Oxford/AstraZeneca ChAdOx1-S","Vectored","2","final",NA,"14+",">=18 years","general pop","included","~54 weeks","pneumonia requiring invasive ventilation","severe","severe","delta/omicron",58.4,39.9,71.2,"Thailand","THA","Asia","East Asia & Pacific",7060,2019,"Thailand","Upper middle income",3,NA,NA,NA,NA,NA
"2952",353,"Nittayasoot","Test-negative case-control",3010,2022-12-12,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"14+",">=18 years","general pop","included","~54 weeks","pneumonia requiring invasive ventilation","severe","severe","delta/omicron",71.7,49.7,84.1,"Thailand","THA","Asia","East Asia & Pacific",7060,2019,"Thailand","Upper middle income",3,NA,NA,NA,NA,NA
"2953",353,"Nittayasoot","Test-negative case-control",3011,2022-12-12,"Heterologous platforms","Multiple","2","final",NA,"14+",">=18 years","general pop","included","~54 weeks","pneumonia requiring invasive ventilation","severe","severe","delta/omicron",71.7,63.2,78.2,"Thailand","THA","Asia","East Asia & Pacific",7060,2019,"Thailand","Upper middle income",3,NA,NA,NA,NA,NA
"2954",353,"Nittayasoot","Test-negative case-control",3012,2022-12-12,"Heterologous platforms","Multiple","2","final",NA,"14+",">=18 years","general pop","included","~54 weeks","pneumonia requiring invasive ventilation","severe","severe","delta/omicron",79.7,7.3,95.6,"Thailand","THA","Asia","East Asia & Pacific",7060,2019,"Thailand","Upper middle income",3,NA,NA,NA,NA,NA
"2955",353,"Nittayasoot","Test-negative case-control",3013,2022-12-12,"Heterologous platforms","Multiple","2","final",NA,"14+",">=18 years","general pop","included","~54 weeks","pneumonia requiring invasive ventilation","severe","severe","delta/omicron",83.1,62.3,92.4,"Thailand","THA","Asia","East Asia & Pacific",7060,2019,"Thailand","Upper middle income",3,NA,NA,NA,NA,NA
"2956",354,"Carazo","Test-negative case-control",3014,2023-07-14,"Multiple or heterologous RNA","mRNA","2","final",NA,"7+",">=60 years",">=60 years","excluded","~60 weeks","hospitalization","severe","severe","omicron",78,75,80,"Canada","CAN","North America","North America",46580,2019,"Canada","High income",4,NA,NA,NA,NA,NA
"2957",354,"Carazo","Test-negative case-control",3015,2023-07-14,"Multiple or heterologous RNA","mRNA","2","final",NA,"7-90",">=60 years",">=60 years","excluded","~60 weeks","hospitalization","severe","severe","omicron",86,78,91,"Canada","CAN","North America","North America",46580,2019,"Canada","High income",4,NA,NA,NA,NA,NA
"2958",354,"Carazo","Test-negative case-control",3016,2023-07-14,"Multiple or heterologous RNA","mRNA","2","final",NA,"270-359",">=60 years",">=60 years","excluded","~60 weeks","hospitalization","severe","severe","omicron",68,37,84,"Canada","CAN","North America","North America",46580,2019,"Canada","High income",4,NA,NA,NA,NA,NA
"2959",354,"Carazo","Test-negative case-control",3017,2023-07-14,"Multiple or heterologous RNA","mRNA","2","final",NA,"7+",">=60 years",">=60 years","excluded","~73 weeks","hospitalization","severe","severe","omicron",60,50,67,"Canada","CAN","North America","North America",46580,2019,"Canada","High income",4,NA,NA,NA,NA,NA
"2960",354,"Carazo","Test-negative case-control",3018,2023-07-14,"Multiple or heterologous RNA","mRNA","2","final",NA,"7-90",">=60 years",">=60 years","excluded","~73 weeks","hospitalization","severe","severe","omicron",66,28,84,"Canada","CAN","North America","North America",46580,2019,"Canada","High income",4,NA,NA,NA,NA,NA
"2961",354,"Carazo","Test-negative case-control",3019,2023-07-14,"Multiple or heterologous RNA","mRNA","2","final",NA,"360-449",">=60 years",">=60 years","excluded","~73 weeks","hospitalization","severe","severe","omicron",73,-13,94,"Canada","CAN","North America","North America",46580,2019,"Canada","High income",4,NA,NA,NA,NA,NA
"2962",354,"Carazo","Test-negative case-control",3020,2023-07-14,"Multiple or heterologous RNA","mRNA","2","final",NA,"7+",">=60 years",">=60 years","excluded","~94 weeks","hospitalization","severe","severe","omicron",40,30,49,"Canada","CAN","North America","North America",46580,2019,"Canada","High income",4,NA,NA,NA,NA,NA
"2963",354,"Carazo","Test-negative case-control",3021,2023-07-14,"Multiple or heterologous RNA","mRNA","2","final",NA,"7-90",">=60 years",">=60 years","excluded","~94 weeks","hospitalization","severe","severe","omicron",55,-95,89,"Canada","CAN","North America","North America",46580,2019,"Canada","High income",4,NA,NA,NA,NA,NA
"2964",354,"Carazo","Test-negative case-control",3022,2023-07-14,"Multiple or heterologous RNA","mRNA","2","final",NA,"360-449",">=60 years",">=60 years","excluded","~94 weeks","hospitalization","severe","severe","omicron",47,35,57,"Canada","CAN","North America","North America",46580,2019,"Canada","High income",4,NA,NA,NA,NA,NA
"2965",354,"Carazo","Test-negative case-control",3023,2023-07-14,"Multiple or heterologous RNA","mRNA","2","final",NA,"7+",">=60 years",">=60 years","pre-Omicron prior infection","~60 weeks","hospitalization","severe","severe","omicron",97,96,99,"Canada","CAN","North America","North America",46580,2019,"Canada","High income",4,NA,NA,NA,NA,NA
"2966",354,"Carazo","Test-negative case-control",3024,2023-07-14,"Multiple or heterologous RNA","mRNA","2","final",NA,"7+",">=60 years",">=60 years","pre-Omicron prior infection","~73 weeks","hospitalization","severe","severe","omicron",92,86,96,"Canada","CAN","North America","North America",46580,2019,"Canada","High income",4,NA,NA,NA,NA,NA
"2967",354,"Carazo","Test-negative case-control",3025,2023-07-14,"Multiple or heterologous RNA","mRNA","2","final",NA,"7+",">=60 years",">=60 years","Omicron prior infection","~73 weeks","hospitalization","severe","severe","omicron",99,94,100,"Canada","CAN","North America","North America",46580,2019,"Canada","High income",4,NA,NA,NA,NA,NA
"2968",354,"Carazo","Test-negative case-control",3026,2023-07-14,"Multiple or heterologous RNA","mRNA","2","final",NA,"7+",">=60 years",">=60 years","pre-Omicron prior infection","~94 weeks","hospitalization","severe","severe","omicron",92,80,97,"Canada","CAN","North America","North America",46580,2019,"Canada","High income",4,NA,NA,NA,NA,NA
"2969",354,"Carazo","Test-negative case-control",3027,2023-07-14,"Multiple or heterologous RNA","mRNA","2","final",NA,"7+",">=60 years",">=60 years","Omicron prior infection","~94 weeks","hospitalization","severe","severe","omicron",91,85,95,"Canada","CAN","North America","North America",46580,2019,"Canada","High income",4,NA,NA,NA,NA,NA
"2970",356,"Horne","Retrospective cohort",3028,2023-01-05,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"21-48","18-39 years","18-39 years","excluded","~45 weeks","infection","infection","infection","other combinations",75,74,76,"UK","GBR","Europe","Europe & Central Asia",43240,2019,"United Kingdom","High income",4,NA,NA,NA,NA,NA
"2971",356,"Horne","Retrospective cohort",3029,2023-01-05,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"245-272","18-39 years","18-39 years","excluded","~45 weeks","infection","infection","infection","other combinations",-83,-294,15,"UK","GBR","Europe","Europe & Central Asia",43240,2019,"United Kingdom","High income",4,NA,NA,NA,NA,NA
"2972",356,"Horne","Retrospective cohort",3030,2023-01-05,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"21-48","18-39 years","18-39 years","excluded","~45 weeks","hospitalization","severe","severe","other combinations",96,93,97,"UK","GBR","Europe","Europe & Central Asia",43240,2019,"United Kingdom","High income",4,NA,NA,NA,NA,NA
"2973",356,"Horne","Retrospective cohort",3031,2023-01-05,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"245-272","18-39 years","18-39 years","excluded","~45 weeks","hospitalization","severe","severe","other combinations",-48,-217,31,"UK","GBR","Europe","Europe & Central Asia",43240,2019,"United Kingdom","High income",4,NA,NA,NA,NA,NA
"2974",356,"Horne","Retrospective cohort",3032,2023-01-05,"Oxford/AstraZeneca ChAdOx1-S","Vectored","2","final",NA,"21-48","40-64 years","40-64 years","excluded","~36 weeks","infection","infection","infection","other combinations",22,19,25,"UK","GBR","Europe","Europe & Central Asia",43240,2019,"United Kingdom","High income",4,NA,NA,NA,NA,NA
"2975",356,"Horne","Retrospective cohort",3033,2023-01-05,"Oxford/AstraZeneca ChAdOx1-S","Vectored","2","final",NA,"301-328","40-64 years","40-64 years","excluded","~36 weeks","infection","infection","infection","other combinations",41,-47,77,"UK","GBR","Europe","Europe & Central Asia",43240,2019,"United Kingdom","High income",4,NA,NA,NA,NA,NA
"2976",356,"Horne","Retrospective cohort",3034,2023-01-05,"Oxford/AstraZeneca ChAdOx1-S","Vectored","2","final",NA,"21-48","40-64 years","40-64 years","excluded","~36 weeks","hospitalization","severe","severe","other combinations",95,93,96,"UK","GBR","Europe","Europe & Central Asia",43240,2019,"United Kingdom","High income",4,NA,NA,NA,NA,NA
"2977",356,"Horne","Retrospective cohort",3035,2023-01-05,"Oxford/AstraZeneca ChAdOx1-S","Vectored","2","final",NA,"301-328","40-64 years","40-64 years","excluded","~36 weeks","hospitalization","severe","severe","other combinations",44,-41,78,"UK","GBR","Europe","Europe & Central Asia",43240,2019,"United Kingdom","High income",4,NA,NA,NA,NA,NA
"2978",356,"Horne","Retrospective cohort",3036,2023-01-05,"Oxford/AstraZeneca ChAdOx1-S","Vectored","2","final",NA,"77-104","40-64 years","40-64 years","excluded","~36 weeks","death","death","death","other combinations",99,96,100,"UK","GBR","Europe","Europe & Central Asia",43240,2019,"United Kingdom","High income",4,NA,NA,NA,NA,NA
"2979",356,"Horne","Retrospective cohort",3037,2023-01-05,"Oxford/AstraZeneca ChAdOx1-S","Vectored","2","final",NA,"217-244","40-64 years","40-64 years","excluded","~36 weeks","death","death","death","other combinations",74,36,89,"UK","GBR","Europe","Europe & Central Asia",43240,2019,"United Kingdom","High income",4,NA,NA,NA,NA,NA
"2980",356,"Horne","Retrospective cohort",3038,2023-01-05,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"21-48","18-64 years clinically vulnerable","18-64 years clinically vulnerable","excluded","~48 weeks","infection","infection","infection","other combinations",78,73,82,"UK","GBR","Europe","Europe & Central Asia",43240,2019,"United Kingdom","High income",4,NA,NA,NA,NA,NA
"2981",356,"Horne","Retrospective cohort",3039,2023-01-05,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"329-356","18-64 years clinically vulnerable","18-64 years clinically vulnerable","excluded","~48 weeks","infection","infection","infection","other combinations",28,-41,63,"UK","GBR","Europe","Europe & Central Asia",43240,2019,"United Kingdom","High income",4,NA,NA,NA,NA,NA
"2982",356,"Horne","Retrospective cohort",3040,2023-01-05,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"21-48","18-64 years clinically vulnerable","18-64 years clinically vulnerable","excluded","~48 weeks","hospitalization","severe","severe","other combinations",97,92,99,"UK","GBR","Europe","Europe & Central Asia",43240,2019,"United Kingdom","High income",4,NA,NA,NA,NA,NA
"2983",356,"Horne","Retrospective cohort",3041,2023-01-05,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"329-356","18-64 years clinically vulnerable","18-64 years clinically vulnerable","excluded","~48 weeks","hospitalization","severe","severe","other combinations",28,-38,62,"UK","GBR","Europe","Europe & Central Asia",43240,2019,"United Kingdom","High income",4,NA,NA,NA,NA,NA
"2984",356,"Horne","Retrospective cohort",3042,2023-01-05,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"105-132","18-64 years clinically vulnerable","18-64 years clinically vulnerable","excluded","~48 weeks","death","death","death","other combinations",96,92,98,"UK","GBR","Europe","Europe & Central Asia",43240,2019,"United Kingdom","High income",4,NA,NA,NA,NA,NA
"2985",356,"Horne","Retrospective cohort",3043,2023-01-05,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"245-272","18-64 years clinically vulnerable","18-64 years clinically vulnerable","excluded","~48 weeks","death","death","death","other combinations",37,-36,70,"UK","GBR","Europe","Europe & Central Asia",43240,2019,"United Kingdom","High income",4,NA,NA,NA,NA,NA
"2986",356,"Horne","Retrospective cohort",3044,2023-01-05,"Oxford/AstraZeneca ChAdOx1-S","Vectored","2","final",NA,"21-48","18-64 years clinically vulnerable","18-64 years clinically vulnerable","excluded","~48 weeks","infection","infection","infection","other combinations",26,20,33,"UK","GBR","Europe","Europe & Central Asia",43240,2019,"United Kingdom","High income",4,NA,NA,NA,NA,NA
"2987",356,"Horne","Retrospective cohort",3045,2023-01-05,"Oxford/AstraZeneca ChAdOx1-S","Vectored","2","final",NA,"329-356","18-64 years clinically vulnerable","18-64 years clinically vulnerable","excluded","~48 weeks","infection","infection","infection","other combinations",14,-42,48,"UK","GBR","Europe","Europe & Central Asia",43240,2019,"United Kingdom","High income",4,NA,NA,NA,NA,NA
"2988",356,"Horne","Retrospective cohort",3046,2023-01-05,"Oxford/AstraZeneca ChAdOx1-S","Vectored","2","final",NA,"21-48","18-64 years clinically vulnerable","18-64 years clinically vulnerable","excluded","~48 weeks","hospitalization","severe","severe","other combinations",93,89,96,"UK","GBR","Europe","Europe & Central Asia",43240,2019,"United Kingdom","High income",4,NA,NA,NA,NA,NA
"2989",356,"Horne","Retrospective cohort",3047,2023-01-05,"Oxford/AstraZeneca ChAdOx1-S","Vectored","2","final",NA,"329-356","18-64 years clinically vulnerable","18-64 years clinically vulnerable","excluded","~48 weeks","hospitalization","severe","severe","other combinations",21,-30,52,"UK","GBR","Europe","Europe & Central Asia",43240,2019,"United Kingdom","High income",4,NA,NA,NA,NA,NA
"2990",356,"Horne","Retrospective cohort",3048,2023-01-05,"Oxford/AstraZeneca ChAdOx1-S","Vectored","2","final",NA,"49-76","18-64 years clinically vulnerable","18-64 years clinically vulnerable","excluded","~48 weeks","death","death","death","other combinations",96,87,99,"UK","GBR","Europe","Europe & Central Asia",43240,2019,"United Kingdom","High income",4,NA,NA,NA,NA,NA
"2991",356,"Horne","Retrospective cohort",3049,2023-01-05,"Oxford/AstraZeneca ChAdOx1-S","Vectored","2","final",NA,"301-328","18-64 years clinically vulnerable","18-64 years clinically vulnerable","excluded","~48 weeks","death","death","death","other combinations",50,-125,89,"UK","GBR","Europe","Europe & Central Asia",43240,2019,"United Kingdom","High income",4,NA,NA,NA,NA,NA
"2992",356,"Horne","Retrospective cohort",3050,2023-01-05,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"21-48",">=65 years",">=65 years","excluded","~48 weeks","infection","infection","infection","other combinations",77,67,84,"UK","GBR","Europe","Europe & Central Asia",43240,2019,"United Kingdom","High income",4,NA,NA,NA,NA,NA
"2993",356,"Horne","Retrospective cohort",3051,2023-01-05,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"329-356",">=65 years",">=65 years","excluded","~48 weeks","infection","infection","infection","other combinations",4,-30,29,"UK","GBR","Europe","Europe & Central Asia",43240,2019,"United Kingdom","High income",4,NA,NA,NA,NA,NA
"2994",356,"Horne","Retrospective cohort",3052,2023-01-05,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"21-48",">=65 years",">=65 years","excluded","~48 weeks","hospitalization","severe","severe","other combinations",92,86,95,"UK","GBR","Europe","Europe & Central Asia",43240,2019,"United Kingdom","High income",4,NA,NA,NA,NA,NA
"2995",356,"Horne","Retrospective cohort",3053,2023-01-05,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"329-356",">=65 years",">=65 years","excluded","~48 weeks","hospitalization","severe","severe","other combinations",2,-34,27,"UK","GBR","Europe","Europe & Central Asia",43240,2019,"United Kingdom","High income",4,NA,NA,NA,NA,NA
"2996",356,"Horne","Retrospective cohort",3054,2023-01-05,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"21-48",">=65 years",">=65 years","excluded","~48 weeks","death","death","death","other combinations",97,92,99,"UK","GBR","Europe","Europe & Central Asia",43240,2019,"United Kingdom","High income",4,NA,NA,NA,NA,NA
"2997",356,"Horne","Retrospective cohort",3055,2023-01-05,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"329-356",">=65 years",">=65 years","excluded","~48 weeks","death","death","death","other combinations",33,-49,70,"UK","GBR","Europe","Europe & Central Asia",43240,2019,"United Kingdom","High income",4,NA,NA,NA,NA,NA
"2998",356,"Horne","Retrospective cohort",3056,2023-01-05,"Oxford/AstraZeneca ChAdOx1-S","Vectored","2","final",NA,"21-48",">=65 years",">=65 years","excluded","~48 weeks","infection","infection","infection","other combinations",47,29,61,"UK","GBR","Europe","Europe & Central Asia",43240,2019,"United Kingdom","High income",4,NA,NA,NA,NA,NA
"2999",356,"Horne","Retrospective cohort",3057,2023-01-05,"Oxford/AstraZeneca ChAdOx1-S","Vectored","2","final",NA,"329-356",">=65 years",">=65 years","excluded","~48 weeks","infection","infection","infection","other combinations",-12,-54,18,"UK","GBR","Europe","Europe & Central Asia",43240,2019,"United Kingdom","High income",4,NA,NA,NA,NA,NA
"3000",356,"Horne","Retrospective cohort",3058,2023-01-05,"Oxford/AstraZeneca ChAdOx1-S","Vectored","2","final",NA,"21-48",">=65 years",">=65 years","excluded","~48 weeks","hospitalization","severe","severe","other combinations",86,75,92,"UK","GBR","Europe","Europe & Central Asia",43240,2019,"United Kingdom","High income",4,NA,NA,NA,NA,NA
"3001",356,"Horne","Retrospective cohort",3059,2023-01-05,"Oxford/AstraZeneca ChAdOx1-S","Vectored","2","final",NA,"329-356",">=65 years",">=65 years","excluded","~48 weeks","hospitalization","severe","severe","other combinations",-12,-53,18,"UK","GBR","Europe","Europe & Central Asia",43240,2019,"United Kingdom","High income",4,NA,NA,NA,NA,NA
"3002",356,"Horne","Retrospective cohort",3060,2023-01-05,"Oxford/AstraZeneca ChAdOx1-S","Vectored","2","final",NA,"49-76",">=65 years",">=65 years","excluded","~48 weeks","death","death","death","other combinations",93,84,97,"UK","GBR","Europe","Europe & Central Asia",43240,2019,"United Kingdom","High income",4,NA,NA,NA,NA,NA
"3003",356,"Horne","Retrospective cohort",3061,2023-01-05,"Oxford/AstraZeneca ChAdOx1-S","Vectored","2","final",NA,"329-356",">=65 years",">=65 years","excluded","~48 weeks","death","death","death","other combinations",23,-82,68,"UK","GBR","Europe","Europe & Central Asia",43240,2019,"United Kingdom","High income",4,NA,NA,NA,NA,NA
"3004",357,"Lewis","Test-negative case-control",3062,2022-12-31,"Multiple or heterologous RNA","mRNA","2","final",NA,"150+",">=18 years","general pop","included","~63 weeks","hospitalization","severe","severe","omicron",46,30,58,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"3005",357,"Lewis","Test-negative case-control",3063,2022-12-31,"Janssen Ad26.COV2.S","Vectored","1","final",NA,"60+",">=18 years","general pop","included","~55 weeks","hospitalization","severe","severe","omicron",36,-4,60,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"3006",358,"Dalton","Test-negative case-control",3064,2023-01-06,"Multiple or heterologous RNA","mRNA","2","final",NA,"14-149",">=18 years, Social Vulnerability Index Quartile 1",">=18 years, Social Vulnerability Index Quartile 1","included","~62 weeks","ED or UC visit","symptomatic","symptomatic","omicron",47,40,53,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"3007",358,"Dalton","Test-negative case-control",3065,2023-01-06,"Multiple or heterologous RNA","mRNA","2","final",NA,"150+",">=18 years, Social Vulnerability Index Quartile 1",">=18 years, Social Vulnerability Index Quartile 1","included","~62 weeks","ED or UC visit","symptomatic","symptomatic","omicron",35,31,40,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"3008",358,"Dalton","Test-negative case-control",3066,2023-01-06,"Multiple or heterologous RNA","mRNA","2","final",NA,"14-149",">=18 years, Social Vulnerability Index Quartile 1",">=18 years, Social Vulnerability Index Quartile 1","included","~62 weeks","hospitalization","severe","severe","omicron",59,39,72,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"3009",358,"Dalton","Test-negative case-control",3067,2023-01-06,"Multiple or heterologous RNA","mRNA","2","final",NA,"150+",">=18 years, Social Vulnerability Index Quartile 1",">=18 years, Social Vulnerability Index Quartile 1","included","~62 weeks","hospitalization","severe","severe","omicron",58,51,65,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"3010",358,"Dalton","Test-negative case-control",3068,2023-01-06,"Multiple or heterologous RNA","mRNA","2","final",NA,"14-149",">=18 years, Social Vulnerability Index Quartile 2",">=18 years, Social Vulnerability Index Quartile 2","included","~62 weeks","ED or UC visit","symptomatic","symptomatic","omicron",42,33,49,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"3011",358,"Dalton","Test-negative case-control",3069,2023-01-06,"Multiple or heterologous RNA","mRNA","2","final",NA,"150+",">=18 years, Social Vulnerability Index Quartile 2",">=18 years, Social Vulnerability Index Quartile 2","included","~62 weeks","ED or UC visit","symptomatic","symptomatic","omicron",37,32,41,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"3012",358,"Dalton","Test-negative case-control",3070,2023-01-06,"Multiple or heterologous RNA","mRNA","2","final",NA,"14-149",">=18 years, Social Vulnerability Index Quartile 2",">=18 years, Social Vulnerability Index Quartile 2","included","~62 weeks","hospitalization","severe","severe","omicron",65,48,76,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"3013",358,"Dalton","Test-negative case-control",3071,2023-01-06,"Multiple or heterologous RNA","mRNA","2","final",NA,"150+",">=18 years, Social Vulnerability Index Quartile 2",">=18 years, Social Vulnerability Index Quartile 2","included","~62 weeks","hospitalization","severe","severe","omicron",57,49,64,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"3014",358,"Dalton","Test-negative case-control",3072,2023-01-06,"Multiple or heterologous RNA","mRNA","2","final",NA,"14-149",">=18 years, Social Vulnerability Index Quartile 3",">=18 years, Social Vulnerability Index Quartile 3","included","~62 weeks","ED or UC visit","symptomatic","symptomatic","omicron",54,47,61,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"3015",358,"Dalton","Test-negative case-control",3073,2023-01-06,"Multiple or heterologous RNA","mRNA","2","final",NA,"150+",">=18 years, Social Vulnerability Index Quartile 3",">=18 years, Social Vulnerability Index Quartile 3","included","~62 weeks","ED or UC visit","symptomatic","symptomatic","omicron",31,25,36,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"3016",358,"Dalton","Test-negative case-control",3074,2023-01-06,"Multiple or heterologous RNA","mRNA","2","final",NA,"14-149",">=18 years, Social Vulnerability Index Quartile 3",">=18 years, Social Vulnerability Index Quartile 3","included","~62 weeks","hospitalization","severe","severe","omicron",62,45,74,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"3017",358,"Dalton","Test-negative case-control",3075,2023-01-06,"Multiple or heterologous RNA","mRNA","2","final",NA,"150+",">=18 years, Social Vulnerability Index Quartile 3",">=18 years, Social Vulnerability Index Quartile 3","included","~62 weeks","hospitalization","severe","severe","omicron",55,47,63,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"3018",358,"Dalton","Test-negative case-control",3076,2023-01-06,"Multiple or heterologous RNA","mRNA","2","final",NA,"14-149",">=18 years, Social Vulnerability Index Quartile 4",">=18 years, Social Vulnerability Index Quartile 4","included","~62 weeks","ED or UC visit","symptomatic","symptomatic","omicron",51,43,58,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"3019",358,"Dalton","Test-negative case-control",3077,2023-01-06,"Multiple or heterologous RNA","mRNA","2","final",NA,"150+",">=18 years, Social Vulnerability Index Quartile 4",">=18 years, Social Vulnerability Index Quartile 4","included","~62 weeks","ED or UC visit","symptomatic","symptomatic","omicron",27,20,33,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"3020",358,"Dalton","Test-negative case-control",3078,2023-01-06,"Multiple or heterologous RNA","mRNA","2","final",NA,"14-149",">=18 years, Social Vulnerability Index Quartile 4",">=18 years, Social Vulnerability Index Quartile 4","included","~62 weeks","hospitalization","severe","severe","omicron",63,43,75,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"3021",358,"Dalton","Test-negative case-control",3079,2023-01-06,"Multiple or heterologous RNA","mRNA","2","final",NA,"150+",">=18 years, Social Vulnerability Index Quartile 4",">=18 years, Social Vulnerability Index Quartile 4","included","~62 weeks","hospitalization","severe","severe","omicron",43,32,52,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"3022",358,"Dalton","Test-negative case-control",3080,2023-01-06,"Multiple or heterologous RNA","mRNA","2","final",NA,"14-149",">=18 years, Social Vulnerability Index Quartile 1",">=18 years, Social Vulnerability Index Quartile 1","included","~48.5 weeks","ED or UC visit","symptomatic","symptomatic","delta",87,84,89,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"3023",358,"Dalton","Test-negative case-control",3081,2023-01-06,"Multiple or heterologous RNA","mRNA","2","final",NA,"150+",">=18 years, Social Vulnerability Index Quartile 1",">=18 years, Social Vulnerability Index Quartile 1","included","~48.5 weeks","ED or UC visit","symptomatic","symptomatic","delta",81,79,82,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"3024",358,"Dalton","Test-negative case-control",3082,2023-01-06,"Multiple or heterologous RNA","mRNA","2","final",NA,"14-149",">=18 years, Social Vulnerability Index Quartile 1",">=18 years, Social Vulnerability Index Quartile 1","included","~48.5 weeks","hospitalization","severe","severe","delta",90,84,94,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"3025",358,"Dalton","Test-negative case-control",3083,2023-01-06,"Multiple or heterologous RNA","mRNA","2","final",NA,"150+",">=18 years, Social Vulnerability Index Quartile 1",">=18 years, Social Vulnerability Index Quartile 1","included","~48.5 weeks","hospitalization","severe","severe","delta",85,82,87,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"3026",358,"Dalton","Test-negative case-control",3084,2023-01-06,"Multiple or heterologous RNA","mRNA","2","final",NA,"14-149",">=18 years, Social Vulnerability Index Quartile 2",">=18 years, Social Vulnerability Index Quartile 2","included","~48.5 weeks","ED or UC visit","symptomatic","symptomatic","delta",85,81,88,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"3027",358,"Dalton","Test-negative case-control",3085,2023-01-06,"Multiple or heterologous RNA","mRNA","2","final",NA,"150+",">=18 years, Social Vulnerability Index Quartile 2",">=18 years, Social Vulnerability Index Quartile 2","included","~48.5 weeks","ED or UC visit","symptomatic","symptomatic","delta",80,77,81,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"3028",358,"Dalton","Test-negative case-control",3086,2023-01-06,"Multiple or heterologous RNA","mRNA","2","final",NA,"14-149",">=18 years, Social Vulnerability Index Quartile 2",">=18 years, Social Vulnerability Index Quartile 2","included","~48.5 weeks","hospitalization","severe","severe","delta",91,85,95,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"3029",358,"Dalton","Test-negative case-control",3087,2023-01-06,"Multiple or heterologous RNA","mRNA","2","final",NA,"150+",">=18 years, Social Vulnerability Index Quartile 2",">=18 years, Social Vulnerability Index Quartile 2","included","~48.5 weeks","hospitalization","severe","severe","delta",86,83,88,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"3030",358,"Dalton","Test-negative case-control",3088,2023-01-06,"Multiple or heterologous RNA","mRNA","2","final",NA,"14-149",">=18 years, Social Vulnerability Index Quartile 3",">=18 years, Social Vulnerability Index Quartile 3","included","~48.5 weeks","ED or UC visit","symptomatic","symptomatic","delta",89,85,91,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"3031",358,"Dalton","Test-negative case-control",3089,2023-01-06,"Multiple or heterologous RNA","mRNA","2","final",NA,"150+",">=18 years, Social Vulnerability Index Quartile 3",">=18 years, Social Vulnerability Index Quartile 3","included","~48.5 weeks","ED or UC visit","symptomatic","symptomatic","delta",74,71,77,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"3032",358,"Dalton","Test-negative case-control",3090,2023-01-06,"Multiple or heterologous RNA","mRNA","2","final",NA,"14-149",">=18 years, Social Vulnerability Index Quartile 3",">=18 years, Social Vulnerability Index Quartile 3","included","~48.5 weeks","hospitalization","severe","severe","delta",94,88,97,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"3033",358,"Dalton","Test-negative case-control",3091,2023-01-06,"Multiple or heterologous RNA","mRNA","2","final",NA,"150+",">=18 years, Social Vulnerability Index Quartile 3",">=18 years, Social Vulnerability Index Quartile 3","included","~48.5 weeks","hospitalization","severe","severe","delta",82,78,85,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"3034",358,"Dalton","Test-negative case-control",3092,2023-01-06,"Multiple or heterologous RNA","mRNA","2","final",NA,"14-149",">=18 years, Social Vulnerability Index Quartile 4",">=18 years, Social Vulnerability Index Quartile 4","included","~48.5 weeks","ED or UC visit","symptomatic","symptomatic","delta",84,79,87,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"3035",358,"Dalton","Test-negative case-control",3093,2023-01-06,"Multiple or heterologous RNA","mRNA","2","final",NA,"150+",">=18 years, Social Vulnerability Index Quartile 4",">=18 years, Social Vulnerability Index Quartile 4","included","~48.5 weeks","ED or UC visit","symptomatic","symptomatic","delta",75,72,78,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"3036",358,"Dalton","Test-negative case-control",3094,2023-01-06,"Multiple or heterologous RNA","mRNA","2","final",NA,"14-149",">=18 years, Social Vulnerability Index Quartile 4",">=18 years, Social Vulnerability Index Quartile 4","included","~48.5 weeks","hospitalization","severe","severe","delta",90,83,94,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"3037",358,"Dalton","Test-negative case-control",3095,2023-01-06,"Multiple or heterologous RNA","mRNA","2","final",NA,"150+",">=18 years, Social Vulnerability Index Quartile 4",">=18 years, Social Vulnerability Index Quartile 4","included","~48.5 weeks","hospitalization","severe","severe","delta",84,80,87,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"3038",359,"Jang","Retrospective cohort",3096,2023-01-09,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"15-30","5-11 years","5-11 years","unknown","~11 weeks","infection","infection","infection","omicron",57.6,51.6,62.8,"South Korea","KOR","Asia","East Asia & Pacific",33830,2019,"Korea, Rep.","High income",4,NA,NA,NA,NA,NA
"3039",359,"Jang","Retrospective cohort",3097,2023-01-09,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"31-60","5-11 years","5-11 years","unknown","~11 weeks","infection","infection","infection","omicron",46.9,43.7,49.9,"South Korea","KOR","Asia","East Asia & Pacific",33830,2019,"Korea, Rep.","High income",4,NA,NA,NA,NA,NA
"3040",359,"Jang","Retrospective cohort",3098,2023-01-09,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"61-90","5-11 years","5-11 years","unknown","~11 weeks","infection","infection","infection","omicron",41.2,34.3,47.4,"South Korea","KOR","Asia","East Asia & Pacific",33830,2019,"Korea, Rep.","High income",4,NA,NA,NA,NA,NA
"3041",359,"Jang","Retrospective cohort",3099,2023-01-09,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"15-30","5-11 years","5-11 years","unknown","~11 weeks","ICU admission or death","severe","severe","omicron",100,100,100,"South Korea","KOR","Asia","East Asia & Pacific",33830,2019,"Korea, Rep.","High income",4,NA,NA,NA,NA,NA
"3042",359,"Jang","Retrospective cohort",3100,2023-01-09,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"31-60","5-11 years","5-11 years","unknown","~11 weeks","ICU admission or death","severe","severe","omicron",100,100,100,"South Korea","KOR","Asia","East Asia & Pacific",33830,2019,"Korea, Rep.","High income",4,NA,NA,NA,NA,NA
"3043",359,"Jang","Retrospective cohort",3101,2023-01-09,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"61-90","5-11 years","5-11 years","unknown","~11 weeks","ICU admission or death","severe","severe","omicron",100,100,100,"South Korea","KOR","Asia","East Asia & Pacific",33830,2019,"Korea, Rep.","High income",4,NA,NA,NA,NA,NA
"3044",360,"Peebles","Retrospective cohort",3102,2023-01-10,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"14+","LTCF staff <65 years","LTCF staff <65 years","excluded","~17 weeks","infection","infection","infection","other combinations",80,67.6,87.7,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"3045",360,"Peebles","Retrospective cohort",3103,2023-01-10,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"14+","LTCF staff <65 years","LTCF staff <65 years","excluded","~17 weeks","symptomatic disease","symptomatic","symptomatic","other combinations",87.5,69.4,94.9,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"3046",360,"Peebles","Retrospective cohort",3104,2023-01-10,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"14+","LTCF staff <65 years","LTCF staff <65 years","excluded","~17 weeks","asymptomatic infection","asymptomatic","infection","other combinations",68.9,36,84.9,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"3047",361,"Tartof","Test-negative case-control",3105,2023-01-11,"Multiple or heterologous RNA","mRNA","2","final",NA,"14+",">=18 years","general pop","excluded","~64.5 weeks","symptomatic disease","symptomatic","symptomatic","omicron",-53,-205,23,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"3048",361,"Tartof","Test-negative case-control",3106,2023-01-11,"Multiple or heterologous RNA","mRNA","2","final",NA,"14+",">=18 years","general pop","prior infection only","~64.5 weeks","symptomatic disease","symptomatic","symptomatic","omicron",45,-4,70,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"3049",361,"Tartof","Test-negative case-control",3107,2023-01-11,"Multiple or heterologous RNA","mRNA","2","final",NA,"14+",">=18 years","general pop","excluded","~46.5 weeks","symptomatic disease","symptomatic","symptomatic","delta",70,11,90,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"3050",361,"Tartof","Test-negative case-control",3108,2023-01-11,"Multiple or heterologous RNA","mRNA","2","final",NA,"14+",">=18 years","general pop","prior infection only","~46.5 weeks","symptomatic disease","symptomatic","symptomatic","delta",23,-225,82,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"3051",361,"Tartof","Test-negative case-control",3109,2023-01-11,"Multiple or heterologous RNA","mRNA","2","final",NA,"14+",">=18 years","general pop","excluded","~64.5 weeks","symptomatic disease","symptomatic","symptomatic","delta/omicron",17,-40,51,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"3052",361,"Tartof","Test-negative case-control",3110,2023-01-11,"Multiple or heterologous RNA","mRNA","2","final",NA,"14+",">=18 years","general pop","prior infection only","~64.5 weeks","symptomatic disease","symptomatic","symptomatic","delta/omicron",42,-1,66,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"3053",363,"Alkadi","Test-negative case-control",3114,2022-12-26,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"14+",">=18 years on chronic hemodialysis",">=18 years on chronic hemodialysis","unknown","~48 weeks","infection","infection","infection","other combinations",94.3,89,97,"Qatar","QAT","Asia","Middle East & North Africa",65700,2019,"Qatar","High income",4,NA,NA,NA,NA,NA
"3054",363,"Alkadi","Test-negative case-control",3115,2022-12-26,"Moderna mRNA-1273","mRNA","2","final",NA,"14+",">=18 years on chronic hemodialysis",">=18 years on chronic hemodialysis","unknown","~40 weeks","infection","infection","infection","other combinations",98.2,88.6,99.9,"Qatar","QAT","Asia","Middle East & North Africa",65700,2019,"Qatar","High income",4,NA,NA,NA,NA,NA
"3055",364,"Heidarzadeh","Test-negative case-control",3116,2022-12-23,"Oxford/AstraZeneca ChAdOx1-S","Vectored","2","final",NA,"31-60",">=5 years","general pop","included","~23 weeks","hospitalization (moderate)","severe","severe","other combinations",97,75,99.5,"Iran","IRN","Asia","Middle East & North Africa",4530,2019,"Iran, Islamic Rep.","Lower middle income",2,NA,NA,NA,NA,NA
"3056",364,"Heidarzadeh","Test-negative case-control",3117,2022-12-23,"Oxford/AstraZeneca ChAdOx1-S","Vectored","2","final",NA,"91-120",">=5 years","general pop","included","~23 weeks","hospitalization (moderate)","severe","severe","other combinations",93,69,99,"Iran","IRN","Asia","Middle East & North Africa",4530,2019,"Iran, Islamic Rep.","Lower middle income",2,NA,NA,NA,NA,NA
"3057",364,"Heidarzadeh","Test-negative case-control",3118,2022-12-23,"Oxford/AstraZeneca ChAdOx1-S","Vectored","2","final",NA,"31-60",">=5 years","general pop","included","~23 weeks","hospitalization (severe)","severe","severe","other combinations",87,80,92,"Iran","IRN","Asia","Middle East & North Africa",4530,2019,"Iran, Islamic Rep.","Lower middle income",2,NA,NA,NA,NA,NA
"3058",364,"Heidarzadeh","Test-negative case-control",3119,2022-12-23,"Oxford/AstraZeneca ChAdOx1-S","Vectored","2","final",NA,"151+",">=5 years","general pop","included","~23 weeks","hospitalization (severe)","severe","severe","other combinations",90,51,98,"Iran","IRN","Asia","Middle East & North Africa",4530,2019,"Iran, Islamic Rep.","Lower middle income",2,NA,NA,NA,NA,NA
"3059",364,"Heidarzadeh","Test-negative case-control",3120,2022-12-23,"Oxford/AstraZeneca ChAdOx1-S","Vectored","2","final",NA,"31-60",">=5 years","general pop","included","~23 weeks","ICU admission","severe","severe","other combinations",57,-41,87,"Iran","IRN","Asia","Middle East & North Africa",4530,2019,"Iran, Islamic Rep.","Lower middle income",2,NA,NA,NA,NA,NA
"3060",364,"Heidarzadeh","Test-negative case-control",3121,2022-12-23,"Oxford/AstraZeneca ChAdOx1-S","Vectored","2","final",NA,"91-120",">=5 years","general pop","included","~23 weeks","ICU admission","severe","severe","other combinations",12,-113,63,"Iran","IRN","Asia","Middle East & North Africa",4530,2019,"Iran, Islamic Rep.","Lower middle income",2,NA,NA,NA,NA,NA
"3061",364,"Heidarzadeh","Test-negative case-control",3122,2022-12-23,"Oxford/AstraZeneca ChAdOx1-S","Vectored","2","final",NA,"31-60",">=5 years","general pop","included","~23 weeks","death","death","death","other combinations",80,48,92,"Iran","IRN","Asia","Middle East & North Africa",4530,2019,"Iran, Islamic Rep.","Lower middle income",2,NA,NA,NA,NA,NA
"3062",364,"Heidarzadeh","Test-negative case-control",3123,2022-12-23,"Oxford/AstraZeneca ChAdOx1-S","Vectored","2","final",NA,"121-150",">=5 years","general pop","included","~23 weeks","death","death","death","other combinations",92,48,99,"Iran","IRN","Asia","Middle East & North Africa",4530,2019,"Iran, Islamic Rep.","Lower middle income",2,NA,NA,NA,NA,NA
"3063",364,"Heidarzadeh","Test-negative case-control",3124,2022-12-23,"Beijing/Sinopharm BBIBP-CorV","Inactivated","2","final",NA,"31-60",">=5 years","general pop","included","~36 weeks","hospitalization (moderate)","severe","severe","other combinations",78,69,84,"Iran","IRN","Asia","Middle East & North Africa",4530,2019,"Iran, Islamic Rep.","Lower middle income",2,NA,NA,NA,NA,NA
"3064",364,"Heidarzadeh","Test-negative case-control",3125,2022-12-23,"Beijing/Sinopharm BBIBP-CorV","Inactivated","2","final",NA,"151+",">=5 years","general pop","included","~36 weeks","hospitalization (moderate)","severe","severe","other combinations",95,67,99.4,"Iran","IRN","Asia","Middle East & North Africa",4530,2019,"Iran, Islamic Rep.","Lower middle income",2,NA,NA,NA,NA,NA
"3065",364,"Heidarzadeh","Test-negative case-control",3126,2022-12-23,"Beijing/Sinopharm BBIBP-CorV","Inactivated","2","final",NA,"31-60",">=5 years","general pop","included","~36 weeks","hospitalization (severe)","severe","severe","other combinations",71,68,75,"Iran","IRN","Asia","Middle East & North Africa",4530,2019,"Iran, Islamic Rep.","Lower middle income",2,NA,NA,NA,NA,NA
"3066",364,"Heidarzadeh","Test-negative case-control",3127,2022-12-23,"Beijing/Sinopharm BBIBP-CorV","Inactivated","2","final",NA,"151+",">=5 years","general pop","included","~36 weeks","hospitalization (severe)","severe","severe","other combinations",85,77,91,"Iran","IRN","Asia","Middle East & North Africa",4530,2019,"Iran, Islamic Rep.","Lower middle income",2,NA,NA,NA,NA,NA
"3067",364,"Heidarzadeh","Test-negative case-control",3128,2022-12-23,"Beijing/Sinopharm BBIBP-CorV","Inactivated","2","final",NA,"31-60",">=5 years","general pop","included","~36 weeks","ICU admission","severe","severe","other combinations",25,-9,48,"Iran","IRN","Asia","Middle East & North Africa",4530,2019,"Iran, Islamic Rep.","Lower middle income",2,NA,NA,NA,NA,NA
"3068",364,"Heidarzadeh","Test-negative case-control",3129,2022-12-23,"Beijing/Sinopharm BBIBP-CorV","Inactivated","2","final",NA,"151+",">=5 years","general pop","included","~36 weeks","ICU admission","severe","severe","other combinations",26,-77,69,"Iran","IRN","Asia","Middle East & North Africa",4530,2019,"Iran, Islamic Rep.","Lower middle income",2,NA,NA,NA,NA,NA
"3069",364,"Heidarzadeh","Test-negative case-control",3130,2022-12-23,"Beijing/Sinopharm BBIBP-CorV","Inactivated","2","final",NA,"31-60",">=5 years","general pop","included","~36 weeks","death","death","death","other combinations",41,23,55,"Iran","IRN","Asia","Middle East & North Africa",4530,2019,"Iran, Islamic Rep.","Lower middle income",2,NA,NA,NA,NA,NA
"3070",364,"Heidarzadeh","Test-negative case-control",3131,2022-12-23,"Beijing/Sinopharm BBIBP-CorV","Inactivated","2","final",NA,"151+",">=5 years","general pop","included","~36 weeks","death","death","death","other combinations",33,-40,69,"Iran","IRN","Asia","Middle East & North Africa",4530,2019,"Iran, Islamic Rep.","Lower middle income",2,NA,NA,NA,NA,NA
"3071",364,"Heidarzadeh","Test-negative case-control",3132,2022-12-23,"Shifa Pharmed COVIran","Inactivated","2","final",NA,"31-60",">=5 years","general pop","included","~21 weeks","hospitalization (moderate)","severe","severe","other combinations",96,68,99.4,"Iran","IRN","Asia","Middle East & North Africa",4530,2019,"Iran, Islamic Rep.","Lower middle income",2,NA,NA,NA,NA,NA
"3072",364,"Heidarzadeh","Test-negative case-control",3133,2022-12-23,"Shifa Pharmed COVIran","Inactivated","2","final",NA,"61-90",">=5 years","general pop","included","~21 weeks","hospitalization (moderate)","severe","severe","other combinations",97,76,99.6,"Iran","IRN","Asia","Middle East & North Africa",4530,2019,"Iran, Islamic Rep.","Lower middle income",2,NA,NA,NA,NA,NA
"3073",364,"Heidarzadeh","Test-negative case-control",3134,2022-12-23,"Shifa Pharmed COVIran","Inactivated","2","final",NA,"31-60",">=5 years","general pop","included","~21 weeks","hospitalization (severe)","severe","severe","other combinations",82,73,88,"Iran","IRN","Asia","Middle East & North Africa",4530,2019,"Iran, Islamic Rep.","Lower middle income",2,NA,NA,NA,NA,NA
"3074",364,"Heidarzadeh","Test-negative case-control",3135,2022-12-23,"Shifa Pharmed COVIran","Inactivated","2","final",NA,"91-120",">=5 years","general pop","included","~21 weeks","hospitalization (severe)","severe","severe","other combinations",92,86,96,"Iran","IRN","Asia","Middle East & North Africa",4530,2019,"Iran, Islamic Rep.","Lower middle income",2,NA,NA,NA,NA,NA
"3075",364,"Heidarzadeh","Test-negative case-control",3136,2022-12-23,"Shifa Pharmed COVIran","Inactivated","2","final",NA,"31-60",">=5 years","general pop","included","~21 weeks","ICU admission","severe","severe","other combinations",61,-61,91,"Iran","IRN","Asia","Middle East & North Africa",4530,2019,"Iran, Islamic Rep.","Lower middle income",2,NA,NA,NA,NA,NA
"3076",364,"Heidarzadeh","Test-negative case-control",3137,2022-12-23,"Shifa Pharmed COVIran","Inactivated","2","final",NA,"91-120",">=5 years","general pop","included","~21 weeks","ICU admission","severe","severe","other combinations",35,-116,80,"Iran","IRN","Asia","Middle East & North Africa",4530,2019,"Iran, Islamic Rep.","Lower middle income",2,NA,NA,NA,NA,NA
"3077",364,"Heidarzadeh","Test-negative case-control",3138,2022-12-23,"Shifa Pharmed COVIran","Inactivated","2","final",NA,"31-60",">=5 years","general pop","included","~21 weeks","death","death","death","other combinations",88,48,97,"Iran","IRN","Asia","Middle East & North Africa",4530,2019,"Iran, Islamic Rep.","Lower middle income",2,NA,NA,NA,NA,NA
"3078",364,"Heidarzadeh","Test-negative case-control",3139,2022-12-23,"Shifa Pharmed COVIran","Inactivated","2","final",NA,"91-120",">=5 years","general pop","included","~21 weeks","death","death","death","other combinations",93,46,99,"Iran","IRN","Asia","Middle East & North Africa",4530,2019,"Iran, Islamic Rep.","Lower middle income",2,NA,NA,NA,NA,NA
"3079",364,"Heidarzadeh","Test-negative case-control",3140,2022-12-23,"Bharat Covaxin/BBV152","Inactivated","2","final",NA,"61-90",">=5 years","general pop","included","~35 weeks","hospitalization (severe)","severe","severe","other combinations",55,-33,85,"Iran","IRN","Asia","Middle East & North Africa",4530,2019,"Iran, Islamic Rep.","Lower middle income",2,NA,NA,NA,NA,NA
"3080",364,"Heidarzadeh","Test-negative case-control",3141,2022-12-23,"Bharat Covaxin/BBV152","Inactivated","2","final",NA,"151+",">=5 years","general pop","included","~35 weeks","hospitalization (severe)","severe","severe","other combinations",96,68,99.5,"Iran","IRN","Asia","Middle East & North Africa",4530,2019,"Iran, Islamic Rep.","Lower middle income",2,NA,NA,NA,NA,NA
"3081",364,"Heidarzadeh","Test-negative case-control",3142,2022-12-23,"Bharat Covaxin/BBV152","Inactivated","2","final",NA,"91-120",">=5 years","general pop","included","~35 weeks","death","death","death","other combinations",4,-671,79,"Iran","IRN","Asia","Middle East & North Africa",4530,2019,"Iran, Islamic Rep.","Lower middle income",2,NA,NA,NA,NA,NA
"3082",364,"Heidarzadeh","Test-negative case-control",3143,2022-12-23,"Gamaleya Gam-COVID-Vac/Sputnik V","Vectored","2","final",NA,"31-60",">=5 years","general pop","included","~40 weeks","hospitalization (moderate)","severe","severe","other combinations",74,-9,94,"Iran","IRN","Asia","Middle East & North Africa",4530,2019,"Iran, Islamic Rep.","Lower middle income",2,NA,NA,NA,NA,NA
"3083",364,"Heidarzadeh","Test-negative case-control",3144,2022-12-23,"Gamaleya Gam-COVID-Vac/Sputnik V","Vectored","2","final",NA,"151+",">=5 years","general pop","included","~40 weeks","hospitalization (moderate)","severe","severe","other combinations",95,79,99,"Iran","IRN","Asia","Middle East & North Africa",4530,2019,"Iran, Islamic Rep.","Lower middle income",2,NA,NA,NA,NA,NA
"3084",364,"Heidarzadeh","Test-negative case-control",3145,2022-12-23,"Gamaleya Gam-COVID-Vac/Sputnik V","Vectored","2","final",NA,"31-60",">=5 years","general pop","included","~40 weeks","hospitalization (severe)","severe","severe","other combinations",62,32,78,"Iran","IRN","Asia","Middle East & North Africa",4530,2019,"Iran, Islamic Rep.","Lower middle income",2,NA,NA,NA,NA,NA
"3085",364,"Heidarzadeh","Test-negative case-control",3146,2022-12-23,"Gamaleya Gam-COVID-Vac/Sputnik V","Vectored","2","final",NA,"151+",">=5 years","general pop","included","~40 weeks","hospitalization (severe)","severe","severe","other combinations",93,88,96,"Iran","IRN","Asia","Middle East & North Africa",4530,2019,"Iran, Islamic Rep.","Lower middle income",2,NA,NA,NA,NA,NA
"3086",364,"Heidarzadeh","Test-negative case-control",3147,2022-12-23,"Gamaleya Gam-COVID-Vac/Sputnik V","Vectored","2","final",NA,"91-120",">=5 years","general pop","included","~40 weeks","ICU admission","severe","severe","other combinations",51,-258,94,"Iran","IRN","Asia","Middle East & North Africa",4530,2019,"Iran, Islamic Rep.","Lower middle income",2,NA,NA,NA,NA,NA
"3087",364,"Heidarzadeh","Test-negative case-control",3148,2022-12-23,"Gamaleya Gam-COVID-Vac/Sputnik V","Vectored","2","final",NA,"151+",">=5 years","general pop","included","~40 weeks","ICU admission","severe","severe","other combinations",18,-136,71,"Iran","IRN","Asia","Middle East & North Africa",4530,2019,"Iran, Islamic Rep.","Lower middle income",2,NA,NA,NA,NA,NA
"3088",364,"Heidarzadeh","Test-negative case-control",3149,2022-12-23,"Gamaleya Gam-COVID-Vac/Sputnik V","Vectored","2","final",NA,"31-60",">=5 years","general pop","included","~40 weeks","death","death","death","other combinations",25,-149,78,"Iran","IRN","Asia","Middle East & North Africa",4530,2019,"Iran, Islamic Rep.","Lower middle income",2,NA,NA,NA,NA,NA
"3089",364,"Heidarzadeh","Test-negative case-control",3150,2022-12-23,"Gamaleya Gam-COVID-Vac/Sputnik V","Vectored","2","final",NA,"151+",">=5 years","general pop","included","~40 weeks","death","death","death","other combinations",93,47,99.1,"Iran","IRN","Asia","Middle East & North Africa",4530,2019,"Iran, Islamic Rep.","Lower middle income",2,NA,NA,NA,NA,NA
"3090",365,"Lin","Retrospective cohort",3151,2023-06-16,"Moderna mRNA-1273","mRNA","2","final",NA,"0 to ~4 weeks","0-4 years","0-4 years","included","~23 weeks","infection","infection","infection","omicron",58,47.5,66.5,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"3091",365,"Lin","Retrospective cohort",3152,2023-06-16,"Moderna mRNA-1273","mRNA","2","final",NA,"~16-21 weeks","0-4 years","0-4 years","included","~23 weeks","infection","infection","infection","omicron",47.6,27.7,62,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"3092",365,"Lin","Retrospective cohort",3153,2023-06-16,"Multiple or heterologous RNA","mRNA","2","final",NA,"0 to ~5 weeks","5-11 years","5-11 years","included","~57 weeks","hospitalization or death","severe","severe","omicron",73.3,8.3,92.3,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"3093",365,"Lin","Retrospective cohort",3154,2023-06-16,"Multiple or heterologous RNA","mRNA","2","final",NA,"~20-25 weeks","5-11 years","5-11 years","included","~57 weeks","hospitalization or death","severe","severe","omicron",2.9,-50.8,37.4,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"3094",365,"Lin","Retrospective cohort",3155,2023-06-16,"Multiple or heterologous RNA","mRNA","2","final",NA,"0 to ~5 weeks","0-4 years","0-4 years","prior infection only","~24 weeks","infection","infection","infection","omicron",37.5,21.2,50.4,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"3095",365,"Lin","Retrospective cohort",3156,2023-06-16,"Multiple or heterologous RNA","mRNA","2","final",NA,"~16-21 weeks","0-4 years","0-4 years","prior infection only","~24 weeks","infection","infection","infection","omicron",46.8,-0.3,71.8,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"3096",365,"Lin","Retrospective cohort",3157,2023-06-16,"Multiple or heterologous RNA","mRNA","2","final",NA,"0 to ~5 weeks","5-11 years","5-11 years","prior infection only","~57 weeks","infection","infection","infection","omicron",65.3,58.1,71.2,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"3097",365,"Lin","Retrospective cohort",3158,2023-06-16,"Multiple or heterologous RNA","mRNA","2","final",NA,"~24-29 weeks","5-11 years","5-11 years","prior infection only","~57 weeks","infection","infection","infection","omicron",4.6,-2.1,10.9,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"3098",365,"Lin","Retrospective cohort",3159,2023-06-16,"Multiple or heterologous RNA","mRNA","2","final",NA,"0 to ~5 weeks","0-4 years","0-4 years","excluded","~24 weeks","infection","infection","infection","omicron",55.7,49.1,61.5,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"3099",365,"Lin","Retrospective cohort",3160,2023-06-16,"Multiple or heterologous RNA","mRNA","2","final",NA,"~16-21 weeks","0-4 years","0-4 years","excluded","~24 weeks","infection","infection","infection","omicron",58.6,48.3,66.9,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"3100",365,"Lin","Retrospective cohort",3161,2023-06-16,"Multiple or heterologous RNA","mRNA","2","final",NA,"0 to ~5 weeks","5-11 years","5-11 years","excluded","~57 weeks","infection","infection","infection","omicron",59.7,58.3,61,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"3101",365,"Lin","Retrospective cohort",3162,2023-06-16,"Multiple or heterologous RNA","mRNA","2","final",NA,"~36-41 weeks","5-11 years","5-11 years","excluded","~57 weeks","infection","infection","infection","omicron",16,13.1,18.7,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"3102",366,"Battacharya","Test-negative case-control",3163,2023-01-06,"Bharat Covaxin/BBV152","Inactivated","2","final",NA,"7+",">=18 years","general pop","included","~22 weeks","hospitalization with symptoms of pulmonary disease","severe","severe","delta",74,50.5,86,"India","IND","Asia","South Asia",2070,2019,"India","Lower middle income",1,NA,NA,NA,NA,NA
"3103",366,"Battacharya","Test-negative case-control",3164,2023-01-06,"Oxford/AstraZeneca ChAdOx1-S","Vectored","2","final",NA,"7+",">=18 years","general pop","included","~22 weeks","hospitalization with symptoms of pulmonary disease","severe","severe","delta",79,53.1,81,"India","IND","Asia","South Asia",2070,2019,"India","Lower middle income",1,7,154,"yes",NA,0
"3104",367,"Ellingson","Prospective cohort",3165,2023-01-26,"Multiple or heterologous RNA","mRNA","2","final",NA,"14+","frontline workers","general pop","prior infection only","~63 weeks","infection","infection","infection","omicron",43,35,57,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"3105",368,"Niesen","Test-negative case-control",3166,2022-04-28,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"14-73",">=18 years","general pop","excluded","~54 weeks","symptomatic disease","symptomatic","symptomatic","delta",80.6,76.9,83.7,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"3106",368,"Niesen","Test-negative case-control",3167,2022-04-28,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"314-355",">=18 years","general pop","excluded","~54 weeks","symptomatic disease","symptomatic","symptomatic","delta",43.3,28.8,54.7,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"3107",368,"Niesen","Test-negative case-control",3168,2022-04-28,"Moderna mRNA-1273","mRNA","2","final",NA,"7-13",">=18 years","general pop","excluded","~54 weeks","symptomatic disease","symptomatic","symptomatic","delta",94.8,88,97.8,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"3108",368,"Niesen","Test-negative case-control",3169,2022-04-28,"Moderna mRNA-1273","mRNA","2","final",NA,"254-313",">=18 years","general pop","excluded","~54 weeks","symptomatic disease","symptomatic","symptomatic","delta",63.2,53.7,70.7,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"3109",369,"Toh","Test-negative case-control",3170,2023-01-27,"Sinovac CoronaVac","Inactivated","2","final",NA,"15+",">=18 years","general pop","included","~24 weeks","hospitalization","severe","severe","other combinations",76.5,45.6,89.8,"Malaysia","MYS","Asia","East Asia & Pacific",10750,2019,"Malaysia","Upper middle income",3,NA,NA,NA,NA,NA
"3110",370,"Tartof","Test-negative case-control",3171,2023-01-28,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"14-89","5-11 years","5-11 years","included","~39 weeks","ED or UC visit","symptomatic","symptomatic","omicron",60,47,69,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"3111",370,"Tartof","Test-negative case-control",3172,2023-01-28,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"90+","5-11 years","5-11 years","included","~39 weeks","ED or UC visit","symptomatic","symptomatic","omicron",28,8,43,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"3112",370,"Tartof","Test-negative case-control",3173,2023-01-28,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"90+","5-11 years","5-11 years","included","~5 weeks","ED or UC visit","symptomatic","symptomatic","delta",85,59,95,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"3113",371,"Sritipsukho","Test-negative case-control",3174,2023-01-30,"Sinovac CoronaVac","Inactivated","2","final",NA,"14+",">=18 years","general pop","excluded","~67 weeks","infection","infection","infection","omicron",26,-9,50,"Thailand","THA","Asia","East Asia & Pacific",7060,2019,"Thailand","Upper middle income",3,NA,NA,NA,NA,NA
"3114",371,"Sritipsukho","Test-negative case-control",3175,2023-01-30,"Sinovac CoronaVac","Inactivated","2","final",NA,"<90 days",">=18 years","general pop","excluded","~67 weeks","infection","infection","infection","omicron",47,7,70,"Thailand","THA","Asia","East Asia & Pacific",7060,2019,"Thailand","Upper middle income",3,NA,NA,NA,NA,NA
"3115",371,"Sritipsukho","Test-negative case-control",3176,2023-01-30,"Sinovac CoronaVac","Inactivated","2","final",NA,">90 days",">=18 years","general pop","excluded","~67 weeks","infection","infection","infection","omicron",21,-15,47,"Thailand","THA","Asia","East Asia & Pacific",7060,2019,"Thailand","Upper middle income",3,NA,NA,NA,NA,NA
"3116",371,"Sritipsukho","Test-negative case-control",3177,2023-01-30,"Sinovac CoronaVac","Inactivated","2","final",NA,"14+",">=18 years","general pop","excluded","~67 weeks","moderate to critical disease","symptomatic","symptomatic","omicron",-4,-50,45,"Thailand","THA","Asia","East Asia & Pacific",7060,2019,"Thailand","Upper middle income",3,NA,NA,NA,NA,NA
"3117",371,"Sritipsukho","Test-negative case-control",3178,2023-01-30,"Oxford/AstraZeneca ChAdOx1-S","Vectored","2","final",NA,"14+",">=18 years","general pop","excluded","~67 weeks","infection","infection","infection","omicron",38,13,56,"Thailand","THA","Asia","East Asia & Pacific",7060,2019,"Thailand","Upper middle income",3,NA,NA,NA,NA,NA
"3118",371,"Sritipsukho","Test-negative case-control",3179,2023-01-30,"Oxford/AstraZeneca ChAdOx1-S","Vectored","2","final",NA,"<90 days",">=18 years","general pop","excluded","~67 weeks","infection","infection","infection","omicron",61,41,74,"Thailand","THA","Asia","East Asia & Pacific",7060,2019,"Thailand","Upper middle income",3,NA,NA,NA,NA,NA
"3119",371,"Sritipsukho","Test-negative case-control",3180,2023-01-30,"Oxford/AstraZeneca ChAdOx1-S","Vectored","2","final",NA,">90 days",">=18 years","general pop","excluded","~67 weeks","infection","infection","infection","omicron",30,0,51,"Thailand","THA","Asia","East Asia & Pacific",7060,2019,"Thailand","Upper middle income",3,NA,NA,NA,NA,NA
"3120",371,"Sritipsukho","Test-negative case-control",3181,2023-01-30,"Oxford/AstraZeneca ChAdOx1-S","Vectored","2","final",NA,"14+",">=18 years","general pop","excluded","~67 weeks","moderate to critical disease","symptomatic","symptomatic","omicron",56,25,74,"Thailand","THA","Asia","East Asia & Pacific",7060,2019,"Thailand","Upper middle income",3,NA,NA,NA,NA,NA
"3121",371,"Sritipsukho","Test-negative case-control",3182,2023-01-30,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"14+",">=18 years","general pop","excluded","~67 weeks","infection","infection","infection","omicron",23,-13,49,"Thailand","THA","Asia","East Asia & Pacific",7060,2019,"Thailand","Upper middle income",3,NA,NA,NA,NA,NA
"3122",371,"Sritipsukho","Test-negative case-control",3183,2023-01-30,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"<90 days",">=18 years","general pop","excluded","~67 weeks","infection","infection","infection","omicron",38,4,60,"Thailand","THA","Asia","East Asia & Pacific",7060,2019,"Thailand","Upper middle income",3,NA,NA,NA,NA,NA
"3123",371,"Sritipsukho","Test-negative case-control",3184,2023-01-30,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,">90 days",">=18 years","general pop","excluded","~67 weeks","infection","infection","infection","omicron",-38,-60,24,"Thailand","THA","Asia","East Asia & Pacific",7060,2019,"Thailand","Upper middle income",3,NA,NA,NA,NA,NA
"3124",371,"Sritipsukho","Test-negative case-control",3185,2023-01-30,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"14+",">=18 years","general pop","excluded","~67 weeks","moderate to critical disease","infection","infection","omicron",30,-37,69,"Thailand","THA","Asia","East Asia & Pacific",7060,2019,"Thailand","Upper middle income",3,NA,NA,NA,NA,NA
"3125",372,"Weng","Retrospective cohort",3186,2023-02-01,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"14+",">=12 years","general pop","included","~48 weeks","infection","infection","infection","alpha",94.6,83.4,98.3,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"3126",372,"Weng","Retrospective cohort",3187,2023-02-01,"Moderna mRNA-1273","mRNA","2","final",NA,"14+",">=12 years","general pop","included","~48 weeks","infection","infection","infection","alpha",97.5,82.5,99.7,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"3127",372,"Weng","Retrospective cohort",3188,2023-02-01,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"14+",">=12 years","general pop","included","~48 weeks","infection","infection","infection","delta",64.8,54.2,73,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"3128",372,"Weng","Retrospective cohort",3189,2023-02-01,"Moderna mRNA-1273","mRNA","2","final",NA,"14+",">=12 years","general pop","included","~48 weeks","infection","infection","infection","delta",65,52.9,74.1,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"3129",372,"Weng","Retrospective cohort",3190,2023-02-01,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"14+",">=12 years","general pop","included","~48 weeks","infection","infection","infection","omicron",31.6,19.6,42.5,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"3130",372,"Weng","Retrospective cohort",3191,2023-02-01,"Moderna mRNA-1273","mRNA","2","final",NA,"14+",">=12 years","general pop","included","~48 weeks","infection","infection","infection","omicron",25.6,10.7,39,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"3131",374,"Bello Chavolla","Test-negative case-control",3194,2023-02-02,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"14+",">=18 years","general pop","excluded","~35 weeks","infection","infection","infection","other combinations",80.3,80.1,80.6,"Mexico","MEX","North America","Latin America & Caribbean",9860,2019,"Mexico","Upper middle income",3,NA,NA,NA,NA,NA
"3132",374,"Bello Chavolla","Test-negative case-control",3195,2023-02-02,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"14+",">=18 years","general pop","excluded","~35 weeks","hospitalization","severe","severe","other combinations",84.3,83.6,84.9,"Mexico","MEX","North America","Latin America & Caribbean",9860,2019,"Mexico","Upper middle income",3,NA,NA,NA,NA,NA
"3133",374,"Bello Chavolla","Test-negative case-control",3196,2023-02-02,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"14+",">=18 years","general pop","excluded","~35 weeks","death","death","death","other combinations",89.8,89.1,90.4,"Mexico","MEX","North America","Latin America & Caribbean",9860,2019,"Mexico","Upper middle income",3,NA,NA,NA,NA,NA
"3134",374,"Bello Chavolla","Test-negative case-control",3197,2023-02-02,"Moderna mRNA-1273","mRNA","2","final",NA,"14+",">=18 years","general pop","excluded","~1 week","infection","infection","infection","other combinations",91.5,90.3,92.4,"Mexico","MEX","North America","Latin America & Caribbean",9860,2019,"Mexico","Upper middle income",3,NA,NA,NA,NA,NA
"3135",374,"Bello Chavolla","Test-negative case-control",3198,2023-02-02,"Moderna mRNA-1273","mRNA","2","final",NA,"14+",">=18 years","general pop","excluded","~1 week","hospitalization","severe","severe","other combinations",78,69,84.4,"Mexico","MEX","North America","Latin America & Caribbean",9860,2019,"Mexico","Upper middle income",3,NA,NA,NA,NA,NA
"3136",374,"Bello Chavolla","Test-negative case-control",3199,2023-02-02,"Moderna mRNA-1273","mRNA","2","final",NA,"14+",">=18 years","general pop","excluded","~1 week","death","death","death","other combinations",93.5,85.9,96.9,"Mexico","MEX","North America","Latin America & Caribbean",9860,2019,"Mexico","Upper middle income",3,NA,NA,NA,NA,NA
"3137",374,"Bello Chavolla","Test-negative case-control",3200,2023-02-02,"Oxford/AstraZeneca ChAdOx1-S","Vectored","2","final",NA,"14+",">=18 years","general pop","excluded","~32 weeks","infection","infection","infection","other combinations",80.8,80.4,81.1,"Mexico","MEX","North America","Latin America & Caribbean",9860,2019,"Mexico","Upper middle income",3,NA,NA,NA,NA,NA
"3138",374,"Bello Chavolla","Test-negative case-control",3201,2023-02-02,"Oxford/AstraZeneca ChAdOx1-S","Vectored","2","final",NA,"14+",">=18 years","general pop","excluded","~32 weeks","hospitalization","severe","severe","other combinations",80.2,79.3,81.1,"Mexico","MEX","North America","Latin America & Caribbean",9860,2019,"Mexico","Upper middle income",3,NA,NA,NA,NA,NA
"3139",374,"Bello Chavolla","Test-negative case-control",3202,2023-02-02,"Oxford/AstraZeneca ChAdOx1-S","Vectored","2","final",NA,"14+",">=18 years","general pop","excluded","~32 weeks","death","death","death","other combinations",86.8,85.9,87.7,"Mexico","MEX","North America","Latin America & Caribbean",9860,2019,"Mexico","Upper middle income",3,NA,NA,NA,NA,NA
"3140",374,"Bello Chavolla","Test-negative case-control",3203,2023-02-02,"Janssen Ad26.COV2.S","Vectored","1","final",NA,"14+",">=18 years","general pop","excluded","~11 weeks","infection","infection","infection","other combinations",82.2,81.4,82.9,"Mexico","MEX","North America","Latin America & Caribbean",9860,2019,"Mexico","Upper middle income",3,NA,NA,NA,NA,NA
"3141",374,"Bello Chavolla","Test-negative case-control",3204,2023-02-02,"Janssen Ad26.COV2.S","Vectored","1","final",NA,"14+",">=18 years","general pop","excluded","~11 weeks","hospitalization","severe","severe","other combinations",77.3,72.9,81,"Mexico","MEX","North America","Latin America & Caribbean",9860,2019,"Mexico","Upper middle income",3,NA,NA,NA,NA,NA
"3142",374,"Bello Chavolla","Test-negative case-control",3205,2023-02-02,"Janssen Ad26.COV2.S","Vectored","1","final",NA,"14+",">=18 years","general pop","excluded","~11 weeks","death","death","death","other combinations",85.8,80.1,89.9,"Mexico","MEX","North America","Latin America & Caribbean",9860,2019,"Mexico","Upper middle income",3,NA,NA,NA,NA,NA
"3143",374,"Bello Chavolla","Test-negative case-control",3206,2023-02-02,"Cansino Ad5-nCoV","Vectored","1","final",NA,"14+",">=18 years","general pop","excluded","~27 weeks","infection","infection","infection","other combinations",70.5,70.1,70.9,"Mexico","MEX","North America","Latin America & Caribbean",9860,2019,"Mexico","Upper middle income",3,NA,NA,NA,NA,NA
"3144",374,"Bello Chavolla","Test-negative case-control",3207,2023-02-02,"Cansino Ad5-nCoV","Vectored","1","final",NA,"14+",">=18 years","general pop","excluded","~27 weeks","hospitalization","severe","severe","other combinations",72.3,71.1,73.5,"Mexico","MEX","North America","Latin America & Caribbean",9860,2019,"Mexico","Upper middle income",3,NA,NA,NA,NA,NA
"3145",374,"Bello Chavolla","Test-negative case-control",3208,2023-02-02,"Cansino Ad5-nCoV","Vectored","1","final",NA,"14+",">=18 years","general pop","excluded","~27 weeks","death","death","death","other combinations",79.9,78.5,81.2,"Mexico","MEX","North America","Latin America & Caribbean",9860,2019,"Mexico","Upper middle income",3,NA,NA,NA,NA,NA
"3146",374,"Bello Chavolla","Test-negative case-control",3209,2023-02-02,"Sinovac CoronaVac","Inactivated","2","final",NA,"14+",">=18 years","general pop","excluded","~27 weeks","infection","infection","infection","other combinations",71.9,71.4,72.5,"Mexico","MEX","North America","Latin America & Caribbean",9860,2019,"Mexico","Upper middle income",3,NA,NA,NA,NA,NA
"3147",374,"Bello Chavolla","Test-negative case-control",3210,2023-02-02,"Sinovac CoronaVac","Inactivated","2","final",NA,"14+",">=18 years","general pop","excluded","~27 weeks","hospitalization","severe","severe","other combinations",73.8,72.5,75,"Mexico","MEX","North America","Latin America & Caribbean",9860,2019,"Mexico","Upper middle income",3,NA,NA,NA,NA,NA
"3148",374,"Bello Chavolla","Test-negative case-control",3211,2023-02-02,"Sinovac CoronaVac","Inactivated","2","final",NA,"14+",">=18 years","general pop","excluded","~27 weeks","death","death","death","other combinations",80.4,79,81.6,"Mexico","MEX","North America","Latin America & Caribbean",9860,2019,"Mexico","Upper middle income",3,NA,NA,NA,NA,NA
"3149",374,"Bello Chavolla","Test-negative case-control",3212,2023-02-02,"Gamaleya Gam-COVID-Vac/Sputnik V","Vectored","2","final",NA,"14+",">=18 years","general pop","excluded","~26 weeks","infection","infection","infection","other combinations",78.8,78.2,79.3,"Mexico","MEX","North America","Latin America & Caribbean",9860,2019,"Mexico","Upper middle income",3,NA,NA,NA,NA,NA
"3150",374,"Bello Chavolla","Test-negative case-control",3213,2023-02-02,"Gamaleya Gam-COVID-Vac/Sputnik V","Vectored","2","final",NA,"14+",">=18 years","general pop","excluded","~26 weeks","hospitalization","severe","severe","other combinations",81.4,79.5,83.1,"Mexico","MEX","North America","Latin America & Caribbean",9860,2019,"Mexico","Upper middle income",3,NA,NA,NA,NA,NA
"3151",374,"Bello Chavolla","Test-negative case-control",3214,2023-02-02,"Gamaleya Gam-COVID-Vac/Sputnik V","Vectored","2","final",NA,"14+",">=18 years","general pop","excluded","~26 weeks","death","death","death","other combinations",87.7,85.8,89.3,"Mexico","MEX","North America","Latin America & Caribbean",9860,2019,"Mexico","Upper middle income",3,NA,NA,NA,NA,NA
"3152",375,"Jorgensen","Test-negative case-control",3215,2023-02-27,"Multiple or heterologous RNA","mRNA","2","final",NA,"14+","infants of mothers vaccinated post-partum","infants of mothers vaccinated post-partum","included","~66 weeks","infection","infection","infection","omicron",13,-14,33,"Canada","CAN","North America","North America",46580,2019,"Canada","High income",4,NA,NA,NA,NA,NA
"3153",375,"Jorgensen","Test-negative case-control",3216,2023-02-27,"Multiple or heterologous RNA","mRNA","2","final",NA,"14+","infants of mothers vaccinated post-partum","infants of mothers vaccinated post-partum","included","~66 weeks","hospitalization","severe","severe","omicron",36,-21,66,"Canada","CAN","North America","North America",46580,2019,"Canada","High income",4,NA,NA,NA,NA,NA
"3154",375,"Jorgensen","Test-negative case-control",3217,2023-02-27,"Multiple or heterologous RNA","mRNA","2","final",NA,"14+","infants of mothers vaccinated post-partum","infants of mothers vaccinated post-partum","included","~66 weeks","infection","infection","infection","omicron",73,72,87,"Canada","CAN","North America","North America",46580,2019,"Canada","High income",4,NA,NA,NA,NA,NA
"3155",376,"Yan","Case-control",3218,2023-02-28,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"14-60","3-17 years","3-17 years","excluded","~68 weeks","infection","infection","infection","omicron",39.7,29,48.7,"Hong Kong","HKG","Asia","East Asia & Pacific",50480,2019,"Hong Kong SAR, China","High income",4,NA,NA,NA,NA,NA
"3156",376,"Yan","Case-control",3219,2023-02-28,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"180+","3-17 years","3-17 years","excluded","~68 weeks","infection","infection","infection","omicron",16.5,8.7,23.6,"Hong Kong","HKG","Asia","East Asia & Pacific",50480,2019,"Hong Kong SAR, China","High income",4,NA,NA,NA,NA,NA
"3157",376,"Yan","Case-control",3220,2023-02-28,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"14-60","3-17 years","3-17 years","excluded","~68 weeks","hospitalization","severe","severe","omicron",45.5,-0.2,70.3,"Hong Kong","HKG","Asia","East Asia & Pacific",50480,2019,"Hong Kong SAR, China","High income",4,NA,NA,NA,NA,NA
"3158",376,"Yan","Case-control",3221,2023-02-28,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"180+","3-17 years","3-17 years","excluded","~68 weeks","hospitalization","severe","severe","omicron",33.6,5.5,53.3,"Hong Kong","HKG","Asia","East Asia & Pacific",50480,2019,"Hong Kong SAR, China","High income",4,NA,NA,NA,NA,NA
"3159",376,"Yan","Case-control",3222,2023-02-28,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"14-60","3-17 years","3-17 years","excluded","~68 weeks","severe disease","severe","severe","omicron",67.3,34.1,83.8,"Hong Kong","HKG","Asia","East Asia & Pacific",50480,2019,"Hong Kong SAR, China","High income",4,NA,NA,NA,NA,NA
"3160",376,"Yan","Case-control",3223,2023-02-28,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"180+","3-17 years","3-17 years","excluded","~68 weeks","severe disease","severe","severe","omicron",29.2,-4.9,52.2,"Hong Kong","HKG","Asia","East Asia & Pacific",50480,2019,"Hong Kong SAR, China","High income",4,NA,NA,NA,NA,NA
"3161",376,"Yan","Case-control",3224,2023-02-28,"Sinovac CoronaVac","Inactivated","2","final",NA,"14-60","3-17 years","3-17 years","excluded","~68 weeks","infection","infection","infection","omicron",29.5,20.1,37.7,"Hong Kong","HKG","Asia","East Asia & Pacific",50480,2019,"Hong Kong SAR, China","High income",4,NA,NA,NA,NA,NA
"3162",376,"Yan","Case-control",3225,2023-02-28,"Sinovac CoronaVac","Inactivated","2","final",NA,"121-179","3-17 years","3-17 years","excluded","~68 weeks","infection","infection","infection","omicron",-35.2,-63.3,-12,"Hong Kong","HKG","Asia","East Asia & Pacific",50480,2019,"Hong Kong SAR, China","High income",4,NA,NA,NA,NA,NA
"3163",376,"Yan","Case-control",3226,2023-02-28,"Sinovac CoronaVac","Inactivated","2","final",NA,"14-60","3-17 years","3-17 years","excluded","~68 weeks","hospitalization","severe","severe","omicron",55.8,34.9,70,"Hong Kong","HKG","Asia","East Asia & Pacific",50480,2019,"Hong Kong SAR, China","High income",4,NA,NA,NA,NA,NA
"3164",376,"Yan","Case-control",3227,2023-02-28,"Sinovac CoronaVac","Inactivated","2","final",NA,"121-179","3-17 years","3-17 years","excluded","~68 weeks","hospitalization","severe","severe","omicron",-66.9,-137.3,17.3,"Hong Kong","HKG","Asia","East Asia & Pacific",50480,2019,"Hong Kong SAR, China","High income",4,NA,NA,NA,NA,NA
"3165",376,"Yan","Case-control",3228,2023-02-28,"Sinovac CoronaVac","Inactivated","2","final",NA,"14-60","3-17 years","3-17 years","excluded","~68 weeks","severe disease","severe","severe","omicron",57.6,32.8,73.2,"Hong Kong","HKG","Asia","East Asia & Pacific",50480,2019,"Hong Kong SAR, China","High income",4,NA,NA,NA,NA,NA
"3166",376,"Yan","Case-control",3229,2023-02-28,"Sinovac CoronaVac","Inactivated","2","final",NA,"121-179","3-17 years","3-17 years","excluded","~68 weeks","severe disease","severe","severe","omicron",-48.8,-120,0.7,"Hong Kong","HKG","Asia","East Asia & Pacific",50480,2019,"Hong Kong SAR, China","High income",4,NA,NA,NA,NA,NA
"3167",378,"Glatman-Freedman","Test-negative case-control",3230,2023-03-02,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"8-14","5-11 years","5-11 years","excluded","4 weeks","infection","infection","infection","omicron",58.1,55.5,60.6,"Israel","ISR","Asia","Middle East & North Africa",43800,2019,"Israel","High income",4,NA,NA,NA,NA,NA
"3168",378,"Glatman-Freedman","Test-negative case-control",3231,2023-03-02,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"36-42","5-11 years","5-11 years","excluded","4 weeks","infection","infection","infection","omicron",39.5,36.1,42.8,"Israel","ISR","Asia","Middle East & North Africa",43800,2019,"Israel","High income",4,NA,NA,NA,NA,NA
"3169",380,"Tamandjou Tchuem","Test-negative case-control",3232,2023-02-27,"Multiple or heterologous RNA","mRNA","2","final",NA,"8-30",">=50 years",">=50 years","included","~54 weeks","symptomatic disease","symptomatic","symptomatic","omicron",69.8,58.3,79.3,"France","FRA","Europe","Europe & Central Asia",42470,2019,"France","High income",4,NA,NA,NA,NA,NA
"3170",380,"Tamandjou Tchuem","Test-negative case-control",3233,2023-02-27,"Multiple or heterologous RNA","mRNA","2","final",NA,">120",">=50 years",">=50 years","included","~54 weeks","symptomatic disease","symptomatic","symptomatic","omicron",19.9,16.3,24.1,"France","FRA","Europe","Europe & Central Asia",42470,2019,"France","High income",4,NA,NA,NA,NA,NA
"3171",380,"Tamandjou Tchuem","Test-negative case-control",3234,2023-02-27,"Multiple or heterologous RNA","mRNA","2","final",NA,"8-30",">=50 years",">=50 years","included","~45 weeks","symptomatic disease","symptomatic","symptomatic","delta",85.9,75.2,92.4,"France","FRA","Europe","Europe & Central Asia",42470,2019,"France","High income",4,NA,NA,NA,NA,NA
"3172",380,"Tamandjou Tchuem","Test-negative case-control",3235,2023-02-27,"Multiple or heterologous RNA","mRNA","2","final",NA,">120",">=50 years",">=50 years","included","~45 weeks","symptomatic disease","symptomatic","symptomatic","delta",60.1,57.2,63,"France","FRA","Europe","Europe & Central Asia",42470,2019,"France","High income",4,NA,NA,NA,NA,NA
"3173",381,"Rojas-Botero","Retrospective cohort",3236,2023-09-08,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"15+",">=18 years","general pop","included","~64 weeks","hospitalization","severe","severe","other combinations",90.5,89.8,91.2,"Colombia","COL","South America","Latin America & Caribbean",6630,2019,"Colombia","Upper middle income",3,NA,NA,NA,NA,NA
"3174",381,"Rojas-Botero","Retrospective cohort",3237,2023-09-08,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"15+",">=18 years","general pop","included","~64 weeks","death","death","death","other combinations",93.5,92.8,94.2,"Colombia","COL","South America","Latin America & Caribbean",6630,2019,"Colombia","Upper middle income",3,NA,NA,NA,NA,NA
"3175",381,"Rojas-Botero","Retrospective cohort",3238,2023-09-08,"Moderna mRNA-1273","mRNA","2","final",NA,"15+",">=18 years","general pop","included","~41 weeks","hospitalization","severe","severe","other combinations",93.7,91.8,95.2,"Colombia","COL","South America","Latin America & Caribbean",6630,2019,"Colombia","Upper middle income",3,NA,NA,NA,NA,NA
"3176",381,"Rojas-Botero","Retrospective cohort",3239,2023-09-08,"Moderna mRNA-1273","mRNA","2","final",NA,"15+",">=18 years","general pop","included","~41 weeks","death","death","death","other combinations",95.7,93.5,97.2,"Colombia","COL","South America","Latin America & Caribbean",6630,2019,"Colombia","Upper middle income",3,NA,NA,NA,NA,NA
"3177",381,"Rojas-Botero","Retrospective cohort",3240,2023-09-08,"Oxford/AstraZeneca ChAdOx1-S","Vectored","2","final",NA,"15+",">=18 years","general pop","included","~57 weeks","hospitalization","severe","severe","other combinations",88,86.8,89.1,"Colombia","COL","South America","Latin America & Caribbean",6630,2019,"Colombia","Upper middle income",3,NA,NA,NA,NA,NA
"3178",381,"Rojas-Botero","Retrospective cohort",3241,2023-09-08,"Oxford/AstraZeneca ChAdOx1-S","Vectored","2","final",NA,"15+",">=18 years","general pop","included","~57 weeks","death","death","death","other combinations",92.6,91.5,93.6,"Colombia","COL","South America","Latin America & Caribbean",6630,2019,"Colombia","Upper middle income",3,NA,NA,NA,NA,NA
"3179",381,"Rojas-Botero","Retrospective cohort",3242,2023-09-08,"Sinovac CoronaVac","Inactivated","2","final",NA,"15+",">=18 years","general pop","included","~64 weeks","hospitalization","severe","severe","other combinations",77.4,76.5,78.2,"Colombia","COL","South America","Latin America & Caribbean",6630,2019,"Colombia","Upper middle income",3,NA,NA,NA,NA,NA
"3180",381,"Rojas-Botero","Retrospective cohort",3243,2023-09-08,"Sinovac CoronaVac","Inactivated","2","final",NA,"15+",">=18 years","general pop","included","~64 weeks","death","death","death","other combinations",81.9,81.2,82.7,"Colombia","COL","South America","Latin America & Caribbean",6630,2019,"Colombia","Upper middle income",3,NA,NA,NA,NA,NA
"3181",381,"Rojas-Botero","Retrospective cohort",3244,2023-09-08,"Janssen Ad26.COV2.S","Vectored","1","final",NA,"15+",">=18 years","general pop","included","~51 weeks","hospitalization","severe","severe","other combinations",85.4,83.8,86.9,"Colombia","COL","South America","Latin America & Caribbean",6630,2019,"Colombia","Upper middle income",3,NA,NA,NA,NA,NA
"3182",381,"Rojas-Botero","Retrospective cohort",3245,2023-09-08,"Janssen Ad26.COV2.S","Vectored","1","final",NA,"15+",">=18 years","general pop","included","~51 weeks","death","death","death","other combinations",90.5,88.8,91.9,"Colombia","COL","South America","Latin America & Caribbean",6630,2019,"Colombia","Upper middle income",3,NA,NA,NA,NA,NA
"3183",382,"Bouillon","Retrospective cohort",3246,2022-06-13,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"14-30",">=50 years",">=50 years","included","~28 weeks","hospitalization","severe","severe","other combinations",90,88,91,"France","FRA","Europe","Europe & Central Asia",42470,2019,"France","High income",4,NA,NA,NA,NA,NA
"3184",382,"Bouillon","Retrospective cohort",3247,2022-06-13,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"152-180",">=50 years",">=50 years","included","~28 weeks","hospitalization","severe","severe","other combinations",94,92,94,"France","FRA","Europe","Europe & Central Asia",42470,2019,"France","High income",4,NA,NA,NA,NA,NA
"3185",382,"Bouillon","Retrospective cohort",3248,2022-06-13,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"14+",">=50 years",">=50 years","included","~28 weeks","death","death","death","other combinations",91,90,93,"France","FRA","Europe","Europe & Central Asia",42470,2019,"France","High income",4,NA,NA,NA,NA,NA
"3186",382,"Bouillon","Retrospective cohort",3249,2022-06-13,"Moderna mRNA-1273","mRNA","2","final",NA,"14-30",">=50 years",">=50 years","included","~28 weeks","hospitalization","severe","severe","other combinations",92,85,95,"France","FRA","Europe","Europe & Central Asia",42470,2019,"France","High income",4,NA,NA,NA,NA,NA
"3187",382,"Bouillon","Retrospective cohort",3250,2022-06-13,"Moderna mRNA-1273","mRNA","2","final",NA,"152-180",">=50 years",">=50 years","included","~28 weeks","hospitalization","severe","severe","other combinations",98,93,100,"France","FRA","Europe","Europe & Central Asia",42470,2019,"France","High income",4,NA,NA,NA,NA,NA
"3188",382,"Bouillon","Retrospective cohort",3251,2022-06-13,"Moderna mRNA-1273","mRNA","2","final",NA,"14+",">=50 years",">=50 years","included","~28 weeks","death","death","death","other combinations",96,92,98,"France","FRA","Europe","Europe & Central Asia",42470,2019,"France","High income",4,NA,NA,NA,NA,NA
"3189",382,"Bouillon","Retrospective cohort",3252,2022-06-13,"Oxford/AstraZeneca ChAdOx1-S","Vectored","2","final",NA,"14-30",">=50 years",">=50 years","included","~23 weeks","hospitalization","severe","severe","other combinations",94,88,97,"France","FRA","Europe","Europe & Central Asia",42470,2019,"France","High income",4,NA,NA,NA,NA,NA
"3190",382,"Bouillon","Retrospective cohort",3253,2022-06-13,"Oxford/AstraZeneca ChAdOx1-S","Vectored","2","final",NA,"90-120",">=50 years",">=50 years","included","~23 weeks","hospitalization","severe","severe","other combinations",90,63,97,"France","FRA","Europe","Europe & Central Asia",42470,2019,"France","High income",4,NA,NA,NA,NA,NA
"3191",382,"Bouillon","Retrospective cohort",3254,2022-06-13,"Oxford/AstraZeneca ChAdOx1-S","Vectored","2","final",NA,"14+",">=50 years",">=50 years","included","~23 weeks","death","death","death","other combinations",88,68,95,"France","FRA","Europe","Europe & Central Asia",42470,2019,"France","High income",4,NA,NA,NA,NA,NA
"3192",383,"Lipshuetz","Retrospective cohort",3255,2023-03-23,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"120 days after birth","infants 0-120 days of unvaccinated mothers and mothers vaccinated during pregnancy at least 5 months prior","infants","excluded","~59 weeks","hospitalization up to 120 days after birth","severe","severe","delta/omicron",-16,-56,14,"Israel","ISR","Asia","Middle East & North Africa",43800,2019,"Israel","High income",4,NA,NA,NA,NA,NA
"3193",384,"Lutz","Test-negative case-control",3256,2023-03-27,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"14+",">=12 years","general pop","included","~45 weeks","hospitalization","severe","severe","other combinations",93.9,85.7,97.4,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"3194",384,"Lutz","Test-negative case-control",3257,2023-03-27,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"14+",">=12 years","general pop","included","~45 weeks","outpatient clinic and emergency visits","symptomatic","symptomatic","other combinations",85.9,60,95,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"3195",384,"Lutz","Test-negative case-control",3258,2023-03-27,"Moderna mRNA-1273","mRNA","2","final",NA,"14+",">=12 years","general pop","included","~45 weeks","hospitalization","severe","severe","other combinations",97.3,88.3,99.4,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"3196",384,"Lutz","Test-negative case-control",3259,2023-03-27,"Moderna mRNA-1273","mRNA","2","final",NA,"14+",">=12 years","general pop","included","~45 weeks","outpatient clinic and emergency visits","symptomatic","symptomatic","other combinations",85.4,39.3,96.5,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"3197",384,"Lutz","Test-negative case-control",3260,2023-03-27,"Multiple or heterologous RNA","mRNA","2","final",NA,"14-149",">=12 years","general pop","included","~45 weeks","hospitalization","severe","severe","other combinations",96.2,94,99.4,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"3198",384,"Lutz","Test-negative case-control",3261,2023-03-27,"Multiple or heterologous RNA","mRNA","2","final",NA,"150+",">=12 years","general pop","included","~45 weeks","hospitalization","severe","severe","other combinations",87.7,69.4,95,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"3199",384,"Lutz","Test-negative case-control",3262,2023-03-27,"Multiple or heterologous RNA","mRNA","2","final",NA,"14-149",">=12 years","general pop","included","~45 weeks","outpatient clinic and emergency visits","symptomatic","symptomatic","other combinations",87.7,60.5,96.2,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"3200",384,"Lutz","Test-negative case-control",3263,2023-03-27,"Multiple or heterologous RNA","mRNA","2","final",NA,"150+",">=12 years","general pop","included","~45 weeks","outpatient clinic and emergency visits","symptomatic","symptomatic","other combinations",87,55.6,96.2,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"3201",385,"Klein","Test-negative case-control",3264,2023-04-07,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"14-59","5-11 years","5-11 years","included","~6 weeks","ED or UC visit","symptomatic","symptomatic","omicron",49,33,61,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"3202",385,"Klein","Test-negative case-control",3265,2023-04-07,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"150+","5-11 years","5-11 years","included","~31 weeks","ED or UC visit","symptomatic","symptomatic","omicron",41,29,51,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"3203",385,"Klein","Test-negative case-control",3266,2023-04-07,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"14-59","12-15 years","12-15 years","included","~6 weeks","ED or UC visit","symptomatic","symptomatic","omicron",64,44,77,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"3204",385,"Klein","Test-negative case-control",3267,2023-04-07,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"150+","12-15 years","12-15 years","included","~62 weeks","ED or UC visit","symptomatic","symptomatic","omicron",13,3,23,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"3205",385,"Klein","Test-negative case-control",3268,2023-04-07,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"60-149","16-17 years","16-17 years","included","~19 weeks","ED or UC visit","symptomatic","symptomatic","omicron",31,10,47,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"3206",385,"Klein","Test-negative case-control",3269,2023-04-07,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"150+","16-17 years","16-17 years","included","~72 weeks","ED or UC visit","symptomatic","symptomatic","omicron",7,-8,20,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"3207",385,"Klein","Test-negative case-control",3270,2023-04-07,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"14-59","12-15 years","12-15 years","included","~6 weeks","ED or UC visit","symptomatic","symptomatic","delta",93,89,95,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"3208",385,"Klein","Test-negative case-control",3271,2023-04-07,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"150+","12-15 years","12-15 years","included","~22 weeks","ED or UC visit","symptomatic","symptomatic","delta",77,69,84,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"3209",385,"Klein","Test-negative case-control",3272,2023-04-07,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"14-59","16-17 years","16-17 years","included","~ 6 weeks","ED or UC visit","symptomatic","symptomatic","delta",93,86,97,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"3210",385,"Klein","Test-negative case-control",3273,2023-04-07,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"150+","16-17 years","16-17 years","included","~32 weeks","ED or UC visit","symptomatic","symptomatic","delta",72,63,79,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"3211",385,"Klein","Test-negative case-control",3274,2023-04-07,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"14-59","12-15 years","12-15 years","included","~6 weeks","hospitalization","severe","severe","delta",98,21,100,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"3212",385,"Klein","Test-negative case-control",3275,2023-04-07,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"60-149","12-15 years","12-15 years","included","~19 weeks","hospitalization","severe","severe","delta",97,74,100,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"3213",385,"Klein","Test-negative case-control",3276,2023-04-07,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"60-149","16-17 years","16-17 years","included","~19 weeks","hospitalization","severe","severe","delta",99,90,100,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"3214",385,"Klein","Test-negative case-control",3277,2023-04-07,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"150+","16-17 years","16-17 years","included","~32 weeks","hospitalization","severe","severe","delta",98,73,100,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"3215",386,"Huang","Retrospective cohort",3278,2023-04-12,"Sinovac CoronaVac","Inactivated","2","final",NA,"8+",">=60 years",">=60 years","Partially excluded (excluded if prior infection prior to study start)","~66 weeks","severe disease","severe","severe","other combinations",65.5,50.9,75.7,"China","CHN","Asia","East Asia & Pacific",10310,2019,"China","Upper middle income",3,NA,NA,NA,NA,NA
"3216",386,"Huang","Retrospective cohort",3279,2023-04-12,"Sinovac CoronaVac","Inactivated","2","final",NA,"8+",">=60 years",">=60 years","Partially excluded (excluded if prior infection prior to study start)","~66 weeks","death","death","death","other combinations",80.4,55.8,91.3,"China","CHN","Asia","East Asia & Pacific",10310,2019,"China","Upper middle income",3,NA,NA,NA,NA,NA
"3217",386,"Huang","Retrospective cohort",3280,2023-04-12,"Beijing/Sinopharm BBIBP-CorV","Inactivated","2","final",NA,"8+",">=60 years",">=60 years","Partially excluded (excluded if prior infection prior to study start)","~66 weeks","severe disease","severe","severe","other combinations",76.4,61.8,85.4,"China","CHN","Asia","East Asia & Pacific",10310,2019,"China","Upper middle income",3,NA,NA,NA,NA,NA
"3218",386,"Huang","Retrospective cohort",3281,2023-04-12,"Beijing/Sinopharm BBIBP-CorV","Inactivated","2","final",NA,"8+",">=60 years",">=60 years","Partially excluded (excluded if prior infection prior to study start)","~66 weeks","death","death","death","other combinations",82.7,53.4,93.6,"China","CHN","Asia","East Asia & Pacific",10310,2019,"China","Upper middle income",3,NA,NA,NA,NA,NA
"3219",387,"Altarawneh","Test-negative case-control",3282,2023-07-27,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"14+","all ages","general pop","excluded","~8 weeks","symptomatic disease","symptomatic","symptomatic","alpha",90.5,83.9,94.4,"Qatar","QAT","Asia","Middle East & North Africa",65700,2019,"Qatar","High income",4,NA,NA,NA,NA,NA
"3220",387,"Altarawneh","Test-negative case-control",3283,2023-07-27,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"14+","all ages","general pop","excluded","~8 weeks","severe, critical or fatal disease","severe","severe","alpha",96.1,71.2,99.5,"Qatar","QAT","Asia","Middle East & North Africa",65700,2019,"Qatar","High income",4,NA,NA,NA,NA,NA
"3221",387,"Altarawneh","Test-negative case-control",3284,2023-07-27,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"14+","all ages","general pop","excluded","~17 weeks","symptomatic disease","symptomatic","symptomatic","beta",80.5,79,82,"Qatar","QAT","Asia","Middle East & North Africa",65700,2019,"Qatar","High income",4,NA,NA,NA,NA,NA
"3222",387,"Altarawneh","Test-negative case-control",3285,2023-07-27,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"14+","all ages","general pop","excluded","~17 weeks","severe, critical or fatal disease","severe","severe","beta",97.4,95.8,98.4,"Qatar","QAT","Asia","Middle East & North Africa",65700,2019,"Qatar","High income",4,NA,NA,NA,NA,NA
"3223",387,"Altarawneh","Test-negative case-control",3286,2023-07-27,"Moderna mRNA-1273","mRNA","2","final",NA,"14+","all ages","general pop","excluded","~17 weeks","symptomatic disease","symptomatic","symptomatic","beta",96,91.6,98.1,"Qatar","QAT","Asia","Middle East & North Africa",65700,2019,"Qatar","High income",4,NA,NA,NA,NA,NA
"3224",387,"Altarawneh","Test-negative case-control",3287,2023-07-27,"Moderna mRNA-1273","mRNA","2","final",NA,"14+","all ages","general pop","excluded","~17 weeks","severe, critical or fatal disease","severe","severe","beta",100,92.2,100,"Qatar","QAT","Asia","Middle East & North Africa",65700,2019,"Qatar","High income",4,NA,NA,NA,NA,NA
"3225",387,"Altarawneh","Test-negative case-control",3288,2023-07-27,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"14+","all ages","general pop","excluded","~48 weeks","symptomatic disease","symptomatic","symptomatic","delta",58.1,54.6,61.3,"Qatar","QAT","Asia","Middle East & North Africa",65700,2019,"Qatar","High income",4,NA,NA,NA,NA,NA
"3226",387,"Altarawneh","Test-negative case-control",3289,2023-07-27,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"14+","all ages","general pop","excluded","~48 weeks","severe, critical or fatal disease","severe","severe","delta",91.1,86.3,94.2,"Qatar","QAT","Asia","Middle East & North Africa",65700,2019,"Qatar","High income",4,14,336,"yes",NA,0
"3227",387,"Altarawneh","Test-negative case-control",3290,2023-07-27,"Moderna mRNA-1273","mRNA","2","final",NA,"14+","all ages","general pop","excluded","~48 weeks","symptomatic disease","symptomatic","symptomatic","delta",71,66.4,74.9,"Qatar","QAT","Asia","Middle East & North Africa",65700,2019,"Qatar","High income",4,NA,NA,NA,NA,NA
"3228",387,"Altarawneh","Test-negative case-control",3291,2023-07-27,"Moderna mRNA-1273","mRNA","2","final",NA,"14+","all ages","general pop","excluded","~48 weeks","severe, critical or fatal disease","severe","severe","delta",97.9,91.2,99.5,"Qatar","QAT","Asia","Middle East & North Africa",65700,2019,"Qatar","High income",4,14,336,"yes",NA,0
"3229",388,"Braeye","Retrospective cohort",3292,2023-04-05,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"7-57","close contacts of unvaccinated index cases, females 45-64 years","close contacts of unvaccinated index cases, females 45-64 years","excluded","~28.5 weeks","infection","infection","infection","omicron",3,1,5,"Belgium","BEL","Europe","Europe & Central Asia",48050,2019,"Belgium","High income",4,NA,NA,NA,NA,NA
"3230",388,"Braeye","Retrospective cohort",3293,2023-04-05,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"157-207","close contacts of unvaccinated index cases, females 45-64 years","close contacts of unvaccinated index cases, females 45-64 years","excluded","~28.5 weeks","infection","infection","infection","omicron",2,0,3,"Belgium","BEL","Europe","Europe & Central Asia",48050,2019,"Belgium","High income",4,NA,NA,NA,NA,NA
"3231",388,"Braeye","Retrospective cohort",3294,2023-04-05,"Moderna mRNA-1273","mRNA","2","final",NA,"14-64","close contacts of unvaccinated index cases, females 45-64 years","close contacts of unvaccinated index cases, females 45-64 years","excluded","~28.5 weeks","infection","infection","infection","omicron",4,1,7,"Belgium","BEL","Europe","Europe & Central Asia",48050,2019,"Belgium","High income",4,NA,NA,NA,NA,NA
"3232",388,"Braeye","Retrospective cohort",3295,2023-04-05,"Moderna mRNA-1273","mRNA","2","final",NA,"164-214","close contacts of unvaccinated index cases, females 45-64 years","close contacts of unvaccinated index cases, females 45-64 years","excluded","~28.5 weeks","infection","infection","infection","omicron",3,0,4,"Belgium","BEL","Europe","Europe & Central Asia",48050,2019,"Belgium","High income",4,NA,NA,NA,NA,NA
"3233",388,"Braeye","Retrospective cohort",3296,2023-04-05,"Oxford/AstraZeneca ChAdOx1-S","Vectored","2","final",NA,"14-64","close contacts of unvaccinated index cases, females 45-64 years","close contacts of unvaccinated index cases, females 45-64 years","excluded","~28.5 weeks","infection","infection","infection","omicron",2,0,4,"Belgium","BEL","Europe","Europe & Central Asia",48050,2019,"Belgium","High income",4,NA,NA,NA,NA,NA
"3234",388,"Braeye","Retrospective cohort",3297,2023-04-05,"Oxford/AstraZeneca ChAdOx1-S","Vectored","2","final",NA,"164-214","close contacts of unvaccinated index cases, females 45-64 years","close contacts of unvaccinated index cases, females 45-64 years","excluded","~28.5 weeks","infection","infection","infection","omicron",1,0,2,"Belgium","BEL","Europe","Europe & Central Asia",48050,2019,"Belgium","High income",4,NA,NA,NA,NA,NA
"3235",388,"Braeye","Retrospective cohort",3298,2023-04-05,"Janssen Ad26.COV2.S","Vectored","1","final",NA,"21-71","close contacts of unvaccinated index cases, females 45-64 years","close contacts of unvaccinated index cases, females 45-64 years","excluded","~28.5 weeks","infection","infection","infection","omicron",1,0,2,"Belgium","BEL","Europe","Europe & Central Asia",48050,2019,"Belgium","High income",4,NA,NA,NA,NA,NA
"3236",388,"Braeye","Retrospective cohort",3299,2023-04-05,"Janssen Ad26.COV2.S","Vectored","1","final",NA,"171-221","close contacts of unvaccinated index cases, females 45-64 years","close contacts of unvaccinated index cases, females 45-64 years","excluded","~28.5 weeks","infection","infection","infection","omicron",1,0,2,"Belgium","BEL","Europe","Europe & Central Asia",48050,2019,"Belgium","High income",4,NA,NA,NA,NA,NA
"3237",388,"Braeye","Retrospective cohort",3300,2023-04-05,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"7-57","close contacts of unvaccinated index cases, females 45-64 years","close contacts of unvaccinated index cases, females 45-64 years","excluded","~28.5 weeks","infection","infection","infection","delta",62,56,66,"Belgium","BEL","Europe","Europe & Central Asia",48050,2019,"Belgium","High income",4,NA,NA,NA,NA,NA
"3238",388,"Braeye","Retrospective cohort",3301,2023-04-05,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"157-207","close contacts of unvaccinated index cases, females 45-64 years","close contacts of unvaccinated index cases, females 45-64 years","excluded","~28.5 weeks","infection","infection","infection","delta",43,41,45,"Belgium","BEL","Europe","Europe & Central Asia",48050,2019,"Belgium","High income",4,NA,NA,NA,NA,NA
"3239",388,"Braeye","Retrospective cohort",3302,2023-04-05,"Moderna mRNA-1273","mRNA","2","final",NA,"14-64","close contacts of unvaccinated index cases, females 45-64 years","close contacts of unvaccinated index cases, females 45-64 years","excluded","~28.5 weeks","infection","infection","infection","delta",75,70,77,"Belgium","BEL","Europe","Europe & Central Asia",48050,2019,"Belgium","High income",4,NA,NA,NA,NA,NA
"3240",388,"Braeye","Retrospective cohort",3303,2023-04-05,"Moderna mRNA-1273","mRNA","2","final",NA,"164-214","close contacts of unvaccinated index cases, females 45-64 years","close contacts of unvaccinated index cases, females 45-64 years","excluded","~28.5 weeks","infection","infection","infection","delta",56,54,58,"Belgium","BEL","Europe","Europe & Central Asia",48050,2019,"Belgium","High income",4,NA,NA,NA,NA,NA
"3241",388,"Braeye","Retrospective cohort",3304,2023-04-05,"Oxford/AstraZeneca ChAdOx1-S","Vectored","2","final",NA,"14-64","close contacts of unvaccinated index cases, females 45-64 years","close contacts of unvaccinated index cases, females 45-64 years","excluded","~28.5 weeks","infection","infection","infection","delta",48,43,55,"Belgium","BEL","Europe","Europe & Central Asia",48050,2019,"Belgium","High income",4,NA,NA,NA,NA,NA
"3242",388,"Braeye","Retrospective cohort",3305,2023-04-05,"Oxford/AstraZeneca ChAdOx1-S","Vectored","2","final",NA,"164-214","close contacts of unvaccinated index cases, females 45-64 years","close contacts of unvaccinated index cases, females 45-64 years","excluded","~28.5 weeks","infection","infection","infection","delta",35,34,38,"Belgium","BEL","Europe","Europe & Central Asia",48050,2019,"Belgium","High income",4,NA,NA,NA,NA,NA
"3243",388,"Braeye","Retrospective cohort",3306,2023-04-05,"Janssen Ad26.COV2.S","Vectored","1","final",NA,"21-71","close contacts of unvaccinated index cases, females 45-64 years","close contacts of unvaccinated index cases, females 45-64 years","excluded","~28.5 weeks","infection","infection","infection","delta",28,26,31,"Belgium","BEL","Europe","Europe & Central Asia",48050,2019,"Belgium","High income",4,NA,NA,NA,NA,NA
"3244",388,"Braeye","Retrospective cohort",3307,2023-04-05,"Janssen Ad26.COV2.S","Vectored","1","final",NA,"171-221","close contacts of unvaccinated index cases, females 45-64 years","close contacts of unvaccinated index cases, females 45-64 years","excluded","~28.5 weeks","infection","infection","infection","delta",27,23,30,"Belgium","BEL","Europe","Europe & Central Asia",48050,2019,"Belgium","High income",4,NA,NA,NA,NA,NA
"3245",389,"DeCuir","Test-negative case-control",3308,2023-04-28,"Multiple or heterologous RNA","mRNA","2","final",NA,"7+",">=18 years","general pop","included","62 weeks","invasive mechanical ventilation or death","severe","severe","omicron",53,37,65,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"3246",389,"DeCuir","Test-negative case-control",3309,2023-04-28,"Multiple or heterologous RNA","mRNA","2","final",NA,"180+",">=18 years","general pop","included","62 weeks","invasive mechanical ventilation or death","severe","severe","omicron",50,32,64,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"3247",390,"Qassim","Test-negative case-control",3310,2023-07-19,"Multiple or heterologous RNA","mRNA","2","final",NA,"14+ (median 459)","all ages","general pop","included","~87 weeks","infection, September 2022","infection","infection","omicron",-5.8,-11.1,-0.3,"Qatar","QAT","Asia","Middle East & North Africa",65700,2019,"Qatar","High income",4,NA,NA,NA,NA,NA
"3248",390,"Qassim","Test-negative case-control",3311,2023-07-19,"Multiple or heterologous RNA","mRNA","2","final",NA,"14+ (median 541)","all ages","general pop","included","~96 weeks","infection, November 2022","infection","infection","omicron",-2.1,-10.5,6.7,"Qatar","QAT","Asia","Middle East & North Africa",65700,2019,"Qatar","High income",4,NA,NA,NA,NA,NA
"3249",390,"Qassim","Test-negative case-control",3312,2023-07-19,"Multiple or heterologous RNA","mRNA","2","final",NA,"14+ (median 453)","all ages","general pop","included","~96 weeks","severe critical, or fatal disease, August-November 2022","severe","severe","omicron",53.1,-41.3,87.1,"Qatar","QAT","Asia","Middle East & North Africa",65700,2019,"Qatar","High income",4,NA,NA,NA,NA,NA
"3250",390,"Qassim","Test-negative case-control",3313,2023-07-19,"Multiple or heterologous RNA","mRNA","2","final",NA,"14+ (median 389)","all ages","general pop","included","~74 weeks","infection, June 2022","infection","infection","omicron",-20.7,-26.7,-14.2,"Qatar","QAT","Asia","Middle East & North Africa",65700,2019,"Qatar","High income",4,NA,NA,NA,NA,NA
"3251",390,"Qassim","Test-negative case-control",3314,2023-07-19,"Multiple or heterologous RNA","mRNA","2","final",NA,"14+ (median 432)","all ages","general pop","included","~83 weeks","infection, August 2022","infection","infection","omicron",-1.1,-7.1,5.1,"Qatar","QAT","Asia","Middle East & North Africa",65700,2019,"Qatar","High income",4,NA,NA,NA,NA,NA
"3252",390,"Qassim","Test-negative case-control",3315,2023-07-19,"Multiple or heterologous RNA","mRNA","2","final",NA,"14+ (median 425)","all ages","general pop","included","~78.5 weeks","severe critical, or fatal disease, May-July 2022","severe","severe","omicron",83.8,14.1,96.9,"Qatar","QAT","Asia","Middle East & North Africa",65700,2019,"Qatar","High income",4,NA,NA,NA,NA,NA
"3253",390,"Qassim","Test-negative case-control",3316,2023-07-19,"Multiple or heterologous RNA","mRNA","2","final",NA,"14+ (median 228)","all ages","general pop","included","~48 weeks","infection, December 2021","infection","infection","omicron",-3.9,-7.8,0,"Qatar","QAT","Asia","Middle East & North Africa",65700,2019,"Qatar","High income",4,NA,NA,NA,NA,NA
"3254",390,"Qassim","Test-negative case-control",3317,2023-07-19,"Multiple or heterologous RNA","mRNA","2","final",NA,"14+ (median 364)","all ages","general pop","included","~70 weeks","infection, May 2022","infection","infection","omicron",-1.6,-14.7,11.9,"Qatar","QAT","Asia","Middle East & North Africa",65700,2019,"Qatar","High income",4,NA,NA,NA,NA,NA
"3255",390,"Qassim","Test-negative case-control",3318,2023-07-19,"Multiple or heterologous RNA","mRNA","2","final",NA,"14+ (median 254)","all ages","general pop","included","~65 weeks","severe critical, or fatal disease, February-April 2022","severe","severe","omicron",81.4,48.5,93.3,"Qatar","QAT","Asia","Middle East & North Africa",65700,2019,"Qatar","High income",4,NA,NA,NA,NA,NA
"3256",390,"Qassim","Test-negative case-control",3319,2023-07-19,"Multiple or heterologous RNA","mRNA","2","final",NA,"14+ (median 64)","all ages","general pop","included","~22 weeks","infection, June 2021","infection","infection","delta",80.7,77.2,83.7,"Qatar","QAT","Asia","Middle East & North Africa",65700,2019,"Qatar","High income",4,NA,NA,NA,NA,NA
"3257",390,"Qassim","Test-negative case-control",3320,2023-07-19,"Multiple or heterologous RNA","mRNA","2","final",NA,"14+ (median 209)","all ages","general pop","included","~44 weeks","infection, November 2021","infection","infection","delta",52.7,46.5,58.2,"Qatar","QAT","Asia","Middle East & North Africa",65700,2019,"Qatar","High income",4,NA,NA,NA,NA,NA
"3258",390,"Qassim","Test-negative case-control",3321,2023-07-19,"Multiple or heterologous RNA","mRNA","2","final",NA,"14+ (median 189)","all ages","general pop","included","~39.5 weeks","severe critical, or fatal disease, August-October 2021","severe","severe","delta",91.4,86.6,94.5,"Qatar","QAT","Asia","Middle East & North Africa",65700,2019,"Qatar","High income",4,NA,NA,NA,NA,NA
"3259",390,"Qassim","Test-negative case-control",3322,2023-07-19,"Multiple or heterologous RNA","mRNA","2","final",NA,"14+ (median 34)","all ages","general pop","included","~9 weeks","infection, March 2021","infection","infection","beta",81.8,79.8,83.6,"Qatar","QAT","Asia","Middle East & North Africa",65700,2019,"Qatar","High income",4,NA,NA,NA,NA,NA
"3260",390,"Qassim","Test-negative case-control",3323,2023-07-19,"Multiple or heterologous RNA","mRNA","2","final",NA,"14+ (median 48)","all ages","general pop","included","~17.5 weeks","infection, May 2021","infection","infection","beta",80.9,78.4,83.1,"Qatar","QAT","Asia","Middle East & North Africa",65700,2019,"Qatar","High income",4,NA,NA,NA,NA,NA
"3261",390,"Qassim","Test-negative case-control",3324,2023-07-19,"Multiple or heterologous RNA","mRNA","2","final",NA,"14+ (median 50)","all ages","general pop","included","~13 weeks","severe critical, or fatal disease, February-April 2021","severe","severe","other combinations",95.4,93.6,96.7,"Qatar","QAT","Asia","Middle East & North Africa",65700,2019,"Qatar","High income",4,NA,NA,NA,NA,NA
"3262",390,"Qassim","Test-negative case-control",3325,2023-07-19,"Multiple or heterologous RNA","mRNA","2","final",NA,"14+ (median 24)","all ages","general pop","included","~4.5 weeks","infection, February 2021","infection","infection","alpha",84.5,77.8,89.2,"Qatar","QAT","Asia","Middle East & North Africa",65700,2019,"Qatar","High income",4,NA,NA,NA,NA,NA
"3263",391,"Huang","Case-control",3326,2023-05-01,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"14-180",">=18 years with substance abuse disorders",">=18 years with substance abuse disorders","excluded","~24 weeks","infection","infection","infection","omicron",20.7,14,27,"Hong Kong","HKG","Asia","East Asia & Pacific",50480,2019,"Hong Kong SAR, China","High income",4,NA,NA,NA,NA,NA
"3264",391,"Huang","Case-control",3327,2023-05-01,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"14+",">=18 years with substance abuse disorders",">=18 years with substance abuse disorders","excluded","~60.5 weeks","hospitalization","severe","severe","omicron",73.3,64.3,80,"Hong Kong","HKG","Asia","East Asia & Pacific",50480,2019,"Hong Kong SAR, China","High income",4,NA,NA,NA,NA,NA
"3265",391,"Huang","Case-control",3328,2023-05-01,"Sinovac CoronaVac","Inactivated","2","final",NA,"14-180",">=18 years with substance abuse disorders",">=18 years with substance abuse disorders","excluded","~24 weeks","infection","infection","infection","omicron",6.1,-0.5,12.3,"Hong Kong","HKG","Asia","East Asia & Pacific",50480,2019,"Hong Kong SAR, China","High income",4,NA,NA,NA,NA,NA
"3266",391,"Huang","Case-control",3329,2023-05-01,"Sinovac CoronaVac","Inactivated","2","final",NA,"14+",">=18 years with substance abuse disorders",">=18 years with substance abuse disorders","excluded","~59.5 weeks","hospitalization","severe","severe","omicron",59.9,50.2,67.7,"Hong Kong","HKG","Asia","East Asia & Pacific",50480,2019,"Hong Kong SAR, China","High income",4,NA,NA,NA,NA,NA
"3267",392,"Yan","Case-control",3330,2023-05-03,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"14-30",">=18 years","general pop","excluded","~32 weeks","hospitalization","severe","severe","omicron",73,69.2,76.3,"Hong Kong","HKG","Asia","East Asia & Pacific",50480,2019,"Hong Kong SAR, China","High income",4,14,30,"yes",NA,0
"3268",392,"Yan","Case-control",3331,2023-05-03,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"211-240",">=18 years","general pop","excluded","~32 weeks","hospitalization","severe","severe","omicron",46.6,40.7,51.8,"Hong Kong","HKG","Asia","East Asia & Pacific",50480,2019,"Hong Kong SAR, China","High income",4,211,224,"no","sequential period",0
"3269",392,"Yan","Case-control",3332,2023-05-03,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"14-30",">=18 years","general pop","excluded","~32 weeks","severe disease","severe","severe","omicron",69.7,50,81.6,"Hong Kong","HKG","Asia","East Asia & Pacific",50480,2019,"Hong Kong SAR, China","High income",4,14,30,"no","duplicated endpoint (use hospitalisation)",0
"3270",392,"Yan","Case-control",3333,2023-05-03,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"211-240",">=18 years","general pop","excluded","~32 weeks","severe disease","severe","severe","omicron",71.8,47.2,84.9,"Hong Kong","HKG","Asia","East Asia & Pacific",50480,2019,"Hong Kong SAR, China","High income",4,211,224,"no","duplicated endpoint (use hospitalisation)",0
"3271",392,"Yan","Case-control",3334,2023-05-03,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"14-30",">=18 years","general pop","excluded","~32 weeks","death","death","death","omicron",89.8,83.7,93.6,"Hong Kong","HKG","Asia","East Asia & Pacific",50480,2019,"Hong Kong SAR, China","High income",4,NA,NA,NA,NA,NA
"3272",392,"Yan","Case-control",3335,2023-05-03,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"211-240",">=18 years","general pop","excluded","~32 weeks","death","death","death","omicron",73.8,55.9,84.4,"Hong Kong","HKG","Asia","East Asia & Pacific",50480,2019,"Hong Kong SAR, China","High income",4,NA,NA,NA,NA,NA
"3273",392,"Yan","Case-control",3336,2023-05-03,"Sinovac CoronaVac","Inactivated","2","final",NA,"14-30",">=18 years","general pop","excluded","~32 weeks","hospitalization","severe","severe","omicron",66,63.5,68.3,"Hong Kong","HKG","Asia","East Asia & Pacific",50480,2019,"Hong Kong SAR, China","High income",4,NA,NA,NA,NA,NA
"3274",392,"Yan","Case-control",3337,2023-05-03,"Sinovac CoronaVac","Inactivated","2","final",NA,"211-240",">=18 years","general pop","excluded","~32 weeks","hospitalization","severe","severe","omicron",36.2,28,43.4,"Hong Kong","HKG","Asia","East Asia & Pacific",50480,2019,"Hong Kong SAR, China","High income",4,NA,NA,NA,NA,NA
"3275",392,"Yan","Case-control",3338,2023-05-03,"Sinovac CoronaVac","Inactivated","2","final",NA,"14-30",">=18 years","general pop","excluded","~32 weeks","severe disease","severe","severe","omicron",54.5,40.6,65.1,"Hong Kong","HKG","Asia","East Asia & Pacific",50480,2019,"Hong Kong SAR, China","High income",4,NA,NA,NA,NA,NA
"3276",392,"Yan","Case-control",3339,2023-05-03,"Sinovac CoronaVac","Inactivated","2","final",NA,"211-240",">=18 years","general pop","excluded","~32 weeks","severe disease","severe","severe","omicron",67.1,34,83.6,"Hong Kong","HKG","Asia","East Asia & Pacific",50480,2019,"Hong Kong SAR, China","High income",4,NA,NA,NA,NA,NA
"3277",392,"Yan","Case-control",3340,2023-05-03,"Sinovac CoronaVac","Inactivated","2","final",NA,"14-30",">=18 years","general pop","excluded","~32 weeks","death","death","death","omicron",81.1,77.4,84.2,"Hong Kong","HKG","Asia","East Asia & Pacific",50480,2019,"Hong Kong SAR, China","High income",4,NA,NA,NA,NA,NA
"3278",392,"Yan","Case-control",3341,2023-05-03,"Sinovac CoronaVac","Inactivated","2","final",NA,"211-240",">=18 years","general pop","excluded","~32 weeks","death","death","death","omicron",76.6,60.8,86,"Hong Kong","HKG","Asia","East Asia & Pacific",50480,2019,"Hong Kong SAR, China","High income",4,NA,NA,NA,NA,NA
"3279",393,"Finci","Test-negative case-control",3342,2023-10-12,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"14+","HCW >=20 years","HCW","included","~65 weeks","infection","infection","infection","omicron",17,-38,50,"Albania","ALB","Europe","Europe & Central Asia",5280,2019,"Albania","Upper middle income",2,NA,NA,NA,NA,NA
"3280",393,"Finci","Test-negative case-control",3343,2023-10-12,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"14+","HCW >=20 years","HCW","included","~65 weeks","symptomatic disease (PCR only)","symptomatic","symptomatic","omicron",26,-53,64,"Albania","ALB","Europe","Europe & Central Asia",5280,2019,"Albania","Upper middle income",2,NA,NA,NA,NA,NA
"3281",393,"Finci","Test-negative case-control",3344,2023-10-12,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"14+","HCW >=20 years","HCW","included","~65 weeks","symptomatic disease (PCR or RAT)","symptomatic","symptomatic","omicron",33,-32,66,"Albania","ALB","Europe","Europe & Central Asia",5280,2019,"Albania","Upper middle income",2,NA,NA,NA,NA,NA
"3282",394,"Surie","Test-negative case-control",3345,2023-06-29,"Multiple or heterologous RNA","mRNA","2","final",NA,"14+",">=18 years","general pop","included","~82 weeks","hospitalization","severe","severe","omicron",20,3,34,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"3283",394,"Surie","Test-negative case-control",3346,2023-06-29,"Multiple or heterologous RNA","mRNA","2","final",NA,"14+",">=18 years","general pop","included","~82 weeks","hospitalization","severe","severe","omicron",32,16,45,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"3284",395,"Langlete","Retrospective cohort",3347,2023-05-10,"Multiple or heterologous RNA","mRNA","2","final",NA,"7-112","HCW 18-66 years","HCW","included","~43 weeks","infection","infection","infection","delta",73.3,70.6,75.8,"Norway","NOR","Europe","Europe & Central Asia",82430,2019,"Norway","High income",4,NA,NA,NA,NA,NA
"3285",395,"Langlete","Retrospective cohort",3348,2023-05-10,"Multiple or heterologous RNA","mRNA","2","final",NA,"225-336","HCW 18-66 years","HCW","included","~43 weeks","infection","infection","infection","delta",8.9,-2.1,18.7,"Norway","NOR","Europe","Europe & Central Asia",82430,2019,"Norway","High income",4,NA,NA,NA,NA,NA
"3286",395,"Langlete","Retrospective cohort",3349,2023-05-10,"Multiple or heterologous RNA","mRNA","2","final",NA,"7-112","18-66 years","18-66 years","included","~43 weeks","infection","infection","infection","delta",68.7,67.7,69.7,"Norway","NOR","Europe","Europe & Central Asia",82430,2019,"Norway","High income",4,NA,NA,NA,NA,NA
"3287",395,"Langlete","Retrospective cohort",3350,2023-05-10,"Multiple or heterologous RNA","mRNA","2","final",NA,"225-336","18-66 years","18-66 years","included","~43 weeks","infection","infection","infection","delta",10.6,-15.4,30.8,"Norway","NOR","Europe","Europe & Central Asia",82430,2019,"Norway","High income",4,NA,NA,NA,NA,NA
"3288",395,"Langlete","Retrospective cohort",3351,2023-05-10,"Multiple or heterologous RNA","mRNA","2","final",NA,"7-112","HCW 18-66 years","HCW","included","~54 weeks","infection","infection","infection","omicron",16.7,10.5,22.4,"Norway","NOR","Europe","Europe & Central Asia",82430,2019,"Norway","High income",4,NA,NA,NA,NA,NA
"3289",395,"Langlete","Retrospective cohort",3352,2023-05-10,"Multiple or heterologous RNA","mRNA","2","final",NA,"225-336","HCW 18-66 years","HCW","included","~54 weeks","infection","infection","infection","omicron",9.7,2.3,16.6,"Norway","NOR","Europe","Europe & Central Asia",82430,2019,"Norway","High income",4,NA,NA,NA,NA,NA
"3290",395,"Langlete","Retrospective cohort",3353,2023-05-10,"Multiple or heterologous RNA","mRNA","2","final",NA,"7-112","18-66 years","18-66 years","included","~54 weeks","infection","infection","infection","omicron",-32.6,-35.6,-29.7,"Norway","NOR","Europe","Europe & Central Asia",82430,2019,"Norway","High income",4,NA,NA,NA,NA,NA
"3291",395,"Langlete","Retrospective cohort",3354,2023-05-10,"Multiple or heterologous RNA","mRNA","2","final",NA,"225-336","18-66 years","18-66 years","included","~54 weeks","infection","infection","infection","omicron",-29.8,-37.9,-22.2,"Norway","NOR","Europe","Europe & Central Asia",82430,2019,"Norway","High income",4,NA,NA,NA,NA,NA
"3292",396,"Park","Retrospective cohort",3355,2023-05-15,"Multiple or heterologous RNA","mRNA","2","final",NA,"14+",">=60 years",">=60 years","included","~80 weeks","death","death","death","omicron",72,70,74,"South Korea","KOR","Asia","East Asia & Pacific",33830,2019,"Korea, Rep.","High income",4,NA,NA,NA,NA,NA
"3293",396,"Park","Retrospective cohort",3356,2023-05-15,"Oxford/AstraZeneca ChAdOx1-S","Vectored","2","final",NA,"14+",">=60 years",">=60 years","included","~80 weeks","death","death","death","omicron",65,62,68,"South Korea","KOR","Asia","East Asia & Pacific",33830,2019,"Korea, Rep.","High income",4,NA,NA,NA,NA,NA
"3294",396,"Park","Retrospective cohort",3357,2023-05-15,"Heterologous platforms","Multiple","2","final",NA,"14+",">=60 years",">=60 years","included","~80 weeks","death","death","death","omicron",55,44,60,"South Korea","KOR","Asia","East Asia & Pacific",33830,2019,"Korea, Rep.","High income",4,NA,NA,NA,NA,NA
"3295",396,"Park","Retrospective cohort",3358,2023-05-15,"Multiple or heterologous RNA","mRNA","2","final",NA,"14+",">=60 years",">=60 years","included","~80 weeks","critical infection","severe","severe","omicron",68,67,69,"South Korea","KOR","Asia","East Asia & Pacific",33830,2019,"Korea, Rep.","High income",4,NA,NA,NA,NA,NA
"3296",396,"Park","Retrospective cohort",3359,2023-05-15,"Oxford/AstraZeneca ChAdOx1-S","Vectored","2","final",NA,"14+",">=60 years",">=60 years","included","~80 weeks","critical infection","severe","severe","omicron",72,70,74,"South Korea","KOR","Asia","East Asia & Pacific",33830,2019,"Korea, Rep.","High income",4,14,560,"yes",NA,1
"3297",396,"Park","Retrospective cohort",3360,2023-05-15,"Heterologous platforms","Multiple","2","final",NA,"14+",">=60 years",">=60 years","included","~80 weeks","critical infection","severe","severe","omicron",61,55,67,"South Korea","KOR","Asia","East Asia & Pacific",33830,2019,"Korea, Rep.","High income",4,NA,NA,NA,NA,NA
"3298",397,"Yung","Retrospective cohort",3361,2023-05-15,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"14+","5-11 years","5-11 years","previously infected only","~34 weeks","infection","infection","infection","omicron",74,67.7,79.1,"Singapore","SGP","Asia","East Asia & Pacific",58810,2019,"Singapore","High income",4,NA,NA,NA,NA,NA
"3299",397,"Yung","Retrospective cohort",3362,2023-05-15,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"14-119","5-11 years","5-11 years","previously infected only","~34 weeks","infection","infection","infection","omicron",67.9,58.5,75.2,"Singapore","SGP","Asia","East Asia & Pacific",58810,2019,"Singapore","High income",4,NA,NA,NA,NA,NA
"3300",397,"Yung","Retrospective cohort",3363,2023-05-15,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"180+","5-11 years","5-11 years","previously infected only","~34 weeks","infection","infection","infection","omicron",78.7,70.4,84.7,"Singapore","SGP","Asia","East Asia & Pacific",58810,2019,"Singapore","High income",4,NA,NA,NA,NA,NA
"3301",397,"Yung","Retrospective cohort",3364,2023-05-15,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"14+","12-17 years","12-17 years","previously infected only","~68 weeks","infection","infection","infection","omicron",84.9,77,90.1,"Singapore","SGP","Asia","East Asia & Pacific",58810,2019,"Singapore","High income",4,NA,NA,NA,NA,NA
"3302",397,"Yung","Retrospective cohort",3365,2023-05-15,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"14+","5-11 years","5-11 years","previously infected only","~47 weeks","infection","infection","infection","omicron",62.8,42.3,76,"Singapore","SGP","Asia","East Asia & Pacific",58810,2019,"Singapore","High income",4,NA,NA,NA,NA,NA
"3303",397,"Yung","Retrospective cohort",3366,2023-05-15,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"14+","12-17 years","12-17 years","previously infected only","~82 weeks","infection","infection","infection","omicron",57.9,33.6,73.3,"Singapore","SGP","Asia","East Asia & Pacific",58810,2019,"Singapore","High income",4,NA,NA,NA,NA,NA
"3304",398,"Ng","Test-negative case-control",3367,2023-05-26,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"<180","3-105 years","general pop","excluded","~63 weeks","infection","infection","infection","omicron",27,4.2,44.5,"Hong Kong","HKG","Asia","East Asia & Pacific",50480,2019,"Hong Kong SAR, China","High income",4,NA,NA,NA,NA,NA
"3305",398,"Ng","Test-negative case-control",3368,2023-05-26,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"180+","3-105 years","general pop","excluded","~63 weeks","infection","infection","infection","omicron",20.9,-4.3,39.9,"Hong Kong","HKG","Asia","East Asia & Pacific",50480,2019,"Hong Kong SAR, China","High income",4,NA,NA,NA,NA,NA
"3306",398,"Ng","Test-negative case-control",3369,2023-05-26,"Sinovac CoronaVac","Inactivated","2","final",NA,"<180","3-105 years","general pop","excluded","~63 weeks","infection","infection","infection","omicron",22.9,1.3,39.7,"Hong Kong","HKG","Asia","East Asia & Pacific",50480,2019,"Hong Kong SAR, China","High income",4,NA,NA,NA,NA,NA
"3307",398,"Ng","Test-negative case-control",3370,2023-05-26,"Sinovac CoronaVac","Inactivated","2","final",NA,"180+","3-105 years","general pop","excluded","~63 weeks","infection","infection","infection","omicron",16.8,-15.4,39.9,"Hong Kong","HKG","Asia","East Asia & Pacific",50480,2019,"Hong Kong SAR, China","High income",4,NA,NA,NA,NA,NA
"3308",399,"Monteiro","Target trial emulation",3371,2023-08-10,"Sinovac CoronaVac","Inactivated","2","final",NA,"14+",">=60 years",">=60 years","excluded","~30 weeks","hospitalization","severe","severe","gamma",55.8,42.7,68.3,"Brazil","BRA","South America","Latin America & Caribbean",9410,2019,"Brazil","Upper middle income",3,NA,NA,NA,NA,NA
"3309",399,"Monteiro","Target trial emulation",3372,2023-08-10,"Sinovac CoronaVac","Inactivated","2","final",NA,"14+",">=60 years",">=60 years","excluded","~30 weeks","ICU admission","severe","severe","gamma",68.4,425.3,86.4,"Brazil","BRA","South America","Latin America & Caribbean",9410,2019,"Brazil","Upper middle income",3,NA,NA,NA,NA,NA
"3310",399,"Monteiro","Target trial emulation",3373,2023-08-10,"Sinovac CoronaVac","Inactivated","2","final",NA,"14+",">=60 years",">=60 years","excluded","~30 weeks","death","death","death","gamma",82.3,66.3,93.9,"Brazil","BRA","South America","Latin America & Caribbean",9410,2019,"Brazil","Upper middle income",3,NA,NA,NA,NA,NA
"3311",401,"Bozio","Retrospective cohort",3374,2023-02-18,"Multiple or heterologous RNA","mRNA","2","final",NA,"14+",">=18 years","general pop","excluded","~73 weeks","ED or UC visit","symptomatic","symptomatic","omicron",18,14,22,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"3312",401,"Bozio","Retrospective cohort",3375,2023-02-18,"Multiple or heterologous RNA","mRNA","2","final",NA,"14-149",">=18 years","general pop","excluded","~73 weeks","ED or UC visit","symptomatic","symptomatic","omicron",21,12,28,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"3313",401,"Bozio","Retrospective cohort",3376,2023-02-18,"Multiple or heterologous RNA","mRNA","2","final",NA,"150+",">=18 years","general pop","excluded","~73 weeks","ED or UC visit","symptomatic","symptomatic","omicron",18,14,22,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"3314",401,"Bozio","Retrospective cohort",3377,2023-02-18,"Multiple or heterologous RNA","mRNA","2","final",NA,"14+",">=18 years","general pop","excluded","~73 weeks","hospitalization","severe","severe","omicron",39,33,44,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"3315",401,"Bozio","Retrospective cohort",3378,2023-02-18,"Multiple or heterologous RNA","mRNA","2","final",NA,"14-149",">=18 years","general pop","excluded","~73 weeks","hospitalization","severe","severe","omicron",39,24,51,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"3316",401,"Bozio","Retrospective cohort",3379,2023-02-18,"Multiple or heterologous RNA","mRNA","2","final",NA,"150+",">=18 years","general pop","excluded","~73 weeks","hospitalization","severe","severe","omicron",39,33,44,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"3317",401,"Bozio","Retrospective cohort",3380,2023-02-18,"Multiple or heterologous RNA","mRNA","2","final",NA,"14+",">=18 years","general pop","excluded","~49 weeks","ED or UC visit","symptomatic","symptomatic","delta",72,70,74,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"3318",401,"Bozio","Retrospective cohort",3381,2023-02-18,"Multiple or heterologous RNA","mRNA","2","final",NA,"14-149",">=18 years","general pop","excluded","~49 weeks","ED or UC visit","symptomatic","symptomatic","delta",82,79,84,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"3319",401,"Bozio","Retrospective cohort",3382,2023-02-18,"Multiple or heterologous RNA","mRNA","2","final",NA,"150+",">=18 years","general pop","excluded","~49 weeks","ED or UC visit","symptomatic","symptomatic","delta",68,65,70,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"3320",401,"Bozio","Retrospective cohort",3383,2023-02-18,"Multiple or heterologous RNA","mRNA","2","final",NA,"14+",">=18 years","general pop","excluded","~49 weeks","hospitalization","severe","severe","delta",73,70,75,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"3321",401,"Bozio","Retrospective cohort",3384,2023-02-18,"Multiple or heterologous RNA","mRNA","2","final",NA,"14-149",">=18 years","general pop","excluded","~49 weeks","hospitalization","severe","severe","delta",85,81,88,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"3322",401,"Bozio","Retrospective cohort",3385,2023-02-18,"Multiple or heterologous RNA","mRNA","2","final",NA,"150+",">=18 years","general pop","excluded","~49 weeks","hospitalization","severe","severe","delta",69,65,72,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"3323",403,"Wu","Target trial emulation",3421,2024-01-09,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"14+","5-11 years","5-11 years","excluded","~48 weeks","infection","infection","infection","omicron",74.3,72.2,76.2,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"3324",403,"Wu","Target trial emulation",3422,2024-01-09,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"14+","5-11 years","5-11 years","excluded","~48 weeks","mild disease","symptomatic","symptomatic","omicron",73.5,69.2,77.1,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"3325",403,"Wu","Target trial emulation",3423,2024-01-09,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"14+","5-11 years","5-11 years","excluded","~48 weeks","moderate or severe disease","symptomatic","symptomatic","omicron",75.5,69,81,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"3326",403,"Wu","Target trial emulation",3424,2024-01-09,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"14+","5-11 years","5-11 years","excluded","~48 weeks","ICU admission","severe","severe","omicron",84.9,64.8,93.5,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"3327",403,"Wu","Target trial emulation",3425,2024-01-09,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"14+","12-20 years","12-20 years","excluded","~52 weeks","infection","infection","infection","omicron",85.5,83.8,87.1,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"3328",403,"Wu","Target trial emulation",3426,2024-01-09,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"14+","12-20 years","12-20 years","excluded","~52 weeks","mild disease","symptomatic","symptomatic","omicron",87,83.5,89.8,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"3329",403,"Wu","Target trial emulation",3427,2024-01-09,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"14+","12-20 years","12-20 years","excluded","~52 weeks","moderate or severe disease","symptomatic","symptomatic","omicron",84.8,77.3,89.9,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"3330",403,"Wu","Target trial emulation",3428,2024-01-09,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"14+","12-20 years","12-20 years","excluded","~52 weeks","ICU admission","severe","severe","omicron",91.5,69.5,97.6,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"3331",403,"Wu","Target trial emulation",3429,2024-01-09,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"14+","12-20 years","12-20 years","excluded","~22 weeks","infection","infection","infection","delta",98.4,98.1,98.7,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"3332",403,"Wu","Target trial emulation",3430,2024-01-09,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"14+","12-20 years","12-20 years","excluded","~22 weeks","mild disease","symptomatic","symptomatic","delta",99,98.5,99.3,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"3333",403,"Wu","Target trial emulation",3431,2024-01-09,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"14+","12-20 years","12-20 years","excluded","~22 weeks","moderate or severe disease","symptomatic","symptomatic","delta",98.7,97.4,99.3,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"3334",403,"Wu","Target trial emulation",3432,2024-01-09,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"14+","12-20 years","12-20 years","excluded","~22 weeks","ICU admission","severe","severe","delta",99,92.5,99.9,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"3335",404,"Spicer","Retrospective cohort",3433,2023-05-12,"Multiple or heterologous RNA","mRNA","2","final",NA,"14-90","12-17 years","12-17 years","excluded","~35 weeks","infection","infection","infection","omicron",31.5,24.6,37.7,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"3336",404,"Spicer","Retrospective cohort",3434,2023-05-12,"Multiple or heterologous RNA","mRNA","2","final",NA,"151+","12-17 years","12-17 years","excluded","~35 weeks","infection","infection","infection","omicron",1.3,-2.4,4.9,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"3337",405,"Lowthian","Retrospective cohort",3435,2023-06-22,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"0+","4-11 years","4-11 years","included","~13 weeks","infection","infection","infection","omicron",87,83,90,"UK","GBR","Europe","Europe & Central Asia",43240,2019,"United Kingdom","High income",4,NA,NA,NA,NA,NA
"3338",405,"Lowthian","Retrospective cohort",3436,2023-06-22,"Multiple or heterologous RNA","mRNA","2","final",NA,"0+","11-16 years","11-16 years","included","~35 weeks","infection","infection","infection","delta/omicron",64,62,65,"UK","GBR","Europe","Europe & Central Asia",43240,2019,"United Kingdom","High income",4,NA,NA,NA,NA,NA
"3339",406,"Aglipay","Test-negative case-control",3437,2023-06-28,"Moderna mRNA-1273","mRNA","2","final",NA,"7+","6m-5 years","6m-5 years","included","~12 weeks","symptomatic disease","symptomatic","symptomatic","omicron",90,53,99,"Canada","CAN","North America","North America",46580,2019,"Canada","High income",4,NA,NA,NA,NA,NA
"3340",406,"Aglipay","Test-negative case-control",3438,2023-06-28,"Moderna mRNA-1273","mRNA","2","final",NA,"7+","6m-5 years","6m-5 years","included","~12 weeks","hospitalization","severe","severe","omicron",82,4,99,"Canada","CAN","North America","North America",46580,2019,"Canada","High income",4,NA,NA,NA,NA,NA
"3341",408,"Cegolon","Retrospective cohort",3447,2023-07-14,"Multiple or heterologous RNA","mRNA","2","final",NA,"8+","HCW","HCW","previously infected only","~104 weeks","infection","infection","infection","omicron",51,37,62,"Italy","ITA","Europe","Europe & Central Asia",34890,2019,"Italy","High income",4,NA,NA,NA,NA,NA
"3342",409,"Tamada","Test-negative case-control",3448,2023-07-22,"Multiple or heterologous RNA","mRNA","2","final",NA,"14-34",">=20 years","general pop","excluded","~27 weeks","infection","infection","infection","delta",89.1,80.5,93.9,"Japan","JPN","Asia","East Asia & Pacific",41970,2019,"Japan","High income",4,NA,NA,NA,NA,NA
"3343",409,"Tamada","Test-negative case-control",3449,2023-07-22,"Multiple or heterologous RNA","mRNA","2","final",NA,"56+",">=20 years","general pop","excluded","~27 weeks","infection","infection","infection","delta",73.1,59.7,82,"Japan","JPN","Asia","East Asia & Pacific",41970,2019,"Japan","High income",4,NA,NA,NA,NA,NA
"3344",409,"Tamada","Test-negative case-control",3450,2023-07-22,"Multiple or heterologous RNA","mRNA","2","final",NA,"14+",">=20 years","general pop","excluded","~27 weeks","hospitalization","severe","severe","delta",81.8,58.2,92.1,"Japan","JPN","Asia","East Asia & Pacific",41970,2019,"Japan","High income",4,NA,NA,NA,NA,NA
"3345",409,"Tamada","Test-negative case-control",3451,2023-07-22,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"14+",">=20 years","general pop","excluded","~27 weeks","infection","infection","infection","delta",78.2,70.5,83.8,"Japan","JPN","Asia","East Asia & Pacific",41970,2019,"Japan","High income",4,NA,NA,NA,NA,NA
"3346",410,"Liu","Retrospective cohort",3452,2023-07-29,"Comparative","mRNA","2","final",NA,"14-63",">=18 years","general pop","excluded","~7 weeks","infection","infection","infection","omicron",-3,-30,18,"Australia","AUS","Oceania","East Asia & Pacific",54890,2019,"Australia","High income",4,NA,NA,NA,NA,NA
"3347",410,"Liu","Retrospective cohort",3453,2023-07-29,"Comparative","Multiple","2","final",NA,"14-63",">=18 years","general pop","excluded","~7 weeks","infection","infection","infection","omicron",-19,-49,5,"Australia","AUS","Oceania","East Asia & Pacific",54890,2019,"Australia","High income",4,NA,NA,NA,NA,NA
"3348",410,"Liu","Retrospective cohort",3454,2023-07-29,"Comparative","Multiple","2","final",NA,"14-63",">=18 years","general pop","excluded","~7 weeks","infection","infection","infection","omicron",-70,-97,-46,"Australia","AUS","Oceania","East Asia & Pacific",54890,2019,"Australia","High income",4,NA,NA,NA,NA,NA
"3349",410,"Liu","Retrospective cohort",3455,2023-07-29,"Comparative","mRNA","2","final",NA,"14-63",">=18 years","general pop","excluded","~7 weeks","infection","infection","infection","omicron",-15,-62,18,"Australia","AUS","Oceania","East Asia & Pacific",54890,2019,"Australia","High income",4,NA,NA,NA,NA,NA
"3350",410,"Liu","Retrospective cohort",3456,2023-07-29,"Comparative","Multiple","2","final",NA,"14-63",">=18 years","general pop","excluded","~7 weeks","infection","infection","infection","omicron",1,-51,35,"Australia","AUS","Oceania","East Asia & Pacific",54890,2019,"Australia","High income",4,NA,NA,NA,NA,NA
"3351",410,"Liu","Retrospective cohort",3457,2023-07-29,"Comparative","Multiple","2","final",NA,"14-63",">=18 years","general pop","excluded","~7 weeks","infection","infection","infection","omicron",-71,-105,-43,"Australia","AUS","Oceania","East Asia & Pacific",54890,2019,"Australia","High income",4,NA,NA,NA,NA,NA
"3352",411,"Rosa","Test-negative case-control",3458,2023-07-26,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"7+",">=12 years","general pop","included","~70 weeks","symptomatic disease","symptomatic","symptomatic","omicron",46.7,19.9,64.6,"Brazil","BRA","South America","Latin America & Caribbean",9410,2019,"Brazil","Upper middle income",3,NA,NA,NA,NA,NA
"3353",411,"Rosa","Test-negative case-control",3459,2023-07-26,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"7-29",">=12 years","general pop","included","~70 weeks","symptomatic disease","symptomatic","symptomatic","omicron",77.7,54.8,89.4,"Brazil","BRA","South America","Latin America & Caribbean",9410,2019,"Brazil","Upper middle income",3,NA,NA,NA,NA,NA
"3354",411,"Rosa","Test-negative case-control",3460,2023-07-26,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"180+",">=12 years","general pop","included","~70 weeks","symptomatic disease","symptomatic","symptomatic","omicron",22.5,-55.2,61.3,"Brazil","BRA","South America","Latin America & Caribbean",9410,2019,"Brazil","Upper middle income",3,NA,NA,NA,NA,NA
"3355",411,"Rosa","Test-negative case-control",3461,2023-07-26,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"14+",">=12 years","general pop","included","~70 weeks","symptomatic disease","symptomatic","symptomatic","omicron",58.2,27.7,76,"Brazil","BRA","South America","Latin America & Caribbean",9410,2019,"Brazil","Upper middle income",3,NA,NA,NA,NA,NA
"3356",411,"Rosa","Test-negative case-control",3462,2023-07-26,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"14+",">=12 years","general pop","included","~70 weeks","symptomatic disease","symptomatic","symptomatic","omicron",51.5,-82.5,69.4,"Brazil","BRA","South America","Latin America & Caribbean",9410,2019,"Brazil","Upper middle income",3,NA,NA,NA,NA,NA
"3357",411,"Rosa","Test-negative case-control",3463,2023-07-26,"Comparative","Multiple","2","final",NA,"14+",">=12 years","general pop","included","~70 weeks","symptomatic disease","symptomatic","symptomatic","omicron",25,5,41,"Brazil","BRA","South America","Latin America & Caribbean",9410,2019,"Brazil","Upper middle income",3,NA,NA,NA,NA,NA
"3358",411,"Rosa","Test-negative case-control",3464,2023-07-26,"Comparative","Multiple","2","final",NA,"14+",">=12 years","general pop","included","~70 weeks","symptomatic disease","symptomatic","symptomatic","omicron",33,8,51,"Brazil","BRA","South America","Latin America & Caribbean",9410,2019,"Brazil","Upper middle income",3,NA,NA,NA,NA,NA
"3359",411,"Rosa","Test-negative case-control",3465,2023-07-26,"Comparative","Multiple","2","final",NA,"14+",">=12 years","general pop","included","~70 weeks","symptomatic disease","symptomatic","symptomatic","omicron",14,-52,51,"Brazil","BRA","South America","Latin America & Caribbean",9410,2019,"Brazil","Upper middle income",3,NA,NA,NA,NA,NA
"3360",412,"Franchi","Nested case-control",3466,2023-08-01,"Multiple or heterologous RNA","mRNA","2","final",NA,"14+",">=12 years","general pop","excluded","~72 weeks","infection","infection","infection","omicron",18,13,23,"Italy","ITA","Europe","Europe & Central Asia",34890,2019,"Italy","High income",4,NA,NA,NA,NA,NA
"3361",412,"Franchi","Nested case-control",3467,2023-08-01,"Multiple or heterologous RNA","mRNA","2","final",NA,"14+",">=12 years","general pop","excluded","~43 weeks","infection","infection","infection","delta",81,65,89,"Italy","ITA","Europe","Europe & Central Asia",34890,2019,"Italy","High income",4,NA,NA,NA,NA,NA
"3362",413,"Whitaker","Retrospective cohort",3468,2023-08-12,"Oxford/AstraZeneca ChAdOx1-S","Vectored","2","final",NA,"14-69","general pop with overrepsentation of clinical risk groups (30%)","general pop with overrepsentation of clinical risk groups (30%)","included","~44 weeks","death","death","death","delta",89.9,86.1,92.6,"UK","GBR","Europe","Europe & Central Asia",43240,2019,"United Kingdom","High income",4,NA,NA,NA,NA,NA
"3363",413,"Whitaker","Retrospective cohort",3469,2023-08-12,"Oxford/AstraZeneca ChAdOx1-S","Vectored","2","final",NA,"182+","general pop with overrepsentation of clinical risk groups (30%)","general pop with overrepsentation of clinical risk groups (30%)","included","~44 weeks","death","death","death","delta",72.3,67.6,76.4,"UK","GBR","Europe","Europe & Central Asia",43240,2019,"United Kingdom","High income",4,NA,NA,NA,NA,NA
"3364",413,"Whitaker","Retrospective cohort",3470,2023-08-12,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"14-69","general pop with overrepsentation of clinical risk groups (30%)","general pop with overrepsentation of clinical risk groups (30%)","included","~47 weeks","death","death","death","delta",95.5,91.8,97.5,"UK","GBR","Europe","Europe & Central Asia",43240,2019,"United Kingdom","High income",4,NA,NA,NA,NA,NA
"3365",413,"Whitaker","Retrospective cohort",3471,2023-08-12,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"182+","general pop with overrepsentation of clinical risk groups (30%)","general pop with overrepsentation of clinical risk groups (30%)","included","~47 weeks","death","death","death","delta",81.7,78.7,84.3,"UK","GBR","Europe","Europe & Central Asia",43240,2019,"United Kingdom","High income",4,NA,NA,NA,NA,NA
"3366",413,"Whitaker","Retrospective cohort",3472,2023-08-12,"Oxford/AstraZeneca ChAdOx1-S","Vectored","2","final",NA,"14-69","general pop with overrepsentation of clinical risk groups (30%)","general pop with overrepsentation of clinical risk groups (30%)","included","~44 weeks","hospitalization","hospitalization","severe","delta",92.5,91.7,93.2,"UK","GBR","Europe","Europe & Central Asia",43240,2019,"United Kingdom","High income",4,NA,NA,NA,NA,NA
"3367",413,"Whitaker","Retrospective cohort",3473,2023-08-12,"Oxford/AstraZeneca ChAdOx1-S","Vectored","2","final",NA,"182+","general pop with overrepsentation of clinical risk groups (30%)","general pop with overrepsentation of clinical risk groups (30%)","included","~44 weeks","hospitalization","hospitalization","severe","delta",68.7,66.3,71,"UK","GBR","Europe","Europe & Central Asia",43240,2019,"United Kingdom","High income",4,NA,NA,NA,NA,NA
"3368",413,"Whitaker","Retrospective cohort",3474,2023-08-12,"Oxford/AstraZeneca ChAdOx1-S","Vectored","2","final",NA,"14-69","Immunocompromised","Immunocompromised","included","~44 weeks","hospitalization","hospitalization","severe","delta",76.6,66.9,83.4,"UK","GBR","Europe","Europe & Central Asia",43240,2019,"United Kingdom","High income",4,NA,NA,NA,NA,NA
"3369",413,"Whitaker","Retrospective cohort",3475,2023-08-12,"Oxford/AstraZeneca ChAdOx1-S","Vectored","2","final",NA,"182+","Immunocompromised","Immunocompromised","included","~44 weeks","hospitalization","hospitalization","severe","delta",62.1,51.4,70.5,"UK","GBR","Europe","Europe & Central Asia",43240,2019,"United Kingdom","High income",4,NA,NA,NA,NA,NA
"3370",413,"Whitaker","Retrospective cohort",3476,2023-08-12,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"14-69","general pop with overrepsentation of clinical risk groups (30%)","general pop with overrepsentation of clinical risk groups (30%)","included","~47 weeks","hospitalization","hospitalization","severe","delta",96,95.1,96.7,"UK","GBR","Europe","Europe & Central Asia",43240,2019,"United Kingdom","High income",4,NA,NA,NA,NA,NA
"3371",413,"Whitaker","Retrospective cohort",3477,2023-08-12,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"182+","general pop with overrepsentation of clinical risk groups (30%)","general pop with overrepsentation of clinical risk groups (30%)","included","~47 weeks","hospitalization","hospitalization","severe","delta",82.9,81.4,84.2,"UK","GBR","Europe","Europe & Central Asia",43240,2019,"United Kingdom","High income",4,NA,NA,NA,NA,NA
"3372",413,"Whitaker","Retrospective cohort",3478,2023-08-12,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"14-69","Immunocompromised","Immunocompromised","included","~47 weeks","hospitalization","hospitalization","severe","delta",86.7,76.8,92.4,"UK","GBR","Europe","Europe & Central Asia",43240,2019,"United Kingdom","High income",4,NA,NA,NA,NA,NA
"3373",413,"Whitaker","Retrospective cohort",3479,2023-08-12,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"182+","Immunocompromised","Immunocompromised","included","~47 weeks","hospitalization","hospitalization","severe","delta",72.1,64.1,78.3,"UK","GBR","Europe","Europe & Central Asia",43240,2019,"United Kingdom","High income",4,NA,NA,NA,NA,NA
"3374",414,"Link-Gelles","Test-negative case-control",3480,2023-08-17,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"14+","6 months - 5 years","6 months - 5 years","included","~44 weeks","ED or UC visit","symptomatic","symptomatic","omicron",37,19,51,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"3375",414,"Link-Gelles","Test-negative case-control",3481,2023-08-17,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"14-59","6 months - 5 years","6 months - 5 years","included","~44 weeks","ED or UC visit","symptomatic","symptomatic","omicron",46,22,62,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"3376",414,"Link-Gelles","Test-negative case-control",3482,2023-08-17,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"60+","6 months - 5 years","6 months - 5 years","included","~44 weeks","ED or UC visit","symptomatic","symptomatic","omicron",27,-2,47,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"3377",414,"Link-Gelles","Test-negative case-control",3483,2023-08-17,"Moderna mRNA-1273","mRNA","2","final",NA,"14+","6 months - 4 years","6 months - 4 years","included","~44 weeks","ED or UC visit","symptomatic","symptomatic","omicron",29,12,42,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"3378",414,"Link-Gelles","Test-negative case-control",3484,2023-08-17,"Moderna mRNA-1273","mRNA","2","final",NA,"14-59","6 months - 4 years","6 months - 4 years","included","~44 weeks","ED or UC visit","symptomatic","symptomatic","omicron",46,17,64,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"3379",414,"Link-Gelles","Test-negative case-control",3485,2023-08-17,"Moderna mRNA-1273","mRNA","2","final",NA,"60+","6 months - 4 years","6 months - 4 years","included","~44 weeks","ED or UC visit","symptomatic","symptomatic","omicron",21,-1,38,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"3380",415,"Zerbo","Test-negative case-control",3486,2023-08-25,"Multiple or heterologous RNA","mRNA","2","final",NA,"<150","16-49 years","16-49 years","excluded","~80 weeks","infection","infection","infection","omicron",22,-7,44,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"3381",415,"Zerbo","Test-negative case-control",3487,2023-08-25,"Multiple or heterologous RNA","mRNA","2","final",NA,"150+","16-49 years","16-49 years","excluded","~80 weeks","infection","infection","infection","omicron",19,-2,50,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"3382",415,"Zerbo","Test-negative case-control",3488,2023-08-25,"Multiple or heterologous RNA","mRNA","2","final",NA,"<150","16-49 years","16-49 years","excluded","~55 weeks","infection","infection","infection","omicron",12,-48,59,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"3383",415,"Zerbo","Test-negative case-control",3489,2023-08-25,"Multiple or heterologous RNA","mRNA","2","final",NA,"150+","16-49 years","16-49 years","excluded","~55 weeks","infection","infection","infection","omicron",-55,-79,-6,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"3384",415,"Zerbo","Test-negative case-control",3490,2023-08-25,"Multiple or heterologous RNA","mRNA","2","final",NA,"<150","16-49 years","16-49 years","excluded","~42 weeks","infection","infection","infection","delta",77,69,82,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"3385",415,"Zerbo","Test-negative case-control",3491,2023-08-25,"Multiple or heterologous RNA","mRNA","2","final",NA,"150+","16-49 years","16-49 years","excluded","~42 weeks","infection","infection","infection","delta",66,49,77,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"3386",415,"Zerbo","Retrospective cohort",3492,2023-08-25,"Multiple or heterologous RNA","mRNA","2","final",NA,"<150","16-49 years","16-49 years","excluded","~80 weeks","infection","infection","infection","omicron",14,-5,30,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"3387",415,"Zerbo","Retrospective cohort",3493,2023-08-25,"Multiple or heterologous RNA","mRNA","2","final",NA,"150+","16-49 years","16-49 years","excluded","~80 weeks","infection","infection","infection","omicron",10,-17,33,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"3388",415,"Zerbo","Retrospective cohort",3494,2023-08-25,"Multiple or heterologous RNA","mRNA","2","final",NA,"<150","16-49 years","16-49 years","excluded","~55 weeks","infection","infection","infection","omicron",-16,-60,43,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"3389",415,"Zerbo","Retrospective cohort",3495,2023-08-25,"Multiple or heterologous RNA","mRNA","2","final",NA,"150+","16-49 years","16-49 years","excluded","~55 weeks","infection","infection","infection","omicron",-33,-65,24,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"3390",415,"Zerbo","Retrospective cohort",3496,2023-08-25,"Multiple or heterologous RNA","mRNA","2","final",NA,"<150","16-49 years","16-49 years","excluded","~42 weeks","infection","infection","infection","delta",78,72,83,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"3391",415,"Zerbo","Retrospective cohort",3497,2023-08-25,"Multiple or heterologous RNA","mRNA","2","final",NA,"150+","16-49 years","16-49 years","excluded","~42 weeks","infection","infection","infection","delta",68,52,78,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"3392",416,"Ogilvie","Retrospective cohort",3498,2023-09-08,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"14+","5-17 years","5-17 years","included","~69 weeks","infection","infection","infection","omicron",9,-1,19,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"3393",416,"Ogilvie","Retrospective cohort",3499,2023-09-08,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"14+","5-17 years","5-17 years","included","~69 weeks","hospitalization or ED visit","symptomatic or severe","symptomatic","omicron",13,-39,46,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"3394",416,"Ogilvie","Retrospective cohort",3500,2023-09-08,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"14+","5-17 years","5-17 years","included","~47 weeks","infection","infection","infection","delta",61,59,64,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"3395",416,"Ogilvie","Retrospective cohort",3501,2023-09-08,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"14+","5-17 years","5-17 years","included","~47 weeks","hospitalization or ED visit","symptomatic or severe","symptomatic","delta",78,71,83,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"3396",416,"Ogilvie","Retrospective cohort",3502,2023-09-08,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"14+","5-17 years","5-17 years","included","~17 weeks","infection","infection","infection","other combinations",61,52,68,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"3397",416,"Ogilvie","Retrospective cohort",3503,2023-09-08,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"14+","5-17 years","5-17 years","included","~17 weeks","hospitalization or ED visit","symptomatic or severe","symptomatic","other combinations",65,4,87,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"3398",417,"Copland","Nested case-control",3504,2023-09-07,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"14-41",">=12 years with blood cancer",">=12 years with blood cancer","included","~65 weeks","hospitalization","severe","severe","other combinations",72,18,89,"UK","GBR","Europe","Europe & Central Asia",43240,2019,"United Kingdom","High income",4,NA,NA,NA,NA,NA
"3399",417,"Copland","Nested case-control",3505,2023-09-07,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"182+",">=12 years with blood cancer",">=12 years with blood cancer","included","~65 weeks","hospitalization","severe","severe","other combinations",-46,-130,7,"UK","GBR","Europe","Europe & Central Asia",43240,2019,"United Kingdom","High income",4,NA,NA,NA,NA,NA
"3400",417,"Copland","Nested case-control",3506,2023-09-07,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"42-97",">=12 years with blood cancer",">=12 years with blood cancer","included","~65 weeks","death","death","death","other combinations",64,-3,87,"UK","GBR","Europe","Europe & Central Asia",43240,2019,"United Kingdom","High income",4,NA,NA,NA,NA,NA
"3401",417,"Copland","Nested case-control",3507,2023-09-07,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"182+",">=12 years with blood cancer",">=12 years with blood cancer","included","~65 weeks","death","death","death","other combinations",-52,-176,17,"UK","GBR","Europe","Europe & Central Asia",43240,2019,"United Kingdom","High income",4,NA,NA,NA,NA,NA
"3402",417,"Copland","Nested case-control",3508,2023-09-07,"Oxford/AstraZeneca ChAdOx1-S","Vectored","2","final",NA,"14-41",">=12 years with blood cancer",">=12 years with blood cancer","included","~56 weeks","hospitalization","severe","severe","other combinations",15,-77,59,"UK","GBR","Europe","Europe & Central Asia",43240,2019,"United Kingdom","High income",4,NA,NA,NA,NA,NA
"3403",417,"Copland","Nested case-control",3509,2023-09-07,"Oxford/AstraZeneca ChAdOx1-S","Vectored","2","final",NA,"182+",">=12 years with blood cancer",">=12 years with blood cancer","included","~56 weeks","hospitalization","severe","severe","other combinations",6,-47,39,"UK","GBR","Europe","Europe & Central Asia",43240,2019,"United Kingdom","High income",4,NA,NA,NA,NA,NA
"3404",417,"Copland","Nested case-control",3510,2023-09-07,"Oxford/AstraZeneca ChAdOx1-S","Vectored","2","final",NA,"42-97",">=12 years with blood cancer",">=12 years with blood cancer","included","~56 weeks","death","death","death","other combinations",-13,-188,55,"UK","GBR","Europe","Europe & Central Asia",43240,2019,"United Kingdom","High income",4,NA,NA,NA,NA,NA
"3405",417,"Copland","Nested case-control",3511,2023-09-07,"Oxford/AstraZeneca ChAdOx1-S","Vectored","2","final",NA,"182+",">=12 years with blood cancer",">=12 years with blood cancer","included","~56 weeks","death","death","death","other combinations",-100,-283,-4,"UK","GBR","Europe","Europe & Central Asia",43240,2019,"United Kingdom","High income",4,NA,NA,NA,NA,NA
"3406",417,"Copland","Nested case-control",3512,2023-09-07,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"14-41",">=12 years","general pop","included","~65 weeks","hospitalization","severe","severe","other combinations",61,56,66,"UK","GBR","Europe","Europe & Central Asia",43240,2019,"United Kingdom","High income",4,NA,NA,NA,NA,NA
"3407",417,"Copland","Nested case-control",3513,2023-09-07,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"182+",">=12 years","general pop","included","~65 weeks","hospitalization","severe","severe","other combinations",-38,-48,-29,"UK","GBR","Europe","Europe & Central Asia",43240,2019,"United Kingdom","High income",4,NA,NA,NA,NA,NA
"3408",417,"Copland","Nested case-control",3514,2023-09-07,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"14-41",">=12 years","general pop","included","~65 weeks","death","death","death","other combinations",80,73,85,"UK","GBR","Europe","Europe & Central Asia",43240,2019,"United Kingdom","High income",4,NA,NA,NA,NA,NA
"3409",417,"Copland","Nested case-control",3515,2023-09-07,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"182+",">=12 years","general pop","included","~65 weeks","death","death","death","other combinations",-97,-127,-72,"UK","GBR","Europe","Europe & Central Asia",43240,2019,"United Kingdom","High income",4,NA,NA,NA,NA,NA
"3410",417,"Copland","Nested case-control",3516,2023-09-07,"Oxford/AstraZeneca ChAdOx1-S","Vectored","2","final",NA,"14-41",">=12 years","general pop","included","~56 weeks","hospitalization","severe","severe","other combinations",66,61,70,"UK","GBR","Europe","Europe & Central Asia",43240,2019,"United Kingdom","High income",4,NA,NA,NA,NA,NA
"3411",417,"Copland","Nested case-control",3517,2023-09-07,"Oxford/AstraZeneca ChAdOx1-S","Vectored","2","final",NA,"182+",">=12 years","general pop","included","~56 weeks","hospitalization","severe","severe","other combinations",-22,-31,-13,"UK","GBR","Europe","Europe & Central Asia",43240,2019,"United Kingdom","High income",4,NA,NA,NA,NA,NA
"3412",417,"Copland","Nested case-control",3518,2023-09-07,"Oxford/AstraZeneca ChAdOx1-S","Vectored","2","final",NA,"14-41",">=12 years","general pop","included","~56 weeks","death","death","death","other combinations",62,43,75,"UK","GBR","Europe","Europe & Central Asia",43240,2019,"United Kingdom","High income",4,NA,NA,NA,NA,NA
"3413",417,"Copland","Nested case-control",3519,2023-09-07,"Oxford/AstraZeneca ChAdOx1-S","Vectored","2","final",NA,"182+",">=12 years","general pop","included","~56 weeks","death","death","death","other combinations",-74,-101,-50,"UK","GBR","Europe","Europe & Central Asia",43240,2019,"United Kingdom","High income",4,NA,NA,NA,NA,NA
"3414",418,"Paternina-Caicedo","Test-negative case-control",3520,2023-09-09,"Oxford/AstraZeneca ChAdOx1-S","Vectored","2","final",NA,"14-44",">=5 years","general pop","excluded","~43 weeks","symptomatic disease","symptomatic","symptomatic","omicron",36,24,47,"Colombia","COL","South America","Latin America & Caribbean",6630,2019,"Colombia","Upper middle income",3,NA,NA,NA,NA,NA
"3415",418,"Paternina-Caicedo","Test-negative case-control",3521,2023-09-09,"Oxford/AstraZeneca ChAdOx1-S","Vectored","2","final",NA,"165+",">=5 years","general pop","excluded","~43 weeks","symptomatic disease","symptomatic","symptomatic","omicron",-8,-34,13,"Colombia","COL","South America","Latin America & Caribbean",6630,2019,"Colombia","Upper middle income",3,NA,NA,NA,NA,NA
"3416",418,"Paternina-Caicedo","Test-negative case-control",3522,2023-09-09,"Oxford/AstraZeneca ChAdOx1-S","Vectored","2","final",NA,"14+",">=5 years","general pop","excluded","~43 weeks","hospitalization","severe","severe","omicron",10,-78,55,"Colombia","COL","South America","Latin America & Caribbean",6630,2019,"Colombia","Upper middle income",3,14,301,"yes",NA,0
"3417",418,"Paternina-Caicedo","Test-negative case-control",3523,2023-09-09,"Sinovac CoronaVac","Inactivated","2","final",NA,"14-44",">=5 years","general pop","excluded","~46 weeks","symptomatic disease","symptomatic","symptomatic","omicron",37,8,56,"Colombia","COL","South America","Latin America & Caribbean",6630,2019,"Colombia","Upper middle income",3,NA,NA,NA,NA,NA
"3418",418,"Paternina-Caicedo","Test-negative case-control",3524,2023-09-09,"Sinovac CoronaVac","Inactivated","2","final",NA,"165+",">=5 years","general pop","excluded","~46 weeks","symptomatic disease","symptomatic","symptomatic","omicron",-36,-48,24,"Colombia","COL","South America","Latin America & Caribbean",6630,2019,"Colombia","Upper middle income",3,NA,NA,NA,NA,NA
"3419",418,"Paternina-Caicedo","Test-negative case-control",3525,2023-09-09,"Sinovac CoronaVac","Inactivated","2","final",NA,"14+",">=5 years","general pop","excluded","~46 weeks","hospitalization","severe","severe","omicron",7,-41,38,"Colombia","COL","South America","Latin America & Caribbean",6630,2019,"Colombia","Upper middle income",3,NA,NA,NA,NA,NA
"3420",418,"Paternina-Caicedo","Test-negative case-control",3526,2023-09-09,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"14-44",">=5 years","general pop","excluded","~47 weeks","symptomatic disease","symptomatic","symptomatic","omicron",59,45,70,"Colombia","COL","South America","Latin America & Caribbean",6630,2019,"Colombia","Upper middle income",3,NA,NA,NA,NA,NA
"3421",418,"Paternina-Caicedo","Test-negative case-control",3527,2023-09-09,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"165+",">=5 years","general pop","excluded","~47 weeks","symptomatic disease","symptomatic","symptomatic","omicron",4,-2,11,"Colombia","COL","South America","Latin America & Caribbean",6630,2019,"Colombia","Upper middle income",3,NA,NA,NA,NA,NA
"3422",418,"Paternina-Caicedo","Test-negative case-control",3528,2023-09-09,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"14+",">=5 years","general pop","excluded","~47 weeks","hospitalization","severe","severe","omicron",45,1,70,"Colombia","COL","South America","Latin America & Caribbean",6630,2019,"Colombia","Upper middle income",3,14,329,"yes",NA,0
"3423",418,"Paternina-Caicedo","Test-negative case-control",3529,2023-09-09,"Moderna mRNA-1273","mRNA","2","final",NA,"14-44",">=5 years","general pop","excluded","~25 weeks","symptomatic disease","symptomatic","symptomatic","omicron",65,54,74,"Colombia","COL","South America","Latin America & Caribbean",6630,2019,"Colombia","Upper middle income",3,NA,NA,NA,NA,NA
"3424",418,"Paternina-Caicedo","Test-negative case-control",3530,2023-09-09,"Moderna mRNA-1273","mRNA","2","final",NA,"165+",">=5 years","general pop","excluded","~25 weeks","symptomatic disease","symptomatic","symptomatic","omicron",-22,-639,80,"Colombia","COL","South America","Latin America & Caribbean",6630,2019,"Colombia","Upper middle income",3,NA,NA,NA,NA,NA
"3425",418,"Paternina-Caicedo","Test-negative case-control",3531,2023-09-09,"Moderna mRNA-1273","mRNA","2","final",NA,"14+",">=5 years","general pop","excluded","~25 weeks","hospitalization","severe","severe","omicron",95,54,99,"Colombia","COL","South America","Latin America & Caribbean",6630,2019,"Colombia","Upper middle income",3,14,175,"yes",NA,0
"3426",418,"Paternina-Caicedo","Test-negative case-control",3532,2023-09-09,"Janssen Ad26.COV2.S","Vectored","1","final",NA,"14-44",">=5 years","general pop","excluded","~33 weeks","symptomatic disease","symptomatic","symptomatic","omicron",34,11,51,"Colombia","COL","South America","Latin America & Caribbean",6630,2019,"Colombia","Upper middle income",3,NA,NA,NA,NA,NA
"3427",418,"Paternina-Caicedo","Test-negative case-control",3533,2023-09-09,"Janssen Ad26.COV2.S","Vectored","1","final",NA,"165+",">=5 years","general pop","excluded","~33 weeks","symptomatic disease","symptomatic","symptomatic","omicron",-29,-43,17,"Colombia","COL","South America","Latin America & Caribbean",6630,2019,"Colombia","Upper middle income",3,NA,NA,NA,NA,NA
"3428",418,"Paternina-Caicedo","Test-negative case-control",3534,2023-09-09,"Janssen Ad26.COV2.S","Vectored","1","final",NA,"14+",">=5 years","general pop","excluded","~33 weeks","hospitalization","severe","severe","omicron",-5,-158,57,"Colombia","COL","South America","Latin America & Caribbean",6630,2019,"Colombia","Upper middle income",3,NA,NA,NA,NA,NA
"3429",418,"Paternina-Caicedo","Test-negative case-control",3535,2023-09-09,"Oxford/AstraZeneca ChAdOx1-S","Vectored","2","final",NA,"14-44",">=5 years","general pop","excluded","~32 weeks","symptomatic disease","symptomatic","symptomatic","delta",-2,-32,21,"Colombia","COL","South America","Latin America & Caribbean",6630,2019,"Colombia","Upper middle income",3,NA,NA,NA,NA,NA
"3430",418,"Paternina-Caicedo","Test-negative case-control",3536,2023-09-09,"Oxford/AstraZeneca ChAdOx1-S","Vectored","2","final",NA,"165+",">=5 years","general pop","excluded","~32 weeks","symptomatic disease","symptomatic","symptomatic","delta",54,-177,92,"Colombia","COL","South America","Latin America & Caribbean",6630,2019,"Colombia","Upper middle income",3,NA,NA,NA,NA,NA
"3431",418,"Paternina-Caicedo","Test-negative case-control",3537,2023-09-09,"Oxford/AstraZeneca ChAdOx1-S","Vectored","2","final",NA,"14+",">=5 years","general pop","excluded","~32 weeks","hospitalization","severe","severe","delta",71,27,89,"Colombia","COL","South America","Latin America & Caribbean",6630,2019,"Colombia","Upper middle income",3,14,224,"yes",NA,0
"3432",418,"Paternina-Caicedo","Test-negative case-control",3538,2023-09-09,"Sinovac CoronaVac","Inactivated","2","final",NA,"14-44",">=5 years","general pop","excluded","~35 weeks","symptomatic disease","symptomatic","symptomatic","delta",31,10,47,"Colombia","COL","South America","Latin America & Caribbean",6630,2019,"Colombia","Upper middle income",3,NA,NA,NA,NA,NA
"3433",418,"Paternina-Caicedo","Test-negative case-control",3539,2023-09-09,"Sinovac CoronaVac","Inactivated","2","final",NA,"165+",">=5 years","general pop","excluded","~35 weeks","symptomatic disease","symptomatic","symptomatic","delta",34,18,47,"Colombia","COL","South America","Latin America & Caribbean",6630,2019,"Colombia","Upper middle income",3,NA,NA,NA,NA,NA
"3434",418,"Paternina-Caicedo","Test-negative case-control",3540,2023-09-09,"Sinovac CoronaVac","Inactivated","2","final",NA,"14+",">=5 years","general pop","excluded","~35 weeks","hospitalization","severe","severe","delta",63,35,79,"Colombia","COL","South America","Latin America & Caribbean",6630,2019,"Colombia","Upper middle income",3,NA,NA,NA,NA,NA
"3435",418,"Paternina-Caicedo","Test-negative case-control",3541,2023-09-09,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"14-44",">=5 years","general pop","excluded","~36 weeks","symptomatic disease","symptomatic","symptomatic","delta",10,-20,33,"Colombia","COL","South America","Latin America & Caribbean",6630,2019,"Colombia","Upper middle income",3,NA,NA,NA,NA,NA
"3436",418,"Paternina-Caicedo","Test-negative case-control",3542,2023-09-09,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"165+",">=5 years","general pop","excluded","~36 weeks","symptomatic disease","symptomatic","symptomatic","delta",62,57,67,"Colombia","COL","South America","Latin America & Caribbean",6630,2019,"Colombia","Upper middle income",3,NA,NA,NA,NA,NA
"3437",418,"Paternina-Caicedo","Test-negative case-control",3543,2023-09-09,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"14+",">=5 years","general pop","excluded","~36 weeks","hospitalization","severe","severe","delta",91,79,96,"Colombia","COL","South America","Latin America & Caribbean",6630,2019,"Colombia","Upper middle income",3,14,252,"yes",NA,0
"3438",418,"Paternina-Caicedo","Test-negative case-control",3544,2023-09-09,"Moderna mRNA-1273","mRNA","2","final",NA,"14-44",">=5 years","general pop","excluded","~14 weeks","symptomatic disease","symptomatic","symptomatic","delta",52,41,61,"Colombia","COL","South America","Latin America & Caribbean",6630,2019,"Colombia","Upper middle income",3,NA,NA,NA,NA,NA
"3439",418,"Paternina-Caicedo","Test-negative case-control",3545,2023-09-09,"Moderna mRNA-1273","mRNA","2","final",NA,"105-134",">=5 years","general pop","excluded","~14 weeks","symptomatic disease","symptomatic","symptomatic","delta",89,-8,99,"Colombia","COL","South America","Latin America & Caribbean",6630,2019,"Colombia","Upper middle income",3,NA,NA,NA,NA,NA
"3440",418,"Paternina-Caicedo","Test-negative case-control",3546,2023-09-09,"Janssen Ad26.COV2.S","Vectored","1","final",NA,"14-44",">=5 years","general pop","excluded","~22 weeks","symptomatic disease","symptomatic","symptomatic","delta",7,-19,27,"Colombia","COL","South America","Latin America & Caribbean",6630,2019,"Colombia","Upper middle income",3,NA,NA,NA,NA,NA
"3441",418,"Paternina-Caicedo","Test-negative case-control",3547,2023-09-09,"Janssen Ad26.COV2.S","Vectored","1","final",NA,"165+",">=5 years","general pop","excluded","~22 weeks","symptomatic disease","symptomatic","symptomatic","delta",70,-5,92,"Colombia","COL","South America","Latin America & Caribbean",6630,2019,"Colombia","Upper middle income",3,NA,NA,NA,NA,NA
"3442",418,"Paternina-Caicedo","Test-negative case-control",3548,2023-09-09,"Janssen Ad26.COV2.S","Vectored","1","final",NA,"14+",">=5 years","general pop","excluded","~22 weeks","hospitalization","severe","severe","delta",73,23,91,"Colombia","COL","South America","Latin America & Caribbean",6630,2019,"Colombia","Upper middle income",3,NA,NA,NA,NA,NA
"3443",418,"Paternina-Caicedo","Test-negative case-control",3549,2023-09-09,"Oxford/AstraZeneca ChAdOx1-S","Vectored","2","final",NA,"14-44",">=5 years","general pop","excluded","~14 weeks","symptomatic disease","symptomatic","symptomatic","mu",62,26,81,"Colombia","COL","South America","Latin America & Caribbean",6630,2019,"Colombia","Upper middle income",3,NA,NA,NA,NA,NA
"3444",418,"Paternina-Caicedo","Test-negative case-control",3550,2023-09-09,"Oxford/AstraZeneca ChAdOx1-S","Vectored","2","final",NA,"14+",">=5 years","general pop","excluded","~14 weeks","hospitalization","severe","severe","mu",-57,-1646,86,"Colombia","COL","South America","Latin America & Caribbean",6630,2019,"Colombia","Upper middle income",3,NA,NA,NA,NA,NA
"3445",418,"Paternina-Caicedo","Test-negative case-control",3551,2023-09-09,"Sinovac CoronaVac","Inactivated","2","final",NA,"14-44",">=5 years","general pop","excluded","~18 weeks","symptomatic disease","symptomatic","symptomatic","mu",56,46,65,"Colombia","COL","South America","Latin America & Caribbean",6630,2019,"Colombia","Upper middle income",3,NA,NA,NA,NA,NA
"3446",418,"Paternina-Caicedo","Test-negative case-control",3552,2023-09-09,"Sinovac CoronaVac","Inactivated","2","final",NA,"165+",">=5 years","general pop","excluded","~18 weeks","symptomatic disease","symptomatic","symptomatic","mu",59,-385,97,"Colombia","COL","South America","Latin America & Caribbean",6630,2019,"Colombia","Upper middle income",3,NA,NA,NA,NA,NA
"3447",418,"Paternina-Caicedo","Test-negative case-control",3553,2023-09-09,"Sinovac CoronaVac","Inactivated","2","final",NA,"14+",">=5 years","general pop","excluded","~18 weeks","hospitalization","severe","severe","mu",68,24,86,"Colombia","COL","South America","Latin America & Caribbean",6630,2019,"Colombia","Upper middle income",3,NA,NA,NA,NA,NA
"3448",418,"Paternina-Caicedo","Test-negative case-control",3554,2023-09-09,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"14-44",">=5 years","general pop","excluded","~19 weeks","symptomatic disease","symptomatic","symptomatic","mu",67,61,72,"Colombia","COL","South America","Latin America & Caribbean",6630,2019,"Colombia","Upper middle income",3,NA,NA,NA,NA,NA
"3449",418,"Paternina-Caicedo","Test-negative case-control",3555,2023-09-09,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"165+",">=5 years","general pop","excluded","~19 weeks","symptomatic disease","symptomatic","symptomatic","mu",77,53,89,"Colombia","COL","South America","Latin America & Caribbean",6630,2019,"Colombia","Upper middle income",3,NA,NA,NA,NA,NA
"3450",418,"Paternina-Caicedo","Test-negative case-control",3556,2023-09-09,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"14+",">=5 years","general pop","excluded","~19 weeks","hospitalization","severe","severe","mu",88,59,96,"Colombia","COL","South America","Latin America & Caribbean",6630,2019,"Colombia","Upper middle income",3,NA,NA,NA,NA,NA
"3451",418,"Paternina-Caicedo","Test-negative case-control",3557,2023-09-09,"Janssen Ad26.COV2.S","Vectored","1","final",NA,"14-44",">=5 years","general pop","excluded","~5 weeks","symptomatic disease","symptomatic","symptomatic","mu",50,33,63,"Colombia","COL","South America","Latin America & Caribbean",6630,2019,"Colombia","Upper middle income",3,NA,NA,NA,NA,NA
"3452",419,"Chen","Nested test-negative case-control",3558,2023-09-14,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"14-41","Immunocompromised","immunocompromised","included","~50 weeks","hospitalization","severe","severe","other combinations",77,63,86,"UK","GBR","Europe","Europe & Central Asia",43240,2019,"United Kingdom","High income",4,NA,NA,NA,NA,NA
"3453",419,"Chen","Nested test-negative case-control",3559,2023-09-14,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"182-272","Immunocompromised","immunocompromised","included","~50 weeks","hospitalization","severe","severe","other combinations",49,13,70,"UK","GBR","Europe","Europe & Central Asia",43240,2019,"United Kingdom","High income",4,NA,NA,NA,NA,NA
"3454",419,"Chen","Nested test-negative case-control",3560,2023-09-14,"Oxford/AstraZeneca ChAdOx1-S","Vectored","2","final",NA,"14-41","Immunocompromised","immunocompromised","included","~50 weeks","hospitalization","severe","severe","other combinations",43,-9,70,"UK","GBR","Europe","Europe & Central Asia",43240,2019,"United Kingdom","High income",4,NA,NA,NA,NA,NA
"3455",419,"Chen","Nested test-negative case-control",3561,2023-09-14,"Oxford/AstraZeneca ChAdOx1-S","Vectored","2","final",NA,"42-97","Immunocompromised","immunocompromised","included","~50 weeks","hospitalization","severe","severe","other combinations",31,-33,64,"UK","GBR","Europe","Europe & Central Asia",43240,2019,"United Kingdom","High income",4,NA,NA,NA,NA,NA
"3456",420,"Irala","Test-negative case-control",3562,2023-09-15,"Multiple or heterologous RNA","mRNA","2","final",NA,"14+",">=5 years","general pop","included","~52 weeks","hospitalization due to SARI","severe","severe","omicron",45.3,5.8,68.7,"Paraguay","PRY","South America","Latin America & Caribbean",5950,2019,"Paraguay","Upper middle income",2,NA,NA,NA,NA,NA
"3457",420,"Irala","Test-negative case-control",3563,2023-09-15,"Oxford/AstraZeneca ChAdOx1-S","Vectored","2","final",NA,"14+",">=5 years","general pop","included","~52 weeks","hospitalization due to SARI","severe","severe","omicron",10,-31.3,38.2,"Paraguay","PRY","South America","Latin America & Caribbean",5950,2019,"Paraguay","Upper middle income",2,14,364,"yes",NA,0
"3458",420,"Irala","Test-negative case-control",3564,2023-09-15,"Gamaleya Gam-COVID-Vac/Sputnik V","Vectored","2","final",NA,"14+",">=5 years","general pop","included","~52 weeks","hospitalization due to SARI","severe","severe","omicron",25.4,-30.2,57.5,"Paraguay","PRY","South America","Latin America & Caribbean",5950,2019,"Paraguay","Upper middle income",2,NA,NA,NA,NA,NA
"3459",420,"Irala","Test-negative case-control",3565,2023-09-15,"Beijing/Sinopharm BBIBP-CorV","Inactivated","2","final",NA,"14+",">=5 years","general pop","included","~52 weeks","hospitalization due to SARI","severe","severe","omicron",42.3,-2,67.6,"Paraguay","PRY","South America","Latin America & Caribbean",5950,2019,"Paraguay","Upper middle income",2,NA,NA,NA,NA,NA
"3460",420,"Irala","Test-negative case-control",3566,2023-09-15,"Bharat Covaxin/BBV152","Inactivated","2","final",NA,"14+",">=5 years","general pop","included","~52 weeks","hospitalization due to SARI","severe","severe","omicron",13,-46.1,48,"Paraguay","PRY","South America","Latin America & Caribbean",5950,2019,"Paraguay","Upper middle income",2,NA,NA,NA,NA,NA
"3461",420,"Irala","Test-negative case-control",3567,2023-09-15,"Multiple or heterologous RNA","mRNA","2","final",NA,"14+",">=5 years","general pop","included","~37 weeks","hospitalization due to SARI","severe","severe","delta",90.4,74.3,97.3,"Paraguay","PRY","South America","Latin America & Caribbean",5950,2019,"Paraguay","Upper middle income",2,NA,NA,NA,NA,NA
"3462",420,"Irala","Test-negative case-control",3568,2023-09-15,"Oxford/AstraZeneca ChAdOx1-S","Vectored","2","final",NA,"14+",">=5 years","general pop","included","~37 weeks","hospitalization due to SARI","severe","severe","delta",83.2,67.8,91.9,"Paraguay","PRY","South America","Latin America & Caribbean",5950,2019,"Paraguay","Upper middle income",2,14,259,"yes",NA,0
"3463",420,"Irala","Test-negative case-control",3569,2023-09-15,"Gamaleya Gam-COVID-Vac/Sputnik V","Vectored","2","final",NA,"14+",">=5 years","general pop","included","~37 weeks","hospitalization due to SARI","severe","severe","delta",82.9,53,95.2,"Paraguay","PRY","South America","Latin America & Caribbean",5950,2019,"Paraguay","Upper middle income",2,NA,NA,NA,NA,NA
"3464",420,"Irala","Test-negative case-control",3570,2023-09-15,"Beijing/Sinopharm BBIBP-CorV","Inactivated","2","final",NA,"14+",">=5 years","general pop","included","~37 weeks","hospitalization due to SARI","severe","severe","delta",29.7,-42.6,67.3,"Paraguay","PRY","South America","Latin America & Caribbean",5950,2019,"Paraguay","Upper middle income",2,NA,NA,NA,NA,NA
"3465",420,"Irala","Test-negative case-control",3571,2023-09-15,"Bharat Covaxin/BBV152","Inactivated","2","final",NA,"14+",">=5 years","general pop","included","~37 weeks","hospitalization due to SARI","severe","severe","delta",24.9,-36.9,59.8,"Paraguay","PRY","South America","Latin America & Caribbean",5950,2019,"Paraguay","Upper middle income",2,NA,NA,NA,NA,NA
"3466",421,"Tartof","Test-negative case-control",3572,2023-09-15,"BioNTech/Pfizer BNT162b2","mRNA","3 (pediatric dose)","final",NA,"14+","6 months - 4 years","6 months - 4 years","included","~35 weeks","ED or UC visit due to ARI","symptomatic","symptomatic","omicron",10,-40,42,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"3467",421,"Tartof","Test-negative case-control",3573,2023-09-15,"BioNTech/Pfizer BNT162b2","mRNA","3 (pediatric dose)","final",NA,"14+","6 months - 4 years","6 months - 4 years","included","~35 weeks","other outpatient encounter due to ARI","symptomatic","symptomatic","omicron",21,-41,56,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"3468",422,"Mimura","Retrospective cohort",3574,2023-09-23,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"7+",">=65 years",">=65 years","excluded","~22 weeks","infection","infection","infection","delta",78.1,65.2,87.8,"Japan","JPN","Asia","East Asia & Pacific",41970,2019,"Japan","High income",4,NA,NA,NA,NA,NA
"3469",422,"Mimura","Retrospective cohort",3575,2023-09-23,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"7+",">=65 years",">=65 years","excluded","~22 weeks","symptomatic disease","symptomatic","symptomatic","delta",79.1,64.6,88.9,"Japan","JPN","Asia","East Asia & Pacific",41970,2019,"Japan","High income",4,NA,NA,NA,NA,NA
"3470",422,"Mimura","Retrospective cohort",3576,2023-09-23,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"7+",">=65 years",">=65 years","excluded","~22 weeks","hospitalization","severe","severe","delta",93.5,83.7,100,"Japan","JPN","Asia","East Asia & Pacific",41970,2019,"Japan","High income",4,7,154,"yes",NA,1
"3471",423,"Patel","Test-negative case-control",3577,2023-09-29,"Multiple or heterologous RNA","mRNA","2","final",NA,"14+",">=18 years with any disability",">=18 years with any disability","included","~82 weeks","ED/UC visit","symptomatic","symptomatic","omicron",45,36,52,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"3472",423,"Patel","Test-negative case-control",3578,2023-09-29,"Multiple or heterologous RNA","mRNA","2","final",NA,"14+",">=18 years with any disability",">=18 years with any disability","included","~82 weeks","hospitalization","severe","severe","omicron",45,38,52,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"3473",423,"Patel","Test-negative case-control",3579,2023-09-29,"Multiple or heterologous RNA","mRNA","2","final",NA,"14+",">=18 years with no disability",">=18 years with no disability","included","~82 weeks","ED/UC visit","symptomatic","symptomatic","omicron",31,29,32,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"3474",423,"Patel","Test-negative case-control",3580,2023-09-29,"Multiple or heterologous RNA","mRNA","2","final",NA,"14+",">=18 years with no disability",">=18 years with no disability","included","~82 weeks","hospitalization","severe","severe","omicron",45,43,48,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"3475",423,"Patel","Test-negative case-control",3581,2023-09-29,"Multiple or heterologous RNA","mRNA","2","final",NA,"14+",">=18 years with any disability",">=18 years with any disability","included","~42 weeks","ED/UC visit","symptomatic","symptomatic","delta",79,75,83,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"3476",423,"Patel","Test-negative case-control",3582,2023-09-29,"Multiple or heterologous RNA","mRNA","2","final",NA,"14+",">=18 years with any disability",">=18 years with any disability","included","~42 weeks","hospitalization","severe","severe","delta",79,76,83,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"3477",423,"Patel","Test-negative case-control",3583,2023-09-29,"Multiple or heterologous RNA","mRNA","2","final",NA,"14+",">=18 years with no disability",">=18 years with no disability","included","~42 weeks","ED/UC visit","symptomatic","symptomatic","delta",82,82,83,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"3478",423,"Patel","Test-negative case-control",3584,2023-09-29,"Multiple or heterologous RNA","mRNA","2","final",NA,"14+",">=18 years with no disability",">=18 years with no disability","included","~42 weeks","hospitalization","severe","severe","delta",87,86,87,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"3479",424,"Chemaitelly","Retrospective cohort",3585,2023-10-04,"Multiple or heterologous RNA","mRNA","2","final",NA,"90+","all ages","all ages","previously infected with Omicron only","~85 weeks","infection","infection","infection","omicron",57,51,61,"Qatar","QAT","Asia","Middle East & North Africa",65700,2019,"Qatar","High income",4,NA,NA,NA,NA,NA
"3480",426,"Hernandez-Avila","Test-negative case-control",3586,2023-10-19,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"<91",">=65 years",">=65 years","excluded","~33 weeks","symptomatic disease","symptomatic","symptomatic","delta",74.3,70.5,77.6,"Mexico","MEX","North America","Latin America & Caribbean",9860,2019,"Mexico","Upper middle income",3,NA,NA,NA,NA,NA
"3481",426,"Hernandez-Avila","Test-negative case-control",3587,2023-10-19,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"141+",">=65 years",">=65 years","excluded","~33 weeks","symptomatic disease","symptomatic","symptomatic","delta",66.9,62.7,70.7,"Mexico","MEX","North America","Latin America & Caribbean",9860,2019,"Mexico","Upper middle income",3,NA,NA,NA,NA,NA
"3482",426,"Hernandez-Avila","Test-negative case-control",3588,2023-10-19,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"<91",">=65 years",">=65 years","excluded","~33 weeks","hospitalization with ARI","severe","severe","delta",87.5,84.9,89.7,"Mexico","MEX","North America","Latin America & Caribbean",9860,2019,"Mexico","Upper middle income",3,NA,91,"yes",NA,1
"3483",426,"Hernandez-Avila","Test-negative case-control",3589,2023-10-19,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"141+",">=65 years",">=65 years","excluded","~33 weeks","hospitalization with ARI","severe","severe","delta",80.5,77.4,83.2,"Mexico","MEX","North America","Latin America & Caribbean",9860,2019,"Mexico","Upper middle income",3,141,231,"no","sequential period",1
"3484",426,"Hernandez-Avila","Test-negative case-control",3590,2023-10-19,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"<91",">=65 years",">=65 years","excluded","~33 weeks","severe disease","severe","severe","delta",90.4,87.8,92.4,"Mexico","MEX","North America","Latin America & Caribbean",9860,2019,"Mexico","Upper middle income",3,NA,91,"no","duplicated endpoint (use hospitalisation)",1
"3485",426,"Hernandez-Avila","Test-negative case-control",3591,2023-10-19,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"141+",">=65 years",">=65 years","excluded","~33 weeks","severe disease","severe","severe","delta",85.3,82.3,87.8,"Mexico","MEX","North America","Latin America & Caribbean",9860,2019,"Mexico","Upper middle income",3,141,231,"no","duplicated endpoint (use hospitalisation)",1
"3486",426,"Hernandez-Avila","Test-negative case-control",3592,2023-10-19,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"<91",">=65 years",">=65 years","excluded","~33 weeks","death","death","death","delta",90.3,87.7,92.4,"Mexico","MEX","North America","Latin America & Caribbean",9860,2019,"Mexico","Upper middle income",3,NA,NA,NA,NA,NA
"3487",426,"Hernandez-Avila","Test-negative case-control",3593,2023-10-19,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"141+",">=65 years",">=65 years","excluded","~33 weeks","death","death","death","delta",85.7,82.8,88.2,"Mexico","MEX","North America","Latin America & Caribbean",9860,2019,"Mexico","Upper middle income",3,NA,NA,NA,NA,NA
"3488",426,"Hernandez-Avila","Test-negative case-control",3594,2023-10-19,"Oxford/AstraZeneca ChAdOx1-S","Vectored","2","final",NA,"<91",">=65 years",">=65 years","excluded","~33 weeks","symptomatic disease","symptomatic","symptomatic","delta",61.2,56.9,65.1,"Mexico","MEX","North America","Latin America & Caribbean",9860,2019,"Mexico","Upper middle income",3,NA,NA,NA,NA,NA
"3489",426,"Hernandez-Avila","Test-negative case-control",3595,2023-10-19,"Oxford/AstraZeneca ChAdOx1-S","Vectored","2","final",NA,"141+",">=65 years",">=65 years","excluded","~33 weeks","symptomatic disease","symptomatic","symptomatic","delta",51.8,43.5,58.8,"Mexico","MEX","North America","Latin America & Caribbean",9860,2019,"Mexico","Upper middle income",3,NA,NA,NA,NA,NA
"3490",426,"Hernandez-Avila","Test-negative case-control",3596,2023-10-19,"Oxford/AstraZeneca ChAdOx1-S","Vectored","2","final",NA,"<91",">=65 years",">=65 years","excluded","~33 weeks","hospitalization with ARI","severe","severe","delta",81.1,78.4,83.5,"Mexico","MEX","North America","Latin America & Caribbean",9860,2019,"Mexico","Upper middle income",3,NA,91,"yes",NA,1
"3491",426,"Hernandez-Avila","Test-negative case-control",3597,2023-10-19,"Oxford/AstraZeneca ChAdOx1-S","Vectored","2","final",NA,"141+",">=65 years",">=65 years","excluded","~33 weeks","hospitalization with ARI","severe","severe","delta",70.5,64.2,75.8,"Mexico","MEX","North America","Latin America & Caribbean",9860,2019,"Mexico","Upper middle income",3,141,231,"no","sequential period",1
"3492",426,"Hernandez-Avila","Test-negative case-control",3598,2023-10-19,"Oxford/AstraZeneca ChAdOx1-S","Vectored","2","final",NA,"<91",">=65 years",">=65 years","excluded","~33 weeks","severe disease","severe","severe","delta",85.3,82.8,87.5,"Mexico","MEX","North America","Latin America & Caribbean",9860,2019,"Mexico","Upper middle income",3,NA,91,"no","duplicated endpoint (use hospitalisation)",1
"3493",426,"Hernandez-Avila","Test-negative case-control",3599,2023-10-19,"Oxford/AstraZeneca ChAdOx1-S","Vectored","2","final",NA,"141+",">=65 years",">=65 years","excluded","~33 weeks","severe disease","severe","severe","delta",73.5,66.5,79.1,"Mexico","MEX","North America","Latin America & Caribbean",9860,2019,"Mexico","Upper middle income",3,141,231,"no","duplicated endpoint (use hospitalisation)",1
"3494",426,"Hernandez-Avila","Test-negative case-control",3600,2023-10-19,"Oxford/AstraZeneca ChAdOx1-S","Vectored","2","final",NA,"<91",">=65 years",">=65 years","excluded","~33 weeks","death","death","death","delta",85.4,82.9,87.6,"Mexico","MEX","North America","Latin America & Caribbean",9860,2019,"Mexico","Upper middle income",3,NA,NA,NA,NA,NA
"3495",426,"Hernandez-Avila","Test-negative case-control",3601,2023-10-19,"Oxford/AstraZeneca ChAdOx1-S","Vectored","2","final",NA,"141+",">=65 years",">=65 years","excluded","~33 weeks","death","death","death","delta",73.6,66.6,79.2,"Mexico","MEX","North America","Latin America & Caribbean",9860,2019,"Mexico","Upper middle income",3,NA,NA,NA,NA,NA
"3496",426,"Hernandez-Avila","Test-negative case-control",3602,2023-10-19,"Sinovac CoronaVac","Inactivated","2","final",NA,"<91",">=65 years",">=65 years","excluded","~33 weeks","symptomatic disease","symptomatic","symptomatic","delta",47,39.6,53.5,"Mexico","MEX","North America","Latin America & Caribbean",9860,2019,"Mexico","Upper middle income",3,NA,NA,NA,NA,NA
"3497",426,"Hernandez-Avila","Test-negative case-control",3603,2023-10-19,"Sinovac CoronaVac","Inactivated","2","final",NA,"141+",">=65 years",">=65 years","excluded","~33 weeks","symptomatic disease","symptomatic","symptomatic","delta",34.9,26.2,42.6,"Mexico","MEX","North America","Latin America & Caribbean",9860,2019,"Mexico","Upper middle income",3,NA,NA,NA,NA,NA
"3498",426,"Hernandez-Avila","Test-negative case-control",3604,2023-10-19,"Sinovac CoronaVac","Inactivated","2","final",NA,"<91",">=65 years",">=65 years","excluded","~33 weeks","hospitalization with ARI","severe","severe","delta",69.8,64.5,74.2,"Mexico","MEX","North America","Latin America & Caribbean",9860,2019,"Mexico","Upper middle income",3,NA,NA,NA,NA,NA
"3499",426,"Hernandez-Avila","Test-negative case-control",3605,2023-10-19,"Sinovac CoronaVac","Inactivated","2","final",NA,"141+",">=65 years",">=65 years","excluded","~33 weeks","hospitalization with ARI","severe","severe","delta",57.8,51,63.6,"Mexico","MEX","North America","Latin America & Caribbean",9860,2019,"Mexico","Upper middle income",3,NA,NA,NA,NA,NA
"3500",426,"Hernandez-Avila","Test-negative case-control",3606,2023-10-19,"Sinovac CoronaVac","Inactivated","2","final",NA,"<91",">=65 years",">=65 years","excluded","~33 weeks","severe disease","severe","severe","delta",75.4,70.3,79.7,"Mexico","MEX","North America","Latin America & Caribbean",9860,2019,"Mexico","Upper middle income",3,NA,NA,NA,NA,NA
"3501",426,"Hernandez-Avila","Test-negative case-control",3607,2023-10-19,"Sinovac CoronaVac","Inactivated","2","final",NA,"141+",">=65 years",">=65 years","excluded","~33 weeks","severe disease","severe","severe","delta",59.2,51.6,65.5,"Mexico","MEX","North America","Latin America & Caribbean",9860,2019,"Mexico","Upper middle income",3,NA,NA,NA,NA,NA
"3502",426,"Hernandez-Avila","Test-negative case-control",3608,2023-10-19,"Sinovac CoronaVac","Inactivated","2","final",NA,"<91",">=65 years",">=65 years","excluded","~33 weeks","death","death","death","delta",75.6,70.5,79.8,"Mexico","MEX","North America","Latin America & Caribbean",9860,2019,"Mexico","Upper middle income",3,NA,NA,NA,NA,NA
"3503",426,"Hernandez-Avila","Test-negative case-control",3609,2023-10-19,"Sinovac CoronaVac","Inactivated","2","final",NA,"141+",">=65 years",">=65 years","excluded","~33 weeks","death","death","death","delta",59.2,51.6,65.5,"Mexico","MEX","North America","Latin America & Caribbean",9860,2019,"Mexico","Upper middle income",3,NA,NA,NA,NA,NA
"3504",426,"Hernandez-Avila","Test-negative case-control",3610,2023-10-19,"Cansino Ad5-nCoV","Vectored","1","final",NA,"<91",">=65 years",">=65 years","excluded","~33 weeks","symptomatic disease","symptomatic","symptomatic","delta",29,5.3,46.7,"Mexico","MEX","North America","Latin America & Caribbean",9860,2019,"Mexico","Upper middle income",3,NA,NA,NA,NA,NA
"3505",426,"Hernandez-Avila","Test-negative case-control",3611,2023-10-19,"Cansino Ad5-nCoV","Vectored","1","final",NA,"141+",">=65 years",">=65 years","excluded","~33 weeks","symptomatic disease","symptomatic","symptomatic","delta",43.6,32.1,53.1,"Mexico","MEX","North America","Latin America & Caribbean",9860,2019,"Mexico","Upper middle income",3,NA,NA,NA,NA,NA
"3506",426,"Hernandez-Avila","Test-negative case-control",3612,2023-10-19,"Cansino Ad5-nCoV","Vectored","1","final",NA,"<91",">=65 years",">=65 years","excluded","~33 weeks","hospitalization with ARI","severe","severe","delta",58.2,39,71.3,"Mexico","MEX","North America","Latin America & Caribbean",9860,2019,"Mexico","Upper middle income",3,NA,NA,NA,NA,NA
"3507",426,"Hernandez-Avila","Test-negative case-control",3613,2023-10-19,"Cansino Ad5-nCoV","Vectored","1","final",NA,"141+",">=65 years",">=65 years","excluded","~33 weeks","hospitalization with ARI","severe","severe","delta",58.8,48.7,66.9,"Mexico","MEX","North America","Latin America & Caribbean",9860,2019,"Mexico","Upper middle income",3,NA,NA,NA,NA,NA
"3508",426,"Hernandez-Avila","Test-negative case-control",3614,2023-10-19,"Cansino Ad5-nCoV","Vectored","1","final",NA,"<91",">=65 years",">=65 years","excluded","~33 weeks","severe disease","severe","severe","delta",69.4,50.6,81,"Mexico","MEX","North America","Latin America & Caribbean",9860,2019,"Mexico","Upper middle income",3,NA,NA,NA,NA,NA
"3509",426,"Hernandez-Avila","Test-negative case-control",3615,2023-10-19,"Cansino Ad5-nCoV","Vectored","1","final",NA,"141+",">=65 years",">=65 years","excluded","~33 weeks","severe disease","severe","severe","delta",63.8,53.2,72,"Mexico","MEX","North America","Latin America & Caribbean",9860,2019,"Mexico","Upper middle income",3,NA,NA,NA,NA,NA
"3510",426,"Hernandez-Avila","Test-negative case-control",3616,2023-10-19,"Cansino Ad5-nCoV","Vectored","1","final",NA,"<91",">=65 years",">=65 years","excluded","~33 weeks","death","death","death","delta",69.1,50,80.8,"Mexico","MEX","North America","Latin America & Caribbean",9860,2019,"Mexico","Upper middle income",3,NA,NA,NA,NA,NA
"3511",426,"Hernandez-Avila","Test-negative case-control",3617,2023-10-19,"Cansino Ad5-nCoV","Vectored","1","final",NA,"141+",">=65 years",">=65 years","excluded","~33 weeks","death","death","death","delta",64.1,53.6,72.3,"Mexico","MEX","North America","Latin America & Caribbean",9860,2019,"Mexico","Upper middle income",3,NA,NA,NA,NA,NA
"3512",426,"Hernandez-Avila","Test-negative case-control",3618,2023-10-19,"Gamaleya Gam-COVID-Vac/Sputnik V","Vectored","2","final",NA,"<91",">=65 years",">=65 years","excluded","~33 weeks","symptomatic disease","symptomatic","symptomatic","delta",68.5,59.5,75.5,"Mexico","MEX","North America","Latin America & Caribbean",9860,2019,"Mexico","Upper middle income",3,NA,NA,NA,NA,NA
"3513",426,"Hernandez-Avila","Test-negative case-control",3619,2023-10-19,"Gamaleya Gam-COVID-Vac/Sputnik V","Vectored","2","final",NA,"141+",">=65 years",">=65 years","excluded","~33 weeks","symptomatic disease","symptomatic","symptomatic","delta",75.5,69.1,80.6,"Mexico","MEX","North America","Latin America & Caribbean",9860,2019,"Mexico","Upper middle income",3,NA,NA,NA,NA,NA
"3514",426,"Hernandez-Avila","Test-negative case-control",3620,2023-10-19,"Gamaleya Gam-COVID-Vac/Sputnik V","Vectored","2","final",NA,"<91",">=65 years",">=65 years","excluded","~33 weeks","hospitalization with ARI","severe","severe","delta",90.4,85.5,93.7,"Mexico","MEX","North America","Latin America & Caribbean",9860,2019,"Mexico","Upper middle income",3,NA,NA,NA,NA,NA
"3515",426,"Hernandez-Avila","Test-negative case-control",3621,2023-10-19,"Gamaleya Gam-COVID-Vac/Sputnik V","Vectored","2","final",NA,"141+",">=65 years",">=65 years","excluded","~33 weeks","hospitalization with ARI","severe","severe","delta",87.1,82.2,90.6,"Mexico","MEX","North America","Latin America & Caribbean",9860,2019,"Mexico","Upper middle income",3,NA,NA,NA,NA,NA
"3516",426,"Hernandez-Avila","Test-negative case-control",3622,2023-10-19,"Gamaleya Gam-COVID-Vac/Sputnik V","Vectored","2","final",NA,"<91",">=65 years",">=65 years","excluded","~33 weeks","severe disease","severe","severe","delta",94.8,90.5,97.2,"Mexico","MEX","North America","Latin America & Caribbean",9860,2019,"Mexico","Upper middle income",3,NA,NA,NA,NA,NA
"3517",426,"Hernandez-Avila","Test-negative case-control",3623,2023-10-19,"Gamaleya Gam-COVID-Vac/Sputnik V","Vectored","2","final",NA,"141+",">=65 years",">=65 years","excluded","~33 weeks","severe disease","severe","severe","delta",91.8,87.3,94.7,"Mexico","MEX","North America","Latin America & Caribbean",9860,2019,"Mexico","Upper middle income",3,NA,NA,NA,NA,NA
"3518",426,"Hernandez-Avila","Test-negative case-control",3624,2023-10-19,"Gamaleya Gam-COVID-Vac/Sputnik V","Vectored","2","final",NA,"<91",">=65 years",">=65 years","excluded","~33 weeks","death","death","death","delta",95.2,91,94.7,"Mexico","MEX","North America","Latin America & Caribbean",9860,2019,"Mexico","Upper middle income",3,NA,NA,NA,NA,NA
"3519",426,"Hernandez-Avila","Test-negative case-control",3625,2023-10-19,"Gamaleya Gam-COVID-Vac/Sputnik V","Vectored","2","final",NA,"141+",">=65 years",">=65 years","excluded","~33 weeks","death","death","death","delta",91.8,87.3,94.7,"Mexico","MEX","North America","Latin America & Caribbean",9860,2019,"Mexico","Upper middle income",3,NA,NA,NA,NA,NA
"3520",427,"Lee","Test-negative case-control",3626,2023-11-24,"Multiple or heterologous RNA","mRNA","2","final",NA,"3 months",">=50 years",">=50 years","excluded","~63 weeks","severe disease","severe","severe","omicron",80,78,83,"Canada","CAN","North America","North America",46580,2019,"Canada","High income",4,NA,NA,NA,NA,NA
"3521",427,"Lee","Test-negative case-control",3627,2023-11-24,"Multiple or heterologous RNA","mRNA","2","final",NA,"15 months",">=50 years",">=50 years","excluded","~63 weeks","severe disease","severe","severe","omicron",80,77,82,"Canada","CAN","North America","North America",46580,2019,"Canada","High income",4,NA,NA,NA,NA,NA
"3522",427,"Lee","Test-negative case-control",3628,2023-11-24,"Multiple or heterologous RNA","mRNA","2","final",NA,"3 months",">=50 years",">=50 years","excluded","~63 weeks","severe disease","severe","severe","omicron",43,19,60,"Canada","CAN","North America","North America",46580,2019,"Canada","High income",4,NA,NA,NA,NA,NA
"3523",427,"Lee","Test-negative case-control",3629,2023-11-24,"Multiple or heterologous RNA","mRNA","2","final",NA,"15 months",">=50 years",">=50 years","excluded","~63 weeks","severe disease","severe","severe","omicron",49,41,56,"Canada","CAN","North America","North America",46580,2019,"Canada","High income",4,NA,NA,NA,NA,NA
"3524",427,"Lee","Test-negative case-control",3630,2023-11-24,"Multiple or heterologous RNA","mRNA","2","final",NA,"3 months",">=50 years",">=50 years","excluded","~63 weeks","severe disease","severe","severe","omicron",25,-61,65,"Canada","CAN","North America","North America",46580,2019,"Canada","High income",4,NA,NA,NA,NA,NA
"3525",427,"Lee","Test-negative case-control",3631,2023-11-24,"Multiple or heterologous RNA","mRNA","2","final",NA,"15 months",">=50 years",">=50 years","excluded","~63 weeks","severe disease","severe","severe","omicron",31,17,43,"Canada","CAN","North America","North America",46580,2019,"Canada","High income",4,NA,NA,NA,NA,NA
"3526",428,"Yiu","Case-control",3632,2023-10-10,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"14+",">=18 years with a mental disorder",">=18 years with a mental disorder","excluded","~70 weeks","hospitalization due to COVID-19","severe","severe","omicron",71.1,68,73.9,"Hong Kong","HKG","Asia","East Asia & Pacific",50480,2019,"Hong Kong SAR, China","High income",4,NA,NA,NA,NA,NA
"3527",428,"Yiu","Case-control",3633,2023-10-10,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"14+",">=18 years with a mental disorder",">=18 years with a mental disorder","excluded","~70 weeks","death","death","death","omicron",86.1,80.5,90.1,"Hong Kong","HKG","Asia","East Asia & Pacific",50480,2019,"Hong Kong SAR, China","High income",4,NA,NA,NA,NA,NA
"3528",428,"Yiu","Case-control",3634,2023-10-10,"Sinovac CoronaVac","Inactivated","2","final",NA,"14+",">=18 years with a mental disorder",">=18 years with a mental disorder","excluded","~71 weeks","hospitalization due to COVID-19","severe","severe","omicron",46.1,42.7,49.3,"Hong Kong","HKG","Asia","East Asia & Pacific",50480,2019,"Hong Kong SAR, China","High income",4,NA,NA,NA,NA,NA
"3529",428,"Yiu","Case-control",3635,2023-10-10,"Sinovac CoronaVac","Inactivated","2","final",NA,"14+",">=18 years with a mental disorder",">=18 years with a mental disorder","excluded","~71 weeks","death","death","death","omicron",59.5,53.7,64.6,"Hong Kong","HKG","Asia","East Asia & Pacific",50480,2019,"Hong Kong SAR, China","High income",4,NA,NA,NA,NA,NA
"3530",429,"Tartof","Test-negative case-control",3636,2023-10-25,"Multiple or heterologous RNA","mRNA","2","final",NA,"14+",">=18 years","general pop","included","~116 weeks","severe disease","severe","severe","omicron",29,-7,53,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"3531",429,"Tartof","Test-negative case-control",3637,2023-10-25,"Multiple or heterologous RNA","mRNA","2","final",NA,"14+",">=18 years","general pop","included","~116 weeks","hospitalization","severe","severe","omicron",27,13,39,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"3532",429,"Tartof","Test-negative case-control",3638,2023-10-25,"Multiple or heterologous RNA","mRNA","2","final",NA,"14+",">=18 years","general pop","included","~116 weeks","ED/UC visit","symptomatic","symptomatic","omicron",18,12,24,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"3533",429,"Tartof","Test-negative case-control",3639,2023-10-25,"Multiple or heterologous RNA","mRNA","2","final",NA,"14+",">=18 years","general pop","included","~116 weeks","outpatient visit","symptomatic","symptomatic","omicron",14,6,21,"USA","USA","North America","North America",66220,2019,"United States","High income",4,NA,NA,NA,NA,NA
"3534",430,"Razafimandimby","Test-negative case-control",3640,2023-10-30,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"14+","5-11 years","5-11 years","excluded","~54 weeks","infection","infection","infection","omicron",20,13,26,"Canada","CAN","North America","North America",46580,2019,"Canada","High income",4,NA,NA,NA,NA,NA
"3535",430,"Razafimandimby","Test-negative case-control",3641,2023-10-30,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"14-55","5-11 years","5-11 years","excluded","~54 weeks","infection","infection","infection","omicron",42,35,49,"Canada","CAN","North America","North America",46580,2019,"Canada","High income",4,NA,NA,NA,NA,NA
"3536",430,"Razafimandimby","Test-negative case-control",3642,2023-10-30,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"56-385","5-11 years","5-11 years","excluded","~54 weeks","infection","infection","infection","omicron",2,-7,11,"Canada","CAN","North America","North America",46580,2019,"Canada","High income",4,NA,NA,NA,NA,NA
"3537",430,"Razafimandimby","Test-negative case-control",3643,2023-10-30,"BioNTech/Pfizer BNT162b2","mRNA","2","final","21-55 days","14+","5-11 years","5-11 years","excluded","~54 weeks","infection","infection","infection","omicron",10,-2,21,"Canada","CAN","North America","North America",46580,2019,"Canada","High income",4,NA,NA,NA,NA,NA
"3538",430,"Razafimandimby","Test-negative case-control",3644,2023-10-30,"BioNTech/Pfizer BNT162b2","mRNA","2","final","84-362 days","14+","5-11 years","5-11 years","excluded","~54 weeks","infection","infection","infection","omicron",39,20,55,"Canada","CAN","North America","North America",46580,2019,"Canada","High income",4,NA,NA,NA,NA,NA
"3539",430,"Razafimandimby","Test-negative case-control",3645,2023-10-30,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"14+","5-11 years","5-11 years","excluded","~54 weeks","symptomatic disease (ambulatory centers)","symptomatic","symptomatic","omicron",47,40,54,"Canada","CAN","North America","North America",46580,2019,"Canada","High income",4,NA,NA,NA,NA,NA
"3540",430,"Razafimandimby","Test-negative case-control",3646,2023-10-30,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"14-55","5-11 years","5-11 years","excluded","~54 weeks","symptomatic disease (ambulatory centers)","symptomatic","symptomatic","omicron",68,62,74,"Canada","CAN","North America","North America",46580,2019,"Canada","High income",4,NA,NA,NA,NA,NA
"3541",430,"Razafimandimby","Test-negative case-control",3647,2023-10-30,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"56-385","5-11 years","5-11 years","excluded","~54 weeks","symptomatic disease (ambulatory centers)","symptomatic","symptomatic","omicron",25,11,36,"Canada","CAN","North America","North America",46580,2019,"Canada","High income",4,NA,NA,NA,NA,NA
"3542",430,"Razafimandimby","Test-negative case-control",3648,2023-10-30,"BioNTech/Pfizer BNT162b2","mRNA","2","final","21-55 days","14+","5-11 years","5-11 years","excluded","~54 weeks","symptomatic disease (ambulatory centers)","symptomatic","symptomatic","omicron",48,36,57,"Canada","CAN","North America","North America",46580,2019,"Canada","High income",4,NA,NA,NA,NA,NA
"3543",430,"Razafimandimby","Test-negative case-control",3649,2023-10-30,"BioNTech/Pfizer BNT162b2","mRNA","2","final","84-362 days","14+","5-11 years","5-11 years","excluded","~54 weeks","symptomatic disease (ambulatory centers)","symptomatic","symptomatic","omicron",45,10,68,"Canada","CAN","North America","North America",46580,2019,"Canada","High income",4,NA,NA,NA,NA,NA
"3544",430,"Razafimandimby","Test-negative case-control",3650,2023-10-30,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"14+","5-11 years","5-11 years","excluded","~54 weeks","symptomatic disease (acute care hospital)","symptomatic","symptomatic","omicron",42,30,52,"Canada","CAN","North America","North America",46580,2019,"Canada","High income",4,NA,NA,NA,NA,NA
"3545",430,"Razafimandimby","Test-negative case-control",3651,2023-10-30,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"14-55","5-11 years","5-11 years","excluded","~54 weeks","symptomatic disease (acute care hospital)","symptomatic","symptomatic","omicron",41,17,59,"Canada","CAN","North America","North America",46580,2019,"Canada","High income",4,NA,NA,NA,NA,NA
"3546",430,"Razafimandimby","Test-negative case-control",3652,2023-10-30,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"56-385","5-11 years","5-11 years","excluded","~54 weeks","symptomatic disease (acute care hospital)","symptomatic","symptomatic","omicron",42,29,53,"Canada","CAN","North America","North America",46580,2019,"Canada","High income",4,NA,NA,NA,NA,NA
"3547",430,"Razafimandimby","Test-negative case-control",3653,2023-10-30,"BioNTech/Pfizer BNT162b2","mRNA","2","final","21-55 days","14+","5-11 years","5-11 years","excluded","~54 weeks","symptomatic disease (acute care hospital)","symptomatic","symptomatic","omicron",18,-17,44,"Canada","CAN","North America","North America",46580,2019,"Canada","High income",4,NA,NA,NA,NA,NA
"3548",430,"Razafimandimby","Test-negative case-control",3654,2023-10-30,"BioNTech/Pfizer BNT162b2","mRNA","2","final","84-362 days","14+","5-11 years","5-11 years","excluded","~54 weeks","symptomatic disease (acute care hospital)","symptomatic","symptomatic","omicron",69,43,86,"Canada","CAN","North America","North America",46580,2019,"Canada","High income",4,NA,NA,NA,NA,NA
"3549",430,"Razafimandimby","Test-negative case-control",3655,2023-10-30,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"14+","5-11 years","5-11 years","excluded","~13 weeks","infection","infection","infection","omicron",40,31,47,"Canada","CAN","North America","North America",46580,2019,"Canada","High income",4,NA,NA,NA,NA,NA
"3550",430,"Razafimandimby","Test-negative case-control",3656,2023-10-30,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"14+","5-11 years","5-11 years","excluded","~13 weeks","symptomatic disease (ambulatory centers)","symptomatic","symptomatic","omicron",70,63,76,"Canada","CAN","North America","North America",46580,2019,"Canada","High income",4,NA,NA,NA,NA,NA
"3551",430,"Razafimandimby","Test-negative case-control",3657,2023-10-30,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"14+","5-11 years","5-11 years","excluded","~13 weeks","symptomatic disease (acute care hospital)","symptomatic","symptomatic","omicron",27,-13,53,"Canada","CAN","North America","North America",46580,2019,"Canada","High income",4,NA,NA,NA,NA,NA
"3552",430,"Razafimandimby","Test-negative case-control",3658,2023-10-30,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"14+","5-11 years","5-11 years","excluded","~25 weeks","infection","infection","infection","omicron",14,0,26,"Canada","CAN","North America","North America",46580,2019,"Canada","High income",4,NA,NA,NA,NA,NA
"3553",430,"Razafimandimby","Test-negative case-control",3659,2023-10-30,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"14+","5-11 years","5-11 years","excluded","~25 weeks","symptomatic disease (ambulatory centers)","symptomatic","symptomatic","omicron",32,13,47,"Canada","CAN","North America","North America",46580,2019,"Canada","High income",4,NA,NA,NA,NA,NA
"3554",430,"Razafimandimby","Test-negative case-control",3660,2023-10-30,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"14+","5-11 years","5-11 years","excluded","~25 weeks","symptomatic disease (acute care hospital)","symptomatic","symptomatic","omicron",47,26,62,"Canada","CAN","North America","North America",46580,2019,"Canada","High income",4,NA,NA,NA,NA,NA
"3555",430,"Razafimandimby","Test-negative case-control",3661,2023-10-30,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"14+","5-11 years","5-11 years","excluded","~54 weeks","infection","infection","infection","omicron",-5,-22,9,"Canada","CAN","North America","North America",46580,2019,"Canada","High income",4,NA,NA,NA,NA,NA
"3556",430,"Razafimandimby","Test-negative case-control",3662,2023-10-30,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"14+","5-11 years","5-11 years","excluded","~54 weeks","symptomatic disease (ambulatory centers)","symptomatic","symptomatic","omicron",-15,-55,14,"Canada","CAN","North America","North America",46580,2019,"Canada","High income",4,NA,NA,NA,NA,NA
"3557",430,"Razafimandimby","Test-negative case-control",3663,2023-10-30,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"14+","5-11 years","5-11 years","excluded","~54 weeks","symptomatic disease (acute care hospital)","symptomatic","symptomatic","omicron",38,18,54,"Canada","CAN","North America","North America",46580,2019,"Canada","High income",4,NA,NA,NA,NA,NA
"3558",431,"Goh","Retrospective cohort",3664,2023-11-10,"Multiple or heterologous RNA","mRNA","2","final",NA,"14+","infants 0-6 months","infants 0-6 months","included (refers to mothers)","~126 weeks","infection","infection","infection","omicron",60.7,-56.6,90.1,"Singapore","SGP","Asia","East Asia & Pacific",58810,2019,"Singapore","High income",4,NA,NA,NA,NA,NA
"3559",431,"Goh","Retrospective cohort",3665,2023-11-10,"Multiple or heterologous RNA","mRNA","2","final",NA,"14+","infants 0-6 months","infants 0-6 months","included (refers to mothers)","~63 weeks","infection","infection","infection","omicron",73,-30.6,94.4,"Singapore","SGP","Asia","East Asia & Pacific",58810,2019,"Singapore","High income",4,NA,NA,NA,NA,NA
"3560",431,"Goh","Retrospective cohort",3666,2023-11-10,"Multiple or heterologous RNA","mRNA","2","final",NA,"14+","infants 0-6 months","infants 0-6 months","included (refers to mothers)","~126 weeks","infection","infection","infection","omicron",18.3,-14.6,41.8,"Singapore","SGP","Asia","East Asia & Pacific",58810,2019,"Singapore","High income",4,NA,NA,NA,NA,NA
"3561",431,"Goh","Retrospective cohort",3667,2023-11-10,"Multiple or heterologous RNA","mRNA","2","final",NA,"14+","infants 0-6 months","infants 0-6 months","included (refers to mothers)","~63 weeks","infection","infection","infection","omicron",37.6,17.2,53.1,"Singapore","SGP","Asia","East Asia & Pacific",58810,2019,"Singapore","High income",4,NA,NA,NA,NA,NA
"3562",432,"Culpan","Retrospective cohort",3668,2023-11-15,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"14+","HCW","HCW","excluded","~30 weeks","infection","infection","infection","delta",82.3,68,90.2,"Turkey","TUR","Asia","Europe & Central Asia",9800,2019,"Trkiye","Upper middle income",3,NA,NA,NA,NA,NA
"3563",432,"Culpan","Retrospective cohort",3669,2023-11-15,"Sinovac CoronaVac","Inactivated","2","final",NA,"14+","HCW","HCW","excluded","~42 weeks","infection","infection","infection","delta",21,-20.7,48.3,"Turkey","TUR","Asia","Europe & Central Asia",9800,2019,"Trkiye","Upper middle income",3,NA,NA,NA,NA,NA
"3564",433,"Szekanecz","Retrospective cohort",3670,2023-11-02,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"14-120","immunocompromised adults 18-84 years","immunocompromised","excluded","~32 weeks","infection","infection","infection","delta",73,68.8,76.7,"Hungary","HUN","Europe","Europe & Central Asia",16570,2019,"Hungary","High income",3,NA,NA,NA,NA,NA
"3565",433,"Szekanecz","Retrospective cohort",3671,2023-11-02,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"181-240","immunocompromised adults 18-84 years","immunocompromised","excluded","~32 weeks","infection","infection","infection","delta",38.7,35.1,42.1,"Hungary","HUN","Europe","Europe & Central Asia",16570,2019,"Hungary","High income",3,NA,NA,NA,NA,NA
"3566",433,"Szekanecz","Retrospective cohort",3672,2023-11-02,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"14-120","immunocompromised adults 18-84 years","immunocompromised","included","~32 weeks","death","death","death","delta",53,7.7,76.1,"Hungary","HUN","Europe","Europe & Central Asia",16570,2019,"Hungary","High income",3,NA,NA,NA,NA,NA
"3567",433,"Szekanecz","Retrospective cohort",3673,2023-11-02,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"181-240","immunocompromised adults 18-84 years","immunocompromised","included","~32 weeks","death","death","death","delta",51.1,33.3,64.1,"Hungary","HUN","Europe","Europe & Central Asia",16570,2019,"Hungary","High income",3,NA,NA,NA,NA,NA
"3568",433,"Szekanecz","Retrospective cohort",3674,2023-11-02,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"14-120","non-immunocompromised adults 18-84 years","immunocompetent adults","excluded","~32 weeks","infection","infection","infection","delta",68.1,66.8,69.3,"Hungary","HUN","Europe","Europe & Central Asia",16570,2019,"Hungary","High income",3,NA,NA,NA,NA,NA
"3569",433,"Szekanecz","Retrospective cohort",3675,2023-11-02,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"181-240","non-immunocompromised adults 18-84 years","immunocompetent adults","excluded","~32 weeks","infection","infection","infection","delta",16.1,14.2,17.9,"Hungary","HUN","Europe","Europe & Central Asia",16570,2019,"Hungary","High income",3,NA,NA,NA,NA,NA
"3570",433,"Szekanecz","Retrospective cohort",3676,2023-11-02,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"14-120","non-immunocompromised adults 18-84 years","immunocompetent adults","included","~32 weeks","death","death","death","delta",74.9,64.6,82.2,"Hungary","HUN","Europe","Europe & Central Asia",16570,2019,"Hungary","High income",3,NA,NA,NA,NA,NA
"3571",433,"Szekanecz","Retrospective cohort",3677,2023-11-02,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"181-240","non-immunocompromised adults 18-84 years","immunocompetent adults","included","~32 weeks","death","death","death","delta",80.8,76.6,84.2,"Hungary","HUN","Europe","Europe & Central Asia",16570,2019,"Hungary","High income",3,NA,NA,NA,NA,NA
"3572",436,"Qin","Retrospective cohort",3687,2023-12-12,"Sinovac CoronaVac","Inactivated","2","final",NA,"0+",">=18 years","general pop","excluded","~88 weeks","hospitalization","severe","severe","delta/omicron",18,6,23,"Hong Kong","HKG","Asia","East Asia & Pacific",50480,2019,"Hong Kong SAR, China","High income",4,NA,NA,NA,NA,NA
"3573",436,"Qin","Retrospective cohort",3688,2023-12-12,"Sinovac CoronaVac","Inactivated","2","final",NA,"0+",">=18 years","general pop","excluded","~88 weeks","severe disease","severe","severe","delta/omicron",29,12,43,"Hong Kong","HKG","Asia","East Asia & Pacific",50480,2019,"Hong Kong SAR, China","High income",4,NA,NA,NA,NA,NA
"3574",436,"Qin","Retrospective cohort",3689,2023-12-12,"Sinovac CoronaVac","Inactivated","2","final",NA,"0+",">=18 years","general pop","excluded","~88 weeks","death","death","death","delta/omicron",77,74,80,"Hong Kong","HKG","Asia","East Asia & Pacific",50480,2019,"Hong Kong SAR, China","High income",4,NA,NA,NA,NA,NA
"3575",436,"Qin","Retrospective cohort",3690,2023-12-12,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"0+",">=18 years","general pop","excluded","~87 weeks","hospitalization","severe","severe","delta/omicron",33,30,37,"Hong Kong","HKG","Asia","East Asia & Pacific",50480,2019,"Hong Kong SAR, China","High income",4,NA,NA,NA,NA,NA
"3576",436,"Qin","Retrospective cohort",3691,2023-12-12,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"0+",">=18 years","general pop","excluded","~87 weeks","severe disease","severe","severe","delta/omicron",57,45,66,"Hong Kong","HKG","Asia","East Asia & Pacific",50480,2019,"Hong Kong SAR, China","High income",4,NA,NA,NA,NA,NA
"3577",436,"Qin","Retrospective cohort",3692,2023-12-12,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"0+",">=18 years","general pop","excluded","~87 weeks","death","death","death","delta/omicron",92,91,94,"Hong Kong","HKG","Asia","East Asia & Pacific",50480,2019,"Hong Kong SAR, China","High income",4,NA,NA,NA,NA,NA
"3578",437,"Arashiro","Retrospective cohort",3693,2023-12-19,"Multiple or heterologous RNA","mRNA","2","final",NA,"14-180 (median 76)",">=16 years","general pop","included","24 weeks","severe disease requiring oxygen therapy","severe","severe","delta",95.2,88.7,98,"Japan","JPN","Asia","East Asia & Pacific",41970,2019,"Japan","High income",4,NA,NA,NA,NA,NA
"3579",437,"Arashiro","Retrospective cohort",3694,2023-12-19,"Multiple or heterologous RNA","mRNA","2","final",NA,"14-180 (median 83)",">=16 years","general pop","included","24 weeks","severe disease requiring mechanical ventilation","severe","severe","delta",99.6,97.3,99.9,"Japan","JPN","Asia","East Asia & Pacific",41970,2019,"Japan","High income",4,NA,NA,NA,NA,NA
"3580",437,"Arashiro","Retrospective cohort",3695,2023-12-19,"Multiple or heterologous RNA","mRNA","2","final",NA,"14-180 (median 83)",">=16 years","general pop","included","24 weeks","death","death","death","delta",98.6,92.3,99.7,"Japan","JPN","Asia","East Asia & Pacific",41970,2019,"Japan","High income",4,NA,NA,NA,NA,NA
"3581",437,"Arashiro","Retrospective cohort",3696,2023-12-19,"Multiple or heterologous RNA","mRNA","2","final",NA,"14-180 (median 79)",">=16 years","general pop","included","24 weeks","severe disease requiring oxygen therapy with respiratory failure","severe","severe","delta",65.5,89.3,98.1,"Japan","JPN","Asia","East Asia & Pacific",41970,2019,"Japan","High income",4,NA,NA,NA,NA,NA
"3582",437,"Arashiro","Retrospective cohort",3697,2023-12-19,"Multiple or heterologous RNA","mRNA","2","final",NA,"14-180 (median 155)",">=16 years","general pop","included","~65 weeks","severe disease requiring oxygen therapy","severe","severe","omicron",37,-50.9,73.7,"Japan","JPN","Asia","East Asia & Pacific",41970,2019,"Japan","High income",4,NA,NA,NA,NA,NA
"3583",437,"Arashiro","Retrospective cohort",3698,2023-12-19,"Multiple or heterologous RNA","mRNA","2","final",NA,"180+ (median 218)",">=16 years","general pop","included","~65 weeks","severe disease requiring oxygen therapy","severe","severe","omicron",47.9,-2.1,73.4,"Japan","JPN","Asia","East Asia & Pacific",41970,2019,"Japan","High income",4,NA,NA,NA,NA,NA
"3584",437,"Arashiro","Retrospective cohort",3699,2023-12-19,"Multiple or heterologous RNA","mRNA","2","final",NA,"14-180 (median 149)",">=16 years","general pop","included","~65 weeks","severe disease requiring mechanical ventilation","severe","severe","omicron",73.7,-30.6,94.7,"Japan","JPN","Asia","East Asia & Pacific",41970,2019,"Japan","High income",4,NA,NA,NA,NA,NA
"3585",437,"Arashiro","Retrospective cohort",3700,2023-12-19,"Multiple or heterologous RNA","mRNA","2","final",NA,"180+ (median 215)",">=16 years","general pop","included","~65 weeks","severe disease requiring mechanical ventilation","severe","severe","omicron",82.7,37.1,95.3,"Japan","JPN","Asia","East Asia & Pacific",41970,2019,"Japan","High income",4,NA,NA,NA,NA,NA
"3586",437,"Arashiro","Retrospective cohort",3701,2023-12-19,"Multiple or heterologous RNA","mRNA","2","final",NA,"14-180 (median 139)",">=16 years","general pop","included","~65 weeks","death","death","death","omicron",43.1,-213.4,89.7,"Japan","JPN","Asia","East Asia & Pacific",41970,2019,"Japan","High income",4,NA,NA,NA,NA,NA
"3587",437,"Arashiro","Retrospective cohort",3702,2023-12-19,"Multiple or heterologous RNA","mRNA","2","final",NA,"180+ (median 216)",">=16 years","general pop","included","~65 weeks","death","death","death","omicron",59.5,-41.9,216,"Japan","JPN","Asia","East Asia & Pacific",41970,2019,"Japan","High income",4,NA,NA,NA,NA,NA
"3588",437,"Arashiro","Retrospective cohort",3703,2023-12-19,"Multiple or heterologous RNA","mRNA","2","final",NA,"14-180 (median 155)",">=16 years","general pop","included","~65 weeks","severe disease requiring oxygen therapy with respiratory failure","severe","severe","omicron",41.1,-43.9,155,"Japan","JPN","Asia","East Asia & Pacific",41970,2019,"Japan","High income",4,NA,NA,NA,NA,NA
"3589",437,"Arashiro","Retrospective cohort",3704,2023-12-19,"Multiple or heterologous RNA","mRNA","2","final",NA,"180+ (median 218)",">=16 years","general pop","included","~65 weeks","severe disease requiring oxygen therapy with respiratory failure","severe","severe","omicron",50.2,1.1,218,"Japan","JPN","Asia","East Asia & Pacific",41970,2019,"Japan","High income",4,NA,NA,NA,NA,NA
"3590",438,"Cheng","Retrospective cohort",3705,2023-12-26,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"14+",">=18 years with chronic kidney disease",">=18 years with chronic kidney disease","excluded","~51 weeks","infection","infection","infection","omicron",35,31,39,"Hong Kong","HKG","Asia","East Asia & Pacific",50480,2019,"Hong Kong SAR, China","High income",4,NA,NA,NA,NA,NA
"3591",438,"Cheng","Retrospective cohort",3706,2023-12-26,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"14+",">=18 years with chronic kidney disease",">=18 years with chronic kidney disease","excluded","~51 weeks","hospitalization","severe","severe","omicron",66,62,80,"Hong Kong","HKG","Asia","East Asia & Pacific",50480,2019,"Hong Kong SAR, China","High income",4,NA,NA,NA,NA,NA
"3592",438,"Cheng","Retrospective cohort",3707,2023-12-26,"Sinovac CoronaVac","Inactivated","2","final",NA,"14+",">=18 years with chronic kidney disease",">=18 years with chronic kidney disease","excluded","~51 weeks","infection","infection","infection","omicron",29,26,32,"Hong Kong","HKG","Asia","East Asia & Pacific",50480,2019,"Hong Kong SAR, China","High income",4,NA,NA,NA,NA,NA
"3593",438,"Cheng","Retrospective cohort",3708,2023-12-26,"Sinovac CoronaVac","Inactivated","2","final",NA,"14+",">=18 years with chronic kidney disease",">=18 years with chronic kidney disease","excluded","~51 weeks","hospitalization","severe","severe","omicron",63,60,66,"Hong Kong","HKG","Asia","East Asia & Pacific",50480,2019,"Hong Kong SAR, China","High income",4,NA,NA,NA,NA,NA
"3594",439,"Birk","Retrospective cohort",3709,2023-12-29,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"0-56","12-15 years","12-15 years","excluded","~24 weeks","infection","infection","infection","delta/omicron",96.2,95.4,96.9,"Denmark","DNK","Europe","Europe & Central Asia",63020,2019,"Denmark","High income",4,NA,NA,NA,NA,NA
"3595",439,"Birk","Retrospective cohort",3710,2023-12-29,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"57-182","12-15 years","12-15 years","excluded","~24 weeks","infection","infection","infection","delta/omicron",5.8,4.6,7,"Denmark","DNK","Europe","Europe & Central Asia",63020,2019,"Denmark","High income",4,NA,NA,NA,NA,NA
"3596",439,"Birk","Retrospective cohort",3711,2023-12-29,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"0-56","16-18 years","16-18 years","excluded","~24 weeks","infection","infection","infection","delta/omicron",95.5,94.8,96.1,"Denmark","DNK","Europe","Europe & Central Asia",63020,2019,"Denmark","High income",4,NA,NA,NA,NA,NA
"3597",439,"Birk","Retrospective cohort",3712,2023-12-29,"BioNTech/Pfizer BNT162b2","mRNA","2","final",NA,"57-182","16-18 years","16-18 years","excluded","~24 weeks","infection","infection","infection","delta/omicron",9.2,7.7,10.6,"Denmark","DNK","Europe","Europe & Central Asia",63020,2019,"Denmark","High income",4,NA,NA,NA,NA,NA
"3598",440,"Ye","Test-negative case-control",3713,2023-12-14,"Sinovac CoronaVac","Inactivated","2","final",NA,"28+",">=3 years",">=3 years","included","~61 weeks","symptomatic disease","symptomatic","symptomatic","omicron",14,-11,33,"China","CHN","Asia","East Asia & Pacific",10310,2019,"China","Upper middle income",3,NA,NA,NA,NA,NA
"3599",440,"Ye","Test-negative case-control",3714,2023-12-14,"Beijing/Sinopharm BBIBP-CorV","Inactivated","2","final",NA,"28+",">=3 years",">=3 years","included","~66 weeks","symptomatic disease","symptomatic","symptomatic","omicron",20,-10,43,"China","CHN","Asia","East Asia & Pacific",10310,2019,"China","Upper middle income",3,NA,NA,NA,NA,NA
